[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftuxI9kyQ400Syd6QsVU-3P8-hE7TKVtkIMzuWsqv3n4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":16,"truncated":17,"activeTrials":18,"phase3Count":19,"totalEnrollment":20,"activePrograms":21,"nonDrugCount":22,"topConditions":23,"upcomingReadouts":48,"phaseBuckets":96,"rows":103},"Peking University",[6,4,7,8,9,10,11,12,13,14,15],"Peking University Third Hospital","Peking University First Hospital","Peking University People's Hospital","Peking University Cancer Hospital & Institute","Peking University Shenzhen Hospital","Peking University Sixth Hospital","Peking University International Hospital","Peking University Aerospace Center Hospital","Peking University Shougang Hospital","Peking University Hospital of Stomatology",2334,false,764,76,6828329,461,1327,[24,27,30,33,36,39,42,45],{"name":25,"count":26},"Dexmedetomidine",43,{"name":28,"count":29},"Gastric Cancer",42,{"name":31,"count":32},"Breast Cancer",40,{"name":34,"count":35},"Immune Thrombocytopenia",35,{"name":37,"count":38},"Prostate Cancer",24,{"name":40,"count":41},"Esketamine",23,{"name":43,"count":44},"Lung Cancer",21,{"name":46,"count":47},"Surgery",20,[49,54,59,63,68,73,78,83,87,91],{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04481932","Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer","2022-06","Trastuzumab combined with Pyrotinib and chemotherapy",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04836156","Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients","2022-06-30","neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer",{"nctId":60,"briefTitle":61,"date":57,"intervention":62},"NCT04750122","Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients","neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03793517","Decitabine Plus mBU\u002FCY for High Risk Acute Leukemia With MRD Pre-HSCT","2023-10","Decitabine",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04616040","A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer","2023-12-01","Camrelizumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT04595162","A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL","2023-12-15","GC019F",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT02430103","Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients","2023-12-31","Goserelin 3.6 MG",{"nctId":84,"briefTitle":85,"date":81,"intervention":86},"NCT05945407","Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","Indication-extended Fertility-sparing Therapy",{"nctId":88,"briefTitle":89,"date":81,"intervention":90},"NCT04047953","Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma","Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1",{"nctId":92,"briefTitle":93,"date":94,"intervention":95},"NCT05104788","A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","2024-03-01","Icotinib",[97,98,99,100,101,102],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[104,476,556,747,866,930,1006,1089,1185,1237,1275,1304,1339,1426,1495,1554,1596,1624,1653,1675,1697,1719,1752,1787,1812,1840,1858,1876,1901,1919,1946,1971,1989,2014,2032,2059,2077,2101,2119,2144,2162,2186,2209,2227,2245,2263,2281,2299,2317,2335,2353,2378,2396,2420,2447,2465,2508,2637,2719,2755,2887,2940,2976,2998,3032,3054,3076,3107,3141,3166,3190,3208,3226,3244,3270,3293,3311,3335,3361,3379,3397,3420,3438,3485,3641,3720,3778,3840,3886,3983,4028,4064,4176,4213,4258,4295,4326,4353,4375,4402,4434,4456,4484,4511,4533,4564,4591,4613,4635,4758,4812,4877,4921,4963,4996,5018,5040,5068,5099,5132,5166,5188,5233,5281,5330,5383,5471,5525,5563,5594,5623,5657,5679,5710,5736,5761,5794,5826,5849,5873,5891,5909,5927,5951,5969,5987,6005,6030,6054,6077,6095,6113,6138,6160,6183,6207,6231,6253,6271,6295,6313,6336,6354,6372,6397,6422,6440,6465,6483,6501,6524,6551,6569,6593,6611,6629,6654,6678,6704,6728,6755,6780,6798,6816,6834,6863,6887,6905,6923,6941,6959,6977,6995,7013,7031,7049,7067,7085,7103,7121,7143,7170,7193,7211,7236,7254,7280,7303,7325,7343,7366,7390,7413,7438,7465,7485,7511,7529,7557,7575,7597,7622,7640,7658,7680,7704,7722,7746,7767,7789,7807,7831,7849,7871,7894,7918,7940,7958,7981,8004,8023,8048,8066,8091,8109,8127,8152,8173,8227,8292,8327,8360,8388,8477,8507,8542,8571,8613,8644,8669,8687,8705,8723,8747,8765,8789,8810,8832,8856,8880,8898,8921,8943,8967,8990,9008,9032,9056,9079,9101,9124,9142,9166,9192,9215,9236,9317,9350,9375,9403,9421,9439,9457,9475,9493,9511,9529,9554,9575,9599,9617,9639,9662,9685,9708,9731,9753,9771,9794,9818,9836,9859,9883,9908,9931,10000,10042,10081,10110,10140,10170,10192,10238,10301,10348,10396,10426,10469,10497,10523,10545,10574,10598,10616,10641,10659,10680,10704,10722,10744,10766,10793,10811,10834,10854,10876,10899,10923,10947,10965,10983,11001,11028,11046,11069,11092,11115,11139,11157,11192,11216,11234,11258,11276,11302,11320,11343,11369,11387,11410,11439,11457,11481,11499,11528,11546,11570,11588,11614,11638,11656,11680,11704,11727,11751,11773,11791,11809,11827,11849,11873,11897,11921,11939,11957,11979,12003,12026,12050,12068,12086,12110,12132,12150,12168,12191,12212,12238,12256,12280,12304,12322,12344,12369,12391,12414,12438,12463,12487,12510,12528,12551,12569,12590,12613,12636,12658,12683,12706,12724,12742,12768,12790,12808,12826,12844,12862,12885,12918,12939,12967,12985,13008,13029,13050,13072,13094,13122,13141,13163,13188,13206,13231,13256,13277,13302,13320,13344,13362,13380,13405,13423,13473,13499,13530,13552,13584,13615,13648,13670,13705,13740,13771,13793,13815,13843,13866,13884,13906,13924,13949,13967,13991,14009,14032,14050,14074,14092,14119,14137,14161,14183,14211,14229,14253,14280,14298,14316,14334,14352,14370,14394,14412,14430,14448,14466,14491,14509,14536,14554,14578,14596,14618,14641,14659,14683,14708,14726,14744,14769,14787,14811,14829,14851,14874,14900,14918,14936,14960,14978,14996,15025,15043,15061,15079,15102,15120,15143,15164,15189,15213,15231,15255,15281,15304,15333,15351,15369,15394,15416,15438,15456,15485,15503,15526,15544,15566,15590,15608,15633,15651,15677,15700,15718,15740,15764,15788,15806,15832,15856,15880,15898,15916,15934,15957,15982,16012,16045,16067,16100,16122,16145,16163,16189,16207,16229,16254,16272,16298,16316,16339,16357,16381,16406,16429,16447,16471,16489,16507,16530,16548,16570,16588,16613,16631,16653,16671,16689,16707,16731,16749,16772,16790,16813,16831,16849,16873,16891,16909,16933,16956,16978,17000,17022,17047,17065,17083,17107,17133,17157,17175,17239,17276,17306,17337,17365,17398,17424,17455,17489,17511,17533,17557,17587,17616,17644,17670,17692,17714,17737,17761,17779,17800,17823,17841,17868,17891,17912,17936,17959,17977,18001,18026,18048,18072,18094,18117,18135,18159,18177,18198,18223,18241,18259,18283,18301,18323,18345,18371,18389,18407,18431,18456,18474,18497,18515,18539,18557,18579,18602,18624,18648,18670,18693,18711,18729,18756,18777,18801,18823,18846,18867,18891,18913,18931,18952,18975,18993,19014,19036,19054,19072,19097,19115,19138,19161,19184,19208,19226,19250,19268,19292,19310,19328,19349,19367,19388,19410,19428,19450,19474,19492,19517,19535,19553,19574,19595,19613,19631,19654,19679,19703,19721,19747,19770,19788,19811,19835,19853,19875,19893,19915,19936,19958,19982,20005,20023,20047,20068,20092,20114,20138,20160,20183,20205,20223,20245,20263,20281,20303,20321,20339,20360,20382,20404,20425,20448,20470,20488,20512,20530,20554,20576,20598,20621,20639,20662,20685,20703,20721,20744,20765,20787,20828,20852,20874,20897,20918,20942,20964,20988,21012,21036,21058,21082,21105,21123,21146,21167,21188,21212,21230,21252,21274,21297,21319,21342,21365,21383,21410,21428,21452,21470,21492,21515,21540,21563,21584,21606,21624,21645,21668,21692,21716,21734,21757,21779,21803,21824,21847,21869,21891,21916,21934,21956,21978,22016,22056,22094,22124,22154,22191,22221,22252,22288,22314,22351,22384,22411,22442,22474,22496,22521,22550,22579,22604,22626,22656,22687,22709,22743,22774,22796,22826,22858,22886,22916,22941,22963,22985,23014,23053,23089,23115,23140,23174,23196,23218,23240,23263,23281,23299,23322,23340,23364,23382,23408,23426,23444,23462,23484,23507,23528,23553,23579,23602,23620,23641,23659,23677,23695,23716,23738,23760,23786,23808,23832,23850,23872,23894,23915,23939,23957,23981,23999,24022,24051,24069,24094,24112,24138,24160,24185,24206,24231,24255,24278,24301,24324,24348,24370,24395,24413,24436,24457,24482,24504,24525,24549,24571,24597,24615,24636,24658,24681,24699,24717,24735,24753,24774,24795,24820,24844,24862,24884,24905,24931,24949,24971,24994,25018,25036,25059,25077,25095,25113,25131,25153,25171,25193,25211,25229,25254,25272,25290,25308,25332,25350,25375,25393,25411,25429,25447,25470,25488,25513,25531,25554,25576,25594,25615,25639,25663,25681,25702,25723,25747,25765,25783,25807,25830,25851,25875,25897,25915,25937,25955,25979,25997,26015,26033,26056,26078,26101,26119,26141,26165,26183,26204,26227,26245,26268,26286,26304,26328,26351,26373,26396,26418,26436,26460,26478,26500,26523,26541,26564,26585,26610,26628,26646,26673,26691,26714,26740,26758,26776,26794,26816,26834,26852,26875,26898,26916,26934,26957,26981,26999,27023,27041,27063],{"intervention":25,"totalTrials":105,"cells":106},29,{"EARLY_PHASE1":107,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":406},{"trials":108,"activeCount":109},[],0,{"trials":111,"activeCount":109},[],{"trials":113,"activeCount":109},[],{"trials":115,"activeCount":109},[],{"trials":117,"activeCount":405,"soonestReadout":314},[118,132,146,161,173,187,197,211,223,237,248,261,273,286,298,310,323,334,345,359,369,381,393],{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":130},"NCT07308756","Impact of Perioperative Dexmedetomidine and Esketamine on Postoperative Quality of Recovery","RECRUITING",[101],"2027-03","2027-04","2026-01-05",316,[128,46,25,40,129],"General Anesthesia","Quality of Recovery",[25,40,131],"Dexmedetomidine-esketamine",{"nctId":133,"briefTitle":134,"status":135,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT02810899","Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy","COMPLETED",[101],"2016-02","2016-06","2015-09",60,[142],"Brain Neoplasms",[144,145],"dexmedetomidine","normal saline",{"nctId":147,"briefTitle":148,"status":135,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":160},"NCT03335527","Impacts of Low-Dose Dexmedetomidine on Sleep Quality in Mechanically Ventilated ICU Patients",[101],"2019-10-31","2019-11-30","2017-11-17",80,[155,156,157,158,159,25],"Aged","Postoperative Period","Intensive Care Units","Mechanical Ventilation Complication","Sleep Disorders",[25],{"nctId":162,"briefTitle":163,"status":135,"phases":164,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":171},"NCT05698407","Dexmedetomidine-Ropivacine Versus Sufentanil-Ropivacaine for Epidural Labor Analgesia",[101],"2023-06-15","2023-08-28","2023-03-16",200,[170],"Pregnancy Related",[25,172],"Sufentanil",{"nctId":174,"briefTitle":175,"status":135,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":186},"NCT03117790","Impact of Dexmedetomidine on Sleep Quality",[101],"2020-01-16","2020-02-18","2017-06-26",118,[182,46,183,25,184,185],"Elderly","Analgesia","Complication,Postoperative","Sleep Quality",[25],{"nctId":188,"briefTitle":189,"status":135,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT04111926","Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery",[101],"2021-04-01","2019-10-07",619,[195],"Overall Survival",[25],{"nctId":198,"briefTitle":199,"status":200,"phases":201,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":210},"NCT04955249","Dexmedetomidine Supplemented Analgesia and Delirium After Hip Fracture Surgery","TERMINATED",[101],"2023-04-11","2023-05-11","2021-11-18",67,[182,207,208,25,209],"Hip Fracture Surgery","Patient-controlled Analgesia","Postoperative Delirium",[25],{"nctId":212,"briefTitle":213,"status":135,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":222},"NCT04608331","Dexmedetomidine Supplemented Analgesia in Patients at High-risk of Obstructive Sleep Apnea",[101],"2022-08-17","2022-09-20","2021-01-29",152,[220,183,25,221,185],"Obstructive Sleep Apnea","High-flow Nasal Cannula",[25],{"nctId":224,"briefTitle":225,"status":135,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":235},"NCT06566469","Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium",[101],"2025-03-28","2025-05-01","2024-09-02",340,[232,233,25,40,128,234],"Older Patients","Nasal Administration","Emergence Delirium",[25,40,236],"Normal saline",{"nctId":238,"briefTitle":239,"status":135,"phases":240,"primaryCompletion":241,"start":242,"enrollment":153,"conditions":243,"interventions":246},"NCT01904760","Dexmedetomidine to Prevent Agitation After Free Flap Surgery",[101],"2013-11","2013-06",[244,245],"Agitation","Delirium",[25,247],"Saline placebo",{"nctId":249,"briefTitle":250,"status":135,"phases":251,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":260},"NCT02809937","Dexmedetomidine and Long-term Outcome in Elderly Patients After Surgery",[101],"2016-12","2017-06","2011-05",700,[155,257,245,25,258,259],"Surgical Procedures, Operative","Mortality","Long-term Survivors",[144],{"nctId":262,"briefTitle":263,"status":135,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":168,"conditions":268,"interventions":272},"NCT04791059","Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Postoperative Analgesia",[101],"2022-09-07","2022-10-07","2021-04-09",[269,270,271,25,172],"Scoliosis Correction","Postoperative Analgesia","S-ketamine",[271,25,172],{"nctId":274,"briefTitle":275,"status":135,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":285},"NCT04642651","Dexmedetomidine as an Adjuvant for Femoral Nerve Block and Functional Recovery After Total Knee Arthroplasty",[101],"2021-11-22","2022-02-25","2020-11-25",170,[182,282,283,25,284],"Total Knee Arthroplasty","Femoral Nerve Block","Functional Outcome",[25],{"nctId":287,"briefTitle":288,"status":135,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":297},"NCT03629262","Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery",[101],"2019-12-06","2022-12-06","2018-10-28",712,[182,295,183,25,209,296],"Orthopedic Surgery","Long-term Outcome",[25],{"nctId":299,"briefTitle":300,"status":121,"phases":301,"primaryCompletion":124,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":308},"NCT06399185","Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort",[101],"2027-05","2024-06-06",1740,[306,307,25,40],"Urinary Catheter","Catheter-related Bladder Discomfort",[236,25,40,309],"Combined dexmedetomidine-esketamine",{"nctId":311,"briefTitle":312,"status":121,"phases":313,"primaryCompletion":314,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":322},"NCT05950646","Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality",[101],"2025-11","2025-12","2023-11-01",154,[319,320,321,25,40,185],"Old Age","Knee Replacement Surgery","Hip Replacement Surgery",[25,40,236],{"nctId":324,"briefTitle":325,"status":200,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":333},"NCT03629483","Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block",[101],"2018-12-14","2018-12-10",3,[182,331,332,25,209,296],"Knee Arthroplasty","Nerve Block",[25],{"nctId":335,"briefTitle":336,"status":135,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT05732064","Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality",[101],"2025-04-20","2025-07-26","2023-05-22",180,[31,343,25,40,185],"Perioperative Period",[25,40,236],{"nctId":346,"briefTitle":347,"status":135,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":358},"NCT03933306","Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes",[101],"2020-10-29","2024-05-30","2019-05-20",496,[354,25,355,356,357],"Blood Pressure","High-risk Patients","Abdominal Surgery","Postoperative Complications",[25],{"nctId":360,"briefTitle":361,"status":135,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT05718544","Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes",[101],"2023-09-07","2023-01-30",199,[269,270,40,25,367],"Chronic Postsurgical Pain",[40,25,172],{"nctId":370,"briefTitle":371,"status":135,"phases":372,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":379},"NCT04509414","Intranasal Dexmedetomidine for Deep-sedated Pediatric Dental Patients",[101],"2022-05-01","2022-05-31","2020-04-10",100,[378,25],"Deep Sedation",[25,380],"Midazolam",{"nctId":382,"briefTitle":383,"status":121,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":376,"conditions":388,"interventions":391},"NCT07151716","Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients",[101],"2026-09","2026-10","2025-10-21",[232,389,390,25,40,245],"Postoperative Care","Intensive Care Unit",[25,392],"Dexmedetomidine-esketamine combination",{"nctId":394,"briefTitle":395,"status":396,"phases":397,"primaryCompletion":398,"completion":315,"start":399,"enrollment":400,"conditions":401,"interventions":404},"NCT03172897","Low-dose Dexmedetomidine in Mechanically Ventilated ICU Patients","SUSPENDED",[101],"2017-08-21","2017-08-20",260,[402,403,158,245,25],"Adult Disease","Intensive Care Unit Syndrome",[25],4,{"trials":407,"activeCount":329,"soonestReadout":470},[408,420,432,443,453,465],{"nctId":409,"briefTitle":410,"status":121,"phases":411,"primaryCompletion":412,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":419},"NCT06030804","Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery",[102],"2025-09","2028-10","2023-09-12",4532,[182,417,25,418],"Cancer Surgery","Long-Term Survivors",[25],{"nctId":421,"briefTitle":422,"status":200,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":29,"conditions":427,"interventions":431},"NCT04876937","Low-Dose Dexmedetomidine for Delirium Prevention in Mechanically Ventilated Septic Patients",[102],"2024-02-02","2024-03-02","2021-05-28",[428,390,429,430,245,25],"Adult","Sepsis","Mechanical Ventilation",[25],{"nctId":433,"briefTitle":434,"status":435,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":109,"conditions":440,"interventions":441},"NCT05246007","Nocturnal Low-dose Dexmedetomidine Infusion and Perioperative Sleep Quality","WITHDRAWN",[102],"2023-12","2026-12","2022-05",[319,320,321,25,185],[25,442],"Normal Saline",{"nctId":444,"briefTitle":445,"status":135,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":255,"conditions":450,"interventions":452},"NCT03436472","Dexmedetomidine and 5-year Outcome in Elderly Patients After Surgery",[102],"2019-01-08","2019-04-01","2017-06-01",[155,451,245,25,258,259],"Operative",[144],{"nctId":454,"briefTitle":455,"status":456,"phases":457,"primaryCompletion":458,"completion":459,"start":314,"enrollment":460,"conditions":461,"interventions":463},"NCT06468436","Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients","NOT_YET_RECRUITING",[102],"2029-12-01","2030-12-01",1508,[155,157,462,25,40,245],"Ventilators, Mechanical",[464,25],"Dexmedetomidine-Esketamine Combination",{"nctId":466,"briefTitle":467,"status":468,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":475},"NCT04204798","Dexmedetomidine and Outcomes of Elderly Admitted to ICU After Surgery","ACTIVE_NOT_RECRUITING",[102],"2025-06-04","2026-06-04","2020-08-28",1410,[182,46,390,25,195],[25],{"intervention":40,"totalTrials":477,"cells":478},10,{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":554},{"trials":480,"activeCount":109},[],{"trials":482,"activeCount":109},[],{"trials":484,"activeCount":109},[],{"trials":486,"activeCount":109},[],{"trials":488,"activeCount":553,"soonestReadout":501},[489,493,497,509,518,525,529,541,545,549],{"nctId":119,"briefTitle":120,"status":121,"phases":490,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":491,"interventions":492},[101],[128,46,25,40,129],[25,40,131],{"nctId":224,"briefTitle":225,"status":135,"phases":494,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":495,"interventions":496},[101],[232,233,25,40,128,234],[25,40,236],{"nctId":498,"briefTitle":499,"status":468,"phases":500,"primaryCompletion":501,"completion":314,"start":502,"enrollment":503,"conditions":504,"interventions":508},"NCT05698394","Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth",[101],"2025-10","2023-09-09",364,[505,506,507],"Prenatal Depression","Ketamine","Postpartum Depression",[40],{"nctId":510,"briefTitle":511,"status":468,"phases":512,"primaryCompletion":513,"completion":386,"start":514,"enrollment":515,"conditions":516,"interventions":517},"NCT06062550","Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery",[101],"2025-10-23","2023-10-24",312,[269,40,25,270,367],[40],{"nctId":519,"briefTitle":520,"status":121,"phases":521,"primaryCompletion":315,"completion":385,"start":522,"enrollment":515,"conditions":523,"interventions":524},"NCT06087510","Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes",[101],"2024-01-24",[269,270,40,25,367],[40],{"nctId":299,"briefTitle":300,"status":121,"phases":526,"primaryCompletion":124,"completion":302,"start":303,"enrollment":304,"conditions":527,"interventions":528},[101],[306,307,25,40],[236,25,40,309],{"nctId":530,"briefTitle":531,"status":135,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":540},"NCT04597320","Esketamine Sedation and Fentanyl Sedation in Pediatric Dental Patients",[101],"2022-02-28","2022-03-12","2022-01-01",48,[506,538,539],"Fentanyl","Sedation Complication",[538,40,380],{"nctId":311,"briefTitle":312,"status":121,"phases":542,"primaryCompletion":314,"completion":315,"start":316,"enrollment":317,"conditions":543,"interventions":544},[101],[319,320,321,25,40,185],[25,40,236],{"nctId":335,"briefTitle":336,"status":135,"phases":546,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":547,"interventions":548},[101],[31,343,25,40,185],[25,40,236],{"nctId":360,"briefTitle":361,"status":135,"phases":550,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":551,"interventions":552},[101],[269,270,40,25,367],[40,25,172],6,{"trials":555,"activeCount":109},[],{"intervention":557,"totalTrials":558,"cells":559},"Dexamethasone",16,{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":662,"PHASE4":674,"NA":709},{"trials":561,"activeCount":109},[],{"trials":563,"activeCount":109},[],{"trials":565,"activeCount":329,"soonestReadout":628},[566,579,591,600,610,624,633,644,653],{"nctId":567,"briefTitle":568,"status":569,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":577},"NCT04747080","The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","UNKNOWN",[99],"2023-03-01","2023-07-01","2021-03-01",120,[576,34],"ITP",[557,578],"Tacrolimus",{"nctId":580,"briefTitle":581,"status":121,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT07065968","The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)",[99],"2027-09-10","2027-12-30","2025-08-19",132,[588],"Immune Thrombocytopenia (ITP)",[590,557],"Teriflunomide",{"nctId":592,"briefTitle":593,"status":435,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":109,"conditions":598,"interventions":599},"NCT06176235","Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia",[99],"2024-12-12","2025-05-12","2023-12-19",[34],[590,557],{"nctId":601,"briefTitle":602,"status":569,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":586,"conditions":607,"interventions":608},"NCT05932524","Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia",[99],"2024-06","2025-06","2023-07-07",[34],[609,557],"Baricitinib 2 MG",{"nctId":611,"briefTitle":612,"status":456,"phases":613,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":621},"NCT07335887","Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis",[99],"2028-02-29","2029-01-31","2026-01-01",39,[619,620],"AL Amyloidosis (AL)","t(11;14) Positive",[622,623,557],"sonrotoclax","Daratumumab",{"nctId":625,"briefTitle":626,"status":456,"phases":627,"primaryCompletion":628,"completion":584,"start":629,"enrollment":586,"conditions":630,"interventions":631},"NCT07064889","The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia",[99],"2027-07-30","2025-07-30",[34],[557,632],"Upadacitinib",{"nctId":634,"briefTitle":635,"status":569,"phases":636,"primaryCompletion":637,"completion":638,"start":639,"enrollment":640,"conditions":641,"interventions":642},"NCT05369364","The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia",[99],"2025-12-30","2026-06-01","2022-06-01",150,[34],[643,557],"Zanubrutinib",{"nctId":645,"briefTitle":646,"status":135,"phases":647,"primaryCompletion":648,"completion":648,"start":649,"enrollment":586,"conditions":650,"interventions":651},"NCT04217148","The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia",[99],"2020-06-30","2020-01-01",[34],[557,652],"ATRA",{"nctId":654,"briefTitle":655,"status":569,"phases":656,"primaryCompletion":657,"completion":657,"start":448,"enrollment":658,"conditions":659,"interventions":660},"NCT04368598","The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP",[99],"2020-12-31",44,[34],[557,661],"Acetylcysteine",{"trials":663,"activeCount":109},[664],{"nctId":665,"briefTitle":666,"status":569,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT02751593","Thrombocytopenia in Gestational Period",[99,100],"2017-12","2016-01",70,[34,672],"Pregnancy",[557],{"trials":675,"activeCount":708,"soonestReadout":680},[676,687,701],{"nctId":677,"briefTitle":678,"status":468,"phases":679,"primaryCompletion":680,"completion":681,"start":682,"enrollment":400,"conditions":683,"interventions":686},"NCT04025840","Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery",[101],"2024-10-22","2026-11","2019-09-11",[684,46,685,557,195],"Pancreatic Cancer","Epidural Block",[557],{"nctId":688,"briefTitle":689,"status":200,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":698},"NCT03172988","Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery",[101],"2018-12-26","2017-08-02",126,[695,46,557,696,697],"Carcinoma, Non-Small-Cell Lung","Flubiprofen Axetil","Long-term Effects Secondary to Cancer Therapy in Adults",[557,236,699,700],"Flurbiprofen axetil","Lipid microsphere",{"nctId":702,"briefTitle":703,"status":200,"phases":704,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":705,"interventions":707},"NCT03200600","Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery",[101],[695,706,557,696,245],"Surgery--Complications",[557,236,699,700],1,{"trials":710,"activeCount":746,"soonestReadout":725},[711,721,736],{"nctId":712,"briefTitle":713,"status":121,"phases":714,"primaryCompletion":438,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT04209218","Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery",[102],"2029-12","2020-04-07",1988,[43,46,719,557,195,357],"Blood Pressure Management",[557],{"nctId":722,"briefTitle":723,"status":121,"phases":724,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT06627309","Rapid dFLC Response Predict CHR in AL Amyloidosis",[],"2026-06-30","2026-12-31","2024-10-26",50,[730],"Systemic AL Amyloidosis",[732,733,557,734,735],"Dara IV","Bortezomib","Cyclophosphamide","Dara SC",{"nctId":737,"briefTitle":738,"status":569,"phases":739,"primaryCompletion":740,"completion":741,"start":742,"enrollment":536,"conditions":743,"interventions":745},"NCT06350565","A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)",[102],"2025-04-30","2025-12-31","2024-04-30",[744],"Respiratory Distress Syndrome of Newborn",[557],2,{"intervention":236,"totalTrials":748,"cells":749},14,{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":758,"NA":835},{"trials":751,"activeCount":109},[],{"trials":753,"activeCount":109},[],{"trials":755,"activeCount":109},[],{"trials":757,"activeCount":109},[],{"trials":759,"activeCount":405,"soonestReadout":314},[760,764,768,781,785,789,793,797,801,813,826],{"nctId":133,"briefTitle":134,"status":135,"phases":761,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":762,"interventions":763},[101],[142],[144,145],{"nctId":224,"briefTitle":225,"status":135,"phases":765,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":766,"interventions":767},[101],[232,233,25,40,128,234],[25,40,236],{"nctId":769,"briefTitle":770,"status":121,"phases":771,"primaryCompletion":772,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":780},"NCT07046364","Remimazolam and Emergence Delirium in Pediatrics",[101],"2027-01-01","2025-01-01",248,[776,777,778,779,234],"Pediatric","Neurosurgery","Sevoflurane Anesthesia","Remimazolam",[779,442],{"nctId":688,"briefTitle":689,"status":200,"phases":782,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":783,"interventions":784},[101],[695,46,557,696,697],[557,236,699,700],{"nctId":299,"briefTitle":300,"status":121,"phases":786,"primaryCompletion":124,"completion":302,"start":303,"enrollment":304,"conditions":787,"interventions":788},[101],[306,307,25,40],[236,25,40,309],{"nctId":311,"briefTitle":312,"status":121,"phases":790,"primaryCompletion":314,"completion":315,"start":316,"enrollment":317,"conditions":791,"interventions":792},[101],[319,320,321,25,40,185],[25,40,236],{"nctId":335,"briefTitle":336,"status":135,"phases":794,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":795,"interventions":796},[101],[31,343,25,40,185],[25,40,236],{"nctId":702,"briefTitle":703,"status":200,"phases":798,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":799,"interventions":800},[101],[695,706,557,696,245],[557,236,699,700],{"nctId":802,"briefTitle":803,"status":456,"phases":804,"primaryCompletion":438,"completion":438,"start":805,"enrollment":574,"conditions":806,"interventions":809},"NCT07523334","Impact of Esketamine on Delayed Neurocognitive Recovery in Older Patients",[101],"2026-04",[182,807,808,209,40],"Noncardiac Surgery","Delayed Neurocognitive Recovery",[810,811,812,236],"Esketamine 1","Esketamine 2","Esketamine 3",{"nctId":814,"briefTitle":815,"status":135,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":153,"conditions":820,"interventions":822},"NCT04396587","Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone",[101],"2023-01-01","2023-06-01","2020-05-20",[821],"Opioid Use",[172,823,824,825],"Hydromorphone","Oxycodone","normal Saline",{"nctId":827,"briefTitle":828,"status":569,"phases":829,"primaryCompletion":830,"start":831,"enrollment":376,"conditions":832,"interventions":833},"NCT02078583","The Effect of Analgesia Based Sedation Protocol on Brain Function of Critical Care Patients",[101],"2015-06","2014-07",[245],[538,834,236],"Remifentanil",{"trials":836,"activeCount":708,"soonestReadout":725},[837,841,851],{"nctId":433,"briefTitle":434,"status":435,"phases":838,"primaryCompletion":437,"completion":438,"start":439,"enrollment":109,"conditions":839,"interventions":840},[102],[319,320,321,25,185],[25,442],{"nctId":842,"briefTitle":843,"status":121,"phases":844,"primaryCompletion":725,"completion":725,"start":845,"enrollment":846,"conditions":847,"interventions":849},"NCT07002723","Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality",[102],"2025-06-20",96,[848],"Hip Fractures",[850,236],"Esketamine combined with dexmedetomidine",{"nctId":852,"briefTitle":853,"status":569,"phases":854,"primaryCompletion":855,"completion":856,"start":857,"enrollment":846,"conditions":858,"interventions":864},"NCT04922359","Effect of Perioperative Lidocaine on Gastrointestinal Function Recovery After Lumbar Spine Surgery in Adults",[102],"2022-10-30","2023-05-15","2021-06-01",[859,860,861,862,863],"Spinal Surgery","Lidocaine","Pain","Opioid Consumption","Gastrointestinal Dysfunction",[865,145],"Lidocain",{"intervention":392,"totalTrials":553,"cells":867},{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":874,"PHASE4":876,"NA":912},{"trials":869,"activeCount":109},[],{"trials":871,"activeCount":109},[],{"trials":873,"activeCount":109},[],{"trials":875,"activeCount":109},[],{"trials":877,"activeCount":405,"soonestReadout":412},[878,889,897,901],{"nctId":879,"briefTitle":880,"status":121,"phases":881,"primaryCompletion":681,"completion":438,"start":882,"enrollment":883,"conditions":884,"interventions":888},"NCT06859892","Dexmedetomidine-Esketamine Combination and Sleep Disturbances After Major Noncardiac Surgery",[101],"2025-03-18",476,[885,886,25,40,887],"Adults","Major Noncardiac Surgery","Postoperative Sleep Disturbances",[392],{"nctId":890,"briefTitle":891,"status":121,"phases":892,"primaryCompletion":412,"completion":315,"start":893,"enrollment":376,"conditions":894,"interventions":896},"NCT06566482","Mini-dose Dexmedetomidine-Esketamine Supplemented Analgesia in Patients at High-risk of OSA",[101],"2024-09-11",[220,46,25,40,895],"Postoperative Sleep Quality",[392],{"nctId":382,"briefTitle":383,"status":121,"phases":898,"primaryCompletion":385,"completion":386,"start":387,"enrollment":376,"conditions":899,"interventions":900},[101],[232,389,390,25,40,245],[25,392],{"nctId":902,"briefTitle":903,"status":456,"phases":904,"primaryCompletion":905,"completion":906,"start":907,"enrollment":140,"conditions":908,"interventions":911},"NCT07610343","Intranasal Dexmedetomidine-esketamine on Sleep and Cognition in Older Adults With Mild-to-moderate Cognitive Impairment",[101],"2027-11","2027-12","2026-06",[909,910,159,25,40],"Older Adults","Cognitive Impairment",[392],{"trials":913,"activeCount":708,"soonestReadout":458},[914,926],{"nctId":915,"briefTitle":916,"status":135,"phases":917,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":925},"NCT06003218","Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation",[102],"2024-09-26","2024-09-28","2023-10-16",88,[923,924,40,25],"Liver Cancer","Radiofrequency Ablation",[392,834,824],{"nctId":454,"briefTitle":455,"status":456,"phases":927,"primaryCompletion":458,"completion":459,"start":314,"enrollment":460,"conditions":928,"interventions":929},[102],[155,157,462,25,40,245],[464,25],{"intervention":931,"totalTrials":553,"cells":932},"Sirolimus",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":973,"PHASE4":984,"NA":996},{"trials":934,"activeCount":109},[],{"trials":936,"activeCount":109},[],{"trials":938,"activeCount":708,"soonestReadout":968},[939,953,964],{"nctId":940,"briefTitle":941,"status":569,"phases":942,"primaryCompletion":604,"completion":943,"start":944,"enrollment":553,"conditions":945,"interventions":949},"NCT06279494","Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors",[98,99],"2025-03","2024-03",[946,947,948],"Acute Leukemia","Myelodysplastic Syndromes","Severe Aplastic Anemia",[931,950,951,952],"Abatacept","MMF","ATG",{"nctId":954,"briefTitle":955,"status":569,"phases":956,"primaryCompletion":957,"completion":958,"start":959,"enrollment":960,"conditions":961,"interventions":963},"NCT03365869","A Pilot-Study of Sirolimus for the Treatment of Systemic Sclerosis",[99],"2018-12-31","2019-06-30","2018-06-01",72,[962],"Systemic Sclerosis",[931],{"nctId":965,"briefTitle":966,"status":456,"phases":967,"primaryCompletion":968,"completion":584,"start":969,"enrollment":670,"conditions":970,"interventions":972},"NCT06504420","The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study",[99],"2026-12-30","2024-10-15",[971],"Primary Antiphospholipid Syndrome",[931],{"trials":974,"activeCount":708,"soonestReadout":315},[975],{"nctId":976,"briefTitle":977,"status":121,"phases":978,"primaryCompletion":315,"completion":438,"start":979,"enrollment":140,"conditions":980,"interventions":982},"NCT04047576","Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis",[99,100],"2018-07-01",[981],"Retroperitoneal Fibrosis",[931,983],"Corticosteroid",{"trials":985,"activeCount":708,"soonestReadout":906},[986],{"nctId":987,"briefTitle":988,"status":121,"phases":989,"primaryCompletion":906,"completion":906,"start":990,"enrollment":991,"conditions":992,"interventions":995},"NCT06722586","Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia",[101],"2025-01-07",84,[993,994],"Antiphospholipid (aPL)-Positive","Thrombocytopaenia",[931],{"trials":997,"activeCount":708,"soonestReadout":726},[998],{"nctId":999,"briefTitle":1000,"status":456,"phases":1001,"primaryCompletion":726,"completion":1002,"start":571,"enrollment":47,"conditions":1003,"interventions":1005},"NCT05746689","Study of Sirolimus in IgG4-related Disease",[102],"2028-12-31",[1004],"IgG4-related Disease",[931],{"intervention":1007,"totalTrials":405,"cells":1008},"Pyrotinib",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1061,"PHASE4":1063,"NA":1076},{"trials":1010,"activeCount":109},[],{"trials":1012,"activeCount":109},[],{"trials":1014,"activeCount":746,"soonestReadout":1019},[1015,1050],{"nctId":1016,"briefTitle":1017,"status":456,"phases":1018,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":1021,"interventions":1023},"NCT06692491","Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS",[99],"2027-12-31","2029-12-31",[1022],"Rare Tumour",[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],"Albumin-Bound Paclitaxel","Epirubicin","Gemcitabine","Vinorelbine","Cisplatin","Irinotecan","Fluorouracil","Nivolumab","Pembrolizumab","Durvalumab","Atezolizumab","Sintilimab","Tislelizumab","Toripalimab","Serplulimab","Adebrelimab","Envafolimab","Osimertinib","Alectinib","Vemurafenib","Pamiparib","Imatinib","Palbociclib","Savolitinib","Entrectinib","Other",{"nctId":1051,"briefTitle":1052,"status":456,"phases":1053,"primaryCompletion":615,"completion":1020,"start":1054,"enrollment":376,"conditions":1055,"interventions":1057},"NCT07417241","SHR-A1811 vs Pyrotinib\u002FCapecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study",[99],"2026-03-31",[31,1056],"HER2-positive Breast Cancer",[1058,1007,1059,1060],"SHR-A1811","Capecitabine","T-DXd",{"trials":1062,"activeCount":109},[],{"trials":1064,"activeCount":708,"soonestReadout":1069},[1065],{"nctId":1066,"briefTitle":1067,"status":456,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":638,"enrollment":1070,"conditions":1071,"interventions":1074},"NCT07600164","Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer",[101],"2031-12-30",500,[1072,1073],"HER2 + Breast Cancer","Advanced Breast Cancer",[1007,1075],"Trastuzumab Rezetecan",{"trials":1077,"activeCount":708,"soonestReadout":1082},[1078],{"nctId":1079,"briefTitle":1080,"status":456,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1054,"enrollment":29,"conditions":1084,"interventions":1085},"NCT07470203","Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer",[],"2029-03-31","2029-09-30",[1056],[1007,1086,1087,1088],"Trastuzuma","Pertuzumab","Combination product: Trastuzumab + Pertuzumab",{"intervention":1090,"totalTrials":1091,"cells":1092},"Prednisone",7,{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1143,"PHASE4":1156,"NA":1183},{"trials":1094,"activeCount":109},[],{"trials":1096,"activeCount":109},[],{"trials":1098,"activeCount":708,"soonestReadout":1103},[1099,1108,1123,1134],{"nctId":1100,"briefTitle":1101,"status":121,"phases":1102,"primaryCompletion":1103,"completion":741,"start":1104,"enrollment":376,"conditions":1105,"interventions":1106},"NCT06577909","Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy",[99],"2024-12-31","2023-10-19",[34],[1090,1107],"IVIg",{"nctId":1109,"briefTitle":1110,"status":569,"phases":1111,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1118},"NCT03617432","Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients",[99],"2020-09-30","2022-09-30","2018-08-28",114,[1117],"Experimental Tumor",[1119,734,1120,1121,1122,1090],"Chidamide","Doxorubicin","Vincristine","Etoposide",{"nctId":1124,"briefTitle":1125,"status":569,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1132},"NCT05459649","Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia",[99],"2024-07-20","2025-07-20","2022-07-20",253,[34],[1133,1090],"Cyclosporine Oral Product",{"nctId":1135,"briefTitle":1136,"status":569,"phases":1137,"primaryCompletion":639,"completion":1138,"start":857,"enrollment":1139,"conditions":1140,"interventions":1141},"NCT05333744","The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy",[99],"2022-09-01",90,[34],[1090,1142],"Recombinant Human TPO",{"trials":1144,"activeCount":109},[1145],{"nctId":1146,"briefTitle":1147,"status":569,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1154},"NCT03952572","Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma",[100],"2023-04-30","2019-05-10",244,[1153],"Peripheral T-cell Lymphoma",[734,1155,1121,1090,1120],"pegylated liposomal doxorubicin",{"trials":1157,"activeCount":708,"soonestReadout":1019},[1158,1171],{"nctId":1159,"briefTitle":1160,"status":569,"phases":1161,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1166,"interventions":1168},"NCT02370550","Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome",[101],"2021-03","2021-12","2015-03",240,[1167],"Sjogren's Syndrome",[1169,1090,1170],"Cyclosporin A","Calcium carbonate D",{"nctId":1172,"briefTitle":1173,"status":456,"phases":1174,"primaryCompletion":1019,"completion":1175,"start":1176,"enrollment":180,"conditions":1177,"interventions":1179},"NCT06364319","Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD",[101],"2028-06-30","2024-04-15",[1178],"cGVHD",[1180,1090,1181,1182],"anti-CD25 rhMAb","Ruxolitinib","Cyclosporine",{"trials":1184,"activeCount":109},[],{"intervention":779,"totalTrials":405,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1195,"NA":1235},{"trials":1188,"activeCount":109},[],{"trials":1190,"activeCount":109},[],{"trials":1192,"activeCount":109},[],{"trials":1194,"activeCount":109},[],{"trials":1196,"activeCount":746,"soonestReadout":501},[1197,1207,1211,1223],{"nctId":1198,"briefTitle":1199,"status":135,"phases":1200,"primaryCompletion":1201,"completion":1202,"start":191,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT04602845","Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients",[101],"2021-06-30","2021-12-31",81,[539,380,779],[538,1206,380,779],"Flurbiprofen",{"nctId":769,"briefTitle":770,"status":121,"phases":1208,"primaryCompletion":772,"completion":772,"start":773,"enrollment":774,"conditions":1209,"interventions":1210},[101],[776,777,778,779,234],[779,442],{"nctId":1212,"briefTitle":1213,"status":135,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1222},"NCT04861337","Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients",[101],"2022-12-31","2023-04-22","2021-05-19",552,[1220,1221,355],"Postoperative Nausea and Vomiting","Benzodiazepine",[779],{"nctId":1224,"briefTitle":1225,"status":121,"phases":1226,"primaryCompletion":501,"completion":386,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1233},"NCT04532606","Impact of Remimazolam on Prognosis After Bladder Cancer Surgery",[101],"2021-02-05",1128,[1230,1231,245,46,1232],"Benzodiazepines","Bladder Cancer","Cancer Recurrence",[779,1234],"Propofol",{"trials":1236,"activeCount":109},[],{"intervention":1238,"totalTrials":746,"cells":1239},"Dose Escalation",{"EARLY_PHASE1":1240,"PHASE1":1255,"PHASE2":1257,"PHASE3":1259,"PHASE4":1261,"NA":1273},{"trials":1241,"activeCount":708,"soonestReadout":1246},[1242],{"nctId":1243,"briefTitle":1244,"status":121,"phases":1245,"primaryCompletion":1246,"completion":386,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1251},"NCT06690476","Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma",[97],"2026-07","2024-10-10",74,[1250],"Esophageal Squamous Cell Carcinoma",[1252,1253,1254],"Dose escalation","Dose expansion","Neoadjuvant therapy cohort",{"trials":1256,"activeCount":109},[],{"trials":1258,"activeCount":109},[],{"trials":1260,"activeCount":109},[],{"trials":1262,"activeCount":708,"soonestReadout":584},[1263],{"nctId":1264,"briefTitle":1265,"status":456,"phases":1266,"primaryCompletion":584,"completion":1267,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1272},"NCT07599137","Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy",[101],"2028-02-01","2026-05-30",86,[1271],"HR+\u002FHER2- Breast Cancer",[1238],{"trials":1274,"activeCount":109},[],{"intervention":1276,"totalTrials":746,"cells":1277},"Combined dexmedetomidine-esketamine administration",{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1284,"PHASE4":1286,"NA":1302},{"trials":1279,"activeCount":109},[],{"trials":1281,"activeCount":109},[],{"trials":1283,"activeCount":109},[],{"trials":1285,"activeCount":109},[],{"trials":1287,"activeCount":746,"soonestReadout":124},[1288,1296],{"nctId":1289,"briefTitle":1290,"status":456,"phases":1291,"primaryCompletion":905,"completion":906,"start":805,"enrollment":1292,"conditions":1293,"interventions":1295},"NCT07525999","Dexmedetomidine-esketamine Combination and Chronic Postsurgical Pain After Spinal Surgery",[101],274,[859,1294,25,40,270],"Pain Intensity",[1276],{"nctId":1297,"briefTitle":1298,"status":456,"phases":1299,"primaryCompletion":124,"completion":302,"start":805,"enrollment":1292,"conditions":1300,"interventions":1301},"NCT07523321","Dexmedetomidine-esketamine Combination and Moderate-to-severe Pain After Spinal Surgery",[101],[859,1294,25,40,270],[1276],{"trials":1303,"activeCount":109},[],{"intervention":1305,"totalTrials":746,"cells":1306},"Dex-Esk",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1315,"NA":1337},{"trials":1308,"activeCount":109},[],{"trials":1310,"activeCount":109},[],{"trials":1312,"activeCount":109},[],{"trials":1314,"activeCount":109},[],{"trials":1316,"activeCount":746,"soonestReadout":1333},[1317,1329],{"nctId":1318,"briefTitle":1319,"status":456,"phases":1320,"primaryCompletion":1321,"completion":1322,"start":907,"enrollment":1323,"conditions":1324,"interventions":1328},"NCT07576543","Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery",[101],"2030-06","2031-06",1160,[232,46,25,40,1325,1326,1327],"Transcranial Direct Current Stimulation","Cognitive Function","Survival",[1305],{"nctId":1330,"briefTitle":1331,"status":456,"phases":1332,"primaryCompletion":1333,"completion":1321,"start":907,"enrollment":1323,"conditions":1334,"interventions":1336},"NCT07576517","Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery",[101],"2029-06",[232,46,25,40,1325,1335],"Perioperative Neurocognitive Disorders",[1305],{"trials":1338,"activeCount":109},[],{"intervention":1234,"totalTrials":1091,"cells":1340},{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1347,"PHASE4":1349,"NA":1355},{"trials":1342,"activeCount":109},[],{"trials":1344,"activeCount":109},[],{"trials":1346,"activeCount":109},[],{"trials":1348,"activeCount":109},[],{"trials":1350,"activeCount":708,"soonestReadout":501},[1351],{"nctId":1224,"briefTitle":1225,"status":121,"phases":1352,"primaryCompletion":501,"completion":386,"start":1227,"enrollment":1228,"conditions":1353,"interventions":1354},[101],[1230,1231,245,46,1232],[779,1234],{"trials":1356,"activeCount":708,"soonestReadout":1384},[1357,1371,1380,1393,1399,1411],{"nctId":1358,"briefTitle":1359,"status":135,"phases":1360,"primaryCompletion":1113,"completion":1361,"start":1362,"enrollment":1363,"conditions":1364,"interventions":1369},"NCT05343260","Impact of Anesthesia Maintenance Methods on 5-year Survival After Surgery",[102],"2023-03-30","2015-04-01",1228,[155,1365,1366,1367,1368,1327],"Neoplasms","Surgical Procedure, Operative","Anesthesia, Inhalation","Anesthesia, Intravenous",[1370,1234],"Sevoflurane",{"nctId":1372,"briefTitle":1373,"status":135,"phases":1374,"primaryCompletion":1375,"completion":1376,"start":1362,"enrollment":1363,"conditions":1377,"interventions":1379},"NCT02662257","Impact of Anesthesia Maintenance Methods on Incidence of Postoperative Delirium",[102],"2017-09-29","2017-11-26",[245,357,1378],"Postoperative Cognitive Dysfunction",[1370,1234],{"nctId":1381,"briefTitle":1382,"status":121,"phases":1383,"primaryCompletion":1384,"completion":1385,"start":639,"enrollment":1386,"conditions":1387,"interventions":1390},"NCT05210764","General Anesthetics-related Changes in Prefrontal EEG During Pediatric Surgical Anesthesia",[],"2026-03","2026-08",366,[1388,1389],"General Anesthetic","Electroencephalogram",[1391,1392,271],"propofol","sevoflurane",{"nctId":1394,"briefTitle":1395,"status":135,"phases":1396,"primaryCompletion":1375,"completion":1112,"start":1362,"enrollment":1363,"conditions":1397,"interventions":1398},"NCT02660411","Impact of Anesthesia Maintenance Methods on Long-term Survival",[102],[155,1365,1366,1367,1368,1327],[1370,1234],{"nctId":1400,"briefTitle":1401,"status":569,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":168,"conditions":1406,"interventions":1409},"NCT05520645","Etomidate Induction in Hysteroscopic Surgery",[102],"2023-09-30","2023-12-30","2022-08-25",[1407,1408],"Etomidate Induced Dose","Hysteroscopic Surgery",[1410,1391],"etomidate",{"nctId":1412,"briefTitle":1413,"status":569,"phases":1414,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":29,"conditions":1418,"interventions":1421},"NCT04924621","Sedation Compaired With Anesthesia With THRIVE in Endotracheal Intubation With Difficult Airways",[102],"2022-05-10","2022-06-10","2021-06-10",[1419,1420],"Sedative, Hypnotic, or Anxiolytic Withdrawal","Airway Control",[380,1422,1234,1423,1424,172,380,1234,1425,1424],"Sufentani","Rocuronium","Drug use target","Tetracaine",{"intervention":1427,"totalTrials":1428,"cells":1429},"Morphine",5,{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1483},{"trials":1431,"activeCount":109},[],{"trials":1433,"activeCount":109},[],{"trials":1435,"activeCount":109},[],{"trials":1437,"activeCount":109},[],{"trials":1439,"activeCount":746,"soonestReadout":438},[1440,1449,1466,1475],{"nctId":1441,"briefTitle":1442,"status":121,"phases":1443,"primaryCompletion":438,"completion":438,"start":1444,"enrollment":1445,"conditions":1446,"interventions":1447},"NCT06411665","Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting",[101],"2024-07-02",252,[1220],[1448,1427],"Oliceridine",{"nctId":1450,"briefTitle":1451,"status":200,"phases":1452,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1457,"interventions":1462},"NCT07246785","Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic Surgery",[101],"2026-02-11","2026-03-11","2025-12-25",13,[1458,1459,1460,1461],"Laparoscopic Surgery","Visceral Pain, Postoperative","Anrikefon","Patient-controlled Intravenous Analgesia",[1463,1464,1465,1427],"High-dose anrikefon","Medium-dose anrikefon","Low-dose anrikefon",{"nctId":1467,"briefTitle":1468,"status":135,"phases":1469,"primaryCompletion":957,"completion":957,"start":1470,"enrollment":153,"conditions":1471,"interventions":1473},"NCT03288428","Analgesia Comparison of Nalbuphine and Morphine for Laparoscopic Myomectomy",[101],"2017-05-01",[1472],"Postoperative Pain",[1474,1427],"Nalbuphine",{"nctId":1476,"briefTitle":1477,"status":121,"phases":1478,"primaryCompletion":123,"completion":124,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1482},"NCT07525986","Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery",[101],"2026-04-14",140,[1458,1459,1460,1461],[1463,1464,1465,1427],{"trials":1484,"activeCount":109},[1485],{"nctId":1486,"briefTitle":1487,"status":135,"phases":1488,"primaryCompletion":1489,"completion":1489,"start":1490,"enrollment":341,"conditions":1491,"interventions":1493},"NCT01917045","Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia",[102],"2013-03","2012-01",[1492],"Post Operative Pain Management",[172,1494,1427],"Sufentanil (R30730, brand name Sufenta) + Morphine",{"intervention":1496,"totalTrials":405,"cells":1497},"Metformin",{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1504,"PHASE4":1506,"NA":1531},{"trials":1499,"activeCount":109},[],{"trials":1501,"activeCount":109},[],{"trials":1503,"activeCount":109},[],{"trials":1505,"activeCount":109},[],{"trials":1507,"activeCount":708,"soonestReadout":1512},[1508,1521],{"nctId":1509,"briefTitle":1510,"status":121,"phases":1511,"primaryCompletion":1512,"completion":1020,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1519},"NCT06742710","Liraglutide Treatment in Obese Infertile PCOS Women",[101],"2029-05-30","2025-05-22",890,[1516,1517,1518],"PCOS","Obesity","Infertility",[1520,1496],"Liraglutide and metformin",{"nctId":1522,"briefTitle":1523,"status":569,"phases":1524,"primaryCompletion":1525,"completion":338,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1530},"NCT05655728","Treatment With Metformin in Chinese Children With Alport Syndrome",[101],"2025-01-31","2023-01-03",78,[1529,1496],"Alport Syndrome",[1496],{"trials":1532,"activeCount":708,"soonestReadout":726},[1533,1544],{"nctId":1534,"briefTitle":1535,"status":456,"phases":1536,"primaryCompletion":726,"completion":1019,"start":1537,"enrollment":1538,"conditions":1539,"interventions":1542},"NCT06775093","Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity",[102],"2025-03-01",392,[1540,1517,1541],"Polycystic Ovary Syndrome","Infertility, Female",[1543,1496],"GLP-1 receptor agonist",{"nctId":1545,"briefTitle":1546,"status":569,"phases":1547,"primaryCompletion":1548,"completion":657,"start":1549,"enrollment":153,"conditions":1550,"interventions":1553},"NCT03538704","Effect of Fertility-sparing Therapy of Early Endometrial Cancer",[102],"2020-03-31","2015-01-01",[1551,1552],"Endometrial Cancer","Fertility",[1496],{"intervention":1555,"totalTrials":329,"cells":1556},"Yunnan Baiyao",{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1561,"PHASE3":1563,"PHASE4":1565,"NA":1583},{"trials":1558,"activeCount":109},[],{"trials":1560,"activeCount":109},[],{"trials":1562,"activeCount":109},[],{"trials":1564,"activeCount":109},[],{"trials":1566,"activeCount":746,"soonestReadout":1103},[1567,1574],{"nctId":1568,"briefTitle":1569,"status":121,"phases":1570,"primaryCompletion":741,"completion":1054,"start":71,"enrollment":376,"conditions":1571,"interventions":1573},"NCT06197412","Multi-center Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot Ulcer",[101],[1572],"Diabetic Foot Ulcer Treatment",[1555],{"nctId":1575,"briefTitle":1576,"status":121,"phases":1577,"primaryCompletion":1103,"completion":1578,"start":71,"enrollment":376,"conditions":1579,"interventions":1582},"NCT06062576","Clinical Observation and Mechanism Study of Yunnan Baiyao in Different Stages of Diabetic Foot",[101],"2025-06-30",[1580,1581],"Diabetic Foot","Therapeutics",[1555],{"trials":1584,"activeCount":109},[1585],{"nctId":1586,"briefTitle":1587,"status":569,"phases":1588,"primaryCompletion":81,"completion":1589,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1594},"NCT05765747","Effectiveness of Yunnan Baiyao in Improving Fracture Pain",[102],"2024-06-01","2023-04-01",58,[1593],"Distal Radius Fracture",[1555,1595],"Celecoxib 200mg",{"intervention":131,"totalTrials":746,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1622},{"trials":1599,"activeCount":109},[],{"trials":1601,"activeCount":109},[],{"trials":1603,"activeCount":109},[],{"trials":1605,"activeCount":109},[],{"trials":1607,"activeCount":708,"soonestReadout":123},[1608,1612],{"nctId":119,"briefTitle":120,"status":121,"phases":1609,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":1610,"interventions":1611},[101],[128,46,25,40,129],[25,40,131],{"nctId":1613,"briefTitle":1614,"status":135,"phases":1615,"primaryCompletion":1616,"completion":1617,"start":316,"enrollment":1618,"conditions":1619,"interventions":1620},"NCT05718024","Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients",[101],"2025-04-22","2025-05-23",174,[390,430,25,40,185],[131,1621],"Routine sedation and analgesia",{"trials":1623,"activeCount":109},[],{"intervention":1182,"totalTrials":746,"cells":1625},{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1651},{"trials":1627,"activeCount":109},[],{"trials":1629,"activeCount":109},[],{"trials":1631,"activeCount":109},[],{"trials":1633,"activeCount":109},[],{"trials":1635,"activeCount":708,"soonestReadout":1019},[1636,1647],{"nctId":1637,"briefTitle":1638,"status":135,"phases":1639,"primaryCompletion":857,"completion":1640,"start":1641,"enrollment":1642,"conditions":1643,"interventions":1645},"NCT05294666","Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment",[101],"2021-07-01","2020-04-01",89,[1644],"Graft Versus Host Disease in Eye",[1182,1646],"tacrolimus",{"nctId":1172,"briefTitle":1173,"status":456,"phases":1648,"primaryCompletion":1019,"completion":1175,"start":1176,"enrollment":180,"conditions":1649,"interventions":1650},[101],[1178],[1180,1090,1181,1182],{"trials":1652,"activeCount":109},[],{"intervention":1463,"totalTrials":746,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1673},{"trials":1656,"activeCount":109},[],{"trials":1658,"activeCount":109},[],{"trials":1660,"activeCount":109},[],{"trials":1662,"activeCount":109},[],{"trials":1664,"activeCount":708,"soonestReadout":123},[1665,1669],{"nctId":1450,"briefTitle":1451,"status":200,"phases":1666,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1667,"interventions":1668},[101],[1458,1459,1460,1461],[1463,1464,1465,1427],{"nctId":1476,"briefTitle":1477,"status":121,"phases":1670,"primaryCompletion":123,"completion":124,"start":1479,"enrollment":1480,"conditions":1671,"interventions":1672},[101],[1458,1459,1460,1461],[1463,1464,1465,1427],{"trials":1674,"activeCount":109},[],{"intervention":1464,"totalTrials":746,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1685,"NA":1695},{"trials":1678,"activeCount":109},[],{"trials":1680,"activeCount":109},[],{"trials":1682,"activeCount":109},[],{"trials":1684,"activeCount":109},[],{"trials":1686,"activeCount":708,"soonestReadout":123},[1687,1691],{"nctId":1450,"briefTitle":1451,"status":200,"phases":1688,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1689,"interventions":1690},[101],[1458,1459,1460,1461],[1463,1464,1465,1427],{"nctId":1476,"briefTitle":1477,"status":121,"phases":1692,"primaryCompletion":123,"completion":124,"start":1479,"enrollment":1480,"conditions":1693,"interventions":1694},[101],[1458,1459,1460,1461],[1463,1464,1465,1427],{"trials":1696,"activeCount":109},[],{"intervention":1465,"totalTrials":746,"cells":1698},{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1703,"PHASE3":1705,"PHASE4":1707,"NA":1717},{"trials":1700,"activeCount":109},[],{"trials":1702,"activeCount":109},[],{"trials":1704,"activeCount":109},[],{"trials":1706,"activeCount":109},[],{"trials":1708,"activeCount":708,"soonestReadout":123},[1709,1713],{"nctId":1450,"briefTitle":1451,"status":200,"phases":1710,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1456,"conditions":1711,"interventions":1712},[101],[1458,1459,1460,1461],[1463,1464,1465,1427],{"nctId":1476,"briefTitle":1477,"status":121,"phases":1714,"primaryCompletion":123,"completion":124,"start":1479,"enrollment":1480,"conditions":1715,"interventions":1716},[101],[1458,1459,1460,1461],[1463,1464,1465,1427],{"trials":1718,"activeCount":109},[],{"intervention":1720,"totalTrials":746,"cells":1721},"Cholecalciferol",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1738,"PHASE4":1740,"NA":1750},{"trials":1723,"activeCount":109},[],{"trials":1725,"activeCount":109},[],{"trials":1727,"activeCount":109},[1728],{"nctId":1729,"briefTitle":1730,"status":135,"phases":1731,"primaryCompletion":426,"completion":1732,"start":1733,"enrollment":140,"conditions":1734,"interventions":1737},"NCT03264625","The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis",[99],"2021-07-30","2017-09-30",[1735,1736],"Peritoneal Dialysis-associated Peritonitis","Vitamin D Deficiency",[1720],{"trials":1739,"activeCount":109},[],{"trials":1741,"activeCount":708,"soonestReadout":1054},[1742],{"nctId":1743,"briefTitle":1744,"status":121,"phases":1745,"primaryCompletion":1054,"completion":1746,"start":165,"enrollment":1747,"conditions":1748,"interventions":1749},"NCT05860270","Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis",[101],"2026-05-31",176,[1735,1736],[1720],{"trials":1751,"activeCount":109},[],{"intervention":1753,"totalTrials":746,"cells":1754},"methylcobalamin",{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1771,"PHASE4":1773,"NA":1785},{"trials":1756,"activeCount":109},[],{"trials":1758,"activeCount":109},[],{"trials":1760,"activeCount":109},[1761],{"nctId":1762,"briefTitle":1763,"status":569,"phases":1764,"primaryCompletion":1765,"completion":1163,"start":1766,"enrollment":1767,"conditions":1768,"interventions":1770},"NCT04372316","A Randomized Controlled Trial of Mecobalamin Injection and Tablet Treatment Efficacy on Mild to Moderate Diabetic Peripheral Neuropathy",[99],"2020-07","2017-12-25",30,[1769],"Diabetic Neuropathies",[1753],{"trials":1772,"activeCount":109},[],{"trials":1774,"activeCount":708,"soonestReadout":1779},[1775],{"nctId":1776,"briefTitle":1777,"status":456,"phases":1778,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1527,"conditions":1781,"interventions":1782},"NCT07344974","Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity",[101],"2027-02-01","2026-02-01",[31],[1783,1784],"Traditional Chinese medicine (TCM) hand and foot baths","Methylcobalamin",{"trials":1786,"activeCount":109},[],{"intervention":1788,"totalTrials":708,"cells":1789},"Tamsulosin 0.2mg",{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1796,"PHASE4":1798,"NA":1810},{"trials":1791,"activeCount":109},[],{"trials":1793,"activeCount":109},[],{"trials":1795,"activeCount":109},[],{"trials":1797,"activeCount":109},[],{"trials":1799,"activeCount":708,"soonestReadout":1804},[1800],{"nctId":1801,"briefTitle":1802,"status":456,"phases":1803,"primaryCompletion":1804,"completion":1804,"start":1780,"enrollment":1805,"conditions":1806,"interventions":1809},"NCT07276919","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy",[101],"2028-01-01",1844,[1807,1808],"Acute Urinary Retention","LUTS(Lower Urinary Tract Symptoms)",[1788],{"trials":1811,"activeCount":109},[],{"intervention":1813,"totalTrials":708,"cells":1814},"allogeneic platelet plasma",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1838},{"trials":1816,"activeCount":109},[],{"trials":1818,"activeCount":109},[],{"trials":1820,"activeCount":109},[],{"trials":1822,"activeCount":109},[],{"trials":1824,"activeCount":708,"soonestReadout":906},[1825],{"nctId":1826,"briefTitle":1827,"status":456,"phases":1828,"primaryCompletion":906,"completion":1829,"start":805,"enrollment":1830,"conditions":1831,"interventions":1836},"NCT07020559","Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial",[101],"2028-05",56,[1832,1833,1834,1835],"Diabetic Wounds","Platelet Rich Plasma","Allogeneic Blood Transfusions","Renal Dysfunction",[1813,1837],"autologous platelet plasma",{"trials":1839,"activeCount":109},[],{"intervention":1837,"totalTrials":708,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1856},{"trials":1843,"activeCount":109},[],{"trials":1845,"activeCount":109},[],{"trials":1847,"activeCount":109},[],{"trials":1849,"activeCount":109},[],{"trials":1851,"activeCount":708,"soonestReadout":906},[1852],{"nctId":1826,"briefTitle":1827,"status":456,"phases":1853,"primaryCompletion":906,"completion":1829,"start":805,"enrollment":1830,"conditions":1854,"interventions":1855},[101],[1832,1833,1834,1835],[1813,1837],{"trials":1857,"activeCount":109},[],{"intervention":1448,"totalTrials":708,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1866,"PHASE4":1868,"NA":1874},{"trials":1861,"activeCount":109},[],{"trials":1863,"activeCount":109},[],{"trials":1865,"activeCount":109},[],{"trials":1867,"activeCount":109},[],{"trials":1869,"activeCount":708,"soonestReadout":438},[1870],{"nctId":1441,"briefTitle":1442,"status":121,"phases":1871,"primaryCompletion":438,"completion":438,"start":1444,"enrollment":1445,"conditions":1872,"interventions":1873},[101],[1220],[1448,1427],{"trials":1875,"activeCount":109},[],{"intervention":1877,"totalTrials":708,"cells":1878},"Combination therapy",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1885,"PHASE4":1887,"NA":1899},{"trials":1880,"activeCount":109},[],{"trials":1882,"activeCount":109},[],{"trials":1884,"activeCount":109},[],{"trials":1886,"activeCount":109},[],{"trials":1888,"activeCount":708,"soonestReadout":1268},[1889],{"nctId":1890,"briefTitle":1891,"status":456,"phases":1892,"primaryCompletion":1268,"completion":726,"start":1893,"enrollment":1894,"conditions":1895,"interventions":1897},"NCT06417489","Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients",[101],"2024-05-31",160,[1896],"Type 2 Diabetes",[1877,1898],"Sequential treatment group",{"trials":1900,"activeCount":109},[],{"intervention":1898,"totalTrials":708,"cells":1902},{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1917},{"trials":1904,"activeCount":109},[],{"trials":1906,"activeCount":109},[],{"trials":1908,"activeCount":109},[],{"trials":1910,"activeCount":109},[],{"trials":1912,"activeCount":708,"soonestReadout":1268},[1913],{"nctId":1890,"briefTitle":1891,"status":456,"phases":1914,"primaryCompletion":1268,"completion":726,"start":1893,"enrollment":1894,"conditions":1915,"interventions":1916},[101],[1896],[1877,1898],{"trials":1918,"activeCount":109},[],{"intervention":1920,"totalTrials":708,"cells":1921},"Doxorubicin+Ifosfamide+Anlotinib",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1944},{"trials":1923,"activeCount":109},[],{"trials":1925,"activeCount":109},[],{"trials":1927,"activeCount":109},[],{"trials":1929,"activeCount":109},[],{"trials":1931,"activeCount":708,"soonestReadout":1937},[1932],{"nctId":1933,"briefTitle":1934,"status":1935,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":1941,"interventions":1943},"NCT05844813","Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma","ENROLLING_BY_INVITATION",[101],"2025-11-01","2027-11-01","2022-11-01",102,[1942],"Retroperitoneal Sarcoma",[1920],{"trials":1945,"activeCount":109},[],{"intervention":1947,"totalTrials":708,"cells":1948},"Metronidazole vaginal suppositories",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1969},{"trials":1950,"activeCount":109},[],{"trials":1952,"activeCount":109},[],{"trials":1954,"activeCount":109},[],{"trials":1956,"activeCount":109},[],{"trials":1958,"activeCount":708,"soonestReadout":1963},[1959],{"nctId":1960,"briefTitle":1961,"status":121,"phases":1962,"primaryCompletion":1963,"completion":1963,"start":1964,"enrollment":1480,"conditions":1965,"interventions":1967},"NCT04771728","A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis",[101],"2026-12-01","2020-02-01",[1966],"Bacterial Vaginosis",[1947,1968],"Metronidazole vaginal suppositories and Probiotics",{"trials":1970,"activeCount":109},[],{"intervention":1968,"totalTrials":708,"cells":1972},{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1977,"PHASE3":1979,"PHASE4":1981,"NA":1987},{"trials":1974,"activeCount":109},[],{"trials":1976,"activeCount":109},[],{"trials":1978,"activeCount":109},[],{"trials":1980,"activeCount":109},[],{"trials":1982,"activeCount":708,"soonestReadout":1963},[1983],{"nctId":1960,"briefTitle":1961,"status":121,"phases":1984,"primaryCompletion":1963,"completion":1963,"start":1964,"enrollment":1480,"conditions":1985,"interventions":1986},[101],[1966],[1947,1968],{"trials":1988,"activeCount":109},[],{"intervention":1990,"totalTrials":708,"cells":1991},"FB1006",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":1998,"PHASE4":2000,"NA":2012},{"trials":1993,"activeCount":109},[],{"trials":1995,"activeCount":109},[],{"trials":1997,"activeCount":109},[],{"trials":1999,"activeCount":109},[],{"trials":2001,"activeCount":708,"soonestReadout":2006},[2002],{"nctId":2003,"briefTitle":2004,"status":121,"phases":2005,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":2008,"conditions":2009,"interventions":2011},"NCT05923905","Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients",[101],"2027-09-30","2023-01-18",64,[2010],"Sporadic and Familial Amyotrophic Lateral Sclerosis",[1990],{"trials":2013,"activeCount":109},[],{"intervention":1520,"totalTrials":708,"cells":2015},{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2024,"NA":2030},{"trials":2017,"activeCount":109},[],{"trials":2019,"activeCount":109},[],{"trials":2021,"activeCount":109},[],{"trials":2023,"activeCount":109},[],{"trials":2025,"activeCount":708,"soonestReadout":1512},[2026],{"nctId":1509,"briefTitle":1510,"status":121,"phases":2027,"primaryCompletion":1512,"completion":1020,"start":1513,"enrollment":1514,"conditions":2028,"interventions":2029},[101],[1516,1517,1518],[1520,1496],{"trials":2031,"activeCount":109},[],{"intervention":2033,"totalTrials":708,"cells":2034},"Nanocrystal Megestrol Acetate in Combination with First-Line Standard Immuno-Chemotherapy Regimen",{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2041,"PHASE4":2043,"NA":2057},{"trials":2036,"activeCount":109},[],{"trials":2038,"activeCount":109},[],{"trials":2040,"activeCount":109},[],{"trials":2042,"activeCount":109},[],{"trials":2044,"activeCount":708,"soonestReadout":2049},[2045],{"nctId":2046,"briefTitle":2047,"status":456,"phases":2048,"primaryCompletion":2049,"completion":2050,"start":2051,"enrollment":2052,"conditions":2053,"interventions":2055},"NCT06963593","Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy",[101],"2027-06-30","2027-08-31","2025-06-01",220,[2054],"Advanced Gastroesophageal Cancer",[2033,2056],"First-Line Standard Immuno-Chemotherapy Regimen",{"trials":2058,"activeCount":109},[],{"intervention":2056,"totalTrials":708,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2067,"PHASE4":2069,"NA":2075},{"trials":2062,"activeCount":109},[],{"trials":2064,"activeCount":109},[],{"trials":2066,"activeCount":109},[],{"trials":2068,"activeCount":109},[],{"trials":2070,"activeCount":708,"soonestReadout":2049},[2071],{"nctId":2046,"briefTitle":2047,"status":456,"phases":2072,"primaryCompletion":2049,"completion":2050,"start":2051,"enrollment":2052,"conditions":2073,"interventions":2074},[101],[2054],[2033,2056],{"trials":2076,"activeCount":109},[],{"intervention":2078,"totalTrials":708,"cells":2079},"Brivudine",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2086,"PHASE4":2088,"NA":2099},{"trials":2081,"activeCount":109},[],{"trials":2083,"activeCount":109},[],{"trials":2085,"activeCount":109},[],{"trials":2087,"activeCount":109},[],{"trials":2089,"activeCount":708,"soonestReadout":726},[2090],{"nctId":2091,"briefTitle":2092,"status":121,"phases":2093,"primaryCompletion":726,"completion":1019,"start":2094,"enrollment":1480,"conditions":2095,"interventions":2097},"NCT07099157","Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster",[101],"2025-08-25",[2096],"Herpes Zoster",[2078,2098],"Famciclovir",{"trials":2100,"activeCount":109},[],{"intervention":2098,"totalTrials":708,"cells":2102},{"EARLY_PHASE1":2103,"PHASE1":2105,"PHASE2":2107,"PHASE3":2109,"PHASE4":2111,"NA":2117},{"trials":2104,"activeCount":109},[],{"trials":2106,"activeCount":109},[],{"trials":2108,"activeCount":109},[],{"trials":2110,"activeCount":109},[],{"trials":2112,"activeCount":708,"soonestReadout":726},[2113],{"nctId":2091,"briefTitle":2092,"status":121,"phases":2114,"primaryCompletion":726,"completion":1019,"start":2094,"enrollment":1480,"conditions":2115,"interventions":2116},[101],[2096],[2078,2098],{"trials":2118,"activeCount":109},[],{"intervention":2120,"totalTrials":708,"cells":2121},"Light anesthesia",{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2142},{"trials":2123,"activeCount":109},[],{"trials":2125,"activeCount":109},[],{"trials":2127,"activeCount":109},[],{"trials":2129,"activeCount":109},[],{"trials":2131,"activeCount":708,"soonestReadout":2136},[2132],{"nctId":2133,"briefTitle":2134,"status":456,"phases":2135,"primaryCompletion":2136,"completion":2136,"start":805,"enrollment":168,"conditions":2137,"interventions":2140},"NCT07479719","Anesthesia Maintenance With Target-controlled Infusion of Propofol and Remifentanil at Fixed Ratio",[101],"2027-01",[182,46,2138,2139,808],"Depth of Anesthesia","Total Intravenous Anesthesia",[2120,2141],"Deep anesthesia",{"trials":2143,"activeCount":109},[],{"intervention":2141,"totalTrials":708,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2152,"PHASE4":2154,"NA":2160},{"trials":2147,"activeCount":109},[],{"trials":2149,"activeCount":109},[],{"trials":2151,"activeCount":109},[],{"trials":2153,"activeCount":109},[],{"trials":2155,"activeCount":708,"soonestReadout":2136},[2156],{"nctId":2133,"briefTitle":2134,"status":456,"phases":2157,"primaryCompletion":2136,"completion":2136,"start":805,"enrollment":168,"conditions":2158,"interventions":2159},[101],[182,46,2138,2139,808],[2120,2141],{"trials":2161,"activeCount":109},[],{"intervention":2163,"totalTrials":708,"cells":2164},"Telitacicept",{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2171,"PHASE4":2173,"NA":2184},{"trials":2166,"activeCount":109},[],{"trials":2168,"activeCount":109},[],{"trials":2170,"activeCount":109},[],{"trials":2172,"activeCount":109},[],{"trials":2174,"activeCount":708,"soonestReadout":2179},[2175],{"nctId":2176,"briefTitle":2177,"status":121,"phases":2178,"primaryCompletion":2179,"completion":2180,"start":2181,"enrollment":47,"conditions":2182,"interventions":2183},"NCT06546540","The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis",[101],"2025-12-10","2026-03-30","2024-06-08",[962],[2163],{"trials":2185,"activeCount":109},[],{"intervention":2187,"totalTrials":708,"cells":2188},"Realgar-Indigo Naturalis Formulation Combined with Anlotinib",{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2195,"PHASE4":2197,"NA":2207},{"trials":2190,"activeCount":109},[],{"trials":2192,"activeCount":109},[],{"trials":2194,"activeCount":109},[],{"trials":2196,"activeCount":109},[],{"trials":2198,"activeCount":708,"soonestReadout":1002},[2199],{"nctId":2200,"briefTitle":2201,"status":456,"phases":2202,"primaryCompletion":1002,"completion":1020,"start":2203,"enrollment":1767,"conditions":2204,"interventions":2206},"NCT07075250","Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study",[101],"2025-09-01",[2205],"Platinum-resistant Ovarian Cancer (PROC)",[2187],{"trials":2208,"activeCount":109},[],{"intervention":1075,"totalTrials":708,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2215,"PHASE3":2217,"PHASE4":2219,"NA":2225},{"trials":2212,"activeCount":109},[],{"trials":2214,"activeCount":109},[],{"trials":2216,"activeCount":109},[],{"trials":2218,"activeCount":109},[],{"trials":2220,"activeCount":708,"soonestReadout":1069},[2221],{"nctId":1066,"briefTitle":1067,"status":456,"phases":2222,"primaryCompletion":1069,"completion":1069,"start":638,"enrollment":1070,"conditions":2223,"interventions":2224},[101],[1072,1073],[1007,1075],{"trials":2226,"activeCount":109},[],{"intervention":309,"totalTrials":708,"cells":2228},{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2235,"PHASE4":2237,"NA":2243},{"trials":2230,"activeCount":109},[],{"trials":2232,"activeCount":109},[],{"trials":2234,"activeCount":109},[],{"trials":2236,"activeCount":109},[],{"trials":2238,"activeCount":708,"soonestReadout":124},[2239],{"nctId":299,"briefTitle":300,"status":121,"phases":2240,"primaryCompletion":124,"completion":302,"start":303,"enrollment":304,"conditions":2241,"interventions":2242},[101],[306,307,25,40],[236,25,40,309],{"trials":2244,"activeCount":109},[],{"intervention":1180,"totalTrials":708,"cells":2246},{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2253,"PHASE4":2255,"NA":2261},{"trials":2248,"activeCount":109},[],{"trials":2250,"activeCount":109},[],{"trials":2252,"activeCount":109},[],{"trials":2254,"activeCount":109},[],{"trials":2256,"activeCount":708,"soonestReadout":1019},[2257],{"nctId":1172,"briefTitle":1173,"status":456,"phases":2258,"primaryCompletion":1019,"completion":1175,"start":1176,"enrollment":180,"conditions":2259,"interventions":2260},[101],[1178],[1180,1090,1181,1182],{"trials":2262,"activeCount":109},[],{"intervention":1181,"totalTrials":708,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2273,"NA":2279},{"trials":2266,"activeCount":109},[],{"trials":2268,"activeCount":109},[],{"trials":2270,"activeCount":109},[],{"trials":2272,"activeCount":109},[],{"trials":2274,"activeCount":708,"soonestReadout":1019},[2275],{"nctId":1172,"briefTitle":1173,"status":456,"phases":2276,"primaryCompletion":1019,"completion":1175,"start":1176,"enrollment":180,"conditions":2277,"interventions":2278},[101],[1178],[1180,1090,1181,1182],{"trials":2280,"activeCount":109},[],{"intervention":810,"totalTrials":708,"cells":2282},{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2289,"PHASE4":2291,"NA":2297},{"trials":2284,"activeCount":109},[],{"trials":2286,"activeCount":109},[],{"trials":2288,"activeCount":109},[],{"trials":2290,"activeCount":109},[],{"trials":2292,"activeCount":708,"soonestReadout":438},[2293],{"nctId":802,"briefTitle":803,"status":456,"phases":2294,"primaryCompletion":438,"completion":438,"start":805,"enrollment":574,"conditions":2295,"interventions":2296},[101],[182,807,808,209,40],[810,811,812,236],{"trials":2298,"activeCount":109},[],{"intervention":811,"totalTrials":708,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2307,"PHASE4":2309,"NA":2315},{"trials":2302,"activeCount":109},[],{"trials":2304,"activeCount":109},[],{"trials":2306,"activeCount":109},[],{"trials":2308,"activeCount":109},[],{"trials":2310,"activeCount":708,"soonestReadout":438},[2311],{"nctId":802,"briefTitle":803,"status":456,"phases":2312,"primaryCompletion":438,"completion":438,"start":805,"enrollment":574,"conditions":2313,"interventions":2314},[101],[182,807,808,209,40],[810,811,812,236],{"trials":2316,"activeCount":109},[],{"intervention":812,"totalTrials":708,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2325,"PHASE4":2327,"NA":2333},{"trials":2320,"activeCount":109},[],{"trials":2322,"activeCount":109},[],{"trials":2324,"activeCount":109},[],{"trials":2326,"activeCount":109},[],{"trials":2328,"activeCount":708,"soonestReadout":438},[2329],{"nctId":802,"briefTitle":803,"status":456,"phases":2330,"primaryCompletion":438,"completion":438,"start":805,"enrollment":574,"conditions":2331,"interventions":2332},[101],[182,807,808,209,40],[810,811,812,236],{"trials":2334,"activeCount":109},[],{"intervention":1783,"totalTrials":708,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2345,"NA":2351},{"trials":2338,"activeCount":109},[],{"trials":2340,"activeCount":109},[],{"trials":2342,"activeCount":109},[],{"trials":2344,"activeCount":109},[],{"trials":2346,"activeCount":708,"soonestReadout":1779},[2347],{"nctId":1776,"briefTitle":1777,"status":456,"phases":2348,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1527,"conditions":2349,"interventions":2350},[101],[31],[1783,1784],{"trials":2352,"activeCount":109},[],{"intervention":2354,"totalTrials":708,"cells":2355},"Bivalirudin",{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2362,"PHASE4":2364,"NA":2376},{"trials":2357,"activeCount":109},[],{"trials":2359,"activeCount":109},[],{"trials":2361,"activeCount":109},[],{"trials":2363,"activeCount":109},[],{"trials":2365,"activeCount":708,"soonestReadout":2370},[2366],{"nctId":2367,"briefTitle":2368,"status":121,"phases":2369,"primaryCompletion":2370,"completion":2371,"start":572,"enrollment":670,"conditions":2372,"interventions":2374},"NCT05984537","A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.",[101],"2025-12-01","2026-01-04",[2373],"Coronary Microvascular Dysfunction",[2354,2375],"standard heparin",{"trials":2377,"activeCount":109},[],{"intervention":2375,"totalTrials":708,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2388,"NA":2394},{"trials":2381,"activeCount":109},[],{"trials":2383,"activeCount":109},[],{"trials":2385,"activeCount":109},[],{"trials":2387,"activeCount":109},[],{"trials":2389,"activeCount":708,"soonestReadout":2370},[2390],{"nctId":2367,"briefTitle":2368,"status":121,"phases":2391,"primaryCompletion":2370,"completion":2371,"start":572,"enrollment":670,"conditions":2392,"interventions":2393},[101],[2373],[2354,2375],{"trials":2395,"activeCount":109},[],{"intervention":2397,"totalTrials":708,"cells":2398},"SURGICEL® Powder",{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2405,"PHASE4":2407,"NA":2418},{"trials":2400,"activeCount":109},[],{"trials":2402,"activeCount":109},[],{"trials":2404,"activeCount":109},[],{"trials":2406,"activeCount":109},[],{"trials":2408,"activeCount":708,"soonestReadout":2413},[2409],{"nctId":2410,"briefTitle":2411,"status":121,"phases":2412,"primaryCompletion":2413,"completion":412,"start":919,"enrollment":2414,"conditions":2415,"interventions":2417},"NCT06608992","Evaluation of the Effect of SURGICEL® Powder in TKA",[101],"2025-08",112,[2416],"Knee Osteoarthritis",[2397],{"trials":2419,"activeCount":109},[],{"intervention":2421,"totalTrials":708,"cells":2422},"Intranasal dexmedetomidine-esketamine",{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2429,"PHASE4":2431,"NA":2445},{"trials":2424,"activeCount":109},[],{"trials":2426,"activeCount":109},[],{"trials":2428,"activeCount":109},[],{"trials":2430,"activeCount":109},[],{"trials":2432,"activeCount":708,"soonestReadout":2437},[2433],{"nctId":2434,"briefTitle":2435,"status":121,"phases":2436,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":1894,"conditions":2439,"interventions":2443},"NCT07479602","Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients",[101],"2027-02","2026-04-07",[2440,2441,2442,25,40,1472],"Adenotonsillectomy","Children","Intranasal Administration",[2421,2444],"Intranasal placebo",{"trials":2446,"activeCount":109},[],{"intervention":2444,"totalTrials":708,"cells":2448},{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2457,"NA":2463},{"trials":2450,"activeCount":109},[],{"trials":2452,"activeCount":109},[],{"trials":2454,"activeCount":109},[],{"trials":2456,"activeCount":109},[],{"trials":2458,"activeCount":708,"soonestReadout":2437},[2459],{"nctId":2434,"briefTitle":2435,"status":121,"phases":2460,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":1894,"conditions":2461,"interventions":2462},[101],[2440,2441,2442,25,40,1472],[2421,2444],{"trials":2464,"activeCount":109},[],{"intervention":2466,"totalTrials":329,"cells":2467},"Tetrandrine",{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2496},{"trials":2469,"activeCount":109},[],{"trials":2471,"activeCount":109},[],{"trials":2473,"activeCount":109},[],{"trials":2475,"activeCount":109},[],{"trials":2477,"activeCount":708,"soonestReadout":2482},[2478,2488],{"nctId":2479,"briefTitle":2480,"status":121,"phases":2481,"primaryCompletion":2482,"completion":772,"start":2483,"enrollment":376,"conditions":2484,"interventions":2487},"NCT07319598","A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease",[101],"2026-10-15","2023-11-02",[2485,2486],"Interstitial Lung Disease (ILD)","Connective Tissue Disease-associated Interstitial Lung Disease",[2466],{"nctId":2489,"briefTitle":2490,"status":435,"phases":2491,"primaryCompletion":2492,"completion":2492,"start":81,"enrollment":109,"conditions":2493,"interventions":2495},"NCT05697029","Tetrandrine Tablets Used in Hospitalized Adults With COVID-19",[101],"2025-12-12",[2494],"COVID-19",[2466],{"trials":2497,"activeCount":109},[2498],{"nctId":2499,"briefTitle":2500,"status":569,"phases":2501,"primaryCompletion":2502,"completion":2503,"start":2504,"enrollment":1165,"conditions":2505,"interventions":2507},"NCT05245448","Tetrandrine in the Treatment of Rheumatoid Arthritis",[102],"2023-10-30","2024-03-31","2022-02-22",[2506],"Rheumatoid Arthritis",[2466],{"intervention":72,"totalTrials":2509,"cells":2510},12,{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2605,"PHASE4":2618,"NA":2620},{"trials":2512,"activeCount":109},[],{"trials":2514,"activeCount":109},[],{"trials":2516,"activeCount":329,"soonestReadout":741},[2517,2526,2538,2551,2555,2564,2573,2583,2593],{"nctId":2518,"briefTitle":2519,"status":569,"phases":2520,"primaryCompletion":1215,"completion":1215,"start":2521,"enrollment":2522,"conditions":2523,"interventions":2525},"NCT04303130","Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC",[99],"2019-12-31",52,[2524],"Non-small Cell Lung Cancer",[72],{"nctId":2527,"briefTitle":2528,"status":569,"phases":2529,"primaryCompletion":1138,"completion":1215,"start":2530,"enrollment":140,"conditions":2531,"interventions":2535},"NCT04351308","Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma",[99],"2020-05-01",[2532,1327,2533,2534],"Osteosarcoma","Chemotherapy Effect","Toxicity, Drug",[2536,2537,72],"MAPI chemotherapy","Apatinib Mesylate",{"nctId":2539,"briefTitle":2540,"status":435,"phases":2541,"primaryCompletion":2542,"completion":1113,"start":2543,"enrollment":109,"conditions":2544,"interventions":2548},"NCT04044378","Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma",[98,99],"2021-09-30","2019-08-15",[2545,2546,2547],"Effect of Drugs","Progression","Pediatric Cancer",[2549,2550,72],"Famitinib","Ifosfamide",{"nctId":1016,"briefTitle":1017,"status":456,"phases":2552,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":2553,"interventions":2554},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":2556,"briefTitle":2557,"status":1935,"phases":2558,"primaryCompletion":1938,"completion":1938,"start":1937,"enrollment":536,"conditions":2559,"interventions":2560},"NCT07312578","Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma",[99],[1250],[2561,2562,2563,1028],"Nimotuzumab","camrelizumab","Albumin paclitaxel",{"nctId":2565,"briefTitle":2566,"status":569,"phases":2567,"primaryCompletion":2568,"completion":2568,"start":2569,"enrollment":991,"conditions":2570,"interventions":2572},"NCT04239170","Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma",[99],"2022-12","2020-01",[2571],"Hodgkin Lymphoma",[72],{"nctId":2574,"briefTitle":2575,"status":569,"phases":2576,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":140,"conditions":2579,"interventions":2581},"NCT05051865","To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma",[99],"2024-08-30","2021-10-09",[2580],"Melanoma",[2562,2582],"SHR1020",{"nctId":2584,"briefTitle":2585,"status":569,"phases":2586,"primaryCompletion":2587,"completion":81,"start":2588,"enrollment":2589,"conditions":2590,"interventions":2592},"NCT04479527","Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma",[99],"2023-08","2021-04",34,[2591],"Hepatocellular Carcinoma",[72],{"nctId":2594,"briefTitle":2595,"status":121,"phases":2596,"primaryCompletion":741,"completion":726,"start":2597,"enrollment":140,"conditions":2598,"interventions":2604},"NCT05512481","Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma",[99],"2022-09-13",[2580,2599,2600,2601,72,2602,2603],"Acral Melanoma","Temozolomide","Apatinib","Neoadjuvant","Pathological Response",[72],{"trials":2606,"activeCount":708,"soonestReadout":2611},[2607],{"nctId":2608,"briefTitle":2609,"status":121,"phases":2610,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":1480,"conditions":2614,"interventions":2615},"NCT05789043","Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma",[100],"2026-08-15","2027-02-15","2023-03-21",[2599],[2616,2617,2562],"camrelizumab+apatinib+TMZ","camrelizumab+apatinib",{"trials":2619,"activeCount":109},[],{"trials":2621,"activeCount":708,"soonestReadout":71},[2622,2629],{"nctId":69,"briefTitle":70,"status":456,"phases":2623,"primaryCompletion":71,"completion":1963,"start":2624,"enrollment":2625,"conditions":2626,"interventions":2628},[],"2020-12-01",1030,[2627],"Esophageal Cancer",[72],{"nctId":2630,"briefTitle":2631,"status":569,"phases":2632,"primaryCompletion":1403,"completion":2633,"start":855,"enrollment":47,"conditions":2634,"interventions":2636},"NCT05600998","A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma",[102],"2024-02-28",[2635],"Ovarian Clear Cell Carcinoma",[72],{"intervention":2638,"totalTrials":553,"cells":2639},"All-trans retinoic acid",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2694,"PHASE4":2715,"NA":2717},{"trials":2641,"activeCount":109},[],{"trials":2643,"activeCount":109},[],{"trials":2645,"activeCount":746,"soonestReadout":2673},[2646,2658,2669,2686],{"nctId":2647,"briefTitle":2648,"status":135,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":2653,"conditions":2654,"interventions":2656},"NCT01667263","The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia",[99],"2016-07-01","2017-02-01","2012-06-01",130,[2655],"Autoimmune Thrombocytopenia",[2638,2657],"Danazol",{"nctId":2659,"briefTitle":2660,"status":569,"phases":2661,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":2666,"interventions":2667},"NCT03304288","The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2021-01-15","2021-02-28","2017-10-11",168,[34],[2668,2638],"Rituximab",{"nctId":2670,"briefTitle":2671,"status":121,"phases":2672,"primaryCompletion":2673,"completion":1019,"start":2674,"enrollment":2052,"conditions":2675,"interventions":2684},"NCT07586826","Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors",[99],"2027-10-31","2025-12-22",[2676,2677,2678,2679,31,43,2680,2681,2682,2683],"Persistent Isolated Chemotherapy-Induced Thrombocytopenia","Chemotherapy-Induced Thrombocytopenia","Gynecologic Cancers","Ovarian Cancer","Non-Small Cell Lung Cancer","Cervical Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer",[2685,2638],"Romiplostim N01",{"nctId":2687,"briefTitle":2688,"status":121,"phases":2689,"primaryCompletion":2673,"completion":1019,"start":2674,"enrollment":2052,"conditions":2690,"interventions":2693},"NCT07586813","Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors",[99],[2676,2677,2691,684,2692],"Gastrointestinal Neoplasms","Colorectal Cancer",[2685,2638],{"trials":2695,"activeCount":708,"soonestReadout":584},[2696,2707],{"nctId":2697,"briefTitle":2698,"status":135,"phases":2699,"primaryCompletion":2700,"completion":2700,"start":2701,"enrollment":846,"conditions":2702,"interventions":2704},"NCT05438875","The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant\u002FRelapse ITP Based on MSC-C5b-9",[100],"2024-11-30","2022-10-12",[2703],"Purpura, Thrombocytopenic, Idiopathic",[2705,2706],"all-trans retinoic acid","Eltrombopag",{"nctId":2708,"briefTitle":2709,"status":456,"phases":2710,"primaryCompletion":584,"completion":2711,"start":1268,"enrollment":2712,"conditions":2713,"interventions":2714},"NCT07597395","ATRA for Management of Primary ITP",[100],"2028-12-30",192,[34],[2705],{"trials":2716,"activeCount":109},[],{"trials":2718,"activeCount":109},[],{"intervention":2720,"totalTrials":746,"cells":2721},"CAR-T",{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2736,"PHASE3":2738,"PHASE4":2751,"NA":2753},{"trials":2723,"activeCount":109},[],{"trials":2725,"activeCount":708,"soonestReadout":2730},[2726],{"nctId":2727,"briefTitle":2728,"status":121,"phases":2729,"primaryCompletion":2730,"completion":1019,"start":2731,"enrollment":2732,"conditions":2733,"interventions":2735},"NCT07143929","To Observe the CD7-targeted CAR-T Therapy in the Treatment of r\u002Fr PTCL",[98],"2026-07-31","2025-08-18",18,[2734],"CD7 Positive R\u002FR PTCL",[2720],{"trials":2737,"activeCount":109},[],{"trials":2739,"activeCount":708,"soonestReadout":584},[2740],{"nctId":2741,"briefTitle":2742,"status":121,"phases":2743,"primaryCompletion":584,"completion":2711,"start":2744,"enrollment":670,"conditions":2745,"interventions":2749},"NCT07441291","CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT",[100],"2025-11-30",[2746,2747,2748],"B ALL","Allogenetic Hematopoietic Stem Cell Transplantation","MRD-positive",[2720,2750],"DLI",{"trials":2752,"activeCount":109},[],{"trials":2754,"activeCount":109},[],{"intervention":2756,"totalTrials":1456,"cells":2757},"Interleukin-2",{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2838,"PHASE4":2857,"NA":2859},{"trials":2759,"activeCount":109},[],{"trials":2761,"activeCount":109},[],{"trials":2763,"activeCount":708,"soonestReadout":2813},[2764,2774,2784,2793,2801,2809,2820,2829],{"nctId":2765,"briefTitle":2766,"status":569,"phases":2767,"primaryCompletion":2768,"completion":1201,"start":2769,"enrollment":2770,"conditions":2771,"interventions":2773},"NCT04062019","Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy",[99],"2021-03-31","2019-08-30",15,[2772],"Inflammatory Myopathy",[2756],{"nctId":2775,"briefTitle":2776,"status":569,"phases":2777,"primaryCompletion":2778,"completion":2779,"start":2780,"enrollment":47,"conditions":2781,"interventions":2782},"NCT04237987","Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy",[99],"2021-01-08","2021-04-08","2020-01-21",[2772],[2756,2783],"ciclosporin and corticosteroid",{"nctId":2785,"briefTitle":2786,"status":135,"phases":2787,"primaryCompletion":2788,"completion":2502,"start":2789,"enrollment":477,"conditions":2790,"interventions":2792},"NCT04077736","Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis",[99],"2023-10-10","2019-11-01",[2791],"Relapsing Polychondritis",[2756],{"nctId":2794,"briefTitle":2795,"status":569,"phases":2796,"primaryCompletion":2797,"completion":1163,"start":1164,"enrollment":670,"conditions":2798,"interventions":2800},"NCT02659657","Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation",[99],"2021-06",[2799],"Acute Graft-versus-host Disease",[2756],{"nctId":2802,"briefTitle":2803,"status":569,"phases":2804,"primaryCompletion":2768,"completion":1201,"start":2805,"enrollment":2770,"conditions":2806,"interventions":2808},"NCT04062006","Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica",[99],"2019-08-31",[2807],"Polymyalgia Rheumatica",[2756],{"nctId":2810,"briefTitle":2811,"status":456,"phases":2812,"primaryCompletion":2813,"completion":637,"start":2814,"enrollment":376,"conditions":2815,"interventions":2818},"NCT06971913","Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia",[99],"2025-09-30","2025-05-20",[2816,2817],"SLE (Systemic Lupus)","CMV",[2756,2819],"Ganciclovir",{"nctId":2821,"briefTitle":2822,"status":569,"phases":2823,"primaryCompletion":668,"completion":2824,"start":2825,"enrollment":553,"conditions":2826,"interventions":2828},"NCT02569463","Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）",[98,99],"2018-06","2014-06",[2827],"Macrophage Activation Syndrome",[2756],{"nctId":2830,"briefTitle":2831,"status":135,"phases":2832,"primaryCompletion":2833,"completion":2577,"start":2834,"enrollment":218,"conditions":2835,"interventions":2837},"NCT04077684","Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial",[99],"2024-03-07","2019-09-10",[2836],"Systemic Lupus Erythematosus",[2756],{"trials":2839,"activeCount":708,"soonestReadout":2203},[2840,2848],{"nctId":2841,"briefTitle":2842,"status":569,"phases":2843,"primaryCompletion":818,"completion":818,"start":2844,"enrollment":477,"conditions":2845,"interventions":2846},"NCT05262686","Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus",[100],"2022-04-01",[2836],[2847,2756],"Belimumab",{"nctId":2849,"briefTitle":2850,"status":1935,"phases":2851,"primaryCompletion":2203,"completion":2852,"start":2853,"enrollment":1165,"conditions":2854,"interventions":2856},"NCT05495321","Interleukin-2 on Active Dermatomyositis",[100],"2026-09-01","2022-12-01",[2855],"Dermatomyositis",[2756],{"trials":2858,"activeCount":109},[],{"trials":2860,"activeCount":109},[2861,2870,2878],{"nctId":2862,"briefTitle":2863,"status":135,"phases":2864,"primaryCompletion":2865,"completion":2866,"start":2867,"enrollment":1767,"conditions":2868,"interventions":2869},"NCT02932137","Anti-infection of Low-does IL-2 in SLE",[102],"2016-12-16","2017-08-30","2016-05-05",[2836],[2756],{"nctId":2871,"briefTitle":2872,"status":200,"phases":2873,"primaryCompletion":2874,"completion":2874,"start":1490,"enrollment":1139,"conditions":2875,"interventions":2877},"NCT01517347","Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation",[102],"2015-08",[2876],"Leukemia",[2756],{"nctId":2879,"briefTitle":2880,"status":135,"phases":2881,"primaryCompletion":2882,"completion":2883,"start":2884,"enrollment":32,"conditions":2885,"interventions":2886},"NCT02084238","Low-dose IL-2( Interleukin-2) Treatment in SLE",[102],"2014-11","2015-10","2013-08",[2836],[2756],{"intervention":983,"totalTrials":405,"cells":2888},{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2893,"PHASE3":2895,"PHASE4":2922,"NA":2924},{"trials":2890,"activeCount":109},[],{"trials":2892,"activeCount":109},[],{"trials":2894,"activeCount":109},[],{"trials":2896,"activeCount":746,"soonestReadout":315},[2897,2901,2912],{"nctId":976,"briefTitle":977,"status":121,"phases":2898,"primaryCompletion":315,"completion":438,"start":979,"enrollment":140,"conditions":2899,"interventions":2900},[99,100],[981],[931,983],{"nctId":2902,"briefTitle":2903,"status":121,"phases":2904,"primaryCompletion":725,"completion":2905,"start":2906,"enrollment":2907,"conditions":2908,"interventions":2910},"NCT05921305","Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD",[100],"2026-09-30","2023-08-03",218,[2909],"Acute Graft Versus Host Disease",[2911,983],"MTX",{"nctId":2913,"briefTitle":2914,"status":135,"phases":2915,"primaryCompletion":2916,"completion":1215,"start":2917,"enrollment":2918,"conditions":2919,"interventions":2921},"NCT04960644","MTX and Steroid as First-line Therapy for aGVHD",[100],"2022-07-31","2021-06-25",157,[2920],"Acute GVH Disease",[2911,983],{"trials":2923,"activeCount":109},[],{"trials":2925,"activeCount":109},[2926],{"nctId":2927,"briefTitle":2928,"status":569,"phases":2929,"primaryCompletion":2930,"completion":2930,"start":669,"enrollment":2931,"conditions":2932,"interventions":2936},"NCT03015974","Registry of IgA Nephropathy in Chinese Children",[],"2024-12",1200,[2933,2934,2935],"IgA Nephropathy","Proteinuria in Nephrotic Range","Immunosuppressive Treatment",[983,734,2937,2938,2939],"Mycophenolate mofetil","Dipyridamole","ACE Inhibitor or Angiotensin receptor antagonist",{"intervention":2941,"totalTrials":746,"cells":2942},"Azacitidine",{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2961,"NA":2963},{"trials":2944,"activeCount":109},[],{"trials":2946,"activeCount":109},[],{"trials":2948,"activeCount":109},[],{"trials":2950,"activeCount":708,"soonestReadout":1267},[2951],{"nctId":2952,"briefTitle":2953,"status":456,"phases":2954,"primaryCompletion":1267,"completion":2955,"start":1780,"enrollment":2956,"conditions":2957,"interventions":2959},"NCT07407660","Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax",[100],"2030-02-01",250,[2958],"Acute Myeloid Leukemia",[2960,2941],"Venetoclax",{"trials":2962,"activeCount":109},[],{"trials":2964,"activeCount":708,"soonestReadout":1963},[2965],{"nctId":2966,"briefTitle":2967,"status":121,"phases":2968,"primaryCompletion":1963,"completion":2969,"start":2970,"enrollment":1767,"conditions":2971,"interventions":2973},"NCT06390306","The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP",[],"2027-12-01","2024-07-01",[2972],"Chronic Myeloid Leukemia",[2974,2941,2960,2975],"Ponatinib","Olverembatinib",{"intervention":2960,"totalTrials":746,"cells":2977},{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2982,"PHASE3":2984,"PHASE4":2990,"NA":2992},{"trials":2979,"activeCount":109},[],{"trials":2981,"activeCount":109},[],{"trials":2983,"activeCount":109},[],{"trials":2985,"activeCount":708,"soonestReadout":1267},[2986],{"nctId":2952,"briefTitle":2953,"status":456,"phases":2987,"primaryCompletion":1267,"completion":2955,"start":1780,"enrollment":2956,"conditions":2988,"interventions":2989},[100],[2958],[2960,2941],{"trials":2991,"activeCount":109},[],{"trials":2993,"activeCount":708,"soonestReadout":1963},[2994],{"nctId":2966,"briefTitle":2967,"status":121,"phases":2995,"primaryCompletion":1963,"completion":2969,"start":2970,"enrollment":1767,"conditions":2996,"interventions":2997},[],[2972],[2974,2941,2960,2975],{"intervention":67,"totalTrials":746,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3006,"PHASE4":3028,"NA":3030},{"trials":3001,"activeCount":109},[],{"trials":3003,"activeCount":109},[],{"trials":3005,"activeCount":109},[],{"trials":3007,"activeCount":708,"soonestReadout":66},[3008,3019],{"nctId":64,"briefTitle":65,"status":121,"phases":3009,"primaryCompletion":66,"completion":386,"start":3010,"enrollment":3011,"conditions":3012,"interventions":3016},[99,100],"2018-09-01",55,[3013,3014,3015],"Stem Cell Transplant Complications","Leukemia, Myeloid, Acute","Leukemia Relapse",[67,3017,3018],"mBU\u002FCY and ATG","mBU\u002FCY",{"nctId":3020,"briefTitle":3021,"status":569,"phases":3022,"primaryCompletion":1202,"completion":81,"start":3023,"enrollment":3011,"conditions":3024,"interventions":3027},"NCT03799224","Decitabine Plus mBU\u002FCY Preconditioning for Relapse\u002FRefractory Acute Leukemia",[99,100],"2018-12-01",[3013,3025,3026],"Relapse Leukemia","Refractory Leukemia",[67,3017,3018],{"trials":3029,"activeCount":109},[],{"trials":3031,"activeCount":109},[],{"intervention":3017,"totalTrials":746,"cells":3033},{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3040,"PHASE4":3050,"NA":3052},{"trials":3035,"activeCount":109},[],{"trials":3037,"activeCount":109},[],{"trials":3039,"activeCount":109},[],{"trials":3041,"activeCount":708,"soonestReadout":66},[3042,3046],{"nctId":64,"briefTitle":65,"status":121,"phases":3043,"primaryCompletion":66,"completion":386,"start":3010,"enrollment":3011,"conditions":3044,"interventions":3045},[99,100],[3013,3014,3015],[67,3017,3018],{"nctId":3020,"briefTitle":3021,"status":569,"phases":3047,"primaryCompletion":1202,"completion":81,"start":3023,"enrollment":3011,"conditions":3048,"interventions":3049},[99,100],[3013,3025,3026],[67,3017,3018],{"trials":3051,"activeCount":109},[],{"trials":3053,"activeCount":109},[],{"intervention":3018,"totalTrials":746,"cells":3055},{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3072,"NA":3074},{"trials":3057,"activeCount":109},[],{"trials":3059,"activeCount":109},[],{"trials":3061,"activeCount":109},[],{"trials":3063,"activeCount":708,"soonestReadout":66},[3064,3068],{"nctId":64,"briefTitle":65,"status":121,"phases":3065,"primaryCompletion":66,"completion":386,"start":3010,"enrollment":3011,"conditions":3066,"interventions":3067},[99,100],[3013,3014,3015],[67,3017,3018],{"nctId":3020,"briefTitle":3021,"status":569,"phases":3069,"primaryCompletion":1202,"completion":81,"start":3023,"enrollment":3011,"conditions":3070,"interventions":3071},[99,100],[3013,3025,3026],[67,3017,3018],{"trials":3073,"activeCount":109},[],{"trials":3075,"activeCount":109},[],{"intervention":3077,"totalTrials":746,"cells":3078},"Interferon",{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3083,"PHASE3":3095,"PHASE4":3103,"NA":3105},{"trials":3080,"activeCount":109},[],{"trials":3082,"activeCount":109},[],{"trials":3084,"activeCount":109},[3085],{"nctId":3086,"briefTitle":3087,"status":569,"phases":3088,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":32,"conditions":3092,"interventions":3093},"NCT01782508","A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma",[99],"2013-12","2014-12","2012-08",[2580],[3094,3077],"imatinib",{"trials":3096,"activeCount":708,"soonestReadout":438},[3097],{"nctId":3098,"briefTitle":3099,"status":121,"phases":3100,"primaryCompletion":438,"completion":438,"start":817,"enrollment":846,"conditions":3101,"interventions":3102},"NCT06802718","Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia",[100],[2958],[3077],{"trials":3104,"activeCount":109},[],{"trials":3106,"activeCount":109},[],{"intervention":3108,"totalTrials":746,"cells":3109},"Sunitinib",{"EARLY_PHASE1":3110,"PHASE1":3112,"PHASE2":3114,"PHASE3":3124,"PHASE4":3137,"NA":3139},{"trials":3111,"activeCount":109},[],{"trials":3113,"activeCount":109},[],{"trials":3115,"activeCount":109},[3116],{"nctId":3117,"briefTitle":3118,"status":569,"phases":3119,"primaryCompletion":3120,"completion":3120,"start":1164,"enrollment":153,"conditions":3121,"interventions":3123},"NCT02398552","A Phase II Trila of Sunitinib Schedule 4\u002F2 vs. Shedule 2\u002F1 as First Line Therapy in Metastatic Renal Cell Carcinoma.",[99],"2017-03",[3122],"Metastatic Renal Cell Carcinoma",[3108],{"trials":3125,"activeCount":708,"soonestReadout":2711},[3126],{"nctId":3127,"briefTitle":3128,"status":456,"phases":3129,"primaryCompletion":2711,"completion":3130,"start":3131,"enrollment":3132,"conditions":3133,"interventions":3135},"NCT07165418","A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI",[100],"2029-12-30","2025-09-25",116,[3134],"Renal Cell Carcinoma (RCC)",[3136,3108],"Vorolanib Tablets+Everolimus",{"trials":3138,"activeCount":109},[],{"trials":3140,"activeCount":109},[],{"intervention":3142,"totalTrials":708,"cells":3143},"KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3150,"PHASE4":3162,"NA":3164},{"trials":3145,"activeCount":109},[],{"trials":3147,"activeCount":109},[],{"trials":3149,"activeCount":109},[],{"trials":3151,"activeCount":708,"soonestReadout":3156},[3152],{"nctId":3153,"briefTitle":3154,"status":121,"phases":3155,"primaryCompletion":3156,"completion":3157,"start":943,"enrollment":3158,"conditions":3159,"interventions":3161},"NCT06879379","KPD Consolidation After ASCT in NDMM Patients",[99,100],"2028-03","2029-03",202,[3160],"Multiple Myeloma, Newly Diagnosed",[3142],{"trials":3163,"activeCount":109},[],{"trials":3165,"activeCount":109},[],{"intervention":3167,"totalTrials":708,"cells":3168},"Goserelin+TAM+AI",{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3175,"PHASE4":3186,"NA":3188},{"trials":3170,"activeCount":109},[],{"trials":3172,"activeCount":109},[],{"trials":3174,"activeCount":109},[],{"trials":3176,"activeCount":708,"soonestReadout":725},[3177],{"nctId":3178,"briefTitle":3179,"status":121,"phases":3180,"primaryCompletion":725,"completion":726,"start":3181,"enrollment":3182,"conditions":3183,"interventions":3184},"NCT02535221","Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer",[100],"2015-07-29",234,[31],[3167,3185],"Epirubicin+CTX+5-Fu",{"trials":3187,"activeCount":109},[],{"trials":3189,"activeCount":109},[],{"intervention":3185,"totalTrials":708,"cells":3191},{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3198,"PHASE4":3204,"NA":3206},{"trials":3193,"activeCount":109},[],{"trials":3195,"activeCount":109},[],{"trials":3197,"activeCount":109},[],{"trials":3199,"activeCount":708,"soonestReadout":725},[3200],{"nctId":3178,"briefTitle":3179,"status":121,"phases":3201,"primaryCompletion":725,"completion":726,"start":3181,"enrollment":3182,"conditions":3202,"interventions":3203},[100],[31],[3167,3185],{"trials":3205,"activeCount":109},[],{"trials":3207,"activeCount":109},[],{"intervention":2616,"totalTrials":708,"cells":3209},{"EARLY_PHASE1":3210,"PHASE1":3212,"PHASE2":3214,"PHASE3":3216,"PHASE4":3222,"NA":3224},{"trials":3211,"activeCount":109},[],{"trials":3213,"activeCount":109},[],{"trials":3215,"activeCount":109},[],{"trials":3217,"activeCount":708,"soonestReadout":2611},[3218],{"nctId":2608,"briefTitle":2609,"status":121,"phases":3219,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":1480,"conditions":3220,"interventions":3221},[100],[2599],[2616,2617,2562],{"trials":3223,"activeCount":109},[],{"trials":3225,"activeCount":109},[],{"intervention":2617,"totalTrials":708,"cells":3227},{"EARLY_PHASE1":3228,"PHASE1":3230,"PHASE2":3232,"PHASE3":3234,"PHASE4":3240,"NA":3242},{"trials":3229,"activeCount":109},[],{"trials":3231,"activeCount":109},[],{"trials":3233,"activeCount":109},[],{"trials":3235,"activeCount":708,"soonestReadout":2611},[3236],{"nctId":2608,"briefTitle":2609,"status":121,"phases":3237,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":1480,"conditions":3238,"interventions":3239},[100],[2599],[2616,2617,2562],{"trials":3241,"activeCount":109},[],{"trials":3243,"activeCount":109},[],{"intervention":3245,"totalTrials":708,"cells":3246},"avatrombopag",{"EARLY_PHASE1":3247,"PHASE1":3249,"PHASE2":3251,"PHASE3":3253,"PHASE4":3266,"NA":3268},{"trials":3248,"activeCount":109},[],{"trials":3250,"activeCount":109},[],{"trials":3252,"activeCount":109},[],{"trials":3254,"activeCount":708,"soonestReadout":3259},[3255],{"nctId":3256,"briefTitle":3257,"status":121,"phases":3258,"primaryCompletion":3259,"completion":3260,"start":3261,"enrollment":3262,"conditions":3263,"interventions":3265},"NCT06202625","Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT",[99,100],"2024-10-30","2025-10-30","2024-05-13",142,[3264,3013],"Thrombocytopenia",[3245],{"trials":3267,"activeCount":109},[],{"trials":3269,"activeCount":109},[],{"intervention":3271,"totalTrials":708,"cells":3272},"Experimental: Baofukang Suppository 7 days",{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3279,"PHASE4":3289,"NA":3291},{"trials":3274,"activeCount":109},[],{"trials":3276,"activeCount":109},[],{"trials":3278,"activeCount":109},[],{"trials":3280,"activeCount":708,"soonestReadout":968},[3281],{"nctId":3282,"briefTitle":3283,"status":121,"phases":3284,"primaryCompletion":968,"completion":968,"start":2530,"enrollment":728,"conditions":3285,"interventions":3287},"NCT04574089","Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository",[100],[3286],"Vaginitis",[3271,3288],"Experimental: Baofukang Suppository 14 days",{"trials":3290,"activeCount":109},[],{"trials":3292,"activeCount":109},[],{"intervention":3288,"totalTrials":708,"cells":3294},{"EARLY_PHASE1":3295,"PHASE1":3297,"PHASE2":3299,"PHASE3":3301,"PHASE4":3307,"NA":3309},{"trials":3296,"activeCount":109},[],{"trials":3298,"activeCount":109},[],{"trials":3300,"activeCount":109},[],{"trials":3302,"activeCount":708,"soonestReadout":968},[3303],{"nctId":3282,"briefTitle":3283,"status":121,"phases":3304,"primaryCompletion":968,"completion":968,"start":2530,"enrollment":728,"conditions":3305,"interventions":3306},[100],[3286],[3271,3288],{"trials":3308,"activeCount":109},[],{"trials":3310,"activeCount":109},[],{"intervention":3312,"totalTrials":708,"cells":3313},"Suxiao Jiuxin Pill",{"EARLY_PHASE1":3314,"PHASE1":3316,"PHASE2":3318,"PHASE3":3320,"PHASE4":3331,"NA":3333},{"trials":3315,"activeCount":109},[],{"trials":3317,"activeCount":109},[],{"trials":3319,"activeCount":109},[],{"trials":3321,"activeCount":708,"soonestReadout":3326},[3322],{"nctId":3323,"briefTitle":3324,"status":456,"phases":3325,"primaryCompletion":3326,"completion":412,"start":3327,"enrollment":2665,"conditions":3328,"interventions":3330},"NCT06531161","EleVation carE: a Randomized Controlled Trial on the Prevention of Acute Mountain Sickness With Suxiao Jiuxin Pill",[99,100],"2024-09","2024-08",[3329],"Acute Mountain Sickness",[3312],{"trials":3332,"activeCount":109},[],{"trials":3334,"activeCount":109},[],{"intervention":3336,"totalTrials":708,"cells":3337},"Camrelizumab ＋Immunotherapy",{"EARLY_PHASE1":3338,"PHASE1":3340,"PHASE2":3342,"PHASE3":3344,"PHASE4":3357,"NA":3359},{"trials":3339,"activeCount":109},[],{"trials":3341,"activeCount":109},[],{"trials":3343,"activeCount":109},[],{"trials":3345,"activeCount":708,"soonestReadout":3350},[3346],{"nctId":3347,"briefTitle":3348,"status":121,"phases":3349,"primaryCompletion":3350,"completion":3351,"start":3352,"enrollment":3353,"conditions":3354,"interventions":3356},"NCT06229041","Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)",[100],"2027-10-01","2029-10-01","2023-03-29",472,[3355],"Rectal Cancer",[3336],{"trials":3358,"activeCount":109},[],{"trials":3360,"activeCount":109},[],{"intervention":2750,"totalTrials":708,"cells":3362},{"EARLY_PHASE1":3363,"PHASE1":3365,"PHASE2":3367,"PHASE3":3369,"PHASE4":3375,"NA":3377},{"trials":3364,"activeCount":109},[],{"trials":3366,"activeCount":109},[],{"trials":3368,"activeCount":109},[],{"trials":3370,"activeCount":708,"soonestReadout":584},[3371],{"nctId":2741,"briefTitle":2742,"status":121,"phases":3372,"primaryCompletion":584,"completion":2711,"start":2744,"enrollment":670,"conditions":3373,"interventions":3374},[100],[2746,2747,2748],[2720,2750],{"trials":3376,"activeCount":109},[],{"trials":3378,"activeCount":109},[],{"intervention":3136,"totalTrials":708,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3387,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":109},[],{"trials":3384,"activeCount":109},[],{"trials":3386,"activeCount":109},[],{"trials":3388,"activeCount":708,"soonestReadout":2711},[3389],{"nctId":3127,"briefTitle":3128,"status":456,"phases":3390,"primaryCompletion":2711,"completion":3130,"start":3131,"enrollment":3132,"conditions":3391,"interventions":3392},[100],[3134],[3136,3108],{"trials":3394,"activeCount":109},[],{"trials":3396,"activeCount":109},[],{"intervention":3398,"totalTrials":708,"cells":3399},"CapeOX",{"EARLY_PHASE1":3400,"PHASE1":3402,"PHASE2":3404,"PHASE3":3406,"PHASE4":3416,"NA":3418},{"trials":3401,"activeCount":109},[],{"trials":3403,"activeCount":109},[],{"trials":3405,"activeCount":109},[],{"trials":3407,"activeCount":708,"soonestReadout":638},[3408],{"nctId":3409,"briefTitle":3410,"status":456,"phases":3411,"primaryCompletion":638,"completion":3412,"start":1589,"enrollment":586,"conditions":3413,"interventions":3414},"NCT06443671","Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR\u002FMSS Locally Advanced Rectal Cancer",[99,100],"2028-06-01",[3355],[3398,3415],"Fruquintinib and Tislelizumab combined with mCapeOX",{"trials":3417,"activeCount":109},[],{"trials":3419,"activeCount":109},[],{"intervention":3415,"totalTrials":708,"cells":3421},{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3428,"PHASE4":3434,"NA":3436},{"trials":3423,"activeCount":109},[],{"trials":3425,"activeCount":109},[],{"trials":3427,"activeCount":109},[],{"trials":3429,"activeCount":708,"soonestReadout":638},[3430],{"nctId":3409,"briefTitle":3410,"status":456,"phases":3431,"primaryCompletion":638,"completion":3412,"start":1589,"enrollment":586,"conditions":3432,"interventions":3433},[99,100],[3355],[3398,3415],{"trials":3435,"activeCount":109},[],{"trials":3437,"activeCount":109},[],{"intervention":2911,"totalTrials":405,"cells":3439},{"EARLY_PHASE1":3440,"PHASE1":3442,"PHASE2":3444,"PHASE3":3460,"PHASE4":3470,"NA":3472},{"trials":3441,"activeCount":109},[],{"trials":3443,"activeCount":109},[],{"trials":3445,"activeCount":109},[3446],{"nctId":3447,"briefTitle":3448,"status":135,"phases":3449,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":3453,"conditions":3454,"interventions":3455},"NCT02467504","Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis",[99],"2017-01-15","2017-08-31","2015-07-01",47,[2506],[3456,3457,2911,3458,3459],"hrIL-2 active","hrIL-2 placebo","Folic Acid","Loxoprofen",{"trials":3461,"activeCount":708,"soonestReadout":725},[3462,3466],{"nctId":2902,"briefTitle":2903,"status":121,"phases":3463,"primaryCompletion":725,"completion":2905,"start":2906,"enrollment":2907,"conditions":3464,"interventions":3465},[100],[2909],[2911,983],{"nctId":2913,"briefTitle":2914,"status":135,"phases":3467,"primaryCompletion":2916,"completion":1215,"start":2917,"enrollment":2918,"conditions":3468,"interventions":3469},[100],[2920],[2911,983],{"trials":3471,"activeCount":109},[],{"trials":3473,"activeCount":109},[3474],{"nctId":3475,"briefTitle":3476,"status":569,"phases":3477,"primaryCompletion":3478,"completion":3479,"start":2883,"enrollment":1165,"conditions":3480,"interventions":3482},"NCT02320630","Combination Therapy Prevents the Relapse of RA",[102],"2017-02","2020-09",[3481],"Recurrence (Disease Attribute)",[3483,3484,2911],"Entanercept","HCQ",{"intervention":1028,"totalTrials":558,"cells":3486},{"EARLY_PHASE1":3487,"PHASE1":3489,"PHASE2":3504,"PHASE3":3580,"PHASE4":3597,"NA":3609},{"trials":3488,"activeCount":109},[],{"trials":3490,"activeCount":708,"soonestReadout":302},[3491],{"nctId":3492,"briefTitle":3493,"status":121,"phases":3494,"primaryCompletion":302,"completion":1829,"start":3495,"enrollment":44,"conditions":3496,"interventions":3498},"NCT06969612","A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC",[98],"2025-05-15",[3497],"NSCLC (Advanced Non-small Cell Lung Cancer)",[1036,3499,1028,3500,3501,3502,3503],"Pemetrexed","Carboplatin","Paclitaxel","Albumin Paclitaxel","Golidocitinib",{"trials":3505,"activeCount":1428,"soonestReadout":94},[3506,3517,3523,3533,3540,3553,3557,3561,3571],{"nctId":3507,"briefTitle":3508,"status":569,"phases":3509,"primaryCompletion":3510,"completion":2824,"start":3511,"enrollment":1894,"conditions":3512,"interventions":3513},"NCT01679340","A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery",[99],"2018-03","2011-04",[28],[3514,3515,3516],"S-1","oxaliplatin","cisplatin",{"nctId":92,"briefTitle":93,"status":121,"phases":3518,"primaryCompletion":94,"completion":1963,"start":3519,"enrollment":3520,"conditions":3521,"interventions":3522},[99],"2021-10-25",27,[2680],[95,1028,3500,3499],{"nctId":3524,"briefTitle":3525,"status":135,"phases":3526,"primaryCompletion":252,"completion":2824,"start":3527,"enrollment":3528,"conditions":3529,"interventions":3531},"NCT01762150","Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma",[99],"2011-06",26,[3530],"Renal Cell Carcinoma",[3532,1026,1028],"Sorafenib",{"nctId":3534,"briefTitle":3535,"status":456,"phases":3536,"primaryCompletion":412,"completion":413,"start":604,"enrollment":2008,"conditions":3537,"interventions":3538},"NCT06426056","Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.",[99],[2681],[3539,1028],"Nab paclitaxel",{"nctId":3541,"briefTitle":3542,"status":135,"phases":3543,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":3548,"interventions":3550},"NCT00842491","Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer",[99],"2010-04","2010-12","2008-11",45,[3549],"Advanced Gastric Cancer",[3551,3552,3516],"endostar, cisplatin, capecitabine","capecitabine",{"nctId":1016,"briefTitle":1017,"status":456,"phases":3554,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":3555,"interventions":3556},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":2556,"briefTitle":2557,"status":1935,"phases":3558,"primaryCompletion":1938,"completion":1938,"start":1937,"enrollment":536,"conditions":3559,"interventions":3560},[99],[1250],[2561,2562,2563,1028],{"nctId":3562,"briefTitle":3563,"status":468,"phases":3564,"primaryCompletion":725,"completion":2049,"start":3565,"enrollment":3566,"conditions":3567,"interventions":3570},"NCT06009861","Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral\u002FOropharyngeal Cancer (NeoSPOT)",[99],"2023-06-27",110,[3568,3569],"Oral Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma",[1036,1024,1028],{"nctId":3572,"briefTitle":3573,"status":200,"phases":3574,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":477,"conditions":3577,"interventions":3579},"NCT04804696","Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma",[99],"2024-11-29","2021-02-10",[3578],"Esophageal Squamous Cell Cancer",[1037,3501,1028],{"trials":3581,"activeCount":109},[3582,3590],{"nctId":3583,"briefTitle":3584,"status":569,"phases":3585,"primaryCompletion":2874,"completion":2874,"start":3586,"enrollment":3587,"conditions":3588,"interventions":3589},"NCT01015339","Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction",[100],"2009-11",320,[3549],[3501,3552,3552,3516],{"nctId":3591,"briefTitle":3592,"status":435,"phases":3593,"primaryCompletion":3594,"completion":3594,"start":2882,"enrollment":109,"conditions":3595,"interventions":3596},"NCT02272699","Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma",[99,100],"2020-12",[1250],[2561,3501,1028],{"trials":3598,"activeCount":109},[3599],{"nctId":3600,"briefTitle":3601,"status":569,"phases":3602,"primaryCompletion":572,"completion":81,"start":3603,"enrollment":168,"conditions":3604,"interventions":3606},"NCT05730777","Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics",[101],"2023-02-15",[3605],"Cancer Therapy-related Cardiovascular Toxicity",[3607,1028,3500,3501,3608],"Bifidobacterium Bifidum Oral","Atlizumab",{"trials":3610,"activeCount":109},[3611,3619,3630],{"nctId":3612,"briefTitle":3613,"status":569,"phases":3614,"primaryCompletion":2930,"completion":315,"start":3594,"enrollment":3615,"conditions":3616,"interventions":3618},"NCT04678791","Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma",[102],286,[3617],"Cervical Squamous Cell Carcinoma",[2561,1028],{"nctId":3620,"briefTitle":3621,"status":135,"phases":3622,"primaryCompletion":448,"completion":3623,"start":3624,"enrollment":3625,"conditions":3626,"interventions":3629},"NCT03909776","Transcatheter Intra-arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma",[102],"2019-04-08","2019-01-01",99,[3627,195,3628,2603],"Event-free Survival","Local-recurrence Free Survival",[1028],{"nctId":3631,"briefTitle":3632,"status":569,"phases":3633,"primaryCompletion":3634,"completion":3635,"start":3636,"enrollment":376,"conditions":3637,"interventions":3639},"NCT03360760","Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum",[102],"2020-02","2025-02","2018-08-01",[3638],"Osteosarcoma of Pelvis",[1120,1028,3640,2550],"Methotrexate",{"intervention":1036,"totalTrials":3642,"cells":3643},8,{"EARLY_PHASE1":3644,"PHASE1":3646,"PHASE2":3662,"PHASE3":3714,"PHASE4":3716,"NA":3718},{"trials":3645,"activeCount":109},[],{"trials":3647,"activeCount":746,"soonestReadout":302},[3648,3652],{"nctId":3492,"briefTitle":3493,"status":121,"phases":3649,"primaryCompletion":302,"completion":1829,"start":3495,"enrollment":44,"conditions":3650,"interventions":3651},[98],[3497],[1036,3499,1028,3500,3501,3502,3503],{"nctId":3653,"briefTitle":3654,"status":121,"phases":3655,"primaryCompletion":3656,"completion":1175,"start":3657,"enrollment":1527,"conditions":3658,"interventions":3660},"NCT06541639","EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors",[98],"2028-03-31","2025-03-04",[3659],"Advanced or Recurrent Solid Tumors",[3661,1036],"EVM16",{"trials":3663,"activeCount":329,"soonestReadout":3668},[3664,3675,3685,3689,3693,3704],{"nctId":3665,"briefTitle":3666,"status":121,"phases":3667,"primaryCompletion":3668,"completion":3669,"start":3670,"enrollment":47,"conditions":3671,"interventions":3674},"NCT05758116","Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients",[99],"2025-07-07","2026-07-07","2022-07-07",[2524,3672,3673],"Consolidation Immunotherapy","Radiotherapy or Sequential Chemoradiation",[1036],{"nctId":3676,"briefTitle":3677,"status":569,"phases":3678,"primaryCompletion":3679,"completion":3680,"start":1162,"enrollment":32,"conditions":3681,"interventions":3683},"NCT04777162","Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer",[99],"2023-01","2023-05",[28,3682],"Colo-rectal Cancer",[1036,3684],"Anlotinib",{"nctId":1016,"briefTitle":1017,"status":456,"phases":3686,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":3687,"interventions":3688},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":3562,"briefTitle":3563,"status":468,"phases":3690,"primaryCompletion":725,"completion":2049,"start":3565,"enrollment":3566,"conditions":3691,"interventions":3692},[99],[3568,3569],[1036,1024,1028],{"nctId":3694,"briefTitle":3695,"status":569,"phases":3696,"primaryCompletion":3697,"completion":3697,"start":3698,"enrollment":3699,"conditions":3700,"interventions":3701},"NCT05104801","Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma",[99],"2023-09","2021-11",37,[2580],[3702,3703],"sitravatinib","tislelizumab",{"nctId":3705,"briefTitle":3706,"status":569,"phases":3707,"primaryCompletion":3708,"completion":1537,"start":3709,"enrollment":47,"conditions":3710,"interventions":3712},"NCT05877001","The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases",[99],"2024-07-30","2023-05-30",[3711],"Colorectal Liver Metastases",[1036,3713],"Regorafenib",{"trials":3715,"activeCount":109},[],{"trials":3717,"activeCount":109},[],{"trials":3719,"activeCount":109},[],{"intervention":3500,"totalTrials":553,"cells":3721},{"EARLY_PHASE1":3722,"PHASE1":3724,"PHASE2":3730,"PHASE3":3768,"PHASE4":3770,"NA":3776},{"trials":3723,"activeCount":109},[],{"trials":3725,"activeCount":708,"soonestReadout":302},[3726],{"nctId":3492,"briefTitle":3493,"status":121,"phases":3727,"primaryCompletion":302,"completion":1829,"start":3495,"enrollment":44,"conditions":3728,"interventions":3729},[98],[3497],[1036,3499,1028,3500,3501,3502,3503],{"trials":3731,"activeCount":329,"soonestReadout":94},[3732,3747,3751,3760],{"nctId":3733,"briefTitle":3734,"status":456,"phases":3735,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":3739,"interventions":3740},"NCT07527806","Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET\u002FCT Molecular Imaging",[99],"2029-05-01","2026-05-01",156,[31],[3741,1087,1088,3742,3743,3744,3745,3746],"Trastuzumab","Docetaxel or Nab-paclitaxel","carboplatin","CDK4\u002F6 inhibitor","Aromatase Inhibitor","ADC",{"nctId":92,"briefTitle":93,"status":121,"phases":3748,"primaryCompletion":94,"completion":1963,"start":3519,"enrollment":3520,"conditions":3749,"interventions":3750},[99],[2680],[95,1028,3500,3499],{"nctId":3752,"briefTitle":3753,"status":456,"phases":3754,"primaryCompletion":3736,"completion":3755,"start":3737,"enrollment":2712,"conditions":3756,"interventions":3758},"NCT07498907","Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma",[99],"2034-03-01",[3757],"Upper Tract Urothelial Carcinoma",[3759,1026,3743],"Disitamab Vedotin",{"nctId":3761,"briefTitle":3762,"status":569,"phases":3763,"primaryCompletion":668,"completion":668,"start":3089,"enrollment":3764,"conditions":3765,"interventions":3766},"NCT02023710","Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma",[99],182,[2580],[3501,3500,3767],"Bevacizumab",{"trials":3769,"activeCount":109},[],{"trials":3771,"activeCount":109},[3772],{"nctId":3600,"briefTitle":3601,"status":569,"phases":3773,"primaryCompletion":572,"completion":81,"start":3603,"enrollment":168,"conditions":3774,"interventions":3775},[101],[3605],[3607,1028,3500,3501,3608],{"trials":3777,"activeCount":109},[],{"intervention":3779,"totalTrials":1428,"cells":3780},"KN046",{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3785,"PHASE3":3834,"PHASE4":3836,"NA":3838},{"trials":3782,"activeCount":109},[],{"trials":3784,"activeCount":109},[],{"trials":3786,"activeCount":405,"soonestReadout":2203},[3787,3798,3807,3817,3826],{"nctId":3788,"briefTitle":3789,"status":135,"phases":3790,"primaryCompletion":3791,"completion":3792,"start":3793,"enrollment":3011,"conditions":3794,"interventions":3796},"NCT04542837","The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma",[99],"2022-02-23","2024-03-15","2020-09-11",[3795],"HCC",[3779,3797],"Lenvatinib",{"nctId":3799,"briefTitle":3800,"status":121,"phases":3801,"primaryCompletion":726,"completion":726,"start":3802,"enrollment":3803,"conditions":3804,"interventions":3805},"NCT05985109","KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer",[99],"2023-10-26",98,[2692],[3779,3806],"regorafenib",{"nctId":3808,"briefTitle":3809,"status":121,"phases":3810,"primaryCompletion":2203,"completion":726,"start":3811,"enrollment":2732,"conditions":3812,"interventions":3814},"NCT06023758","Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC",[99],"2023-09-22",[3813],"HER2-positive Locally Advanced Resectable Gastric Cancer",[3815,3779,3816],"KN026","XELOX",{"nctId":3818,"briefTitle":3819,"status":456,"phases":3820,"primaryCompletion":726,"completion":726,"start":3821,"enrollment":153,"conditions":3822,"interventions":3825},"NCT05985707","KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma",[99],"2023-08-15",[3823,3824],"HER2-positive Colorectal Cancer","HER2-positive Biliary Tract Cancer",[3815,3779,3816],{"nctId":3827,"briefTitle":3828,"status":121,"phases":3829,"primaryCompletion":726,"completion":726,"start":3830,"enrollment":617,"conditions":3831,"interventions":3833},"NCT06099821","KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1\u002FPD-L1 Blockade",[99],"2023-10-25",[3832],"Digestive System Cancers",[3779,3713,2601],{"trials":3835,"activeCount":109},[],{"trials":3837,"activeCount":109},[],{"trials":3839,"activeCount":109},[],{"intervention":1024,"totalTrials":405,"cells":3841},{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3880,"PHASE4":3882,"NA":3884},{"trials":3843,"activeCount":109},[],{"trials":3845,"activeCount":109},[],{"trials":3847,"activeCount":405,"soonestReadout":3870},[3848,3858,3862,3866],{"nctId":3849,"briefTitle":3850,"status":456,"phases":3851,"primaryCompletion":2094,"completion":3852,"start":3853,"enrollment":1139,"conditions":3854,"interventions":3856},"NCT06222944","Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC\u002FGEJA",[99],"2026-08-25","2024-02-25",[28,3855],"Adenocarcinoma of Esophagogastric Junction",[3684,3857,1024],"TQB2450",{"nctId":1016,"briefTitle":1017,"status":456,"phases":3859,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":3860,"interventions":3861},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":3562,"briefTitle":3563,"status":468,"phases":3863,"primaryCompletion":725,"completion":2049,"start":3565,"enrollment":3566,"conditions":3864,"interventions":3865},[99],[3568,3569],[1036,1024,1028],{"nctId":3867,"briefTitle":3868,"status":456,"phases":3869,"primaryCompletion":3870,"completion":386,"start":66,"enrollment":3871,"conditions":3872,"interventions":3876},"NCT06028633","Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients",[99],"2024-10",28,[3873,3874,3875],"Advanced Non-squamous Non-small-cell Lung Cancer","Recurrent Non-Squamous Non-Small Cell Lung Cancer","Metastatic Non-squamous Non Small Cell Lung Cancer",[3877,3878,3879],"pembrolizumab","lenvatinib","albumin-bound paclitaxel",{"trials":3881,"activeCount":109},[],{"trials":3883,"activeCount":109},[],{"trials":3885,"activeCount":109},[],{"intervention":1037,"totalTrials":3887,"cells":3888},9,{"EARLY_PHASE1":3889,"PHASE1":3891,"PHASE2":3893,"PHASE3":3963,"PHASE4":3979,"NA":3981},{"trials":3890,"activeCount":109},[],{"trials":3892,"activeCount":109},[],{"trials":3894,"activeCount":329,"soonestReadout":3919},[3895,3906,3915,3928,3937,3941,3945,3955],{"nctId":3896,"briefTitle":3897,"status":569,"phases":3898,"primaryCompletion":3899,"completion":3900,"start":3901,"enrollment":1767,"conditions":3902,"interventions":3904},"NCT04180995","Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma",[99],"2022-07-06","2022-12-30","2019-08-06",[3903],"Mucosal Melanoma",[3905],"TORIPALIMAB",{"nctId":3907,"briefTitle":3908,"status":456,"phases":3909,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":32,"conditions":3912,"interventions":3913},"NCT07412171","NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC",[99],"2028-12","2026-02",[3757],[1037,3914],"9MW2821",{"nctId":3916,"briefTitle":3917,"status":121,"phases":3918,"primaryCompletion":3919,"completion":3920,"start":3624,"enrollment":1767,"conditions":3921,"interventions":3926},"NCT06889649","SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC",[99],"2027-02-28","2028-02-20",[3922,3923,3924,3925],"Radiation Therapy","Targeted Therapy","Immunotherapy","Renal Cancer Metastatic",[3905,3927],"Axitinib",{"nctId":3929,"briefTitle":3930,"status":569,"phases":3931,"primaryCompletion":3932,"completion":3680,"start":3933,"enrollment":26,"conditions":3934,"interventions":3935},"NCT04880811","Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification",[99],"2022-10","2021-07",[1250],[3936,1037],"Afatinib",{"nctId":1016,"briefTitle":1017,"status":456,"phases":3938,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":3939,"interventions":3940},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":3572,"briefTitle":3573,"status":200,"phases":3942,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":477,"conditions":3943,"interventions":3944},[99],[3578],[1037,3501,1028],{"nctId":3946,"briefTitle":3947,"status":569,"phases":3948,"primaryCompletion":3949,"completion":3950,"start":3951,"enrollment":658,"conditions":3952,"interventions":3954},"NCT04988191","Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer",[98,99],"2023-06-24","2023-12-24","2020-12-24",[3953],"Colorectal Carcinoma",[1037,3767,1029],{"nctId":3956,"briefTitle":3957,"status":569,"phases":3958,"primaryCompletion":2700,"completion":1578,"start":3959,"enrollment":3960,"conditions":3961,"interventions":3962},"NCT04462965","Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study",[99],"2020-05-30",294,[3903],[1037,2600],{"trials":3964,"activeCount":109},[3965],{"nctId":3966,"briefTitle":3967,"status":569,"phases":3968,"primaryCompletion":3969,"completion":3970,"start":3971,"enrollment":3972,"conditions":3973,"interventions":3975},"NCT03992911","Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma",[99,100],"2022-06-20","2023-06-20","2019-06-19",336,[3974],"Neuroendocrine Carcinoma of the Bladder",[3976,1037,3977,3978],"Simmtecan, 5-FU and l-LV","Etoposide, Cisplatin","Etoposide, Carboplatin",{"trials":3980,"activeCount":109},[],{"trials":3982,"activeCount":109},[],{"intervention":1032,"totalTrials":405,"cells":3984},{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":4022,"PHASE4":4024,"NA":4026},{"trials":3986,"activeCount":109},[],{"trials":3988,"activeCount":109},[],{"trials":3990,"activeCount":329,"soonestReadout":3870},[3991,3995,4005,4009],{"nctId":1016,"briefTitle":1017,"status":456,"phases":3992,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":3993,"interventions":3994},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":3996,"briefTitle":3997,"status":569,"phases":3998,"primaryCompletion":3999,"completion":4000,"start":2853,"enrollment":4001,"conditions":4002,"interventions":4003},"NCT05386056","Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma",[99],"2023-10-31","2024-06-30",54,[1250],[1032,4004],"Sinoporphyrin Sodium",{"nctId":3867,"briefTitle":3868,"status":456,"phases":4006,"primaryCompletion":3870,"completion":386,"start":66,"enrollment":3871,"conditions":4007,"interventions":4008},[99],[3873,3874,3875],[3877,3878,3879],{"nctId":4010,"briefTitle":4011,"status":121,"phases":4012,"primaryCompletion":4013,"completion":4014,"start":4015,"enrollment":4001,"conditions":4016,"interventions":4021},"NCT05072600","Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer",[99],"2024-12-07","2029-11-01","2021-12-07",[1231,4017,4018,4019,4020],"Bladder Neoplasms","Bladder Tumors","Urinary Bladder Cancer","Neoplasms, Bladder",[1032],{"trials":4023,"activeCount":109},[],{"trials":4025,"activeCount":109},[],{"trials":4027,"activeCount":109},[],{"intervention":632,"totalTrials":329,"cells":4029},{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4058,"PHASE4":4060,"NA":4062},{"trials":4031,"activeCount":109},[],{"trials":4033,"activeCount":109},[],{"trials":4035,"activeCount":329,"soonestReadout":4040},[4036,4045,4054],{"nctId":4037,"briefTitle":4038,"status":121,"phases":4039,"primaryCompletion":4040,"completion":726,"start":4041,"enrollment":1767,"conditions":4042,"interventions":4043},"NCT06873100","Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis",[98,99],"2026-08-01","2024-11-15",[2791],[632,4044],"corticosteroids and immunosuppressants",{"nctId":4046,"briefTitle":4047,"status":456,"phases":4048,"primaryCompletion":968,"completion":2050,"start":4049,"enrollment":1767,"conditions":4050,"interventions":4052},"NCT06862284","Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome",[99],"2025-03-10",[4051],"Primary Sjögren's Syndrome (pSS)",[632,4053],"Hydroxychloroquine",{"nctId":625,"briefTitle":626,"status":456,"phases":4055,"primaryCompletion":628,"completion":584,"start":629,"enrollment":586,"conditions":4056,"interventions":4057},[99],[34],[557,632],{"trials":4059,"activeCount":109},[],{"trials":4061,"activeCount":109},[],{"trials":4063,"activeCount":109},[],{"intervention":3767,"totalTrials":4065,"cells":4066},11,{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4080,"PHASE3":4131,"PHASE4":4133,"NA":4135},{"trials":4068,"activeCount":109},[],{"trials":4070,"activeCount":109},[4071],{"nctId":4072,"briefTitle":4073,"status":569,"phases":4074,"primaryCompletion":830,"completion":830,"start":4075,"enrollment":2732,"conditions":4076,"interventions":4078},"NCT01852409","Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites",[98],"2013-05",[4077],"Refractory Malignant Ascites",[4079],"bevacizumab",{"trials":4081,"activeCount":746,"soonestReadout":3130},[4082,4086,4094,4107,4111,4120],{"nctId":3761,"briefTitle":3762,"status":569,"phases":4083,"primaryCompletion":668,"completion":668,"start":3089,"enrollment":3764,"conditions":4084,"interventions":4085},[99],[2580],[3501,3500,3767],{"nctId":4087,"briefTitle":4088,"status":569,"phases":4089,"primaryCompletion":4090,"completion":4090,"start":3090,"enrollment":4091,"conditions":4092,"interventions":4093},"NCT02330783","Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients",[99],"2018-12",106,[3122],[3767,3532],{"nctId":4095,"briefTitle":4096,"status":456,"phases":4097,"primaryCompletion":3130,"completion":4098,"start":4099,"enrollment":4100,"conditions":4101,"interventions":4105},"NCT07182708","High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC",[99],"2030-06-30","2025-10-01",62,[4102,4103,4104],"NSCLC (Non-small Cell Lung Cancer)","EGFR Activating Mutation","Resectable Lung Non-Small Cell Carcinoma",[4106,3767],"Firmonertinib Mesilate",{"nctId":3946,"briefTitle":3947,"status":569,"phases":4108,"primaryCompletion":3949,"completion":3950,"start":3951,"enrollment":658,"conditions":4109,"interventions":4110},[98,99],[3953],[1037,3767,1029],{"nctId":4112,"briefTitle":4113,"status":456,"phases":4114,"primaryCompletion":1020,"completion":1020,"start":1780,"enrollment":4091,"conditions":4115,"interventions":4117},"NCT07383285","CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant\u002FMSS Metastatic Rectal Cancer",[99],[4116],"Rectal Neoplasms Malignant",[4118,1059,3767,4119],"Iparomlimab and Tuvonralimab","Oxaliplatin",{"nctId":4121,"briefTitle":4122,"status":569,"phases":4123,"primaryCompletion":4124,"completion":4125,"start":4126,"enrollment":4127,"conditions":4128,"interventions":4130},"NCT02942043","Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer",[99],"2019-05","2019-10","2016-10",87,[4129],"Malignant Pleural Effusion",[3767],{"trials":4132,"activeCount":109},[],{"trials":4134,"activeCount":109},[],{"trials":4136,"activeCount":708,"soonestReadout":3656},[4137,4148,4157,4166],{"nctId":4138,"briefTitle":4139,"status":135,"phases":4140,"primaryCompletion":4141,"completion":3545,"start":4142,"enrollment":4143,"conditions":4144,"interventions":4146},"NCT01306591","Bevacizumab for Neovascular Age-related Macular Degeneration",[102],"2010-06","2008-01",210,[4145],"Exudative Age-related Macular Degeneration",[4147,3767],"Bevacizumab 1",{"nctId":4149,"briefTitle":4150,"status":569,"phases":4151,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":2956,"conditions":4154,"interventions":4156},"NCT01860144","An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer",[],"2015-12","2012-06",[4155],"Metastatic Colorectal Cancer",[3767],{"nctId":4158,"briefTitle":4159,"status":121,"phases":4160,"primaryCompletion":3656,"completion":1082,"start":1054,"enrollment":32,"conditions":4161,"interventions":4163},"NCT07466238","HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer",[102],[4162],"Biliary Tract Cancer (BTC)",[3767,4164,4165],"PD-1\u002FPD-L1 inhibitor","Gemcitabin",{"nctId":4167,"briefTitle":4168,"status":569,"phases":4169,"primaryCompletion":52,"completion":437,"start":4170,"enrollment":4171,"conditions":4172,"interventions":4175},"NCT04213222","Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases",[],"2020-10",300,[4173,3355,4174],"Colon Cancer","Liver Metastases",[3767],{"intervention":1026,"totalTrials":405,"cells":4177},{"EARLY_PHASE1":4178,"PHASE1":4180,"PHASE2":4182,"PHASE3":4207,"PHASE4":4209,"NA":4211},{"trials":4179,"activeCount":109},[],{"trials":4181,"activeCount":109},[],{"trials":4183,"activeCount":746,"soonestReadout":1019},[4184,4188,4192,4196],{"nctId":3524,"briefTitle":3525,"status":135,"phases":4185,"primaryCompletion":252,"completion":2824,"start":3527,"enrollment":3528,"conditions":4186,"interventions":4187},[99],[3530],[3532,1026,1028],{"nctId":3752,"briefTitle":3753,"status":456,"phases":4189,"primaryCompletion":3736,"completion":3755,"start":3737,"enrollment":2712,"conditions":4190,"interventions":4191},[99],[3757],[3759,1026,3743],{"nctId":1016,"briefTitle":1017,"status":456,"phases":4193,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":4194,"interventions":4195},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":4197,"briefTitle":4198,"status":569,"phases":4199,"primaryCompletion":4200,"completion":4201,"start":4202,"enrollment":32,"conditions":4203,"interventions":4204},"NCT03636308","Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer",[99],"2020-08-01","2021-08-01","2018-07-17",[684],[4205,4206,1026],"nanoparticle albumin-bound paclitaxel","S1",{"trials":4208,"activeCount":109},[],{"trials":4210,"activeCount":109},[],{"trials":4212,"activeCount":109},[],{"intervention":1035,"totalTrials":405,"cells":4214},{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4252,"PHASE4":4254,"NA":4256},{"trials":4216,"activeCount":109},[],{"trials":4218,"activeCount":109},[],{"trials":4220,"activeCount":746,"soonestReadout":412},[4221,4230,4234,4243],{"nctId":4222,"briefTitle":4223,"status":569,"phases":4224,"primaryCompletion":1138,"completion":2853,"start":4225,"enrollment":153,"conditions":4226,"interventions":4228},"NCT04202601","Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer",[98,99],"2019-12-13",[4227],"Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",[1035,4229],"IBI310",{"nctId":1016,"briefTitle":1017,"status":456,"phases":4231,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":4232,"interventions":4233},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":4235,"briefTitle":4236,"status":569,"phases":4237,"primaryCompletion":4238,"completion":637,"start":4239,"enrollment":1767,"conditions":4240,"interventions":4241},"NCT04052659","Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL",[99],"2024-12-30","2021-04-15",[1153],[1035,1119,4242],"Azacidine",{"nctId":4244,"briefTitle":4245,"status":121,"phases":4246,"primaryCompletion":412,"completion":412,"start":4247,"enrollment":1767,"conditions":4248,"interventions":4250},"NCT05165407","Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)",[99],"2022-07-12",[4249],"Neuroendocrine Neoplasm",[1035,4229,4251],"Surufatinib",{"trials":4253,"activeCount":109},[],{"trials":4255,"activeCount":109},[],{"trials":4257,"activeCount":109},[],{"intervention":3927,"totalTrials":329,"cells":4259},{"EARLY_PHASE1":4260,"PHASE1":4262,"PHASE2":4274,"PHASE3":4289,"PHASE4":4291,"NA":4293},{"trials":4261,"activeCount":109},[],{"trials":4263,"activeCount":109},[4264],{"nctId":4265,"briefTitle":4266,"status":569,"phases":4267,"primaryCompletion":3999,"completion":81,"start":4268,"enrollment":1767,"conditions":4269,"interventions":4271},"NCT05070221","Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis",[98],"2021-10-01",[4270],"Melanoma Stage IV",[4272,4273,3927],"Recombinant Oncolytic HSV-2 Therapeutic Injecta","Recombinant humanized anti-PD-1 monoclonal antibody for",{"trials":4275,"activeCount":746,"soonestReadout":3911},[4276,4285],{"nctId":4277,"briefTitle":4278,"status":121,"phases":4279,"primaryCompletion":3911,"completion":2437,"start":4280,"enrollment":1767,"conditions":4281,"interventions":4283},"NCT06211114","Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma",[99],"2024-02-09",[4282],"Collecting Duct Carcinoma",[4284,3927],"PD-(L)1 inhibitor",{"nctId":3916,"briefTitle":3917,"status":121,"phases":4286,"primaryCompletion":3919,"completion":3920,"start":3624,"enrollment":1767,"conditions":4287,"interventions":4288},[99],[3922,3923,3924,3925],[3905,3927],{"trials":4290,"activeCount":109},[],{"trials":4292,"activeCount":109},[],{"trials":4294,"activeCount":109},[],{"intervention":4296,"totalTrials":746,"cells":4297},"IFN-Α",{"EARLY_PHASE1":4298,"PHASE1":4300,"PHASE2":4302,"PHASE3":4320,"PHASE4":4322,"NA":4324},{"trials":4299,"activeCount":109},[],{"trials":4301,"activeCount":109},[],{"trials":4303,"activeCount":746,"soonestReadout":741},[4304,4312],{"nctId":4305,"briefTitle":4306,"status":121,"phases":4307,"primaryCompletion":741,"completion":725,"start":4308,"enrollment":35,"conditions":4309,"interventions":4311},"NCT06130579","Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT",[99],"2024-01-01",[4310,947],"Myeloid Leukemia",[4296],{"nctId":4313,"briefTitle":4314,"status":456,"phases":4315,"primaryCompletion":726,"completion":2049,"start":4316,"enrollment":376,"conditions":4317,"interventions":4318},"NCT07449286","IFN-α in Relapse Prevention.",[99],"2026-03-01",[2958,947],[4319],"IFN-α",{"trials":4321,"activeCount":109},[],{"trials":4323,"activeCount":109},[],{"trials":4325,"activeCount":109},[],{"intervention":3503,"totalTrials":746,"cells":4327},{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4336,"PHASE3":4347,"PHASE4":4349,"NA":4351},{"trials":4329,"activeCount":109},[],{"trials":4331,"activeCount":708,"soonestReadout":302},[4332],{"nctId":3492,"briefTitle":3493,"status":121,"phases":4333,"primaryCompletion":302,"completion":1829,"start":3495,"enrollment":44,"conditions":4334,"interventions":4335},[98],[3497],[1036,3499,1028,3500,3501,3502,3503],{"trials":4337,"activeCount":708,"soonestReadout":4342},[4338],{"nctId":4339,"briefTitle":4340,"status":456,"phases":4341,"primaryCompletion":4342,"completion":4343,"start":3260,"enrollment":4344,"conditions":4345,"interventions":4346},"NCT07196163","An Exploratory Study of Golidocitinib in Adult Patients With ITP",[98,99],"2028-10-30","2029-10-30",138,[588],[3503],{"trials":4348,"activeCount":109},[],{"trials":4350,"activeCount":109},[],{"trials":4352,"activeCount":109},[],{"intervention":3499,"totalTrials":746,"cells":4354},{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4363,"PHASE3":4369,"PHASE4":4371,"NA":4373},{"trials":4356,"activeCount":109},[],{"trials":4358,"activeCount":708,"soonestReadout":302},[4359],{"nctId":3492,"briefTitle":3493,"status":121,"phases":4360,"primaryCompletion":302,"completion":1829,"start":3495,"enrollment":44,"conditions":4361,"interventions":4362},[98],[3497],[1036,3499,1028,3500,3501,3502,3503],{"trials":4364,"activeCount":708,"soonestReadout":94},[4365],{"nctId":92,"briefTitle":93,"status":121,"phases":4366,"primaryCompletion":94,"completion":1963,"start":3519,"enrollment":3520,"conditions":4367,"interventions":4368},[99],[2680],[95,1028,3500,3499],{"trials":4370,"activeCount":109},[],{"trials":4372,"activeCount":109},[],{"trials":4374,"activeCount":109},[],{"intervention":3759,"totalTrials":746,"cells":4376},{"EARLY_PHASE1":4377,"PHASE1":4379,"PHASE2":4381,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4378,"activeCount":109},[],{"trials":4380,"activeCount":109},[],{"trials":4382,"activeCount":746,"soonestReadout":4391},[4383,4387],{"nctId":3752,"briefTitle":3753,"status":456,"phases":4384,"primaryCompletion":3736,"completion":3755,"start":3737,"enrollment":2712,"conditions":4385,"interventions":4386},[99],[3757],[3759,1026,3743],{"nctId":4388,"briefTitle":4389,"status":121,"phases":4390,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":140,"conditions":4393,"interventions":4395},"NCT06210490","A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery",[99],"2028-05-31","2024-02-20",[4394],"Upper Urinary Tract Urothelial Carcinoma",[3759],{"trials":4397,"activeCount":109},[],{"trials":4399,"activeCount":109},[],{"trials":4401,"activeCount":109},[],{"intervention":4403,"totalTrials":746,"cells":4404},"Iparomlimab\u002FTuvonralimab",{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4428,"PHASE4":4430,"NA":4432},{"trials":4406,"activeCount":109},[],{"trials":4408,"activeCount":109},[],{"trials":4410,"activeCount":746,"soonestReadout":726},[4411,4419],{"nctId":4412,"briefTitle":4413,"status":456,"phases":4414,"primaryCompletion":4415,"completion":4416,"start":638,"enrollment":1767,"conditions":4417,"interventions":4418},"NCT07595523","Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability\u002FMismatch Repair Deficiency",[99],"2028-07-01","2029-07-01",[28],[4403],{"nctId":4420,"briefTitle":4421,"status":456,"phases":4422,"primaryCompletion":726,"completion":726,"start":2051,"enrollment":4001,"conditions":4423,"interventions":4426},"NCT07007728","Iparomlimab\u002FTuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis",[99],[4424,4425],"Colorectal Neoplasms","Secondary Malignant Neoplasm of Liver",[4403,4427],"Bevacizumab + CAPEOX",{"trials":4429,"activeCount":109},[],{"trials":4431,"activeCount":109},[],{"trials":4433,"activeCount":109},[],{"intervention":2685,"totalTrials":746,"cells":4435},{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4450,"PHASE4":4452,"NA":4454},{"trials":4437,"activeCount":109},[],{"trials":4439,"activeCount":109},[],{"trials":4441,"activeCount":746,"soonestReadout":2673},[4442,4446],{"nctId":2670,"briefTitle":2671,"status":121,"phases":4443,"primaryCompletion":2673,"completion":1019,"start":2674,"enrollment":2052,"conditions":4444,"interventions":4445},[99],[2676,2677,2678,2679,31,43,2680,2681,2682,2683],[2685,2638],{"nctId":2687,"briefTitle":2688,"status":121,"phases":4447,"primaryCompletion":2673,"completion":1019,"start":2674,"enrollment":2052,"conditions":4448,"interventions":4449},[99],[2676,2677,2691,684,2692],[2685,2638],{"trials":4451,"activeCount":109},[],{"trials":4453,"activeCount":109},[],{"trials":4455,"activeCount":109},[],{"intervention":1058,"totalTrials":746,"cells":4457},{"EARLY_PHASE1":4458,"PHASE1":4460,"PHASE2":4462,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4459,"activeCount":109},[],{"trials":4461,"activeCount":109},[],{"trials":4463,"activeCount":746,"soonestReadout":4468},[4464,4474],{"nctId":4465,"briefTitle":4466,"status":456,"phases":4467,"primaryCompletion":4468,"completion":1083,"start":2813,"enrollment":4469,"conditions":4470,"interventions":4473},"NCT07177950","A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases",[98,99],"2028-09-30",51,[31,4471,4472],"Brain Metastases","Leptomeningeal Metastasis",[1058,1058],{"nctId":1051,"briefTitle":1052,"status":456,"phases":4475,"primaryCompletion":615,"completion":1020,"start":1054,"enrollment":376,"conditions":4476,"interventions":4477},[99],[31,1056],[1058,1007,1059,1060],{"trials":4479,"activeCount":109},[],{"trials":4481,"activeCount":109},[],{"trials":4483,"activeCount":109},[],{"intervention":1039,"totalTrials":746,"cells":4485},{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4505,"PHASE4":4507,"NA":4509},{"trials":4487,"activeCount":109},[],{"trials":4489,"activeCount":109},[],{"trials":4491,"activeCount":746,"soonestReadout":1019},[4492,4496],{"nctId":1016,"briefTitle":1017,"status":456,"phases":4493,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":4494,"interventions":4495},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":4497,"briefTitle":4498,"status":456,"phases":4499,"primaryCompletion":4500,"completion":4342,"start":4501,"enrollment":658,"conditions":4502,"interventions":4504},"NCT07357532","Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD",[99],"2028-09-26","2026-01-31",[4503],"Small Cell Lung Carcinoma",[1039,2537],{"trials":4506,"activeCount":109},[],{"trials":4508,"activeCount":109},[],{"trials":4510,"activeCount":109},[],{"intervention":2563,"totalTrials":746,"cells":4512},{"EARLY_PHASE1":4513,"PHASE1":4515,"PHASE2":4521,"PHASE3":4527,"PHASE4":4529,"NA":4531},{"trials":4514,"activeCount":109},[],{"trials":4516,"activeCount":708,"soonestReadout":302},[4517],{"nctId":3492,"briefTitle":3493,"status":121,"phases":4518,"primaryCompletion":302,"completion":1829,"start":3495,"enrollment":44,"conditions":4519,"interventions":4520},[98],[3497],[1036,3499,1028,3500,3501,3502,3503],{"trials":4522,"activeCount":708,"soonestReadout":1938},[4523],{"nctId":2556,"briefTitle":2557,"status":1935,"phases":4524,"primaryCompletion":1938,"completion":1938,"start":1937,"enrollment":536,"conditions":4525,"interventions":4526},[99],[1250],[2561,2562,2563,1028],{"trials":4528,"activeCount":109},[],{"trials":4530,"activeCount":109},[],{"trials":4532,"activeCount":109},[],{"intervention":4534,"totalTrials":746,"cells":4535},"Dara-CyBorD",{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4558,"PHASE4":4560,"NA":4562},{"trials":4537,"activeCount":109},[],{"trials":4539,"activeCount":109},[],{"trials":4541,"activeCount":746,"soonestReadout":741},[4542,4550],{"nctId":4543,"briefTitle":4544,"status":456,"phases":4545,"primaryCompletion":741,"completion":725,"start":4546,"enrollment":477,"conditions":4547,"interventions":4549},"NCT06771180","Dara-BCD for Rare MGRS",[99],"2025-01-15",[4548],"Monoclonal Gammopathy of Renal Significance (MGRS)",[4534],{"nctId":4551,"briefTitle":4552,"status":121,"phases":4553,"primaryCompletion":741,"completion":726,"start":4554,"enrollment":47,"conditions":4555,"interventions":4557},"NCT06418477","Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD",[99],"2024-06-15",[4556],"Monoclonal Gammopathy of Renal Significance",[4534],{"trials":4559,"activeCount":109},[],{"trials":4561,"activeCount":109},[],{"trials":4563,"activeCount":109},[],{"intervention":4118,"totalTrials":746,"cells":4565},{"EARLY_PHASE1":4566,"PHASE1":4568,"PHASE2":4570,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4567,"activeCount":109},[],{"trials":4569,"activeCount":109},[],{"trials":4571,"activeCount":746,"soonestReadout":1019},[4572,4576],{"nctId":4112,"briefTitle":4113,"status":456,"phases":4573,"primaryCompletion":1020,"completion":1020,"start":1780,"enrollment":4091,"conditions":4574,"interventions":4575},[99],[4116],[4118,1059,3767,4119],{"nctId":4577,"briefTitle":4578,"status":456,"phases":4579,"primaryCompletion":1019,"completion":1002,"start":2203,"enrollment":4091,"conditions":4580,"interventions":4583},"NCT07127822","Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H\u002FdMMR Gastric Cancer",[99],[4581,4582],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma","MSI-H Cancer",[4118,4584],"First line chemotherapy plus PD-1\u002FPD-L1 antibody",{"trials":4586,"activeCount":109},[],{"trials":4588,"activeCount":109},[],{"trials":4590,"activeCount":109},[],{"intervention":3815,"totalTrials":746,"cells":4592},{"EARLY_PHASE1":4593,"PHASE1":4595,"PHASE2":4597,"PHASE3":4607,"PHASE4":4609,"NA":4611},{"trials":4594,"activeCount":109},[],{"trials":4596,"activeCount":109},[],{"trials":4598,"activeCount":746,"soonestReadout":2203},[4599,4603],{"nctId":3808,"briefTitle":3809,"status":121,"phases":4600,"primaryCompletion":2203,"completion":726,"start":3811,"enrollment":2732,"conditions":4601,"interventions":4602},[99],[3813],[3815,3779,3816],{"nctId":3818,"briefTitle":3819,"status":456,"phases":4604,"primaryCompletion":726,"completion":726,"start":3821,"enrollment":153,"conditions":4605,"interventions":4606},[99],[3823,3824],[3815,3779,3816],{"trials":4608,"activeCount":109},[],{"trials":4610,"activeCount":109},[],{"trials":4612,"activeCount":109},[],{"intervention":3816,"totalTrials":746,"cells":4614},{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4629,"PHASE4":4631,"NA":4633},{"trials":4616,"activeCount":109},[],{"trials":4618,"activeCount":109},[],{"trials":4620,"activeCount":746,"soonestReadout":2203},[4621,4625],{"nctId":3808,"briefTitle":3809,"status":121,"phases":4622,"primaryCompletion":2203,"completion":726,"start":3811,"enrollment":2732,"conditions":4623,"interventions":4624},[99],[3813],[3815,3779,3816],{"nctId":3818,"briefTitle":3819,"status":456,"phases":4626,"primaryCompletion":726,"completion":726,"start":3821,"enrollment":153,"conditions":4627,"interventions":4628},[99],[3823,3824],[3815,3779,3816],{"trials":4630,"activeCount":109},[],{"trials":4632,"activeCount":109},[],{"trials":4634,"activeCount":109},[],{"intervention":4119,"totalTrials":1456,"cells":4636},{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4641,"PHASE3":4695,"PHASE4":4728,"NA":4730},{"trials":4638,"activeCount":109},[],{"trials":4640,"activeCount":109},[],{"trials":4642,"activeCount":708,"soonestReadout":1020},[4643,4647,4656,4666,4674,4682,4686],{"nctId":3507,"briefTitle":3508,"status":569,"phases":4644,"primaryCompletion":3510,"completion":2824,"start":3511,"enrollment":1894,"conditions":4645,"interventions":4646},[99],[28],[3514,3515,3516],{"nctId":4648,"briefTitle":4649,"status":569,"phases":4650,"primaryCompletion":4651,"completion":1404,"start":4652,"enrollment":2653,"conditions":4653,"interventions":4655},"NCT03567629","Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer",[99],"2021-12-30","2018-05-29",[4654],"mCRC",[1029,4119],{"nctId":4657,"briefTitle":4658,"status":569,"phases":4659,"primaryCompletion":1765,"completion":4660,"start":4661,"enrollment":4662,"conditions":4663,"interventions":4664},"NCT04340401","Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen",[99],"2022-04","2020-05-25",25,[3355],[4665,4119,1059],"SHR-1210",{"nctId":4667,"briefTitle":4668,"status":135,"phases":4669,"primaryCompletion":4670,"completion":4670,"start":4671,"enrollment":1203,"conditions":4672,"interventions":4673},"NCT02864849","Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer",[99],"2019-06","2016-08",[3355],[4119,1059],{"nctId":4675,"briefTitle":4676,"status":435,"phases":4677,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":109,"conditions":4680,"interventions":4681},"NCT04863430","Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach",[99],"2023-07-06","2021-05-11",[28],[2601,4119,4206],{"nctId":4112,"briefTitle":4113,"status":456,"phases":4683,"primaryCompletion":1020,"completion":1020,"start":1780,"enrollment":4091,"conditions":4684,"interventions":4685},[99],[4116],[4118,1059,3767,4119],{"nctId":4687,"briefTitle":4688,"status":569,"phases":4689,"primaryCompletion":4690,"completion":139,"start":4691,"enrollment":47,"conditions":4692,"interventions":4694},"NCT01471132","Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis",[99],"2013-09","2011-09",[28,4693],"Metastases to Perineum",[4119,3501],{"trials":4696,"activeCount":109},[4697,4708,4715],{"nctId":4698,"briefTitle":4699,"status":569,"phases":4700,"primaryCompletion":57,"completion":4701,"start":4702,"enrollment":4703,"conditions":4704,"interventions":4706},"NCT03691454","Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.",[99,100],"2023-06-30","2018-06-28",258,[4705],"Gastric Adenocarcinoma",[4707,4119],"Docetaxel",{"nctId":4709,"briefTitle":4710,"status":569,"phases":4711,"primaryCompletion":668,"completion":4090,"start":4712,"enrollment":2712,"conditions":4713,"interventions":4714},"NCT02767375","Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection",[99,100],"2015-02",[2591],[4119],{"nctId":4716,"briefTitle":4717,"status":569,"phases":4718,"primaryCompletion":4719,"completion":4308,"start":4720,"enrollment":4721,"conditions":4722,"interventions":4725},"NCT03448549","SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients",[100],"2021-01-01","2018-01-01",1191,[4723,4724],"Colorectal Cancer Stage III","Adjuvant Chemotherapy",[4119,4726,4727],"Tegafur，gimeracil and oteracil potassium","Xeloda",{"trials":4729,"activeCount":109},[],{"trials":4731,"activeCount":708,"soonestReadout":4736},[4732,4744,4751],{"nctId":4733,"briefTitle":4734,"status":121,"phases":4735,"primaryCompletion":4736,"completion":2673,"start":4737,"enrollment":4738,"conditions":4739,"interventions":4741},"NCT06894797","Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.",[102],"2026-10-31","2025-04-01",68,[4740],"Locally Advanced Rectal Cancer",[4742,4119,4743],"irinotecan hydrochloride liposome","5-FU",{"nctId":4745,"briefTitle":4746,"status":569,"phases":4747,"primaryCompletion":1404,"completion":1404,"start":4661,"enrollment":4001,"conditions":4748,"interventions":4750},"NCT04405206","Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer",[],[4749],"Rectum Cancer",[4119,1059],{"nctId":4752,"briefTitle":4753,"status":135,"phases":4754,"primaryCompletion":4755,"completion":4755,"start":4671,"enrollment":4738,"conditions":4756,"interventions":4757},"NCT02860234","Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment",[],"2019-11",[3355],[4119,1059],{"intervention":1059,"totalTrials":3887,"cells":4759},{"EARLY_PHASE1":4760,"PHASE1":4762,"PHASE2":4764,"PHASE3":4794,"PHASE4":4800,"NA":4802},{"trials":4761,"activeCount":109},[],{"trials":4763,"activeCount":109},[],{"trials":4765,"activeCount":746,"soonestReadout":615},[4766,4770,4778,4782,4786,4790],{"nctId":4657,"briefTitle":4658,"status":569,"phases":4767,"primaryCompletion":1765,"completion":4660,"start":4661,"enrollment":4662,"conditions":4768,"interventions":4769},[99],[3355],[4665,4119,1059],{"nctId":4771,"briefTitle":4772,"status":569,"phases":4773,"primaryCompletion":3089,"completion":3089,"start":4774,"enrollment":140,"conditions":4775,"interventions":4776},"NCT01167049","Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis",[99],"2009-08",[28],[4777],"CAPECITABINE",{"nctId":3541,"briefTitle":3542,"status":135,"phases":4779,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":4780,"interventions":4781},[99],[3549],[3551,3552,3516],{"nctId":4667,"briefTitle":4668,"status":135,"phases":4783,"primaryCompletion":4670,"completion":4670,"start":4671,"enrollment":1203,"conditions":4784,"interventions":4785},[99],[3355],[4119,1059],{"nctId":1051,"briefTitle":1052,"status":456,"phases":4787,"primaryCompletion":615,"completion":1020,"start":1054,"enrollment":376,"conditions":4788,"interventions":4789},[99],[31,1056],[1058,1007,1059,1060],{"nctId":4112,"briefTitle":4113,"status":456,"phases":4791,"primaryCompletion":1020,"completion":1020,"start":1780,"enrollment":4091,"conditions":4792,"interventions":4793},[99],[4116],[4118,1059,3767,4119],{"trials":4795,"activeCount":109},[4796],{"nctId":3583,"briefTitle":3584,"status":569,"phases":4797,"primaryCompletion":2874,"completion":2874,"start":3586,"enrollment":3587,"conditions":4798,"interventions":4799},[100],[3549],[3501,3552,3552,3516],{"trials":4801,"activeCount":109},[],{"trials":4803,"activeCount":109},[4804,4808],{"nctId":4745,"briefTitle":4746,"status":569,"phases":4805,"primaryCompletion":1404,"completion":1404,"start":4661,"enrollment":4001,"conditions":4806,"interventions":4807},[],[4749],[4119,1059],{"nctId":4752,"briefTitle":4753,"status":135,"phases":4809,"primaryCompletion":4755,"completion":4755,"start":4671,"enrollment":4738,"conditions":4810,"interventions":4811},[],[3355],[4119,1059],{"intervention":2561,"totalTrials":3642,"cells":4813},{"EARLY_PHASE1":4814,"PHASE1":4816,"PHASE2":4818,"PHASE3":4856,"PHASE4":4862,"NA":4864},{"trials":4815,"activeCount":109},[],{"trials":4817,"activeCount":109},[],{"trials":4819,"activeCount":708,"soonestReadout":1938},[4820,4829,4837,4844,4848],{"nctId":4821,"briefTitle":4822,"status":569,"phases":4823,"primaryCompletion":638,"completion":638,"start":1589,"enrollment":4824,"conditions":4825,"interventions":4827},"NCT06422156","SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer",[99],73,[4826],"Advanced Pancreatic Cancer",[2561,4828],"mono-chemotherapy",{"nctId":4830,"briefTitle":4831,"status":569,"phases":4832,"primaryCompletion":4833,"completion":2825,"start":2884,"enrollment":3887,"conditions":4834,"interventions":4835},"NCT01993784","Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.",[98,99],"2014-03",[3578],[4836],"nimotuzumab",{"nctId":4838,"briefTitle":4839,"status":569,"phases":4840,"primaryCompletion":2824,"completion":2824,"start":830,"enrollment":3011,"conditions":4841,"interventions":4843},"NCT03400592","Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma",[99],[4842],"Stomach Neoplasms",[1029,4836],{"nctId":2556,"briefTitle":2557,"status":1935,"phases":4845,"primaryCompletion":1938,"completion":1938,"start":1937,"enrollment":536,"conditions":4846,"interventions":4847},[99],[1250],[2561,2562,2563,1028],{"nctId":4849,"briefTitle":4850,"status":569,"phases":4851,"primaryCompletion":4852,"start":4853,"enrollment":670,"conditions":4854,"interventions":4855},"NCT01336049","Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer",[99],"2011-12","2011-03",[3578],[2561],{"trials":4857,"activeCount":109},[4858],{"nctId":3591,"briefTitle":3592,"status":435,"phases":4859,"primaryCompletion":3594,"completion":3594,"start":2882,"enrollment":109,"conditions":4860,"interventions":4861},[99,100],[1250],[2561,3501,1028],{"trials":4863,"activeCount":109},[],{"trials":4865,"activeCount":708,"soonestReadout":315},[4866,4870],{"nctId":3612,"briefTitle":3613,"status":569,"phases":4867,"primaryCompletion":2930,"completion":315,"start":3594,"enrollment":3615,"conditions":4868,"interventions":4869},[102],[3617],[2561,1028],{"nctId":4871,"briefTitle":4872,"status":456,"phases":4873,"primaryCompletion":315,"completion":438,"start":3933,"enrollment":4874,"conditions":4875,"interventions":4876},"NCT04976478","Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma",[],125,[3617],[2561],{"intervention":3713,"totalTrials":1428,"cells":4878},{"EARLY_PHASE1":4879,"PHASE1":4881,"PHASE2":4883,"PHASE3":4897,"PHASE4":4899,"NA":4901},{"trials":4880,"activeCount":109},[],{"trials":4882,"activeCount":109},[],{"trials":4884,"activeCount":746,"soonestReadout":726},[4885,4889,4893],{"nctId":3705,"briefTitle":3706,"status":569,"phases":4886,"primaryCompletion":3708,"completion":1537,"start":3709,"enrollment":47,"conditions":4887,"interventions":4888},[99],[3711],[1036,3713],{"nctId":3799,"briefTitle":3800,"status":121,"phases":4890,"primaryCompletion":726,"completion":726,"start":3802,"enrollment":3803,"conditions":4891,"interventions":4892},[99],[2692],[3779,3806],{"nctId":3827,"briefTitle":3828,"status":121,"phases":4894,"primaryCompletion":726,"completion":726,"start":3830,"enrollment":617,"conditions":4895,"interventions":4896},[99],[3832],[3779,3713,2601],{"trials":4898,"activeCount":109},[],{"trials":4900,"activeCount":109},[],{"trials":4902,"activeCount":109},[4903,4912],{"nctId":4904,"briefTitle":4905,"status":569,"phases":4906,"primaryCompletion":4201,"completion":4907,"start":4661,"enrollment":4908,"conditions":4909,"interventions":4910},"NCT04431791","Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer",[],"2022-02-01",268,[2692],[3713,4911],"Fruquintinib",{"nctId":4913,"briefTitle":4914,"status":569,"phases":4915,"primaryCompletion":1215,"completion":1215,"start":4916,"enrollment":140,"conditions":4917,"interventions":4920},"NCT05025592","cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC",[],"2021-09-10",[3795,4918,4919,3713],"Transarterial Chemoembolization","Hepatic Arterial Infusion Chemotherapy",[3713],{"intervention":4922,"totalTrials":329,"cells":4923},"Letrozole",{"EARLY_PHASE1":4924,"PHASE1":4926,"PHASE2":4928,"PHASE3":4939,"PHASE4":4941,"NA":4943},{"trials":4925,"activeCount":109},[],{"trials":4927,"activeCount":109},[],{"trials":4929,"activeCount":708,"soonestReadout":3350},[4930],{"nctId":4931,"briefTitle":4932,"status":1935,"phases":4933,"primaryCompletion":3350,"completion":4934,"start":228,"enrollment":376,"conditions":4935,"interventions":4937},"NCT06650748","Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4\u002F6 Inhibitors in HR+\u002FHER2- Breast Cancer",[99],"2028-04-01",[31,4936],"Early-stage Breast Cancer",[4938,4922],"Dalpiciclib",{"trials":4940,"activeCount":109},[],{"trials":4942,"activeCount":109},[],{"trials":4944,"activeCount":708,"soonestReadout":315},[4945,4955],{"nctId":4946,"briefTitle":4947,"status":121,"phases":4948,"primaryCompletion":315,"completion":907,"start":4949,"enrollment":4950,"conditions":4951,"interventions":4954},"NCT04169451","IUI With Letrozole Versus in Natural Cycle",[102],"2022-09-29",982,[4952,4953],"Intrauterine Insemination","Unexplained Infertility",[4922],{"nctId":4956,"briefTitle":4957,"status":135,"phases":4958,"primaryCompletion":958,"completion":2521,"start":4959,"enrollment":376,"conditions":4960,"interventions":4961},"NCT03455426","Intrauterine Insemination With Letrozole Versus in Natural Cycle",[102],"2018-03-15",[1518,4952],[4962],"letrozole",{"intervention":3797,"totalTrials":329,"cells":4964},{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4979,"PHASE4":4981,"NA":4983},{"trials":4966,"activeCount":109},[],{"trials":4968,"activeCount":109},[],{"trials":4970,"activeCount":708,"soonestReadout":3870},[4971,4975],{"nctId":3788,"briefTitle":3789,"status":135,"phases":4972,"primaryCompletion":3791,"completion":3792,"start":3793,"enrollment":3011,"conditions":4973,"interventions":4974},[99],[3795],[3779,3797],{"nctId":3867,"briefTitle":3868,"status":456,"phases":4976,"primaryCompletion":3870,"completion":386,"start":66,"enrollment":3871,"conditions":4977,"interventions":4978},[99],[3873,3874,3875],[3877,3878,3879],{"trials":4980,"activeCount":109},[],{"trials":4982,"activeCount":109},[],{"trials":4984,"activeCount":708,"soonestReadout":725},[4985],{"nctId":4986,"briefTitle":4987,"status":456,"phases":4988,"primaryCompletion":725,"completion":4989,"start":4316,"enrollment":640,"conditions":4990,"interventions":4992},"NCT07466225","HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion",[],"2026-08-31",[4991],"Hepatocellular Carcinoma (HCC)",[3797,4993,4994,4995],"PD-1 Inhibitors","Lenvatinib 1","PD-1 inhibitors 1",{"intervention":1087,"totalTrials":746,"cells":4997},{"EARLY_PHASE1":4998,"PHASE1":5000,"PHASE2":5002,"PHASE3":5008,"PHASE4":5010,"NA":5012},{"trials":4999,"activeCount":109},[],{"trials":5001,"activeCount":109},[],{"trials":5003,"activeCount":708,"soonestReadout":3736},[5004],{"nctId":3733,"briefTitle":3734,"status":456,"phases":5005,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":5006,"interventions":5007},[99],[31],[3741,1087,1088,3742,3743,3744,3745,3746],{"trials":5009,"activeCount":109},[],{"trials":5011,"activeCount":109},[],{"trials":5013,"activeCount":708,"soonestReadout":1082},[5014],{"nctId":1079,"briefTitle":1080,"status":456,"phases":5015,"primaryCompletion":1082,"completion":1083,"start":1054,"enrollment":29,"conditions":5016,"interventions":5017},[],[1056],[1007,1086,1087,1088],{"intervention":1088,"totalTrials":746,"cells":5019},{"EARLY_PHASE1":5020,"PHASE1":5022,"PHASE2":5024,"PHASE3":5030,"PHASE4":5032,"NA":5034},{"trials":5021,"activeCount":109},[],{"trials":5023,"activeCount":109},[],{"trials":5025,"activeCount":708,"soonestReadout":3736},[5026],{"nctId":3733,"briefTitle":3734,"status":456,"phases":5027,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":5028,"interventions":5029},[99],[31],[3741,1087,1088,3742,3743,3744,3745,3746],{"trials":5031,"activeCount":109},[],{"trials":5033,"activeCount":109},[],{"trials":5035,"activeCount":708,"soonestReadout":1082},[5036],{"nctId":1079,"briefTitle":1080,"status":456,"phases":5037,"primaryCompletion":1082,"completion":1083,"start":1054,"enrollment":29,"conditions":5038,"interventions":5039},[],[1056],[1007,1086,1087,1088],{"intervention":3746,"totalTrials":746,"cells":5041},{"EARLY_PHASE1":5042,"PHASE1":5044,"PHASE2":5046,"PHASE3":5052,"PHASE4":5054,"NA":5056},{"trials":5043,"activeCount":109},[],{"trials":5045,"activeCount":109},[],{"trials":5047,"activeCount":708,"soonestReadout":3736},[5048],{"nctId":3733,"briefTitle":3734,"status":456,"phases":5049,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":5050,"interventions":5051},[99],[31],[3741,1087,1088,3742,3743,3744,3745,3746],{"trials":5053,"activeCount":109},[],{"trials":5055,"activeCount":109},[],{"trials":5057,"activeCount":708,"soonestReadout":772},[5058],{"nctId":5059,"briefTitle":5060,"status":456,"phases":5061,"primaryCompletion":772,"completion":5062,"start":5063,"enrollment":168,"conditions":5064,"interventions":5065},"NCT06798246","HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study",[],"2030-01-01","2025-02-01",[3757],[5066,3924,3746,5067],"Chemotherapy","Chemotherapy combined with immunotherapy",{"intervention":5069,"totalTrials":746,"cells":5070},"AK104",{"EARLY_PHASE1":5071,"PHASE1":5073,"PHASE2":5075,"PHASE3":5084,"PHASE4":5086,"NA":5088},{"trials":5072,"activeCount":109},[],{"trials":5074,"activeCount":109},[],{"trials":5076,"activeCount":708,"soonestReadout":438},[5077],{"nctId":5078,"briefTitle":5079,"status":468,"phases":5080,"primaryCompletion":438,"completion":3910,"start":2633,"enrollment":3453,"conditions":5081,"interventions":5083},"NCT04556253","AK104 in Locally Advanced MSI-H\u002FdMMR Gastric Carcinoma and Colorectal Cancer",[99],[5082],"MSI-H\u002FdMMR Gastric Carcinoma and Colorectal Cancer",[5069],{"trials":5085,"activeCount":109},[],{"trials":5087,"activeCount":109},[],{"trials":5089,"activeCount":708,"soonestReadout":5094},[5090],{"nctId":5091,"briefTitle":5092,"status":456,"phases":5093,"primaryCompletion":5094,"completion":5095,"start":5096,"enrollment":2732,"conditions":5097,"interventions":5098},"NCT06062589","AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer",[],"2025-01-11","2027-10-11","2023-10-11",[2681],[5069],{"intervention":5100,"totalTrials":746,"cells":5101},"Lenalidomide",{"EARLY_PHASE1":5102,"PHASE1":5104,"PHASE2":5106,"PHASE3":5118,"PHASE4":5120,"NA":5122},{"trials":5103,"activeCount":109},[],{"trials":5105,"activeCount":109},[],{"trials":5107,"activeCount":708,"soonestReadout":584},[5108],{"nctId":5109,"briefTitle":5110,"status":121,"phases":5111,"primaryCompletion":584,"completion":3130,"start":5112,"enrollment":26,"conditions":5113,"interventions":5116},"NCT07460362","Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma",[99],"2025-08-11",[5114,5115],"MCL","Relapsed or Refractory Mantle Cell Lymphoma (MCL)",[5117,5100],"Glofitamab",{"trials":5119,"activeCount":109},[],{"trials":5121,"activeCount":109},[],{"trials":5123,"activeCount":708,"soonestReadout":726},[5124],{"nctId":5125,"briefTitle":5126,"status":121,"phases":5127,"primaryCompletion":726,"completion":1019,"start":5128,"enrollment":376,"conditions":5129,"interventions":5131},"NCT06697483","Risk Stratification and MRD-driven Maintenance for MM After ASCT",[102],"2024-12-01",[5130],"Multiple Myeloma",[623,5100],{"intervention":5133,"totalTrials":746,"cells":5134},"Lorlatinib 100 mg",{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5139,"PHASE3":5150,"PHASE4":5152,"NA":5154},{"trials":5136,"activeCount":109},[],{"trials":5138,"activeCount":109},[],{"trials":5140,"activeCount":708,"soonestReadout":5145},[5141],{"nctId":5142,"briefTitle":5143,"status":456,"phases":5144,"primaryCompletion":5145,"completion":5146,"start":4041,"enrollment":4662,"conditions":5147,"interventions":5149},"NCT06682884","Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer",[99],"2026-04-30","2027-05-31",[5148],"Neoadjuvant Non-Small Cell Lung Cancer",[5133],{"trials":5151,"activeCount":109},[],{"trials":5153,"activeCount":109},[],{"trials":5155,"activeCount":708,"soonestReadout":5160},[5156],{"nctId":5157,"briefTitle":5158,"status":456,"phases":5159,"primaryCompletion":5160,"completion":5161,"start":5162,"enrollment":376,"conditions":5163,"interventions":5165},"NCT06690541","Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC",[],"2027-04-30","2030-10-31","2024-11-10",[5164],"Lung Cancer, Non-Small Cell",[5133],{"intervention":623,"totalTrials":746,"cells":5167},{"EARLY_PHASE1":5168,"PHASE1":5170,"PHASE2":5172,"PHASE3":5178,"PHASE4":5180,"NA":5182},{"trials":5169,"activeCount":109},[],{"trials":5171,"activeCount":109},[],{"trials":5173,"activeCount":708,"soonestReadout":614},[5174],{"nctId":611,"briefTitle":612,"status":456,"phases":5175,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":5176,"interventions":5177},[99],[619,620],[622,623,557],{"trials":5179,"activeCount":109},[],{"trials":5181,"activeCount":109},[],{"trials":5183,"activeCount":708,"soonestReadout":726},[5184],{"nctId":5125,"briefTitle":5126,"status":121,"phases":5185,"primaryCompletion":726,"completion":1019,"start":5128,"enrollment":376,"conditions":5186,"interventions":5187},[102],[5130],[623,5100],{"intervention":5189,"totalTrials":329,"cells":5190},"Aspirin",{"EARLY_PHASE1":5191,"PHASE1":5193,"PHASE2":5195,"PHASE3":5206,"PHASE4":5219,"NA":5231},{"trials":5192,"activeCount":109},[],{"trials":5194,"activeCount":109},[],{"trials":5196,"activeCount":708,"soonestReadout":726},[5197],{"nctId":5198,"briefTitle":5199,"status":456,"phases":5200,"primaryCompletion":726,"completion":1019,"start":5201,"enrollment":536,"conditions":5202,"interventions":5204},"NCT06531525","Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency",[99],"2024-08-01",[170,5203],"Protein S Deficiency",[5205,5189,5205],"Enoxaparin",{"trials":5207,"activeCount":109},[5208],{"nctId":5209,"briefTitle":5210,"status":135,"phases":5211,"primaryCompletion":5212,"completion":5213,"start":5214,"enrollment":5215,"conditions":5216,"interventions":5218},"NCT02797249","Low Dose Aspirin in the Prevention of Preeclampsia in China",[100],"2019-01-19","2019-03-30","2016-12-07",1000,[5217],"Preeclampsia",[5189],{"trials":5220,"activeCount":109},[5221],{"nctId":5222,"briefTitle":5223,"status":135,"phases":5224,"primaryCompletion":254,"completion":3527,"start":5225,"enrollment":168,"conditions":5226,"interventions":5229},"NCT00847860","Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions",[101],"2008-03",[5227,5228],"Vascular Dementia","Stroke",[5230,5189],"Cilostazol",{"trials":5232,"activeCount":109},[],{"intervention":5234,"totalTrials":405,"cells":5235},"N-acetyl-L-cysteine",{"EARLY_PHASE1":5236,"PHASE1":5238,"PHASE2":5240,"PHASE3":5258,"PHASE4":5277,"NA":5279},{"trials":5237,"activeCount":109},[],{"trials":5239,"activeCount":109},[],{"trials":5241,"activeCount":708,"soonestReadout":5254},[5242,5250],{"nctId":5243,"briefTitle":5244,"status":135,"phases":5245,"primaryCompletion":979,"completion":3023,"start":5246,"enrollment":35,"conditions":5247,"interventions":5249},"NCT03236220","Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation",[99],"2017-08-01",[5248],"Haploidentical Hematopoietic Stem Cell Transplantation",[5234],{"nctId":5251,"briefTitle":5252,"status":468,"phases":5253,"primaryCompletion":5254,"completion":2203,"start":5255,"enrollment":1767,"conditions":5256,"interventions":5257},"NCT06024031","NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy",[99],"2024-09-01","2023-09-10",[2958],[5234],{"trials":5259,"activeCount":109},[5260,5268],{"nctId":5261,"briefTitle":5262,"status":200,"phases":5263,"primaryCompletion":5264,"completion":5264,"start":5265,"enrollment":2770,"conditions":5266,"interventions":5267},"NCT03391856","Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy",[99,100],"2018-12-30","2018-03-01",[3264,3013],[5234],{"nctId":5269,"briefTitle":5270,"status":569,"phases":5271,"primaryCompletion":5272,"completion":5273,"start":5274,"enrollment":2653,"conditions":5275,"interventions":5276},"NCT03967665","Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution",[100],"2021-09-05","2024-10-01","2018-10-01",[3013],[5234],{"trials":5278,"activeCount":109},[],{"trials":5280,"activeCount":109},[],{"intervention":5282,"totalTrials":405,"cells":5283},"Iguratimod",{"EARLY_PHASE1":5284,"PHASE1":5286,"PHASE2":5288,"PHASE3":5315,"PHASE4":5326,"NA":5328},{"trials":5285,"activeCount":109},[],{"trials":5287,"activeCount":109},[],{"trials":5289,"activeCount":708,"soonestReadout":968},[5290,5298,5306],{"nctId":5291,"briefTitle":5292,"status":569,"phases":5293,"primaryCompletion":5294,"completion":1404,"start":5295,"enrollment":574,"conditions":5296,"interventions":5297},"NCT05281068","The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2023-09-01","2021-09-01",[576,34],[5282,2657],{"nctId":5299,"briefTitle":5300,"status":569,"phases":5301,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":376,"conditions":5304,"interventions":5305},"NCT05302024","Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2023-12-12","2022-03-22",[34],[5282],{"nctId":5307,"briefTitle":5308,"status":456,"phases":5309,"primaryCompletion":968,"completion":5310,"start":5311,"enrollment":574,"conditions":5312,"interventions":5313},"NCT07057778","Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP",[99],"2027-07-01","2025-07-01",[588],[5282,5314],"low-dose rituximab",{"trials":5316,"activeCount":109},[5317],{"nctId":5318,"briefTitle":5319,"status":569,"phases":5320,"primaryCompletion":2930,"completion":2930,"start":5321,"enrollment":640,"conditions":5322,"interventions":5325},"NCT05216757","Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)",[99,100],"2022-03",[5323,5324],"Hand Osteoarthritis","Inflammatory Arthritis",[5282],{"trials":5327,"activeCount":109},[],{"trials":5329,"activeCount":109},[],{"intervention":5331,"totalTrials":405,"cells":5332},"Pirarubicin",{"EARLY_PHASE1":5333,"PHASE1":5335,"PHASE2":5337,"PHASE3":5365,"PHASE4":5379,"NA":5381},{"trials":5334,"activeCount":109},[],{"trials":5336,"activeCount":109},[],{"trials":5338,"activeCount":708,"soonestReadout":5352},[5339,5348,5358],{"nctId":5340,"briefTitle":5341,"status":569,"phases":5342,"primaryCompletion":3698,"start":5343,"enrollment":168,"conditions":5344,"interventions":5347},"NCT02923557","Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients",[99],"2016-11",[5345,3757,5346],"Bladder Recurrence","Nephroureterectomy",[5331],{"nctId":5349,"briefTitle":5350,"status":121,"phases":5351,"primaryCompletion":5352,"completion":314,"start":5353,"enrollment":728,"conditions":5354,"interventions":5355},"NCT06714383","Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma",[99],"2025-07","2024-11-13",[2532],[5356,5331,5357],"Trilaciclib","Lobaplatin",{"nctId":5359,"briefTitle":5360,"status":569,"phases":5361,"primaryCompletion":5362,"completion":439,"start":4671,"enrollment":168,"conditions":5363,"interventions":5364},"NCT02740426","Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients",[99],"2021-05",[3757,5345],[5331],{"trials":5366,"activeCount":109},[5367],{"nctId":5368,"briefTitle":5369,"status":435,"phases":5370,"primaryCompletion":5371,"completion":5372,"start":5373,"enrollment":109,"conditions":5374,"interventions":5377},"NCT03342300","Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma",[99,100],"2020-11-15","2020-12-30","2017-11-06",[5375,195,5376],"Progression-free Survival","Toxicity",[1155,5378],"pirarubicin",{"trials":5380,"activeCount":109},[],{"trials":5382,"activeCount":109},[],{"intervention":2601,"totalTrials":477,"cells":5384},{"EARLY_PHASE1":5385,"PHASE1":5387,"PHASE2":5395,"PHASE3":5465,"PHASE4":5467,"NA":5469},{"trials":5386,"activeCount":109},[],{"trials":5388,"activeCount":109},[5389],{"nctId":5390,"briefTitle":5391,"status":135,"phases":5392,"primaryCompletion":4090,"completion":4090,"start":669,"enrollment":2509,"conditions":5393,"interventions":5394},"NCT02645864","Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma",[98],[1250],[2601,1029],{"trials":5396,"activeCount":708,"soonestReadout":726},[5397,5406,5415,5424,5432,5440,5444,5451,5461],{"nctId":5398,"briefTitle":5399,"status":569,"phases":5400,"primaryCompletion":5401,"completion":5401,"start":5402,"enrollment":1767,"conditions":5403,"interventions":5405},"NCT03422445","A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma",[99],"2019-02","2018-01-08",[5404],"Advanced Melanoma",[2601,2600],{"nctId":5407,"briefTitle":5408,"status":396,"phases":5409,"primaryCompletion":5410,"completion":5410,"start":191,"enrollment":658,"conditions":5411,"interventions":5413},"NCT04824352","Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma",[99],"2026-04-01",[5412,2534],"Effect of Drug",[5414],"apatinib",{"nctId":5416,"briefTitle":5417,"status":135,"phases":5418,"primaryCompletion":5419,"completion":5420,"start":4720,"enrollment":26,"conditions":5421,"interventions":5423},"NCT03359018","Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma",[99],"2019-10-22","2020-01-30",[5375,195,5422,5376],"Clinical Benefit Rate",[2601,4665],{"nctId":5425,"briefTitle":5426,"status":200,"phases":5427,"primaryCompletion":5428,"completion":5428,"start":5429,"enrollment":4065,"conditions":5430,"interventions":5431},"NCT03251417","Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma",[99],"2021-04-25","2017-09-10",[1250],[1029,2601],{"nctId":5433,"briefTitle":5434,"status":135,"phases":5435,"primaryCompletion":5436,"completion":5436,"start":5437,"enrollment":1767,"conditions":5438,"interventions":5439},"NCT02878057","Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)",[99],"2020-09-02","2016-05",[31],[2601],{"nctId":4675,"briefTitle":4676,"status":435,"phases":5441,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":109,"conditions":5442,"interventions":5443},[99],[28],[2601,4119,4206],{"nctId":5445,"briefTitle":5446,"status":569,"phases":5447,"primaryCompletion":4090,"completion":5448,"start":2883,"enrollment":1767,"conditions":5449,"interventions":5450},"NCT02727309","A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients",[98,99],"2019-03",[2591],[2601],{"nctId":5452,"briefTitle":5453,"status":435,"phases":5454,"primaryCompletion":958,"completion":5455,"start":5456,"enrollment":109,"conditions":5457,"interventions":5460},"NCT03104335","Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial",[99],"2020-03-01","2017-04-01",[5458,5459],"Soft Tissue Sarcoma Adult","Advanced Cancer",[2601],{"nctId":3827,"briefTitle":3828,"status":121,"phases":5462,"primaryCompletion":726,"completion":726,"start":3830,"enrollment":617,"conditions":5463,"interventions":5464},[99],[3832],[3779,3713,2601],{"trials":5466,"activeCount":109},[],{"trials":5468,"activeCount":109},[],{"trials":5470,"activeCount":109},[],{"intervention":1029,"totalTrials":3642,"cells":5472},{"EARLY_PHASE1":5473,"PHASE1":5475,"PHASE2":5481,"PHASE3":5519,"PHASE4":5521,"NA":5523},{"trials":5474,"activeCount":109},[],{"trials":5476,"activeCount":109},[5477],{"nctId":5390,"briefTitle":5391,"status":135,"phases":5478,"primaryCompletion":4090,"completion":4090,"start":669,"enrollment":2509,"conditions":5479,"interventions":5480},[98],[1250],[2601,1029],{"trials":5482,"activeCount":708,"soonestReadout":1019},[5483,5487,5495,5503,5507,5511,5515],{"nctId":4648,"briefTitle":4649,"status":569,"phases":5484,"primaryCompletion":4651,"completion":1404,"start":4652,"enrollment":2653,"conditions":5485,"interventions":5486},[99],[4654],[1029,4119],{"nctId":5488,"briefTitle":5489,"status":569,"phases":5490,"primaryCompletion":3634,"completion":3594,"start":5491,"enrollment":3453,"conditions":5492,"interventions":5494},"NCT03416517","Anlotinib and Irinotecan for Ewing Sarcoma",[98,99],"2018-01-22",[5493],"Ewing's Tumor Metastatic",[3684,1029],{"nctId":5496,"briefTitle":5497,"status":569,"phases":5498,"primaryCompletion":3635,"completion":3911,"start":5499,"enrollment":960,"conditions":5500,"interventions":5502},"NCT05818982","To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC",[99],"2023-02-09",[5501],"Advanced Esophageal Squamous Cell Carcinoma",[3936,1029],{"nctId":1016,"briefTitle":1017,"status":456,"phases":5504,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":5505,"interventions":5506},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":5425,"briefTitle":5426,"status":200,"phases":5508,"primaryCompletion":5428,"completion":5428,"start":5429,"enrollment":4065,"conditions":5509,"interventions":5510},[99],[1250],[1029,2601],{"nctId":4838,"briefTitle":4839,"status":569,"phases":5512,"primaryCompletion":2824,"completion":2824,"start":830,"enrollment":3011,"conditions":5513,"interventions":5514},[99],[4842],[1029,4836],{"nctId":3946,"briefTitle":3947,"status":569,"phases":5516,"primaryCompletion":3949,"completion":3950,"start":3951,"enrollment":658,"conditions":5517,"interventions":5518},[98,99],[3953],[1037,3767,1029],{"trials":5520,"activeCount":109},[],{"trials":5522,"activeCount":109},[],{"trials":5524,"activeCount":109},[],{"intervention":590,"totalTrials":405,"cells":5526},{"EARLY_PHASE1":5527,"PHASE1":5529,"PHASE2":5531,"PHASE3":5557,"PHASE4":5559,"NA":5561},{"trials":5528,"activeCount":109},[],{"trials":5530,"activeCount":109},[],{"trials":5532,"activeCount":708,"soonestReadout":583},[5533,5537,5541,5549],{"nctId":580,"briefTitle":581,"status":121,"phases":5534,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":5535,"interventions":5536},[99],[588],[590,557],{"nctId":592,"briefTitle":593,"status":435,"phases":5538,"primaryCompletion":595,"completion":596,"start":597,"enrollment":109,"conditions":5539,"interventions":5540},[99],[34],[590,557],{"nctId":5542,"briefTitle":5543,"status":569,"phases":5544,"primaryCompletion":969,"completion":5545,"start":5546,"enrollment":32,"conditions":5547,"interventions":5548},"NCT06190145","Teriflunomide for Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2025-06-15","2023-12-05",[34],[590],{"nctId":5550,"briefTitle":5551,"status":569,"phases":5552,"primaryCompletion":4238,"completion":5553,"start":5546,"enrollment":5554,"conditions":5555,"interventions":5556},"NCT06176911","The Combination of Teriflunomide and Danazol for Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2025-07-15",124,[34],[590,2657],{"trials":5558,"activeCount":109},[],{"trials":5560,"activeCount":109},[],{"trials":5562,"activeCount":109},[],{"intervention":1045,"totalTrials":329,"cells":5564},{"EARLY_PHASE1":5565,"PHASE1":5567,"PHASE2":5569,"PHASE3":5588,"PHASE4":5590,"NA":5592},{"trials":5566,"activeCount":109},[],{"trials":5568,"activeCount":109},[],{"trials":5570,"activeCount":708,"soonestReadout":1019},[5571,5575,5579],{"nctId":3086,"briefTitle":3087,"status":569,"phases":5572,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":32,"conditions":5573,"interventions":5574},[99],[2580],[3094,3077],{"nctId":1016,"briefTitle":1017,"status":456,"phases":5576,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":5577,"interventions":5578},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":5580,"briefTitle":5581,"status":135,"phases":5582,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":708,"conditions":5585,"interventions":5587},"NCT00881049","Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma",[99],"2011-01","2008-12",[5586],"Metastatic Melanoma",[1045],{"trials":5589,"activeCount":109},[],{"trials":5591,"activeCount":109},[],{"trials":5593,"activeCount":109},[],{"intervention":3744,"totalTrials":746,"cells":5595},{"EARLY_PHASE1":5596,"PHASE1":5598,"PHASE2":5600,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5597,"activeCount":109},[],{"trials":5599,"activeCount":109},[],{"trials":5601,"activeCount":708,"soonestReadout":3736},[5602,5606],{"nctId":3733,"briefTitle":3734,"status":456,"phases":5603,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":5604,"interventions":5605},[99],[31],[3741,1087,1088,3742,3743,3744,3745,3746],{"nctId":5607,"briefTitle":5608,"status":569,"phases":5609,"primaryCompletion":5610,"completion":5611,"start":5612,"enrollment":5613,"conditions":5614,"interventions":5616},"NCT05969184","Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC",[99],"2023-12-25","2024-12-25","2021-12-25",94,[5615],"Breast Neoplasm Female",[3744],{"trials":5618,"activeCount":109},[],{"trials":5620,"activeCount":109},[],{"trials":5622,"activeCount":109},[],{"intervention":5624,"totalTrials":746,"cells":5625},"Camrelizumab plus Apatinib",{"EARLY_PHASE1":5626,"PHASE1":5628,"PHASE2":5630,"PHASE3":5651,"PHASE4":5653,"NA":5655},{"trials":5627,"activeCount":109},[],{"trials":5629,"activeCount":109},[],{"trials":5631,"activeCount":708,"soonestReadout":5636},[5632,5643],{"nctId":5633,"briefTitle":5634,"status":121,"phases":5635,"primaryCompletion":5636,"completion":3656,"start":4308,"enrollment":5637,"conditions":5638,"interventions":5640},"NCT06360042","Anti-PD-1\u002FPD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC",[99],"2027-03-31",111,[5639],"Unresectable Hepatocellular Carcinoma",[5641,5642,5624],"Adebrelimab plus Apatinib","Adebrelimab plus Bevacizumab",{"nctId":5644,"briefTitle":5645,"status":569,"phases":5646,"primaryCompletion":81,"completion":1103,"start":5647,"enrollment":2008,"conditions":5648,"interventions":5649},"NCT04609176","Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",[99],"2020-11-18",[28],[5650,5624],"Camrelizumab plus Apatinib and SOX",{"trials":5652,"activeCount":109},[],{"trials":5654,"activeCount":109},[],{"trials":5656,"activeCount":109},[],{"intervention":4229,"totalTrials":746,"cells":5658},{"EARLY_PHASE1":5659,"PHASE1":5661,"PHASE2":5663,"PHASE3":5673,"PHASE4":5675,"NA":5677},{"trials":5660,"activeCount":109},[],{"trials":5662,"activeCount":109},[],{"trials":5664,"activeCount":708,"soonestReadout":412},[5665,5669],{"nctId":4222,"briefTitle":4223,"status":569,"phases":5666,"primaryCompletion":1138,"completion":2853,"start":4225,"enrollment":153,"conditions":5667,"interventions":5668},[98,99],[4227],[1035,4229],{"nctId":4244,"briefTitle":4245,"status":121,"phases":5670,"primaryCompletion":412,"completion":412,"start":4247,"enrollment":1767,"conditions":5671,"interventions":5672},[99],[4249],[1035,4229,4251],{"trials":5674,"activeCount":109},[],{"trials":5676,"activeCount":109},[],{"trials":5678,"activeCount":109},[],{"intervention":5680,"totalTrials":746,"cells":5681},"Ensartinib",{"EARLY_PHASE1":5682,"PHASE1":5684,"PHASE2":5686,"PHASE3":5704,"PHASE4":5706,"NA":5708},{"trials":5683,"activeCount":109},[],{"trials":5685,"activeCount":109},[],{"trials":5687,"activeCount":708,"soonestReadout":5699},[5688,5695],{"nctId":5689,"briefTitle":5690,"status":569,"phases":5691,"primaryCompletion":1404,"completion":4000,"start":215,"enrollment":477,"conditions":5692,"interventions":5694},"NCT05380024","A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer",[99],[5693],"Non Small Cell Lung Cancer",[5680],{"nctId":5696,"briefTitle":5697,"status":456,"phases":5698,"primaryCompletion":5699,"completion":5700,"start":4546,"enrollment":670,"conditions":5701,"interventions":5703},"NCT06780839","Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD",[99],"2029-01-15","2030-01-15",[5702],"NSCLC, Stage I, II, IIIA, IIIB",[5680],{"trials":5705,"activeCount":109},[],{"trials":5707,"activeCount":109},[],{"trials":5709,"activeCount":109},[],{"intervention":1031,"totalTrials":746,"cells":5711},{"EARLY_PHASE1":5712,"PHASE1":5714,"PHASE2":5716,"PHASE3":5730,"PHASE4":5732,"NA":5734},{"trials":5713,"activeCount":109},[],{"trials":5715,"activeCount":109},[],{"trials":5717,"activeCount":708,"soonestReadout":1019},[5718,5726],{"nctId":5719,"briefTitle":5720,"status":569,"phases":5721,"primaryCompletion":648,"completion":5722,"start":5723,"enrollment":960,"conditions":5724,"interventions":5725},"NCT04023617","A Study of Nivolumab +\u002F- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC",[99],"2021-05-30","2019-07-08",[695,4707,1031],[1031],{"nctId":1016,"briefTitle":1017,"status":456,"phases":5727,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":5728,"interventions":5729},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":5731,"activeCount":109},[],{"trials":5733,"activeCount":109},[],{"trials":5735,"activeCount":109},[],{"intervention":1046,"totalTrials":746,"cells":5737},{"EARLY_PHASE1":5738,"PHASE1":5740,"PHASE2":5742,"PHASE3":5755,"PHASE4":5757,"NA":5759},{"trials":5739,"activeCount":109},[],{"trials":5741,"activeCount":109},[],{"trials":5743,"activeCount":708,"soonestReadout":1019},[5744,5748],{"nctId":1016,"briefTitle":1017,"status":456,"phases":5745,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":5746,"interventions":5747},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"nctId":5749,"briefTitle":5750,"status":569,"phases":5751,"primaryCompletion":2521,"completion":648,"start":5752,"enrollment":140,"conditions":5753,"interventions":5754},"NCT03454919","Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations",[99],"2018-03-30",[2580],[1046],{"trials":5756,"activeCount":109},[],{"trials":5758,"activeCount":109},[],{"trials":5760,"activeCount":109},[],{"intervention":5762,"totalTrials":746,"cells":5763},"Niraparib",{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5778,"PHASE3":5788,"PHASE4":5790,"NA":5792},{"trials":5765,"activeCount":109},[],{"trials":5767,"activeCount":109},[5768],{"nctId":5769,"briefTitle":5770,"status":569,"phases":5771,"primaryCompletion":5772,"completion":5773,"start":191,"enrollment":2522,"conditions":5774,"interventions":5777},"NCT04764084","Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors",[98],"2021-11-01","2023-02-28",[5775,4705,5776,684],"HER2-negative Breast Cancer","Cholangiocarcinoma",[5762,3684],{"trials":5779,"activeCount":708,"soonestReadout":385},[5780],{"nctId":5781,"briefTitle":5782,"status":121,"phases":5783,"primaryCompletion":385,"completion":5784,"start":316,"enrollment":3132,"conditions":5785,"interventions":5787},"NCT06141265","Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab",[99],"2027-09",[5786],"Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma",[5762],{"trials":5789,"activeCount":109},[],{"trials":5791,"activeCount":109},[],{"trials":5793,"activeCount":109},[],{"intervention":5795,"totalTrials":746,"cells":5796},"Baricitinib",{"EARLY_PHASE1":5797,"PHASE1":5799,"PHASE2":5801,"PHASE3":5820,"PHASE4":5822,"NA":5824},{"trials":5798,"activeCount":109},[],{"trials":5800,"activeCount":109},[],{"trials":5802,"activeCount":708,"soonestReadout":1019},[5803,5813],{"nctId":5804,"briefTitle":5805,"status":456,"phases":5806,"primaryCompletion":1019,"completion":5807,"start":5808,"enrollment":3871,"conditions":5809,"interventions":5812},"NCT07535645","Baricitinib for Post-HSCT Persistent Thrombocytopenia",[98,99],"2029-09-15","2026-04-15",[5810,5811],"Persistent Thrombocytopenia","Allogeneic Hematopoietic Stem Cell Transplantation",[5795],{"nctId":5814,"briefTitle":5815,"status":569,"phases":5816,"primaryCompletion":818,"completion":71,"start":5817,"enrollment":35,"conditions":5818,"interventions":5819},"NCT05446831","Baricitinib for Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2022-07-13",[576,34],[5795],{"trials":5821,"activeCount":109},[],{"trials":5823,"activeCount":109},[],{"trials":5825,"activeCount":109},[],{"intervention":5827,"totalTrials":708,"cells":5828},"Camrelizumab+Fluzoparib",{"EARLY_PHASE1":5829,"PHASE1":5831,"PHASE2":5833,"PHASE3":5843,"PHASE4":5845,"NA":5847},{"trials":5830,"activeCount":109},[],{"trials":5832,"activeCount":109},[],{"trials":5834,"activeCount":708,"soonestReadout":742},[5835],{"nctId":5836,"briefTitle":5837,"status":1935,"phases":5838,"primaryCompletion":742,"completion":726,"start":5839,"enrollment":5613,"conditions":5840,"interventions":5842},"NCT05576389","Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer",[99],"2022-10-01",[5841],"Germline BRCA-mutated HER2-negative Breast Cancer",[5827],{"trials":5844,"activeCount":109},[],{"trials":5846,"activeCount":109},[],{"trials":5848,"activeCount":109},[],{"intervention":5850,"totalTrials":708,"cells":5851},"regorafenib combined with envafolimab",{"EARLY_PHASE1":5852,"PHASE1":5854,"PHASE2":5856,"PHASE3":5867,"PHASE4":5869,"NA":5871},{"trials":5853,"activeCount":109},[],{"trials":5855,"activeCount":109},[],{"trials":5857,"activeCount":708,"soonestReadout":628},[5858],{"nctId":5859,"briefTitle":5860,"status":456,"phases":5861,"primaryCompletion":628,"completion":5862,"start":629,"enrollment":376,"conditions":5863,"interventions":5865},"NCT06772233","A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment",[99],"2028-07-30",[5864],"Metastatic Gastrointestinal Stromal Tumors (GIST)",[5850,5866],"Control Group",{"trials":5868,"activeCount":109},[],{"trials":5870,"activeCount":109},[],{"trials":5872,"activeCount":109},[],{"intervention":5866,"totalTrials":708,"cells":5874},{"EARLY_PHASE1":5875,"PHASE1":5877,"PHASE2":5879,"PHASE3":5885,"PHASE4":5887,"NA":5889},{"trials":5876,"activeCount":109},[],{"trials":5878,"activeCount":109},[],{"trials":5880,"activeCount":708,"soonestReadout":628},[5881],{"nctId":5859,"briefTitle":5860,"status":456,"phases":5882,"primaryCompletion":628,"completion":5862,"start":629,"enrollment":376,"conditions":5883,"interventions":5884},[99],[5864],[5850,5866],{"trials":5886,"activeCount":109},[],{"trials":5888,"activeCount":109},[],{"trials":5890,"activeCount":109},[],{"intervention":3742,"totalTrials":708,"cells":5892},{"EARLY_PHASE1":5893,"PHASE1":5895,"PHASE2":5897,"PHASE3":5903,"PHASE4":5905,"NA":5907},{"trials":5894,"activeCount":109},[],{"trials":5896,"activeCount":109},[],{"trials":5898,"activeCount":708,"soonestReadout":3736},[5899],{"nctId":3733,"briefTitle":3734,"status":456,"phases":5900,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":5901,"interventions":5902},[99],[31],[3741,1087,1088,3742,3743,3744,3745,3746],{"trials":5904,"activeCount":109},[],{"trials":5906,"activeCount":109},[],{"trials":5908,"activeCount":109},[],{"intervention":3745,"totalTrials":708,"cells":5910},{"EARLY_PHASE1":5911,"PHASE1":5913,"PHASE2":5915,"PHASE3":5921,"PHASE4":5923,"NA":5925},{"trials":5912,"activeCount":109},[],{"trials":5914,"activeCount":109},[],{"trials":5916,"activeCount":708,"soonestReadout":3736},[5917],{"nctId":3733,"briefTitle":3734,"status":456,"phases":5918,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":5919,"interventions":5920},[99],[31],[3741,1087,1088,3742,3743,3744,3745,3746],{"trials":5922,"activeCount":109},[],{"trials":5924,"activeCount":109},[],{"trials":5926,"activeCount":109},[],{"intervention":5928,"totalTrials":708,"cells":5929},"DAPT regimen plus radiotherapy",{"EARLY_PHASE1":5930,"PHASE1":5932,"PHASE2":5934,"PHASE3":5945,"PHASE4":5947,"NA":5949},{"trials":5931,"activeCount":109},[],{"trials":5933,"activeCount":109},[],{"trials":5935,"activeCount":708,"soonestReadout":438},[5936],{"nctId":5937,"briefTitle":5938,"status":121,"phases":5939,"primaryCompletion":438,"completion":3910,"start":5940,"enrollment":5941,"conditions":5942,"interventions":5944},"NCT07000617","A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I\u002FII Extranodal NK\u002FT-cell Lymphoma",[99],"2025-03-21",57,[5943],"NK\u002FT Cell Lymphoma",[5928],{"trials":5946,"activeCount":109},[],{"trials":5948,"activeCount":109},[],{"trials":5950,"activeCount":109},[],{"intervention":5117,"totalTrials":708,"cells":5952},{"EARLY_PHASE1":5953,"PHASE1":5955,"PHASE2":5957,"PHASE3":5963,"PHASE4":5965,"NA":5967},{"trials":5954,"activeCount":109},[],{"trials":5956,"activeCount":109},[],{"trials":5958,"activeCount":708,"soonestReadout":584},[5959],{"nctId":5109,"briefTitle":5110,"status":121,"phases":5960,"primaryCompletion":584,"completion":3130,"start":5112,"enrollment":26,"conditions":5961,"interventions":5962},[99],[5114,5115],[5117,5100],{"trials":5964,"activeCount":109},[],{"trials":5966,"activeCount":109},[],{"trials":5968,"activeCount":109},[],{"intervention":95,"totalTrials":708,"cells":5970},{"EARLY_PHASE1":5971,"PHASE1":5973,"PHASE2":5975,"PHASE3":5981,"PHASE4":5983,"NA":5985},{"trials":5972,"activeCount":109},[],{"trials":5974,"activeCount":109},[],{"trials":5976,"activeCount":708,"soonestReadout":94},[5977],{"nctId":92,"briefTitle":93,"status":121,"phases":5978,"primaryCompletion":94,"completion":1963,"start":3519,"enrollment":3520,"conditions":5979,"interventions":5980},[99],[2680],[95,1028,3500,3499],{"trials":5982,"activeCount":109},[],{"trials":5984,"activeCount":109},[],{"trials":5986,"activeCount":109},[],{"intervention":1107,"totalTrials":708,"cells":5988},{"EARLY_PHASE1":5989,"PHASE1":5991,"PHASE2":5993,"PHASE3":5999,"PHASE4":6001,"NA":6003},{"trials":5990,"activeCount":109},[],{"trials":5992,"activeCount":109},[],{"trials":5994,"activeCount":708,"soonestReadout":1103},[5995],{"nctId":1100,"briefTitle":1101,"status":121,"phases":5996,"primaryCompletion":1103,"completion":741,"start":1104,"enrollment":376,"conditions":5997,"interventions":5998},[99],[34],[1090,1107],{"trials":6000,"activeCount":109},[],{"trials":6002,"activeCount":109},[],{"trials":6004,"activeCount":109},[],{"intervention":6006,"totalTrials":708,"cells":6007},"niacin sustained release",{"EARLY_PHASE1":6008,"PHASE1":6010,"PHASE2":6012,"PHASE3":6024,"PHASE4":6026,"NA":6028},{"trials":6009,"activeCount":109},[],{"trials":6011,"activeCount":109},[],{"trials":6013,"activeCount":708,"soonestReadout":6018},[6014],{"nctId":6015,"briefTitle":6016,"status":456,"phases":6017,"primaryCompletion":6018,"completion":6019,"start":6020,"enrollment":140,"conditions":6021,"interventions":6023},"NCT07004725","Therapy of Niacin for Rheumatoid Arthritis",[99],"2027-01-03","2027-06-15","2025-05-28",[6022],"Rheumatoid Arthritis (RA)",[6006],{"trials":6025,"activeCount":109},[],{"trials":6027,"activeCount":109},[],{"trials":6029,"activeCount":109},[],{"intervention":6031,"totalTrials":708,"cells":6032},"Darolutamide+ADT",{"EARLY_PHASE1":6033,"PHASE1":6035,"PHASE2":6037,"PHASE3":6048,"PHASE4":6050,"NA":6052},{"trials":6034,"activeCount":109},[],{"trials":6036,"activeCount":109},[],{"trials":6038,"activeCount":708,"soonestReadout":6043},[6039],{"nctId":6040,"briefTitle":6041,"status":121,"phases":6042,"primaryCompletion":6043,"completion":2730,"start":6044,"enrollment":6045,"conditions":6046,"interventions":6047},"NCT06029036","A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer",[99],"2025-07-31","2023-08-05",53,[37],[6031],{"trials":6049,"activeCount":109},[],{"trials":6051,"activeCount":109},[],{"trials":6053,"activeCount":109},[],{"intervention":6055,"totalTrials":708,"cells":6056},"N Acetyl L Cysteine",{"EARLY_PHASE1":6057,"PHASE1":6059,"PHASE2":6061,"PHASE3":6071,"PHASE4":6073,"NA":6075},{"trials":6058,"activeCount":109},[],{"trials":6060,"activeCount":109},[],{"trials":6062,"activeCount":708,"soonestReadout":1103},[6063],{"nctId":6064,"briefTitle":6065,"status":456,"phases":6066,"primaryCompletion":1103,"completion":5311,"start":6067,"enrollment":1767,"conditions":6068,"interventions":6070},"NCT06518044","NAC for Hematopoietic Recovery in SAA",[99],"2024-07-25",[6069],"Aplastic Anemia",[6055],{"trials":6072,"activeCount":109},[],{"trials":6074,"activeCount":109},[],{"trials":6076,"activeCount":109},[],{"intervention":5641,"totalTrials":708,"cells":6078},{"EARLY_PHASE1":6079,"PHASE1":6081,"PHASE2":6083,"PHASE3":6089,"PHASE4":6091,"NA":6093},{"trials":6080,"activeCount":109},[],{"trials":6082,"activeCount":109},[],{"trials":6084,"activeCount":708,"soonestReadout":5636},[6085],{"nctId":5633,"briefTitle":5634,"status":121,"phases":6086,"primaryCompletion":5636,"completion":3656,"start":4308,"enrollment":5637,"conditions":6087,"interventions":6088},[99],[5639],[5641,5642,5624],{"trials":6090,"activeCount":109},[],{"trials":6092,"activeCount":109},[],{"trials":6094,"activeCount":109},[],{"intervention":5642,"totalTrials":708,"cells":6096},{"EARLY_PHASE1":6097,"PHASE1":6099,"PHASE2":6101,"PHASE3":6107,"PHASE4":6109,"NA":6111},{"trials":6098,"activeCount":109},[],{"trials":6100,"activeCount":109},[],{"trials":6102,"activeCount":708,"soonestReadout":5636},[6103],{"nctId":5633,"briefTitle":5634,"status":121,"phases":6104,"primaryCompletion":5636,"completion":3656,"start":4308,"enrollment":5637,"conditions":6105,"interventions":6106},[99],[5639],[5641,5642,5624],{"trials":6108,"activeCount":109},[],{"trials":6110,"activeCount":109},[],{"trials":6112,"activeCount":109},[],{"intervention":6114,"totalTrials":708,"cells":6115},"Human Dental Fulp Stem Cells",{"EARLY_PHASE1":6116,"PHASE1":6118,"PHASE2":6120,"PHASE3":6132,"PHASE4":6134,"NA":6136},{"trials":6117,"activeCount":109},[],{"trials":6119,"activeCount":109},[],{"trials":6121,"activeCount":708,"soonestReadout":6126},[6122],{"nctId":6123,"briefTitle":6124,"status":121,"phases":6125,"primaryCompletion":6126,"completion":2905,"start":6127,"enrollment":6128,"conditions":6129,"interventions":6131},"NCT05924373","Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients",[99],"2025-03-07","2023-11-27",204,[6130],"Periodontitis",[6114],{"trials":6133,"activeCount":109},[],{"trials":6135,"activeCount":109},[],{"trials":6137,"activeCount":109},[],{"intervention":6139,"totalTrials":708,"cells":6140},"neoadjuvant Radiation plus SOX and PD-1 antibody",{"EARLY_PHASE1":6141,"PHASE1":6143,"PHASE2":6145,"PHASE3":6154,"PHASE4":6156,"NA":6158},{"trials":6142,"activeCount":109},[],{"trials":6144,"activeCount":109},[],{"trials":6146,"activeCount":708,"soonestReadout":6151},[6147],{"nctId":6148,"briefTitle":6149,"status":456,"phases":6150,"primaryCompletion":6151,"completion":906,"start":3679,"enrollment":3528,"conditions":6152,"interventions":6153},"NCT05505461","Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma",[99],"2025-01",[3855],[6139],{"trials":6155,"activeCount":109},[],{"trials":6157,"activeCount":109},[],{"trials":6159,"activeCount":109},[],{"intervention":6161,"totalTrials":708,"cells":6162},"Nanobody-Based CD19\u002FCD22 Tandem Dual CAR-T",{"EARLY_PHASE1":6163,"PHASE1":6165,"PHASE2":6167,"PHASE3":6177,"PHASE4":6179,"NA":6181},{"trials":6164,"activeCount":109},[],{"trials":6166,"activeCount":109},[],{"trials":6168,"activeCount":708,"soonestReadout":726},[6169],{"nctId":6170,"briefTitle":6171,"status":121,"phases":6172,"primaryCompletion":726,"completion":1002,"start":6173,"enrollment":728,"conditions":6174,"interventions":6176},"NCT06880913","Nanobody-Based CD19\u002FCD22 Tandem Dual CAR-T Therapy for R\u002FR B-ALL",[98,99],"2024-11-14",[6175],"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma",[6161],{"trials":6178,"activeCount":109},[],{"trials":6180,"activeCount":109},[],{"trials":6182,"activeCount":109},[],{"intervention":6184,"totalTrials":708,"cells":6185},"herombopag",{"EARLY_PHASE1":6186,"PHASE1":6188,"PHASE2":6190,"PHASE3":6201,"PHASE4":6203,"NA":6205},{"trials":6187,"activeCount":109},[],{"trials":6189,"activeCount":109},[],{"trials":6191,"activeCount":708,"soonestReadout":1578},[6192],{"nctId":6193,"briefTitle":6194,"status":456,"phases":6195,"primaryCompletion":1578,"completion":629,"start":773,"enrollment":1767,"conditions":6196,"interventions":6200},"NCT06745219","Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer",[99],[6197,2681,6198,6199],"Thrombopenia","Radiotherapy Side Effect","Chemotherapeutic Toxicity",[6184],{"trials":6202,"activeCount":109},[],{"trials":6204,"activeCount":109},[],{"trials":6206,"activeCount":109},[],{"intervention":6208,"totalTrials":708,"cells":6209},"Cadonilimab plus anlotinib",{"EARLY_PHASE1":6210,"PHASE1":6212,"PHASE2":6214,"PHASE3":6225,"PHASE4":6227,"NA":6229},{"trials":6211,"activeCount":109},[],{"trials":6213,"activeCount":109},[],{"trials":6215,"activeCount":708,"soonestReadout":6220},[6216],{"nctId":6217,"briefTitle":6218,"status":456,"phases":6219,"primaryCompletion":6220,"completion":302,"start":6221,"enrollment":4662,"conditions":6222,"interventions":6224},"NCT06426797","Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma",[99],"2025-05","2024-05",[6223],"Locally Advanced Esophageal Squamous Cell Carcinoma",[6208],{"trials":6226,"activeCount":109},[],{"trials":6228,"activeCount":109},[],{"trials":6230,"activeCount":109},[],{"intervention":58,"totalTrials":708,"cells":6232},{"EARLY_PHASE1":6233,"PHASE1":6235,"PHASE2":6237,"PHASE3":6247,"PHASE4":6249,"NA":6251},{"trials":6234,"activeCount":109},[],{"trials":6236,"activeCount":109},[],{"trials":6238,"activeCount":708,"soonestReadout":57},[6239],{"nctId":55,"briefTitle":56,"status":121,"phases":6240,"primaryCompletion":57,"completion":726,"start":6241,"enrollment":6242,"conditions":6243,"interventions":6245},[98,99],"2021-04-02",46,[6244],"HER2-negative Early Breast Cancer",[58,6246],"neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer",{"trials":6248,"activeCount":109},[],{"trials":6250,"activeCount":109},[],{"trials":6252,"activeCount":109},[],{"intervention":6246,"totalTrials":708,"cells":6254},{"EARLY_PHASE1":6255,"PHASE1":6257,"PHASE2":6259,"PHASE3":6265,"PHASE4":6267,"NA":6269},{"trials":6256,"activeCount":109},[],{"trials":6258,"activeCount":109},[],{"trials":6260,"activeCount":708,"soonestReadout":57},[6261],{"nctId":55,"briefTitle":56,"status":121,"phases":6262,"primaryCompletion":57,"completion":726,"start":6241,"enrollment":6242,"conditions":6263,"interventions":6264},[98,99],[6244],[58,6246],{"trials":6266,"activeCount":109},[],{"trials":6268,"activeCount":109},[],{"trials":6270,"activeCount":109},[],{"intervention":6272,"totalTrials":708,"cells":6273},"Adebrelimab Induction Therapy Group",{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6278,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6275,"activeCount":109},[],{"trials":6277,"activeCount":109},[],{"trials":6279,"activeCount":708,"soonestReadout":6284},[6280],{"nctId":6281,"briefTitle":6282,"status":456,"phases":6283,"primaryCompletion":6284,"completion":6284,"start":1384,"enrollment":19,"conditions":6285,"interventions":6287},"NCT07381543","Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone",[99],"2028-08",[6286],"Localized Small Cell Lung Cancer",[6272,6288],"Adebrelimab Maintenance Therapy Group",{"trials":6290,"activeCount":109},[],{"trials":6292,"activeCount":109},[],{"trials":6294,"activeCount":109},[],{"intervention":6288,"totalTrials":708,"cells":6296},{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6298,"activeCount":109},[],{"trials":6300,"activeCount":109},[],{"trials":6302,"activeCount":708,"soonestReadout":6284},[6303],{"nctId":6281,"briefTitle":6282,"status":456,"phases":6304,"primaryCompletion":6284,"completion":6284,"start":1384,"enrollment":19,"conditions":6305,"interventions":6306},[99],[6286],[6272,6288],{"trials":6308,"activeCount":109},[],{"trials":6310,"activeCount":109},[],{"trials":6312,"activeCount":109},[],{"intervention":6314,"totalTrials":708,"cells":6315},"Zimberelimab",{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6330,"PHASE4":6332,"NA":6334},{"trials":6317,"activeCount":109},[],{"trials":6319,"activeCount":109},[],{"trials":6321,"activeCount":708,"soonestReadout":1246},[6322],{"nctId":6323,"briefTitle":6324,"status":456,"phases":6325,"primaryCompletion":1246,"completion":6326,"start":2587,"enrollment":846,"conditions":6327,"interventions":6329},"NCT06009029","SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)",[99],"2027-07",[6328],"Locally Advanced Pancreatic Cancer",[6314],{"trials":6331,"activeCount":109},[],{"trials":6333,"activeCount":109},[],{"trials":6335,"activeCount":109},[],{"intervention":4044,"totalTrials":708,"cells":6337},{"EARLY_PHASE1":6338,"PHASE1":6340,"PHASE2":6342,"PHASE3":6348,"PHASE4":6350,"NA":6352},{"trials":6339,"activeCount":109},[],{"trials":6341,"activeCount":109},[],{"trials":6343,"activeCount":708,"soonestReadout":4040},[6344],{"nctId":4037,"briefTitle":4038,"status":121,"phases":6345,"primaryCompletion":4040,"completion":726,"start":4041,"enrollment":1767,"conditions":6346,"interventions":6347},[98,99],[2791],[632,4044],{"trials":6349,"activeCount":109},[],{"trials":6351,"activeCount":109},[],{"trials":6353,"activeCount":109},[],{"intervention":3914,"totalTrials":708,"cells":6355},{"EARLY_PHASE1":6356,"PHASE1":6358,"PHASE2":6360,"PHASE3":6366,"PHASE4":6368,"NA":6370},{"trials":6357,"activeCount":109},[],{"trials":6359,"activeCount":109},[],{"trials":6361,"activeCount":708,"soonestReadout":3910},[6362],{"nctId":3907,"briefTitle":3908,"status":456,"phases":6363,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":32,"conditions":6364,"interventions":6365},[99],[3757],[1037,3914],{"trials":6367,"activeCount":109},[],{"trials":6369,"activeCount":109},[],{"trials":6371,"activeCount":109},[],{"intervention":6373,"totalTrials":708,"cells":6374},"Treatment",{"EARLY_PHASE1":6375,"PHASE1":6377,"PHASE2":6379,"PHASE3":6391,"PHASE4":6393,"NA":6395},{"trials":6376,"activeCount":109},[],{"trials":6378,"activeCount":109},[],{"trials":6380,"activeCount":708,"soonestReadout":6385},[6381],{"nctId":6382,"briefTitle":6383,"status":456,"phases":6384,"primaryCompletion":6385,"completion":6386,"start":2371,"enrollment":1767,"conditions":6387,"interventions":6390},"NCT07339553","Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.",[99],"2029-01-30","2029-02-26",[6388,6389],"Ovariancancer","Platinum-sensitive Recurrent",[6373],{"trials":6392,"activeCount":109},[],{"trials":6394,"activeCount":109},[],{"trials":6396,"activeCount":109},[],{"intervention":6398,"totalTrials":708,"cells":6399},"Lutetium[177Lu] Oxodotreotide",{"EARLY_PHASE1":6400,"PHASE1":6402,"PHASE2":6404,"PHASE3":6416,"PHASE4":6418,"NA":6420},{"trials":6401,"activeCount":109},[],{"trials":6403,"activeCount":109},[],{"trials":6405,"activeCount":708,"soonestReadout":6410},[6406],{"nctId":6407,"briefTitle":6408,"status":456,"phases":6409,"primaryCompletion":6410,"completion":6411,"start":6412,"enrollment":32,"conditions":6413,"interventions":6415},"NCT05894486","Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors",[99],"2025-06-05","2026-06-05","2023-06-05",[6414],"Neuroendocrine Tumors",[6398],{"trials":6417,"activeCount":109},[],{"trials":6419,"activeCount":109},[],{"trials":6421,"activeCount":109},[],{"intervention":3539,"totalTrials":708,"cells":6423},{"EARLY_PHASE1":6424,"PHASE1":6426,"PHASE2":6428,"PHASE3":6434,"PHASE4":6436,"NA":6438},{"trials":6425,"activeCount":109},[],{"trials":6427,"activeCount":109},[],{"trials":6429,"activeCount":708,"soonestReadout":412},[6430],{"nctId":3534,"briefTitle":3535,"status":456,"phases":6431,"primaryCompletion":412,"completion":413,"start":604,"enrollment":2008,"conditions":6432,"interventions":6433},[99],[2681],[3539,1028],{"trials":6435,"activeCount":109},[],{"trials":6437,"activeCount":109},[],{"trials":6439,"activeCount":109},[],{"intervention":6441,"totalTrials":708,"cells":6442},"Rezvilutamide",{"EARLY_PHASE1":6443,"PHASE1":6445,"PHASE2":6447,"PHASE3":6459,"PHASE4":6461,"NA":6463},{"trials":6444,"activeCount":109},[],{"trials":6446,"activeCount":109},[],{"trials":6448,"activeCount":708,"soonestReadout":6453},[6449],{"nctId":6450,"briefTitle":6451,"status":121,"phases":6452,"primaryCompletion":6453,"completion":6454,"start":1247,"enrollment":3699,"conditions":6455,"interventions":6457},"NCT06348264","Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma",[99],"2029-03-30","2031-03-30",[6456],"Salivary Gland Neoplasm Duct",[6441,6458],"Leuprolide Acetate",{"trials":6460,"activeCount":109},[],{"trials":6462,"activeCount":109},[],{"trials":6464,"activeCount":109},[],{"intervention":6458,"totalTrials":708,"cells":6466},{"EARLY_PHASE1":6467,"PHASE1":6469,"PHASE2":6471,"PHASE3":6477,"PHASE4":6479,"NA":6481},{"trials":6468,"activeCount":109},[],{"trials":6470,"activeCount":109},[],{"trials":6472,"activeCount":708,"soonestReadout":6453},[6473],{"nctId":6450,"briefTitle":6451,"status":121,"phases":6474,"primaryCompletion":6453,"completion":6454,"start":1247,"enrollment":3699,"conditions":6475,"interventions":6476},[99],[6456],[6441,6458],{"trials":6478,"activeCount":109},[],{"trials":6480,"activeCount":109},[],{"trials":6482,"activeCount":109},[],{"intervention":4284,"totalTrials":708,"cells":6484},{"EARLY_PHASE1":6485,"PHASE1":6487,"PHASE2":6489,"PHASE3":6495,"PHASE4":6497,"NA":6499},{"trials":6486,"activeCount":109},[],{"trials":6488,"activeCount":109},[],{"trials":6490,"activeCount":708,"soonestReadout":3911},[6491],{"nctId":4277,"briefTitle":4278,"status":121,"phases":6492,"primaryCompletion":3911,"completion":2437,"start":4280,"enrollment":1767,"conditions":6493,"interventions":6494},[99],[4282],[4284,3927],{"trials":6496,"activeCount":109},[],{"trials":6498,"activeCount":109},[],{"trials":6500,"activeCount":109},[],{"intervention":6502,"totalTrials":708,"cells":6503},"SBRT plus tislelizumab and regorafenib",{"EARLY_PHASE1":6504,"PHASE1":6506,"PHASE2":6508,"PHASE3":6518,"PHASE4":6520,"NA":6522},{"trials":6505,"activeCount":109},[],{"trials":6507,"activeCount":109},[],{"trials":6509,"activeCount":708,"soonestReadout":637},[6510],{"nctId":6511,"briefTitle":6512,"status":121,"phases":6513,"primaryCompletion":637,"completion":968,"start":6514,"enrollment":617,"conditions":6515,"interventions":6517},"NCT05917431","Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC",[99],"2023-06",[5639,6516],"Oligometastatic Disease",[6502],{"trials":6519,"activeCount":109},[],{"trials":6521,"activeCount":109},[],{"trials":6523,"activeCount":109},[],{"intervention":6525,"totalTrials":708,"cells":6526},"Ivonescimab\u002Fsurgery",{"EARLY_PHASE1":6527,"PHASE1":6529,"PHASE2":6531,"PHASE3":6545,"PHASE4":6547,"NA":6549},{"trials":6528,"activeCount":109},[],{"trials":6530,"activeCount":109},[],{"trials":6532,"activeCount":708,"soonestReadout":6537},[6533],{"nctId":6534,"briefTitle":6535,"status":456,"phases":6536,"primaryCompletion":6537,"completion":6538,"start":2744,"enrollment":6539,"conditions":6540,"interventions":6543},"NCT07241819","Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant\u002FAdjuvant Therapy for Resectable Non-small Cell Lung Cancer",[99],"2027-11-30","2028-11-30",66,[6541,6542],"II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer","Perioperative",[6525,6544,6544,6544],"Ivonescimab\u002Fchemotherapy\u002Fsurgery",{"trials":6546,"activeCount":109},[],{"trials":6548,"activeCount":109},[],{"trials":6550,"activeCount":109},[],{"intervention":6544,"totalTrials":708,"cells":6552},{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6563,"PHASE4":6565,"NA":6567},{"trials":6554,"activeCount":109},[],{"trials":6556,"activeCount":109},[],{"trials":6558,"activeCount":708,"soonestReadout":6537},[6559],{"nctId":6534,"briefTitle":6535,"status":456,"phases":6560,"primaryCompletion":6537,"completion":6538,"start":2744,"enrollment":6539,"conditions":6561,"interventions":6562},[99],[6541,6542],[6525,6544,6544,6544],{"trials":6564,"activeCount":109},[],{"trials":6566,"activeCount":109},[],{"trials":6568,"activeCount":109},[],{"intervention":6570,"totalTrials":708,"cells":6571},"Telitacicept 160mg",{"EARLY_PHASE1":6572,"PHASE1":6574,"PHASE2":6576,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6573,"activeCount":109},[],{"trials":6575,"activeCount":109},[],{"trials":6577,"activeCount":708,"soonestReadout":6582},[6578],{"nctId":6579,"briefTitle":6580,"status":468,"phases":6581,"primaryCompletion":6582,"completion":6582,"start":6583,"enrollment":477,"conditions":6584,"interventions":6586},"NCT07111338","Telitacicept for PGNMID: A Single-Arm Study",[99],"2027-05-29","2025-07-12",[6585],"Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits",[6570],{"trials":6588,"activeCount":109},[],{"trials":6590,"activeCount":109},[],{"trials":6592,"activeCount":109},[],{"intervention":5356,"totalTrials":708,"cells":6594},{"EARLY_PHASE1":6595,"PHASE1":6597,"PHASE2":6599,"PHASE3":6605,"PHASE4":6607,"NA":6609},{"trials":6596,"activeCount":109},[],{"trials":6598,"activeCount":109},[],{"trials":6600,"activeCount":708,"soonestReadout":5352},[6601],{"nctId":5349,"briefTitle":5350,"status":121,"phases":6602,"primaryCompletion":5352,"completion":314,"start":5353,"enrollment":728,"conditions":6603,"interventions":6604},[99],[2532],[5356,5331,5357],{"trials":6606,"activeCount":109},[],{"trials":6608,"activeCount":109},[],{"trials":6610,"activeCount":109},[],{"intervention":5357,"totalTrials":708,"cells":6612},{"EARLY_PHASE1":6613,"PHASE1":6615,"PHASE2":6617,"PHASE3":6623,"PHASE4":6625,"NA":6627},{"trials":6614,"activeCount":109},[],{"trials":6616,"activeCount":109},[],{"trials":6618,"activeCount":708,"soonestReadout":5352},[6619],{"nctId":5349,"briefTitle":5350,"status":121,"phases":6620,"primaryCompletion":5352,"completion":314,"start":5353,"enrollment":728,"conditions":6621,"interventions":6622},[99],[2532],[5356,5331,5357],{"trials":6624,"activeCount":109},[],{"trials":6626,"activeCount":109},[],{"trials":6628,"activeCount":109},[],{"intervention":6630,"totalTrials":708,"cells":6631},"linperlisib combined with CHOP regimen",{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6636,"PHASE3":6648,"PHASE4":6650,"NA":6652},{"trials":6633,"activeCount":109},[],{"trials":6635,"activeCount":109},[],{"trials":6637,"activeCount":708,"soonestReadout":6642},[6638],{"nctId":6639,"briefTitle":6640,"status":121,"phases":6641,"primaryCompletion":6642,"completion":6643,"start":6644,"enrollment":4001,"conditions":6645,"interventions":6647},"NCT06347653","Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)",[99],"2027-01-31","2030-01-31","2023-11-28",[6646],"Nodal T-follicular Helper Cell Lymphoma",[6630],{"trials":6649,"activeCount":109},[],{"trials":6651,"activeCount":109},[],{"trials":6653,"activeCount":109},[],{"intervention":6655,"totalTrials":708,"cells":6656},"tauroursodeoxycholic acid",{"EARLY_PHASE1":6657,"PHASE1":6659,"PHASE2":6661,"PHASE3":6672,"PHASE4":6674,"NA":6676},{"trials":6658,"activeCount":109},[],{"trials":6660,"activeCount":109},[],{"trials":6662,"activeCount":708,"soonestReadout":1268},[6663],{"nctId":6664,"briefTitle":6665,"status":456,"phases":6666,"primaryCompletion":1268,"completion":6667,"start":6668,"enrollment":153,"conditions":6669,"interventions":6671},"NCT07517276","TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index",[99],"2026-07-30","2026-04-02",[6670],"Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development",[6655],{"trials":6673,"activeCount":109},[],{"trials":6675,"activeCount":109},[],{"trials":6677,"activeCount":109},[],{"intervention":6679,"totalTrials":708,"cells":6680},"Firmonertinib 160mg",{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6685,"PHASE3":6698,"PHASE4":6700,"NA":6702},{"trials":6682,"activeCount":109},[],{"trials":6684,"activeCount":109},[],{"trials":6686,"activeCount":708,"soonestReadout":6691},[6687],{"nctId":6688,"briefTitle":6689,"status":456,"phases":6690,"primaryCompletion":6691,"completion":6692,"start":616,"enrollment":3871,"conditions":6693,"interventions":6697},"NCT07298148","Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg",[99],"2030-12-31","2032-12-31",[6694,6695,6696],"NSCLC Stage IV","EGFR Positive Non-small Cell Lung Cancer","EGFR-TKI Sensitizing Mutation",[6679],{"trials":6699,"activeCount":109},[],{"trials":6701,"activeCount":109},[],{"trials":6703,"activeCount":109},[],{"intervention":6705,"totalTrials":708,"cells":6706},"Vebreltinib combined with Furmonertinib",{"EARLY_PHASE1":6707,"PHASE1":6709,"PHASE2":6711,"PHASE3":6722,"PHASE4":6724,"NA":6726},{"trials":6708,"activeCount":109},[],{"trials":6710,"activeCount":109},[],{"trials":6712,"activeCount":708,"soonestReadout":124},[6713],{"nctId":6714,"briefTitle":6715,"status":121,"phases":6716,"primaryCompletion":124,"completion":6717,"start":6718,"enrollment":29,"conditions":6719,"interventions":6721},"NCT07087223","Phase Ib\u002FII Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure",[98,99],"2028-04","2025-04-08",[6720],"Non Small Cell Lung Cancer NSCLC",[6705,6705,6705],{"trials":6723,"activeCount":109},[],{"trials":6725,"activeCount":109},[],{"trials":6727,"activeCount":109},[],{"intervention":6729,"totalTrials":708,"cells":6730},"RC48+carboplatin±bevacizumab",{"EARLY_PHASE1":6731,"PHASE1":6733,"PHASE2":6735,"PHASE3":6749,"PHASE4":6751,"NA":6753},{"trials":6732,"activeCount":109},[],{"trials":6734,"activeCount":109},[],{"trials":6736,"activeCount":708,"soonestReadout":6741},[6737],{"nctId":6738,"briefTitle":6739,"status":121,"phases":6740,"primaryCompletion":6741,"completion":6742,"start":6743,"enrollment":4001,"conditions":6744,"interventions":6748},"NCT06420973","RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression",[99],"2027-05-17","2027-09-17","2024-05-16",[6745,6746,6747],"Ovarian Carcinoma","Fallopian Tube Carcinoma","Primary Peritoneal Carcinoma",[6729],{"trials":6750,"activeCount":109},[],{"trials":6752,"activeCount":109},[],{"trials":6754,"activeCount":109},[],{"intervention":6756,"totalTrials":708,"cells":6757},"CD5-targeted CAR-T cells",{"EARLY_PHASE1":6758,"PHASE1":6760,"PHASE2":6762,"PHASE3":6774,"PHASE4":6776,"NA":6778},{"trials":6759,"activeCount":109},[],{"trials":6761,"activeCount":109},[],{"trials":6763,"activeCount":708,"soonestReadout":726},[6764],{"nctId":6765,"briefTitle":6766,"status":121,"phases":6767,"primaryCompletion":726,"completion":1019,"start":6768,"enrollment":1767,"conditions":6769,"interventions":6773},"NCT06874946","Nanobody-Based Anti-CD5 CAR-T for Relapsed\u002FRefractory T-ALL\u002FNHL",[98,99],"2025-02-14",[6770,6771,6772],"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","T - Cell Lymphoma","PTCL",[6756],{"trials":6775,"activeCount":109},[],{"trials":6777,"activeCount":109},[],{"trials":6779,"activeCount":109},[],{"intervention":5205,"totalTrials":708,"cells":6781},{"EARLY_PHASE1":6782,"PHASE1":6784,"PHASE2":6786,"PHASE3":6792,"PHASE4":6794,"NA":6796},{"trials":6783,"activeCount":109},[],{"trials":6785,"activeCount":109},[],{"trials":6787,"activeCount":708,"soonestReadout":726},[6788],{"nctId":5198,"briefTitle":5199,"status":456,"phases":6789,"primaryCompletion":726,"completion":1019,"start":5201,"enrollment":536,"conditions":6790,"interventions":6791},[99],[170,5203],[5205,5189,5205],{"trials":6793,"activeCount":109},[],{"trials":6795,"activeCount":109},[],{"trials":6797,"activeCount":109},[],{"intervention":2819,"totalTrials":708,"cells":6799},{"EARLY_PHASE1":6800,"PHASE1":6802,"PHASE2":6804,"PHASE3":6810,"PHASE4":6812,"NA":6814},{"trials":6801,"activeCount":109},[],{"trials":6803,"activeCount":109},[],{"trials":6805,"activeCount":708,"soonestReadout":2813},[6806],{"nctId":2810,"briefTitle":2811,"status":456,"phases":6807,"primaryCompletion":2813,"completion":637,"start":2814,"enrollment":376,"conditions":6808,"interventions":6809},[99],[2816,2817],[2756,2819],{"trials":6811,"activeCount":109},[],{"trials":6813,"activeCount":109},[],{"trials":6815,"activeCount":109},[],{"intervention":3857,"totalTrials":708,"cells":6817},{"EARLY_PHASE1":6818,"PHASE1":6820,"PHASE2":6822,"PHASE3":6828,"PHASE4":6830,"NA":6832},{"trials":6819,"activeCount":109},[],{"trials":6821,"activeCount":109},[],{"trials":6823,"activeCount":708,"soonestReadout":2094},[6824],{"nctId":3849,"briefTitle":3850,"status":456,"phases":6825,"primaryCompletion":2094,"completion":3852,"start":3853,"enrollment":1139,"conditions":6826,"interventions":6827},[99],[28,3855],[3684,3857,1024],{"trials":6829,"activeCount":109},[],{"trials":6831,"activeCount":109},[],{"trials":6833,"activeCount":109},[],{"intervention":6835,"totalTrials":708,"cells":6836},"BCMA-CD19 CAR-T therapy",{"EARLY_PHASE1":6837,"PHASE1":6839,"PHASE2":6841,"PHASE3":6857,"PHASE4":6859,"NA":6861},{"trials":6838,"activeCount":109},[],{"trials":6840,"activeCount":109},[],{"trials":6842,"activeCount":708,"soonestReadout":584},[6843],{"nctId":6844,"briefTitle":6845,"status":121,"phases":6846,"primaryCompletion":584,"completion":1019,"start":6847,"enrollment":728,"conditions":6848,"interventions":6856},"NCT06794008","BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases",[99],"2024-12-26",[2836,2772,6849,6850,6851,6852,6853,6854,6855],"Systemic Sclerosis (SSc)","ANCA-associated Vasculitis","IgG4-Related Diseases","Antiphospholipid Syndrome","Acquired Thrombotic Thrombocytopenic Purpura","Behcet Disease","Sjogren Syndrome",[6835],{"trials":6858,"activeCount":109},[],{"trials":6860,"activeCount":109},[],{"trials":6862,"activeCount":109},[],{"intervention":6864,"totalTrials":708,"cells":6865},"statins (oral atorvastatin calcium tablet 20mg\u002F day; Or rosuvastatin 5mg\u002F day; Or pivastatin 2mg\u002F day);",{"EARLY_PHASE1":6866,"PHASE1":6868,"PHASE2":6870,"PHASE3":6881,"PHASE4":6883,"NA":6885},{"trials":6867,"activeCount":109},[],{"trials":6869,"activeCount":109},[],{"trials":6871,"activeCount":708,"soonestReadout":6876},[6872],{"nctId":6873,"briefTitle":6874,"status":121,"phases":6875,"primaryCompletion":6876,"completion":2203,"start":1590,"enrollment":6877,"conditions":6878,"interventions":6880},"NCT06102863","Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia",[99],"2025-08-01",38,[6879],"Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I",[6864],{"trials":6882,"activeCount":109},[],{"trials":6884,"activeCount":109},[],{"trials":6886,"activeCount":109},[],{"intervention":1025,"totalTrials":708,"cells":6888},{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6893,"PHASE3":6899,"PHASE4":6901,"NA":6903},{"trials":6890,"activeCount":109},[],{"trials":6892,"activeCount":109},[],{"trials":6894,"activeCount":708,"soonestReadout":1019},[6895],{"nctId":1016,"briefTitle":1017,"status":456,"phases":6896,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":6897,"interventions":6898},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":6900,"activeCount":109},[],{"trials":6902,"activeCount":109},[],{"trials":6904,"activeCount":109},[],{"intervention":1027,"totalTrials":708,"cells":6906},{"EARLY_PHASE1":6907,"PHASE1":6909,"PHASE2":6911,"PHASE3":6917,"PHASE4":6919,"NA":6921},{"trials":6908,"activeCount":109},[],{"trials":6910,"activeCount":109},[],{"trials":6912,"activeCount":708,"soonestReadout":1019},[6913],{"nctId":1016,"briefTitle":1017,"status":456,"phases":6914,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":6915,"interventions":6916},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":6918,"activeCount":109},[],{"trials":6920,"activeCount":109},[],{"trials":6922,"activeCount":109},[],{"intervention":1030,"totalTrials":708,"cells":6924},{"EARLY_PHASE1":6925,"PHASE1":6927,"PHASE2":6929,"PHASE3":6935,"PHASE4":6937,"NA":6939},{"trials":6926,"activeCount":109},[],{"trials":6928,"activeCount":109},[],{"trials":6930,"activeCount":708,"soonestReadout":1019},[6931],{"nctId":1016,"briefTitle":1017,"status":456,"phases":6932,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":6933,"interventions":6934},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":6936,"activeCount":109},[],{"trials":6938,"activeCount":109},[],{"trials":6940,"activeCount":109},[],{"intervention":1033,"totalTrials":708,"cells":6942},{"EARLY_PHASE1":6943,"PHASE1":6945,"PHASE2":6947,"PHASE3":6953,"PHASE4":6955,"NA":6957},{"trials":6944,"activeCount":109},[],{"trials":6946,"activeCount":109},[],{"trials":6948,"activeCount":708,"soonestReadout":1019},[6949],{"nctId":1016,"briefTitle":1017,"status":456,"phases":6950,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":6951,"interventions":6952},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":6954,"activeCount":109},[],{"trials":6956,"activeCount":109},[],{"trials":6958,"activeCount":109},[],{"intervention":1034,"totalTrials":708,"cells":6960},{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6965,"PHASE3":6971,"PHASE4":6973,"NA":6975},{"trials":6962,"activeCount":109},[],{"trials":6964,"activeCount":109},[],{"trials":6966,"activeCount":708,"soonestReadout":1019},[6967],{"nctId":1016,"briefTitle":1017,"status":456,"phases":6968,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":6969,"interventions":6970},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":6972,"activeCount":109},[],{"trials":6974,"activeCount":109},[],{"trials":6976,"activeCount":109},[],{"intervention":1038,"totalTrials":708,"cells":6978},{"EARLY_PHASE1":6979,"PHASE1":6981,"PHASE2":6983,"PHASE3":6989,"PHASE4":6991,"NA":6993},{"trials":6980,"activeCount":109},[],{"trials":6982,"activeCount":109},[],{"trials":6984,"activeCount":708,"soonestReadout":1019},[6985],{"nctId":1016,"briefTitle":1017,"status":456,"phases":6986,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":6987,"interventions":6988},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":6990,"activeCount":109},[],{"trials":6992,"activeCount":109},[],{"trials":6994,"activeCount":109},[],{"intervention":1041,"totalTrials":708,"cells":6996},{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":6998,"activeCount":109},[],{"trials":7000,"activeCount":109},[],{"trials":7002,"activeCount":708,"soonestReadout":1019},[7003],{"nctId":1016,"briefTitle":1017,"status":456,"phases":7004,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":7005,"interventions":7006},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":7008,"activeCount":109},[],{"trials":7010,"activeCount":109},[],{"trials":7012,"activeCount":109},[],{"intervention":1042,"totalTrials":708,"cells":7014},{"EARLY_PHASE1":7015,"PHASE1":7017,"PHASE2":7019,"PHASE3":7025,"PHASE4":7027,"NA":7029},{"trials":7016,"activeCount":109},[],{"trials":7018,"activeCount":109},[],{"trials":7020,"activeCount":708,"soonestReadout":1019},[7021],{"nctId":1016,"briefTitle":1017,"status":456,"phases":7022,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":7023,"interventions":7024},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":7026,"activeCount":109},[],{"trials":7028,"activeCount":109},[],{"trials":7030,"activeCount":109},[],{"intervention":1043,"totalTrials":708,"cells":7032},{"EARLY_PHASE1":7033,"PHASE1":7035,"PHASE2":7037,"PHASE3":7043,"PHASE4":7045,"NA":7047},{"trials":7034,"activeCount":109},[],{"trials":7036,"activeCount":109},[],{"trials":7038,"activeCount":708,"soonestReadout":1019},[7039],{"nctId":1016,"briefTitle":1017,"status":456,"phases":7040,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":7041,"interventions":7042},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":7044,"activeCount":109},[],{"trials":7046,"activeCount":109},[],{"trials":7048,"activeCount":109},[],{"intervention":1044,"totalTrials":708,"cells":7050},{"EARLY_PHASE1":7051,"PHASE1":7053,"PHASE2":7055,"PHASE3":7061,"PHASE4":7063,"NA":7065},{"trials":7052,"activeCount":109},[],{"trials":7054,"activeCount":109},[],{"trials":7056,"activeCount":708,"soonestReadout":1019},[7057],{"nctId":1016,"briefTitle":1017,"status":456,"phases":7058,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":7059,"interventions":7060},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":7062,"activeCount":109},[],{"trials":7064,"activeCount":109},[],{"trials":7066,"activeCount":109},[],{"intervention":1047,"totalTrials":708,"cells":7068},{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7073,"PHASE3":7079,"PHASE4":7081,"NA":7083},{"trials":7070,"activeCount":109},[],{"trials":7072,"activeCount":109},[],{"trials":7074,"activeCount":708,"soonestReadout":1019},[7075],{"nctId":1016,"briefTitle":1017,"status":456,"phases":7076,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":7077,"interventions":7078},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":7080,"activeCount":109},[],{"trials":7082,"activeCount":109},[],{"trials":7084,"activeCount":109},[],{"intervention":1048,"totalTrials":708,"cells":7086},{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7091,"PHASE3":7097,"PHASE4":7099,"NA":7101},{"trials":7088,"activeCount":109},[],{"trials":7090,"activeCount":109},[],{"trials":7092,"activeCount":708,"soonestReadout":1019},[7093],{"nctId":1016,"briefTitle":1017,"status":456,"phases":7094,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":7095,"interventions":7096},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":7098,"activeCount":109},[],{"trials":7100,"activeCount":109},[],{"trials":7102,"activeCount":109},[],{"intervention":1049,"totalTrials":708,"cells":7104},{"EARLY_PHASE1":7105,"PHASE1":7107,"PHASE2":7109,"PHASE3":7115,"PHASE4":7117,"NA":7119},{"trials":7106,"activeCount":109},[],{"trials":7108,"activeCount":109},[],{"trials":7110,"activeCount":708,"soonestReadout":1019},[7111],{"nctId":1016,"briefTitle":1017,"status":456,"phases":7112,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":7113,"interventions":7114},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":7116,"activeCount":109},[],{"trials":7118,"activeCount":109},[],{"trials":7120,"activeCount":109},[],{"intervention":7122,"totalTrials":708,"cells":7123},"Camrelizumab + Nab-paclitaxel + Cisplatin",{"EARLY_PHASE1":7124,"PHASE1":7126,"PHASE2":7128,"PHASE3":7137,"PHASE4":7139,"NA":7141},{"trials":7125,"activeCount":109},[],{"trials":7127,"activeCount":109},[],{"trials":7129,"activeCount":708,"soonestReadout":1020},[7130],{"nctId":7131,"briefTitle":7132,"status":121,"phases":7133,"primaryCompletion":1020,"completion":1020,"start":740,"enrollment":7134,"conditions":7135,"interventions":7136},"NCT06869226","A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer",[99],283,[2627],[7122],{"trials":7138,"activeCount":109},[],{"trials":7140,"activeCount":109},[],{"trials":7142,"activeCount":109},[],{"intervention":7144,"totalTrials":708,"cells":7145},"Pembrolizumab 200 mg IV",{"EARLY_PHASE1":7146,"PHASE1":7148,"PHASE2":7150,"PHASE3":7164,"PHASE4":7166,"NA":7168},{"trials":7147,"activeCount":109},[],{"trials":7149,"activeCount":109},[],{"trials":7151,"activeCount":708,"soonestReadout":7156},[7152],{"nctId":7153,"briefTitle":7154,"status":468,"phases":7155,"primaryCompletion":7156,"completion":7156,"start":7157,"enrollment":670,"conditions":7158,"interventions":7163},"NCT05894889","Pembrolizumab and Chemotherapy Neoadjuvant\u002FAdjuvant of NSCLC",[99],"2027-08-01","2024-01-30",[7159,7160,7161,7162],"Stage IIIB(N2) Non-small Cell Lung Cancer","Stage IIA Non-small Cell Lung Cancer","Stage IIB Non-small Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer",[7144],{"trials":7165,"activeCount":109},[],{"trials":7167,"activeCount":109},[],{"trials":7169,"activeCount":109},[],{"intervention":7171,"totalTrials":708,"cells":7172},"five - flavor sophora flavescens enteric - coated capsules plus glutamine and warm - water sitz baths",{"EARLY_PHASE1":7173,"PHASE1":7175,"PHASE2":7177,"PHASE3":7187,"PHASE4":7189,"NA":7191},{"trials":7174,"activeCount":109},[],{"trials":7176,"activeCount":109},[],{"trials":7178,"activeCount":708,"soonestReadout":725},[7179],{"nctId":7180,"briefTitle":7181,"status":456,"phases":7182,"primaryCompletion":725,"completion":725,"start":1578,"enrollment":5554,"conditions":7183,"interventions":7185},"NCT07053761","A Randomized Controlled Trial of Five - Flavor Sophora Flavescens Enteric - Coated Capsules for Radiation - Induced Proctitis After Pelvic Radiotherapy",[99],[7184],"Radiation - Induced Proctitis",[7171,7186],"glutamine and warm - water sitz baths",{"trials":7188,"activeCount":109},[],{"trials":7190,"activeCount":109},[],{"trials":7192,"activeCount":109},[],{"intervention":7186,"totalTrials":708,"cells":7194},{"EARLY_PHASE1":7195,"PHASE1":7197,"PHASE2":7199,"PHASE3":7205,"PHASE4":7207,"NA":7209},{"trials":7196,"activeCount":109},[],{"trials":7198,"activeCount":109},[],{"trials":7200,"activeCount":708,"soonestReadout":725},[7201],{"nctId":7180,"briefTitle":7181,"status":456,"phases":7202,"primaryCompletion":725,"completion":725,"start":1578,"enrollment":5554,"conditions":7203,"interventions":7204},[99],[7184],[7171,7186],{"trials":7206,"activeCount":109},[],{"trials":7208,"activeCount":109},[],{"trials":7210,"activeCount":109},[],{"intervention":7212,"totalTrials":708,"cells":7213},"Perioperative treatment with albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules and sintilimab.",{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7218,"PHASE3":7230,"PHASE4":7232,"NA":7234},{"trials":7215,"activeCount":109},[],{"trials":7217,"activeCount":109},[],{"trials":7219,"activeCount":708,"soonestReadout":7224},[7220],{"nctId":7221,"briefTitle":7222,"status":121,"phases":7223,"primaryCompletion":7224,"completion":7225,"start":7226,"enrollment":1767,"conditions":7227,"interventions":7229},"NCT07178340","Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach",[99],"2027-09-20","2028-09-20","2025-09-18",[7228],"Hepatoid Adenocarcinoma of Stomach",[7212],{"trials":7231,"activeCount":109},[],{"trials":7233,"activeCount":109},[],{"trials":7235,"activeCount":109},[],{"intervention":4106,"totalTrials":708,"cells":7237},{"EARLY_PHASE1":7238,"PHASE1":7240,"PHASE2":7242,"PHASE3":7248,"PHASE4":7250,"NA":7252},{"trials":7239,"activeCount":109},[],{"trials":7241,"activeCount":109},[],{"trials":7243,"activeCount":708,"soonestReadout":3130},[7244],{"nctId":4095,"briefTitle":4096,"status":456,"phases":7245,"primaryCompletion":3130,"completion":4098,"start":4099,"enrollment":4100,"conditions":7246,"interventions":7247},[99],[4102,4103,4104],[4106,3767],{"trials":7249,"activeCount":109},[],{"trials":7251,"activeCount":109},[],{"trials":7253,"activeCount":109},[],{"intervention":7255,"totalTrials":708,"cells":7256},"DCVAC\u002FOvCa",{"EARLY_PHASE1":7257,"PHASE1":7259,"PHASE2":7261,"PHASE3":7274,"PHASE4":7276,"NA":7278},{"trials":7258,"activeCount":109},[],{"trials":7260,"activeCount":109},[],{"trials":7262,"activeCount":708,"soonestReadout":7267},[7263],{"nctId":7264,"briefTitle":7265,"status":121,"phases":7266,"primaryCompletion":7267,"completion":7268,"start":7269,"enrollment":7270,"conditions":7271,"interventions":7273},"NCT04834544","A Study of Maintenance DCVAC\u002FOvCa After First-line Chemotherapy Added Standard of Care",[99],"2024-10-20","2027-04-20","2021-04-19",75,[7272,6746,6747],"Epithelial Ovarian Carcinoma",[7255],{"trials":7275,"activeCount":109},[],{"trials":7277,"activeCount":109},[],{"trials":7279,"activeCount":109},[],{"intervention":7281,"totalTrials":708,"cells":7282},"Dalpiciclib + Pyrotinib",{"EARLY_PHASE1":7283,"PHASE1":7285,"PHASE2":7287,"PHASE3":7297,"PHASE4":7299,"NA":7301},{"trials":7284,"activeCount":109},[],{"trials":7286,"activeCount":109},[],{"trials":7288,"activeCount":708,"soonestReadout":3260},[7289],{"nctId":7290,"briefTitle":7291,"status":121,"phases":7292,"primaryCompletion":3260,"completion":7293,"start":7294,"enrollment":35,"conditions":7295,"interventions":7296},"NCT06684600","Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma",[99],"2027-10-30","2024-11-01",[1250],[7281],{"trials":7298,"activeCount":109},[],{"trials":7300,"activeCount":109},[],{"trials":7302,"activeCount":109},[],{"intervention":7304,"totalTrials":708,"cells":7305},"Carilizumab and Apatinib",{"EARLY_PHASE1":7306,"PHASE1":7308,"PHASE2":7310,"PHASE3":7319,"PHASE4":7321,"NA":7323},{"trials":7307,"activeCount":109},[],{"trials":7309,"activeCount":109},[],{"trials":7311,"activeCount":708,"soonestReadout":805},[7312],{"nctId":7313,"briefTitle":7314,"status":121,"phases":7315,"primaryCompletion":805,"completion":124,"start":7316,"enrollment":47,"conditions":7317,"interventions":7318},"NCT06792162","PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer",[99],"2023-04-20",[28],[7304],{"trials":7320,"activeCount":109},[],{"trials":7322,"activeCount":109},[],{"trials":7324,"activeCount":109},[],{"intervention":4938,"totalTrials":708,"cells":7326},{"EARLY_PHASE1":7327,"PHASE1":7329,"PHASE2":7331,"PHASE3":7337,"PHASE4":7339,"NA":7341},{"trials":7328,"activeCount":109},[],{"trials":7330,"activeCount":109},[],{"trials":7332,"activeCount":708,"soonestReadout":3350},[7333],{"nctId":4931,"briefTitle":4932,"status":1935,"phases":7334,"primaryCompletion":3350,"completion":4934,"start":228,"enrollment":376,"conditions":7335,"interventions":7336},[99],[31,4936],[4938,4922],{"trials":7338,"activeCount":109},[],{"trials":7340,"activeCount":109},[],{"trials":7342,"activeCount":109},[],{"intervention":7344,"totalTrials":708,"cells":7345},"Reduced ATG plus mini PTCy",{"EARLY_PHASE1":7346,"PHASE1":7348,"PHASE2":7350,"PHASE3":7360,"PHASE4":7362,"NA":7364},{"trials":7347,"activeCount":109},[],{"trials":7349,"activeCount":109},[],{"trials":7351,"activeCount":708,"soonestReadout":6043},[7352],{"nctId":7353,"briefTitle":7354,"status":121,"phases":7355,"primaryCompletion":6043,"completion":2730,"start":7356,"enrollment":32,"conditions":7357,"interventions":7359},"NCT06984536","Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT",[99],"2025-05-21",[7358,946],"Myelodysplastic Syndrome",[7344],{"trials":7361,"activeCount":109},[],{"trials":7363,"activeCount":109},[],{"trials":7365,"activeCount":109},[],{"intervention":7367,"totalTrials":708,"cells":7368},"anti-CD19 CAR-T cells",{"EARLY_PHASE1":7369,"PHASE1":7371,"PHASE2":7373,"PHASE3":7384,"PHASE4":7386,"NA":7388},{"trials":7370,"activeCount":109},[],{"trials":7372,"activeCount":109},[],{"trials":7374,"activeCount":708,"soonestReadout":1019},[7375],{"nctId":7376,"briefTitle":7377,"status":456,"phases":7378,"primaryCompletion":1019,"completion":1002,"start":1537,"enrollment":3887,"conditions":7379,"interventions":7383},"NCT06821659","Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases",[98,99],[7380,6849,7381,7382,6855],"Systemic Lupus Erthematosus","Inflammatory Myopathies","ANCA Associated Vasculitis (AAV)",[7367],{"trials":7385,"activeCount":109},[],{"trials":7387,"activeCount":109},[],{"trials":7389,"activeCount":109},[],{"intervention":7391,"totalTrials":708,"cells":7392},"AK112 monotherapy",{"EARLY_PHASE1":7393,"PHASE1":7395,"PHASE2":7397,"PHASE3":7407,"PHASE4":7409,"NA":7411},{"trials":7394,"activeCount":109},[],{"trials":7396,"activeCount":109},[],{"trials":7398,"activeCount":708,"soonestReadout":7403},[7399],{"nctId":7400,"briefTitle":7401,"status":456,"phases":7402,"primaryCompletion":7403,"completion":7404,"start":1127,"enrollment":1767,"conditions":7405,"interventions":7406},"NCT06472895","A Study of AK112 Monotherapy in Advanced\u002FMetastatic Renal Cell Carcinoma",[98,99],"2025-12-20","2027-12-20",[3530],[7391],{"trials":7408,"activeCount":109},[],{"trials":7410,"activeCount":109},[],{"trials":7412,"activeCount":109},[],{"intervention":7414,"totalTrials":708,"cells":7415},"Adebrelimab with concurrent chemoradiotherapy",{"EARLY_PHASE1":7416,"PHASE1":7418,"PHASE2":7420,"PHASE3":7432,"PHASE4":7434,"NA":7436},{"trials":7417,"activeCount":109},[],{"trials":7419,"activeCount":109},[],{"trials":7421,"activeCount":708,"soonestReadout":7426},[7422],{"nctId":7423,"briefTitle":7424,"status":456,"phases":7425,"primaryCompletion":7426,"completion":7427,"start":2813,"enrollment":1767,"conditions":7428,"interventions":7431},"NCT07200154","Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC",[99],"2028-03-30","2028-09",[7429,7430],"Limited-stage Small-cell Lung Cancer","Concurrent Chemoradiation Therapy",[7414],{"trials":7433,"activeCount":109},[],{"trials":7435,"activeCount":109},[],{"trials":7437,"activeCount":109},[],{"intervention":7439,"totalTrials":708,"cells":7440},"Medroxyprogesterone acetate + Atorvastatin",{"EARLY_PHASE1":7441,"PHASE1":7443,"PHASE2":7445,"PHASE3":7459,"PHASE4":7461,"NA":7463},{"trials":7442,"activeCount":109},[],{"trials":7444,"activeCount":109},[],{"trials":7446,"activeCount":708,"soonestReadout":7451},[7447],{"nctId":7448,"briefTitle":7449,"status":121,"phases":7450,"primaryCompletion":7451,"completion":7452,"start":7453,"enrollment":7454,"conditions":7455,"interventions":7458},"NCT05675787","Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia",[99],"2025-08-31","2025-10-31","2023-01-06",82,[7456,7457],"Atypical Endometrial Hyperplasia","Endometrial Carcinoma Stage I",[7439],{"trials":7460,"activeCount":109},[],{"trials":7462,"activeCount":109},[],{"trials":7464,"activeCount":109},[],{"intervention":62,"totalTrials":708,"cells":7466},{"EARLY_PHASE1":7467,"PHASE1":7469,"PHASE2":7471,"PHASE3":7479,"PHASE4":7481,"NA":7483},{"trials":7468,"activeCount":109},[],{"trials":7470,"activeCount":109},[],{"trials":7472,"activeCount":708,"soonestReadout":57},[7473],{"nctId":60,"briefTitle":61,"status":121,"phases":7474,"primaryCompletion":57,"completion":726,"start":7475,"enrollment":6242,"conditions":7476,"interventions":7478},[98,99],"2021-03-28",[7477],"HER2-positive Early Breast Cancer",[62],{"trials":7480,"activeCount":109},[],{"trials":7482,"activeCount":109},[],{"trials":7484,"activeCount":109},[],{"intervention":7486,"totalTrials":708,"cells":7487},"PD1\u002FPDL1 antibody monotherapy, up to 24 weeks",{"EARLY_PHASE1":7488,"PHASE1":7490,"PHASE2":7492,"PHASE3":7505,"PHASE4":7507,"NA":7509},{"trials":7489,"activeCount":109},[],{"trials":7491,"activeCount":109},[],{"trials":7493,"activeCount":708,"soonestReadout":7498},[7494],{"nctId":7495,"briefTitle":7496,"status":121,"phases":7497,"primaryCompletion":7498,"completion":7498,"start":7499,"enrollment":2589,"conditions":7500,"interventions":7503},"NCT06580574","Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR\u002FMSI-H Gastric or Colon Cancers",[99],"2029-06-01","2024-09-13",[28,4173,7501,7502],"MSI-H","DMMR Cancer",[7486,7504],"Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks",{"trials":7506,"activeCount":109},[],{"trials":7508,"activeCount":109},[],{"trials":7510,"activeCount":109},[],{"intervention":7504,"totalTrials":708,"cells":7512},{"EARLY_PHASE1":7513,"PHASE1":7515,"PHASE2":7517,"PHASE3":7523,"PHASE4":7525,"NA":7527},{"trials":7514,"activeCount":109},[],{"trials":7516,"activeCount":109},[],{"trials":7518,"activeCount":708,"soonestReadout":7498},[7519],{"nctId":7495,"briefTitle":7496,"status":121,"phases":7520,"primaryCompletion":7498,"completion":7498,"start":7499,"enrollment":2589,"conditions":7521,"interventions":7522},[99],[28,4173,7501,7502],[7486,7504],{"trials":7524,"activeCount":109},[],{"trials":7526,"activeCount":109},[],{"trials":7528,"activeCount":109},[],{"intervention":7530,"totalTrials":708,"cells":7531},"Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy",{"EARLY_PHASE1":7532,"PHASE1":7534,"PHASE2":7536,"PHASE3":7551,"PHASE4":7553,"NA":7555},{"trials":7533,"activeCount":109},[],{"trials":7535,"activeCount":109},[],{"trials":7537,"activeCount":708,"soonestReadout":1020},[7538],{"nctId":7539,"briefTitle":7540,"status":121,"phases":7541,"primaryCompletion":1020,"completion":1020,"start":6876,"enrollment":7542,"conditions":7543,"interventions":7549},"NCT06970912","ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive\u002FHER2-Negative Breast Cancer",[99],393,[7544,7545,7546,5775,7547,7548],"Hormone Receptor-Positive Breast Cancer","High-risk Breast Cancer","Early-Stage Breast Cancer","ctDNA Monitoring","Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[7530,7550],"Taxane-Based Neoadjuvant Chemotherapy",{"trials":7552,"activeCount":109},[],{"trials":7554,"activeCount":109},[],{"trials":7556,"activeCount":109},[],{"intervention":7550,"totalTrials":708,"cells":7558},{"EARLY_PHASE1":7559,"PHASE1":7561,"PHASE2":7563,"PHASE3":7569,"PHASE4":7571,"NA":7573},{"trials":7560,"activeCount":109},[],{"trials":7562,"activeCount":109},[],{"trials":7564,"activeCount":708,"soonestReadout":1020},[7565],{"nctId":7539,"briefTitle":7540,"status":121,"phases":7566,"primaryCompletion":1020,"completion":1020,"start":6876,"enrollment":7542,"conditions":7567,"interventions":7568},[99],[7544,7545,7546,5775,7547,7548],[7530,7550],{"trials":7570,"activeCount":109},[],{"trials":7572,"activeCount":109},[],{"trials":7574,"activeCount":109},[],{"intervention":7576,"totalTrials":708,"cells":7577},"Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy",{"EARLY_PHASE1":7578,"PHASE1":7580,"PHASE2":7582,"PHASE3":7591,"PHASE4":7593,"NA":7595},{"trials":7579,"activeCount":109},[],{"trials":7581,"activeCount":109},[],{"trials":7583,"activeCount":708,"soonestReadout":3910},[7584],{"nctId":7585,"briefTitle":7586,"status":456,"phases":7587,"primaryCompletion":3910,"completion":7588,"start":1246,"enrollment":1527,"conditions":7589,"interventions":7590},"NCT07567326","Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC",[99],"2030-12",[5693],[7576],{"trials":7592,"activeCount":109},[],{"trials":7594,"activeCount":109},[],{"trials":7596,"activeCount":109},[],{"intervention":7598,"totalTrials":708,"cells":7599},"Thiotepa ;busulfan;fludarabine",{"EARLY_PHASE1":7600,"PHASE1":7602,"PHASE2":7604,"PHASE3":7616,"PHASE4":7618,"NA":7620},{"trials":7601,"activeCount":109},[],{"trials":7603,"activeCount":109},[],{"trials":7605,"activeCount":708,"soonestReadout":4934},[7606],{"nctId":7607,"briefTitle":7608,"status":121,"phases":7609,"primaryCompletion":4934,"completion":7610,"start":228,"enrollment":1830,"conditions":7611,"interventions":7615},"NCT06869265","Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia",[99],"2029-04-01",[7612,7613,7614],"Acute Myeloid Leukemia (AML)","High Risk Acute Myeloid Leukemia(AML)","Relapsed\u002FRefractory Acute Myeloid Leukemia (AML)",[7598],{"trials":7617,"activeCount":109},[],{"trials":7619,"activeCount":109},[],{"trials":7621,"activeCount":109},[],{"intervention":622,"totalTrials":708,"cells":7623},{"EARLY_PHASE1":7624,"PHASE1":7626,"PHASE2":7628,"PHASE3":7634,"PHASE4":7636,"NA":7638},{"trials":7625,"activeCount":109},[],{"trials":7627,"activeCount":109},[],{"trials":7629,"activeCount":708,"soonestReadout":614},[7630],{"nctId":611,"briefTitle":612,"status":456,"phases":7631,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":7632,"interventions":7633},[99],[619,620],[622,623,557],{"trials":7635,"activeCount":109},[],{"trials":7637,"activeCount":109},[],{"trials":7639,"activeCount":109},[],{"intervention":4053,"totalTrials":708,"cells":7641},{"EARLY_PHASE1":7642,"PHASE1":7644,"PHASE2":7646,"PHASE3":7652,"PHASE4":7654,"NA":7656},{"trials":7643,"activeCount":109},[],{"trials":7645,"activeCount":109},[],{"trials":7647,"activeCount":708,"soonestReadout":968},[7648],{"nctId":4046,"briefTitle":4047,"status":456,"phases":7649,"primaryCompletion":968,"completion":2050,"start":4049,"enrollment":1767,"conditions":7650,"interventions":7651},[99],[4051],[632,4053],{"trials":7653,"activeCount":109},[],{"trials":7655,"activeCount":109},[],{"trials":7657,"activeCount":109},[],{"intervention":7659,"totalTrials":708,"cells":7660},"Disitamab Vedotin combined with Radiotherapy",{"EARLY_PHASE1":7661,"PHASE1":7663,"PHASE2":7665,"PHASE3":7674,"PHASE4":7676,"NA":7678},{"trials":7662,"activeCount":109},[],{"trials":7664,"activeCount":109},[],{"trials":7666,"activeCount":708,"soonestReadout":4391},[7667],{"nctId":7668,"briefTitle":7669,"status":456,"phases":7670,"primaryCompletion":4391,"completion":1002,"start":2203,"enrollment":1767,"conditions":7671,"interventions":7673},"NCT07100184","RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients",[99],[7672],"HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT",[7659],{"trials":7675,"activeCount":109},[],{"trials":7677,"activeCount":109},[],{"trials":7679,"activeCount":109},[],{"intervention":7681,"totalTrials":708,"cells":7682},"First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC",{"EARLY_PHASE1":7683,"PHASE1":7685,"PHASE2":7687,"PHASE3":7698,"PHASE4":7700,"NA":7702},{"trials":7684,"activeCount":109},[],{"trials":7686,"activeCount":109},[],{"trials":7688,"activeCount":708,"soonestReadout":2136},[7689],{"nctId":7690,"briefTitle":7691,"status":456,"phases":7692,"primaryCompletion":2136,"completion":7693,"start":3635,"enrollment":140,"conditions":7694,"interventions":7697},"NCT06768307","Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer",[99],"2028-01",[7695,3924,5066,7696],"SCLC, Extensive Stage","Radiotherapy",[7681],{"trials":7699,"activeCount":109},[],{"trials":7701,"activeCount":109},[],{"trials":7703,"activeCount":109},[],{"intervention":4251,"totalTrials":708,"cells":7705},{"EARLY_PHASE1":7706,"PHASE1":7708,"PHASE2":7710,"PHASE3":7716,"PHASE4":7718,"NA":7720},{"trials":7707,"activeCount":109},[],{"trials":7709,"activeCount":109},[],{"trials":7711,"activeCount":708,"soonestReadout":412},[7712],{"nctId":4244,"briefTitle":4245,"status":121,"phases":7713,"primaryCompletion":412,"completion":412,"start":4247,"enrollment":1767,"conditions":7714,"interventions":7715},[99],[4249],[1035,4229,4251],{"trials":7717,"activeCount":109},[],{"trials":7719,"activeCount":109},[],{"trials":7721,"activeCount":109},[],{"intervention":7723,"totalTrials":708,"cells":7724},"Adebelizumab combined with irinotecan liposome as second-line therapy",{"EARLY_PHASE1":7725,"PHASE1":7727,"PHASE2":7729,"PHASE3":7740,"PHASE4":7742,"NA":7744},{"trials":7726,"activeCount":109},[],{"trials":7728,"activeCount":109},[],{"trials":7730,"activeCount":708,"soonestReadout":7735},[7731],{"nctId":7732,"briefTitle":7733,"status":456,"phases":7734,"primaryCompletion":7735,"completion":7736,"start":2051,"enrollment":6242,"conditions":7737,"interventions":7739},"NCT07004712","Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer",[99],"2028-03-01","2028-09-01",[7738],"Small Cell Lung Cancer",[7723],{"trials":7741,"activeCount":109},[],{"trials":7743,"activeCount":109},[],{"trials":7745,"activeCount":109},[],{"intervention":7747,"totalTrials":708,"cells":7748},"anti-CD19 CAR T cell therapy",{"EARLY_PHASE1":7749,"PHASE1":7751,"PHASE2":7753,"PHASE3":7761,"PHASE4":7763,"NA":7765},{"trials":7750,"activeCount":109},[],{"trials":7752,"activeCount":109},[],{"trials":7754,"activeCount":708,"soonestReadout":1019},[7755],{"nctId":7756,"briefTitle":7757,"status":121,"phases":7758,"primaryCompletion":1019,"completion":1019,"start":5311,"enrollment":3887,"conditions":7759,"interventions":7760},"NCT06828042","Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases",[98,99],[7380,6849,6855,7382,7381,6852],[7747],{"trials":7762,"activeCount":109},[],{"trials":7764,"activeCount":109},[],{"trials":7766,"activeCount":109},[],{"intervention":7768,"totalTrials":708,"cells":7769},"Darolutamide",{"EARLY_PHASE1":7770,"PHASE1":7772,"PHASE2":7774,"PHASE3":7783,"PHASE4":7785,"NA":7787},{"trials":7771,"activeCount":109},[],{"trials":7773,"activeCount":109},[],{"trials":7775,"activeCount":708,"soonestReadout":3157},[7776],{"nctId":7777,"briefTitle":7778,"status":456,"phases":7779,"primaryCompletion":3157,"completion":1333,"start":7780,"enrollment":32,"conditions":7781,"interventions":7782},"NCT07282197","Darolutamide+ADT Post-RP w\u002Fo ePLND in hrPC: Briganti 2019",[99],"2026-01",[37],[7768],{"trials":7784,"activeCount":109},[],{"trials":7786,"activeCount":109},[],{"trials":7788,"activeCount":109},[],{"intervention":1060,"totalTrials":708,"cells":7790},{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7795,"PHASE3":7801,"PHASE4":7803,"NA":7805},{"trials":7792,"activeCount":109},[],{"trials":7794,"activeCount":109},[],{"trials":7796,"activeCount":708,"soonestReadout":615},[7797],{"nctId":1051,"briefTitle":1052,"status":456,"phases":7798,"primaryCompletion":615,"completion":1020,"start":1054,"enrollment":376,"conditions":7799,"interventions":7800},[99],[31,1056],[1058,1007,1059,1060],{"trials":7802,"activeCount":109},[],{"trials":7804,"activeCount":109},[],{"trials":7806,"activeCount":109},[],{"intervention":7808,"totalTrials":708,"cells":7809},"chidamide+Camrelizumab+Apatinib",{"EARLY_PHASE1":7810,"PHASE1":7812,"PHASE2":7814,"PHASE3":7825,"PHASE4":7827,"NA":7829},{"trials":7811,"activeCount":109},[],{"trials":7813,"activeCount":109},[],{"trials":7815,"activeCount":708,"soonestReadout":1779},[7816],{"nctId":7817,"briefTitle":7818,"status":456,"phases":7819,"primaryCompletion":1779,"completion":1267,"start":5063,"enrollment":7820,"conditions":7821,"interventions":7823},"NCT06745193","A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer",[99],63,[7822],"Advanced Esophageal Carcinoma",[7808,7824],"Irinotecan or Docetaxel or Paclitaxel",{"trials":7826,"activeCount":109},[],{"trials":7828,"activeCount":109},[],{"trials":7830,"activeCount":109},[],{"intervention":7824,"totalTrials":708,"cells":7832},{"EARLY_PHASE1":7833,"PHASE1":7835,"PHASE2":7837,"PHASE3":7843,"PHASE4":7845,"NA":7847},{"trials":7834,"activeCount":109},[],{"trials":7836,"activeCount":109},[],{"trials":7838,"activeCount":708,"soonestReadout":1779},[7839],{"nctId":7817,"briefTitle":7818,"status":456,"phases":7840,"primaryCompletion":1779,"completion":1267,"start":5063,"enrollment":7820,"conditions":7841,"interventions":7842},[99],[7822],[7808,7824],{"trials":7844,"activeCount":109},[],{"trials":7846,"activeCount":109},[],{"trials":7848,"activeCount":109},[],{"intervention":7850,"totalTrials":708,"cells":7851},"chidamide and golidocitinib",{"EARLY_PHASE1":7852,"PHASE1":7854,"PHASE2":7856,"PHASE3":7865,"PHASE4":7867,"NA":7869},{"trials":7853,"activeCount":109},[],{"trials":7855,"activeCount":109},[],{"trials":7857,"activeCount":708,"soonestReadout":2711},[7858],{"nctId":7859,"briefTitle":7860,"status":456,"phases":7861,"primaryCompletion":2711,"completion":7862,"start":4238,"enrollment":3547,"conditions":7863,"interventions":7864},"NCT06757387","Chidamide Plus Golidocitinib in Relapsed\u002FRefractory Peripheral T-Cell Lymphoma",[98,99],"2030-12-30",[1153],[7850],{"trials":7866,"activeCount":109},[],{"trials":7868,"activeCount":109},[],{"trials":7870,"activeCount":109},[],{"intervention":7872,"totalTrials":708,"cells":7873},"Toripalimab plus Chemotherapy",{"EARLY_PHASE1":7874,"PHASE1":7876,"PHASE2":7878,"PHASE3":7888,"PHASE4":7890,"NA":7892},{"trials":7875,"activeCount":109},[],{"trials":7877,"activeCount":109},[],{"trials":7879,"activeCount":708,"soonestReadout":725},[7880],{"nctId":7881,"briefTitle":7882,"status":456,"phases":7883,"primaryCompletion":725,"completion":725,"start":7884,"enrollment":693,"conditions":7885,"interventions":7887},"NCT05962021","Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation",[99],"2023-08-01",[7886,6695],"Non Squamous Non Small Cell Lung Cancer",[7872],{"trials":7889,"activeCount":109},[],{"trials":7891,"activeCount":109},[],{"trials":7893,"activeCount":109},[],{"intervention":7895,"totalTrials":708,"cells":7896},"Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy",{"EARLY_PHASE1":7897,"PHASE1":7899,"PHASE2":7901,"PHASE3":7912,"PHASE4":7914,"NA":7916},{"trials":7898,"activeCount":109},[],{"trials":7900,"activeCount":109},[],{"trials":7902,"activeCount":708,"soonestReadout":1385},[7903],{"nctId":7904,"briefTitle":7905,"status":456,"phases":7906,"primaryCompletion":1385,"completion":7693,"start":3635,"enrollment":1767,"conditions":7907,"interventions":7911},"NCT06784206","Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer",[99],[7908,7909,7910],"Small Cell Lung Cancer, Limited Stage","Hyperfractionated Accelerated Radiotherapy","Simultaneous Radiotherapy and Chemotherapy",[7895],{"trials":7913,"activeCount":109},[],{"trials":7915,"activeCount":109},[],{"trials":7917,"activeCount":109},[],{"intervention":7919,"totalTrials":708,"cells":7920},"CDK4\u002F6 inhibitor with endocrine therapy",{"EARLY_PHASE1":7921,"PHASE1":7923,"PHASE2":7925,"PHASE3":7934,"PHASE4":7936,"NA":7938},{"trials":7922,"activeCount":109},[],{"trials":7924,"activeCount":109},[],{"trials":7926,"activeCount":708,"soonestReadout":1804},[7927],{"nctId":7928,"briefTitle":7929,"status":456,"phases":7930,"primaryCompletion":1804,"completion":1020,"start":1780,"enrollment":7931,"conditions":7932,"interventions":7933},"NCT07366112","CDK4\u002F6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment",[99],158,[7544,7545,7546,5775,7547],[7919],{"trials":7935,"activeCount":109},[],{"trials":7937,"activeCount":109},[],{"trials":7939,"activeCount":109},[],{"intervention":4584,"totalTrials":708,"cells":7941},{"EARLY_PHASE1":7942,"PHASE1":7944,"PHASE2":7946,"PHASE3":7952,"PHASE4":7954,"NA":7956},{"trials":7943,"activeCount":109},[],{"trials":7945,"activeCount":109},[],{"trials":7947,"activeCount":708,"soonestReadout":1019},[7948],{"nctId":4577,"briefTitle":4578,"status":456,"phases":7949,"primaryCompletion":1019,"completion":1002,"start":2203,"enrollment":4091,"conditions":7950,"interventions":7951},[99],[4581,4582],[4118,4584],{"trials":7953,"activeCount":109},[],{"trials":7955,"activeCount":109},[],{"trials":7957,"activeCount":109},[],{"intervention":7959,"totalTrials":708,"cells":7960},"Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin",{"EARLY_PHASE1":7961,"PHASE1":7963,"PHASE2":7965,"PHASE3":7975,"PHASE4":7977,"NA":7979},{"trials":7962,"activeCount":109},[],{"trials":7964,"activeCount":109},[],{"trials":7966,"activeCount":708,"soonestReadout":1019},[7967],{"nctId":7968,"briefTitle":7969,"status":121,"phases":7970,"primaryCompletion":1019,"completion":1019,"start":7971,"enrollment":1767,"conditions":7972,"interventions":7974},"NCT06869213","A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma",[99],"2025-03-31",[7973],"Esophageal Cancer (EsC)",[7959],{"trials":7976,"activeCount":109},[],{"trials":7978,"activeCount":109},[],{"trials":7980,"activeCount":109},[],{"intervention":7982,"totalTrials":708,"cells":7983},"QL1706 Plus Celecoxib Group",{"EARLY_PHASE1":7984,"PHASE1":7986,"PHASE2":7988,"PHASE3":7998,"PHASE4":8000,"NA":8002},{"trials":7985,"activeCount":109},[],{"trials":7987,"activeCount":109},[],{"trials":7989,"activeCount":708,"soonestReadout":7994},[7990],{"nctId":7991,"briefTitle":7992,"status":456,"phases":7993,"primaryCompletion":7994,"completion":7995,"start":5553,"enrollment":35,"conditions":7996,"interventions":7997},"NCT07049185","QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma",[99],"2027-03-01","2027-09-01",[1250],[7982],{"trials":7999,"activeCount":109},[],{"trials":8001,"activeCount":109},[],{"trials":8003,"activeCount":109},[],{"intervention":53,"totalTrials":708,"cells":8005},{"EARLY_PHASE1":8006,"PHASE1":8008,"PHASE2":8010,"PHASE3":8017,"PHASE4":8019,"NA":8021},{"trials":8007,"activeCount":109},[],{"trials":8009,"activeCount":109},[],{"trials":8011,"activeCount":708,"soonestReadout":52},[8012],{"nctId":50,"briefTitle":51,"status":121,"phases":8013,"primaryCompletion":52,"completion":438,"start":1765,"enrollment":8014,"conditions":8015,"interventions":8016},[99],104,[1056],[53],{"trials":8018,"activeCount":109},[],{"trials":8020,"activeCount":109},[],{"trials":8022,"activeCount":109},[],{"intervention":8024,"totalTrials":708,"cells":8025},"Liposomal Irinotecan",{"EARLY_PHASE1":8026,"PHASE1":8028,"PHASE2":8030,"PHASE3":8042,"PHASE4":8044,"NA":8046},{"trials":8027,"activeCount":109},[],{"trials":8029,"activeCount":109},[],{"trials":8031,"activeCount":708,"soonestReadout":8036},[8032],{"nctId":8033,"briefTitle":8034,"status":121,"phases":8035,"primaryCompletion":8036,"completion":1804,"start":8037,"enrollment":1830,"conditions":8038,"interventions":8040},"NCT07479732","Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma",[98,99],"2027-03-05","2026-03-05",[2532,8039],"Osteosarcoma Metastatic",[8024,8041],"Apatinib in arm1",{"trials":8043,"activeCount":109},[],{"trials":8045,"activeCount":109},[],{"trials":8047,"activeCount":109},[],{"intervention":8041,"totalTrials":708,"cells":8049},{"EARLY_PHASE1":8050,"PHASE1":8052,"PHASE2":8054,"PHASE3":8060,"PHASE4":8062,"NA":8064},{"trials":8051,"activeCount":109},[],{"trials":8053,"activeCount":109},[],{"trials":8055,"activeCount":708,"soonestReadout":8036},[8056],{"nctId":8033,"briefTitle":8034,"status":121,"phases":8057,"primaryCompletion":8036,"completion":1804,"start":8037,"enrollment":1830,"conditions":8058,"interventions":8059},[98,99],[2532,8039],[8024,8041],{"trials":8061,"activeCount":109},[],{"trials":8063,"activeCount":109},[],{"trials":8065,"activeCount":109},[],{"intervention":8067,"totalTrials":708,"cells":8068},"a targeted probe B7H3-IRDye800CW",{"EARLY_PHASE1":8069,"PHASE1":8071,"PHASE2":8073,"PHASE3":8085,"PHASE4":8087,"NA":8089},{"trials":8070,"activeCount":109},[],{"trials":8072,"activeCount":109},[],{"trials":8074,"activeCount":708,"soonestReadout":2051},[8075],{"nctId":8076,"briefTitle":8077,"status":121,"phases":8078,"primaryCompletion":2051,"completion":726,"start":4308,"enrollment":8079,"conditions":8080,"interventions":8084},"NCT06778603","B7-H3 NIR Imaging for Osteosarcoma Surgery",[98,99],32,[2532,8081,8082,8083],"Resection Margins","B7-H3 Probe","Local Recurrence",[8067],{"trials":8086,"activeCount":109},[],{"trials":8088,"activeCount":109},[],{"trials":8090,"activeCount":109},[],{"intervention":5314,"totalTrials":708,"cells":8092},{"EARLY_PHASE1":8093,"PHASE1":8095,"PHASE2":8097,"PHASE3":8103,"PHASE4":8105,"NA":8107},{"trials":8094,"activeCount":109},[],{"trials":8096,"activeCount":109},[],{"trials":8098,"activeCount":708,"soonestReadout":968},[8099],{"nctId":5307,"briefTitle":5308,"status":456,"phases":8100,"primaryCompletion":968,"completion":5310,"start":5311,"enrollment":574,"conditions":8101,"interventions":8102},[99],[588],[5282,5314],{"trials":8104,"activeCount":109},[],{"trials":8106,"activeCount":109},[],{"trials":8108,"activeCount":109},[],{"intervention":4427,"totalTrials":708,"cells":8110},{"EARLY_PHASE1":8111,"PHASE1":8113,"PHASE2":8115,"PHASE3":8121,"PHASE4":8123,"NA":8125},{"trials":8112,"activeCount":109},[],{"trials":8114,"activeCount":109},[],{"trials":8116,"activeCount":708,"soonestReadout":726},[8117],{"nctId":4420,"briefTitle":4421,"status":456,"phases":8118,"primaryCompletion":726,"completion":726,"start":2051,"enrollment":4001,"conditions":8119,"interventions":8120},[99],[4424,4425],[4403,4427],{"trials":8122,"activeCount":109},[],{"trials":8124,"activeCount":109},[],{"trials":8126,"activeCount":109},[],{"intervention":8128,"totalTrials":708,"cells":8129},"Nimotuzumab combined with chemoradiotherapy",{"EARLY_PHASE1":8130,"PHASE1":8132,"PHASE2":8134,"PHASE3":8146,"PHASE4":8148,"NA":8150},{"trials":8131,"activeCount":109},[],{"trials":8133,"activeCount":109},[],{"trials":8135,"activeCount":708,"soonestReadout":8140},[8136],{"nctId":8137,"briefTitle":8138,"status":1935,"phases":8139,"primaryCompletion":8140,"completion":8141,"start":8142,"enrollment":1767,"conditions":8143,"interventions":8145},"NCT07386704","Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer",[99],"2026-12-09","2027-12-09","2025-12-09",[8144],"Pancreatic Cancer Non-resectable",[8128],{"trials":8147,"activeCount":109},[],{"trials":8149,"activeCount":109},[],{"trials":8151,"activeCount":109},[],{"intervention":8153,"totalTrials":708,"cells":8154},"Perioperative treatment",{"EARLY_PHASE1":8155,"PHASE1":8157,"PHASE2":8159,"PHASE3":8167,"PHASE4":8169,"NA":8171},{"trials":8156,"activeCount":109},[],{"trials":8158,"activeCount":109},[],{"trials":8160,"activeCount":708,"soonestReadout":726},[8161],{"nctId":8162,"briefTitle":8163,"status":121,"phases":8164,"primaryCompletion":726,"completion":1020,"start":2814,"enrollment":1767,"conditions":8165,"interventions":8166},"NCT06992362","Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach",[99],[7228],[8153],{"trials":8168,"activeCount":109},[],{"trials":8170,"activeCount":109},[],{"trials":8172,"activeCount":109},[],{"intervention":3684,"totalTrials":1091,"cells":8174},{"EARLY_PHASE1":8175,"PHASE1":8177,"PHASE2":8183,"PHASE3":8215,"PHASE4":8217,"NA":8219},{"trials":8176,"activeCount":109},[],{"trials":8178,"activeCount":109},[8179],{"nctId":5769,"briefTitle":5770,"status":569,"phases":8180,"primaryCompletion":5772,"completion":5773,"start":191,"enrollment":2522,"conditions":8181,"interventions":8182},[98],[5775,4705,5776,684],[5762,3684],{"trials":8184,"activeCount":708,"soonestReadout":2094},[8185,8195,8199,8203,8207],{"nctId":8186,"briefTitle":8187,"status":569,"phases":8188,"primaryCompletion":8189,"completion":8190,"start":8191,"enrollment":728,"conditions":8192,"interventions":8194},"NCT04147728","Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC",[99],"2021-12-15","2022-12-15","2019-12-24",[8193],"Stereotactic Body Radiation Therapy",[3684],{"nctId":5488,"briefTitle":5489,"status":569,"phases":8196,"primaryCompletion":3634,"completion":3594,"start":5491,"enrollment":3453,"conditions":8197,"interventions":8198},[98,99],[5493],[3684,1029],{"nctId":3849,"briefTitle":3850,"status":456,"phases":8200,"primaryCompletion":2094,"completion":3852,"start":3853,"enrollment":1139,"conditions":8201,"interventions":8202},[99],[28,3855],[3684,3857,1024],{"nctId":3676,"briefTitle":3677,"status":569,"phases":8204,"primaryCompletion":3679,"completion":3680,"start":1162,"enrollment":32,"conditions":8205,"interventions":8206},[99],[28,3682],[1036,3684],{"nctId":8208,"briefTitle":8209,"status":569,"phases":8210,"primaryCompletion":2530,"completion":2530,"start":8211,"enrollment":26,"conditions":8212,"interventions":8214},"NCT03732846","Anlotinib in Treatment of Recurrent Small Cell Lung Cancer",[99],"2018-11-01",[8213],"Recurrent Small Cell Lung Cancer",[3684],{"trials":8216,"activeCount":109},[],{"trials":8218,"activeCount":109},[],{"trials":8220,"activeCount":109},[8221],{"nctId":8222,"briefTitle":8223,"status":135,"phases":8224,"primaryCompletion":857,"completion":857,"start":3450,"enrollment":1767,"conditions":8225,"interventions":8226},"NCT04912128","Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC",[],[8193],[3684],{"intervention":2537,"totalTrials":1091,"cells":8228},{"EARLY_PHASE1":8229,"PHASE1":8231,"PHASE2":8241,"PHASE3":8269,"PHASE4":8271,"NA":8273},{"trials":8230,"activeCount":109},[],{"trials":8232,"activeCount":109},[8233],{"nctId":8234,"briefTitle":8235,"status":569,"phases":8236,"primaryCompletion":4670,"completion":4125,"start":5437,"enrollment":1767,"conditions":8237,"interventions":8239},"NCT03050411","Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer",[98],[8238],"Nonsmall Cell Lung Cancer",[2537,8240],"EGFR-TKIs",{"trials":8242,"activeCount":708,"soonestReadout":4500},[8243,8247,8257,8265],{"nctId":2527,"briefTitle":2528,"status":569,"phases":8244,"primaryCompletion":1138,"completion":1215,"start":2530,"enrollment":140,"conditions":8245,"interventions":8246},[99],[2532,1327,2533,2534],[2536,2537,72],{"nctId":8248,"briefTitle":8249,"status":569,"phases":8250,"primaryCompletion":375,"completion":8251,"start":8252,"enrollment":1767,"conditions":8253,"interventions":8254},"NCT03955354","PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma",[99],"2021-04-10","2019-03-05",[2580],[8255,8256],"SHR1210","apatinib mesylate",{"nctId":8258,"briefTitle":8259,"status":569,"phases":8260,"primaryCompletion":52,"completion":8261,"start":8262,"enrollment":32,"conditions":8263,"interventions":8264},"NCT04397770","Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma",[99],"2023-02","2020-05",[2580],[8255,8256,2600],{"nctId":4497,"briefTitle":4498,"status":456,"phases":8266,"primaryCompletion":4500,"completion":4342,"start":4501,"enrollment":658,"conditions":8267,"interventions":8268},[99],[4503],[1039,2537],{"trials":8270,"activeCount":109},[],{"trials":8272,"activeCount":109},[],{"trials":8274,"activeCount":109},[8275,8283],{"nctId":8276,"briefTitle":8277,"status":135,"phases":8278,"primaryCompletion":649,"completion":1641,"start":8279,"enrollment":32,"conditions":8280,"interventions":8282},"NCT04260113","Apatinib for Inoperable Advanced Chondrosarcoma",[102],"2019-10-01",[8281,2534],"Efficacy",[2537],{"nctId":8284,"briefTitle":8285,"status":135,"phases":8286,"primaryCompletion":573,"completion":857,"start":2624,"enrollment":8287,"conditions":8288,"interventions":8290},"NCT04690231","Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma",[102],79,[5412,2534,8289],"Secondary Resistance",[2537,8291],"ifosfamide and etoposide",{"intervention":3741,"totalTrials":329,"cells":8293},{"EARLY_PHASE1":8294,"PHASE1":8296,"PHASE2":8298,"PHASE3":8304,"PHASE4":8306,"NA":8308},{"trials":8295,"activeCount":109},[],{"trials":8297,"activeCount":109},[],{"trials":8299,"activeCount":708,"soonestReadout":3736},[8300],{"nctId":3733,"briefTitle":3734,"status":456,"phases":8301,"primaryCompletion":3736,"completion":1020,"start":3737,"enrollment":3738,"conditions":8302,"interventions":8303},[99],[31],[3741,1087,1088,3742,3743,3744,3745,3746],{"trials":8305,"activeCount":109},[],{"trials":8307,"activeCount":109},[],{"trials":8309,"activeCount":109},[8310,8320],{"nctId":8311,"briefTitle":8312,"status":569,"phases":8313,"primaryCompletion":8314,"completion":4651,"start":8315,"enrollment":1767,"conditions":8316,"interventions":8319},"NCT04961307","Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab",[],"2021-12-01","2019-07-05",[8317,8318,31,3741],"Cardiotoxicity","Antitumor Drugs",[3741],{"nctId":8321,"briefTitle":8322,"status":569,"phases":8323,"primaryCompletion":857,"completion":4651,"start":2778,"enrollment":1165,"conditions":8324,"interventions":8326},"NCT04962425","Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients",[],[8325,8318,31],"Cardiac Toxicity",[3741],{"intervention":8328,"totalTrials":746,"cells":8329},"Amlodipine",{"EARLY_PHASE1":8330,"PHASE1":8332,"PHASE2":8334,"PHASE3":8342,"PHASE4":8344,"NA":8346},{"trials":8331,"activeCount":109},[],{"trials":8333,"activeCount":109},[],{"trials":8335,"activeCount":708,"soonestReadout":772},[8336],{"nctId":8337,"briefTitle":8338,"status":456,"phases":8339,"primaryCompletion":772,"completion":2969,"start":5553,"enrollment":1480,"conditions":8340,"interventions":8341},"NCT06942377","Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy",[99],[1551],[8328],{"trials":8343,"activeCount":109},[],{"trials":8345,"activeCount":109},[],{"trials":8347,"activeCount":109},[8348],{"nctId":8349,"briefTitle":8350,"status":569,"phases":8351,"primaryCompletion":8352,"completion":3594,"start":8353,"enrollment":8354,"conditions":8355,"interventions":8357},"NCT03626506","Spironolactone Versus Indapamide in Obese and Hypertensive Patients",[102],"2020-08","2019-02-13",400,[8356],"Hypertension",[8358,8359,8328],"Spironolactone","Indapamide",{"intervention":1040,"totalTrials":746,"cells":8361},{"EARLY_PHASE1":8362,"PHASE1":8364,"PHASE2":8366,"PHASE3":8372,"PHASE4":8374,"NA":8376},{"trials":8363,"activeCount":109},[],{"trials":8365,"activeCount":109},[],{"trials":8367,"activeCount":708,"soonestReadout":1019},[8368],{"nctId":1016,"briefTitle":1017,"status":456,"phases":8369,"primaryCompletion":1019,"completion":1020,"start":773,"enrollment":168,"conditions":8370,"interventions":8371},[99],[1022],[1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,72,1037,1038,1039,1040,1041,1042,1043,1044,1007,1045,1046,1047,1048,1049],{"trials":8373,"activeCount":109},[],{"trials":8375,"activeCount":109},[],{"trials":8377,"activeCount":109},[8378],{"nctId":8379,"briefTitle":8380,"status":569,"phases":8381,"primaryCompletion":6743,"completion":8382,"start":8383,"enrollment":1767,"conditions":8384,"interventions":8385},"NCT05879796","Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer",[],"2026-05-16","2023-05-16",[2681],[8386,1040,8387],"cis-platinum","Recombinant Human Endostatin",{"intervention":734,"totalTrials":477,"cells":8389},{"EARLY_PHASE1":8390,"PHASE1":8403,"PHASE2":8436,"PHASE3":8452,"PHASE4":8458,"NA":8460},{"trials":8391,"activeCount":708,"soonestReadout":1019},[8392],{"nctId":8393,"briefTitle":8394,"status":456,"phases":8395,"primaryCompletion":1019,"completion":1019,"start":1537,"enrollment":2732,"conditions":8396,"interventions":8400},"NCT06825455","Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors",[97],[8397,8398,8399],"Advanced Solid Tumors","Ovarian Cancers","Peritoneal (metastatic) Cancer",[8401,734,8402],"Fludarabine","B7H3 CAR-γδT cells",{"trials":8404,"activeCount":708,"soonestReadout":5310},[8405,8414,8427],{"nctId":8406,"briefTitle":8407,"status":435,"phases":8408,"primaryCompletion":8409,"completion":8409,"start":5343,"enrollment":109,"conditions":8410,"interventions":8411},"NCT02867332","PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.",[98],"2020-11",[3122],[8412,734,8413],"PD-1 Knockout T Cells","IL-2",{"nctId":8415,"briefTitle":8416,"status":456,"phases":8417,"primaryCompletion":5310,"completion":8418,"start":5311,"enrollment":47,"conditions":8419,"interventions":8425},"NCT07024147","JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",[98],"2030-07-01",[8420,8421,8422,8423,8424],"B-Cell Non-Hodgkin Lymphoma","Large B Cell Diffuse Lymphoma","Follicular Lymphoma","Marginal Zone B Cell Lymphoma","Mantle Cell Lymphoma (MCL)",[8426,8401,734],"JWCAR239",{"nctId":8428,"briefTitle":8429,"status":435,"phases":8430,"primaryCompletion":8431,"completion":8431,"start":8432,"enrollment":109,"conditions":8433,"interventions":8435},"NCT02863913","PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer",[98],"2019-09","2016-09",[8434],"Invasive Bladder Cancer Stage IV",[8412,734,8413],{"trials":8437,"activeCount":109},[8438,8442],{"nctId":1109,"briefTitle":1110,"status":569,"phases":8439,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":8440,"interventions":8441},[99],[1117],[1119,734,1120,1121,1122,1090],{"nctId":8443,"briefTitle":8444,"status":569,"phases":8445,"primaryCompletion":8446,"completion":8447,"start":1526,"enrollment":47,"conditions":8448,"interventions":8450},"NCT05590221","Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma",[99],"2024-02-10","2024-12-10",[8449],"B-cell Lymphoma",[8451,8401,734],"Relmacabtagene Autoleucel",{"trials":8453,"activeCount":109},[8454],{"nctId":1146,"briefTitle":1147,"status":569,"phases":8455,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":8456,"interventions":8457},[100],[1153],[734,1155,1121,1090,1120],{"trials":8459,"activeCount":109},[],{"trials":8461,"activeCount":708,"soonestReadout":725},[8462,8466,8470],{"nctId":2927,"briefTitle":2928,"status":569,"phases":8463,"primaryCompletion":2930,"completion":2930,"start":669,"enrollment":2931,"conditions":8464,"interventions":8465},[],[2933,2934,2935],[983,734,2937,2938,2939],{"nctId":722,"briefTitle":723,"status":121,"phases":8467,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":8468,"interventions":8469},[],[730],[732,733,557,734,735],{"nctId":8471,"briefTitle":8472,"status":435,"phases":8473,"primaryCompletion":8409,"completion":3594,"start":5343,"enrollment":109,"conditions":8474,"interventions":8476},"NCT02867345","PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer",[],[8475],"Hormone Refractory Prostate Cancer",[8412,734,8413],{"intervention":8478,"totalTrials":746,"cells":8479},"[225Ac]Ac-DOTATATE",{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8499,"PHASE3":8501,"PHASE4":8503,"NA":8505},{"trials":8481,"activeCount":109},[],{"trials":8483,"activeCount":746,"soonestReadout":741},[8484,8492],{"nctId":8485,"briefTitle":8486,"status":121,"phases":8487,"primaryCompletion":741,"completion":1054,"start":8488,"enrollment":8489,"conditions":8490,"interventions":8491},"NCT06732505","A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens",[98],"2024-09-29",36,[4249],[8478],{"nctId":8493,"briefTitle":8494,"status":121,"phases":8495,"primaryCompletion":726,"completion":1175,"start":8496,"enrollment":38,"conditions":8497,"interventions":8498},"NCT07413042","A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment",[98],"2026-01-20",[7695],[8478],{"trials":8500,"activeCount":109},[],{"trials":8502,"activeCount":109},[],{"trials":8504,"activeCount":109},[],{"trials":8506,"activeCount":109},[],{"intervention":8401,"totalTrials":405,"cells":8508},{"EARLY_PHASE1":8509,"PHASE1":8515,"PHASE2":8521,"PHASE3":8527,"PHASE4":8529,"NA":8531},{"trials":8510,"activeCount":708,"soonestReadout":1019},[8511],{"nctId":8393,"briefTitle":8394,"status":456,"phases":8512,"primaryCompletion":1019,"completion":1019,"start":1537,"enrollment":2732,"conditions":8513,"interventions":8514},[97],[8397,8398,8399],[8401,734,8402],{"trials":8516,"activeCount":708,"soonestReadout":5310},[8517],{"nctId":8415,"briefTitle":8416,"status":456,"phases":8518,"primaryCompletion":5310,"completion":8418,"start":5311,"enrollment":47,"conditions":8519,"interventions":8520},[98],[8420,8421,8422,8423,8424],[8426,8401,734],{"trials":8522,"activeCount":109},[8523],{"nctId":8443,"briefTitle":8444,"status":569,"phases":8524,"primaryCompletion":8446,"completion":8447,"start":1526,"enrollment":47,"conditions":8525,"interventions":8526},[99],[8449],[8451,8401,734],{"trials":8528,"activeCount":109},[],{"trials":8530,"activeCount":109},[],{"trials":8532,"activeCount":109},[8533],{"nctId":8534,"briefTitle":8535,"status":569,"phases":8536,"primaryCompletion":4651,"completion":8537,"start":8538,"enrollment":3011,"conditions":8539,"interventions":8541},"NCT03821987","Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA",[102],"2022-03-30","2018-12-17",[6069,3013,8540],"Engraft Failure",[8401],{"intervention":4742,"totalTrials":746,"cells":8543},{"EARLY_PHASE1":8544,"PHASE1":8546,"PHASE2":8559,"PHASE3":8561,"PHASE4":8563,"NA":8565},{"trials":8545,"activeCount":109},[],{"trials":8547,"activeCount":708,"soonestReadout":8552},[8548],{"nctId":8549,"briefTitle":8550,"status":121,"phases":8551,"primaryCompletion":8552,"completion":8553,"start":8554,"enrollment":658,"conditions":8555,"interventions":8557},"NCT06340204","Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma",[98],"2026-03-25","2026-12-25","2024-03-25",[8556],"Ewing Sarcoma",[8558],"Irinotecan Hydrochloride Liposome",{"trials":8560,"activeCount":109},[],{"trials":8562,"activeCount":109},[],{"trials":8564,"activeCount":109},[],{"trials":8566,"activeCount":708,"soonestReadout":4736},[8567],{"nctId":4733,"briefTitle":4734,"status":121,"phases":8568,"primaryCompletion":4736,"completion":2673,"start":4737,"enrollment":4738,"conditions":8569,"interventions":8570},[102],[4740],[4742,4119,4743],{"intervention":3501,"totalTrials":1091,"cells":8572},{"EARLY_PHASE1":8573,"PHASE1":8575,"PHASE2":8581,"PHASE3":8595,"PHASE4":8605,"NA":8611},{"trials":8574,"activeCount":109},[],{"trials":8576,"activeCount":708,"soonestReadout":302},[8577],{"nctId":3492,"briefTitle":3493,"status":121,"phases":8578,"primaryCompletion":302,"completion":1829,"start":3495,"enrollment":44,"conditions":8579,"interventions":8580},[98],[3497],[1036,3499,1028,3500,3501,3502,3503],{"trials":8582,"activeCount":109},[8583,8587,8591],{"nctId":3761,"briefTitle":3762,"status":569,"phases":8584,"primaryCompletion":668,"completion":668,"start":3089,"enrollment":3764,"conditions":8585,"interventions":8586},[99],[2580],[3501,3500,3767],{"nctId":3572,"briefTitle":3573,"status":200,"phases":8588,"primaryCompletion":3575,"completion":3575,"start":3576,"enrollment":477,"conditions":8589,"interventions":8590},[99],[3578],[1037,3501,1028],{"nctId":4687,"briefTitle":4688,"status":569,"phases":8592,"primaryCompletion":4690,"completion":139,"start":4691,"enrollment":47,"conditions":8593,"interventions":8594},[99],[28,4693],[4119,3501],{"trials":8596,"activeCount":109},[8597,8601],{"nctId":3583,"briefTitle":3584,"status":569,"phases":8598,"primaryCompletion":2874,"completion":2874,"start":3586,"enrollment":3587,"conditions":8599,"interventions":8600},[100],[3549],[3501,3552,3552,3516],{"nctId":3591,"briefTitle":3592,"status":435,"phases":8602,"primaryCompletion":3594,"completion":3594,"start":2882,"enrollment":109,"conditions":8603,"interventions":8604},[99,100],[1250],[2561,3501,1028],{"trials":8606,"activeCount":109},[8607],{"nctId":3600,"briefTitle":3601,"status":569,"phases":8608,"primaryCompletion":572,"completion":81,"start":3603,"enrollment":168,"conditions":8609,"interventions":8610},[101],[3605],[3607,1028,3500,3501,3608],{"trials":8612,"activeCount":109},[],{"intervention":8614,"totalTrials":746,"cells":8615},"Nimotuzumab and Radiotherapy",{"EARLY_PHASE1":8616,"PHASE1":8618,"PHASE2":8627,"PHASE3":8638,"PHASE4":8640,"NA":8642},{"trials":8617,"activeCount":109},[],{"trials":8619,"activeCount":708,"soonestReadout":2049},[8620],{"nctId":8621,"briefTitle":8622,"status":456,"phases":8623,"primaryCompletion":2049,"completion":2049,"start":1578,"enrollment":1767,"conditions":8624,"interventions":8626},"NCT07053735","An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer",[98],[8625],"Bladder (Urothelial, Transitional Cell) Cancer",[8614],{"trials":8628,"activeCount":109},[8629],{"nctId":8630,"briefTitle":8631,"status":569,"phases":8632,"primaryCompletion":8633,"completion":1489,"start":4853,"enrollment":8634,"conditions":8635,"interventions":8637},"NCT01393184","Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN",[99],"2013-02",92,[8636],"SCCHN",[8614],{"trials":8639,"activeCount":109},[],{"trials":8641,"activeCount":109},[],{"trials":8643,"activeCount":109},[],{"intervention":8645,"totalTrials":708,"cells":8646},"Zanubrutinib 80mg\u002Fd",{"EARLY_PHASE1":8647,"PHASE1":8649,"PHASE2":8661,"PHASE3":8663,"PHASE4":8665,"NA":8667},{"trials":8648,"activeCount":109},[],{"trials":8650,"activeCount":708,"soonestReadout":2711},[8651],{"nctId":8652,"briefTitle":8653,"status":456,"phases":8654,"primaryCompletion":2711,"completion":8655,"start":1455,"enrollment":140,"conditions":8656,"interventions":8657},"NCT07315373","Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia",[98],"2029-06-30",[34],[8645,8658,8659,8660],"High dose dexamethasone","Zanubrutinib 160mg\u002Fd","Zanubrutinib 240mg\u002Fd",{"trials":8662,"activeCount":109},[],{"trials":8664,"activeCount":109},[],{"trials":8666,"activeCount":109},[],{"trials":8668,"activeCount":109},[],{"intervention":8658,"totalTrials":708,"cells":8670},{"EARLY_PHASE1":8671,"PHASE1":8673,"PHASE2":8679,"PHASE3":8681,"PHASE4":8683,"NA":8685},{"trials":8672,"activeCount":109},[],{"trials":8674,"activeCount":708,"soonestReadout":2711},[8675],{"nctId":8652,"briefTitle":8653,"status":456,"phases":8676,"primaryCompletion":2711,"completion":8655,"start":1455,"enrollment":140,"conditions":8677,"interventions":8678},[98],[34],[8645,8658,8659,8660],{"trials":8680,"activeCount":109},[],{"trials":8682,"activeCount":109},[],{"trials":8684,"activeCount":109},[],{"trials":8686,"activeCount":109},[],{"intervention":8659,"totalTrials":708,"cells":8688},{"EARLY_PHASE1":8689,"PHASE1":8691,"PHASE2":8697,"PHASE3":8699,"PHASE4":8701,"NA":8703},{"trials":8690,"activeCount":109},[],{"trials":8692,"activeCount":708,"soonestReadout":2711},[8693],{"nctId":8652,"briefTitle":8653,"status":456,"phases":8694,"primaryCompletion":2711,"completion":8655,"start":1455,"enrollment":140,"conditions":8695,"interventions":8696},[98],[34],[8645,8658,8659,8660],{"trials":8698,"activeCount":109},[],{"trials":8700,"activeCount":109},[],{"trials":8702,"activeCount":109},[],{"trials":8704,"activeCount":109},[],{"intervention":8660,"totalTrials":708,"cells":8706},{"EARLY_PHASE1":8707,"PHASE1":8709,"PHASE2":8715,"PHASE3":8717,"PHASE4":8719,"NA":8721},{"trials":8708,"activeCount":109},[],{"trials":8710,"activeCount":708,"soonestReadout":2711},[8711],{"nctId":8652,"briefTitle":8653,"status":456,"phases":8712,"primaryCompletion":2711,"completion":8655,"start":1455,"enrollment":140,"conditions":8713,"interventions":8714},[98],[34],[8645,8658,8659,8660],{"trials":8716,"activeCount":109},[],{"trials":8718,"activeCount":109},[],{"trials":8720,"activeCount":109},[],{"trials":8722,"activeCount":109},[],{"intervention":8724,"totalTrials":708,"cells":8725},"NW-301V",{"EARLY_PHASE1":8726,"PHASE1":8728,"PHASE2":8739,"PHASE3":8741,"PHASE4":8743,"NA":8745},{"trials":8727,"activeCount":109},[],{"trials":8729,"activeCount":708,"soonestReadout":726},[8730],{"nctId":8731,"briefTitle":8732,"status":456,"phases":8733,"primaryCompletion":726,"completion":1019,"start":8734,"enrollment":658,"conditions":8735,"interventions":8737},"NCT06956261","NW-301 TCR-T in Patients With Advanced Solid Tumor",[98],"2025-05-10",[8736],"Tumor, Solid",[8724,8738],"Drug: NW-301D",{"trials":8740,"activeCount":109},[],{"trials":8742,"activeCount":109},[],{"trials":8744,"activeCount":109},[],{"trials":8746,"activeCount":109},[],{"intervention":8738,"totalTrials":708,"cells":8748},{"EARLY_PHASE1":8749,"PHASE1":8751,"PHASE2":8757,"PHASE3":8759,"PHASE4":8761,"NA":8763},{"trials":8750,"activeCount":109},[],{"trials":8752,"activeCount":708,"soonestReadout":726},[8753],{"nctId":8731,"briefTitle":8732,"status":456,"phases":8754,"primaryCompletion":726,"completion":1019,"start":8734,"enrollment":658,"conditions":8755,"interventions":8756},[98],[8736],[8724,8738],{"trials":8758,"activeCount":109},[],{"trials":8760,"activeCount":109},[],{"trials":8762,"activeCount":109},[],{"trials":8764,"activeCount":109},[],{"intervention":8766,"totalTrials":708,"cells":8767},"LUCAR-20SP cells",{"EARLY_PHASE1":8768,"PHASE1":8770,"PHASE2":8781,"PHASE3":8783,"PHASE4":8785,"NA":8787},{"trials":8769,"activeCount":109},[],{"trials":8771,"activeCount":708,"soonestReadout":385},[8772],{"nctId":8773,"briefTitle":8774,"status":121,"phases":8775,"primaryCompletion":385,"completion":7427,"start":8776,"enrollment":29,"conditions":8777,"interventions":8780},"NCT06313957","A Study of LUCAR-20SP in Subjects With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[98],"2024-03-14",[8778,8779],"Relapsed B-cell Non-Hodgkin Lymphoma","Refractory B-cell Non-Hodgkin Lymphoma",[8766],{"trials":8782,"activeCount":109},[],{"trials":8784,"activeCount":109},[],{"trials":8786,"activeCount":109},[],{"trials":8788,"activeCount":109},[],{"intervention":77,"totalTrials":708,"cells":8790},{"EARLY_PHASE1":8791,"PHASE1":8793,"PHASE2":8802,"PHASE3":8804,"PHASE4":8806,"NA":8808},{"trials":8792,"activeCount":109},[],{"trials":8794,"activeCount":708,"soonestReadout":76},[8795],{"nctId":74,"briefTitle":75,"status":456,"phases":8796,"primaryCompletion":76,"completion":8797,"start":8798,"enrollment":2509,"conditions":8799,"interventions":8801},[98],"2035-12-15","2021-03-15",[8800],"B-cell Acute Lymphoblastic Leukemia",[77],{"trials":8803,"activeCount":109},[],{"trials":8805,"activeCount":109},[],{"trials":8807,"activeCount":109},[],{"trials":8809,"activeCount":109},[],{"intervention":8811,"totalTrials":708,"cells":8812},"Drug: CT041 autologous CAR T-cell",{"EARLY_PHASE1":8813,"PHASE1":8815,"PHASE2":8824,"PHASE3":8826,"PHASE4":8828,"NA":8830},{"trials":8814,"activeCount":109},[],{"trials":8816,"activeCount":708,"soonestReadout":2049},[8817],{"nctId":8818,"briefTitle":8819,"status":456,"phases":8820,"primaryCompletion":2049,"completion":4098,"start":4049,"enrollment":536,"conditions":8821,"interventions":8823},"NCT06857786","Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G\u002FGEJ) Adenocarcinoma Patients",[98],[8822,4705],"Gastroesophageal Junction Adenocarcinoma",[8811],{"trials":8825,"activeCount":109},[],{"trials":8827,"activeCount":109},[],{"trials":8829,"activeCount":109},[],{"trials":8831,"activeCount":109},[],{"intervention":8833,"totalTrials":708,"cells":8834},"CAR-T cells chimeric antigen receptor T cells",{"EARLY_PHASE1":8835,"PHASE1":8837,"PHASE2":8848,"PHASE3":8850,"PHASE4":8852,"NA":8854},{"trials":8836,"activeCount":109},[],{"trials":8838,"activeCount":708,"soonestReadout":1019},[8839],{"nctId":8840,"briefTitle":8841,"status":121,"phases":8842,"primaryCompletion":1019,"completion":1020,"start":8843,"enrollment":3520,"conditions":8844,"interventions":8847},"NCT07617285","Allogeneic CAR-T(CT0890B) in NKG2DL+ R\u002FR AML",[98],"2026-05-07",[8845,8846],"AML","Refractory\u002FRelapse Acute Myeloid Leukemia",[8833],{"trials":8849,"activeCount":109},[],{"trials":8851,"activeCount":109},[],{"trials":8853,"activeCount":109},[],{"trials":8855,"activeCount":109},[],{"intervention":8857,"totalTrials":708,"cells":8858},"YK1101 cells",{"EARLY_PHASE1":8859,"PHASE1":8861,"PHASE2":8872,"PHASE3":8874,"PHASE4":8876,"NA":8878},{"trials":8860,"activeCount":109},[],{"trials":8862,"activeCount":708,"soonestReadout":8867},[8863],{"nctId":8864,"briefTitle":8865,"status":121,"phases":8866,"primaryCompletion":8867,"completion":4415,"start":8868,"enrollment":477,"conditions":8869,"interventions":8871},"NCT07139067","Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors",[98],"2026-07-01","2025-04-27",[8870],"Advanced Solid Tumor Cancer",[8857],{"trials":8873,"activeCount":109},[],{"trials":8875,"activeCount":109},[],{"trials":8877,"activeCount":109},[],{"trials":8879,"activeCount":109},[],{"intervention":8426,"totalTrials":708,"cells":8881},{"EARLY_PHASE1":8882,"PHASE1":8884,"PHASE2":8890,"PHASE3":8892,"PHASE4":8894,"NA":8896},{"trials":8883,"activeCount":109},[],{"trials":8885,"activeCount":708,"soonestReadout":5310},[8886],{"nctId":8415,"briefTitle":8416,"status":456,"phases":8887,"primaryCompletion":5310,"completion":8418,"start":5311,"enrollment":47,"conditions":8888,"interventions":8889},[98],[8420,8421,8422,8423,8424],[8426,8401,734],{"trials":8891,"activeCount":109},[],{"trials":8893,"activeCount":109},[],{"trials":8895,"activeCount":109},[],{"trials":8897,"activeCount":109},[],{"intervention":8899,"totalTrials":708,"cells":8900},"CAR-NKT Cells treatment",{"EARLY_PHASE1":8901,"PHASE1":8903,"PHASE2":8913,"PHASE3":8915,"PHASE4":8917,"NA":8919},{"trials":8902,"activeCount":109},[],{"trials":8904,"activeCount":708,"soonestReadout":8909},[8905],{"nctId":8906,"briefTitle":8907,"status":121,"phases":8908,"primaryCompletion":8909,"completion":8909,"start":6173,"enrollment":1456,"conditions":8910,"interventions":8912},"NCT06728189","A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors",[98],"2026-10-17",[8911],"Advanced Malignant Solid Tumors",[8899],{"trials":8914,"activeCount":109},[],{"trials":8916,"activeCount":109},[],{"trials":8918,"activeCount":109},[],{"trials":8920,"activeCount":109},[],{"intervention":8922,"totalTrials":708,"cells":8923},"Recombinant Humanized Type III Collagen",{"EARLY_PHASE1":8924,"PHASE1":8926,"PHASE2":8935,"PHASE3":8937,"PHASE4":8939,"NA":8941},{"trials":8925,"activeCount":109},[],{"trials":8927,"activeCount":708,"soonestReadout":637},[8928],{"nctId":8929,"briefTitle":8930,"status":121,"phases":8931,"primaryCompletion":637,"completion":2711,"start":5128,"enrollment":1767,"conditions":8932,"interventions":8934},"NCT06725082","Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery",[98],[31,8933],"Collagen Protein",[8922],{"trials":8936,"activeCount":109},[],{"trials":8938,"activeCount":109},[],{"trials":8940,"activeCount":109},[],{"trials":8942,"activeCount":109},[],{"intervention":8944,"totalTrials":708,"cells":8945},"KD-496",{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8959,"PHASE3":8961,"PHASE4":8963,"NA":8965},{"trials":8947,"activeCount":109},[],{"trials":8949,"activeCount":708,"soonestReadout":725},[8950],{"nctId":8951,"briefTitle":8952,"status":456,"phases":8953,"primaryCompletion":725,"completion":8954,"start":8955,"enrollment":2509,"conditions":8956,"interventions":8958},"NCT06134960","NKG2D\u002FCLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+\u002FCLDN18.2+ Solid Tumor",[98],"2026-11-15","2023-11-16",[28,684,8957],"Solid Tumor",[8944],{"trials":8960,"activeCount":109},[],{"trials":8962,"activeCount":109},[],{"trials":8964,"activeCount":109},[],{"trials":8966,"activeCount":109},[],{"intervention":8968,"totalTrials":708,"cells":8969},"AK104+Axitinib",{"EARLY_PHASE1":8970,"PHASE1":8972,"PHASE2":8982,"PHASE3":8984,"PHASE4":8986,"NA":8988},{"trials":8971,"activeCount":109},[],{"trials":8973,"activeCount":708,"soonestReadout":741},[8974],{"nctId":8975,"briefTitle":8976,"status":456,"phases":8977,"primaryCompletion":741,"completion":1019,"start":8978,"enrollment":140,"conditions":8979,"interventions":8980},"NCT06424626","A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma",[98],"2024-05-21",[2580,3903,5586],[8968,8981],"AK112+Axitinib",{"trials":8983,"activeCount":109},[],{"trials":8985,"activeCount":109},[],{"trials":8987,"activeCount":109},[],{"trials":8989,"activeCount":109},[],{"intervention":8981,"totalTrials":708,"cells":8991},{"EARLY_PHASE1":8992,"PHASE1":8994,"PHASE2":9000,"PHASE3":9002,"PHASE4":9004,"NA":9006},{"trials":8993,"activeCount":109},[],{"trials":8995,"activeCount":708,"soonestReadout":741},[8996],{"nctId":8975,"briefTitle":8976,"status":456,"phases":8997,"primaryCompletion":741,"completion":1019,"start":8978,"enrollment":140,"conditions":8998,"interventions":8999},[98],[2580,3903,5586],[8968,8981],{"trials":9001,"activeCount":109},[],{"trials":9003,"activeCount":109},[],{"trials":9005,"activeCount":109},[],{"trials":9007,"activeCount":109},[],{"intervention":9009,"totalTrials":708,"cells":9010},"intraperitoneal PX in combination with nab-paclitaxel",{"EARLY_PHASE1":9011,"PHASE1":9013,"PHASE2":9024,"PHASE3":9026,"PHASE4":9028,"NA":9030},{"trials":9012,"activeCount":109},[],{"trials":9014,"activeCount":708,"soonestReadout":726},[9015],{"nctId":9016,"briefTitle":9017,"status":456,"phases":9018,"primaryCompletion":726,"completion":1019,"start":9019,"enrollment":9020,"conditions":9021,"interventions":9023},"NCT07454031","Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma",[98],"2026-03-15",22,[9022],"Peritoneal (Metastatic) Cancer",[9009],{"trials":9025,"activeCount":109},[],{"trials":9027,"activeCount":109},[],{"trials":9029,"activeCount":109},[],{"trials":9031,"activeCount":109},[],{"intervention":9033,"totalTrials":708,"cells":9034},"RS-C1001",{"EARLY_PHASE1":9035,"PHASE1":9037,"PHASE2":9048,"PHASE3":9050,"PHASE4":9052,"NA":9054},{"trials":9036,"activeCount":109},[],{"trials":9038,"activeCount":708,"soonestReadout":1578},[9039],{"nctId":9040,"briefTitle":9041,"status":121,"phases":9042,"primaryCompletion":1578,"completion":9043,"start":9044,"enrollment":960,"conditions":9045,"interventions":9047},"NCT06669429","A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects",[98],"2025-08-30","2024-09-25",[9046],"Dyslipidemia",[9033,9033,9033],{"trials":9049,"activeCount":109},[],{"trials":9051,"activeCount":109},[],{"trials":9053,"activeCount":109},[],{"trials":9055,"activeCount":109},[],{"intervention":9057,"totalTrials":708,"cells":9058},"CAR-T Therapy",{"EARLY_PHASE1":9059,"PHASE1":9061,"PHASE2":9071,"PHASE3":9073,"PHASE4":9075,"NA":9077},{"trials":9060,"activeCount":109},[],{"trials":9062,"activeCount":708,"soonestReadout":9067},[9063],{"nctId":9064,"briefTitle":9065,"status":121,"phases":9066,"primaryCompletion":9067,"completion":1019,"start":2731,"enrollment":2732,"conditions":9068,"interventions":9070},"NCT07280494","To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL\u002FLBL Post Allo-HSCT",[98],"2026-08-30",[9069],"CD7+ T-ALL\u002FLBL",[9057],{"trials":9072,"activeCount":109},[],{"trials":9074,"activeCount":109},[],{"trials":9076,"activeCount":109},[],{"trials":9078,"activeCount":109},[],{"intervention":9080,"totalTrials":708,"cells":9081},"OriC902",{"EARLY_PHASE1":9082,"PHASE1":9084,"PHASE2":9093,"PHASE3":9095,"PHASE4":9097,"NA":9099},{"trials":9083,"activeCount":109},[],{"trials":9085,"activeCount":708,"soonestReadout":1019},[9086],{"nctId":9087,"briefTitle":9088,"status":121,"phases":9089,"primaryCompletion":1019,"completion":3656,"start":9090,"enrollment":658,"conditions":9091,"interventions":9092},"NCT06891742","Phase I Study of OriC902 in Treatment of Advanced HCC",[98],"2025-02-24",[3795],[9080],{"trials":9094,"activeCount":109},[],{"trials":9096,"activeCount":109},[],{"trials":9098,"activeCount":109},[],{"trials":9100,"activeCount":109},[],{"intervention":9102,"totalTrials":708,"cells":9103},"SIG001",{"EARLY_PHASE1":9104,"PHASE1":9106,"PHASE2":9116,"PHASE3":9118,"PHASE4":9120,"NA":9122},{"trials":9105,"activeCount":109},[],{"trials":9107,"activeCount":708,"soonestReadout":6717},[9108],{"nctId":9109,"briefTitle":9110,"status":456,"phases":9111,"primaryCompletion":6717,"completion":9112,"start":1384,"enrollment":6539,"conditions":9113,"interventions":9115},"NCT07486700","The Phase I Study of SIG001 Antibody on Cancer Therapy.",[98],"2028-07",[9114],"Neoplams",[9102,9102],{"trials":9117,"activeCount":109},[],{"trials":9119,"activeCount":109},[],{"trials":9121,"activeCount":109},[],{"trials":9123,"activeCount":109},[],{"intervention":3661,"totalTrials":708,"cells":9125},{"EARLY_PHASE1":9126,"PHASE1":9128,"PHASE2":9134,"PHASE3":9136,"PHASE4":9138,"NA":9140},{"trials":9127,"activeCount":109},[],{"trials":9129,"activeCount":708,"soonestReadout":3656},[9130],{"nctId":3653,"briefTitle":3654,"status":121,"phases":9131,"primaryCompletion":3656,"completion":1175,"start":3657,"enrollment":1527,"conditions":9132,"interventions":9133},[98],[3659],[3661,1036],{"trials":9135,"activeCount":109},[],{"trials":9137,"activeCount":109},[],{"trials":9139,"activeCount":109},[],{"trials":9141,"activeCount":109},[],{"intervention":9143,"totalTrials":708,"cells":9144},"YK0901 cells",{"EARLY_PHASE1":9145,"PHASE1":9147,"PHASE2":9158,"PHASE3":9160,"PHASE4":9162,"NA":9164},{"trials":9146,"activeCount":109},[],{"trials":9148,"activeCount":708,"soonestReadout":9153},[9149],{"nctId":9150,"briefTitle":9151,"status":456,"phases":9152,"primaryCompletion":9153,"completion":1246,"start":9154,"enrollment":4065,"conditions":9155,"interventions":9157},"NCT05933668","Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor",[98],"2024-07","2023-07",[9156],"Advanced Solid Tumor",[9143],{"trials":9159,"activeCount":109},[],{"trials":9161,"activeCount":109},[],{"trials":9163,"activeCount":109},[],{"trials":9165,"activeCount":109},[],{"intervention":9167,"totalTrials":708,"cells":9168},"CAR-T（RD140 injection）",{"EARLY_PHASE1":9169,"PHASE1":9171,"PHASE2":9184,"PHASE3":9186,"PHASE4":9188,"NA":9190},{"trials":9170,"activeCount":109},[],{"trials":9172,"activeCount":708,"soonestReadout":9177},[9173],{"nctId":9174,"briefTitle":9175,"status":456,"phases":9176,"primaryCompletion":9177,"completion":9178,"start":9179,"enrollment":2509,"conditions":9180,"interventions":9183},"NCT06655519","An Exploratory Study of RD140 Injection in Patients With Relapsed\u002FRefractory Multiple Myeloma or Plasma Cell Leukemia",[98],"2028-07-05","2041-07-05","2024-10-25",[9181,9182],"Relapsed\u002FRefractory Multiple Myeloma","Plasma Cell Leukemia",[9167],{"trials":9185,"activeCount":109},[],{"trials":9187,"activeCount":109},[],{"trials":9189,"activeCount":109},[],{"trials":9191,"activeCount":109},[],{"intervention":9193,"totalTrials":708,"cells":9194},"NK cell",{"EARLY_PHASE1":9195,"PHASE1":9197,"PHASE2":9207,"PHASE3":9209,"PHASE4":9211,"NA":9213},{"trials":9196,"activeCount":109},[],{"trials":9198,"activeCount":708,"soonestReadout":741},[9199],{"nctId":9200,"briefTitle":9201,"status":456,"phases":9202,"primaryCompletion":741,"completion":725,"start":5128,"enrollment":2509,"conditions":9203,"interventions":9206},"NCT06641648","A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.",[98],[7612,9204,9205],"Acute Myeloid Leukemia (AML) Relapse","NK Cell",[9193],{"trials":9208,"activeCount":109},[],{"trials":9210,"activeCount":109},[],{"trials":9212,"activeCount":109},[],{"trials":9214,"activeCount":109},[],{"intervention":9216,"totalTrials":708,"cells":9217},"TCR-MAGE-A4 T-Cells",{"EARLY_PHASE1":9218,"PHASE1":9220,"PHASE2":9228,"PHASE3":9230,"PHASE4":9232,"NA":9234},{"trials":9219,"activeCount":109},[],{"trials":9221,"activeCount":708,"soonestReadout":741},[9222],{"nctId":9223,"briefTitle":9224,"status":121,"phases":9225,"primaryCompletion":741,"completion":1002,"start":4308,"enrollment":47,"conditions":9226,"interventions":9227},"NCT06170294","MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors",[98],[9156],[9216],{"trials":9229,"activeCount":109},[],{"trials":9231,"activeCount":109},[],{"trials":9233,"activeCount":109},[],{"trials":9235,"activeCount":109},[],{"intervention":9237,"totalTrials":3887,"cells":9238},"18F-FDG",{"EARLY_PHASE1":9239,"PHASE1":9250,"PHASE2":9252,"PHASE3":9254,"PHASE4":9256,"NA":9258},{"trials":9240,"activeCount":708,"soonestReadout":741},[9241],{"nctId":9242,"briefTitle":9243,"status":121,"phases":9244,"primaryCompletion":741,"completion":3910,"start":9245,"enrollment":728,"conditions":9246,"interventions":9248},"NCT06717113","A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma",[97],"2025-04-15",[9247],"Multiple Myeloma and Malignant Plasma Cell Neoplasms",[9237,9249],"68Ga-BC1",{"trials":9251,"activeCount":109},[],{"trials":9253,"activeCount":109},[],{"trials":9255,"activeCount":109},[],{"trials":9257,"activeCount":109},[],{"trials":9259,"activeCount":1428,"soonestReadout":438},[9260,9267,9275,9283,9290,9297,9304,9311],{"nctId":9261,"briefTitle":9262,"status":121,"phases":9263,"primaryCompletion":438,"completion":906,"start":9264,"enrollment":2770,"conditions":9265,"interventions":9266},"NCT05436093","CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors",[102],"2022-06-23",[8957],[9237],{"nctId":9268,"briefTitle":9269,"status":569,"phases":9270,"primaryCompletion":9271,"completion":9271,"start":9272,"enrollment":47,"conditions":9273,"interventions":9274},"NCT05803746","PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor",[102],"2024-07-15","2022-07-15",[43,2692],[9237],{"nctId":9276,"briefTitle":9277,"status":569,"phases":9278,"primaryCompletion":228,"completion":228,"start":9279,"enrollment":376,"conditions":9280,"interventions":9282},"NCT05840094","Multimodalitic Imaging in the N-stage of Lung Cancer",[102],"2023-05-01",[9281],"Neoplasm of Lung",[9237],{"nctId":9284,"briefTitle":9285,"status":456,"phases":9286,"primaryCompletion":2049,"completion":584,"start":638,"enrollment":47,"conditions":9287,"interventions":9288},"NCT07589101","5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors",[102],[43,31],[9237,9289],"68Ga-MY",{"nctId":9291,"briefTitle":9292,"status":569,"phases":9293,"primaryCompletion":5128,"completion":315,"start":9294,"enrollment":47,"conditions":9295,"interventions":9296},"NCT05322512","Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors",[102],"2024-05-01",[8957],[9237],{"nctId":9298,"briefTitle":9299,"status":121,"phases":9300,"primaryCompletion":438,"completion":438,"start":1746,"enrollment":47,"conditions":9301,"interventions":9303},"NCT05321316","Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma",[102],[9302],"Urothelial Carcinoma",[9237],{"nctId":9305,"briefTitle":9306,"status":121,"phases":9307,"primaryCompletion":438,"completion":438,"start":8447,"enrollment":140,"conditions":9308,"interventions":9309},"NCT06715020","Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging",[102],[31],[9237,9310],"[68Ga]Ga-TTP",{"nctId":9312,"briefTitle":9313,"status":456,"phases":9314,"primaryCompletion":726,"completion":726,"start":773,"enrollment":1767,"conditions":9315,"interventions":9316},"NCT06720298","CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors",[],[8957],[9237],{"intervention":9318,"totalTrials":746,"cells":9319},"IASO207",{"EARLY_PHASE1":9320,"PHASE1":9340,"PHASE2":9342,"PHASE3":9344,"PHASE4":9346,"NA":9348},{"trials":9321,"activeCount":746,"soonestReadout":9326},[9322,9331],{"nctId":9323,"briefTitle":9324,"status":456,"phases":9325,"primaryCompletion":9326,"completion":9327,"start":5145,"enrollment":2732,"conditions":9328,"interventions":9330},"NCT07574346","IASO207 Injection in the Treatment of Relapsed\u002FRefractory B-cell Malignancies",[97],"2029-04-30","2042-04-30",[9329],"Malignancies",[9318],{"nctId":9332,"briefTitle":9333,"status":121,"phases":9334,"primaryCompletion":1512,"completion":9335,"start":9336,"enrollment":2732,"conditions":9337,"interventions":9339},"NCT07617740","IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)",[97],"2030-05-30","2026-05-25",[9338],"REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS",[9318],{"trials":9341,"activeCount":109},[],{"trials":9343,"activeCount":109},[],{"trials":9345,"activeCount":109},[],{"trials":9347,"activeCount":109},[],{"trials":9349,"activeCount":109},[],{"intervention":9351,"totalTrials":708,"cells":9352},"JCXH-212",{"EARLY_PHASE1":9353,"PHASE1":9365,"PHASE2":9367,"PHASE3":9369,"PHASE4":9371,"NA":9373},{"trials":9354,"activeCount":708,"soonestReadout":9359},[9355],{"nctId":9356,"briefTitle":9357,"status":121,"phases":9358,"primaryCompletion":9359,"completion":9360,"start":9361,"enrollment":38,"conditions":9362,"interventions":9364},"NCT05579275","Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors",[97],"2026-04-28","2027-04-28","2023-02-06",[9363],"Malignant Solid Tumors",[9351],{"trials":9366,"activeCount":109},[],{"trials":9368,"activeCount":109},[],{"trials":9370,"activeCount":109},[],{"trials":9372,"activeCount":109},[],{"trials":9374,"activeCount":109},[],{"intervention":9376,"totalTrials":708,"cells":9377},"IIA1：1E9 PFU of oncolytic virus, sequentially combination",{"EARLY_PHASE1":9378,"PHASE1":9393,"PHASE2":9395,"PHASE3":9397,"PHASE4":9399,"NA":9401},{"trials":9379,"activeCount":708,"soonestReadout":637},[9380],{"nctId":9381,"briefTitle":9382,"status":121,"phases":9383,"primaryCompletion":637,"completion":7293,"start":9384,"enrollment":1642,"conditions":9385,"interventions":9387},"NCT06380309","A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE",[97],"2024-05-06",[9386],"Advanced Malignant Solid Tumor of Digestive System",[9376,9388,9389,9390,9391,9392],"IIA2：3E9 PFU of oncolytic virus, sequentially combination","IIC1：1E9 PFU of oncolytic virus, early combination","IIC2：3E9 PFU of oncolytic virus, early combination","IID：3E9 PFU of oncolytic virus, Immuno-Oncology free combination","IIB：Other Gastrointestinal tumors",{"trials":9394,"activeCount":109},[],{"trials":9396,"activeCount":109},[],{"trials":9398,"activeCount":109},[],{"trials":9400,"activeCount":109},[],{"trials":9402,"activeCount":109},[],{"intervention":9388,"totalTrials":708,"cells":9404},{"EARLY_PHASE1":9405,"PHASE1":9411,"PHASE2":9413,"PHASE3":9415,"PHASE4":9417,"NA":9419},{"trials":9406,"activeCount":708,"soonestReadout":637},[9407],{"nctId":9381,"briefTitle":9382,"status":121,"phases":9408,"primaryCompletion":637,"completion":7293,"start":9384,"enrollment":1642,"conditions":9409,"interventions":9410},[97],[9386],[9376,9388,9389,9390,9391,9392],{"trials":9412,"activeCount":109},[],{"trials":9414,"activeCount":109},[],{"trials":9416,"activeCount":109},[],{"trials":9418,"activeCount":109},[],{"trials":9420,"activeCount":109},[],{"intervention":9389,"totalTrials":708,"cells":9422},{"EARLY_PHASE1":9423,"PHASE1":9429,"PHASE2":9431,"PHASE3":9433,"PHASE4":9435,"NA":9437},{"trials":9424,"activeCount":708,"soonestReadout":637},[9425],{"nctId":9381,"briefTitle":9382,"status":121,"phases":9426,"primaryCompletion":637,"completion":7293,"start":9384,"enrollment":1642,"conditions":9427,"interventions":9428},[97],[9386],[9376,9388,9389,9390,9391,9392],{"trials":9430,"activeCount":109},[],{"trials":9432,"activeCount":109},[],{"trials":9434,"activeCount":109},[],{"trials":9436,"activeCount":109},[],{"trials":9438,"activeCount":109},[],{"intervention":9390,"totalTrials":708,"cells":9440},{"EARLY_PHASE1":9441,"PHASE1":9447,"PHASE2":9449,"PHASE3":9451,"PHASE4":9453,"NA":9455},{"trials":9442,"activeCount":708,"soonestReadout":637},[9443],{"nctId":9381,"briefTitle":9382,"status":121,"phases":9444,"primaryCompletion":637,"completion":7293,"start":9384,"enrollment":1642,"conditions":9445,"interventions":9446},[97],[9386],[9376,9388,9389,9390,9391,9392],{"trials":9448,"activeCount":109},[],{"trials":9450,"activeCount":109},[],{"trials":9452,"activeCount":109},[],{"trials":9454,"activeCount":109},[],{"trials":9456,"activeCount":109},[],{"intervention":9391,"totalTrials":708,"cells":9458},{"EARLY_PHASE1":9459,"PHASE1":9465,"PHASE2":9467,"PHASE3":9469,"PHASE4":9471,"NA":9473},{"trials":9460,"activeCount":708,"soonestReadout":637},[9461],{"nctId":9381,"briefTitle":9382,"status":121,"phases":9462,"primaryCompletion":637,"completion":7293,"start":9384,"enrollment":1642,"conditions":9463,"interventions":9464},[97],[9386],[9376,9388,9389,9390,9391,9392],{"trials":9466,"activeCount":109},[],{"trials":9468,"activeCount":109},[],{"trials":9470,"activeCount":109},[],{"trials":9472,"activeCount":109},[],{"trials":9474,"activeCount":109},[],{"intervention":9392,"totalTrials":708,"cells":9476},{"EARLY_PHASE1":9477,"PHASE1":9483,"PHASE2":9485,"PHASE3":9487,"PHASE4":9489,"NA":9491},{"trials":9478,"activeCount":708,"soonestReadout":637},[9479],{"nctId":9381,"briefTitle":9382,"status":121,"phases":9480,"primaryCompletion":637,"completion":7293,"start":9384,"enrollment":1642,"conditions":9481,"interventions":9482},[97],[9386],[9376,9388,9389,9390,9391,9392],{"trials":9484,"activeCount":109},[],{"trials":9486,"activeCount":109},[],{"trials":9488,"activeCount":109},[],{"trials":9490,"activeCount":109},[],{"trials":9492,"activeCount":109},[],{"intervention":1253,"totalTrials":708,"cells":9494},{"EARLY_PHASE1":9495,"PHASE1":9501,"PHASE2":9503,"PHASE3":9505,"PHASE4":9507,"NA":9509},{"trials":9496,"activeCount":708,"soonestReadout":1246},[9497],{"nctId":1243,"briefTitle":1244,"status":121,"phases":9498,"primaryCompletion":1246,"completion":386,"start":1247,"enrollment":1248,"conditions":9499,"interventions":9500},[97],[1250],[1252,1253,1254],{"trials":9502,"activeCount":109},[],{"trials":9504,"activeCount":109},[],{"trials":9506,"activeCount":109},[],{"trials":9508,"activeCount":109},[],{"trials":9510,"activeCount":109},[],{"intervention":1254,"totalTrials":708,"cells":9512},{"EARLY_PHASE1":9513,"PHASE1":9519,"PHASE2":9521,"PHASE3":9523,"PHASE4":9525,"NA":9527},{"trials":9514,"activeCount":708,"soonestReadout":1246},[9515],{"nctId":1243,"briefTitle":1244,"status":121,"phases":9516,"primaryCompletion":1246,"completion":386,"start":1247,"enrollment":1248,"conditions":9517,"interventions":9518},[97],[1250],[1252,1253,1254],{"trials":9520,"activeCount":109},[],{"trials":9522,"activeCount":109},[],{"trials":9524,"activeCount":109},[],{"trials":9526,"activeCount":109},[],{"trials":9528,"activeCount":109},[],{"intervention":9530,"totalTrials":708,"cells":9531},"BCT301",{"EARLY_PHASE1":9532,"PHASE1":9544,"PHASE2":9546,"PHASE3":9548,"PHASE4":9550,"NA":9552},{"trials":9533,"activeCount":708,"soonestReadout":1019},[9534],{"nctId":9535,"briefTitle":9536,"status":456,"phases":9537,"primaryCompletion":1019,"completion":1002,"start":9538,"enrollment":477,"conditions":9539,"interventions":9543},"NCT07301164","Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases",[97],"2025-12-11",[9540,6849,9541,6852,9542,6855],"System Lupus Erythematosus","Inflammatory Myositis","ANCA Associated Vasculitis",[9530],{"trials":9545,"activeCount":109},[],{"trials":9547,"activeCount":109},[],{"trials":9549,"activeCount":109},[],{"trials":9551,"activeCount":109},[],{"trials":9553,"activeCount":109},[],{"intervention":9555,"totalTrials":708,"cells":9556},"[177Lu]Lu-PSMA-137",{"EARLY_PHASE1":9557,"PHASE1":9565,"PHASE2":9567,"PHASE3":9569,"PHASE4":9571,"NA":9573},{"trials":9558,"activeCount":708,"soonestReadout":1537},[9559],{"nctId":9560,"briefTitle":9561,"status":456,"phases":9562,"primaryCompletion":1537,"completion":1963,"start":5201,"enrollment":2509,"conditions":9563,"interventions":9564},"NCT06546527","Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）",[97],[37],[9555],{"trials":9566,"activeCount":109},[],{"trials":9568,"activeCount":109},[],{"trials":9570,"activeCount":109},[],{"trials":9572,"activeCount":109},[],{"trials":9574,"activeCount":109},[],{"intervention":9576,"totalTrials":708,"cells":9577},"Antipsychotics plus Levothyroxine Sodium",{"EARLY_PHASE1":9578,"PHASE1":9589,"PHASE2":9591,"PHASE3":9593,"PHASE4":9595,"NA":9597},{"trials":9579,"activeCount":708,"soonestReadout":5310},[9580],{"nctId":9581,"briefTitle":9582,"status":456,"phases":9583,"primaryCompletion":5310,"completion":5310,"start":5311,"enrollment":1139,"conditions":9584,"interventions":9587},"NCT07011953","A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia",[97],[9585,9586],"Schizophrenia","Avolition",[9576,9588],"Antipsychotics plus Placebo",{"trials":9590,"activeCount":109},[],{"trials":9592,"activeCount":109},[],{"trials":9594,"activeCount":109},[],{"trials":9596,"activeCount":109},[],{"trials":9598,"activeCount":109},[],{"intervention":9588,"totalTrials":708,"cells":9600},{"EARLY_PHASE1":9601,"PHASE1":9607,"PHASE2":9609,"PHASE3":9611,"PHASE4":9613,"NA":9615},{"trials":9602,"activeCount":708,"soonestReadout":5310},[9603],{"nctId":9581,"briefTitle":9582,"status":456,"phases":9604,"primaryCompletion":5310,"completion":5310,"start":5311,"enrollment":1139,"conditions":9605,"interventions":9606},[97],[9585,9586],[9576,9588],{"trials":9608,"activeCount":109},[],{"trials":9610,"activeCount":109},[],{"trials":9612,"activeCount":109},[],{"trials":9614,"activeCount":109},[],{"trials":9616,"activeCount":109},[],{"intervention":9618,"totalTrials":708,"cells":9619},"Hepatitis B Immunoglobulin",{"EARLY_PHASE1":9620,"PHASE1":9629,"PHASE2":9631,"PHASE3":9633,"PHASE4":9635,"NA":9637},{"trials":9621,"activeCount":708,"soonestReadout":1002},[9622],{"nctId":9623,"briefTitle":9624,"status":121,"phases":9625,"primaryCompletion":1002,"completion":1002,"start":616,"enrollment":586,"conditions":9626,"interventions":9628},"NCT07328711","Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B",[97],[9627],"Chronic Hepaititis B",[9618],{"trials":9630,"activeCount":109},[],{"trials":9632,"activeCount":109},[],{"trials":9634,"activeCount":109},[],{"trials":9636,"activeCount":109},[],{"trials":9638,"activeCount":109},[],{"intervention":9640,"totalTrials":708,"cells":9641},"CAR-DC treatment",{"EARLY_PHASE1":9642,"PHASE1":9652,"PHASE2":9654,"PHASE3":9656,"PHASE4":9658,"NA":9660},{"trials":9643,"activeCount":708,"soonestReadout":9648},[9644],{"nctId":9645,"briefTitle":9646,"status":121,"phases":9647,"primaryCompletion":9648,"completion":9648,"start":9649,"enrollment":477,"conditions":9650,"interventions":9651},"NCT07504445","Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors",[97],"2028-04-03","2026-04-03",[8397],[9640],{"trials":9653,"activeCount":109},[],{"trials":9655,"activeCount":109},[],{"trials":9657,"activeCount":109},[],{"trials":9659,"activeCount":109},[],{"trials":9661,"activeCount":109},[],{"intervention":9663,"totalTrials":708,"cells":9664},"JD123",{"EARLY_PHASE1":9665,"PHASE1":9675,"PHASE2":9677,"PHASE3":9679,"PHASE4":9681,"NA":9683},{"trials":9666,"activeCount":708,"soonestReadout":637},[9667],{"nctId":9668,"briefTitle":9669,"status":121,"phases":9670,"primaryCompletion":637,"completion":637,"start":1404,"enrollment":2509,"conditions":9671,"interventions":9674},"NCT06201247","Off-the-shelf CD123 CAR-NK for R\u002FR AML",[97],[9672,9673],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory",[9663],{"trials":9676,"activeCount":109},[],{"trials":9678,"activeCount":109},[],{"trials":9680,"activeCount":109},[],{"trials":9682,"activeCount":109},[],{"trials":9684,"activeCount":109},[],{"intervention":9686,"totalTrials":708,"cells":9687},"CAR-T cell therapy",{"EARLY_PHASE1":9688,"PHASE1":9698,"PHASE2":9700,"PHASE3":9702,"PHASE4":9704,"NA":9706},{"trials":9689,"activeCount":708,"soonestReadout":5636},[9690],{"nctId":9691,"briefTitle":9692,"status":121,"phases":9693,"primaryCompletion":5636,"completion":4391,"start":9694,"enrollment":2732,"conditions":9695,"interventions":9697},"NCT07344818","An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma",[97],"2026-01-07",[9696],"R\u002FR Aggressive B-cell Lymphoma",[9686],{"trials":9699,"activeCount":109},[],{"trials":9701,"activeCount":109},[],{"trials":9703,"activeCount":109},[],{"trials":9705,"activeCount":109},[],{"trials":9707,"activeCount":109},[],{"intervention":9709,"totalTrials":708,"cells":9710},"[ Lu-177]-Catalase",{"EARLY_PHASE1":9711,"PHASE1":9721,"PHASE2":9723,"PHASE3":9725,"PHASE4":9727,"NA":9729},{"trials":9712,"activeCount":708,"soonestReadout":9717},[9713],{"nctId":9714,"briefTitle":9715,"status":121,"phases":9716,"primaryCompletion":9717,"completion":9717,"start":4678,"enrollment":477,"conditions":9718,"interventions":9720},"NCT05985278","Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy",[97],"2026-06-15",[9719],"Advanced Malignant Neoplasm",[9709],{"trials":9722,"activeCount":109},[],{"trials":9724,"activeCount":109},[],{"trials":9726,"activeCount":109},[],{"trials":9728,"activeCount":109},[],{"trials":9730,"activeCount":109},[],{"intervention":9732,"totalTrials":708,"cells":9733},"Each patient will undergo 68Ga\u002F18F-CAIX-LT-BCH PET\u002FCT imaging, with an administered radioactive dose of approximately 0.05-0.1 mCi\u002Fkg.",{"EARLY_PHASE1":9734,"PHASE1":9743,"PHASE2":9745,"PHASE3":9747,"PHASE4":9749,"NA":9751},{"trials":9735,"activeCount":708,"soonestReadout":726},[9736],{"nctId":9737,"briefTitle":9738,"status":121,"phases":9739,"primaryCompletion":726,"completion":726,"start":1537,"enrollment":329,"conditions":9740,"interventions":9742},"NCT07590310","Clinical Application of CAIX-Targeted PET Imaging in Tumors",[97],[9741],"Kidney Cancers",[9732],{"trials":9744,"activeCount":109},[],{"trials":9746,"activeCount":109},[],{"trials":9748,"activeCount":109},[],{"trials":9750,"activeCount":109},[],{"trials":9752,"activeCount":109},[],{"intervention":9249,"totalTrials":708,"cells":9754},{"EARLY_PHASE1":9755,"PHASE1":9761,"PHASE2":9763,"PHASE3":9765,"PHASE4":9767,"NA":9769},{"trials":9756,"activeCount":708,"soonestReadout":741},[9757],{"nctId":9242,"briefTitle":9243,"status":121,"phases":9758,"primaryCompletion":741,"completion":3910,"start":9245,"enrollment":728,"conditions":9759,"interventions":9760},[97],[9247],[9237,9249],{"trials":9762,"activeCount":109},[],{"trials":9764,"activeCount":109},[],{"trials":9766,"activeCount":109},[],{"trials":9768,"activeCount":109},[],{"trials":9770,"activeCount":109},[],{"intervention":9772,"totalTrials":708,"cells":9773},"Biological: cizutamig",{"EARLY_PHASE1":9774,"PHASE1":9784,"PHASE2":9786,"PHASE3":9788,"PHASE4":9790,"NA":9792},{"trials":9775,"activeCount":708,"soonestReadout":315},[9776],{"nctId":9777,"briefTitle":9778,"status":1935,"phases":9779,"primaryCompletion":315,"completion":2136,"start":9780,"enrollment":2770,"conditions":9781,"interventions":9783},"NCT07135219","A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy",[97],"2025-07-16",[9782],"Immunoglobulin A Nephropathy (IgAN)",[9772],{"trials":9785,"activeCount":109},[],{"trials":9787,"activeCount":109},[],{"trials":9789,"activeCount":109},[],{"trials":9791,"activeCount":109},[],{"trials":9793,"activeCount":109},[],{"intervention":9795,"totalTrials":708,"cells":9796},"RD06-04 Cell Injection",{"EARLY_PHASE1":9797,"PHASE1":9808,"PHASE2":9810,"PHASE3":9812,"PHASE4":9814,"NA":9816},{"trials":9798,"activeCount":708,"soonestReadout":741},[9799],{"nctId":9800,"briefTitle":9801,"status":456,"phases":9802,"primaryCompletion":741,"completion":726,"start":9803,"enrollment":2509,"conditions":9804,"interventions":9807},"NCT06986018","Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV",[97],"2025-06-14",[9805,9806],"Idiopathic Inflammatory Myopathies","ANCA-Associated Vasculitis",[9795],{"trials":9809,"activeCount":109},[],{"trials":9811,"activeCount":109},[],{"trials":9813,"activeCount":109},[],{"trials":9815,"activeCount":109},[],{"trials":9817,"activeCount":109},[],{"intervention":8402,"totalTrials":708,"cells":9819},{"EARLY_PHASE1":9820,"PHASE1":9826,"PHASE2":9828,"PHASE3":9830,"PHASE4":9832,"NA":9834},{"trials":9821,"activeCount":708,"soonestReadout":1019},[9822],{"nctId":8393,"briefTitle":8394,"status":456,"phases":9823,"primaryCompletion":1019,"completion":1019,"start":1537,"enrollment":2732,"conditions":9824,"interventions":9825},[97],[8397,8398,8399],[8401,734,8402],{"trials":9827,"activeCount":109},[],{"trials":9829,"activeCount":109},[],{"trials":9831,"activeCount":109},[],{"trials":9833,"activeCount":109},[],{"trials":9835,"activeCount":109},[],{"intervention":9837,"totalTrials":708,"cells":9838},"68Ga-ICAM-1pep",{"EARLY_PHASE1":9839,"PHASE1":9849,"PHASE2":9851,"PHASE3":9853,"PHASE4":9855,"NA":9857},{"trials":9840,"activeCount":708,"soonestReadout":741},[9841],{"nctId":9842,"briefTitle":9843,"status":121,"phases":9844,"primaryCompletion":741,"completion":741,"start":9845,"enrollment":47,"conditions":9846,"interventions":9848},"NCT04596670","68Ga-ICAM-1pep PET\u002FCT in Cancer Patients",[97],"2024-09-20",[9847],"Cancer",[9837],{"trials":9850,"activeCount":109},[],{"trials":9852,"activeCount":109},[],{"trials":9854,"activeCount":109},[],{"trials":9856,"activeCount":109},[],{"trials":9858,"activeCount":109},[],{"intervention":9860,"totalTrials":708,"cells":9861},"SNUG01",{"EARLY_PHASE1":9862,"PHASE1":9873,"PHASE2":9875,"PHASE3":9877,"PHASE4":9879,"NA":9881},{"trials":9863,"activeCount":708,"soonestReadout":9245},[9864],{"nctId":9865,"briefTitle":9866,"status":456,"phases":9867,"primaryCompletion":9245,"completion":9868,"start":9869,"enrollment":1091,"conditions":9870,"interventions":9872},"NCT06645197","An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis",[97],"2029-10-15","2024-10-16",[9871],"Amyotrophic Lateral Sclerosis (ALS)",[9860],{"trials":9874,"activeCount":109},[],{"trials":9876,"activeCount":109},[],{"trials":9878,"activeCount":109},[],{"trials":9880,"activeCount":109},[],{"trials":9882,"activeCount":109},[],{"intervention":9884,"totalTrials":708,"cells":9885},"[68Ga] B7H3 Affibody-BCH",{"EARLY_PHASE1":9886,"PHASE1":9898,"PHASE2":9900,"PHASE3":9902,"PHASE4":9904,"NA":9906},{"trials":9887,"activeCount":708,"soonestReadout":2700},[9888],{"nctId":9889,"briefTitle":9890,"status":121,"phases":9891,"primaryCompletion":2700,"completion":9892,"start":4308,"enrollment":728,"conditions":9893,"interventions":9897},"NCT06454955","Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors",[97],"2026-11-30",[9894,9895,9896],"B7H3","CD276 Affibody","PET\u002FCT Imaing",[9884],{"trials":9899,"activeCount":109},[],{"trials":9901,"activeCount":109},[],{"trials":9903,"activeCount":109},[],{"trials":9905,"activeCount":109},[],{"trials":9907,"activeCount":109},[],{"intervention":9909,"totalTrials":708,"cells":9910},"68Ga-NB381",{"EARLY_PHASE1":9911,"PHASE1":9921,"PHASE2":9923,"PHASE3":9925,"PHASE4":9927,"NA":9929},{"trials":9912,"activeCount":708,"soonestReadout":9917},[9913],{"nctId":9914,"briefTitle":9915,"status":121,"phases":9916,"primaryCompletion":9917,"completion":726,"start":9918,"enrollment":1767,"conditions":9919,"interventions":9920},"NCT06385652","PET Imaging Study of 68Ga-NB381 in Multiple Myeloma",[97],"2025-06-03","2024-04-01",[5130],[9909],{"trials":9922,"activeCount":109},[],{"trials":9924,"activeCount":109},[],{"trials":9926,"activeCount":109},[],{"trials":9928,"activeCount":109},[],{"trials":9930,"activeCount":109},[],{"intervention":5066,"totalTrials":553,"cells":9932},{"EARLY_PHASE1":9933,"PHASE1":9935,"PHASE2":9949,"PHASE3":9961,"PHASE4":9973,"NA":9975},{"trials":9934,"activeCount":109},[],{"trials":9936,"activeCount":109},[9937],{"nctId":9938,"briefTitle":9939,"status":135,"phases":9940,"primaryCompletion":9941,"completion":9942,"start":9943,"enrollment":9944,"conditions":9945,"interventions":9946},"NCT03874897","Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.",[98],"2021-03-20","2024-01-26","2019-03-26",134,[9156],[9947,9948,5066],"CAR-CLDN18.2 T-Cells","PD-1 Monoclonal Antibody",{"trials":9950,"activeCount":109},[9951],{"nctId":9952,"briefTitle":9953,"status":569,"phases":9954,"primaryCompletion":2542,"completion":1113,"start":9955,"enrollment":9956,"conditions":9957,"interventions":9958},"NCT03917069","Nab-PCE vs PC for MM After Failure of Anti-PD-1",[99],"2019-03-23",145,[5404],[9959,9960],"Chemotherapeutic Combinations","chemotherapy",{"trials":9962,"activeCount":109},[9963],{"nctId":9964,"briefTitle":9965,"status":135,"phases":9966,"primaryCompletion":9967,"completion":9968,"start":831,"enrollment":9969,"conditions":9970,"interventions":9972},"NCT02042690","Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients",[100],"2018-02","2019-04",131,[9971],"Acute Lymphoblastic Leukemia",[5066],{"trials":9974,"activeCount":109},[],{"trials":9976,"activeCount":329,"soonestReadout":4316},[9977,9987,9991],{"nctId":9978,"briefTitle":9979,"status":456,"phases":9980,"primaryCompletion":4316,"completion":9981,"start":1537,"enrollment":376,"conditions":9982,"interventions":9986},"NCT06776198","Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study",[],"2027-06-01",[2532,9983,9984,9985],"Transcriptome","Tumor Microenvironment","Precision Medicine",[5066],{"nctId":5059,"briefTitle":5060,"status":456,"phases":9988,"primaryCompletion":772,"completion":5062,"start":5063,"enrollment":168,"conditions":9989,"interventions":9990},[],[3757],[5066,3924,3746,5067],{"nctId":9992,"briefTitle":9993,"status":121,"phases":9994,"primaryCompletion":9995,"completion":9996,"start":535,"enrollment":9997,"conditions":9998,"interventions":9999},"NCT06120374","Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC",[],"2027-06-08","2029-06-08",178,[9302],[5066,3924],{"intervention":10001,"totalTrials":329,"cells":10002},"Dopamine",{"EARLY_PHASE1":10003,"PHASE1":10005,"PHASE2":10007,"PHASE3":10009,"PHASE4":10011,"NA":10013},{"trials":10004,"activeCount":109},[],{"trials":10006,"activeCount":109},[],{"trials":10008,"activeCount":109},[],{"trials":10010,"activeCount":109},[],{"trials":10012,"activeCount":109},[],{"trials":10014,"activeCount":329,"soonestReadout":7971},[10015,10026,10033],{"nctId":10016,"briefTitle":10017,"status":121,"phases":10018,"primaryCompletion":10019,"completion":10020,"start":10021,"enrollment":168,"conditions":10022,"interventions":10025},"NCT06447740","Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis",[102],"2026-06-03","2027-04-03","2024-06-03",[10023,10024],"Renal Artery Stenosis Atherosclerotic","Secondary Hypertension Renal Arterial",[10001],{"nctId":10027,"briefTitle":10028,"status":121,"phases":10029,"primaryCompletion":7971,"completion":7971,"start":10030,"enrollment":376,"conditions":10031,"interventions":10032},"NCT05732077","Fractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting",[102],"2023-01-31",[10023,10024],[10001],{"nctId":10034,"briefTitle":10035,"status":456,"phases":10036,"primaryCompletion":10037,"completion":10038,"start":9043,"enrollment":168,"conditions":10039,"interventions":10040},"NCT07111442","A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients",[102],"2028-08-30","2029-08-30",[10023,10024],[10041],"dopamine",{"intervention":4993,"totalTrials":329,"cells":10043},{"EARLY_PHASE1":10044,"PHASE1":10046,"PHASE2":10048,"PHASE3":10062,"PHASE4":10064,"NA":10066},{"trials":10045,"activeCount":109},[],{"trials":10047,"activeCount":109},[],{"trials":10049,"activeCount":109},[10050],{"nctId":10051,"briefTitle":10052,"status":135,"phases":10053,"primaryCompletion":10054,"completion":10055,"start":10056,"enrollment":6539,"conditions":10057,"interventions":10059},"NCT05166239","HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT",[99],"2023-12-29","2025-12-28","2022-01-10",[2591,10058],"Portal Vein Thrombosis",[4994,4993,10060,10061],"Lenvatinib 2","PD-1 inhibitors 2",{"trials":10063,"activeCount":109},[],{"trials":10065,"activeCount":109},[],{"trials":10067,"activeCount":746,"soonestReadout":725},[10068,10072],{"nctId":4986,"briefTitle":4987,"status":456,"phases":10069,"primaryCompletion":725,"completion":4989,"start":4316,"enrollment":640,"conditions":10070,"interventions":10071},[],[4991],[3797,4993,4994,4995],{"nctId":10073,"briefTitle":10074,"status":468,"phases":10075,"primaryCompletion":10076,"completion":7293,"start":5311,"enrollment":153,"conditions":10077,"interventions":10079},"NCT07359040","Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer",[],"2026-12-21",[2680,10078,4993,3924],"Neoadjuvant Therapy",[10080,4993],"Ivonescimab",{"intervention":10082,"totalTrials":746,"cells":10083},"18-FDG",{"EARLY_PHASE1":10084,"PHASE1":10086,"PHASE2":10088,"PHASE3":10090,"PHASE4":10092,"NA":10094},{"trials":10085,"activeCount":109},[],{"trials":10087,"activeCount":109},[],{"trials":10089,"activeCount":109},[],{"trials":10091,"activeCount":109},[],{"trials":10093,"activeCount":109},[],{"trials":10095,"activeCount":746,"soonestReadout":726},[10096,10102],{"nctId":10097,"briefTitle":10098,"status":456,"phases":10099,"primaryCompletion":726,"completion":726,"start":773,"enrollment":1767,"conditions":10100,"interventions":10101},"NCT06719856","MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors",[],[8957],[10082],{"nctId":10103,"briefTitle":10104,"status":456,"phases":10105,"primaryCompletion":726,"completion":726,"start":10106,"enrollment":47,"conditions":10107,"interventions":10109},"NCT06755086","TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors",[],"2025-01-06",[10108],"Solid Tumors",[10082],{"intervention":10111,"totalTrials":746,"cells":10112},"Sacituzumab Govitecan",{"EARLY_PHASE1":10113,"PHASE1":10115,"PHASE2":10117,"PHASE3":10119,"PHASE4":10121,"NA":10123},{"trials":10114,"activeCount":109},[],{"trials":10116,"activeCount":109},[],{"trials":10118,"activeCount":109},[],{"trials":10120,"activeCount":109},[],{"trials":10122,"activeCount":109},[],{"trials":10124,"activeCount":746,"soonestReadout":726},[10125,10132],{"nctId":10126,"briefTitle":10127,"status":121,"phases":10128,"primaryCompletion":7994,"completion":7995,"start":1537,"enrollment":47,"conditions":10129,"interventions":10131},"NCT07046455","Trop-2 Targeted PET Probes in Advanced TNBC",[102],[10130],"TNBC - Triple-Negative Breast Cancer",[10111],{"nctId":10133,"briefTitle":10134,"status":121,"phases":10135,"primaryCompletion":726,"completion":1019,"start":5201,"enrollment":376,"conditions":10136,"interventions":10139},"NCT07251868","Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study",[],[31,10137,10138],"Brain Metastases From Breast Cancer","Trop2",[10111],{"intervention":10141,"totalTrials":746,"cells":10142},"[68Ga]P3",{"EARLY_PHASE1":10143,"PHASE1":10145,"PHASE2":10147,"PHASE3":10149,"PHASE4":10151,"NA":10153},{"trials":10144,"activeCount":109},[],{"trials":10146,"activeCount":109},[],{"trials":10148,"activeCount":109},[],{"trials":10150,"activeCount":109},[],{"trials":10152,"activeCount":109},[],{"trials":10154,"activeCount":746,"soonestReadout":6043},[10155,10163],{"nctId":10156,"briefTitle":10157,"status":121,"phases":10158,"primaryCompletion":6043,"completion":6043,"start":10159,"enrollment":10160,"conditions":10161,"interventions":10162},"NCT05887687","68Ga-P3 PET\u002FCT Imaging in Malignancy",[102],"2023-05-20",350,[1365],[10141],{"nctId":10164,"briefTitle":10165,"status":121,"phases":10166,"primaryCompletion":6043,"completion":6043,"start":10167,"enrollment":1767,"conditions":10168,"interventions":10169},"NCT05940259","68Ga-P3 PET\u002FCT Imaging in Prostate",[102],"2023-05-29",[1365],[10141],{"intervention":3924,"totalTrials":746,"cells":10171},{"EARLY_PHASE1":10172,"PHASE1":10174,"PHASE2":10176,"PHASE3":10178,"PHASE4":10180,"NA":10182},{"trials":10173,"activeCount":109},[],{"trials":10175,"activeCount":109},[],{"trials":10177,"activeCount":109},[],{"trials":10179,"activeCount":109},[],{"trials":10181,"activeCount":109},[],{"trials":10183,"activeCount":746,"soonestReadout":772},[10184,10188],{"nctId":5059,"briefTitle":5060,"status":456,"phases":10185,"primaryCompletion":772,"completion":5062,"start":5063,"enrollment":168,"conditions":10186,"interventions":10187},[],[3757],[5066,3924,3746,5067],{"nctId":9992,"briefTitle":9993,"status":121,"phases":10189,"primaryCompletion":9995,"completion":9996,"start":535,"enrollment":9997,"conditions":10190,"interventions":10191},[],[9302],[5066,3924],{"intervention":271,"totalTrials":1428,"cells":10193},{"EARLY_PHASE1":10194,"PHASE1":10196,"PHASE2":10198,"PHASE3":10200,"PHASE4":10202,"NA":10218},{"trials":10195,"activeCount":109},[],{"trials":10197,"activeCount":109},[],{"trials":10199,"activeCount":109},[],{"trials":10201,"activeCount":109},[],{"trials":10203,"activeCount":109},[10204,10214],{"nctId":10205,"briefTitle":10206,"status":135,"phases":10207,"primaryCompletion":4737,"completion":10208,"start":10209,"enrollment":10210,"conditions":10211,"interventions":10213},"NCT04964219","Analgesic Effects of Low-dose S-ketamine in Major Spine Fusion Surgery",[101],"2025-05-02","2022-02-08",164,[271,270,10212],"Spine Fusion",[271],{"nctId":262,"briefTitle":263,"status":135,"phases":10215,"primaryCompletion":265,"completion":266,"start":267,"enrollment":168,"conditions":10216,"interventions":10217},[101],[269,270,271,25,172],[271,25,172],{"trials":10219,"activeCount":708,"soonestReadout":1384},[10220,10228,10234],{"nctId":10221,"briefTitle":10222,"status":135,"phases":10223,"primaryCompletion":10224,"completion":10224,"start":10225,"enrollment":503,"conditions":10226,"interventions":10227},"NCT04414943","Low-dose S-ketamine in Women With Prenatal Depression",[102],"2022-08-03","2020-06-19",[505,506,507],[271],{"nctId":10229,"briefTitle":10230,"status":135,"phases":10231,"primaryCompletion":10224,"completion":10224,"start":10225,"enrollment":503,"conditions":10232,"interventions":10233},"NCT03927378","Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression",[102],[505,506,507],[271],{"nctId":1381,"briefTitle":1382,"status":121,"phases":10235,"primaryCompletion":1384,"completion":1385,"start":639,"enrollment":1386,"conditions":10236,"interventions":10237},[],[1388,1389],[1391,1392,271],{"intervention":10239,"totalTrials":1428,"cells":10240},"Escitalopram",{"EARLY_PHASE1":10241,"PHASE1":10243,"PHASE2":10245,"PHASE3":10247,"PHASE4":10249,"NA":10251},{"trials":10242,"activeCount":109},[],{"trials":10244,"activeCount":109},[],{"trials":10246,"activeCount":109},[],{"trials":10248,"activeCount":109},[],{"trials":10250,"activeCount":109},[],{"trials":10252,"activeCount":708,"soonestReadout":726},[10253,10264,10272,10281,10291],{"nctId":10254,"briefTitle":10255,"status":569,"phases":10256,"primaryCompletion":2930,"completion":315,"start":10257,"enrollment":1445,"conditions":10258,"interventions":10260},"NCT05389046","Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia",[102],"2022-08-15",[10259],"Outpatients \u002F Inpatients With Depression",[10239,10261,10262,10263],"Escitalopram+Aripiprazole","Escitalopram+omega-3 PUFAs","Escitalopram+Aripiprazole+omega-3 PUFAs",{"nctId":10265,"briefTitle":10266,"status":456,"phases":10267,"primaryCompletion":726,"completion":726,"start":10268,"enrollment":168,"conditions":10269,"interventions":10271},"NCT07480525","Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder",[102],"2026-03-20",[10270],"Depression - Major Depressive Disorder",[10239],{"nctId":10273,"briefTitle":10274,"status":569,"phases":10275,"primaryCompletion":4651,"completion":57,"start":449,"enrollment":574,"conditions":10276,"interventions":10278},"NCT03148522","A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System",[102],[10277],"Diagnosis and Treatment of Depression",[10239,10279,10280],"Duloxetine","Mirtazapine",{"nctId":10282,"briefTitle":10283,"status":135,"phases":10284,"primaryCompletion":10285,"completion":10285,"start":10286,"enrollment":640,"conditions":10287,"interventions":10289},"NCT06758167","RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD",[102],"2024-04-02","2020-11-14",[10288],"Major Depression",[10290,10239],"XingpiJieyu formula",{"nctId":10292,"briefTitle":10293,"status":135,"phases":10294,"primaryCompletion":10295,"completion":5264,"start":10296,"enrollment":10297,"conditions":10298,"interventions":10300},"NCT04013464","Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder",[102],"2018-05-31","2016-05-01",31,[10299],"Depressive Disorder, Major",[10239],{"intervention":643,"totalTrials":1428,"cells":10302},{"EARLY_PHASE1":10303,"PHASE1":10305,"PHASE2":10307,"PHASE3":10326,"PHASE4":10328,"NA":10330},{"trials":10304,"activeCount":109},[],{"trials":10306,"activeCount":109},[],{"trials":10308,"activeCount":109},[10309,10315,10319],{"nctId":10310,"briefTitle":10311,"status":569,"phases":10312,"primaryCompletion":2051,"completion":637,"start":639,"enrollment":640,"conditions":10313,"interventions":10314},"NCT05369377","Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia",[99],[34],[643,2706],{"nctId":634,"briefTitle":635,"status":569,"phases":10316,"primaryCompletion":637,"completion":638,"start":639,"enrollment":640,"conditions":10317,"interventions":10318},[99],[34],[643,557],{"nctId":10320,"briefTitle":10321,"status":135,"phases":10322,"primaryCompletion":855,"completion":855,"start":535,"enrollment":47,"conditions":10323,"interventions":10325},"NCT05279872","A Study of Zanubrutinib in Patients With ITP",[99],[34,10324],"Bruton Tyrosine Kinase",[643],{"trials":10327,"activeCount":109},[],{"trials":10329,"activeCount":109},[],{"trials":10331,"activeCount":708,"soonestReadout":2051},[10332,10340],{"nctId":10333,"briefTitle":10334,"status":456,"phases":10335,"primaryCompletion":2051,"completion":637,"start":5201,"enrollment":10336,"conditions":10337,"interventions":10339},"NCT06489184","The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China",[],490,[10338],"CLL",[643],{"nctId":10341,"briefTitle":10342,"status":569,"phases":10343,"primaryCompletion":3679,"completion":5352,"start":10344,"enrollment":47,"conditions":10345,"interventions":10347},"NCT05117814","Zanubrutinib Monotherapy in Relapsed\u002FRefractory Central Nervous System Lymphoma",[102],"2021-09",[10346],"CNS Lymphoma",[643],{"intervention":10349,"totalTrials":405,"cells":10350},"Orelabrutinib",{"EARLY_PHASE1":10351,"PHASE1":10353,"PHASE2":10355,"PHASE3":10373,"PHASE4":10375,"NA":10377},{"trials":10352,"activeCount":109},[],{"trials":10354,"activeCount":109},[],{"trials":10356,"activeCount":109},[10357,10364],{"nctId":10358,"briefTitle":10359,"status":569,"phases":10360,"primaryCompletion":10361,"completion":639,"start":8314,"enrollment":477,"conditions":10362,"interventions":10363},"NCT05124028","A Study of Orelabrutinib in Patients With ITP",[98,99],"2022-03-01",[34],[10349],{"nctId":10365,"briefTitle":10366,"status":569,"phases":10367,"primaryCompletion":10368,"completion":2577,"start":535,"enrollment":1767,"conditions":10369,"interventions":10371},"NCT05491044","A Study of Orelabrutinib in CLL\u002FSLL Patients Who Are Slowly Responding to Ibrutinib",[99],"2024-08-28",[10370],"CLL\u002FSLL",[10372],"orelabrutinib",{"trials":10374,"activeCount":109},[],{"trials":10376,"activeCount":109},[],{"trials":10378,"activeCount":708,"soonestReadout":10383},[10379,10389],{"nctId":10380,"briefTitle":10381,"status":121,"phases":10382,"primaryCompletion":10383,"completion":10383,"start":6876,"enrollment":2589,"conditions":10384,"interventions":10386},"NCT07257510","Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma",[102],"2028-08-01",[8424,10385],"POZ",[10387,10349,10388,10388],"Pomalidomide","Zuberitamab",{"nctId":10390,"briefTitle":10391,"status":569,"phases":10392,"primaryCompletion":8447,"completion":4049,"start":10393,"enrollment":1767,"conditions":10394,"interventions":10395},"NCT05495828","Orelabrutinib Therapy in Patients With r\u002Fr B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors",[],"2023-11-10",[8449],[10349],{"intervention":1370,"totalTrials":405,"cells":10397},{"EARLY_PHASE1":10398,"PHASE1":10400,"PHASE2":10402,"PHASE3":10404,"PHASE4":10406,"NA":10408},{"trials":10399,"activeCount":109},[],{"trials":10401,"activeCount":109},[],{"trials":10403,"activeCount":109},[],{"trials":10405,"activeCount":109},[],{"trials":10407,"activeCount":109},[],{"trials":10409,"activeCount":708,"soonestReadout":1384},[10410,10414,10418,10422],{"nctId":1358,"briefTitle":1359,"status":135,"phases":10411,"primaryCompletion":1113,"completion":1361,"start":1362,"enrollment":1363,"conditions":10412,"interventions":10413},[102],[155,1365,1366,1367,1368,1327],[1370,1234],{"nctId":1372,"briefTitle":1373,"status":135,"phases":10415,"primaryCompletion":1375,"completion":1376,"start":1362,"enrollment":1363,"conditions":10416,"interventions":10417},[102],[245,357,1378],[1370,1234],{"nctId":1381,"briefTitle":1382,"status":121,"phases":10419,"primaryCompletion":1384,"completion":1385,"start":639,"enrollment":1386,"conditions":10420,"interventions":10421},[],[1388,1389],[1391,1392,271],{"nctId":1394,"briefTitle":1395,"status":135,"phases":10423,"primaryCompletion":1375,"completion":1112,"start":1362,"enrollment":1363,"conditions":10424,"interventions":10425},[102],[155,1365,1366,1367,1368,1327],[1370,1234],{"intervention":10427,"totalTrials":329,"cells":10428},"Sitagliptin",{"EARLY_PHASE1":10429,"PHASE1":10431,"PHASE2":10433,"PHASE3":10444,"PHASE4":10446,"NA":10457},{"trials":10430,"activeCount":109},[],{"trials":10432,"activeCount":109},[],{"trials":10434,"activeCount":109},[10435],{"nctId":10436,"briefTitle":10437,"status":569,"phases":10438,"primaryCompletion":2853,"completion":10439,"start":857,"enrollment":574,"conditions":10440,"interventions":10443},"NCT05353673","The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2023-02-01",[34,10441,3264,10442],"Blood Coagulation Disorders","Physiological Effects of Drugs",[10427,2657],{"trials":10445,"activeCount":109},[],{"trials":10447,"activeCount":109},[10448],{"nctId":10449,"briefTitle":10450,"status":569,"phases":10451,"primaryCompletion":3999,"completion":2503,"start":535,"enrollment":2712,"conditions":10452,"interventions":10455},"NCT05386186","The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes",[101],[10453,10454],"Diabetes Mellitus, Type 2","Severe Insulin Deficient Diabetes",[10456,10427],"Glimepiride",{"trials":10458,"activeCount":708,"soonestReadout":4415},[10459],{"nctId":10460,"briefTitle":10461,"status":121,"phases":10462,"primaryCompletion":4415,"completion":4416,"start":10463,"enrollment":4171,"conditions":10464,"interventions":10466},"NCT06587698","Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS",[102],"2024-08-21",[10465],"Polycystic Ovarian Syndrome",[10427,10467,10468],"BeiDouGen","Sitagliptin+BeiDouGen",{"intervention":4707,"totalTrials":746,"cells":10470},{"EARLY_PHASE1":10471,"PHASE1":10473,"PHASE2":10475,"PHASE3":10477,"PHASE4":10483,"NA":10485},{"trials":10472,"activeCount":109},[],{"trials":10474,"activeCount":109},[],{"trials":10476,"activeCount":109},[],{"trials":10478,"activeCount":109},[10479],{"nctId":4698,"briefTitle":4699,"status":569,"phases":10480,"primaryCompletion":57,"completion":4701,"start":4702,"enrollment":4703,"conditions":10481,"interventions":10482},[99,100],[4705],[4707,4119],{"trials":10484,"activeCount":109},[],{"trials":10486,"activeCount":708,"soonestReadout":2852},[10487],{"nctId":10488,"briefTitle":10489,"status":121,"phases":10490,"primaryCompletion":2852,"completion":10491,"start":10492,"enrollment":10493,"conditions":10494,"interventions":10496},"NCT06864533","Adjuvant Chemotherapy for High Malignant Prostate Cancer",[102],"2031-09-01","2019-09-01",315,[37,3922,5066,10495],"Gleason Score",[4707],{"intervention":733,"totalTrials":746,"cells":10498},{"EARLY_PHASE1":10499,"PHASE1":10501,"PHASE2":10503,"PHASE3":10505,"PHASE4":10507,"NA":10509},{"trials":10500,"activeCount":109},[],{"trials":10502,"activeCount":109},[],{"trials":10504,"activeCount":109},[],{"trials":10506,"activeCount":109},[],{"trials":10508,"activeCount":109},[],{"trials":10510,"activeCount":708,"soonestReadout":725},[10511,10519],{"nctId":10512,"briefTitle":10513,"status":569,"phases":10514,"primaryCompletion":2744,"completion":2744,"start":10515,"enrollment":1767,"conditions":10516,"interventions":10518},"NCT06203145","A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM",[102],"2024-01-02",[5130,10517],"Renal Injury",[733],{"nctId":722,"briefTitle":723,"status":121,"phases":10520,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":10521,"interventions":10522},[],[730],[732,733,557,734,735],{"intervention":4994,"totalTrials":746,"cells":10524},{"EARLY_PHASE1":10525,"PHASE1":10527,"PHASE2":10529,"PHASE3":10535,"PHASE4":10537,"NA":10539},{"trials":10526,"activeCount":109},[],{"trials":10528,"activeCount":109},[],{"trials":10530,"activeCount":109},[10531],{"nctId":10051,"briefTitle":10052,"status":135,"phases":10532,"primaryCompletion":10054,"completion":10055,"start":10056,"enrollment":6539,"conditions":10533,"interventions":10534},[99],[2591,10058],[4994,4993,10060,10061],{"trials":10536,"activeCount":109},[],{"trials":10538,"activeCount":109},[],{"trials":10540,"activeCount":708,"soonestReadout":725},[10541],{"nctId":4986,"briefTitle":4987,"status":456,"phases":10542,"primaryCompletion":725,"completion":4989,"start":4316,"enrollment":640,"conditions":10543,"interventions":10544},[],[4991],[3797,4993,4994,4995],{"intervention":10546,"totalTrials":746,"cells":10547},"11C-Choline",{"EARLY_PHASE1":10548,"PHASE1":10550,"PHASE2":10552,"PHASE3":10554,"PHASE4":10556,"NA":10558},{"trials":10549,"activeCount":109},[],{"trials":10551,"activeCount":109},[],{"trials":10553,"activeCount":109},[],{"trials":10555,"activeCount":109},[],{"trials":10557,"activeCount":109},[],{"trials":10559,"activeCount":708,"soonestReadout":5128},[10560,10567],{"nctId":10561,"briefTitle":10562,"status":468,"phases":10563,"primaryCompletion":5128,"completion":5128,"start":10564,"enrollment":728,"conditions":10565,"interventions":10566},"NCT04560725","PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer",[102],"2020-10-22",[37],[10546],{"nctId":10568,"briefTitle":10569,"status":569,"phases":10570,"primaryCompletion":10571,"completion":595,"start":2662,"enrollment":47,"conditions":10572,"interventions":10573},"NCT04693169","[Al18F]PSMA137 PET\u002FCT Imaging for PSMA-Positive Cancer Patients",[102],"2024-06-12",[37],[10546],{"intervention":10575,"totalTrials":708,"cells":10576},"Mailuo Shutong Pills",{"EARLY_PHASE1":10577,"PHASE1":10579,"PHASE2":10581,"PHASE3":10583,"PHASE4":10585,"NA":10587},{"trials":10578,"activeCount":109},[],{"trials":10580,"activeCount":109},[],{"trials":10582,"activeCount":109},[],{"trials":10584,"activeCount":109},[],{"trials":10586,"activeCount":109},[],{"trials":10588,"activeCount":708,"soonestReadout":1963},[10589],{"nctId":10590,"briefTitle":10591,"status":456,"phases":10592,"primaryCompletion":1963,"completion":2969,"start":2370,"enrollment":1830,"conditions":10593,"interventions":10596},"NCT07258381","Mailuo Shutong Pills for Diabetic Wound Healing: A Multicenter Randomized Trial",[102],[10594,10595],"Diabetic Wound","Chronic Wound Care",[10575,10597],"Blank control",{"intervention":10597,"totalTrials":708,"cells":10599},{"EARLY_PHASE1":10600,"PHASE1":10602,"PHASE2":10604,"PHASE3":10606,"PHASE4":10608,"NA":10610},{"trials":10601,"activeCount":109},[],{"trials":10603,"activeCount":109},[],{"trials":10605,"activeCount":109},[],{"trials":10607,"activeCount":109},[],{"trials":10609,"activeCount":109},[],{"trials":10611,"activeCount":708,"soonestReadout":1963},[10612],{"nctId":10590,"briefTitle":10591,"status":456,"phases":10613,"primaryCompletion":1963,"completion":2969,"start":2370,"enrollment":1830,"conditions":10614,"interventions":10615},[102],[10594,10595],[10575,10597],{"intervention":10617,"totalTrials":708,"cells":10618},"GAHT for transgender men",{"EARLY_PHASE1":10619,"PHASE1":10621,"PHASE2":10623,"PHASE3":10625,"PHASE4":10627,"NA":10629},{"trials":10620,"activeCount":109},[],{"trials":10622,"activeCount":109},[],{"trials":10624,"activeCount":109},[],{"trials":10626,"activeCount":109},[],{"trials":10628,"activeCount":109},[],{"trials":10630,"activeCount":708,"soonestReadout":1019},[10631],{"nctId":10632,"briefTitle":10633,"status":121,"phases":10634,"primaryCompletion":1019,"completion":1002,"start":10635,"enrollment":1165,"conditions":10636,"interventions":10639},"NCT05318755","China Gender-affirming Hormone Therapy Study",[],"2022-04-16",[10637,10638],"Transgender","Gender Incongruence",[10617,10640],"GAHT for transgender women",{"intervention":10640,"totalTrials":708,"cells":10642},{"EARLY_PHASE1":10643,"PHASE1":10645,"PHASE2":10647,"PHASE3":10649,"PHASE4":10651,"NA":10653},{"trials":10644,"activeCount":109},[],{"trials":10646,"activeCount":109},[],{"trials":10648,"activeCount":109},[],{"trials":10650,"activeCount":109},[],{"trials":10652,"activeCount":109},[],{"trials":10654,"activeCount":708,"soonestReadout":1019},[10655],{"nctId":10632,"briefTitle":10633,"status":121,"phases":10656,"primaryCompletion":1019,"completion":1002,"start":10635,"enrollment":1165,"conditions":10657,"interventions":10658},[],[10637,10638],[10617,10640],{"intervention":10660,"totalTrials":708,"cells":10661},"BTK inhibitor",{"EARLY_PHASE1":10662,"PHASE1":10664,"PHASE2":10666,"PHASE3":10668,"PHASE4":10670,"NA":10672},{"trials":10663,"activeCount":109},[],{"trials":10665,"activeCount":109},[],{"trials":10667,"activeCount":109},[],{"trials":10669,"activeCount":109},[],{"trials":10671,"activeCount":109},[],{"trials":10673,"activeCount":708,"soonestReadout":2852},[10674],{"nctId":10675,"briefTitle":10676,"status":456,"phases":10677,"primaryCompletion":2852,"completion":584,"start":5254,"enrollment":5215,"conditions":10678,"interventions":10679},"NCT06557304","The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China",[],[10338],[10660],{"intervention":10681,"totalTrials":708,"cells":10682},"Rivastigmine Mini-Tablet",{"EARLY_PHASE1":10683,"PHASE1":10685,"PHASE2":10687,"PHASE3":10689,"PHASE4":10691,"NA":10693},{"trials":10684,"activeCount":109},[],{"trials":10686,"activeCount":109},[],{"trials":10688,"activeCount":109},[],{"trials":10690,"activeCount":109},[],{"trials":10692,"activeCount":109},[],{"trials":10694,"activeCount":708,"soonestReadout":726},[10695],{"nctId":10696,"briefTitle":10697,"status":456,"phases":10698,"primaryCompletion":726,"completion":726,"start":10699,"enrollment":5215,"conditions":10700,"interventions":10702},"NCT06828289","Rivastigmine Mini-Tablet for Alzheimer's Disease",[],"2025-02-28",[10701],"Alzheimer's Disease",[10681,10703],"Donepezil Hydrochloride",{"intervention":10703,"totalTrials":708,"cells":10705},{"EARLY_PHASE1":10706,"PHASE1":10708,"PHASE2":10710,"PHASE3":10712,"PHASE4":10714,"NA":10716},{"trials":10707,"activeCount":109},[],{"trials":10709,"activeCount":109},[],{"trials":10711,"activeCount":109},[],{"trials":10713,"activeCount":109},[],{"trials":10715,"activeCount":109},[],{"trials":10717,"activeCount":708,"soonestReadout":726},[10718],{"nctId":10696,"briefTitle":10697,"status":456,"phases":10719,"primaryCompletion":726,"completion":726,"start":10699,"enrollment":5215,"conditions":10720,"interventions":10721},[],[10701],[10681,10703],{"intervention":10723,"totalTrials":708,"cells":10724},"Neoadjuvant drug therapy",{"EARLY_PHASE1":10725,"PHASE1":10727,"PHASE2":10729,"PHASE3":10731,"PHASE4":10733,"NA":10735},{"trials":10726,"activeCount":109},[],{"trials":10728,"activeCount":109},[],{"trials":10730,"activeCount":109},[],{"trials":10732,"activeCount":109},[],{"trials":10734,"activeCount":109},[],{"trials":10736,"activeCount":708,"soonestReadout":1578},[10737],{"nctId":10738,"briefTitle":10739,"status":456,"phases":10740,"primaryCompletion":1578,"completion":8655,"start":4000,"enrollment":32,"conditions":10741,"interventions":10743},"NCT06472752","Neoadjuvant Radiotherapy for High-risk UTUC",[],[10742],"Urothelial Carcinoma of the Renal Pelvis and Ureter",[10723],{"intervention":10745,"totalTrials":708,"cells":10746},"Amphotericin B",{"EARLY_PHASE1":10747,"PHASE1":10749,"PHASE2":10751,"PHASE3":10753,"PHASE4":10755,"NA":10757},{"trials":10748,"activeCount":109},[],{"trials":10750,"activeCount":109},[],{"trials":10752,"activeCount":109},[],{"trials":10754,"activeCount":109},[],{"trials":10756,"activeCount":109},[],{"trials":10758,"activeCount":708,"soonestReadout":3910},[10759],{"nctId":10760,"briefTitle":10761,"status":456,"phases":10762,"primaryCompletion":3910,"completion":1002,"start":805,"enrollment":2770,"conditions":10763,"interventions":10765},"NCT07559032","Amphotericin B for Breakthrough Fungal Infections After Triazole Prophylaxis in Hematological Patients",[102],[10764],"Invasive Fungal Disease",[10745],{"intervention":10767,"totalTrials":708,"cells":10768},"Infliximab",{"EARLY_PHASE1":10769,"PHASE1":10771,"PHASE2":10773,"PHASE3":10775,"PHASE4":10777,"NA":10779},{"trials":10770,"activeCount":109},[],{"trials":10772,"activeCount":109},[],{"trials":10774,"activeCount":109},[],{"trials":10776,"activeCount":109},[],{"trials":10778,"activeCount":109},[],{"trials":10780,"activeCount":708,"soonestReadout":10785},[10781],{"nctId":10782,"briefTitle":10783,"status":456,"phases":10784,"primaryCompletion":10785,"completion":10786,"start":4099,"enrollment":10787,"conditions":10788,"interventions":10791},"NCT07176754","TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.",[102],"2028-07-31","2028-10-31",208,[10789,10790],"Cardiac Arrest (CA)","Post Cardiac Arrest Syndrome",[10767,10792],"Sodium chloride injection USP, 0.9%",{"intervention":10792,"totalTrials":708,"cells":10794},{"EARLY_PHASE1":10795,"PHASE1":10797,"PHASE2":10799,"PHASE3":10801,"PHASE4":10803,"NA":10805},{"trials":10796,"activeCount":109},[],{"trials":10798,"activeCount":109},[],{"trials":10800,"activeCount":109},[],{"trials":10802,"activeCount":109},[],{"trials":10804,"activeCount":109},[],{"trials":10806,"activeCount":708,"soonestReadout":10785},[10807],{"nctId":10782,"briefTitle":10783,"status":456,"phases":10808,"primaryCompletion":10785,"completion":10786,"start":4099,"enrollment":10787,"conditions":10809,"interventions":10810},[102],[10789,10790],[10767,10792],{"intervention":10812,"totalTrials":708,"cells":10813},"total glucosides of paeony treatment",{"EARLY_PHASE1":10814,"PHASE1":10816,"PHASE2":10818,"PHASE3":10820,"PHASE4":10822,"NA":10824},{"trials":10815,"activeCount":109},[],{"trials":10817,"activeCount":109},[],{"trials":10819,"activeCount":109},[],{"trials":10821,"activeCount":109},[],{"trials":10823,"activeCount":109},[],{"trials":10825,"activeCount":708,"soonestReadout":2711},[10826],{"nctId":10827,"briefTitle":10828,"status":121,"phases":10829,"primaryCompletion":2711,"completion":2711,"start":10830,"enrollment":3738,"conditions":10831,"interventions":10833},"NCT05973097","Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy",[102],"2023-07-30",[10832],"Oral Lichen Planus",[10812],{"intervention":82,"totalTrials":708,"cells":10835},{"EARLY_PHASE1":10836,"PHASE1":10838,"PHASE2":10840,"PHASE3":10842,"PHASE4":10844,"NA":10846},{"trials":10837,"activeCount":109},[],{"trials":10839,"activeCount":109},[],{"trials":10841,"activeCount":109},[],{"trials":10843,"activeCount":109},[],{"trials":10845,"activeCount":109},[],{"trials":10847,"activeCount":708,"soonestReadout":81},[10848],{"nctId":79,"briefTitle":80,"status":468,"phases":10849,"primaryCompletion":81,"completion":1103,"start":10850,"enrollment":10851,"conditions":10852,"interventions":10853},[],"2015-12-25",349,[31],[82],{"intervention":10855,"totalTrials":708,"cells":10856},"IM19 CAR-T cells",{"EARLY_PHASE1":10857,"PHASE1":10859,"PHASE2":10861,"PHASE3":10863,"PHASE4":10865,"NA":10867},{"trials":10858,"activeCount":109},[],{"trials":10860,"activeCount":109},[],{"trials":10862,"activeCount":109},[],{"trials":10864,"activeCount":109},[],{"trials":10866,"activeCount":109},[],{"trials":10868,"activeCount":708,"soonestReadout":741},[10869],{"nctId":10870,"briefTitle":10871,"status":121,"phases":10872,"primaryCompletion":741,"completion":1019,"start":3708,"enrollment":553,"conditions":10873,"interventions":10875},"NCT06513429","IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)",[102],[10874],"Refractory Systemic Lupus Erythematosus",[10855],{"intervention":10877,"totalTrials":708,"cells":10878},"fecal microbiota transplantation",{"EARLY_PHASE1":10879,"PHASE1":10881,"PHASE2":10883,"PHASE3":10885,"PHASE4":10887,"NA":10889},{"trials":10880,"activeCount":109},[],{"trials":10882,"activeCount":109},[],{"trials":10884,"activeCount":109},[],{"trials":10886,"activeCount":109},[],{"trials":10888,"activeCount":109},[],{"trials":10890,"activeCount":708,"soonestReadout":725},[10891],{"nctId":10892,"briefTitle":10893,"status":456,"phases":10894,"primaryCompletion":725,"completion":726,"start":773,"enrollment":32,"conditions":10895,"interventions":10898},"NCT06475430","Fecal Microbiota Transplantation in the Treatment of Major LARS",[102],[10896,10897],"Low Anterior Resection Syndrome","Fecal Microbiota Transplantation",[10877],{"intervention":10900,"totalTrials":708,"cells":10901},"Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days",{"EARLY_PHASE1":10902,"PHASE1":10904,"PHASE2":10906,"PHASE3":10908,"PHASE4":10910,"NA":10912},{"trials":10903,"activeCount":109},[],{"trials":10905,"activeCount":109},[],{"trials":10907,"activeCount":109},[],{"trials":10909,"activeCount":109},[],{"trials":10911,"activeCount":109},[],{"trials":10913,"activeCount":708,"soonestReadout":10918},[10914],{"nctId":10915,"briefTitle":10916,"status":121,"phases":10917,"primaryCompletion":10918,"completion":10918,"start":10919,"enrollment":670,"conditions":10920,"interventions":10922},"NCT07439445","Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication",[102],"2027-02-13","2026-04-25",[10921],"Helicobacter Pylori Infection",[10900],{"intervention":10924,"totalTrials":708,"cells":10925},"narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide",{"EARLY_PHASE1":10926,"PHASE1":10928,"PHASE2":10930,"PHASE3":10932,"PHASE4":10934,"NA":10936},{"trials":10927,"activeCount":109},[],{"trials":10929,"activeCount":109},[],{"trials":10931,"activeCount":109},[],{"trials":10933,"activeCount":109},[],{"trials":10935,"activeCount":109},[],{"trials":10937,"activeCount":708,"soonestReadout":10942},[10938],{"nctId":10939,"briefTitle":10940,"status":121,"phases":10941,"primaryCompletion":10942,"completion":726,"start":9294,"enrollment":140,"conditions":10943,"interventions":10945},"NCT06302465","Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells",[102],"2026-11-01",[10944],"Malignant Bone Tumor",[10924,10946],"doxorubicin、cisplatin、methotrexate、ifosfamide",{"intervention":10946,"totalTrials":708,"cells":10948},{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10953,"PHASE3":10955,"PHASE4":10957,"NA":10959},{"trials":10950,"activeCount":109},[],{"trials":10952,"activeCount":109},[],{"trials":10954,"activeCount":109},[],{"trials":10956,"activeCount":109},[],{"trials":10958,"activeCount":109},[],{"trials":10960,"activeCount":708,"soonestReadout":10942},[10961],{"nctId":10939,"briefTitle":10940,"status":121,"phases":10962,"primaryCompletion":10942,"completion":726,"start":9294,"enrollment":140,"conditions":10963,"interventions":10964},[102],[10944],[10924,10946],{"intervention":1086,"totalTrials":708,"cells":10966},{"EARLY_PHASE1":10967,"PHASE1":10969,"PHASE2":10971,"PHASE3":10973,"PHASE4":10975,"NA":10977},{"trials":10968,"activeCount":109},[],{"trials":10970,"activeCount":109},[],{"trials":10972,"activeCount":109},[],{"trials":10974,"activeCount":109},[],{"trials":10976,"activeCount":109},[],{"trials":10978,"activeCount":708,"soonestReadout":1082},[10979],{"nctId":1079,"briefTitle":1080,"status":456,"phases":10980,"primaryCompletion":1082,"completion":1083,"start":1054,"enrollment":29,"conditions":10981,"interventions":10982},[],[1056],[1007,1086,1087,1088],{"intervention":1543,"totalTrials":708,"cells":10984},{"EARLY_PHASE1":10985,"PHASE1":10987,"PHASE2":10989,"PHASE3":10991,"PHASE4":10993,"NA":10995},{"trials":10986,"activeCount":109},[],{"trials":10988,"activeCount":109},[],{"trials":10990,"activeCount":109},[],{"trials":10992,"activeCount":109},[],{"trials":10994,"activeCount":109},[],{"trials":10996,"activeCount":708,"soonestReadout":726},[10997],{"nctId":1534,"briefTitle":1535,"status":456,"phases":10998,"primaryCompletion":726,"completion":1019,"start":1537,"enrollment":1538,"conditions":10999,"interventions":11000},[102],[1540,1517,1541],[1543,1496],{"intervention":11002,"totalTrials":708,"cells":11003},"Protocol-based management of perioperative antithrombotic therapy",{"EARLY_PHASE1":11004,"PHASE1":11006,"PHASE2":11008,"PHASE3":11010,"PHASE4":11012,"NA":11014},{"trials":11005,"activeCount":109},[],{"trials":11007,"activeCount":109},[],{"trials":11009,"activeCount":109},[],{"trials":11011,"activeCount":109},[],{"trials":11013,"activeCount":109},[],{"trials":11015,"activeCount":708,"soonestReadout":315},[11016],{"nctId":11017,"briefTitle":11018,"status":121,"phases":11019,"primaryCompletion":315,"completion":7780,"start":11020,"enrollment":11021,"conditions":11022,"interventions":11026},"NCT04852406","Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy",[102],"2021-04-21",526,[11023,11024,11025],"Antithrombotic Therapy","Perioperative Care","Perioperative Outcomes",[11002,11027],"Routine management of perioperative antithrombotic therapy",{"intervention":11027,"totalTrials":708,"cells":11029},{"EARLY_PHASE1":11030,"PHASE1":11032,"PHASE2":11034,"PHASE3":11036,"PHASE4":11038,"NA":11040},{"trials":11031,"activeCount":109},[],{"trials":11033,"activeCount":109},[],{"trials":11035,"activeCount":109},[],{"trials":11037,"activeCount":109},[],{"trials":11039,"activeCount":109},[],{"trials":11041,"activeCount":708,"soonestReadout":315},[11042],{"nctId":11017,"briefTitle":11018,"status":121,"phases":11043,"primaryCompletion":315,"completion":7780,"start":11020,"enrollment":11021,"conditions":11044,"interventions":11045},[102],[11023,11024,11025],[11002,11027],{"intervention":11047,"totalTrials":708,"cells":11048},"Systematic drug treatment",{"EARLY_PHASE1":11049,"PHASE1":11051,"PHASE2":11053,"PHASE3":11055,"PHASE4":11057,"NA":11059},{"trials":11050,"activeCount":109},[],{"trials":11052,"activeCount":109},[],{"trials":11054,"activeCount":109},[],{"trials":11056,"activeCount":109},[],{"trials":11058,"activeCount":109},[],{"trials":11060,"activeCount":708,"soonestReadout":726},[11061],{"nctId":11062,"briefTitle":11063,"status":121,"phases":11064,"primaryCompletion":726,"completion":3130,"start":535,"enrollment":1940,"conditions":11065,"interventions":11068},"NCT06652022","Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs",[102],[6516,11066,11067],"Ureter Cancer","Renal Pelvic Carcinoma",[11047],{"intervention":11070,"totalTrials":708,"cells":11071},"drug adjuvant therapy",{"EARLY_PHASE1":11072,"PHASE1":11074,"PHASE2":11076,"PHASE3":11078,"PHASE4":11080,"NA":11082},{"trials":11073,"activeCount":109},[],{"trials":11075,"activeCount":109},[],{"trials":11077,"activeCount":109},[],{"trials":11079,"activeCount":109},[],{"trials":11081,"activeCount":109},[],{"trials":11083,"activeCount":708,"soonestReadout":4554},[11084],{"nctId":11085,"briefTitle":11086,"status":456,"phases":11087,"primaryCompletion":4554,"completion":11088,"start":11089,"enrollment":341,"conditions":11090,"interventions":11091},"NCT05411809","The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer",[102],"2027-05-15","2022-06-15",[8193],[11070],{"intervention":11093,"totalTrials":708,"cells":11094},"Eravacycline combination therapy group",{"EARLY_PHASE1":11095,"PHASE1":11097,"PHASE2":11099,"PHASE3":11101,"PHASE4":11103,"NA":11105},{"trials":11096,"activeCount":109},[],{"trials":11098,"activeCount":109},[],{"trials":11100,"activeCount":109},[],{"trials":11102,"activeCount":109},[],{"trials":11104,"activeCount":109},[],{"trials":11106,"activeCount":708,"soonestReadout":501},[11107],{"nctId":11108,"briefTitle":11109,"status":456,"phases":11110,"primaryCompletion":501,"completion":386,"start":3870,"enrollment":728,"conditions":11111,"interventions":11114},"NCT06670872","A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia",[],[11112,11113],"Pneumonitis","Acinetobacter Baumannii",[11093],{"intervention":11116,"totalTrials":708,"cells":11117},"Edoxaban 60 mg",{"EARLY_PHASE1":11118,"PHASE1":11120,"PHASE2":11122,"PHASE3":11124,"PHASE4":11126,"NA":11128},{"trials":11119,"activeCount":109},[],{"trials":11121,"activeCount":109},[],{"trials":11123,"activeCount":109},[],{"trials":11125,"activeCount":109},[],{"trials":11127,"activeCount":109},[],{"trials":11129,"activeCount":708,"soonestReadout":3911},[11130],{"nctId":11131,"briefTitle":11132,"status":456,"phases":11133,"primaryCompletion":3911,"completion":3911,"start":412,"enrollment":140,"conditions":11134,"interventions":11137},"NCT07116239","Edoxaban Steady-State PK\u002FPD in Adults With Nephrotic Syndrome",[102],[11135,11136],"Nephrotic Syndrome","Hypoalbuminemia",[11116,11138],"Enoxaparin 40 mg",{"intervention":11138,"totalTrials":708,"cells":11140},{"EARLY_PHASE1":11141,"PHASE1":11143,"PHASE2":11145,"PHASE3":11147,"PHASE4":11149,"NA":11151},{"trials":11142,"activeCount":109},[],{"trials":11144,"activeCount":109},[],{"trials":11146,"activeCount":109},[],{"trials":11148,"activeCount":109},[],{"trials":11150,"activeCount":109},[],{"trials":11152,"activeCount":708,"soonestReadout":3911},[11153],{"nctId":11131,"briefTitle":11132,"status":456,"phases":11154,"primaryCompletion":3911,"completion":3911,"start":412,"enrollment":140,"conditions":11155,"interventions":11156},[102],[11135,11136],[11116,11138],{"intervention":11158,"totalTrials":708,"cells":11159},"Detection of genotype and RNA profile in platelet and white blood cell",{"EARLY_PHASE1":11160,"PHASE1":11162,"PHASE2":11164,"PHASE3":11166,"PHASE4":11168,"NA":11170},{"trials":11161,"activeCount":109},[],{"trials":11163,"activeCount":109},[],{"trials":11165,"activeCount":109},[],{"trials":11167,"activeCount":109},[],{"trials":11169,"activeCount":109},[],{"trials":11171,"activeCount":708,"soonestReadout":438},[11172],{"nctId":11173,"briefTitle":11174,"status":456,"phases":11175,"primaryCompletion":438,"completion":906,"start":11176,"enrollment":11177,"conditions":11178,"interventions":11191},"NCT05764356","Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II",[],"2023-03",2000,[11179,11180,11181,11182,11183,11184,11185,11186,11187,11188,11189,11190],"Novel Oral Anticoagulants","NOACs","Rivaroxaban","Apixaban","Edoxaban","Dabigatran","Ticagrelor","Pharmacodynamics","Pharmacogenomics","RNA Profile","Bleeding","Biomarker",[11158],{"intervention":11193,"totalTrials":708,"cells":11194},"Weight loss and psoriasis treatment",{"EARLY_PHASE1":11195,"PHASE1":11197,"PHASE2":11199,"PHASE3":11201,"PHASE4":11203,"NA":11205},{"trials":11196,"activeCount":109},[],{"trials":11198,"activeCount":109},[],{"trials":11200,"activeCount":109},[],{"trials":11202,"activeCount":109},[],{"trials":11204,"activeCount":109},[],{"trials":11206,"activeCount":708,"soonestReadout":1019},[11207],{"nctId":11208,"briefTitle":11209,"status":456,"phases":11210,"primaryCompletion":1019,"completion":1019,"start":11211,"enrollment":670,"conditions":11212,"interventions":11214},"NCT07382388","A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight\u002FObese Patients With Plaque Psoriasis",[],"2026-01-28",[11213],"Psoriasis",[11193,11215],"psoriasis treatment",{"intervention":11215,"totalTrials":708,"cells":11217},{"EARLY_PHASE1":11218,"PHASE1":11220,"PHASE2":11222,"PHASE3":11224,"PHASE4":11226,"NA":11228},{"trials":11219,"activeCount":109},[],{"trials":11221,"activeCount":109},[],{"trials":11223,"activeCount":109},[],{"trials":11225,"activeCount":109},[],{"trials":11227,"activeCount":109},[],{"trials":11229,"activeCount":708,"soonestReadout":1019},[11230],{"nctId":11208,"briefTitle":11209,"status":456,"phases":11231,"primaryCompletion":1019,"completion":1019,"start":11211,"enrollment":670,"conditions":11232,"interventions":11233},[],[11213],[11193,11215],{"intervention":11235,"totalTrials":708,"cells":11236},"First-Line Dara-BorCyD Treatment",{"EARLY_PHASE1":11237,"PHASE1":11239,"PHASE2":11241,"PHASE3":11243,"PHASE4":11245,"NA":11247},{"trials":11238,"activeCount":109},[],{"trials":11240,"activeCount":109},[],{"trials":11242,"activeCount":109},[],{"trials":11244,"activeCount":109},[],{"trials":11246,"activeCount":109},[],{"trials":11248,"activeCount":708,"soonestReadout":11253},[11249],{"nctId":11250,"briefTitle":11251,"status":456,"phases":11252,"primaryCompletion":11253,"completion":11253,"start":501,"enrollment":728,"conditions":11254,"interventions":11257},"NCT07215494","A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis",[102],"2029-09",[11255,11256],"Light Chain (AL) Amyloidosis","MRD",[11235],{"intervention":9289,"totalTrials":708,"cells":11259},{"EARLY_PHASE1":11260,"PHASE1":11262,"PHASE2":11264,"PHASE3":11266,"PHASE4":11268,"NA":11270},{"trials":11261,"activeCount":109},[],{"trials":11263,"activeCount":109},[],{"trials":11265,"activeCount":109},[],{"trials":11267,"activeCount":109},[],{"trials":11269,"activeCount":109},[],{"trials":11271,"activeCount":708,"soonestReadout":2049},[11272],{"nctId":9284,"briefTitle":9285,"status":456,"phases":11273,"primaryCompletion":2049,"completion":584,"start":638,"enrollment":47,"conditions":11274,"interventions":11275},[102],[43,31],[9237,9289],{"intervention":11277,"totalTrials":708,"cells":11278},"ETV,TDF,TAF,TMF combination with PEG IFNα-2b",{"EARLY_PHASE1":11279,"PHASE1":11281,"PHASE2":11283,"PHASE3":11285,"PHASE4":11287,"NA":11289},{"trials":11280,"activeCount":109},[],{"trials":11282,"activeCount":109},[],{"trials":11284,"activeCount":109},[],{"trials":11286,"activeCount":109},[],{"trials":11288,"activeCount":109},[],{"trials":11290,"activeCount":708,"soonestReadout":11295},[11291],{"nctId":11292,"briefTitle":11293,"status":456,"phases":11294,"primaryCompletion":11295,"completion":11296,"start":605,"enrollment":11297,"conditions":11298,"interventions":11300},"NCT07007286","Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer",[],"2032-01","2032-12",1500,[11299,3795],"HBV",[11277,11301],"ETV,TDF,TAF or TMF",{"intervention":11301,"totalTrials":708,"cells":11303},{"EARLY_PHASE1":11304,"PHASE1":11306,"PHASE2":11308,"PHASE3":11310,"PHASE4":11312,"NA":11314},{"trials":11305,"activeCount":109},[],{"trials":11307,"activeCount":109},[],{"trials":11309,"activeCount":109},[],{"trials":11311,"activeCount":109},[],{"trials":11313,"activeCount":109},[],{"trials":11315,"activeCount":708,"soonestReadout":11295},[11316],{"nctId":11292,"briefTitle":11293,"status":456,"phases":11317,"primaryCompletion":11295,"completion":11296,"start":605,"enrollment":11297,"conditions":11318,"interventions":11319},[],[11299,3795],[11277,11301],{"intervention":11321,"totalTrials":708,"cells":11322},"Aponermin, pomalidomide, dexamethasone",{"EARLY_PHASE1":11323,"PHASE1":11325,"PHASE2":11327,"PHASE3":11329,"PHASE4":11331,"NA":11333},{"trials":11324,"activeCount":109},[],{"trials":11326,"activeCount":109},[],{"trials":11328,"activeCount":109},[],{"trials":11330,"activeCount":109},[],{"trials":11332,"activeCount":109},[],{"trials":11334,"activeCount":708,"soonestReadout":726},[11335],{"nctId":11336,"briefTitle":11337,"status":468,"phases":11338,"primaryCompletion":726,"completion":2049,"start":1537,"enrollment":11339,"conditions":11340,"interventions":11342},"NCT06924424","Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed\u002F Refractory Multiple Myeloma",[102],105,[11341],"Multiple Myeloma, Neoplasms",[11321],{"intervention":11344,"totalTrials":708,"cells":11345},"Etoposide + cisplatin\u002Fcarboplatin",{"EARLY_PHASE1":11346,"PHASE1":11348,"PHASE2":11350,"PHASE3":11352,"PHASE4":11354,"NA":11356},{"trials":11347,"activeCount":109},[],{"trials":11349,"activeCount":109},[],{"trials":11351,"activeCount":109},[],{"trials":11353,"activeCount":109},[],{"trials":11355,"activeCount":109},[],{"trials":11357,"activeCount":708,"soonestReadout":6018},[11358],{"nctId":11359,"briefTitle":11360,"status":121,"phases":11361,"primaryCompletion":6018,"completion":11362,"start":11363,"enrollment":11364,"conditions":11365,"interventions":11367},"NCT06869239","Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy",[],"2028-01-03","2025-02-25",65,[11366],"Limited-stage Small Cell Lung Cancer (LS-SCLC)",[11344,11368],"PD-L1 inhibitor",{"intervention":11368,"totalTrials":708,"cells":11370},{"EARLY_PHASE1":11371,"PHASE1":11373,"PHASE2":11375,"PHASE3":11377,"PHASE4":11379,"NA":11381},{"trials":11372,"activeCount":109},[],{"trials":11374,"activeCount":109},[],{"trials":11376,"activeCount":109},[],{"trials":11378,"activeCount":109},[],{"trials":11380,"activeCount":109},[],{"trials":11382,"activeCount":708,"soonestReadout":6018},[11383],{"nctId":11359,"briefTitle":11360,"status":121,"phases":11384,"primaryCompletion":6018,"completion":11362,"start":11363,"enrollment":11364,"conditions":11385,"interventions":11386},[],[11366],[11344,11368],{"intervention":11388,"totalTrials":708,"cells":11389},"TBF regimen",{"EARLY_PHASE1":11390,"PHASE1":11392,"PHASE2":11394,"PHASE3":11396,"PHASE4":11398,"NA":11400},{"trials":11391,"activeCount":109},[],{"trials":11393,"activeCount":109},[],{"trials":11395,"activeCount":109},[],{"trials":11397,"activeCount":109},[],{"trials":11399,"activeCount":109},[],{"trials":11401,"activeCount":708,"soonestReadout":1829},[11402],{"nctId":11403,"briefTitle":11404,"status":121,"phases":11405,"primaryCompletion":1829,"completion":1829,"start":11406,"enrollment":10297,"conditions":11407,"interventions":11409},"NCT07588594","Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia",[102],"2026-02-13",[11408],"Chronic Myelomonocytic Leukemia (CMML)",[11388],{"intervention":11411,"totalTrials":708,"cells":11412},"Targeted blood-pressure management",{"EARLY_PHASE1":11413,"PHASE1":11415,"PHASE2":11417,"PHASE3":11419,"PHASE4":11421,"NA":11423},{"trials":11414,"activeCount":109},[],{"trials":11416,"activeCount":109},[],{"trials":11418,"activeCount":109},[],{"trials":11420,"activeCount":109},[],{"trials":11422,"activeCount":109},[],{"trials":11424,"activeCount":708,"soonestReadout":315},[11425],{"nctId":11426,"briefTitle":11427,"status":121,"phases":11428,"primaryCompletion":315,"completion":1246,"start":11429,"enrollment":11430,"conditions":11431,"interventions":11437},"NCT03629418","Targeted Blood-pressure Management and Acute Kidney Injury After Coronary Artery Bypass Surgery",[102],"2018-08-14",612,[11432,11433,11434,11435,11436],"Coronary Artery Bypass, Off-Pump","Intraoperative Hypotension","Acute Kidney Injury","Preventive Medicine","Intraoperative Care",[11411,11438],"Routine blood-pressure management",{"intervention":11438,"totalTrials":708,"cells":11440},{"EARLY_PHASE1":11441,"PHASE1":11443,"PHASE2":11445,"PHASE3":11447,"PHASE4":11449,"NA":11451},{"trials":11442,"activeCount":109},[],{"trials":11444,"activeCount":109},[],{"trials":11446,"activeCount":109},[],{"trials":11448,"activeCount":109},[],{"trials":11450,"activeCount":109},[],{"trials":11452,"activeCount":708,"soonestReadout":315},[11453],{"nctId":11426,"briefTitle":11427,"status":121,"phases":11454,"primaryCompletion":315,"completion":1246,"start":11429,"enrollment":11430,"conditions":11455,"interventions":11456},[102],[11432,11433,11434,11435,11436],[11411,11438],{"intervention":11458,"totalTrials":708,"cells":11459},"Lorlatinib",{"EARLY_PHASE1":11460,"PHASE1":11462,"PHASE2":11464,"PHASE3":11466,"PHASE4":11468,"NA":11470},{"trials":11461,"activeCount":109},[],{"trials":11463,"activeCount":109},[],{"trials":11465,"activeCount":109},[],{"trials":11467,"activeCount":109},[],{"trials":11469,"activeCount":109},[],{"trials":11471,"activeCount":708,"soonestReadout":412},[11472],{"nctId":11473,"briefTitle":11474,"status":1935,"phases":11475,"primaryCompletion":412,"completion":11476,"start":969,"enrollment":11477,"conditions":11478,"interventions":11480},"NCT06876675","LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer",[],"2029-08",167,[2680,11479],"Hyperlipidemia",[11458],{"intervention":4995,"totalTrials":708,"cells":11482},{"EARLY_PHASE1":11483,"PHASE1":11485,"PHASE2":11487,"PHASE3":11489,"PHASE4":11491,"NA":11493},{"trials":11484,"activeCount":109},[],{"trials":11486,"activeCount":109},[],{"trials":11488,"activeCount":109},[],{"trials":11490,"activeCount":109},[],{"trials":11492,"activeCount":109},[],{"trials":11494,"activeCount":708,"soonestReadout":725},[11495],{"nctId":4986,"briefTitle":4987,"status":456,"phases":11496,"primaryCompletion":725,"completion":4989,"start":4316,"enrollment":640,"conditions":11497,"interventions":11498},[],[4991],[3797,4993,4994,4995],{"intervention":11500,"totalTrials":708,"cells":11501},"FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.",{"EARLY_PHASE1":11502,"PHASE1":11504,"PHASE2":11506,"PHASE3":11508,"PHASE4":11510,"NA":11512},{"trials":11503,"activeCount":109},[],{"trials":11505,"activeCount":109},[],{"trials":11507,"activeCount":109},[],{"trials":11509,"activeCount":109},[],{"trials":11511,"activeCount":109},[],{"trials":11513,"activeCount":708,"soonestReadout":11518},[11514],{"nctId":11515,"briefTitle":11516,"status":468,"phases":11517,"primaryCompletion":11518,"completion":943,"start":11519,"enrollment":11520,"conditions":11521,"interventions":11526},"NCT04584008","Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics",[102],"2024-11","2020-09-23",600,[11522,28,1250,2692,11523,684,6414,11524,11525],"Biliary Tract Neoplasms","Gastrointestinal Stromal Tumors","Unknown Primary Cancer","Digestive Cancer",[11500,11527],"Other Therapy",{"intervention":11527,"totalTrials":708,"cells":11529},{"EARLY_PHASE1":11530,"PHASE1":11532,"PHASE2":11534,"PHASE3":11536,"PHASE4":11538,"NA":11540},{"trials":11531,"activeCount":109},[],{"trials":11533,"activeCount":109},[],{"trials":11535,"activeCount":109},[],{"trials":11537,"activeCount":109},[],{"trials":11539,"activeCount":109},[],{"trials":11541,"activeCount":708,"soonestReadout":11518},[11542],{"nctId":11515,"briefTitle":11516,"status":468,"phases":11543,"primaryCompletion":11518,"completion":943,"start":11519,"enrollment":11520,"conditions":11544,"interventions":11545},[102],[11522,28,1250,2692,11523,684,6414,11524,11525],[11500,11527],{"intervention":11547,"totalTrials":708,"cells":11548},"anti-cytokine antibodies",{"EARLY_PHASE1":11549,"PHASE1":11551,"PHASE2":11553,"PHASE3":11555,"PHASE4":11557,"NA":11559},{"trials":11550,"activeCount":109},[],{"trials":11552,"activeCount":109},[],{"trials":11554,"activeCount":109},[],{"trials":11556,"activeCount":109},[],{"trials":11558,"activeCount":109},[],{"trials":11560,"activeCount":708,"soonestReadout":8867},[11561],{"nctId":11562,"briefTitle":11563,"status":121,"phases":11564,"primaryCompletion":8867,"completion":726,"start":11565,"enrollment":168,"conditions":11566,"interventions":11568},"NCT07181525","Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease",[],"2025-08-15",[11567],"Inflamatory Bowel Disease",[11547,11569],"anti-integrin antibodies",{"intervention":11569,"totalTrials":708,"cells":11571},{"EARLY_PHASE1":11572,"PHASE1":11574,"PHASE2":11576,"PHASE3":11578,"PHASE4":11580,"NA":11582},{"trials":11573,"activeCount":109},[],{"trials":11575,"activeCount":109},[],{"trials":11577,"activeCount":109},[],{"trials":11579,"activeCount":109},[],{"trials":11581,"activeCount":109},[],{"trials":11583,"activeCount":708,"soonestReadout":8867},[11584],{"nctId":11562,"briefTitle":11563,"status":121,"phases":11585,"primaryCompletion":8867,"completion":726,"start":11565,"enrollment":168,"conditions":11586,"interventions":11587},[],[11567],[11547,11569],{"intervention":11589,"totalTrials":708,"cells":11590},"Budesonide irrigation",{"EARLY_PHASE1":11591,"PHASE1":11593,"PHASE2":11595,"PHASE3":11597,"PHASE4":11599,"NA":11601},{"trials":11592,"activeCount":109},[],{"trials":11594,"activeCount":109},[],{"trials":11596,"activeCount":109},[],{"trials":11598,"activeCount":109},[],{"trials":11600,"activeCount":109},[],{"trials":11602,"activeCount":708,"soonestReadout":11607},[11603],{"nctId":11604,"briefTitle":11605,"status":456,"phases":11606,"primaryCompletion":11607,"completion":11607,"start":11608,"enrollment":11609,"conditions":11610,"interventions":11613},"NCT06837051","The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS",[102],"2027-03-14","2025-03-14",213,[11611,11612],"Olfactory Dysfunction","Chronic Rhinosinusitis",[11589],{"intervention":11615,"totalTrials":708,"cells":11616},"Rabbit Anti-Human T-Lymphocyte Immunoglobulin",{"EARLY_PHASE1":11617,"PHASE1":11619,"PHASE2":11621,"PHASE3":11623,"PHASE4":11625,"NA":11627},{"trials":11618,"activeCount":109},[],{"trials":11620,"activeCount":109},[],{"trials":11622,"activeCount":109},[],{"trials":11624,"activeCount":109},[],{"trials":11626,"activeCount":109},[],{"trials":11628,"activeCount":708,"soonestReadout":616},[11629],{"nctId":11630,"briefTitle":11631,"status":121,"phases":11632,"primaryCompletion":616,"completion":772,"start":11633,"enrollment":38,"conditions":11634,"interventions":11637},"NCT06895538","Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy",[],"2025-05-03",[2876,11635,11636],"MDS","Lymphoma",[11615],{"intervention":4743,"totalTrials":708,"cells":11639},{"EARLY_PHASE1":11640,"PHASE1":11642,"PHASE2":11644,"PHASE3":11646,"PHASE4":11648,"NA":11650},{"trials":11641,"activeCount":109},[],{"trials":11643,"activeCount":109},[],{"trials":11645,"activeCount":109},[],{"trials":11647,"activeCount":109},[],{"trials":11649,"activeCount":109},[],{"trials":11651,"activeCount":708,"soonestReadout":4736},[11652],{"nctId":4733,"briefTitle":4734,"status":121,"phases":11653,"primaryCompletion":4736,"completion":2673,"start":4737,"enrollment":4738,"conditions":11654,"interventions":11655},[102],[4740],[4742,4119,4743],{"intervention":11657,"totalTrials":708,"cells":11658},"Icodextrin",{"EARLY_PHASE1":11659,"PHASE1":11661,"PHASE2":11663,"PHASE3":11665,"PHASE4":11667,"NA":11669},{"trials":11660,"activeCount":109},[],{"trials":11662,"activeCount":109},[],{"trials":11664,"activeCount":109},[],{"trials":11666,"activeCount":109},[],{"trials":11668,"activeCount":109},[],{"trials":11670,"activeCount":708,"soonestReadout":11675},[11671],{"nctId":11672,"briefTitle":11673,"status":456,"phases":11674,"primaryCompletion":11675,"completion":11675,"start":11676,"enrollment":558,"conditions":11677,"interventions":11679},"NCT06552546","Pharmacokinetics of Single- and Double-dose Icodextrin",[102],"2025-03-30","2024-08-15",[11678],"Peritoneal Dialysis",[11657],{"intervention":11681,"totalTrials":708,"cells":11682},"Usually, all enrolled patients with acute ischemic stroke will receive routine medication and\u002For surgical treatment according to clinical diagnosis and treatment protocols.",{"EARLY_PHASE1":11683,"PHASE1":11685,"PHASE2":11687,"PHASE3":11689,"PHASE4":11691,"NA":11693},{"trials":11684,"activeCount":109},[],{"trials":11686,"activeCount":109},[],{"trials":11688,"activeCount":109},[],{"trials":11690,"activeCount":109},[],{"trials":11692,"activeCount":109},[],{"trials":11694,"activeCount":708,"soonestReadout":4989},[11695],{"nctId":11696,"briefTitle":11697,"status":456,"phases":11698,"primaryCompletion":4989,"completion":11699,"start":11700,"enrollment":11297,"conditions":11701,"interventions":11703},"NCT07269288","The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke",[],"2028-02-28","2026-01-25",[11702],"Acute Ischemic Stroke",[11681],{"intervention":11705,"totalTrials":708,"cells":11706},"Immunotherapy+radiotherapy",{"EARLY_PHASE1":11707,"PHASE1":11709,"PHASE2":11711,"PHASE3":11713,"PHASE4":11715,"NA":11717},{"trials":11708,"activeCount":109},[],{"trials":11710,"activeCount":109},[],{"trials":11712,"activeCount":109},[],{"trials":11714,"activeCount":109},[],{"trials":11716,"activeCount":109},[],{"trials":11718,"activeCount":708,"soonestReadout":726},[11719],{"nctId":11720,"briefTitle":11721,"status":121,"phases":11722,"primaryCompletion":726,"completion":11723,"start":535,"enrollment":140,"conditions":11724,"interventions":11726},"NCT06598761","Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC",[],"2027-08-30",[11066,11067,11725],"Advanced Urothelial Carcinoma",[11705],{"intervention":11728,"totalTrials":708,"cells":11729},"Equecabtagene Autoleucel",{"EARLY_PHASE1":11730,"PHASE1":11732,"PHASE2":11734,"PHASE3":11736,"PHASE4":11738,"NA":11740},{"trials":11731,"activeCount":109},[],{"trials":11733,"activeCount":109},[],{"trials":11735,"activeCount":109},[],{"trials":11737,"activeCount":109},[],{"trials":11739,"activeCount":109},[],{"trials":11741,"activeCount":708,"soonestReadout":11746},[11742],{"nctId":11743,"briefTitle":11744,"status":456,"phases":11745,"primaryCompletion":11746,"completion":11747,"start":11748,"enrollment":400,"conditions":11749,"interventions":11750},"NCT06369935","A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.",[],"2026-08-20","2027-08-20","2024-06-20",[9181],[11728],{"intervention":11752,"totalTrials":708,"cells":11753},"68Ga-Her2-affibody",{"EARLY_PHASE1":11754,"PHASE1":11756,"PHASE2":11758,"PHASE3":11760,"PHASE4":11762,"NA":11764},{"trials":11755,"activeCount":109},[],{"trials":11757,"activeCount":109},[],{"trials":11759,"activeCount":109},[],{"trials":11761,"activeCount":109},[],{"trials":11763,"activeCount":109},[],{"trials":11765,"activeCount":708,"soonestReadout":629},[11766],{"nctId":11767,"briefTitle":11768,"status":121,"phases":11769,"primaryCompletion":629,"completion":9043,"start":11770,"enrollment":1767,"conditions":11771,"interventions":11772},"NCT06289517","PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression",[102],"2024-05-28",[1365],[11752],{"intervention":850,"totalTrials":708,"cells":11774},{"EARLY_PHASE1":11775,"PHASE1":11777,"PHASE2":11779,"PHASE3":11781,"PHASE4":11783,"NA":11785},{"trials":11776,"activeCount":109},[],{"trials":11778,"activeCount":109},[],{"trials":11780,"activeCount":109},[],{"trials":11782,"activeCount":109},[],{"trials":11784,"activeCount":109},[],{"trials":11786,"activeCount":708,"soonestReadout":725},[11787],{"nctId":842,"briefTitle":843,"status":121,"phases":11788,"primaryCompletion":725,"completion":725,"start":845,"enrollment":846,"conditions":11789,"interventions":11790},[102],[848],[850,236],{"intervention":10387,"totalTrials":708,"cells":11792},{"EARLY_PHASE1":11793,"PHASE1":11795,"PHASE2":11797,"PHASE3":11799,"PHASE4":11801,"NA":11803},{"trials":11794,"activeCount":109},[],{"trials":11796,"activeCount":109},[],{"trials":11798,"activeCount":109},[],{"trials":11800,"activeCount":109},[],{"trials":11802,"activeCount":109},[],{"trials":11804,"activeCount":708,"soonestReadout":10383},[11805],{"nctId":10380,"briefTitle":10381,"status":121,"phases":11806,"primaryCompletion":10383,"completion":10383,"start":6876,"enrollment":2589,"conditions":11807,"interventions":11808},[102],[8424,10385],[10387,10349,10388,10388],{"intervention":10388,"totalTrials":708,"cells":11810},{"EARLY_PHASE1":11811,"PHASE1":11813,"PHASE2":11815,"PHASE3":11817,"PHASE4":11819,"NA":11821},{"trials":11812,"activeCount":109},[],{"trials":11814,"activeCount":109},[],{"trials":11816,"activeCount":109},[],{"trials":11818,"activeCount":109},[],{"trials":11820,"activeCount":109},[],{"trials":11822,"activeCount":708,"soonestReadout":10383},[11823],{"nctId":10380,"briefTitle":10381,"status":121,"phases":11824,"primaryCompletion":10383,"completion":10383,"start":6876,"enrollment":2589,"conditions":11825,"interventions":11826},[102],[8424,10385],[10387,10349,10388,10388],{"intervention":11828,"totalTrials":708,"cells":11829},"Traditional Chinese Medicine",{"EARLY_PHASE1":11830,"PHASE1":11832,"PHASE2":11834,"PHASE3":11836,"PHASE4":11838,"NA":11840},{"trials":11831,"activeCount":109},[],{"trials":11833,"activeCount":109},[],{"trials":11835,"activeCount":109},[],{"trials":11837,"activeCount":109},[],{"trials":11839,"activeCount":109},[],{"trials":11841,"activeCount":708,"soonestReadout":615},[11842],{"nctId":11843,"briefTitle":11844,"status":456,"phases":11845,"primaryCompletion":615,"completion":615,"start":1780,"enrollment":4171,"conditions":11846,"interventions":11848},"NCT07375446","Traditional Chinese Medicine Hand-Foot Soak for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome",[],[11847],"Patients With Solid Tumors",[11828],{"intervention":11850,"totalTrials":708,"cells":11851},"neoadjuvant immunotherapy",{"EARLY_PHASE1":11852,"PHASE1":11854,"PHASE2":11856,"PHASE3":11858,"PHASE4":11860,"NA":11862},{"trials":11853,"activeCount":109},[],{"trials":11855,"activeCount":109},[],{"trials":11857,"activeCount":109},[],{"trials":11859,"activeCount":109},[],{"trials":11861,"activeCount":109},[],{"trials":11863,"activeCount":708,"soonestReadout":1054},[11864],{"nctId":11865,"briefTitle":11866,"status":121,"phases":11867,"primaryCompletion":1054,"completion":3656,"start":5128,"enrollment":1070,"conditions":11868,"interventions":11872},"NCT06926179","Safety, Efficacy, and Survival Outcomes of Neoadjuvant\u002FInduction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer",[],[11869,11870,7696,11871],"Lung Cancer (NSCLC)","Neoadjuvant Immunotherapy","Lung Surgery",[11850],{"intervention":11874,"totalTrials":708,"cells":11875},"iPSC-derived islet cell",{"EARLY_PHASE1":11876,"PHASE1":11878,"PHASE2":11880,"PHASE3":11882,"PHASE4":11884,"NA":11886},{"trials":11877,"activeCount":109},[],{"trials":11879,"activeCount":109},[],{"trials":11881,"activeCount":109},[],{"trials":11883,"activeCount":109},[],{"trials":11885,"activeCount":109},[],{"trials":11887,"activeCount":708,"soonestReadout":1002},[11888],{"nctId":11889,"briefTitle":11890,"status":456,"phases":11891,"primaryCompletion":1002,"completion":11892,"start":11893,"enrollment":1767,"conditions":11894,"interventions":11896},"NCT07464119","A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy",[102],"2033-12-31","2026-03-16",[11895],"Diabetes Mellitus",[11874],{"intervention":11898,"totalTrials":708,"cells":11899},"NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group",{"EARLY_PHASE1":11900,"PHASE1":11902,"PHASE2":11904,"PHASE3":11906,"PHASE4":11908,"NA":11910},{"trials":11901,"activeCount":109},[],{"trials":11903,"activeCount":109},[],{"trials":11905,"activeCount":109},[],{"trials":11907,"activeCount":109},[],{"trials":11909,"activeCount":109},[],{"trials":11911,"activeCount":708,"soonestReadout":1385},[11912],{"nctId":11913,"briefTitle":11914,"status":456,"phases":11915,"primaryCompletion":1385,"completion":385,"start":6151,"enrollment":140,"conditions":11916,"interventions":11918},"NCT06772324","An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders",[102],[11917],"Autism Spectrum Disorder",[11898,11919,11920],"NORSPAN Buprenorphine Transdermal Patchs for Lower dose group","NORSPAN Buprenorphine Transdermal Patchs for higher dose group",{"intervention":11919,"totalTrials":708,"cells":11922},{"EARLY_PHASE1":11923,"PHASE1":11925,"PHASE2":11927,"PHASE3":11929,"PHASE4":11931,"NA":11933},{"trials":11924,"activeCount":109},[],{"trials":11926,"activeCount":109},[],{"trials":11928,"activeCount":109},[],{"trials":11930,"activeCount":109},[],{"trials":11932,"activeCount":109},[],{"trials":11934,"activeCount":708,"soonestReadout":1385},[11935],{"nctId":11913,"briefTitle":11914,"status":456,"phases":11936,"primaryCompletion":1385,"completion":385,"start":6151,"enrollment":140,"conditions":11937,"interventions":11938},[102],[11917],[11898,11919,11920],{"intervention":11920,"totalTrials":708,"cells":11940},{"EARLY_PHASE1":11941,"PHASE1":11943,"PHASE2":11945,"PHASE3":11947,"PHASE4":11949,"NA":11951},{"trials":11942,"activeCount":109},[],{"trials":11944,"activeCount":109},[],{"trials":11946,"activeCount":109},[],{"trials":11948,"activeCount":109},[],{"trials":11950,"activeCount":109},[],{"trials":11952,"activeCount":708,"soonestReadout":1385},[11953],{"nctId":11913,"briefTitle":11914,"status":456,"phases":11954,"primaryCompletion":1385,"completion":385,"start":6151,"enrollment":140,"conditions":11955,"interventions":11956},[102],[11917],[11898,11919,11920],{"intervention":11958,"totalTrials":708,"cells":11959},"Gene polymorphic detection",{"EARLY_PHASE1":11960,"PHASE1":11962,"PHASE2":11964,"PHASE3":11966,"PHASE4":11968,"NA":11970},{"trials":11961,"activeCount":109},[],{"trials":11963,"activeCount":109},[],{"trials":11965,"activeCount":109},[],{"trials":11967,"activeCount":109},[],{"trials":11969,"activeCount":109},[],{"trials":11971,"activeCount":708,"soonestReadout":6326},[11972],{"nctId":11973,"briefTitle":11974,"status":121,"phases":11975,"primaryCompletion":6326,"completion":9112,"start":5254,"enrollment":230,"conditions":11976,"interventions":11978},"NCT07468474","Establishment of Screening Pathway for High-Risk Population of Type 1 Diabetes",[],[11977],"Type 1 Diabetes Mellitus",[11958],{"intervention":11980,"totalTrials":708,"cells":11981},"68Ga-C1",{"EARLY_PHASE1":11982,"PHASE1":11984,"PHASE2":11986,"PHASE3":11988,"PHASE4":11990,"NA":11992},{"trials":11983,"activeCount":109},[],{"trials":11985,"activeCount":109},[],{"trials":11987,"activeCount":109},[],{"trials":11989,"activeCount":109},[],{"trials":11991,"activeCount":109},[],{"trials":11993,"activeCount":708,"soonestReadout":725},[11994],{"nctId":11995,"briefTitle":11996,"status":121,"phases":11997,"primaryCompletion":725,"completion":726,"start":3708,"enrollment":168,"conditions":11998,"interventions":12002},"NCT06519760","68Ga-C1 PET\u002F CT Imaging in Clear Cell Renal Cell Carcinoma",[102],[11999,12000,12001],"Carbonic Anhydrase IX","PET-CT","Clear Cell Renal Cell Carcinoma",[11980],{"intervention":12004,"totalTrials":708,"cells":12005},"Ruxolitinib 1.5% Cream BID",{"EARLY_PHASE1":12006,"PHASE1":12008,"PHASE2":12010,"PHASE3":12012,"PHASE4":12014,"NA":12016},{"trials":12007,"activeCount":109},[],{"trials":12009,"activeCount":109},[],{"trials":12011,"activeCount":109},[],{"trials":12013,"activeCount":109},[],{"trials":12015,"activeCount":109},[],{"trials":12017,"activeCount":708,"soonestReadout":2049},[12018],{"nctId":12019,"briefTitle":12020,"status":121,"phases":12021,"primaryCompletion":2049,"completion":1019,"start":12022,"enrollment":280,"conditions":12023,"interventions":12025},"NCT07153666","A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo",[],"2025-12-08",[12024],"Vitiligo",[12004],{"intervention":12027,"totalTrials":708,"cells":12028},"Chinese medicine and Lactobacillus",{"EARLY_PHASE1":12029,"PHASE1":12031,"PHASE2":12033,"PHASE3":12035,"PHASE4":12037,"NA":12039},{"trials":12030,"activeCount":109},[],{"trials":12032,"activeCount":109},[],{"trials":12034,"activeCount":109},[],{"trials":12036,"activeCount":109},[],{"trials":12038,"activeCount":109},[],{"trials":12040,"activeCount":708,"soonestReadout":1103},[12041],{"nctId":12042,"briefTitle":12043,"status":121,"phases":12044,"primaryCompletion":1103,"completion":1103,"start":571,"enrollment":1165,"conditions":12045,"interventions":12047},"NCT06467942","Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection",[102],[12046],"Human Papilloma Virus Infection",[12027,12048,12049],"Chinese medicine","Lactobacillus",{"intervention":12048,"totalTrials":708,"cells":12051},{"EARLY_PHASE1":12052,"PHASE1":12054,"PHASE2":12056,"PHASE3":12058,"PHASE4":12060,"NA":12062},{"trials":12053,"activeCount":109},[],{"trials":12055,"activeCount":109},[],{"trials":12057,"activeCount":109},[],{"trials":12059,"activeCount":109},[],{"trials":12061,"activeCount":109},[],{"trials":12063,"activeCount":708,"soonestReadout":1103},[12064],{"nctId":12042,"briefTitle":12043,"status":121,"phases":12065,"primaryCompletion":1103,"completion":1103,"start":571,"enrollment":1165,"conditions":12066,"interventions":12067},[102],[12046],[12027,12048,12049],{"intervention":12049,"totalTrials":708,"cells":12069},{"EARLY_PHASE1":12070,"PHASE1":12072,"PHASE2":12074,"PHASE3":12076,"PHASE4":12078,"NA":12080},{"trials":12071,"activeCount":109},[],{"trials":12073,"activeCount":109},[],{"trials":12075,"activeCount":109},[],{"trials":12077,"activeCount":109},[],{"trials":12079,"activeCount":109},[],{"trials":12081,"activeCount":708,"soonestReadout":1103},[12082],{"nctId":12042,"briefTitle":12043,"status":121,"phases":12083,"primaryCompletion":1103,"completion":1103,"start":571,"enrollment":1165,"conditions":12084,"interventions":12085},[102],[12046],[12027,12048,12049],{"intervention":12087,"totalTrials":708,"cells":12088},"Iruplinalkib",{"EARLY_PHASE1":12089,"PHASE1":12091,"PHASE2":12093,"PHASE3":12095,"PHASE4":12097,"NA":12099},{"trials":12090,"activeCount":109},[],{"trials":12092,"activeCount":109},[],{"trials":12094,"activeCount":109},[],{"trials":12096,"activeCount":109},[],{"trials":12098,"activeCount":109},[],{"trials":12100,"activeCount":708,"soonestReadout":1002},[12101],{"nctId":12102,"briefTitle":12103,"status":121,"phases":12104,"primaryCompletion":1002,"completion":1002,"start":4501,"enrollment":47,"conditions":12105,"interventions":12109},"NCT07374614","Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib",[],[2680,12106,12087,11458,12107,12108],"ALK","Real-world Study","Observational Study",[12087],{"intervention":12111,"totalTrials":708,"cells":12112},"Suspective gene mutations and family history",{"EARLY_PHASE1":12113,"PHASE1":12115,"PHASE2":12117,"PHASE3":12119,"PHASE4":12121,"NA":12123},{"trials":12114,"activeCount":109},[],{"trials":12116,"activeCount":109},[],{"trials":12118,"activeCount":109},[],{"trials":12120,"activeCount":109},[],{"trials":12122,"activeCount":109},[],{"trials":12124,"activeCount":708,"soonestReadout":726},[12125],{"nctId":12126,"briefTitle":12127,"status":121,"phases":12128,"primaryCompletion":726,"completion":726,"start":4308,"enrollment":5215,"conditions":12129,"interventions":12131},"NCT06564428","A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration",[],[12130],"Ovarian Neoplasms",[12111],{"intervention":2974,"totalTrials":708,"cells":12133},{"EARLY_PHASE1":12134,"PHASE1":12136,"PHASE2":12138,"PHASE3":12140,"PHASE4":12142,"NA":12144},{"trials":12135,"activeCount":109},[],{"trials":12137,"activeCount":109},[],{"trials":12139,"activeCount":109},[],{"trials":12141,"activeCount":109},[],{"trials":12143,"activeCount":109},[],{"trials":12145,"activeCount":708,"soonestReadout":1963},[12146],{"nctId":2966,"briefTitle":2967,"status":121,"phases":12147,"primaryCompletion":1963,"completion":2969,"start":2970,"enrollment":1767,"conditions":12148,"interventions":12149},[],[2972],[2974,2941,2960,2975],{"intervention":2975,"totalTrials":708,"cells":12151},{"EARLY_PHASE1":12152,"PHASE1":12154,"PHASE2":12156,"PHASE3":12158,"PHASE4":12160,"NA":12162},{"trials":12153,"activeCount":109},[],{"trials":12155,"activeCount":109},[],{"trials":12157,"activeCount":109},[],{"trials":12159,"activeCount":109},[],{"trials":12161,"activeCount":109},[],{"trials":12163,"activeCount":708,"soonestReadout":1963},[12164],{"nctId":2966,"briefTitle":2967,"status":121,"phases":12165,"primaryCompletion":1963,"completion":2969,"start":2970,"enrollment":1767,"conditions":12166,"interventions":12167},[],[2972],[2974,2941,2960,2975],{"intervention":12169,"totalTrials":708,"cells":12170},"Ciprofol",{"EARLY_PHASE1":12171,"PHASE1":12173,"PHASE2":12175,"PHASE3":12177,"PHASE4":12179,"NA":12181},{"trials":12172,"activeCount":109},[],{"trials":12174,"activeCount":109},[],{"trials":12176,"activeCount":109},[],{"trials":12178,"activeCount":109},[],{"trials":12180,"activeCount":109},[],{"trials":12182,"activeCount":708,"soonestReadout":725},[12183],{"nctId":12184,"briefTitle":12185,"status":121,"phases":12186,"primaryCompletion":725,"completion":725,"start":5311,"enrollment":12187,"conditions":12188,"interventions":12190},"NCT07294989","The Effective Blood Concentration of Ciprofol",[],101,[12189],"Thyroid Disease",[12169],{"intervention":12192,"totalTrials":708,"cells":12193},"ddEC-ddT",{"EARLY_PHASE1":12194,"PHASE1":12196,"PHASE2":12198,"PHASE3":12200,"PHASE4":12202,"NA":12204},{"trials":12195,"activeCount":109},[],{"trials":12197,"activeCount":109},[],{"trials":12199,"activeCount":109},[],{"trials":12201,"activeCount":109},[],{"trials":12203,"activeCount":109},[],{"trials":12205,"activeCount":708,"soonestReadout":1385},[12206],{"nctId":12207,"briefTitle":12208,"status":121,"phases":12209,"primaryCompletion":1385,"completion":681,"start":1416,"enrollment":1940,"conditions":12210,"interventions":12211},"NCT05341141","Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy",[102],[31],[12192],{"intervention":12213,"totalTrials":708,"cells":12214},"Autologous NK cells",{"EARLY_PHASE1":12215,"PHASE1":12217,"PHASE2":12219,"PHASE3":12221,"PHASE4":12223,"NA":12225},{"trials":12216,"activeCount":109},[],{"trials":12218,"activeCount":109},[],{"trials":12220,"activeCount":109},[],{"trials":12222,"activeCount":109},[],{"trials":12224,"activeCount":109},[],{"trials":12226,"activeCount":708,"soonestReadout":7588},[12227],{"nctId":12228,"briefTitle":12229,"status":121,"phases":12230,"primaryCompletion":7588,"completion":6691,"start":805,"enrollment":3520,"conditions":12231,"interventions":12237},"NCT07552233","NK Cell Therapy for Malignant Solid Brain Tumors",[102],[12232,12233,12234,12235,12236],"Malignant Solid Brain Tumors","Glioblastoma (GBM)","Glioblastoma Multiforme (GBM)","Brain Metastasis","Malignant Meningioma",[12213],{"intervention":10080,"totalTrials":708,"cells":12239},{"EARLY_PHASE1":12240,"PHASE1":12242,"PHASE2":12244,"PHASE3":12246,"PHASE4":12248,"NA":12250},{"trials":12241,"activeCount":109},[],{"trials":12243,"activeCount":109},[],{"trials":12245,"activeCount":109},[],{"trials":12247,"activeCount":109},[],{"trials":12249,"activeCount":109},[],{"trials":12251,"activeCount":708,"soonestReadout":10076},[12252],{"nctId":10073,"briefTitle":10074,"status":468,"phases":12253,"primaryCompletion":10076,"completion":7293,"start":5311,"enrollment":153,"conditions":12254,"interventions":12255},[],[2680,10078,4993,3924],[10080,4993],{"intervention":12257,"totalTrials":708,"cells":12258},"RNA-seq",{"EARLY_PHASE1":12259,"PHASE1":12261,"PHASE2":12263,"PHASE3":12265,"PHASE4":12267,"NA":12269},{"trials":12260,"activeCount":109},[],{"trials":12262,"activeCount":109},[],{"trials":12264,"activeCount":109},[],{"trials":12266,"activeCount":109},[],{"trials":12268,"activeCount":109},[],{"trials":12270,"activeCount":708,"soonestReadout":4099},[12271],{"nctId":12272,"briefTitle":12273,"status":468,"phases":12274,"primaryCompletion":4099,"completion":12275,"start":773,"enrollment":168,"conditions":12276,"interventions":12279},"NCT06751251","The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination",[],"2026-10-01",[12277,12278,2546],"Sarcoma","Biomarkers",[12257],{"intervention":12281,"totalTrials":708,"cells":12282},"Sacituzumab Govitecan Monotherapy or Combination Therapy",{"EARLY_PHASE1":12283,"PHASE1":12285,"PHASE2":12287,"PHASE3":12289,"PHASE4":12291,"NA":12293},{"trials":12284,"activeCount":109},[],{"trials":12286,"activeCount":109},[],{"trials":12288,"activeCount":109},[],{"trials":12290,"activeCount":109},[],{"trials":12292,"activeCount":109},[],{"trials":12294,"activeCount":708,"soonestReadout":228},[12295],{"nctId":12296,"briefTitle":12297,"status":468,"phases":12298,"primaryCompletion":228,"completion":2203,"start":9279,"enrollment":670,"conditions":12299,"interventions":12303},"NCT07018427","Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer",[],[12300,12301,12302,31],"Breast Neoplasms","Triple Negative Breast Cancer","HR+, HER2-, Advanced Breast Cancer",[12281],{"intervention":5067,"totalTrials":708,"cells":12305},{"EARLY_PHASE1":12306,"PHASE1":12308,"PHASE2":12310,"PHASE3":12312,"PHASE4":12314,"NA":12316},{"trials":12307,"activeCount":109},[],{"trials":12309,"activeCount":109},[],{"trials":12311,"activeCount":109},[],{"trials":12313,"activeCount":109},[],{"trials":12315,"activeCount":109},[],{"trials":12317,"activeCount":708,"soonestReadout":772},[12318],{"nctId":5059,"briefTitle":5060,"status":456,"phases":12319,"primaryCompletion":772,"completion":5062,"start":5063,"enrollment":168,"conditions":12320,"interventions":12321},[],[3757],[5066,3924,3746,5067],{"intervention":12323,"totalTrials":708,"cells":12324},"Irinotecan Liposome",{"EARLY_PHASE1":12325,"PHASE1":12327,"PHASE2":12329,"PHASE3":12331,"PHASE4":12333,"NA":12335},{"trials":12326,"activeCount":109},[],{"trials":12328,"activeCount":109},[],{"trials":12330,"activeCount":109},[],{"trials":12332,"activeCount":109},[],{"trials":12334,"activeCount":109},[],{"trials":12336,"activeCount":708,"soonestReadout":8867},[12337],{"nctId":12338,"briefTitle":12339,"status":121,"phases":12340,"primaryCompletion":8867,"completion":4040,"start":9271,"enrollment":12341,"conditions":12342,"interventions":12343},"NCT06443307","Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan",[],933,[2692,8957],[12323],{"intervention":12345,"totalTrials":708,"cells":12346},"Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.",{"EARLY_PHASE1":12347,"PHASE1":12349,"PHASE2":12351,"PHASE3":12353,"PHASE4":12355,"NA":12357},{"trials":12348,"activeCount":109},[],{"trials":12350,"activeCount":109},[],{"trials":12352,"activeCount":109},[],{"trials":12354,"activeCount":109},[],{"trials":12356,"activeCount":109},[],{"trials":12358,"activeCount":708,"soonestReadout":12363},[12359],{"nctId":12360,"briefTitle":12361,"status":468,"phases":12362,"primaryCompletion":12363,"completion":12364,"start":12365,"enrollment":11177,"conditions":12366,"interventions":12368},"NCT03401619","Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study",[],"2026-09-22","2027-09-22","2017-09-21",[12367],"Osteoporosis，Neurological Disorders",[12345],{"intervention":12370,"totalTrials":708,"cells":12371},"18F-G1",{"EARLY_PHASE1":12372,"PHASE1":12374,"PHASE2":12376,"PHASE3":12378,"PHASE4":12380,"NA":12382},{"trials":12373,"activeCount":109},[],{"trials":12375,"activeCount":109},[],{"trials":12377,"activeCount":109},[],{"trials":12379,"activeCount":109},[],{"trials":12381,"activeCount":109},[],{"trials":12383,"activeCount":708,"soonestReadout":726},[12384],{"nctId":12385,"briefTitle":12386,"status":456,"phases":12387,"primaryCompletion":726,"completion":9981,"start":5553,"enrollment":574,"conditions":12388,"interventions":12390},"NCT07039474","The Application of 18F-G1 PET\u002FCT Targeting Granzyme B in the Pan-cancer Immunotherapy",[],[12389],"Solid Tumors and Hematological Tumors",[12370],{"intervention":12392,"totalTrials":708,"cells":12393},"[68Ga]N188",{"EARLY_PHASE1":12394,"PHASE1":12396,"PHASE2":12398,"PHASE3":12400,"PHASE4":12402,"NA":12404},{"trials":12395,"activeCount":109},[],{"trials":12397,"activeCount":109},[],{"trials":12399,"activeCount":109},[],{"trials":12401,"activeCount":109},[],{"trials":12403,"activeCount":109},[],{"trials":12405,"activeCount":708,"soonestReadout":6043},[12406],{"nctId":12407,"briefTitle":12408,"status":121,"phases":12409,"primaryCompletion":6043,"completion":6043,"start":12410,"enrollment":12411,"conditions":12412,"interventions":12413},"NCT05593107","68Ga-N188 PET\u002FCT Imaging in Malignancy",[102],"2022-08-12",203,[1365],[12392],{"intervention":12415,"totalTrials":708,"cells":12416},"Standard Therapy",{"EARLY_PHASE1":12417,"PHASE1":12419,"PHASE2":12421,"PHASE3":12423,"PHASE4":12425,"NA":12427},{"trials":12418,"activeCount":109},[],{"trials":12420,"activeCount":109},[],{"trials":12422,"activeCount":109},[],{"trials":12424,"activeCount":109},[],{"trials":12426,"activeCount":109},[],{"trials":12428,"activeCount":708,"soonestReadout":12433},[12429],{"nctId":12430,"briefTitle":12431,"status":121,"phases":12432,"primaryCompletion":12433,"completion":1020,"start":12434,"enrollment":3615,"conditions":12435,"interventions":12437},"NCT06924710","Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD",[102],"2029-06-15","2025-04-06",[12436],"NSCLC",[12415],{"intervention":12439,"totalTrials":708,"cells":12440},"RB001",{"EARLY_PHASE1":12441,"PHASE1":12443,"PHASE2":12445,"PHASE3":12447,"PHASE4":12449,"NA":12451},{"trials":12442,"activeCount":109},[],{"trials":12444,"activeCount":109},[],{"trials":12446,"activeCount":109},[],{"trials":12448,"activeCount":109},[],{"trials":12450,"activeCount":109},[],{"trials":12452,"activeCount":708,"soonestReadout":12457},[12453],{"nctId":12454,"briefTitle":12455,"status":121,"phases":12456,"primaryCompletion":12457,"completion":1019,"start":12458,"enrollment":3642,"conditions":12459,"interventions":12462},"NCT07014020","RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)",[102],"2027-05-01","2025-06-16",[12460,12461],"Phelan-McDermid Syndrome","SHANK3 Haploinsufficiency",[12439],{"intervention":86,"totalTrials":708,"cells":12464},{"EARLY_PHASE1":12465,"PHASE1":12467,"PHASE2":12469,"PHASE3":12471,"PHASE4":12473,"NA":12475},{"trials":12466,"activeCount":109},[],{"trials":12468,"activeCount":109},[],{"trials":12470,"activeCount":109},[],{"trials":12472,"activeCount":109},[],{"trials":12474,"activeCount":109},[],{"trials":12476,"activeCount":708,"soonestReadout":81},[12477],{"nctId":84,"briefTitle":85,"status":121,"phases":12478,"primaryCompletion":81,"completion":1019,"start":12479,"enrollment":5941,"conditions":12480,"interventions":12486},[102],"2016-08-01",[12481,12482,12483,12484,12485],"Endometrial Neoplasms","Endometrial Neoplasm Malignant","Endometrial Neoplasm Malignant Stage I","Carcinoma, Endometrioid","Fertility Preservation",[86],{"intervention":12488,"totalTrials":708,"cells":12489},"Targeted and immunotherapy",{"EARLY_PHASE1":12490,"PHASE1":12492,"PHASE2":12494,"PHASE3":12496,"PHASE4":12498,"NA":12500},{"trials":12491,"activeCount":109},[],{"trials":12493,"activeCount":109},[],{"trials":12495,"activeCount":109},[],{"trials":12497,"activeCount":109},[],{"trials":12499,"activeCount":109},[],{"trials":12501,"activeCount":708,"soonestReadout":5636},[12502],{"nctId":12503,"briefTitle":12504,"status":121,"phases":12505,"primaryCompletion":5636,"completion":5636,"start":424,"enrollment":4171,"conditions":12506,"interventions":12509},"NCT06583070","SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer",[],[3922,12507,12508],"Metastatic Renal Cancer","Recurrent Renal Cell Cancer",[12488],{"intervention":9310,"totalTrials":708,"cells":12511},{"EARLY_PHASE1":12512,"PHASE1":12514,"PHASE2":12516,"PHASE3":12518,"PHASE4":12520,"NA":12522},{"trials":12513,"activeCount":109},[],{"trials":12515,"activeCount":109},[],{"trials":12517,"activeCount":109},[],{"trials":12519,"activeCount":109},[],{"trials":12521,"activeCount":109},[],{"trials":12523,"activeCount":708,"soonestReadout":438},[12524],{"nctId":9305,"briefTitle":9306,"status":121,"phases":12525,"primaryCompletion":438,"completion":438,"start":8447,"enrollment":140,"conditions":12526,"interventions":12527},[102],[31],[9237,9310],{"intervention":12529,"totalTrials":708,"cells":12530},"Darolutamide in addition to androgen deprivation therapy",{"EARLY_PHASE1":12531,"PHASE1":12533,"PHASE2":12535,"PHASE3":12537,"PHASE4":12539,"NA":12541},{"trials":12532,"activeCount":109},[],{"trials":12534,"activeCount":109},[],{"trials":12536,"activeCount":109},[],{"trials":12538,"activeCount":109},[],{"trials":12540,"activeCount":109},[],{"trials":12542,"activeCount":708,"soonestReadout":8867},[12543],{"nctId":12544,"briefTitle":12545,"status":456,"phases":12546,"primaryCompletion":8867,"completion":1020,"start":1589,"enrollment":12547,"conditions":12548,"interventions":12549},"NCT06435702","Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study",[],108,[37],[12529,12550],"androgen deprivation therapy only",{"intervention":12550,"totalTrials":708,"cells":12552},{"EARLY_PHASE1":12553,"PHASE1":12555,"PHASE2":12557,"PHASE3":12559,"PHASE4":12561,"NA":12563},{"trials":12554,"activeCount":109},[],{"trials":12556,"activeCount":109},[],{"trials":12558,"activeCount":109},[],{"trials":12560,"activeCount":109},[],{"trials":12562,"activeCount":109},[],{"trials":12564,"activeCount":708,"soonestReadout":8867},[12565],{"nctId":12544,"briefTitle":12545,"status":456,"phases":12566,"primaryCompletion":8867,"completion":1020,"start":1589,"enrollment":12547,"conditions":12567,"interventions":12568},[],[37],[12529,12550],{"intervention":12570,"totalTrials":708,"cells":12571},"18F-LF13",{"EARLY_PHASE1":12572,"PHASE1":12574,"PHASE2":12576,"PHASE3":12578,"PHASE4":12580,"NA":12582},{"trials":12573,"activeCount":109},[],{"trials":12575,"activeCount":109},[],{"trials":12577,"activeCount":109},[],{"trials":12579,"activeCount":109},[],{"trials":12581,"activeCount":109},[],{"trials":12583,"activeCount":708,"soonestReadout":741},[12584],{"nctId":12585,"briefTitle":12586,"status":456,"phases":12587,"primaryCompletion":741,"completion":726,"start":4041,"enrollment":47,"conditions":12588,"interventions":12589},"NCT06641674","EGFR Mutation Targeting Molecular Probe for PET Imaging",[],[9847],[12570],{"intervention":12591,"totalTrials":708,"cells":12592},"Fucoidan",{"EARLY_PHASE1":12593,"PHASE1":12595,"PHASE2":12597,"PHASE3":12599,"PHASE4":12601,"NA":12603},{"trials":12594,"activeCount":109},[],{"trials":12596,"activeCount":109},[],{"trials":12598,"activeCount":109},[],{"trials":12600,"activeCount":109},[],{"trials":12602,"activeCount":109},[],{"trials":12604,"activeCount":708,"soonestReadout":438},[12605],{"nctId":12606,"briefTitle":12607,"status":121,"phases":12608,"primaryCompletion":438,"completion":6326,"start":12609,"enrollment":32,"conditions":12610,"interventions":12612},"NCT07045896","Fucoidan in the Treatment of Active Rheumatoid Arthritis",[102],"2026-01-10",[12611],"Arthritis, Rheumatoid",[12591],{"intervention":12614,"totalTrials":708,"cells":12615},"Sacituzumab Govitecan (SG)+Toripalimab",{"EARLY_PHASE1":12616,"PHASE1":12618,"PHASE2":12620,"PHASE3":12622,"PHASE4":12624,"NA":12626},{"trials":12617,"activeCount":109},[],{"trials":12619,"activeCount":109},[],{"trials":12621,"activeCount":109},[],{"trials":12623,"activeCount":109},[],{"trials":12625,"activeCount":109},[],{"trials":12627,"activeCount":708,"soonestReadout":12457},[12628],{"nctId":12629,"briefTitle":12630,"status":121,"phases":12631,"primaryCompletion":12457,"completion":12632,"start":228,"enrollment":4469,"conditions":12633,"interventions":12635},"NCT06991790","Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration",[],"2028-05-01",[12634],"TNBC",[12614],{"intervention":12637,"totalTrials":708,"cells":12638},"Fuzheng Yangxin prescription",{"EARLY_PHASE1":12639,"PHASE1":12641,"PHASE2":12643,"PHASE3":12645,"PHASE4":12647,"NA":12649},{"trials":12640,"activeCount":109},[],{"trials":12642,"activeCount":109},[],{"trials":12644,"activeCount":109},[],{"trials":12646,"activeCount":109},[],{"trials":12648,"activeCount":109},[],{"trials":12650,"activeCount":708,"soonestReadout":638},[12651],{"nctId":12652,"briefTitle":12653,"status":121,"phases":12654,"primaryCompletion":638,"completion":725,"start":8734,"enrollment":4171,"conditions":12655,"interventions":12657},"NCT06961136","Prospective Cohort Study on Fuzheng Yangxin Prescription For Rapid Rehabilitation of Patients With Qi-Yin Deficiency Syndrome After Coronary Artery Bypass Grafting",[],[12656],"Coronary Artery Bypass",[12637],{"intervention":12659,"totalTrials":708,"cells":12660},"Sintilimab or Pembrolizumab and medroxyprogesterone acetate",{"EARLY_PHASE1":12661,"PHASE1":12663,"PHASE2":12665,"PHASE3":12667,"PHASE4":12669,"NA":12671},{"trials":12662,"activeCount":109},[],{"trials":12664,"activeCount":109},[],{"trials":12666,"activeCount":109},[],{"trials":12668,"activeCount":109},[],{"trials":12670,"activeCount":109},[],{"trials":12672,"activeCount":708,"soonestReadout":12677},[12673],{"nctId":12674,"briefTitle":12675,"status":456,"phases":12676,"primaryCompletion":12677,"completion":12678,"start":3870,"enrollment":477,"conditions":12679,"interventions":12682},"NCT06549855","PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer",[102],"2029-07","2029-10",[1551,12680,12681],"Endometrioid Carcinoma","Mismatch Repair Deficiency",[12659],{"intervention":12684,"totalTrials":708,"cells":12685},"Ivarmacitinib Sulfate",{"EARLY_PHASE1":12686,"PHASE1":12688,"PHASE2":12690,"PHASE3":12692,"PHASE4":12694,"NA":12696},{"trials":12687,"activeCount":109},[],{"trials":12689,"activeCount":109},[],{"trials":12691,"activeCount":109},[],{"trials":12693,"activeCount":109},[],{"trials":12695,"activeCount":109},[],{"trials":12697,"activeCount":708,"soonestReadout":2049},[12698],{"nctId":12699,"briefTitle":12700,"status":456,"phases":12701,"primaryCompletion":2049,"completion":12702,"start":1054,"enrollment":4171,"conditions":12703,"interventions":12705},"NCT07550452","Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study",[102],"2027-07-31",[12704],"Atopic Dermatitis (AD)",[12684],{"intervention":4164,"totalTrials":708,"cells":12707},{"EARLY_PHASE1":12708,"PHASE1":12710,"PHASE2":12712,"PHASE3":12714,"PHASE4":12716,"NA":12718},{"trials":12709,"activeCount":109},[],{"trials":12711,"activeCount":109},[],{"trials":12713,"activeCount":109},[],{"trials":12715,"activeCount":109},[],{"trials":12717,"activeCount":109},[],{"trials":12719,"activeCount":708,"soonestReadout":3656},[12720],{"nctId":4158,"briefTitle":4159,"status":121,"phases":12721,"primaryCompletion":3656,"completion":1082,"start":1054,"enrollment":32,"conditions":12722,"interventions":12723},[102],[4162],[3767,4164,4165],{"intervention":4165,"totalTrials":708,"cells":12725},{"EARLY_PHASE1":12726,"PHASE1":12728,"PHASE2":12730,"PHASE3":12732,"PHASE4":12734,"NA":12736},{"trials":12727,"activeCount":109},[],{"trials":12729,"activeCount":109},[],{"trials":12731,"activeCount":109},[],{"trials":12733,"activeCount":109},[],{"trials":12735,"activeCount":109},[],{"trials":12737,"activeCount":708,"soonestReadout":3656},[12738],{"nctId":4158,"briefTitle":4159,"status":121,"phases":12739,"primaryCompletion":3656,"completion":1082,"start":1054,"enrollment":32,"conditions":12740,"interventions":12741},[102],[4162],[3767,4164,4165],{"intervention":12743,"totalTrials":708,"cells":12744},"AI-assisted, village doctors and express services-involved personalized fall prevention strategy",{"EARLY_PHASE1":12745,"PHASE1":12747,"PHASE2":12749,"PHASE3":12751,"PHASE4":12753,"NA":12755},{"trials":12746,"activeCount":109},[],{"trials":12748,"activeCount":109},[],{"trials":12750,"activeCount":109},[],{"trials":12752,"activeCount":109},[],{"trials":12754,"activeCount":109},[],{"trials":12756,"activeCount":708,"soonestReadout":9043},[12757],{"nctId":12758,"briefTitle":12759,"status":468,"phases":12760,"primaryCompletion":9043,"completion":9067,"start":12761,"enrollment":12762,"conditions":12763,"interventions":12767},"NCT06984978","EXpress Prevent Rural oldEr Adults' fallS, fractureS and Dependency (EXPRESS)",[102],"2024-08-06",1881,[12764,12765,12766],"Falls","Falls Injury","Fall Prevention",[12743],{"intervention":12769,"totalTrials":708,"cells":12770},"No Interventions",{"EARLY_PHASE1":12771,"PHASE1":12773,"PHASE2":12775,"PHASE3":12777,"PHASE4":12779,"NA":12781},{"trials":12772,"activeCount":109},[],{"trials":12774,"activeCount":109},[],{"trials":12776,"activeCount":109},[],{"trials":12778,"activeCount":109},[],{"trials":12780,"activeCount":109},[],{"trials":12782,"activeCount":708,"soonestReadout":741},[12783],{"nctId":12784,"briefTitle":12785,"status":1935,"phases":12786,"primaryCompletion":741,"completion":8867,"start":9845,"enrollment":1894,"conditions":12787,"interventions":12789},"NCT06645223","Correlation Between Gut Microbiota and Pancreatic Β-Cell Function in Diabetic Patients",[],[11895,12788],"Gut Microbiota",[12769],{"intervention":10467,"totalTrials":708,"cells":12791},{"EARLY_PHASE1":12792,"PHASE1":12794,"PHASE2":12796,"PHASE3":12798,"PHASE4":12800,"NA":12802},{"trials":12793,"activeCount":109},[],{"trials":12795,"activeCount":109},[],{"trials":12797,"activeCount":109},[],{"trials":12799,"activeCount":109},[],{"trials":12801,"activeCount":109},[],{"trials":12803,"activeCount":708,"soonestReadout":4415},[12804],{"nctId":10460,"briefTitle":10461,"status":121,"phases":12805,"primaryCompletion":4415,"completion":4416,"start":10463,"enrollment":4171,"conditions":12806,"interventions":12807},[102],[10465],[10427,10467,10468],{"intervention":10468,"totalTrials":708,"cells":12809},{"EARLY_PHASE1":12810,"PHASE1":12812,"PHASE2":12814,"PHASE3":12816,"PHASE4":12818,"NA":12820},{"trials":12811,"activeCount":109},[],{"trials":12813,"activeCount":109},[],{"trials":12815,"activeCount":109},[],{"trials":12817,"activeCount":109},[],{"trials":12819,"activeCount":109},[],{"trials":12821,"activeCount":708,"soonestReadout":4415},[12822],{"nctId":10460,"briefTitle":10461,"status":121,"phases":12823,"primaryCompletion":4415,"completion":4416,"start":10463,"enrollment":4171,"conditions":12824,"interventions":12825},[102],[10465],[10427,10467,10468],{"intervention":732,"totalTrials":708,"cells":12827},{"EARLY_PHASE1":12828,"PHASE1":12830,"PHASE2":12832,"PHASE3":12834,"PHASE4":12836,"NA":12838},{"trials":12829,"activeCount":109},[],{"trials":12831,"activeCount":109},[],{"trials":12833,"activeCount":109},[],{"trials":12835,"activeCount":109},[],{"trials":12837,"activeCount":109},[],{"trials":12839,"activeCount":708,"soonestReadout":725},[12840],{"nctId":722,"briefTitle":723,"status":121,"phases":12841,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":12842,"interventions":12843},[],[730],[732,733,557,734,735],{"intervention":735,"totalTrials":708,"cells":12845},{"EARLY_PHASE1":12846,"PHASE1":12848,"PHASE2":12850,"PHASE3":12852,"PHASE4":12854,"NA":12856},{"trials":12847,"activeCount":109},[],{"trials":12849,"activeCount":109},[],{"trials":12851,"activeCount":109},[],{"trials":12853,"activeCount":109},[],{"trials":12855,"activeCount":109},[],{"trials":12857,"activeCount":708,"soonestReadout":725},[12858],{"nctId":722,"briefTitle":723,"status":121,"phases":12859,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":12860,"interventions":12861},[],[730],[732,733,557,734,735],{"intervention":12863,"totalTrials":708,"cells":12864},"Deucravacitinib 6mg po qd",{"EARLY_PHASE1":12865,"PHASE1":12867,"PHASE2":12869,"PHASE3":12871,"PHASE4":12873,"NA":12875},{"trials":12866,"activeCount":109},[],{"trials":12868,"activeCount":109},[],{"trials":12870,"activeCount":109},[],{"trials":12872,"activeCount":109},[],{"trials":12874,"activeCount":109},[],{"trials":12876,"activeCount":708,"soonestReadout":8867},[12877],{"nctId":12878,"briefTitle":12879,"status":121,"phases":12880,"primaryCompletion":8867,"completion":12275,"start":12881,"enrollment":477,"conditions":12882,"interventions":12884},"NCT07564271","Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies",[],"2025-10-05",[12883],"Idiopathic Inflammatory Myopathies (IIMs)",[12863],{"intervention":12886,"totalTrials":708,"cells":12887},"Medication",{"EARLY_PHASE1":12888,"PHASE1":12890,"PHASE2":12892,"PHASE3":12894,"PHASE4":12896,"NA":12898},{"trials":12889,"activeCount":109},[],{"trials":12891,"activeCount":109},[],{"trials":12893,"activeCount":109},[],{"trials":12895,"activeCount":109},[],{"trials":12897,"activeCount":109},[],{"trials":12899,"activeCount":708,"soonestReadout":1002},[12900],{"nctId":12901,"briefTitle":12902,"status":456,"phases":12903,"primaryCompletion":1002,"completion":1002,"start":3495,"enrollment":12904,"conditions":12905,"interventions":12917},"NCT06967363","Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)",[],360,[12906,12907,12908,12909,12910,12911,12912,12913,12914,12915,12916],"Chronic Low Back Pain (CLBP)","Acute Low Back Pain","Low Back Pain","Chronic Pain","Acute Pain","Mental Disorders","Sleep Disorder","Fibromyalgia (FM)","Nociplastic Pain","Neuropathic Pain","Nonspecific Low Back Pain",[12886],{"intervention":12919,"totalTrials":708,"cells":12920},"68Ga-HSA",{"EARLY_PHASE1":12921,"PHASE1":12923,"PHASE2":12925,"PHASE3":12927,"PHASE4":12929,"NA":12931},{"trials":12922,"activeCount":109},[],{"trials":12924,"activeCount":109},[],{"trials":12926,"activeCount":109},[],{"trials":12928,"activeCount":109},[],{"trials":12930,"activeCount":109},[],{"trials":12932,"activeCount":708,"soonestReadout":741},[12933],{"nctId":12934,"briefTitle":12935,"status":456,"phases":12936,"primaryCompletion":741,"completion":1746,"start":228,"enrollment":728,"conditions":12937,"interventions":12938},"NCT06716788","68Ga-HSA PET\u002FCT Imaging for Protein-losing Enteropathy",[],[9847],[12919],{"intervention":12940,"totalTrials":708,"cells":12941},"Modified olfactory training device",{"EARLY_PHASE1":12942,"PHASE1":12944,"PHASE2":12946,"PHASE3":12948,"PHASE4":12950,"NA":12952},{"trials":12943,"activeCount":109},[],{"trials":12945,"activeCount":109},[],{"trials":12947,"activeCount":109},[],{"trials":12949,"activeCount":109},[],{"trials":12951,"activeCount":109},[],{"trials":12953,"activeCount":708,"soonestReadout":12958},[12954],{"nctId":12955,"briefTitle":12956,"status":456,"phases":12957,"primaryCompletion":12958,"completion":12959,"start":12960,"enrollment":1115,"conditions":12961,"interventions":12965},"NCT06821828","The Efficacy of Modified Olfactory Training for MCI High-Risk Individuals",[102],"2027-03-22","2027-05-22","2025-03-22",[12962,11611,12963,12964],"Subjective Cognitive Decline (SCD)","Mild Cognitive Impairment (MCI)","ELDERLY PEOPLE",[12940,12966],"Conventional olfactory training device",{"intervention":12966,"totalTrials":708,"cells":12968},{"EARLY_PHASE1":12969,"PHASE1":12971,"PHASE2":12973,"PHASE3":12975,"PHASE4":12977,"NA":12979},{"trials":12970,"activeCount":109},[],{"trials":12972,"activeCount":109},[],{"trials":12974,"activeCount":109},[],{"trials":12976,"activeCount":109},[],{"trials":12978,"activeCount":109},[],{"trials":12980,"activeCount":708,"soonestReadout":12958},[12981],{"nctId":12955,"briefTitle":12956,"status":456,"phases":12982,"primaryCompletion":12958,"completion":12959,"start":12960,"enrollment":1115,"conditions":12983,"interventions":12984},[102],[12962,11611,12963,12964],[12940,12966],{"intervention":12986,"totalTrials":708,"cells":12987},"Teclistamab",{"EARLY_PHASE1":12988,"PHASE1":12990,"PHASE2":12992,"PHASE3":12994,"PHASE4":12996,"NA":12998},{"trials":12989,"activeCount":109},[],{"trials":12991,"activeCount":109},[],{"trials":12993,"activeCount":109},[],{"trials":12995,"activeCount":109},[],{"trials":12997,"activeCount":109},[],{"trials":12999,"activeCount":708,"soonestReadout":741},[13000],{"nctId":13001,"briefTitle":13002,"status":121,"phases":13003,"primaryCompletion":741,"completion":726,"start":13004,"enrollment":47,"conditions":13005,"interventions":13007},"NCT06699394","Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis",[102],"2025-03-29",[13006],"AL Amyloidosis",[12986],{"intervention":13009,"totalTrials":708,"cells":13010},"systematic therapy",{"EARLY_PHASE1":13011,"PHASE1":13013,"PHASE2":13015,"PHASE3":13017,"PHASE4":13019,"NA":13021},{"trials":13012,"activeCount":109},[],{"trials":13014,"activeCount":109},[],{"trials":13016,"activeCount":109},[],{"trials":13018,"activeCount":109},[],{"trials":13020,"activeCount":109},[],{"trials":13022,"activeCount":708,"soonestReadout":6043},[13023],{"nctId":13024,"briefTitle":13025,"status":456,"phases":13026,"primaryCompletion":6043,"completion":2730,"start":5201,"enrollment":168,"conditions":13027,"interventions":13028},"NCT06522542","Gastric Cancer Complicated With Bleeding",[],[28],[13009],{"intervention":13030,"totalTrials":708,"cells":13031},"Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg\u002Fd or MA 320mg\u002Fd.",{"EARLY_PHASE1":13032,"PHASE1":13034,"PHASE2":13036,"PHASE3":13038,"PHASE4":13040,"NA":13042},{"trials":13033,"activeCount":109},[],{"trials":13035,"activeCount":109},[],{"trials":13037,"activeCount":109},[],{"trials":13039,"activeCount":109},[],{"trials":13041,"activeCount":109},[],{"trials":13043,"activeCount":708,"soonestReadout":9112},[13044],{"nctId":13045,"briefTitle":13046,"status":456,"phases":13047,"primaryCompletion":9112,"completion":413,"start":9153,"enrollment":558,"conditions":13048,"interventions":13049},"NCT06468215","Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer",[102],[12484,12485],[13030],{"intervention":13051,"totalTrials":708,"cells":13052},"Steroid nasal drops combined with olfactory training",{"EARLY_PHASE1":13053,"PHASE1":13055,"PHASE2":13057,"PHASE3":13059,"PHASE4":13061,"NA":13063},{"trials":13054,"activeCount":109},[],{"trials":13056,"activeCount":109},[],{"trials":13058,"activeCount":109},[],{"trials":13060,"activeCount":109},[],{"trials":13062,"activeCount":109},[],{"trials":13064,"activeCount":708,"soonestReadout":1002},[13065],{"nctId":13066,"briefTitle":13067,"status":456,"phases":13068,"primaryCompletion":1002,"completion":1002,"start":4316,"enrollment":376,"conditions":13069,"interventions":13071},"NCT07386860","The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD",[102],[13070],"Smell Dysfunction",[13051],{"intervention":13073,"totalTrials":708,"cells":13074},"Voltaren",{"EARLY_PHASE1":13075,"PHASE1":13077,"PHASE2":13079,"PHASE3":13081,"PHASE4":13083,"NA":13085},{"trials":13076,"activeCount":109},[],{"trials":13078,"activeCount":109},[],{"trials":13080,"activeCount":109},[],{"trials":13082,"activeCount":109},[],{"trials":13084,"activeCount":109},[],{"trials":13086,"activeCount":708,"soonestReadout":725},[13087],{"nctId":13088,"briefTitle":13089,"status":468,"phases":13090,"primaryCompletion":725,"completion":725,"start":1589,"enrollment":153,"conditions":13091,"interventions":13093},"NCT07613346","Integrated Traditional Chinese and Western Medicine for Patellar Dislocation Pain: A Concurrent Non-Randomized Controlled Trial",[102],[13092],"Postoperative Pain After Patellar Dislocation Surgery",[13073],{"intervention":13095,"totalTrials":708,"cells":13096},"HAIC+targeted therapy+PD-1 inhibitor",{"EARLY_PHASE1":13097,"PHASE1":13099,"PHASE2":13101,"PHASE3":13103,"PHASE4":13105,"NA":13107},{"trials":13098,"activeCount":109},[],{"trials":13100,"activeCount":109},[],{"trials":13102,"activeCount":109},[],{"trials":13104,"activeCount":109},[],{"trials":13106,"activeCount":109},[],{"trials":13108,"activeCount":708,"soonestReadout":13113},[13109],{"nctId":13110,"briefTitle":13111,"status":468,"phases":13112,"primaryCompletion":13113,"completion":13114,"start":13115,"enrollment":3453,"conditions":13116,"interventions":13121},"NCT06199232","Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment",[102],"2026-05-23","2027-05-23","2024-01-23",[13117,13118,13119,13120],"Liver Metastasis Colon Cancer","ctDNA Genotype","MSS","Failed From Standard Treatment",[13095],{"intervention":90,"totalTrials":708,"cells":13123},{"EARLY_PHASE1":13124,"PHASE1":13126,"PHASE2":13128,"PHASE3":13130,"PHASE4":13132,"NA":13134},{"trials":13125,"activeCount":109},[],{"trials":13127,"activeCount":109},[],{"trials":13129,"activeCount":109},[],{"trials":13131,"activeCount":109},[],{"trials":13133,"activeCount":109},[],{"trials":13135,"activeCount":708,"soonestReadout":81},[13136],{"nctId":88,"briefTitle":89,"status":121,"phases":13137,"primaryCompletion":81,"completion":681,"start":2834,"enrollment":13138,"conditions":13139,"interventions":13140},[102],95,[4705],[90],{"intervention":13142,"totalTrials":708,"cells":13143},"Tumor Neoantigen-Sensitized Autologous Dendritic Cell",{"EARLY_PHASE1":13144,"PHASE1":13146,"PHASE2":13148,"PHASE3":13150,"PHASE4":13152,"NA":13154},{"trials":13145,"activeCount":109},[],{"trials":13147,"activeCount":109},[],{"trials":13149,"activeCount":109},[],{"trials":13151,"activeCount":109},[],{"trials":13153,"activeCount":109},[],{"trials":13155,"activeCount":708,"soonestReadout":2006},[13156],{"nctId":13157,"briefTitle":13158,"status":456,"phases":13159,"primaryCompletion":2006,"completion":6537,"start":4316,"enrollment":3887,"conditions":13160,"interventions":13162},"NCT07455071","A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer",[102],[13161],"HRD-negative Epithelial Ovarian Cancer",[13142],{"intervention":13164,"totalTrials":708,"cells":13165},"Levofloxacin Plus Metronidazole Suppositories",{"EARLY_PHASE1":13166,"PHASE1":13168,"PHASE2":13170,"PHASE3":13172,"PHASE4":13174,"NA":13176},{"trials":13167,"activeCount":109},[],{"trials":13169,"activeCount":109},[],{"trials":13171,"activeCount":109},[],{"trials":13173,"activeCount":109},[],{"trials":13175,"activeCount":109},[],{"trials":13177,"activeCount":708,"soonestReadout":13182},[13178],{"nctId":13179,"briefTitle":13180,"status":456,"phases":13181,"primaryCompletion":13182,"completion":968,"start":680,"enrollment":13183,"conditions":13184,"interventions":13186},"NCT06650540","Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis",[102],"2025-10-22",800,[13185],"IVF",[13164,13187],"Levofloxacin co-administered with Metronidazole",{"intervention":13187,"totalTrials":708,"cells":13189},{"EARLY_PHASE1":13190,"PHASE1":13192,"PHASE2":13194,"PHASE3":13196,"PHASE4":13198,"NA":13200},{"trials":13191,"activeCount":109},[],{"trials":13193,"activeCount":109},[],{"trials":13195,"activeCount":109},[],{"trials":13197,"activeCount":109},[],{"trials":13199,"activeCount":109},[],{"trials":13201,"activeCount":708,"soonestReadout":13182},[13202],{"nctId":13179,"briefTitle":13180,"status":456,"phases":13203,"primaryCompletion":13182,"completion":968,"start":680,"enrollment":13183,"conditions":13204,"interventions":13205},[102],[13185],[13164,13187],{"intervention":13207,"totalTrials":708,"cells":13208},"Senl_B19 autologous CAR-T (S1904) treatment",{"EARLY_PHASE1":13209,"PHASE1":13211,"PHASE2":13213,"PHASE3":13215,"PHASE4":13217,"NA":13219},{"trials":13210,"activeCount":109},[],{"trials":13212,"activeCount":109},[],{"trials":13214,"activeCount":109},[],{"trials":13216,"activeCount":109},[],{"trials":13218,"activeCount":109},[],{"trials":13220,"activeCount":708,"soonestReadout":2050},[13221],{"nctId":13222,"briefTitle":13223,"status":121,"phases":13224,"primaryCompletion":2050,"completion":13225,"start":5273,"enrollment":2653,"conditions":13226,"interventions":13230},"NCT06581081","Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r\u002Fr B-cell Acute Lymphoblastic Leukemia",[102],"2029-08-31",[13227,8800,13228,13229],"Relapsed Adult ALL","Refractory Acute Lymphoblastic Leukemia","Relapsed Pediatric ALL",[13207],{"intervention":13232,"totalTrials":708,"cells":13233},"Elranatamab",{"EARLY_PHASE1":13234,"PHASE1":13236,"PHASE2":13238,"PHASE3":13240,"PHASE4":13242,"NA":13244},{"trials":13235,"activeCount":109},[],{"trials":13237,"activeCount":109},[],{"trials":13239,"activeCount":109},[],{"trials":13241,"activeCount":109},[],{"trials":13243,"activeCount":109},[],{"trials":13245,"activeCount":708,"soonestReadout":13250},[13246],{"nctId":13247,"briefTitle":13248,"status":456,"phases":13249,"primaryCompletion":13250,"completion":13251,"start":637,"enrollment":13252,"conditions":13253,"interventions":13255},"NCT07320326","ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab",[],"2028-07-18","2028-09-18",159,[13254],"TCE-RRMM",[13232],{"intervention":13257,"totalTrials":708,"cells":13258},"Allogeneic γδ T (ABOUT) cells",{"EARLY_PHASE1":13259,"PHASE1":13261,"PHASE2":13263,"PHASE3":13265,"PHASE4":13267,"NA":13269},{"trials":13260,"activeCount":109},[],{"trials":13262,"activeCount":109},[],{"trials":13264,"activeCount":109},[],{"trials":13266,"activeCount":109},[],{"trials":13268,"activeCount":109},[],{"trials":13270,"activeCount":708,"soonestReadout":906},[13271],{"nctId":13272,"briefTitle":13273,"status":121,"phases":13274,"primaryCompletion":906,"completion":7588,"start":4737,"enrollment":2732,"conditions":13275,"interventions":13276},"NCT07144735","Allogeneic γδT Cells in Glioblastoma",[102],[12233,12234],[13257],{"intervention":13278,"totalTrials":708,"cells":13279},"Conservative management of ankylosing spondylitis",{"EARLY_PHASE1":13280,"PHASE1":13282,"PHASE2":13284,"PHASE3":13286,"PHASE4":13288,"NA":13290},{"trials":13281,"activeCount":109},[],{"trials":13283,"activeCount":109},[],{"trials":13285,"activeCount":109},[],{"trials":13287,"activeCount":109},[],{"trials":13289,"activeCount":109},[],{"trials":13291,"activeCount":708,"soonestReadout":6643},[13292],{"nctId":13293,"briefTitle":13294,"status":468,"phases":13295,"primaryCompletion":6643,"completion":6691,"start":649,"enrollment":13296,"conditions":13297,"interventions":13300},"NCT07093827","A Prospective Cohort Study on the Effect of Spinal Spinal Cord Injury on Sexual Function in Male Patients",[],1600,[13298,13299],"Sexual Function Abnormal","Spinal Cord Injuries (SCI)",[13278,13301],"Conservative management of lumbar spinal stenosis",{"intervention":13301,"totalTrials":708,"cells":13303},{"EARLY_PHASE1":13304,"PHASE1":13306,"PHASE2":13308,"PHASE3":13310,"PHASE4":13312,"NA":13314},{"trials":13305,"activeCount":109},[],{"trials":13307,"activeCount":109},[],{"trials":13309,"activeCount":109},[],{"trials":13311,"activeCount":109},[],{"trials":13313,"activeCount":109},[],{"trials":13315,"activeCount":708,"soonestReadout":6643},[13316],{"nctId":13293,"briefTitle":13294,"status":468,"phases":13317,"primaryCompletion":6643,"completion":6691,"start":649,"enrollment":13296,"conditions":13318,"interventions":13319},[],[13298,13299],[13278,13301],{"intervention":13321,"totalTrials":708,"cells":13322},"Intravenous normal saline",{"EARLY_PHASE1":13323,"PHASE1":13325,"PHASE2":13327,"PHASE3":13329,"PHASE4":13331,"NA":13333},{"trials":13324,"activeCount":109},[],{"trials":13326,"activeCount":109},[],{"trials":13328,"activeCount":109},[],{"trials":13330,"activeCount":109},[],{"trials":13332,"activeCount":109},[],{"trials":13334,"activeCount":708,"soonestReadout":6667},[13335],{"nctId":13336,"briefTitle":13337,"status":121,"phases":13338,"primaryCompletion":6667,"completion":6667,"start":6876,"enrollment":3625,"conditions":13339,"interventions":13341},"NCT07089173","The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study",[102],[13340],"Hemodynamics",[13321,13342,13343],"intravenous sufentanil","Intravenous lidocaine",{"intervention":13342,"totalTrials":708,"cells":13345},{"EARLY_PHASE1":13346,"PHASE1":13348,"PHASE2":13350,"PHASE3":13352,"PHASE4":13354,"NA":13356},{"trials":13347,"activeCount":109},[],{"trials":13349,"activeCount":109},[],{"trials":13351,"activeCount":109},[],{"trials":13353,"activeCount":109},[],{"trials":13355,"activeCount":109},[],{"trials":13357,"activeCount":708,"soonestReadout":6667},[13358],{"nctId":13336,"briefTitle":13337,"status":121,"phases":13359,"primaryCompletion":6667,"completion":6667,"start":6876,"enrollment":3625,"conditions":13360,"interventions":13361},[102],[13340],[13321,13342,13343],{"intervention":13343,"totalTrials":708,"cells":13363},{"EARLY_PHASE1":13364,"PHASE1":13366,"PHASE2":13368,"PHASE3":13370,"PHASE4":13372,"NA":13374},{"trials":13365,"activeCount":109},[],{"trials":13367,"activeCount":109},[],{"trials":13369,"activeCount":109},[],{"trials":13371,"activeCount":109},[],{"trials":13373,"activeCount":109},[],{"trials":13375,"activeCount":708,"soonestReadout":6667},[13376],{"nctId":13336,"briefTitle":13337,"status":121,"phases":13377,"primaryCompletion":6667,"completion":6667,"start":6876,"enrollment":3625,"conditions":13378,"interventions":13379},[102],[13340],[13321,13342,13343],{"intervention":13381,"totalTrials":708,"cells":13382},"Conservative treatment",{"EARLY_PHASE1":13383,"PHASE1":13385,"PHASE2":13387,"PHASE3":13389,"PHASE4":13391,"NA":13393},{"trials":13384,"activeCount":109},[],{"trials":13386,"activeCount":109},[],{"trials":13388,"activeCount":109},[],{"trials":13390,"activeCount":109},[],{"trials":13392,"activeCount":109},[],{"trials":13394,"activeCount":708,"soonestReadout":726},[13395],{"nctId":13396,"briefTitle":13397,"status":121,"phases":13398,"primaryCompletion":726,"completion":726,"start":4308,"enrollment":13399,"conditions":13400,"interventions":13403},"NCT06953622","Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale",[],330,[13401,13402],"Migraine","Patent Foramen Ovale",[13381,13404],"Antipaletet drug",{"intervention":13404,"totalTrials":708,"cells":13406},{"EARLY_PHASE1":13407,"PHASE1":13409,"PHASE2":13411,"PHASE3":13413,"PHASE4":13415,"NA":13417},{"trials":13408,"activeCount":109},[],{"trials":13410,"activeCount":109},[],{"trials":13412,"activeCount":109},[],{"trials":13414,"activeCount":109},[],{"trials":13416,"activeCount":109},[],{"trials":13418,"activeCount":708,"soonestReadout":726},[13419],{"nctId":13396,"briefTitle":13397,"status":121,"phases":13420,"primaryCompletion":726,"completion":726,"start":4308,"enrollment":13399,"conditions":13421,"interventions":13422},[],[13401,13402],[13381,13404],{"intervention":13424,"totalTrials":405,"cells":13425},"PEG-rhG-CSF",{"EARLY_PHASE1":13426,"PHASE1":13428,"PHASE2":13430,"PHASE3":13432,"PHASE4":13434,"NA":13471},{"trials":13427,"activeCount":109},[],{"trials":13429,"activeCount":109},[],{"trials":13431,"activeCount":109},[],{"trials":13433,"activeCount":109},[],{"trials":13435,"activeCount":109},[13436,13443,13453,13463],{"nctId":13437,"briefTitle":13438,"status":569,"phases":13439,"primaryCompletion":4090,"start":4152,"enrollment":846,"conditions":13440,"interventions":13441},"NCT02905942","PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation",[101],[11636],[13424,13442],"rhG-CSF",{"nctId":13444,"briefTitle":13445,"status":569,"phases":13446,"primaryCompletion":2824,"start":138,"enrollment":13447,"conditions":13448,"interventions":13452},"NCT02905916","The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy",[101],217,[13449,11636,13450,13451],"Mammary Cancer","Bone Tumour","Gynecological Tumors",[13424],{"nctId":13454,"briefTitle":13455,"status":135,"phases":13456,"primaryCompletion":13457,"completion":13458,"start":13459,"enrollment":8014,"conditions":13460,"interventions":13462},"NCT04009941","Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer",[101],"2020-01-18","2020-01-31","2019-08-01",[31,13461],"Neutropenia",[13424],{"nctId":13464,"briefTitle":13465,"status":135,"phases":13466,"primaryCompletion":1375,"completion":1733,"start":13467,"enrollment":1165,"conditions":13468,"interventions":13470},"NCT02944604","The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy",[101],"2016-09-08",[13469],"Breastcancer",[13424],{"trials":13472,"activeCount":109},[],{"intervention":538,"totalTrials":329,"cells":13474},{"EARLY_PHASE1":13475,"PHASE1":13477,"PHASE2":13479,"PHASE3":13481,"PHASE4":13483,"NA":13497},{"trials":13476,"activeCount":109},[],{"trials":13478,"activeCount":109},[],{"trials":13480,"activeCount":109},[],{"trials":13482,"activeCount":109},[],{"trials":13484,"activeCount":109},[13485,13489,13493],{"nctId":1198,"briefTitle":1199,"status":135,"phases":13486,"primaryCompletion":1201,"completion":1202,"start":191,"enrollment":1203,"conditions":13487,"interventions":13488},[101],[539,380,779],[538,1206,380,779],{"nctId":530,"briefTitle":531,"status":135,"phases":13490,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":13491,"interventions":13492},[101],[506,538,539],[538,40,380],{"nctId":827,"briefTitle":828,"status":569,"phases":13494,"primaryCompletion":830,"start":831,"enrollment":376,"conditions":13495,"interventions":13496},[101],[245],[538,834,236],{"trials":13498,"activeCount":109},[],{"intervention":13500,"totalTrials":746,"cells":13501},"Penehyclidine inhalation",{"EARLY_PHASE1":13502,"PHASE1":13504,"PHASE2":13506,"PHASE3":13508,"PHASE4":13510,"NA":13528},{"trials":13503,"activeCount":109},[],{"trials":13505,"activeCount":109},[],{"trials":13507,"activeCount":109},[],{"trials":13509,"activeCount":109},[],{"trials":13511,"activeCount":109},[13512,13520],{"nctId":13513,"briefTitle":13514,"status":135,"phases":13515,"primaryCompletion":8314,"completion":8314,"start":13516,"enrollment":13517,"conditions":13518,"interventions":13519},"NCT03868709","Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery",[101],"2019-03-12",864,[357,296],[13500],{"nctId":13521,"briefTitle":13522,"status":135,"phases":13523,"primaryCompletion":13524,"completion":328,"start":13525,"enrollment":13517,"conditions":13526,"interventions":13527},"NCT02644876","Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications",[101],"2018-11-08","2015-09-01",[357],[13500],{"trials":13529,"activeCount":109},[],{"intervention":1646,"totalTrials":746,"cells":13531},{"EARLY_PHASE1":13532,"PHASE1":13534,"PHASE2":13536,"PHASE3":13542,"PHASE4":13544,"NA":13550},{"trials":13533,"activeCount":109},[],{"trials":13535,"activeCount":109},[],{"trials":13537,"activeCount":109},[13538],{"nctId":567,"briefTitle":568,"status":569,"phases":13539,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":13540,"interventions":13541},[99],[576,34],[557,578],{"trials":13543,"activeCount":109},[],{"trials":13545,"activeCount":109},[13546],{"nctId":1637,"briefTitle":1638,"status":135,"phases":13547,"primaryCompletion":857,"completion":1640,"start":1641,"enrollment":1642,"conditions":13548,"interventions":13549},[101],[1644],[1182,1646],{"trials":13551,"activeCount":109},[],{"intervention":13553,"totalTrials":746,"cells":13554},"atomoxetine",{"EARLY_PHASE1":13555,"PHASE1":13557,"PHASE2":13559,"PHASE3":13561,"PHASE4":13563,"NA":13582},{"trials":13556,"activeCount":109},[],{"trials":13558,"activeCount":109},[],{"trials":13560,"activeCount":109},[],{"trials":13562,"activeCount":109},[],{"trials":13564,"activeCount":109},[13565,13572],{"nctId":13566,"briefTitle":13567,"status":569,"phases":13568,"primaryCompletion":4852,"start":4853,"enrollment":376,"conditions":13569,"interventions":13571},"NCT01339286","Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)",[101],[13570],"Attention Deficit Hyperactivity Disorder",[13553],{"nctId":13573,"briefTitle":13574,"status":135,"phases":13575,"primaryCompletion":3545,"completion":3545,"start":13576,"enrollment":13577,"conditions":13578,"interventions":13579},"NCT01065259","Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children",[101],"2008-04",262,[13570],[13580,13581],"OROS MPH","Atomoxetine",{"trials":13583,"activeCount":109},[],{"intervention":13585,"totalTrials":746,"cells":13586},"Fluconazole",{"EARLY_PHASE1":13587,"PHASE1":13589,"PHASE2":13591,"PHASE3":13593,"PHASE4":13595,"NA":13613},{"trials":13588,"activeCount":109},[],{"trials":13590,"activeCount":109},[],{"trials":13592,"activeCount":109},[],{"trials":13594,"activeCount":109},[],{"trials":13596,"activeCount":109},[13597,13605],{"nctId":13598,"briefTitle":13599,"status":135,"phases":13600,"primaryCompletion":2825,"completion":2825,"start":2884,"enrollment":1480,"conditions":13601,"interventions":13603},"NCT02180100","Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis",[101],[13602],"Vulvovaginal Candidiasis",[13604,13585],"Terconazole Vaginal Suppository",{"nctId":13606,"briefTitle":13607,"status":135,"phases":13608,"primaryCompletion":139,"completion":139,"start":831,"enrollment":1165,"conditions":13609,"interventions":13611},"NCT02180828","Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis",[101],[13610],"Candidiasis, Vulvovaginal",[13612,13585],"Clotrimazole vaginal",{"trials":13614,"activeCount":109},[],{"intervention":13616,"totalTrials":746,"cells":13617},"artificial tear eyedrops",{"EARLY_PHASE1":13618,"PHASE1":13620,"PHASE2":13622,"PHASE3":13624,"PHASE4":13626,"NA":13646},{"trials":13619,"activeCount":109},[],{"trials":13621,"activeCount":109},[],{"trials":13623,"activeCount":109},[],{"trials":13625,"activeCount":109},[],{"trials":13627,"activeCount":109},[13628,13637],{"nctId":13629,"briefTitle":13630,"status":569,"phases":13631,"primaryCompletion":81,"completion":81,"start":13632,"enrollment":140,"conditions":13633,"interventions":13635},"NCT06043908","The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye",[101],"2022-08-31",[13634],"Dry Eye",[13616,13636],"0.05% cyclosporine eyedrops",{"nctId":13638,"briefTitle":13639,"status":135,"phases":13640,"primaryCompletion":13641,"completion":13642,"start":13643,"enrollment":140,"conditions":13644,"interventions":13645},"NCT06824844","The Effect of 0.05% CsA Eye Drops on Diabetic Patients with Dry Eye Disease",[101],"2024-03-04","2024-06-04","2021-12-02",[13634],[13616,13636],{"trials":13647,"activeCount":109},[],{"intervention":13636,"totalTrials":746,"cells":13649},{"EARLY_PHASE1":13650,"PHASE1":13652,"PHASE2":13654,"PHASE3":13656,"PHASE4":13658,"NA":13668},{"trials":13651,"activeCount":109},[],{"trials":13653,"activeCount":109},[],{"trials":13655,"activeCount":109},[],{"trials":13657,"activeCount":109},[],{"trials":13659,"activeCount":109},[13660,13664],{"nctId":13629,"briefTitle":13630,"status":569,"phases":13661,"primaryCompletion":81,"completion":81,"start":13632,"enrollment":140,"conditions":13662,"interventions":13663},[101],[13634],[13616,13636],{"nctId":13638,"briefTitle":13639,"status":135,"phases":13665,"primaryCompletion":13641,"completion":13642,"start":13643,"enrollment":140,"conditions":13666,"interventions":13667},[101],[13634],[13616,13636],{"trials":13669,"activeCount":109},[],{"intervention":13671,"totalTrials":746,"cells":13672},"atorvastatin",{"EARLY_PHASE1":13673,"PHASE1":13675,"PHASE2":13677,"PHASE3":13686,"PHASE4":13688,"NA":13703},{"trials":13674,"activeCount":109},[],{"trials":13676,"activeCount":109},[],{"trials":13678,"activeCount":109},[13679],{"nctId":13680,"briefTitle":13681,"status":569,"phases":13682,"primaryCompletion":649,"completion":817,"start":13683,"enrollment":168,"conditions":13684,"interventions":13685},"NCT03460808","The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[98,99],"2018-03-10",[34],[13671,661,2657],{"trials":13687,"activeCount":109},[],{"trials":13689,"activeCount":109},[13690],{"nctId":13691,"briefTitle":13692,"status":135,"phases":13693,"primaryCompletion":13694,"completion":13694,"start":4141,"enrollment":13695,"conditions":13696,"interventions":13700},"NCT01293097","Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI",[101],"2011-10",2884,[13697,13698,13699],"Non-ST Segment Elevation Myocardial Infarction","Unstable Angina Pectoris","Stable Angina Pectoris",[13701,13702],"Atorvastatin","Statin",{"trials":13704,"activeCount":109},[],{"intervention":13706,"totalTrials":746,"cells":13707},"injection of Botulinum type A",{"EARLY_PHASE1":13708,"PHASE1":13710,"PHASE2":13712,"PHASE3":13726,"PHASE4":13728,"NA":13738},{"trials":13709,"activeCount":109},[],{"trials":13711,"activeCount":109},[],{"trials":13713,"activeCount":109},[13714],{"nctId":13715,"briefTitle":13716,"status":135,"phases":13717,"primaryCompletion":13718,"completion":13719,"start":13720,"enrollment":13721,"conditions":13722,"interventions":13725},"NCT05127018","Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile",[98,99],"2020-08-20","2021-10-20","2019-11-20",33,[13723,13724],"Smiling","Botulinum Toxins, Type A",[13706],{"trials":13727,"activeCount":109},[],{"trials":13729,"activeCount":109},[13730],{"nctId":13731,"briefTitle":13732,"status":135,"phases":13733,"primaryCompletion":13720,"completion":13734,"start":13735,"enrollment":3011,"conditions":13736,"interventions":13737},"NCT04820543","Effects of Dose and Injection Site for Gummy Smile Treatment With Botulinum Type A",[101],"2020-06-20","2019-02-20",[13723,13724],[13706],{"trials":13739,"activeCount":109},[],{"intervention":13741,"totalTrials":746,"cells":13742},"Entecavir prophylaxis",{"EARLY_PHASE1":13743,"PHASE1":13745,"PHASE2":13747,"PHASE3":13749,"PHASE4":13751,"NA":13769},{"trials":13744,"activeCount":109},[],{"trials":13746,"activeCount":109},[],{"trials":13748,"activeCount":109},[],{"trials":13750,"activeCount":109},[],{"trials":13752,"activeCount":109},[13753,13761],{"nctId":13754,"briefTitle":13755,"status":569,"phases":13756,"primaryCompletion":668,"completion":668,"start":13757,"enrollment":153,"conditions":13758,"interventions":13760},"NCT01768195","Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy",[101],"2013-01",[13759],"Hepatitis B",[13741],{"nctId":13762,"briefTitle":13763,"status":569,"phases":13764,"primaryCompletion":668,"completion":668,"start":13757,"enrollment":13765,"conditions":13766,"interventions":13767},"NCT01765231","Prophylactic Use of Entecavir for HBsAg Negative\u002FHBcAb Positive\u002FHepatitis B Virus DNA Negative Patients With Lymphoma",[101],190,[13759],[13741,13768],"Observation arm",{"trials":13770,"activeCount":109},[],{"intervention":699,"totalTrials":746,"cells":13772},{"EARLY_PHASE1":13773,"PHASE1":13775,"PHASE2":13777,"PHASE3":13779,"PHASE4":13781,"NA":13791},{"trials":13774,"activeCount":109},[],{"trials":13776,"activeCount":109},[],{"trials":13778,"activeCount":109},[],{"trials":13780,"activeCount":109},[],{"trials":13782,"activeCount":109},[13783,13787],{"nctId":688,"briefTitle":689,"status":200,"phases":13784,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":13785,"interventions":13786},[101],[695,46,557,696,697],[557,236,699,700],{"nctId":702,"briefTitle":703,"status":200,"phases":13788,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":13789,"interventions":13790},[101],[695,706,557,696,245],[557,236,699,700],{"trials":13792,"activeCount":109},[],{"intervention":700,"totalTrials":746,"cells":13794},{"EARLY_PHASE1":13795,"PHASE1":13797,"PHASE2":13799,"PHASE3":13801,"PHASE4":13803,"NA":13813},{"trials":13796,"activeCount":109},[],{"trials":13798,"activeCount":109},[],{"trials":13800,"activeCount":109},[],{"trials":13802,"activeCount":109},[],{"trials":13804,"activeCount":109},[13805,13809],{"nctId":688,"briefTitle":689,"status":200,"phases":13806,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":13807,"interventions":13808},[101],[695,46,557,696,697],[557,236,699,700],{"nctId":702,"briefTitle":703,"status":200,"phases":13810,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":13811,"interventions":13812},[101],[695,706,557,696,245],[557,236,699,700],{"trials":13814,"activeCount":109},[],{"intervention":13612,"totalTrials":746,"cells":13816},{"EARLY_PHASE1":13817,"PHASE1":13819,"PHASE2":13821,"PHASE3":13823,"PHASE4":13825,"NA":13841},{"trials":13818,"activeCount":109},[],{"trials":13820,"activeCount":109},[],{"trials":13822,"activeCount":109},[],{"trials":13824,"activeCount":109},[],{"trials":13826,"activeCount":109},[13827,13831],{"nctId":13606,"briefTitle":13607,"status":135,"phases":13828,"primaryCompletion":139,"completion":139,"start":831,"enrollment":1165,"conditions":13829,"interventions":13830},[101],[13610],[13612,13585],{"nctId":13832,"briefTitle":13833,"status":135,"phases":13834,"primaryCompletion":1404,"completion":1404,"start":13835,"enrollment":1480,"conditions":13836,"interventions":13838},"NCT04699240","Study of Lactobacillus in Adjuvant Treatment of RVVC",[101],"2020-07-01",[13837],"Recurrent Vulvovaginal Candidiasis",[13839,13840],"clotrimazole vaginal","Clotrimazole vaginal tablets+ Lactobacillus",{"trials":13842,"activeCount":109},[],{"intervention":13844,"totalTrials":708,"cells":13845},"Busulfan",{"EARLY_PHASE1":13846,"PHASE1":13848,"PHASE2":13850,"PHASE3":13852,"PHASE4":13854,"NA":13864},{"trials":13847,"activeCount":109},[],{"trials":13849,"activeCount":109},[],{"trials":13851,"activeCount":109},[],{"trials":13853,"activeCount":109},[],{"trials":13855,"activeCount":109},[13856],{"nctId":13857,"briefTitle":13858,"status":569,"phases":13859,"primaryCompletion":1103,"completion":741,"start":13860,"enrollment":1894,"conditions":13861,"interventions":13862},"NCT06069180","The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA",[101],"2023-11-15",[948],[13844,13863],"Flu\u002FCy\u002FATG or Cy\u002FATG",{"trials":13865,"activeCount":109},[],{"intervention":13863,"totalTrials":708,"cells":13867},{"EARLY_PHASE1":13868,"PHASE1":13870,"PHASE2":13872,"PHASE3":13874,"PHASE4":13876,"NA":13882},{"trials":13869,"activeCount":109},[],{"trials":13871,"activeCount":109},[],{"trials":13873,"activeCount":109},[],{"trials":13875,"activeCount":109},[],{"trials":13877,"activeCount":109},[13878],{"nctId":13857,"briefTitle":13858,"status":569,"phases":13879,"primaryCompletion":1103,"completion":741,"start":13860,"enrollment":1894,"conditions":13880,"interventions":13881},[101],[948],[13844,13863],{"trials":13883,"activeCount":109},[],{"intervention":13885,"totalTrials":708,"cells":13886},"\"Probiotics\" and \"Metronidazole\"",{"EARLY_PHASE1":13887,"PHASE1":13889,"PHASE2":13891,"PHASE3":13893,"PHASE4":13895,"NA":13904},{"trials":13888,"activeCount":109},[],{"trials":13890,"activeCount":109},[],{"trials":13892,"activeCount":109},[],{"trials":13894,"activeCount":109},[],{"trials":13896,"activeCount":109},[13897],{"nctId":13898,"briefTitle":13899,"status":135,"phases":13900,"primaryCompletion":5372,"completion":5372,"start":9943,"enrollment":693,"conditions":13901,"interventions":13902},"NCT03894813","Probiotics as Adjuvant Treatment for Bacterial Vaginosis",[101],[1966],[13885,13903],"Metronidazole Vaginal",{"trials":13905,"activeCount":109},[],{"intervention":13903,"totalTrials":708,"cells":13907},{"EARLY_PHASE1":13908,"PHASE1":13910,"PHASE2":13912,"PHASE3":13914,"PHASE4":13916,"NA":13922},{"trials":13909,"activeCount":109},[],{"trials":13911,"activeCount":109},[],{"trials":13913,"activeCount":109},[],{"trials":13915,"activeCount":109},[],{"trials":13917,"activeCount":109},[13918],{"nctId":13898,"briefTitle":13899,"status":135,"phases":13919,"primaryCompletion":5372,"completion":5372,"start":9943,"enrollment":693,"conditions":13920,"interventions":13921},[101],[1966],[13885,13903],{"trials":13923,"activeCount":109},[],{"intervention":13925,"totalTrials":708,"cells":13926},"Tenofovir Alafenamide 25 MG",{"EARLY_PHASE1":13927,"PHASE1":13929,"PHASE2":13931,"PHASE3":13933,"PHASE4":13935,"NA":13947},{"trials":13928,"activeCount":109},[],{"trials":13930,"activeCount":109},[],{"trials":13932,"activeCount":109},[],{"trials":13934,"activeCount":109},[],{"trials":13936,"activeCount":109},[13937],{"nctId":13938,"briefTitle":13939,"status":569,"phases":13940,"primaryCompletion":437,"completion":437,"start":13941,"enrollment":574,"conditions":13942,"interventions":13945},"NCT04997564","The Efficacy and Safety of 12-week SOF\u002FVEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV\u002FHBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China",[101],"2021-08",[13943,13944],"Chronic Hepatitis C","Chronic Hepatitis B",[13925,13946],"Sofosbuvir \u002F Velpatasvir",{"trials":13948,"activeCount":109},[],{"intervention":13946,"totalTrials":708,"cells":13950},{"EARLY_PHASE1":13951,"PHASE1":13953,"PHASE2":13955,"PHASE3":13957,"PHASE4":13959,"NA":13965},{"trials":13952,"activeCount":109},[],{"trials":13954,"activeCount":109},[],{"trials":13956,"activeCount":109},[],{"trials":13958,"activeCount":109},[],{"trials":13960,"activeCount":109},[13961],{"nctId":13938,"briefTitle":13939,"status":569,"phases":13962,"primaryCompletion":437,"completion":437,"start":13941,"enrollment":574,"conditions":13963,"interventions":13964},[101],[13943,13944],[13925,13946],{"trials":13966,"activeCount":109},[],{"intervention":13968,"totalTrials":708,"cells":13969},"Shuxinin",{"EARLY_PHASE1":13970,"PHASE1":13972,"PHASE2":13974,"PHASE3":13976,"PHASE4":13978,"NA":13989},{"trials":13971,"activeCount":109},[],{"trials":13973,"activeCount":109},[],{"trials":13975,"activeCount":109},[],{"trials":13977,"activeCount":109},[],{"trials":13979,"activeCount":109},[13980],{"nctId":13981,"briefTitle":13982,"status":569,"phases":13983,"primaryCompletion":8314,"completion":8314,"start":13984,"enrollment":13985,"conditions":13986,"interventions":13987},"NCT04950790","Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke",[101],"2018-04-01",480,[11702],[13968,13988],"Basic treatment",{"trials":13990,"activeCount":109},[],{"intervention":13988,"totalTrials":708,"cells":13992},{"EARLY_PHASE1":13993,"PHASE1":13995,"PHASE2":13997,"PHASE3":13999,"PHASE4":14001,"NA":14007},{"trials":13994,"activeCount":109},[],{"trials":13996,"activeCount":109},[],{"trials":13998,"activeCount":109},[],{"trials":14000,"activeCount":109},[],{"trials":14002,"activeCount":109},[14003],{"nctId":13981,"briefTitle":13982,"status":569,"phases":14004,"primaryCompletion":8314,"completion":8314,"start":13984,"enrollment":13985,"conditions":14005,"interventions":14006},[101],[11702],[13968,13988],{"trials":14008,"activeCount":109},[],{"intervention":14010,"totalTrials":708,"cells":14011},"Ketotifen Fumarate",{"EARLY_PHASE1":14012,"PHASE1":14014,"PHASE2":14016,"PHASE3":14018,"PHASE4":14020,"NA":14030},{"trials":14013,"activeCount":109},[],{"trials":14015,"activeCount":109},[],{"trials":14017,"activeCount":109},[],{"trials":14019,"activeCount":109},[],{"trials":14021,"activeCount":109},[14022],{"nctId":14023,"briefTitle":14024,"status":569,"phases":14025,"primaryCompletion":81,"completion":1103,"start":1138,"enrollment":140,"conditions":14026,"interventions":14028},"NCT05511831","The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI",[101],[14027],"ST-segment Elevation Myocardial Infarction (STEMI)",[14010,14029],"standard treatment",{"trials":14031,"activeCount":109},[],{"intervention":14029,"totalTrials":708,"cells":14033},{"EARLY_PHASE1":14034,"PHASE1":14036,"PHASE2":14038,"PHASE3":14040,"PHASE4":14042,"NA":14048},{"trials":14035,"activeCount":109},[],{"trials":14037,"activeCount":109},[],{"trials":14039,"activeCount":109},[],{"trials":14041,"activeCount":109},[],{"trials":14043,"activeCount":109},[14044],{"nctId":14023,"briefTitle":14024,"status":569,"phases":14045,"primaryCompletion":81,"completion":1103,"start":1138,"enrollment":140,"conditions":14046,"interventions":14047},[101],[14027],[14010,14029],{"trials":14049,"activeCount":109},[],{"intervention":14051,"totalTrials":708,"cells":14052},"Roxadustat",{"EARLY_PHASE1":14053,"PHASE1":14055,"PHASE2":14057,"PHASE3":14059,"PHASE4":14061,"NA":14072},{"trials":14054,"activeCount":109},[],{"trials":14056,"activeCount":109},[],{"trials":14058,"activeCount":109},[],{"trials":14060,"activeCount":109},[],{"trials":14062,"activeCount":109},[14063],{"nctId":14064,"briefTitle":14065,"status":135,"phases":14066,"primaryCompletion":14067,"completion":14068,"start":13835,"enrollment":376,"conditions":14069,"interventions":14071},"NCT04454879","Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients",[101],"2021-04-03","2021-08-03",[14070],"Renal Anemia",[14051],{"trials":14073,"activeCount":109},[],{"intervention":13604,"totalTrials":708,"cells":14075},{"EARLY_PHASE1":14076,"PHASE1":14078,"PHASE2":14080,"PHASE3":14082,"PHASE4":14084,"NA":14090},{"trials":14077,"activeCount":109},[],{"trials":14079,"activeCount":109},[],{"trials":14081,"activeCount":109},[],{"trials":14083,"activeCount":109},[],{"trials":14085,"activeCount":109},[14086],{"nctId":13598,"briefTitle":13599,"status":135,"phases":14087,"primaryCompletion":2825,"completion":2825,"start":2884,"enrollment":1480,"conditions":14088,"interventions":14089},[101],[13602],[13604,13585],{"trials":14091,"activeCount":109},[],{"intervention":14093,"totalTrials":708,"cells":14094},"Zhi Kang",{"EARLY_PHASE1":14095,"PHASE1":14097,"PHASE2":14099,"PHASE3":14101,"PHASE4":14103,"NA":14117},{"trials":14096,"activeCount":109},[],{"trials":14098,"activeCount":109},[],{"trials":14100,"activeCount":109},[],{"trials":14102,"activeCount":109},[],{"trials":14104,"activeCount":109},[14105],{"nctId":14106,"briefTitle":14107,"status":569,"phases":14108,"primaryCompletion":14109,"completion":14110,"start":14111,"enrollment":14112,"conditions":14113,"interventions":14115},"NCT03363971","Treatment of Posttraumatic Swelling and Pain With Zhi Kang Capsule",[101],"2017-12-20","2018-03-13","2017-03-13",2200,[14114],"Soft Tissue Injuries",[14093,14116],"Simulant agent for Zhi Kang",{"trials":14118,"activeCount":109},[],{"intervention":14116,"totalTrials":708,"cells":14120},{"EARLY_PHASE1":14121,"PHASE1":14123,"PHASE2":14125,"PHASE3":14127,"PHASE4":14129,"NA":14135},{"trials":14122,"activeCount":109},[],{"trials":14124,"activeCount":109},[],{"trials":14126,"activeCount":109},[],{"trials":14128,"activeCount":109},[],{"trials":14130,"activeCount":109},[14131],{"nctId":14106,"briefTitle":14107,"status":569,"phases":14132,"primaryCompletion":14109,"completion":14110,"start":14111,"enrollment":14112,"conditions":14133,"interventions":14134},[101],[14114],[14093,14116],{"trials":14136,"activeCount":109},[],{"intervention":14138,"totalTrials":708,"cells":14139},"Xingnaojing injection + Shuxuetong oral liquid",{"EARLY_PHASE1":14140,"PHASE1":14142,"PHASE2":14144,"PHASE3":14146,"PHASE4":14148,"NA":14159},{"trials":14141,"activeCount":109},[],{"trials":14143,"activeCount":109},[],{"trials":14145,"activeCount":109},[],{"trials":14147,"activeCount":109},[],{"trials":14149,"activeCount":109},[14150],{"nctId":14151,"briefTitle":14152,"status":569,"phases":14153,"primaryCompletion":13835,"completion":5295,"start":14154,"enrollment":14155,"conditions":14156,"interventions":14158},"NCT04946474","Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke",[101],"2019-06-01",520,[14157],"Acute Hemorrhagic Stroke",[14138],{"trials":14160,"activeCount":109},[],{"intervention":14162,"totalTrials":708,"cells":14163},"Individualized therapy",{"EARLY_PHASE1":14164,"PHASE1":14166,"PHASE2":14168,"PHASE3":14170,"PHASE4":14172,"NA":14181},{"trials":14165,"activeCount":109},[],{"trials":14167,"activeCount":109},[],{"trials":14169,"activeCount":109},[],{"trials":14171,"activeCount":109},[],{"trials":14173,"activeCount":109},[14174],{"nctId":14175,"briefTitle":14176,"status":135,"phases":14177,"primaryCompletion":374,"completion":57,"start":8279,"enrollment":6539,"conditions":14178,"interventions":14180},"NCT04088305","Vancomycin Dosage Strategy Based on a Trough Concentration Model",[101],[14179],"Pneumonia, Staphylococcal",[14162],{"trials":14182,"activeCount":109},[],{"intervention":14184,"totalTrials":708,"cells":14185},"test product (T) azithromycin capsule and reference product (R) azithromycin capsule \"Sumamed®\"",{"EARLY_PHASE1":14186,"PHASE1":14188,"PHASE2":14190,"PHASE3":14192,"PHASE4":14194,"NA":14209},{"trials":14187,"activeCount":109},[],{"trials":14189,"activeCount":109},[],{"trials":14191,"activeCount":109},[],{"trials":14193,"activeCount":109},[],{"trials":14195,"activeCount":109},[14196],{"nctId":14197,"briefTitle":14198,"status":135,"phases":14199,"primaryCompletion":14200,"completion":14200,"start":14201,"enrollment":536,"conditions":14202,"interventions":14208},"NCT06149117","Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China",[101],"2023-04-03","2022-11-16",[14203,14204,14205,14206,14207],"Upper Respiratory Tract Infection","Lower Respiratory Infection","Skin Infection","Subcutaneous Tissues Infection","Genital Infection",[14184],{"trials":14210,"activeCount":109},[],{"intervention":1206,"totalTrials":708,"cells":14212},{"EARLY_PHASE1":14213,"PHASE1":14215,"PHASE2":14217,"PHASE3":14219,"PHASE4":14221,"NA":14227},{"trials":14214,"activeCount":109},[],{"trials":14216,"activeCount":109},[],{"trials":14218,"activeCount":109},[],{"trials":14220,"activeCount":109},[],{"trials":14222,"activeCount":109},[14223],{"nctId":1198,"briefTitle":1199,"status":135,"phases":14224,"primaryCompletion":1201,"completion":1202,"start":191,"enrollment":1203,"conditions":14225,"interventions":14226},[101],[539,380,779],[538,1206,380,779],{"trials":14228,"activeCount":109},[],{"intervention":14230,"totalTrials":708,"cells":14231},"bupropion",{"EARLY_PHASE1":14232,"PHASE1":14234,"PHASE2":14236,"PHASE3":14238,"PHASE4":14240,"NA":14251},{"trials":14233,"activeCount":109},[],{"trials":14235,"activeCount":109},[],{"trials":14237,"activeCount":109},[],{"trials":14239,"activeCount":109},[],{"trials":14241,"activeCount":109},[14242],{"nctId":14243,"briefTitle":14244,"status":569,"phases":14245,"primaryCompletion":14246,"completion":14246,"start":449,"enrollment":4171,"conditions":14247,"interventions":14248},"NCT03148509","A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway",[101],"2019-12-30",[10277],[14249,14250,14230],"risperidone","aripiprazole",{"trials":14252,"activeCount":109},[],{"intervention":14254,"totalTrials":708,"cells":14255},"without triamcinolone",{"EARLY_PHASE1":14256,"PHASE1":14258,"PHASE2":14260,"PHASE3":14262,"PHASE4":14264,"NA":14278},{"trials":14257,"activeCount":109},[],{"trials":14259,"activeCount":109},[],{"trials":14261,"activeCount":109},[],{"trials":14263,"activeCount":109},[],{"trials":14265,"activeCount":109},[14266],{"nctId":14267,"briefTitle":14268,"status":135,"phases":14269,"primaryCompletion":14270,"completion":9294,"start":14271,"enrollment":574,"conditions":14272,"interventions":14274},"NCT05997238","Evaluation of the Effect of Triamcinolone at Different Doses on LIA During TKA",[101],"2024-02-12","2023-04-25",[14273],"Osteoarthritis, Knee",[14254,14275,14276,14277],"20mg triamcinolone","40mg triamcinolone","80mg triamcinolone",{"trials":14279,"activeCount":109},[],{"intervention":14275,"totalTrials":708,"cells":14281},{"EARLY_PHASE1":14282,"PHASE1":14284,"PHASE2":14286,"PHASE3":14288,"PHASE4":14290,"NA":14296},{"trials":14283,"activeCount":109},[],{"trials":14285,"activeCount":109},[],{"trials":14287,"activeCount":109},[],{"trials":14289,"activeCount":109},[],{"trials":14291,"activeCount":109},[14292],{"nctId":14267,"briefTitle":14268,"status":135,"phases":14293,"primaryCompletion":14270,"completion":9294,"start":14271,"enrollment":574,"conditions":14294,"interventions":14295},[101],[14273],[14254,14275,14276,14277],{"trials":14297,"activeCount":109},[],{"intervention":14276,"totalTrials":708,"cells":14299},{"EARLY_PHASE1":14300,"PHASE1":14302,"PHASE2":14304,"PHASE3":14306,"PHASE4":14308,"NA":14314},{"trials":14301,"activeCount":109},[],{"trials":14303,"activeCount":109},[],{"trials":14305,"activeCount":109},[],{"trials":14307,"activeCount":109},[],{"trials":14309,"activeCount":109},[14310],{"nctId":14267,"briefTitle":14268,"status":135,"phases":14311,"primaryCompletion":14270,"completion":9294,"start":14271,"enrollment":574,"conditions":14312,"interventions":14313},[101],[14273],[14254,14275,14276,14277],{"trials":14315,"activeCount":109},[],{"intervention":14277,"totalTrials":708,"cells":14317},{"EARLY_PHASE1":14318,"PHASE1":14320,"PHASE2":14322,"PHASE3":14324,"PHASE4":14326,"NA":14332},{"trials":14319,"activeCount":109},[],{"trials":14321,"activeCount":109},[],{"trials":14323,"activeCount":109},[],{"trials":14325,"activeCount":109},[],{"trials":14327,"activeCount":109},[14328],{"nctId":14267,"briefTitle":14268,"status":135,"phases":14329,"primaryCompletion":14270,"completion":9294,"start":14271,"enrollment":574,"conditions":14330,"interventions":14331},[101],[14273],[14254,14275,14276,14277],{"trials":14333,"activeCount":109},[],{"intervention":3607,"totalTrials":708,"cells":14335},{"EARLY_PHASE1":14336,"PHASE1":14338,"PHASE2":14340,"PHASE3":14342,"PHASE4":14344,"NA":14350},{"trials":14337,"activeCount":109},[],{"trials":14339,"activeCount":109},[],{"trials":14341,"activeCount":109},[],{"trials":14343,"activeCount":109},[],{"trials":14345,"activeCount":109},[14346],{"nctId":3600,"briefTitle":3601,"status":569,"phases":14347,"primaryCompletion":572,"completion":81,"start":3603,"enrollment":168,"conditions":14348,"interventions":14349},[101],[3605],[3607,1028,3500,3501,3608],{"trials":14351,"activeCount":109},[],{"intervention":3608,"totalTrials":708,"cells":14353},{"EARLY_PHASE1":14354,"PHASE1":14356,"PHASE2":14358,"PHASE3":14360,"PHASE4":14362,"NA":14368},{"trials":14355,"activeCount":109},[],{"trials":14357,"activeCount":109},[],{"trials":14359,"activeCount":109},[],{"trials":14361,"activeCount":109},[],{"trials":14363,"activeCount":109},[14364],{"nctId":3600,"briefTitle":3601,"status":569,"phases":14365,"primaryCompletion":572,"completion":81,"start":3603,"enrollment":168,"conditions":14366,"interventions":14367},[101],[3605],[3607,1028,3500,3501,3608],{"trials":14369,"activeCount":109},[],{"intervention":14371,"totalTrials":708,"cells":14372},"PAD",{"EARLY_PHASE1":14373,"PHASE1":14375,"PHASE2":14377,"PHASE3":14379,"PHASE4":14381,"NA":14392},{"trials":14374,"activeCount":109},[],{"trials":14376,"activeCount":109},[],{"trials":14378,"activeCount":109},[],{"trials":14380,"activeCount":109},[],{"trials":14382,"activeCount":109},[14383],{"nctId":14384,"briefTitle":14385,"status":569,"phases":14386,"primaryCompletion":14387,"completion":14388,"start":4075,"enrollment":728,"conditions":14389,"interventions":14390},"NCT01868828","A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma",[101],"2015-05","2017-05",[5130],[14371,14391],"VCD",{"trials":14393,"activeCount":109},[],{"intervention":14391,"totalTrials":708,"cells":14395},{"EARLY_PHASE1":14396,"PHASE1":14398,"PHASE2":14400,"PHASE3":14402,"PHASE4":14404,"NA":14410},{"trials":14397,"activeCount":109},[],{"trials":14399,"activeCount":109},[],{"trials":14401,"activeCount":109},[],{"trials":14403,"activeCount":109},[],{"trials":14405,"activeCount":109},[14406],{"nctId":14384,"briefTitle":14385,"status":569,"phases":14407,"primaryCompletion":14387,"completion":14388,"start":4075,"enrollment":728,"conditions":14408,"interventions":14409},[101],[5130],[14371,14391],{"trials":14411,"activeCount":109},[],{"intervention":13442,"totalTrials":708,"cells":14413},{"EARLY_PHASE1":14414,"PHASE1":14416,"PHASE2":14418,"PHASE3":14420,"PHASE4":14422,"NA":14428},{"trials":14415,"activeCount":109},[],{"trials":14417,"activeCount":109},[],{"trials":14419,"activeCount":109},[],{"trials":14421,"activeCount":109},[],{"trials":14423,"activeCount":109},[14424],{"nctId":13437,"briefTitle":13438,"status":569,"phases":14425,"primaryCompletion":4090,"start":4152,"enrollment":846,"conditions":14426,"interventions":14427},[101],[11636],[13424,13442],{"trials":14429,"activeCount":109},[],{"intervention":1621,"totalTrials":708,"cells":14431},{"EARLY_PHASE1":14432,"PHASE1":14434,"PHASE2":14436,"PHASE3":14438,"PHASE4":14440,"NA":14446},{"trials":14433,"activeCount":109},[],{"trials":14435,"activeCount":109},[],{"trials":14437,"activeCount":109},[],{"trials":14439,"activeCount":109},[],{"trials":14441,"activeCount":109},[14442],{"nctId":1613,"briefTitle":1614,"status":135,"phases":14443,"primaryCompletion":1616,"completion":1617,"start":316,"enrollment":1618,"conditions":14444,"interventions":14445},[101],[390,430,25,40,185],[131,1621],{"trials":14447,"activeCount":109},[],{"intervention":247,"totalTrials":708,"cells":14449},{"EARLY_PHASE1":14450,"PHASE1":14452,"PHASE2":14454,"PHASE3":14456,"PHASE4":14458,"NA":14464},{"trials":14451,"activeCount":109},[],{"trials":14453,"activeCount":109},[],{"trials":14455,"activeCount":109},[],{"trials":14457,"activeCount":109},[],{"trials":14459,"activeCount":109},[14460],{"nctId":238,"briefTitle":239,"status":135,"phases":14461,"primaryCompletion":241,"start":242,"enrollment":153,"conditions":14462,"interventions":14463},[101],[244,245],[25,247],{"trials":14465,"activeCount":109},[],{"intervention":14467,"totalTrials":708,"cells":14468},"SGLT-2 inhibitor",{"EARLY_PHASE1":14469,"PHASE1":14471,"PHASE2":14473,"PHASE3":14475,"PHASE4":14477,"NA":14489},{"trials":14470,"activeCount":109},[],{"trials":14472,"activeCount":109},[],{"trials":14474,"activeCount":109},[],{"trials":14476,"activeCount":109},[],{"trials":14478,"activeCount":109},[14479],{"nctId":14480,"briefTitle":14481,"status":200,"phases":14482,"primaryCompletion":14483,"completion":14483,"start":14484,"enrollment":4065,"conditions":14485,"interventions":14488},"NCT05737186","SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency",[101],"2024-04-16","2023-03-09",[14486,14487],"Heart Failure With Reduced Ejection Fraction","Renal Insufficiency, Chronic",[14467],{"trials":14490,"activeCount":109},[],{"intervention":1474,"totalTrials":708,"cells":14492},{"EARLY_PHASE1":14493,"PHASE1":14495,"PHASE2":14497,"PHASE3":14499,"PHASE4":14501,"NA":14507},{"trials":14494,"activeCount":109},[],{"trials":14496,"activeCount":109},[],{"trials":14498,"activeCount":109},[],{"trials":14500,"activeCount":109},[],{"trials":14502,"activeCount":109},[14503],{"nctId":1467,"briefTitle":1468,"status":135,"phases":14504,"primaryCompletion":957,"completion":957,"start":1470,"enrollment":153,"conditions":14505,"interventions":14506},[101],[1472],[1474,1427],{"trials":14508,"activeCount":109},[],{"intervention":14510,"totalTrials":708,"cells":14511},"Vecuronium Bromide",{"EARLY_PHASE1":14512,"PHASE1":14514,"PHASE2":14516,"PHASE3":14518,"PHASE4":14520,"NA":14534},{"trials":14513,"activeCount":109},[],{"trials":14515,"activeCount":109},[],{"trials":14517,"activeCount":109},[],{"trials":14519,"activeCount":109},[],{"trials":14521,"activeCount":109},[14522],{"nctId":14523,"briefTitle":14524,"status":569,"phases":14525,"primaryCompletion":14526,"completion":3090,"start":14527,"enrollment":14528,"conditions":14529,"interventions":14532},"NCT01690338","A Study of Residual Curarization Incidence in China",[101],"2014-10","2012-10",6090,[14530,14531],"Perioperative\u002FPostoperative Complications","PORC (Postoperative Residual Curarization)",[14510,1423,14533],"Cisatracurium",{"trials":14535,"activeCount":109},[],{"intervention":14533,"totalTrials":708,"cells":14537},{"EARLY_PHASE1":14538,"PHASE1":14540,"PHASE2":14542,"PHASE3":14544,"PHASE4":14546,"NA":14552},{"trials":14539,"activeCount":109},[],{"trials":14541,"activeCount":109},[],{"trials":14543,"activeCount":109},[],{"trials":14545,"activeCount":109},[],{"trials":14547,"activeCount":109},[14548],{"nctId":14523,"briefTitle":14524,"status":569,"phases":14549,"primaryCompletion":14526,"completion":3090,"start":14527,"enrollment":14528,"conditions":14550,"interventions":14551},[101],[14530,14531],[14510,1423,14533],{"trials":14553,"activeCount":109},[],{"intervention":14555,"totalTrials":708,"cells":14556},"Staphylococcus and Neisseria",{"EARLY_PHASE1":14557,"PHASE1":14559,"PHASE2":14561,"PHASE3":14563,"PHASE4":14565,"NA":14576},{"trials":14558,"activeCount":109},[],{"trials":14560,"activeCount":109},[],{"trials":14562,"activeCount":109},[],{"trials":14564,"activeCount":109},[],{"trials":14566,"activeCount":109},[14567],{"nctId":14568,"briefTitle":14569,"status":569,"phases":14570,"primaryCompletion":3635,"completion":5352,"start":14571,"enrollment":14572,"conditions":14573,"interventions":14575},"NCT05975788","Effect of Staphylococcus and Neisseria Tablets on Clinical Outcome Among Patients With Chronic Obstructive Pulmonary Disease",[101],"2023-11",750,[14574],"Chronic Obstructive Pulmonary Disease",[14555],{"trials":14577,"activeCount":109},[],{"intervention":13580,"totalTrials":708,"cells":14579},{"EARLY_PHASE1":14580,"PHASE1":14582,"PHASE2":14584,"PHASE3":14586,"PHASE4":14588,"NA":14594},{"trials":14581,"activeCount":109},[],{"trials":14583,"activeCount":109},[],{"trials":14585,"activeCount":109},[],{"trials":14587,"activeCount":109},[],{"trials":14589,"activeCount":109},[14590],{"nctId":13573,"briefTitle":13574,"status":135,"phases":14591,"primaryCompletion":3545,"completion":3545,"start":13576,"enrollment":13577,"conditions":14592,"interventions":14593},[101],[13570],[13580,13581],{"trials":14595,"activeCount":109},[],{"intervention":14597,"totalTrials":708,"cells":14598},"Hepatitis B vaccine",{"EARLY_PHASE1":14599,"PHASE1":14601,"PHASE2":14603,"PHASE3":14605,"PHASE4":14607,"NA":14616},{"trials":14600,"activeCount":109},[],{"trials":14602,"activeCount":109},[],{"trials":14604,"activeCount":109},[],{"trials":14606,"activeCount":109},[],{"trials":14608,"activeCount":109},[14609],{"nctId":14610,"briefTitle":14611,"status":135,"phases":14612,"primaryCompletion":138,"completion":252,"start":4833,"enrollment":14613,"conditions":14614,"interventions":14615},"NCT02203357","A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults",[101],353,[13759],[14597],{"trials":14617,"activeCount":109},[],{"intervention":14619,"totalTrials":708,"cells":14620},"Zoledronic Acid",{"EARLY_PHASE1":14621,"PHASE1":14623,"PHASE2":14625,"PHASE3":14627,"PHASE4":14629,"NA":14639},{"trials":14622,"activeCount":109},[],{"trials":14624,"activeCount":109},[],{"trials":14626,"activeCount":109},[],{"trials":14628,"activeCount":109},[],{"trials":14630,"activeCount":109},[14631],{"nctId":14632,"briefTitle":14633,"status":569,"phases":14634,"primaryCompletion":3870,"completion":11518,"start":14635,"enrollment":2008,"conditions":14636,"interventions":14638},"NCT04719650","Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid",[101],"2021-10",[14637],"Postmenopausal Osteoporosis",[14619,14619,14619],{"trials":14640,"activeCount":109},[],{"intervention":10456,"totalTrials":708,"cells":14642},{"EARLY_PHASE1":14643,"PHASE1":14645,"PHASE2":14647,"PHASE3":14649,"PHASE4":14651,"NA":14657},{"trials":14644,"activeCount":109},[],{"trials":14646,"activeCount":109},[],{"trials":14648,"activeCount":109},[],{"trials":14650,"activeCount":109},[],{"trials":14652,"activeCount":109},[14653],{"nctId":10449,"briefTitle":10450,"status":569,"phases":14654,"primaryCompletion":3999,"completion":2503,"start":535,"enrollment":2712,"conditions":14655,"interventions":14656},[101],[10453,10454],[10456,10427],{"trials":14658,"activeCount":109},[],{"intervention":14660,"totalTrials":708,"cells":14661},"Flupentixol melitracen",{"EARLY_PHASE1":14662,"PHASE1":14664,"PHASE2":14666,"PHASE3":14668,"PHASE4":14670,"NA":14681},{"trials":14663,"activeCount":109},[],{"trials":14665,"activeCount":109},[],{"trials":14667,"activeCount":109},[],{"trials":14669,"activeCount":109},[],{"trials":14671,"activeCount":109},[14672],{"nctId":14673,"briefTitle":14674,"status":135,"phases":14675,"primaryCompletion":13458,"completion":14676,"start":4720,"enrollment":376,"conditions":14677,"interventions":14680},"NCT04970667","Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder",[101],"2020-04-30",[14678,14679],"Emotional Disorder","Neurologic Disorder",[14660],{"trials":14682,"activeCount":109},[],{"intervention":14684,"totalTrials":708,"cells":14685},"Calcitriol",{"EARLY_PHASE1":14686,"PHASE1":14688,"PHASE2":14690,"PHASE3":14692,"PHASE4":14694,"NA":14706},{"trials":14687,"activeCount":109},[],{"trials":14689,"activeCount":109},[],{"trials":14691,"activeCount":109},[],{"trials":14693,"activeCount":109},[],{"trials":14695,"activeCount":109},[14696],{"nctId":14697,"briefTitle":14698,"status":569,"phases":14699,"primaryCompletion":14700,"completion":4853,"start":14701,"enrollment":32,"conditions":14702,"interventions":14705},"NCT00862693","Calcitriol in the Treatment of Immunoglobulin A Nephropathy",[101],"2010-08","2009-03",[14703,14704],"Glomerulonephritis","Autoimmune Diseases",[14684],{"trials":14707,"activeCount":109},[],{"intervention":1169,"totalTrials":708,"cells":14709},{"EARLY_PHASE1":14710,"PHASE1":14712,"PHASE2":14714,"PHASE3":14716,"PHASE4":14718,"NA":14724},{"trials":14711,"activeCount":109},[],{"trials":14713,"activeCount":109},[],{"trials":14715,"activeCount":109},[],{"trials":14717,"activeCount":109},[],{"trials":14719,"activeCount":109},[14720],{"nctId":1159,"briefTitle":1160,"status":569,"phases":14721,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":14722,"interventions":14723},[101],[1167],[1169,1090,1170],{"trials":14725,"activeCount":109},[],{"intervention":1170,"totalTrials":708,"cells":14727},{"EARLY_PHASE1":14728,"PHASE1":14730,"PHASE2":14732,"PHASE3":14734,"PHASE4":14736,"NA":14742},{"trials":14729,"activeCount":109},[],{"trials":14731,"activeCount":109},[],{"trials":14733,"activeCount":109},[],{"trials":14735,"activeCount":109},[],{"trials":14737,"activeCount":109},[14738],{"nctId":1159,"briefTitle":1160,"status":569,"phases":14739,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":14740,"interventions":14741},[101],[1167],[1169,1090,1170],{"trials":14743,"activeCount":109},[],{"intervention":14745,"totalTrials":708,"cells":14746},"Sofosbuvir\u002FVelpatasvir + Ribavirin",{"EARLY_PHASE1":14747,"PHASE1":14749,"PHASE2":14751,"PHASE3":14753,"PHASE4":14755,"NA":14767},{"trials":14748,"activeCount":109},[],{"trials":14750,"activeCount":109},[],{"trials":14752,"activeCount":109},[],{"trials":14754,"activeCount":109},[],{"trials":14756,"activeCount":109},[14757],{"nctId":14758,"briefTitle":14759,"status":569,"phases":14760,"primaryCompletion":14761,"completion":81,"start":1138,"enrollment":376,"conditions":14762,"interventions":14765},"NCT05467826","Efficacy and Safety of SOF\u002FVEL + RBV and SOF\u002FVEL\u002FVOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis",[101],"2023-11-30",[14763,14764],"Hepatitis C","Cirrhosis",[14745,14766],"Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir",{"trials":14768,"activeCount":109},[],{"intervention":14766,"totalTrials":708,"cells":14770},{"EARLY_PHASE1":14771,"PHASE1":14773,"PHASE2":14775,"PHASE3":14777,"PHASE4":14779,"NA":14785},{"trials":14772,"activeCount":109},[],{"trials":14774,"activeCount":109},[],{"trials":14776,"activeCount":109},[],{"trials":14778,"activeCount":109},[],{"trials":14780,"activeCount":109},[14781],{"nctId":14758,"briefTitle":14759,"status":569,"phases":14782,"primaryCompletion":14761,"completion":81,"start":1138,"enrollment":376,"conditions":14783,"interventions":14784},[101],[14763,14764],[14745,14766],{"trials":14786,"activeCount":109},[],{"intervention":14788,"totalTrials":708,"cells":14789},"Madopar monotherapy",{"EARLY_PHASE1":14790,"PHASE1":14792,"PHASE2":14794,"PHASE3":14796,"PHASE4":14798,"NA":14809},{"trials":14791,"activeCount":109},[],{"trials":14793,"activeCount":109},[],{"trials":14795,"activeCount":109},[],{"trials":14797,"activeCount":109},[],{"trials":14799,"activeCount":109},[14800],{"nctId":14801,"briefTitle":14802,"status":569,"phases":14803,"primaryCompletion":1202,"completion":1202,"start":4720,"enrollment":640,"conditions":14804,"interventions":14807},"NCT04968613","Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease",[101],[14805,14806],"Parkinson Disease","Memory Impairment",[14788,14808],"senfrol monotherapy",{"trials":14810,"activeCount":109},[],{"intervention":14808,"totalTrials":708,"cells":14812},{"EARLY_PHASE1":14813,"PHASE1":14815,"PHASE2":14817,"PHASE3":14819,"PHASE4":14821,"NA":14827},{"trials":14814,"activeCount":109},[],{"trials":14816,"activeCount":109},[],{"trials":14818,"activeCount":109},[],{"trials":14820,"activeCount":109},[],{"trials":14822,"activeCount":109},[14823],{"nctId":14801,"briefTitle":14802,"status":569,"phases":14824,"primaryCompletion":1202,"completion":1202,"start":4720,"enrollment":640,"conditions":14825,"interventions":14826},[101],[14805,14806],[14788,14808],{"trials":14828,"activeCount":109},[],{"intervention":14830,"totalTrials":708,"cells":14831},"Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin",{"EARLY_PHASE1":14832,"PHASE1":14834,"PHASE2":14836,"PHASE3":14838,"PHASE4":14840,"NA":14849},{"trials":14833,"activeCount":109},[],{"trials":14835,"activeCount":109},[],{"trials":14837,"activeCount":109},[],{"trials":14839,"activeCount":109},[],{"trials":14841,"activeCount":109},[14842],{"nctId":14843,"briefTitle":14844,"status":569,"phases":14845,"primaryCompletion":1589,"completion":1103,"start":9272,"enrollment":140,"conditions":14846,"interventions":14848},"NCT05747768","A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients",[101],[14847],"Chronic Kidney Disease",[14830],{"trials":14850,"activeCount":109},[],{"intervention":14852,"totalTrials":708,"cells":14853},"The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.",{"EARLY_PHASE1":14854,"PHASE1":14856,"PHASE2":14858,"PHASE3":14860,"PHASE4":14862,"NA":14872},{"trials":14855,"activeCount":109},[],{"trials":14857,"activeCount":109},[],{"trials":14859,"activeCount":109},[],{"trials":14861,"activeCount":109},[],{"trials":14863,"activeCount":109},[14864],{"nctId":14865,"briefTitle":14866,"status":569,"phases":14867,"primaryCompletion":741,"completion":741,"start":14868,"enrollment":536,"conditions":14869,"interventions":14871},"NCT06273215","Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients",[101],"2023-03-05",[14870],"Diabetes",[14852],{"trials":14873,"activeCount":109},[],{"intervention":14875,"totalTrials":708,"cells":14876},"Metformin Hydrochloride 500 MG",{"EARLY_PHASE1":14877,"PHASE1":14879,"PHASE2":14881,"PHASE3":14883,"PHASE4":14885,"NA":14898},{"trials":14878,"activeCount":109},[],{"trials":14880,"activeCount":109},[],{"trials":14882,"activeCount":109},[],{"trials":14884,"activeCount":109},[],{"trials":14886,"activeCount":109},[14887],{"nctId":14888,"briefTitle":14889,"status":569,"phases":14890,"primaryCompletion":1103,"completion":1578,"start":14891,"enrollment":7270,"conditions":14892,"interventions":14895},"NCT05702905","Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome",[101],"2023-05-09",[14893,14894],"PCOS (Polycystic Ovary Syndrome)","Semaglutide",[14875,14896,14897],"Semaglutide, 1.34 mg\u002FmL","Semaglutide, 1.34 mg\u002FmL and Metformin Hydrochloride 500 MG",{"trials":14899,"activeCount":109},[],{"intervention":14896,"totalTrials":708,"cells":14901},{"EARLY_PHASE1":14902,"PHASE1":14904,"PHASE2":14906,"PHASE3":14908,"PHASE4":14910,"NA":14916},{"trials":14903,"activeCount":109},[],{"trials":14905,"activeCount":109},[],{"trials":14907,"activeCount":109},[],{"trials":14909,"activeCount":109},[],{"trials":14911,"activeCount":109},[14912],{"nctId":14888,"briefTitle":14889,"status":569,"phases":14913,"primaryCompletion":1103,"completion":1578,"start":14891,"enrollment":7270,"conditions":14914,"interventions":14915},[101],[14893,14894],[14875,14896,14897],{"trials":14917,"activeCount":109},[],{"intervention":14897,"totalTrials":708,"cells":14919},{"EARLY_PHASE1":14920,"PHASE1":14922,"PHASE2":14924,"PHASE3":14926,"PHASE4":14928,"NA":14934},{"trials":14921,"activeCount":109},[],{"trials":14923,"activeCount":109},[],{"trials":14925,"activeCount":109},[],{"trials":14927,"activeCount":109},[],{"trials":14929,"activeCount":109},[14930],{"nctId":14888,"briefTitle":14889,"status":569,"phases":14931,"primaryCompletion":1103,"completion":1578,"start":14891,"enrollment":7270,"conditions":14932,"interventions":14933},[101],[14893,14894],[14875,14896,14897],{"trials":14935,"activeCount":109},[],{"intervention":14937,"totalTrials":708,"cells":14938},"Acarbose",{"EARLY_PHASE1":14939,"PHASE1":14941,"PHASE2":14943,"PHASE3":14945,"PHASE4":14947,"NA":14958},{"trials":14940,"activeCount":109},[],{"trials":14942,"activeCount":109},[],{"trials":14944,"activeCount":109},[],{"trials":14946,"activeCount":109},[],{"trials":14948,"activeCount":109},[14949],{"nctId":14950,"briefTitle":14951,"status":569,"phases":14952,"primaryCompletion":668,"completion":14953,"start":14954,"enrollment":376,"conditions":14955,"interventions":14956},"NCT02999841","Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients",[101],"2018-01","2016-03",[10453,1517],[14937,14957],"Vildagliptin",{"trials":14959,"activeCount":109},[],{"intervention":14957,"totalTrials":708,"cells":14961},{"EARLY_PHASE1":14962,"PHASE1":14964,"PHASE2":14966,"PHASE3":14968,"PHASE4":14970,"NA":14976},{"trials":14963,"activeCount":109},[],{"trials":14965,"activeCount":109},[],{"trials":14967,"activeCount":109},[],{"trials":14969,"activeCount":109},[],{"trials":14971,"activeCount":109},[14972],{"nctId":14950,"briefTitle":14951,"status":569,"phases":14973,"primaryCompletion":668,"completion":14953,"start":14954,"enrollment":376,"conditions":14974,"interventions":14975},[101],[10453,1517],[14937,14957],{"trials":14977,"activeCount":109},[],{"intervention":5230,"totalTrials":708,"cells":14979},{"EARLY_PHASE1":14980,"PHASE1":14982,"PHASE2":14984,"PHASE3":14986,"PHASE4":14988,"NA":14994},{"trials":14981,"activeCount":109},[],{"trials":14983,"activeCount":109},[],{"trials":14985,"activeCount":109},[],{"trials":14987,"activeCount":109},[],{"trials":14989,"activeCount":109},[14990],{"nctId":5222,"briefTitle":5223,"status":135,"phases":14991,"primaryCompletion":254,"completion":3527,"start":5225,"enrollment":168,"conditions":14992,"interventions":14993},[101],[5227,5228],[5230,5189],{"trials":14995,"activeCount":109},[],{"intervention":14997,"totalTrials":708,"cells":14998},"Esketamine 0.2 mg\u002Fkg",{"EARLY_PHASE1":14999,"PHASE1":15001,"PHASE2":15003,"PHASE3":15005,"PHASE4":15007,"NA":15023},{"trials":15000,"activeCount":109},[],{"trials":15002,"activeCount":109},[],{"trials":15004,"activeCount":109},[],{"trials":15006,"activeCount":109},[],{"trials":15008,"activeCount":109},[15009],{"nctId":15010,"briefTitle":15011,"status":135,"phases":15012,"primaryCompletion":15013,"completion":15014,"start":15015,"enrollment":574,"conditions":15016,"interventions":15019},"NCT06613243","Different Doses of Dexmedetomidine Combined With Esketamine in Women Undergoing Cesarean Delivery",[101],"2024-12-02","2024-12-09","2024-10-08",[15017,40,15018,25],"Cesarean Delivery","Neuropsychiatric Symptoms",[14997,15020,15021,15022],"Esketamine 0.2 mg\u002Fkg + dexmedetomidine 0.1 µg\u002Fkg","Esketamine 0.2 mg\u002Fkg + dexmedetomidine 0.15 µg\u002Fkg","Esketamine 0.2 mg\u002Fkg + dexmedetomidine 0.2 µg\u002Fkg",{"trials":15024,"activeCount":109},[],{"intervention":15020,"totalTrials":708,"cells":15026},{"EARLY_PHASE1":15027,"PHASE1":15029,"PHASE2":15031,"PHASE3":15033,"PHASE4":15035,"NA":15041},{"trials":15028,"activeCount":109},[],{"trials":15030,"activeCount":109},[],{"trials":15032,"activeCount":109},[],{"trials":15034,"activeCount":109},[],{"trials":15036,"activeCount":109},[15037],{"nctId":15010,"briefTitle":15011,"status":135,"phases":15038,"primaryCompletion":15013,"completion":15014,"start":15015,"enrollment":574,"conditions":15039,"interventions":15040},[101],[15017,40,15018,25],[14997,15020,15021,15022],{"trials":15042,"activeCount":109},[],{"intervention":15021,"totalTrials":708,"cells":15044},{"EARLY_PHASE1":15045,"PHASE1":15047,"PHASE2":15049,"PHASE3":15051,"PHASE4":15053,"NA":15059},{"trials":15046,"activeCount":109},[],{"trials":15048,"activeCount":109},[],{"trials":15050,"activeCount":109},[],{"trials":15052,"activeCount":109},[],{"trials":15054,"activeCount":109},[15055],{"nctId":15010,"briefTitle":15011,"status":135,"phases":15056,"primaryCompletion":15013,"completion":15014,"start":15015,"enrollment":574,"conditions":15057,"interventions":15058},[101],[15017,40,15018,25],[14997,15020,15021,15022],{"trials":15060,"activeCount":109},[],{"intervention":15022,"totalTrials":708,"cells":15062},{"EARLY_PHASE1":15063,"PHASE1":15065,"PHASE2":15067,"PHASE3":15069,"PHASE4":15071,"NA":15077},{"trials":15064,"activeCount":109},[],{"trials":15066,"activeCount":109},[],{"trials":15068,"activeCount":109},[],{"trials":15070,"activeCount":109},[],{"trials":15072,"activeCount":109},[15073],{"nctId":15010,"briefTitle":15011,"status":135,"phases":15074,"primaryCompletion":15013,"completion":15014,"start":15015,"enrollment":574,"conditions":15075,"interventions":15076},[101],[15017,40,15018,25],[14997,15020,15021,15022],{"trials":15078,"activeCount":109},[],{"intervention":15080,"totalTrials":708,"cells":15081},"Levosimendan",{"EARLY_PHASE1":15082,"PHASE1":15084,"PHASE2":15086,"PHASE3":15088,"PHASE4":15090,"NA":15100},{"trials":15083,"activeCount":109},[],{"trials":15085,"activeCount":109},[],{"trials":15087,"activeCount":109},[],{"trials":15089,"activeCount":109},[],{"trials":15091,"activeCount":109},[15092],{"nctId":15093,"briefTitle":15094,"status":569,"phases":15095,"primaryCompletion":1103,"completion":1103,"start":7884,"enrollment":140,"conditions":15096,"interventions":15098},"NCT05956431","RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest",[101],[15097],"Heart Arrest",[15080,15099],"physiological saline",{"trials":15101,"activeCount":109},[],{"intervention":15099,"totalTrials":708,"cells":15103},{"EARLY_PHASE1":15104,"PHASE1":15106,"PHASE2":15108,"PHASE3":15110,"PHASE4":15112,"NA":15118},{"trials":15105,"activeCount":109},[],{"trials":15107,"activeCount":109},[],{"trials":15109,"activeCount":109},[],{"trials":15111,"activeCount":109},[],{"trials":15113,"activeCount":109},[15114],{"nctId":15093,"briefTitle":15094,"status":569,"phases":15115,"primaryCompletion":1103,"completion":1103,"start":7884,"enrollment":140,"conditions":15116,"interventions":15117},[101],[15097],[15080,15099],{"trials":15119,"activeCount":109},[],{"intervention":15121,"totalTrials":708,"cells":15122},"anti thymoglobulin",{"EARLY_PHASE1":15123,"PHASE1":15125,"PHASE2":15127,"PHASE3":15129,"PHASE4":15131,"NA":15141},{"trials":15124,"activeCount":109},[],{"trials":15126,"activeCount":109},[],{"trials":15128,"activeCount":109},[],{"trials":15130,"activeCount":109},[],{"trials":15132,"activeCount":109},[15133],{"nctId":15134,"briefTitle":15135,"status":135,"phases":15136,"primaryCompletion":2824,"completion":4670,"start":15137,"enrollment":4171,"conditions":15138,"interventions":15140},"NCT01856803","Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis",[101],"2013-10",[15139],"Leukemia, GVHD, ATG, Transplantation",[15121],{"trials":15142,"activeCount":109},[],{"intervention":15144,"totalTrials":708,"cells":15145},"Pravastatin Sodium 80 MG",{"EARLY_PHASE1":15146,"PHASE1":15148,"PHASE2":15150,"PHASE3":15152,"PHASE4":15154,"NA":15162},{"trials":15147,"activeCount":109},[],{"trials":15149,"activeCount":109},[],{"trials":15151,"activeCount":109},[],{"trials":15153,"activeCount":109},[],{"trials":15155,"activeCount":109},[15156],{"nctId":15157,"briefTitle":15158,"status":569,"phases":15159,"primaryCompletion":3698,"completion":4660,"start":3698,"enrollment":3566,"conditions":15160,"interventions":15161},"NCT04719481","Pravastatin Reduces Acute Phase Response of Zoledronic Acid",[101],[14637],[15144],{"trials":15163,"activeCount":109},[],{"intervention":15165,"totalTrials":708,"cells":15166},"oral vitamin C",{"EARLY_PHASE1":15167,"PHASE1":15169,"PHASE2":15171,"PHASE3":15173,"PHASE4":15175,"NA":15187},{"trials":15168,"activeCount":109},[],{"trials":15170,"activeCount":109},[],{"trials":15172,"activeCount":109},[],{"trials":15174,"activeCount":109},[],{"trials":15176,"activeCount":109},[15177],{"nctId":15178,"briefTitle":15179,"status":135,"phases":15180,"primaryCompletion":4153,"completion":4153,"start":15181,"enrollment":15182,"conditions":15183,"interventions":15186},"NCT01356433","Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients",[101],"2011-08",128,[15184,15185],"Uremia","Inflammation",[15165,15165],{"trials":15188,"activeCount":109},[],{"intervention":15190,"totalTrials":708,"cells":15191},"erythropoietin",{"EARLY_PHASE1":15192,"PHASE1":15194,"PHASE2":15196,"PHASE3":15198,"PHASE4":15200,"NA":15211},{"trials":15193,"activeCount":109},[],{"trials":15195,"activeCount":109},[],{"trials":15197,"activeCount":109},[],{"trials":15199,"activeCount":109},[],{"trials":15201,"activeCount":109},[15202],{"nctId":15203,"briefTitle":15204,"status":569,"phases":15205,"primaryCompletion":668,"completion":4090,"start":4126,"enrollment":670,"conditions":15206,"interventions":15209},"NCT03010579","Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation",[101],[15207,11636,15208],"Anemia","Hematopoietic Stem Cell Transplantation",[15190,15210],"iron supplementation",{"trials":15212,"activeCount":109},[],{"intervention":15210,"totalTrials":708,"cells":15214},{"EARLY_PHASE1":15215,"PHASE1":15217,"PHASE2":15219,"PHASE3":15221,"PHASE4":15223,"NA":15229},{"trials":15216,"activeCount":109},[],{"trials":15218,"activeCount":109},[],{"trials":15220,"activeCount":109},[],{"trials":15222,"activeCount":109},[],{"trials":15224,"activeCount":109},[15225],{"nctId":15203,"briefTitle":15204,"status":569,"phases":15226,"primaryCompletion":668,"completion":4090,"start":4126,"enrollment":670,"conditions":15227,"interventions":15228},[101],[15207,11636,15208],[15190,15210],{"trials":15230,"activeCount":109},[],{"intervention":15232,"totalTrials":708,"cells":15233},"Rabies vaccine, manufactured by ChengDa",{"EARLY_PHASE1":15234,"PHASE1":15236,"PHASE2":15238,"PHASE3":15240,"PHASE4":15242,"NA":15253},{"trials":15235,"activeCount":109},[],{"trials":15237,"activeCount":109},[],{"trials":15239,"activeCount":109},[],{"trials":15241,"activeCount":109},[],{"trials":15243,"activeCount":109},[15244],{"nctId":15245,"briefTitle":15246,"status":569,"phases":15247,"primaryCompletion":14700,"completion":15248,"start":15249,"enrollment":1894,"conditions":15250,"interventions":15252},"NCT01173302","Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose",[101],"2010-09","2010-05",[15251],"Rabies",[15232],{"trials":15254,"activeCount":109},[],{"intervention":15256,"totalTrials":708,"cells":15257},"ticagrelor + ASA",{"EARLY_PHASE1":15258,"PHASE1":15260,"PHASE2":15262,"PHASE3":15264,"PHASE4":15266,"NA":15279},{"trials":15259,"activeCount":109},[],{"trials":15261,"activeCount":109},[],{"trials":15263,"activeCount":109},[],{"trials":15265,"activeCount":109},[],{"trials":15267,"activeCount":109},[15268],{"nctId":15269,"briefTitle":15270,"status":135,"phases":15271,"primaryCompletion":15272,"completion":150,"start":15273,"enrollment":15274,"conditions":15275,"interventions":15278},"NCT04962451","Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke",[101],"2019-09-30","2017-09-01",13000,[15276,15277],"Cerebrovascular Accident","Cerebrovascular Accident, Acute",[15256],{"trials":15280,"activeCount":109},[],{"intervention":15282,"totalTrials":708,"cells":15283},"Shexiang Tongxin Dropping Pills + routine treatment",{"EARLY_PHASE1":15284,"PHASE1":15286,"PHASE2":15288,"PHASE3":15290,"PHASE4":15292,"NA":15302},{"trials":15285,"activeCount":109},[],{"trials":15287,"activeCount":109},[],{"trials":15289,"activeCount":109},[],{"trials":15291,"activeCount":109},[],{"trials":15293,"activeCount":109},[15294],{"nctId":15295,"briefTitle":15296,"status":569,"phases":15297,"primaryCompletion":2916,"completion":15298,"start":4201,"enrollment":140,"conditions":15299,"interventions":15301},"NCT04952259","Effect of Shexiang Tongxin Dropping Pills on Microcirculation in Patients With AMI",[101],"2023-07-31",[15300],"Acute Myocardial Infarction",[15282],{"trials":15303,"activeCount":109},[],{"intervention":15305,"totalTrials":708,"cells":15306},"sufentanil-ropivacaine combination",{"EARLY_PHASE1":15307,"PHASE1":15309,"PHASE2":15311,"PHASE3":15313,"PHASE4":15315,"NA":15331},{"trials":15308,"activeCount":109},[],{"trials":15310,"activeCount":109},[],{"trials":15312,"activeCount":109},[],{"trials":15314,"activeCount":109},[],{"trials":15316,"activeCount":109},[15317],{"nctId":15318,"briefTitle":15319,"status":135,"phases":15320,"primaryCompletion":15321,"completion":15322,"start":15323,"enrollment":4171,"conditions":15324,"interventions":15328},"NCT07145775","Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia",[101],"2026-01-29","2026-03-13","2025-09-05",[15325,15326,172,25,40,15327],"Epidural Analgesia","Labor Pain","Ropivacaine",[15305,15329,15330],"dexmedetomidine-esketamine-ropivacaine combination 1","dexmedetomidine-esketamine-ropivacaine combination 2",{"trials":15332,"activeCount":109},[],{"intervention":15329,"totalTrials":708,"cells":15334},{"EARLY_PHASE1":15335,"PHASE1":15337,"PHASE2":15339,"PHASE3":15341,"PHASE4":15343,"NA":15349},{"trials":15336,"activeCount":109},[],{"trials":15338,"activeCount":109},[],{"trials":15340,"activeCount":109},[],{"trials":15342,"activeCount":109},[],{"trials":15344,"activeCount":109},[15345],{"nctId":15318,"briefTitle":15319,"status":135,"phases":15346,"primaryCompletion":15321,"completion":15322,"start":15323,"enrollment":4171,"conditions":15347,"interventions":15348},[101],[15325,15326,172,25,40,15327],[15305,15329,15330],{"trials":15350,"activeCount":109},[],{"intervention":15330,"totalTrials":708,"cells":15352},{"EARLY_PHASE1":15353,"PHASE1":15355,"PHASE2":15357,"PHASE3":15359,"PHASE4":15361,"NA":15367},{"trials":15354,"activeCount":109},[],{"trials":15356,"activeCount":109},[],{"trials":15358,"activeCount":109},[],{"trials":15360,"activeCount":109},[],{"trials":15362,"activeCount":109},[15363],{"nctId":15318,"briefTitle":15319,"status":135,"phases":15364,"primaryCompletion":15321,"completion":15322,"start":15323,"enrollment":4171,"conditions":15365,"interventions":15366},[101],[15325,15326,172,25,40,15327],[15305,15329,15330],{"trials":15368,"activeCount":109},[],{"intervention":15370,"totalTrials":708,"cells":15371},"Cetylpyridinium Chloride Buccal",{"EARLY_PHASE1":15372,"PHASE1":15374,"PHASE2":15376,"PHASE3":15378,"PHASE4":15380,"NA":15392},{"trials":15373,"activeCount":109},[],{"trials":15375,"activeCount":109},[],{"trials":15377,"activeCount":109},[],{"trials":15379,"activeCount":109},[],{"trials":15381,"activeCount":109},[15382],{"nctId":15383,"briefTitle":15384,"status":135,"phases":15385,"primaryCompletion":15386,"completion":15386,"start":15387,"enrollment":477,"conditions":15388,"interventions":15391},"NCT05802628","Salivary Drug Concentration Exploratory Study of Cetylpyridinium Chloride Buccal Tablets",[101],"2023-04-18","2023-04-10",[15389,15390],"Pharyngitis Acute","Gingivitis",[15370],{"trials":15393,"activeCount":109},[],{"intervention":15395,"totalTrials":708,"cells":15396},"Nifedipine GITS",{"EARLY_PHASE1":15397,"PHASE1":15399,"PHASE2":15401,"PHASE3":15403,"PHASE4":15405,"NA":15414},{"trials":15398,"activeCount":109},[],{"trials":15400,"activeCount":109},[],{"trials":15402,"activeCount":109},[],{"trials":15404,"activeCount":109},[],{"trials":15406,"activeCount":109},[15407],{"nctId":15408,"briefTitle":15409,"status":569,"phases":15410,"primaryCompletion":15411,"completion":15411,"start":2883,"enrollment":255,"conditions":15412,"interventions":15413},"NCT02641821","Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension",[101],"2019-12",[8356],[15395],{"trials":15415,"activeCount":109},[],{"intervention":15417,"totalTrials":708,"cells":15418},"Minodronate",{"EARLY_PHASE1":15419,"PHASE1":15421,"PHASE2":15423,"PHASE3":15425,"PHASE4":15427,"NA":15436},{"trials":15420,"activeCount":109},[],{"trials":15422,"activeCount":109},[],{"trials":15424,"activeCount":109},[],{"trials":15426,"activeCount":109},[],{"trials":15428,"activeCount":109},[15429],{"nctId":15430,"briefTitle":15431,"status":569,"phases":15432,"primaryCompletion":81,"completion":9918,"start":817,"enrollment":960,"conditions":15433,"interventions":15434},"NCT05645289","Efficacy and Safety of Minodronate in Patients With Low Back Pain",[101],[14637],[15417,15435],"Alendronate",{"trials":15437,"activeCount":109},[],{"intervention":15435,"totalTrials":708,"cells":15439},{"EARLY_PHASE1":15440,"PHASE1":15442,"PHASE2":15444,"PHASE3":15446,"PHASE4":15448,"NA":15454},{"trials":15441,"activeCount":109},[],{"trials":15443,"activeCount":109},[],{"trials":15445,"activeCount":109},[],{"trials":15447,"activeCount":109},[],{"trials":15449,"activeCount":109},[15450],{"nctId":15430,"briefTitle":15431,"status":569,"phases":15451,"primaryCompletion":81,"completion":9918,"start":817,"enrollment":960,"conditions":15452,"interventions":15453},[101],[14637],[15417,15435],{"trials":15455,"activeCount":109},[],{"intervention":15457,"totalTrials":708,"cells":15458},"Performing paravertebral nerve block with lipo-bupivacaine",{"EARLY_PHASE1":15459,"PHASE1":15461,"PHASE2":15463,"PHASE3":15465,"PHASE4":15467,"NA":15483},{"trials":15460,"activeCount":109},[],{"trials":15462,"activeCount":109},[],{"trials":15464,"activeCount":109},[],{"trials":15466,"activeCount":109},[],{"trials":15468,"activeCount":109},[15469],{"nctId":15470,"briefTitle":15471,"status":135,"phases":15472,"primaryCompletion":15473,"completion":15474,"start":15475,"enrollment":15476,"conditions":15477,"interventions":15481},"NCT06231355","Liposomal vs. Conventional Bupivacaine for Pain Control",[101],"2024-09-09","2024-10-14","2024-02-21",61,[15478,183,15479,15480],"Local Anesthetics","Regional Block","Paravertebral Block",[15457,15482],"Performing paravertebral nerve block with bupivacaine",{"trials":15484,"activeCount":109},[],{"intervention":15482,"totalTrials":708,"cells":15486},{"EARLY_PHASE1":15487,"PHASE1":15489,"PHASE2":15491,"PHASE3":15493,"PHASE4":15495,"NA":15501},{"trials":15488,"activeCount":109},[],{"trials":15490,"activeCount":109},[],{"trials":15492,"activeCount":109},[],{"trials":15494,"activeCount":109},[],{"trials":15496,"activeCount":109},[15497],{"nctId":15470,"briefTitle":15471,"status":135,"phases":15498,"primaryCompletion":15473,"completion":15474,"start":15475,"enrollment":15476,"conditions":15499,"interventions":15500},[101],[15478,183,15479,15480],[15457,15482],{"trials":15502,"activeCount":109},[],{"intervention":15504,"totalTrials":708,"cells":15505},"IDegLira",{"EARLY_PHASE1":15506,"PHASE1":15508,"PHASE2":15510,"PHASE3":15512,"PHASE4":15514,"NA":15524},{"trials":15507,"activeCount":109},[],{"trials":15509,"activeCount":109},[],{"trials":15511,"activeCount":109},[],{"trials":15513,"activeCount":109},[],{"trials":15515,"activeCount":109},[15516],{"nctId":15517,"briefTitle":15518,"status":569,"phases":15519,"primaryCompletion":3259,"completion":10699,"start":742,"enrollment":15520,"conditions":15521,"interventions":15522},"NCT06408532","The Efficacy and Safety of Insulin Degludec\u002FLiraglutide Combination (IDegLira) in Patients With Type 2 Diabetes",[101],256,[10453],[15504,15523],"Premixed insulin",{"trials":15525,"activeCount":109},[],{"intervention":15523,"totalTrials":708,"cells":15527},{"EARLY_PHASE1":15528,"PHASE1":15530,"PHASE2":15532,"PHASE3":15534,"PHASE4":15536,"NA":15542},{"trials":15529,"activeCount":109},[],{"trials":15531,"activeCount":109},[],{"trials":15533,"activeCount":109},[],{"trials":15535,"activeCount":109},[],{"trials":15537,"activeCount":109},[15538],{"nctId":15517,"briefTitle":15518,"status":569,"phases":15539,"primaryCompletion":3259,"completion":10699,"start":742,"enrollment":15520,"conditions":15540,"interventions":15541},[101],[10453],[15504,15523],{"trials":15543,"activeCount":109},[],{"intervention":15545,"totalTrials":708,"cells":15546},"Benvitimod",{"EARLY_PHASE1":15547,"PHASE1":15549,"PHASE2":15551,"PHASE3":15553,"PHASE4":15555,"NA":15564},{"trials":15548,"activeCount":109},[],{"trials":15550,"activeCount":109},[],{"trials":15552,"activeCount":109},[],{"trials":15554,"activeCount":109},[],{"trials":15556,"activeCount":109},[15557],{"nctId":15558,"briefTitle":15559,"status":569,"phases":15560,"primaryCompletion":2503,"completion":15561,"start":857,"enrollment":11177,"conditions":15562,"interventions":15563},"NCT05064748","Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults",[101],"2024-09-30",[11213],[15545],{"trials":15565,"activeCount":109},[],{"intervention":15567,"totalTrials":708,"cells":15568},"Metronidazole",{"EARLY_PHASE1":15569,"PHASE1":15571,"PHASE2":15573,"PHASE3":15575,"PHASE4":15577,"NA":15588},{"trials":15570,"activeCount":109},[],{"trials":15572,"activeCount":109},[],{"trials":15574,"activeCount":109},[],{"trials":15576,"activeCount":109},[],{"trials":15578,"activeCount":109},[15579],{"nctId":15580,"briefTitle":15581,"status":135,"phases":15582,"primaryCompletion":5372,"completion":5372,"start":15583,"enrollment":6539,"conditions":15584,"interventions":15586},"NCT03099408","Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis",[101],"2017-07-01",[1966,15585],"Recurrence",[15567,15587],"\"Metronidazole\" and \"Lactobacillus\"",{"trials":15589,"activeCount":109},[],{"intervention":15587,"totalTrials":708,"cells":15591},{"EARLY_PHASE1":15592,"PHASE1":15594,"PHASE2":15596,"PHASE3":15598,"PHASE4":15600,"NA":15606},{"trials":15593,"activeCount":109},[],{"trials":15595,"activeCount":109},[],{"trials":15597,"activeCount":109},[],{"trials":15599,"activeCount":109},[],{"trials":15601,"activeCount":109},[15602],{"nctId":15580,"briefTitle":15581,"status":135,"phases":15603,"primaryCompletion":5372,"completion":5372,"start":15583,"enrollment":6539,"conditions":15604,"interventions":15605},[101],[1966,15585],[15567,15587],{"trials":15607,"activeCount":109},[],{"intervention":15609,"totalTrials":708,"cells":15610},"XingpiJieyu Formula (XPJYF) + Escitalopram",{"EARLY_PHASE1":15611,"PHASE1":15613,"PHASE2":15615,"PHASE3":15617,"PHASE4":15619,"NA":15631},{"trials":15612,"activeCount":109},[],{"trials":15614,"activeCount":109},[],{"trials":15616,"activeCount":109},[],{"trials":15618,"activeCount":109},[],{"trials":15620,"activeCount":109},[15621],{"nctId":15622,"briefTitle":15623,"status":135,"phases":15624,"primaryCompletion":11211,"completion":4501,"start":15625,"enrollment":640,"conditions":15626,"interventions":15629},"NCT07590609","Effect of XingpiJieyu Formula on Mitochondrial Energy Metabolism in Severe Liver-Stagnation and Spleen-Deficiency Depression.",[101],"2023-05-23",[15627,15628],"Liver-Stagnation and Spleen-Deficiency","Severe Major Depression Disorder",[15609,15630],"XingpiJieyu Placebo + Escitalopram",{"trials":15632,"activeCount":109},[],{"intervention":15630,"totalTrials":708,"cells":15634},{"EARLY_PHASE1":15635,"PHASE1":15637,"PHASE2":15639,"PHASE3":15641,"PHASE4":15643,"NA":15649},{"trials":15636,"activeCount":109},[],{"trials":15638,"activeCount":109},[],{"trials":15640,"activeCount":109},[],{"trials":15642,"activeCount":109},[],{"trials":15644,"activeCount":109},[15645],{"nctId":15622,"briefTitle":15623,"status":135,"phases":15646,"primaryCompletion":11211,"completion":4501,"start":15625,"enrollment":640,"conditions":15647,"interventions":15648},[101],[15627,15628],[15609,15630],{"trials":15650,"activeCount":109},[],{"intervention":15652,"totalTrials":708,"cells":15653},"Oxytocin nasal spray",{"EARLY_PHASE1":15654,"PHASE1":15656,"PHASE2":15658,"PHASE3":15660,"PHASE4":15662,"NA":15675},{"trials":15655,"activeCount":109},[],{"trials":15657,"activeCount":109},[],{"trials":15659,"activeCount":109},[],{"trials":15661,"activeCount":109},[],{"trials":15663,"activeCount":109},[15664],{"nctId":15665,"briefTitle":15666,"status":135,"phases":15667,"primaryCompletion":15668,"completion":15668,"start":15669,"enrollment":574,"conditions":15670,"interventions":15674},"NCT05823441","Effect of Oxytocin Nasal Inhalation on Empathy Analgesia",[101],"2024-01-21","2023-06-03",[15671,861,15672,15673,183],"Oxytocin","Empathy","Social Familiarity",[15652],{"trials":15676,"activeCount":109},[],{"intervention":15678,"totalTrials":708,"cells":15679},"lithium carbonate combined with SSRI antidepressant treatment",{"EARLY_PHASE1":15680,"PHASE1":15682,"PHASE2":15684,"PHASE3":15686,"PHASE4":15688,"NA":15698},{"trials":15681,"activeCount":109},[],{"trials":15683,"activeCount":109},[],{"trials":15685,"activeCount":109},[],{"trials":15687,"activeCount":109},[],{"trials":15689,"activeCount":109},[15690],{"nctId":15691,"briefTitle":15692,"status":569,"phases":15693,"primaryCompletion":3023,"completion":3023,"start":449,"enrollment":376,"conditions":15694,"interventions":15696},"NCT03148535","Guidance Model of Standardized Treatment of Antidepressants in Bipolar Disorder",[101],[15695],"the Use of Antidepressants in Patients With Bipolar Depression",[15697,15678],"Lithium Carbonate",{"trials":15699,"activeCount":109},[],{"intervention":823,"totalTrials":708,"cells":15701},{"EARLY_PHASE1":15702,"PHASE1":15704,"PHASE2":15706,"PHASE3":15708,"PHASE4":15710,"NA":15716},{"trials":15703,"activeCount":109},[],{"trials":15705,"activeCount":109},[],{"trials":15707,"activeCount":109},[],{"trials":15709,"activeCount":109},[],{"trials":15711,"activeCount":109},[15712],{"nctId":814,"briefTitle":815,"status":135,"phases":15713,"primaryCompletion":817,"completion":818,"start":819,"enrollment":153,"conditions":15714,"interventions":15715},[101],[821],[172,823,824,825],{"trials":15717,"activeCount":109},[],{"intervention":15719,"totalTrials":708,"cells":15720},"Tafamidis Pill",{"EARLY_PHASE1":15721,"PHASE1":15723,"PHASE2":15725,"PHASE3":15727,"PHASE4":15729,"NA":15738},{"trials":15722,"activeCount":109},[],{"trials":15724,"activeCount":109},[],{"trials":15726,"activeCount":109},[],{"trials":15728,"activeCount":109},[],{"trials":15730,"activeCount":109},[15731],{"nctId":15732,"briefTitle":15733,"status":569,"phases":15734,"primaryCompletion":639,"completion":818,"start":857,"enrollment":477,"conditions":15735,"interventions":15737},"NCT04963985","The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients",[101],[15736],"Transthyretin Amyloidosis",[15719],{"trials":15739,"activeCount":109},[],{"intervention":15741,"totalTrials":708,"cells":15742},"Triptorelin acetate",{"EARLY_PHASE1":15743,"PHASE1":15745,"PHASE2":15747,"PHASE3":15749,"PHASE4":15751,"NA":15762},{"trials":15744,"activeCount":109},[],{"trials":15746,"activeCount":109},[],{"trials":15748,"activeCount":109},[],{"trials":15750,"activeCount":109},[],{"trials":15752,"activeCount":109},[15753],{"nctId":15754,"briefTitle":15755,"status":569,"phases":15756,"primaryCompletion":15757,"completion":657,"start":15758,"enrollment":15759,"conditions":15760,"interventions":15761},"NCT03809221","The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation",[101],"2020-09-01","2019-02-01",1892,[1541],[15741],{"trials":15763,"activeCount":109},[],{"intervention":506,"totalTrials":708,"cells":15765},{"EARLY_PHASE1":15766,"PHASE1":15768,"PHASE2":15770,"PHASE3":15772,"PHASE4":15774,"NA":15786},{"trials":15767,"activeCount":109},[],{"trials":15769,"activeCount":109},[],{"trials":15771,"activeCount":109},[],{"trials":15773,"activeCount":109},[],{"trials":15775,"activeCount":109},[15776],{"nctId":15777,"briefTitle":15778,"status":135,"phases":15779,"primaryCompletion":15780,"completion":15781,"start":15782,"enrollment":2008,"conditions":15783,"interventions":15785},"NCT03336541","Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression",[101],"2018-05-14","2018-06-25","2017-11-23",[15784,506,15017,507],"Perinatal Depression",[506],{"trials":15787,"activeCount":109},[],{"intervention":13840,"totalTrials":708,"cells":15789},{"EARLY_PHASE1":15790,"PHASE1":15792,"PHASE2":15794,"PHASE3":15796,"PHASE4":15798,"NA":15804},{"trials":15791,"activeCount":109},[],{"trials":15793,"activeCount":109},[],{"trials":15795,"activeCount":109},[],{"trials":15797,"activeCount":109},[],{"trials":15799,"activeCount":109},[15800],{"nctId":13832,"briefTitle":13833,"status":135,"phases":15801,"primaryCompletion":1404,"completion":1404,"start":13835,"enrollment":1480,"conditions":15802,"interventions":15803},[101],[13837],[13839,13840],{"trials":15805,"activeCount":109},[],{"intervention":15807,"totalTrials":708,"cells":15808},"Diquafosol",{"EARLY_PHASE1":15809,"PHASE1":15811,"PHASE2":15813,"PHASE3":15815,"PHASE4":15817,"NA":15830},{"trials":15810,"activeCount":109},[],{"trials":15812,"activeCount":109},[],{"trials":15814,"activeCount":109},[],{"trials":15816,"activeCount":109},[],{"trials":15818,"activeCount":109},[15819],{"nctId":15820,"briefTitle":15821,"status":569,"phases":15822,"primaryCompletion":5839,"completion":15823,"start":15824,"enrollment":4738,"conditions":15825,"interventions":15829},"NCT04668118","The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye",[101],"2023-03-25","2021-02-01",[15826,15827,15828],"Dry Eye Syndromes","Computer Vision Syndrome","Asthenopia",[15807],{"trials":15831,"activeCount":109},[],{"intervention":15833,"totalTrials":708,"cells":15834},"Plerixafor,G-CSF",{"EARLY_PHASE1":15835,"PHASE1":15837,"PHASE2":15839,"PHASE3":15841,"PHASE4":15843,"NA":15854},{"trials":15836,"activeCount":109},[],{"trials":15838,"activeCount":109},[],{"trials":15840,"activeCount":109},[],{"trials":15842,"activeCount":109},[],{"trials":15844,"activeCount":109},[15845],{"nctId":15846,"briefTitle":15847,"status":569,"phases":15848,"primaryCompletion":15849,"completion":15850,"start":15851,"enrollment":1480,"conditions":15852,"interventions":15853},"NCT05510544","Plerixafor for Poorly Mobilized Lymphoma",[101],"2023-12-20","2024-01-31","2022-12-19",[11636],[15833],{"trials":15855,"activeCount":109},[],{"intervention":15857,"totalTrials":708,"cells":15858},"Metaraminol 2.7μg\u002Fkg\u002Fmin",{"EARLY_PHASE1":15859,"PHASE1":15861,"PHASE2":15863,"PHASE3":15865,"PHASE4":15867,"NA":15878},{"trials":15860,"activeCount":109},[],{"trials":15862,"activeCount":109},[],{"trials":15864,"activeCount":109},[],{"trials":15866,"activeCount":109},[],{"trials":15868,"activeCount":109},[15869],{"nctId":15870,"briefTitle":15871,"status":135,"phases":15872,"primaryCompletion":15850,"completion":15850,"start":15873,"enrollment":5554,"conditions":15874,"interventions":15876},"NCT05084599","Effect of 90% Effective Dose of Metaraminol in Supine and Left Tilt Positions on Cesarean Section",[101],"2022-05-12",[15875],"Cesarean Section Complications",[15857,15877],"Metaraminol 2μg\u002Fkg\u002Fmin",{"trials":15879,"activeCount":109},[],{"intervention":15877,"totalTrials":708,"cells":15881},{"EARLY_PHASE1":15882,"PHASE1":15884,"PHASE2":15886,"PHASE3":15888,"PHASE4":15890,"NA":15896},{"trials":15883,"activeCount":109},[],{"trials":15885,"activeCount":109},[],{"trials":15887,"activeCount":109},[],{"trials":15889,"activeCount":109},[],{"trials":15891,"activeCount":109},[15892],{"nctId":15870,"briefTitle":15871,"status":135,"phases":15893,"primaryCompletion":15850,"completion":15850,"start":15873,"enrollment":5554,"conditions":15894,"interventions":15895},[101],[15875],[15857,15877],{"trials":15897,"activeCount":109},[],{"intervention":13702,"totalTrials":708,"cells":15899},{"EARLY_PHASE1":15900,"PHASE1":15902,"PHASE2":15904,"PHASE3":15906,"PHASE4":15908,"NA":15914},{"trials":15901,"activeCount":109},[],{"trials":15903,"activeCount":109},[],{"trials":15905,"activeCount":109},[],{"trials":15907,"activeCount":109},[],{"trials":15909,"activeCount":109},[15910],{"nctId":13691,"briefTitle":13692,"status":135,"phases":15911,"primaryCompletion":13694,"completion":13694,"start":4141,"enrollment":13695,"conditions":15912,"interventions":15913},[101],[13697,13698,13699],[13701,13702],{"trials":15915,"activeCount":109},[],{"intervention":13768,"totalTrials":708,"cells":15917},{"EARLY_PHASE1":15918,"PHASE1":15920,"PHASE2":15922,"PHASE3":15924,"PHASE4":15926,"NA":15932},{"trials":15919,"activeCount":109},[],{"trials":15921,"activeCount":109},[],{"trials":15923,"activeCount":109},[],{"trials":15925,"activeCount":109},[],{"trials":15927,"activeCount":109},[15928],{"nctId":13762,"briefTitle":13763,"status":569,"phases":15929,"primaryCompletion":668,"completion":668,"start":13757,"enrollment":13765,"conditions":15930,"interventions":15931},[101],[13759],[13741,13768],{"trials":15933,"activeCount":109},[],{"intervention":15935,"totalTrials":708,"cells":15936},"nicorandil",{"EARLY_PHASE1":15937,"PHASE1":15939,"PHASE2":15941,"PHASE3":15943,"PHASE4":15945,"NA":15955},{"trials":15938,"activeCount":109},[],{"trials":15940,"activeCount":109},[],{"trials":15942,"activeCount":109},[],{"trials":15944,"activeCount":109},[],{"trials":15946,"activeCount":109},[15947],{"nctId":15948,"briefTitle":15949,"status":135,"phases":15950,"primaryCompletion":15951,"completion":15951,"start":3623,"enrollment":15476,"conditions":15952,"interventions":15954},"NCT05087797","The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion",[101],"2020-07-08",[15953],"Coronary Artery Disease",[15935],{"trials":15956,"activeCount":109},[],{"intervention":15958,"totalTrials":708,"cells":15959},"sodium zirconium cyclic silicate",{"EARLY_PHASE1":15960,"PHASE1":15962,"PHASE2":15964,"PHASE3":15966,"PHASE4":15968,"NA":15980},{"trials":15961,"activeCount":109},[],{"trials":15963,"activeCount":109},[],{"trials":15965,"activeCount":109},[],{"trials":15967,"activeCount":109},[],{"trials":15969,"activeCount":109},[15970],{"nctId":15971,"briefTitle":15972,"status":569,"phases":15973,"primaryCompletion":1103,"completion":1103,"start":15974,"enrollment":15476,"conditions":15975,"interventions":15979},"NCT06242041","The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study)",[101],"2022-02-14",[15976,15977,15978],"Potassium Imbalance","Cardiac Arrhythmia","Dialysis; Complications",[15958],{"trials":15981,"activeCount":109},[],{"intervention":1121,"totalTrials":329,"cells":15983},{"EARLY_PHASE1":15984,"PHASE1":15986,"PHASE2":15988,"PHASE3":16002,"PHASE4":16008,"NA":16010},{"trials":15985,"activeCount":109},[],{"trials":15987,"activeCount":109},[],{"trials":15989,"activeCount":109},[15990,15994],{"nctId":1109,"briefTitle":1110,"status":569,"phases":15991,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":15992,"interventions":15993},[99],[1117],[1119,734,1120,1121,1122,1090],{"nctId":15995,"briefTitle":15996,"status":569,"phases":15997,"primaryCompletion":15998,"completion":10699,"start":15999,"enrollment":140,"conditions":16000,"interventions":16001},"NCT03359005","Irinotecan and Temozolomide for Ewing Sarcoma",[99],"2022-11-28","2018-02-07",[8556],[1121,2600],{"trials":16003,"activeCount":109},[16004],{"nctId":1146,"briefTitle":1147,"status":569,"phases":16005,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":16006,"interventions":16007},[100],[1153],[734,1155,1121,1090,1120],{"trials":16009,"activeCount":109},[],{"trials":16011,"activeCount":109},[],{"intervention":4724,"totalTrials":746,"cells":16013},{"EARLY_PHASE1":16014,"PHASE1":16016,"PHASE2":16018,"PHASE3":16029,"PHASE4":16041,"NA":16043},{"trials":16015,"activeCount":109},[],{"trials":16017,"activeCount":109},[],{"trials":16019,"activeCount":109},[16020],{"nctId":16021,"briefTitle":16022,"status":569,"phases":16023,"primaryCompletion":279,"completion":16024,"start":16025,"enrollment":1940,"conditions":16026,"interventions":16027},"NCT02404753","A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy",[99],"2022-11-25","2015-04",[28],[16028,4724],"Neoadjuvant Chemotherapy",{"trials":16030,"activeCount":109},[16031],{"nctId":16032,"briefTitle":16033,"status":569,"phases":16034,"primaryCompletion":16035,"completion":8262,"start":16036,"enrollment":16037,"conditions":16038,"interventions":16039},"NCT02193594","Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma",[99,100],"2017-09","2014-01",214,[8822],[16040],"Adjuvant chemotherapy",{"trials":16042,"activeCount":109},[],{"trials":16044,"activeCount":109},[],{"intervention":1155,"totalTrials":746,"cells":16046},{"EARLY_PHASE1":16047,"PHASE1":16049,"PHASE2":16051,"PHASE3":16053,"PHASE4":16063,"NA":16065},{"trials":16048,"activeCount":109},[],{"trials":16050,"activeCount":109},[],{"trials":16052,"activeCount":109},[],{"trials":16054,"activeCount":109},[16055,16059],{"nctId":1146,"briefTitle":1147,"status":569,"phases":16056,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":16057,"interventions":16058},[100],[1153],[734,1155,1121,1090,1120],{"nctId":5368,"briefTitle":5369,"status":435,"phases":16060,"primaryCompletion":5371,"completion":5372,"start":5373,"enrollment":109,"conditions":16061,"interventions":16062},[99,100],[5375,195,5376],[1155,5378],{"trials":16064,"activeCount":109},[],{"trials":16066,"activeCount":109},[],{"intervention":16068,"totalTrials":746,"cells":16069},"Riluzole",{"EARLY_PHASE1":16070,"PHASE1":16081,"PHASE2":16083,"PHASE3":16085,"PHASE4":16096,"NA":16098},{"trials":16071,"activeCount":109},[16072],{"nctId":16073,"briefTitle":16074,"status":135,"phases":16075,"primaryCompletion":16076,"completion":16076,"start":10296,"enrollment":47,"conditions":16077,"interventions":16079},"NCT04454840","Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis",[97],"2019-05-01",[16078],"Amyotrophic Lateral Sclerosis",[16080,16068],"Plasma from healthy young people treatment + Riluzole",{"trials":16082,"activeCount":109},[],{"trials":16084,"activeCount":109},[],{"trials":16086,"activeCount":109},[16087],{"nctId":16088,"briefTitle":16089,"status":569,"phases":16090,"primaryCompletion":1202,"completion":1215,"start":16091,"enrollment":16092,"conditions":16093,"interventions":16094},"NCT04950933","The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules",[99,100],"2020-06-01",144,[16078],[16095,16068],"Huolingshengji Granules",{"trials":16097,"activeCount":109},[],{"trials":16099,"activeCount":109},[],{"intervention":16101,"totalTrials":708,"cells":16102},"neoadjuvant chemotherapy with oxaliplatin and capecitabine",{"EARLY_PHASE1":16103,"PHASE1":16105,"PHASE2":16107,"PHASE3":16109,"PHASE4":16118,"NA":16120},{"trials":16104,"activeCount":109},[],{"trials":16106,"activeCount":109},[],{"trials":16108,"activeCount":109},[],{"trials":16110,"activeCount":109},[16111],{"nctId":16112,"briefTitle":16113,"status":569,"phases":16114,"primaryCompletion":4141,"completion":830,"start":4142,"enrollment":1538,"conditions":16115,"interventions":16117},"NCT00630045","Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis",[100],[2692,16116],"Resectable Liver Metastasis",[16101],{"trials":16119,"activeCount":109},[],{"trials":16121,"activeCount":109},[],{"intervention":16123,"totalTrials":708,"cells":16124},"Keto Acid",{"EARLY_PHASE1":16125,"PHASE1":16127,"PHASE2":16129,"PHASE3":16131,"PHASE4":16141,"NA":16143},{"trials":16126,"activeCount":109},[],{"trials":16128,"activeCount":109},[],{"trials":16130,"activeCount":109},[],{"trials":16132,"activeCount":109},[16133],{"nctId":16134,"briefTitle":16135,"status":135,"phases":16136,"primaryCompletion":16137,"completion":16137,"start":3511,"enrollment":376,"conditions":16138,"interventions":16140},"NCT01496092","Study of Keto Acid (KA) on Insulin Resistance in Peritoneal Dialysis (PD) Patients",[100],"2012-12",[16139],"Insulin Resistance",[16123],{"trials":16142,"activeCount":109},[],{"trials":16144,"activeCount":109},[],{"intervention":2847,"totalTrials":708,"cells":16146},{"EARLY_PHASE1":16147,"PHASE1":16149,"PHASE2":16151,"PHASE3":16153,"PHASE4":16159,"NA":16161},{"trials":16148,"activeCount":109},[],{"trials":16150,"activeCount":109},[],{"trials":16152,"activeCount":109},[],{"trials":16154,"activeCount":109},[16155],{"nctId":2841,"briefTitle":2842,"status":569,"phases":16156,"primaryCompletion":818,"completion":818,"start":2844,"enrollment":477,"conditions":16157,"interventions":16158},[100],[2836],[2847,2756],{"trials":16160,"activeCount":109},[],{"trials":16162,"activeCount":109},[],{"intervention":16164,"totalTrials":708,"cells":16165},"Y-2 sublingual",{"EARLY_PHASE1":16166,"PHASE1":16168,"PHASE2":16170,"PHASE3":16172,"PHASE4":16185,"NA":16187},{"trials":16167,"activeCount":109},[],{"trials":16169,"activeCount":109},[],{"trials":16171,"activeCount":109},[],{"trials":16173,"activeCount":109},[16174],{"nctId":16175,"briefTitle":16176,"status":135,"phases":16177,"primaryCompletion":16178,"completion":16179,"start":16180,"enrollment":16181,"conditions":16182,"interventions":16183},"NCT04950920","Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke",[100],"2022-08-10","2022-11-14","2021-06-28",914,[5228],[16164,16184],"d-borneol",{"trials":16186,"activeCount":109},[],{"trials":16188,"activeCount":109},[],{"intervention":16184,"totalTrials":708,"cells":16190},{"EARLY_PHASE1":16191,"PHASE1":16193,"PHASE2":16195,"PHASE3":16197,"PHASE4":16203,"NA":16205},{"trials":16192,"activeCount":109},[],{"trials":16194,"activeCount":109},[],{"trials":16196,"activeCount":109},[],{"trials":16198,"activeCount":109},[16199],{"nctId":16175,"briefTitle":16176,"status":135,"phases":16200,"primaryCompletion":16178,"completion":16179,"start":16180,"enrollment":16181,"conditions":16201,"interventions":16202},[100],[5228],[16164,16184],{"trials":16204,"activeCount":109},[],{"trials":16206,"activeCount":109},[],{"intervention":16208,"totalTrials":708,"cells":16209},"sumatriptan 85mg and naproxen sodium 500mg",{"EARLY_PHASE1":16210,"PHASE1":16212,"PHASE2":16214,"PHASE3":16216,"PHASE4":16225,"NA":16227},{"trials":16211,"activeCount":109},[],{"trials":16213,"activeCount":109},[],{"trials":16215,"activeCount":109},[],{"trials":16217,"activeCount":109},[16218],{"nctId":16219,"briefTitle":16220,"status":569,"phases":16221,"primaryCompletion":8314,"completion":8314,"start":3636,"enrollment":1165,"conditions":16222,"interventions":16224},"NCT04948164","Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks",[100],[16223],"Migraine in Adults",[16208],{"trials":16226,"activeCount":109},[],{"trials":16228,"activeCount":109},[],{"intervention":16230,"totalTrials":708,"cells":16231},"Cetuximab plus FOLFIRI\u002FFOLFOX",{"EARLY_PHASE1":16232,"PHASE1":16234,"PHASE2":16236,"PHASE3":16238,"PHASE4":16250,"NA":16252},{"trials":16233,"activeCount":109},[],{"trials":16235,"activeCount":109},[],{"trials":16237,"activeCount":109},[],{"trials":16239,"activeCount":109},[16240],{"nctId":16241,"briefTitle":16242,"status":135,"phases":16243,"primaryCompletion":5372,"completion":5372,"start":669,"enrollment":16244,"conditions":16245,"interventions":16248},"NCT03031444","Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis",[99,100],135,[16246,16247],"Colorectal Cancer Stage IV","Metastasis",[16230,16249],"FOLFIRI\u002FFOLFOX\u002FCapeOX",{"trials":16251,"activeCount":109},[],{"trials":16253,"activeCount":109},[],{"intervention":16249,"totalTrials":708,"cells":16255},{"EARLY_PHASE1":16256,"PHASE1":16258,"PHASE2":16260,"PHASE3":16262,"PHASE4":16268,"NA":16270},{"trials":16257,"activeCount":109},[],{"trials":16259,"activeCount":109},[],{"trials":16261,"activeCount":109},[],{"trials":16263,"activeCount":109},[16264],{"nctId":16241,"briefTitle":16242,"status":135,"phases":16265,"primaryCompletion":5372,"completion":5372,"start":669,"enrollment":16244,"conditions":16266,"interventions":16267},[99,100],[16246,16247],[16230,16249],{"trials":16269,"activeCount":109},[],{"trials":16271,"activeCount":109},[],{"intervention":16273,"totalTrials":708,"cells":16274},"Oxaliplatin capecitabine",{"EARLY_PHASE1":16275,"PHASE1":16277,"PHASE2":16279,"PHASE3":16281,"PHASE4":16294,"NA":16296},{"trials":16276,"activeCount":109},[],{"trials":16278,"activeCount":109},[],{"trials":16280,"activeCount":109},[],{"trials":16282,"activeCount":109},[16283],{"nctId":16284,"briefTitle":16285,"status":569,"phases":16286,"primaryCompletion":16287,"completion":10344,"start":16288,"enrollment":16289,"conditions":16290,"interventions":16292},"NCT01534546","Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection",[100],"2019-07","2012-03",1094,[16291],"Advanced Gastric Carcinoma",[16273,16293,16293],"Oxaliplatin S-1",{"trials":16295,"activeCount":109},[],{"trials":16297,"activeCount":109},[],{"intervention":16293,"totalTrials":708,"cells":16299},{"EARLY_PHASE1":16300,"PHASE1":16302,"PHASE2":16304,"PHASE3":16306,"PHASE4":16312,"NA":16314},{"trials":16301,"activeCount":109},[],{"trials":16303,"activeCount":109},[],{"trials":16305,"activeCount":109},[],{"trials":16307,"activeCount":109},[16308],{"nctId":16284,"briefTitle":16285,"status":569,"phases":16309,"primaryCompletion":16287,"completion":10344,"start":16288,"enrollment":16289,"conditions":16310,"interventions":16311},[100],[16291],[16273,16293,16293],{"trials":16313,"activeCount":109},[],{"trials":16315,"activeCount":109},[],{"intervention":16317,"totalTrials":708,"cells":16318},"Oxaliplatin plus S-1",{"EARLY_PHASE1":16319,"PHASE1":16321,"PHASE2":16323,"PHASE3":16325,"PHASE4":16335,"NA":16337},{"trials":16320,"activeCount":109},[],{"trials":16322,"activeCount":109},[],{"trials":16324,"activeCount":109},[],{"trials":16326,"activeCount":109},[16327],{"nctId":16328,"briefTitle":16329,"status":200,"phases":16330,"primaryCompletion":5295,"completion":5295,"start":16331,"enrollment":105,"conditions":16332,"interventions":16333},"NCT02867839","Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer",[100],"2017-04-24",[28],[16317,16334],"S-1 only",{"trials":16336,"activeCount":109},[],{"trials":16338,"activeCount":109},[],{"intervention":16334,"totalTrials":708,"cells":16340},{"EARLY_PHASE1":16341,"PHASE1":16343,"PHASE2":16345,"PHASE3":16347,"PHASE4":16353,"NA":16355},{"trials":16342,"activeCount":109},[],{"trials":16344,"activeCount":109},[],{"trials":16346,"activeCount":109},[],{"trials":16348,"activeCount":109},[16349],{"nctId":16328,"briefTitle":16329,"status":200,"phases":16350,"primaryCompletion":5295,"completion":5295,"start":16331,"enrollment":105,"conditions":16351,"interventions":16352},[100],[28],[16317,16334],{"trials":16354,"activeCount":109},[],{"trials":16356,"activeCount":109},[],{"intervention":16358,"totalTrials":708,"cells":16359},"IBI311",{"EARLY_PHASE1":16360,"PHASE1":16362,"PHASE2":16364,"PHASE3":16366,"PHASE4":16377,"NA":16379},{"trials":16361,"activeCount":109},[],{"trials":16363,"activeCount":109},[],{"trials":16365,"activeCount":109},[],{"trials":16367,"activeCount":109},[16368],{"nctId":16369,"briefTitle":16370,"status":135,"phases":16371,"primaryCompletion":16372,"completion":16373,"start":4308,"enrollment":6045,"conditions":16374,"interventions":16376},"NCT06269393","A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy",[100],"2025-04-03","2025-07-03",[16375],"Thyroid Associated Ophthalmopathy",[16358],{"trials":16378,"activeCount":109},[],{"trials":16380,"activeCount":109},[],{"intervention":16382,"totalTrials":708,"cells":16383},"Methylprednisolone pulse",{"EARLY_PHASE1":16384,"PHASE1":16386,"PHASE2":16388,"PHASE3":16390,"PHASE4":16402,"NA":16404},{"trials":16385,"activeCount":109},[],{"trials":16387,"activeCount":109},[],{"trials":16389,"activeCount":109},[],{"trials":16391,"activeCount":109},[16392],{"nctId":16393,"briefTitle":16394,"status":200,"phases":16395,"primaryCompletion":4170,"completion":4170,"start":14954,"enrollment":477,"conditions":16396,"interventions":16401},"NCT02647255","Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy",[99,100],[16397,16398,16399,16400],"Glomerulonephritis, IGA","Kidney Diseases","Acute Renal Insufficiency","Rapidly Progressive Glomerulonephritis",[16382],{"trials":16403,"activeCount":109},[],{"trials":16405,"activeCount":109},[],{"intervention":16407,"totalTrials":708,"cells":16408},"Prescription of traditional Chinese Medicine named Er Zhi Wan combined with Si Wu Tang",{"EARLY_PHASE1":16409,"PHASE1":16411,"PHASE2":16413,"PHASE3":16415,"PHASE4":16425,"NA":16427},{"trials":16410,"activeCount":109},[],{"trials":16412,"activeCount":109},[],{"trials":16414,"activeCount":109},[],{"trials":16416,"activeCount":109},[16417],{"nctId":16418,"briefTitle":16419,"status":569,"phases":16420,"primaryCompletion":3900,"completion":3900,"start":16421,"enrollment":1139,"conditions":16422,"interventions":16423},"NCT04935073","Traditional Chinese Medicine Herbs in the Freeze-all IVF Cycle",[100],"2021-06-15",[1541],[16407,16424],"Recombinant Human Follitropin Alfa for Injection、Fructose Injection、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder for",{"trials":16426,"activeCount":109},[],{"trials":16428,"activeCount":109},[],{"intervention":16424,"totalTrials":708,"cells":16430},{"EARLY_PHASE1":16431,"PHASE1":16433,"PHASE2":16435,"PHASE3":16437,"PHASE4":16443,"NA":16445},{"trials":16432,"activeCount":109},[],{"trials":16434,"activeCount":109},[],{"trials":16436,"activeCount":109},[],{"trials":16438,"activeCount":109},[16439],{"nctId":16418,"briefTitle":16419,"status":569,"phases":16440,"primaryCompletion":3900,"completion":3900,"start":16421,"enrollment":1139,"conditions":16441,"interventions":16442},[100],[1541],[16407,16424],{"trials":16444,"activeCount":109},[],{"trials":16446,"activeCount":109},[],{"intervention":16448,"totalTrials":708,"cells":16449},"FOLFOX",{"EARLY_PHASE1":16450,"PHASE1":16452,"PHASE2":16454,"PHASE3":16456,"PHASE4":16467,"NA":16469},{"trials":16451,"activeCount":109},[],{"trials":16453,"activeCount":109},[],{"trials":16455,"activeCount":109},[],{"trials":16457,"activeCount":109},[16458],{"nctId":16459,"briefTitle":16460,"status":200,"phases":16461,"primaryCompletion":7452,"completion":7452,"start":16462,"enrollment":2732,"conditions":16463,"interventions":16464},"NCT05171166","Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.",[99,100],"2021-12-24",[2591],[16448,16465,16466],"cTACE or DEB-TACE","Donafenib",{"trials":16468,"activeCount":109},[],{"trials":16470,"activeCount":109},[],{"intervention":16465,"totalTrials":708,"cells":16472},{"EARLY_PHASE1":16473,"PHASE1":16475,"PHASE2":16477,"PHASE3":16479,"PHASE4":16485,"NA":16487},{"trials":16474,"activeCount":109},[],{"trials":16476,"activeCount":109},[],{"trials":16478,"activeCount":109},[],{"trials":16480,"activeCount":109},[16481],{"nctId":16459,"briefTitle":16460,"status":200,"phases":16482,"primaryCompletion":7452,"completion":7452,"start":16462,"enrollment":2732,"conditions":16483,"interventions":16484},[99,100],[2591],[16448,16465,16466],{"trials":16486,"activeCount":109},[],{"trials":16488,"activeCount":109},[],{"intervention":16466,"totalTrials":708,"cells":16490},{"EARLY_PHASE1":16491,"PHASE1":16493,"PHASE2":16495,"PHASE3":16497,"PHASE4":16503,"NA":16505},{"trials":16492,"activeCount":109},[],{"trials":16494,"activeCount":109},[],{"trials":16496,"activeCount":109},[],{"trials":16498,"activeCount":109},[16499],{"nctId":16459,"briefTitle":16460,"status":200,"phases":16500,"primaryCompletion":7452,"completion":7452,"start":16462,"enrollment":2732,"conditions":16501,"interventions":16502},[99,100],[2591],[16448,16465,16466],{"trials":16504,"activeCount":109},[],{"trials":16506,"activeCount":109},[],{"intervention":16508,"totalTrials":708,"cells":16509},"Temozolomide Plus Cisplatin",{"EARLY_PHASE1":16510,"PHASE1":16512,"PHASE2":16514,"PHASE3":16516,"PHASE4":16526,"NA":16528},{"trials":16511,"activeCount":109},[],{"trials":16513,"activeCount":109},[],{"trials":16515,"activeCount":109},[],{"trials":16517,"activeCount":109},[16518],{"nctId":16519,"briefTitle":16520,"status":569,"phases":16521,"primaryCompletion":9967,"completion":5401,"start":16522,"enrollment":6128,"conditions":16523,"interventions":16524},"NCT03435302","HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma",[100],"2014-02",[2580],[16508,16525],"High-Dose IFN-a2b",{"trials":16527,"activeCount":109},[],{"trials":16529,"activeCount":109},[],{"intervention":16525,"totalTrials":708,"cells":16531},{"EARLY_PHASE1":16532,"PHASE1":16534,"PHASE2":16536,"PHASE3":16538,"PHASE4":16544,"NA":16546},{"trials":16533,"activeCount":109},[],{"trials":16535,"activeCount":109},[],{"trials":16537,"activeCount":109},[],{"trials":16539,"activeCount":109},[16540],{"nctId":16519,"briefTitle":16520,"status":569,"phases":16541,"primaryCompletion":9967,"completion":5401,"start":16522,"enrollment":6128,"conditions":16542,"interventions":16543},[100],[2580],[16508,16525],{"trials":16545,"activeCount":109},[],{"trials":16547,"activeCount":109},[],{"intervention":16549,"totalTrials":708,"cells":16550},"Er Zhi Wan combined with Si Wu Tang",{"EARLY_PHASE1":16551,"PHASE1":16553,"PHASE2":16555,"PHASE3":16557,"PHASE4":16566,"NA":16568},{"trials":16552,"activeCount":109},[],{"trials":16554,"activeCount":109},[],{"trials":16556,"activeCount":109},[],{"trials":16558,"activeCount":109},[16559],{"nctId":16560,"briefTitle":16561,"status":569,"phases":16562,"primaryCompletion":3900,"completion":3900,"start":4239,"enrollment":168,"conditions":16563,"interventions":16564},"NCT04842825","Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients",[100],[1541],[16549,16565],"Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder",{"trials":16567,"activeCount":109},[],{"trials":16569,"activeCount":109},[],{"intervention":16565,"totalTrials":708,"cells":16571},{"EARLY_PHASE1":16572,"PHASE1":16574,"PHASE2":16576,"PHASE3":16578,"PHASE4":16584,"NA":16586},{"trials":16573,"activeCount":109},[],{"trials":16575,"activeCount":109},[],{"trials":16577,"activeCount":109},[],{"trials":16579,"activeCount":109},[16580],{"nctId":16560,"briefTitle":16561,"status":569,"phases":16581,"primaryCompletion":3900,"completion":3900,"start":4239,"enrollment":168,"conditions":16582,"interventions":16583},[100],[1541],[16549,16565],{"trials":16585,"activeCount":109},[],{"trials":16587,"activeCount":109},[],{"intervention":16589,"totalTrials":708,"cells":16590},"Medical prescription before ovulation",{"EARLY_PHASE1":16591,"PHASE1":16593,"PHASE2":16595,"PHASE3":16597,"PHASE4":16609,"NA":16611},{"trials":16592,"activeCount":109},[],{"trials":16594,"activeCount":109},[],{"trials":16596,"activeCount":109},[],{"trials":16598,"activeCount":109},[16599],{"nctId":16600,"briefTitle":16601,"status":569,"phases":16602,"primaryCompletion":4238,"completion":4238,"start":16603,"enrollment":16604,"conditions":16605,"interventions":16607},"NCT05577455","Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients",[100],"2022-11-10",266,[16606,1541],"Diminished Ovarian Reserve",[16589,16608],"Medical prescription after ovulation",{"trials":16610,"activeCount":109},[],{"trials":16612,"activeCount":109},[],{"intervention":16608,"totalTrials":708,"cells":16614},{"EARLY_PHASE1":16615,"PHASE1":16617,"PHASE2":16619,"PHASE3":16621,"PHASE4":16627,"NA":16629},{"trials":16616,"activeCount":109},[],{"trials":16618,"activeCount":109},[],{"trials":16620,"activeCount":109},[],{"trials":16622,"activeCount":109},[16623],{"nctId":16600,"briefTitle":16601,"status":569,"phases":16624,"primaryCompletion":4238,"completion":4238,"start":16603,"enrollment":16604,"conditions":16625,"interventions":16626},[100],[16606,1541],[16589,16608],{"trials":16628,"activeCount":109},[],{"trials":16630,"activeCount":109},[],{"intervention":16632,"totalTrials":708,"cells":16633},"LY03003",{"EARLY_PHASE1":16634,"PHASE1":16636,"PHASE2":16638,"PHASE3":16640,"PHASE4":16649,"NA":16651},{"trials":16635,"activeCount":109},[],{"trials":16637,"activeCount":109},[],{"trials":16639,"activeCount":109},[],{"trials":16641,"activeCount":109},[16642],{"nctId":16643,"briefTitle":16644,"status":135,"phases":16645,"primaryCompletion":15758,"completion":15758,"start":3636,"enrollment":3960,"conditions":16646,"interventions":16648},"NCT04455555","Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease",[100],[16647],"Parkinson's Disease",[16632],{"trials":16650,"activeCount":109},[],{"trials":16652,"activeCount":109},[],{"intervention":3976,"totalTrials":708,"cells":16654},{"EARLY_PHASE1":16655,"PHASE1":16657,"PHASE2":16659,"PHASE3":16661,"PHASE4":16667,"NA":16669},{"trials":16656,"activeCount":109},[],{"trials":16658,"activeCount":109},[],{"trials":16660,"activeCount":109},[],{"trials":16662,"activeCount":109},[16663],{"nctId":3966,"briefTitle":3967,"status":569,"phases":16664,"primaryCompletion":3969,"completion":3970,"start":3971,"enrollment":3972,"conditions":16665,"interventions":16666},[99,100],[3974],[3976,1037,3977,3978],{"trials":16668,"activeCount":109},[],{"trials":16670,"activeCount":109},[],{"intervention":3977,"totalTrials":708,"cells":16672},{"EARLY_PHASE1":16673,"PHASE1":16675,"PHASE2":16677,"PHASE3":16679,"PHASE4":16685,"NA":16687},{"trials":16674,"activeCount":109},[],{"trials":16676,"activeCount":109},[],{"trials":16678,"activeCount":109},[],{"trials":16680,"activeCount":109},[16681],{"nctId":3966,"briefTitle":3967,"status":569,"phases":16682,"primaryCompletion":3969,"completion":3970,"start":3971,"enrollment":3972,"conditions":16683,"interventions":16684},[99,100],[3974],[3976,1037,3977,3978],{"trials":16686,"activeCount":109},[],{"trials":16688,"activeCount":109},[],{"intervention":3978,"totalTrials":708,"cells":16690},{"EARLY_PHASE1":16691,"PHASE1":16693,"PHASE2":16695,"PHASE3":16697,"PHASE4":16703,"NA":16705},{"trials":16692,"activeCount":109},[],{"trials":16694,"activeCount":109},[],{"trials":16696,"activeCount":109},[],{"trials":16698,"activeCount":109},[16699],{"nctId":3966,"briefTitle":3967,"status":569,"phases":16700,"primaryCompletion":3969,"completion":3970,"start":3971,"enrollment":3972,"conditions":16701,"interventions":16702},[99,100],[3974],[3976,1037,3977,3978],{"trials":16704,"activeCount":109},[],{"trials":16706,"activeCount":109},[],{"intervention":16708,"totalTrials":708,"cells":16709},"Umbilical cord blood mononuclear cell gel（MNC）",{"EARLY_PHASE1":16710,"PHASE1":16712,"PHASE2":16714,"PHASE3":16716,"PHASE4":16727,"NA":16729},{"trials":16711,"activeCount":109},[],{"trials":16713,"activeCount":109},[],{"trials":16715,"activeCount":109},[],{"trials":16717,"activeCount":109},[16718],{"nctId":16719,"briefTitle":16720,"status":569,"phases":16721,"primaryCompletion":81,"completion":1103,"start":16722,"enrollment":32,"conditions":16723,"interventions":16725},"NCT04689425","Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer",[100],"2021-03-30",[16724],"Diabetic Foot Ulcer",[16708,16726],"The platelet rich plasma（PRP）",{"trials":16728,"activeCount":109},[],{"trials":16730,"activeCount":109},[],{"intervention":16726,"totalTrials":708,"cells":16732},{"EARLY_PHASE1":16733,"PHASE1":16735,"PHASE2":16737,"PHASE3":16739,"PHASE4":16745,"NA":16747},{"trials":16734,"activeCount":109},[],{"trials":16736,"activeCount":109},[],{"trials":16738,"activeCount":109},[],{"trials":16740,"activeCount":109},[16741],{"nctId":16719,"briefTitle":16720,"status":569,"phases":16742,"primaryCompletion":81,"completion":1103,"start":16722,"enrollment":32,"conditions":16743,"interventions":16744},[100],[16724],[16708,16726],{"trials":16746,"activeCount":109},[],{"trials":16748,"activeCount":109},[],{"intervention":16750,"totalTrials":708,"cells":16751},"Ibrutinib combined with As2O3",{"EARLY_PHASE1":16752,"PHASE1":16754,"PHASE2":16756,"PHASE3":16758,"PHASE4":16768,"NA":16770},{"trials":16753,"activeCount":109},[],{"trials":16755,"activeCount":109},[],{"trials":16757,"activeCount":109},[],{"trials":16759,"activeCount":109},[16760],{"nctId":16761,"briefTitle":16762,"status":569,"phases":16763,"primaryCompletion":668,"completion":4090,"start":252,"enrollment":670,"conditions":16764,"interventions":16766},"NCT02757040","Combination of Ibrutinib and As2O3 in the Treatment of CLL",[100],[16765],"Leukemia, Lymphocytic, Chronic, B-Cell",[16750,16767],"ibrutinib",{"trials":16769,"activeCount":109},[],{"trials":16771,"activeCount":109},[],{"intervention":16767,"totalTrials":708,"cells":16773},{"EARLY_PHASE1":16774,"PHASE1":16776,"PHASE2":16778,"PHASE3":16780,"PHASE4":16786,"NA":16788},{"trials":16775,"activeCount":109},[],{"trials":16777,"activeCount":109},[],{"trials":16779,"activeCount":109},[],{"trials":16781,"activeCount":109},[16782],{"nctId":16761,"briefTitle":16762,"status":569,"phases":16783,"primaryCompletion":668,"completion":4090,"start":252,"enrollment":670,"conditions":16784,"interventions":16785},[100],[16765],[16750,16767],{"trials":16787,"activeCount":109},[],{"trials":16789,"activeCount":109},[],{"intervention":16791,"totalTrials":708,"cells":16792},"S-1 and Paclitaxel",{"EARLY_PHASE1":16793,"PHASE1":16795,"PHASE2":16797,"PHASE3":16799,"PHASE4":16809,"NA":16811},{"trials":16794,"activeCount":109},[],{"trials":16796,"activeCount":109},[],{"trials":16798,"activeCount":109},[],{"trials":16800,"activeCount":109},[16801],{"nctId":16802,"briefTitle":16803,"status":200,"phases":16804,"primaryCompletion":3120,"completion":3120,"start":3091,"enrollment":405,"conditions":16805,"interventions":16806},"NCT01704690","Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer",[99,100],[2627],[16791,16807,16808],"Paclitaxel and Cisplatin","5-FU and Cisplatin",{"trials":16810,"activeCount":109},[],{"trials":16812,"activeCount":109},[],{"intervention":16807,"totalTrials":708,"cells":16814},{"EARLY_PHASE1":16815,"PHASE1":16817,"PHASE2":16819,"PHASE3":16821,"PHASE4":16827,"NA":16829},{"trials":16816,"activeCount":109},[],{"trials":16818,"activeCount":109},[],{"trials":16820,"activeCount":109},[],{"trials":16822,"activeCount":109},[16823],{"nctId":16802,"briefTitle":16803,"status":200,"phases":16824,"primaryCompletion":3120,"completion":3120,"start":3091,"enrollment":405,"conditions":16825,"interventions":16826},[99,100],[2627],[16791,16807,16808],{"trials":16828,"activeCount":109},[],{"trials":16830,"activeCount":109},[],{"intervention":16808,"totalTrials":708,"cells":16832},{"EARLY_PHASE1":16833,"PHASE1":16835,"PHASE2":16837,"PHASE3":16839,"PHASE4":16845,"NA":16847},{"trials":16834,"activeCount":109},[],{"trials":16836,"activeCount":109},[],{"trials":16838,"activeCount":109},[],{"trials":16840,"activeCount":109},[16841],{"nctId":16802,"briefTitle":16803,"status":200,"phases":16842,"primaryCompletion":3120,"completion":3120,"start":3091,"enrollment":405,"conditions":16843,"interventions":16844},[99,100],[2627],[16791,16807,16808],{"trials":16846,"activeCount":109},[],{"trials":16848,"activeCount":109},[],{"intervention":16850,"totalTrials":708,"cells":16851},"CapeOX（Capecitabine+Oxaliplatin）",{"EARLY_PHASE1":16852,"PHASE1":16854,"PHASE2":16856,"PHASE3":16858,"PHASE4":16869,"NA":16871},{"trials":16853,"activeCount":109},[],{"trials":16855,"activeCount":109},[],{"trials":16857,"activeCount":109},[],{"trials":16859,"activeCount":109},[16860],{"nctId":16861,"briefTitle":16862,"status":569,"phases":16863,"primaryCompletion":16864,"completion":16865,"start":449,"enrollment":16866,"conditions":16867,"interventions":16868},"NCT03199989","Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)",[100],"2021-07-31","2024-07-31",1254,[4724],[16850],{"trials":16870,"activeCount":109},[],{"trials":16872,"activeCount":109},[],{"intervention":4726,"totalTrials":708,"cells":16874},{"EARLY_PHASE1":16875,"PHASE1":16877,"PHASE2":16879,"PHASE3":16881,"PHASE4":16887,"NA":16889},{"trials":16876,"activeCount":109},[],{"trials":16878,"activeCount":109},[],{"trials":16880,"activeCount":109},[],{"trials":16882,"activeCount":109},[16883],{"nctId":4716,"briefTitle":4717,"status":569,"phases":16884,"primaryCompletion":4719,"completion":4308,"start":4720,"enrollment":4721,"conditions":16885,"interventions":16886},[100],[4723,4724],[4119,4726,4727],{"trials":16888,"activeCount":109},[],{"trials":16890,"activeCount":109},[],{"intervention":4727,"totalTrials":708,"cells":16892},{"EARLY_PHASE1":16893,"PHASE1":16895,"PHASE2":16897,"PHASE3":16899,"PHASE4":16905,"NA":16907},{"trials":16894,"activeCount":109},[],{"trials":16896,"activeCount":109},[],{"trials":16898,"activeCount":109},[],{"trials":16900,"activeCount":109},[16901],{"nctId":4716,"briefTitle":4717,"status":569,"phases":16902,"primaryCompletion":4719,"completion":4308,"start":4720,"enrollment":4721,"conditions":16903,"interventions":16904},[100],[4723,4724],[4119,4726,4727],{"trials":16906,"activeCount":109},[],{"trials":16908,"activeCount":109},[],{"intervention":16910,"totalTrials":708,"cells":16911},"Yiqi Huoxue Huatan granule",{"EARLY_PHASE1":16912,"PHASE1":16914,"PHASE2":16916,"PHASE3":16918,"PHASE4":16929,"NA":16931},{"trials":16913,"activeCount":109},[],{"trials":16915,"activeCount":109},[],{"trials":16917,"activeCount":109},[],{"trials":16919,"activeCount":109},[16920],{"nctId":16921,"briefTitle":16922,"status":569,"phases":16923,"primaryCompletion":1163,"completion":1163,"start":16924,"enrollment":16925,"conditions":16926,"interventions":16928},"NCT04208581","Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure",[100],"2019-10-08",372,[14574,16927],"Chronic Respiratory Failure",[16910],{"trials":16930,"activeCount":109},[],{"trials":16932,"activeCount":109},[],{"intervention":16934,"totalTrials":708,"cells":16935},"leflunomide combined with prednisone",{"EARLY_PHASE1":16936,"PHASE1":16938,"PHASE2":16940,"PHASE3":16942,"PHASE4":16952,"NA":16954},{"trials":16937,"activeCount":109},[],{"trials":16939,"activeCount":109},[],{"trials":16941,"activeCount":109},[],{"trials":16943,"activeCount":109},[16944],{"nctId":16945,"briefTitle":16946,"status":135,"phases":16947,"start":16948,"conditions":16949,"interventions":16951},"NCT00268567","Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone",[99,100],"2002-10",[16950],"Nephritis, Lupus",[16934],{"trials":16953,"activeCount":109},[],{"trials":16955,"activeCount":109},[],{"intervention":16957,"totalTrials":708,"cells":16958},"Tolterodine",{"EARLY_PHASE1":16959,"PHASE1":16961,"PHASE2":16963,"PHASE3":16965,"PHASE4":16974,"NA":16976},{"trials":16960,"activeCount":109},[],{"trials":16962,"activeCount":109},[],{"trials":16964,"activeCount":109},[],{"trials":16966,"activeCount":109},[16967],{"nctId":16968,"briefTitle":16969,"status":569,"phases":16970,"primaryCompletion":4125,"completion":4170,"start":2874,"enrollment":5215,"conditions":16971,"interventions":16973},"NCT02599311","the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery",[100],[16972],"Pelvic Organ Prolapse",[16957],{"trials":16975,"activeCount":109},[],{"trials":16977,"activeCount":109},[],{"intervention":16979,"totalTrials":708,"cells":16980},"Cyclophosphamid",{"EARLY_PHASE1":16981,"PHASE1":16983,"PHASE2":16985,"PHASE3":16987,"PHASE4":16996,"NA":16998},{"trials":16982,"activeCount":109},[],{"trials":16984,"activeCount":109},[],{"trials":16986,"activeCount":109},[],{"trials":16988,"activeCount":109},[16989],{"nctId":16990,"briefTitle":16991,"status":200,"phases":16992,"primaryCompletion":1103,"completion":1103,"start":316,"enrollment":6539,"conditions":16993,"interventions":16995},"NCT06108739","ATG Plus Low-dose PT-Cy for GVHD Prevention",[100],[16994],"Hematologic Malignancy",[16979,952],{"trials":16997,"activeCount":109},[],{"trials":16999,"activeCount":109},[],{"intervention":17001,"totalTrials":708,"cells":17002},"Trimetazidine",{"EARLY_PHASE1":17003,"PHASE1":17005,"PHASE2":17007,"PHASE3":17009,"PHASE4":17018,"NA":17020},{"trials":17004,"activeCount":109},[],{"trials":17006,"activeCount":109},[],{"trials":17008,"activeCount":109},[],{"trials":17010,"activeCount":109},[17011],{"nctId":17012,"briefTitle":17013,"status":569,"phases":17014,"primaryCompletion":17015,"completion":13632,"start":2917,"enrollment":153,"conditions":17016,"interventions":17017},"NCT04939857","Effect of Trimetazidine on Radiotherapy-induced Heart Damage.",[99,100],"2022-07-30",[8317],[17001],{"trials":17019,"activeCount":109},[],{"trials":17021,"activeCount":109},[],{"intervention":17023,"totalTrials":708,"cells":17024},"UC-MSC",{"EARLY_PHASE1":17025,"PHASE1":17027,"PHASE2":17029,"PHASE3":17031,"PHASE4":17043,"NA":17045},{"trials":17026,"activeCount":109},[],{"trials":17028,"activeCount":109},[],{"trials":17030,"activeCount":109},[],{"trials":17032,"activeCount":109},[17033],{"nctId":17034,"briefTitle":17035,"status":135,"phases":17036,"primaryCompletion":17037,"completion":17038,"start":15824,"enrollment":2653,"conditions":17039,"interventions":17041},"NCT04738981","Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT",[100],"2022-05-30","2023-05-02",[17040],"Graft Vs Host Disease",[17023,17042],"Anti-CD25 mAb",{"trials":17044,"activeCount":109},[],{"trials":17046,"activeCount":109},[],{"intervention":17042,"totalTrials":708,"cells":17048},{"EARLY_PHASE1":17049,"PHASE1":17051,"PHASE2":17053,"PHASE3":17055,"PHASE4":17061,"NA":17063},{"trials":17050,"activeCount":109},[],{"trials":17052,"activeCount":109},[],{"trials":17054,"activeCount":109},[],{"trials":17056,"activeCount":109},[17057],{"nctId":17034,"briefTitle":17035,"status":135,"phases":17058,"primaryCompletion":17037,"completion":17038,"start":15824,"enrollment":2653,"conditions":17059,"interventions":17060},[100],[17040],[17023,17042],{"trials":17062,"activeCount":109},[],{"trials":17064,"activeCount":109},[],{"intervention":16095,"totalTrials":708,"cells":17066},{"EARLY_PHASE1":17067,"PHASE1":17069,"PHASE2":17071,"PHASE3":17073,"PHASE4":17079,"NA":17081},{"trials":17068,"activeCount":109},[],{"trials":17070,"activeCount":109},[],{"trials":17072,"activeCount":109},[],{"trials":17074,"activeCount":109},[17075],{"nctId":16088,"briefTitle":16089,"status":569,"phases":17076,"primaryCompletion":1202,"completion":1215,"start":16091,"enrollment":16092,"conditions":17077,"interventions":17078},[99,100],[16078],[16095,16068],{"trials":17080,"activeCount":109},[],{"trials":17082,"activeCount":109},[],{"intervention":17084,"totalTrials":708,"cells":17085},"tacrolimus combined with prednisone",{"EARLY_PHASE1":17086,"PHASE1":17088,"PHASE2":17090,"PHASE3":17092,"PHASE4":17103,"NA":17105},{"trials":17087,"activeCount":109},[],{"trials":17089,"activeCount":109},[],{"trials":17091,"activeCount":109},[],{"trials":17093,"activeCount":109},[17094],{"nctId":17095,"briefTitle":17096,"status":135,"phases":17097,"completion":17098,"start":17099,"conditions":17100,"interventions":17102},"NCT00362531","Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome",[99,100],"2007-01","2004-11",[17101,11135],"Idiopathic Membranous Nephropathy",[17084],{"trials":17104,"activeCount":109},[],{"trials":17106,"activeCount":109},[],{"intervention":17108,"totalTrials":708,"cells":17109},"Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid",{"EARLY_PHASE1":17110,"PHASE1":17112,"PHASE2":17114,"PHASE3":17116,"PHASE4":17129,"NA":17131},{"trials":17111,"activeCount":109},[],{"trials":17113,"activeCount":109},[],{"trials":17115,"activeCount":109},[],{"trials":17117,"activeCount":109},[17118],{"nctId":17119,"briefTitle":17120,"status":569,"phases":17121,"primaryCompletion":17122,"completion":17123,"start":17124,"enrollment":17125,"conditions":17126,"interventions":17128},"NCT04175587","Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL",[100],"2021-08-31","2023-08-31","2019-12-01",109,[17127],"Acute Promyelocytic Leukaemia",[17108],{"trials":17130,"activeCount":109},[],{"trials":17132,"activeCount":109},[],{"intervention":17134,"totalTrials":708,"cells":17135},"surgical robot",{"EARLY_PHASE1":17136,"PHASE1":17138,"PHASE2":17140,"PHASE3":17142,"PHASE4":17153,"NA":17155},{"trials":17137,"activeCount":109},[],{"trials":17139,"activeCount":109},[],{"trials":17141,"activeCount":109},[],{"trials":17143,"activeCount":109},[17144],{"nctId":17145,"briefTitle":17146,"status":135,"phases":17147,"primaryCompletion":957,"completion":957,"start":15273,"enrollment":140,"conditions":17148,"interventions":17151},"NCT04956588","Evaluation of the Safety and Efficacy of Smart Orthopedic Minimally Invasive Surgical Systems for Spinal Surgery",[100],[17149,17150],"Spine Disease","Spinal Fractures",[17134,17152],"controlled approach",{"trials":17154,"activeCount":109},[],{"trials":17156,"activeCount":109},[],{"intervention":17152,"totalTrials":708,"cells":17158},{"EARLY_PHASE1":17159,"PHASE1":17161,"PHASE2":17163,"PHASE3":17165,"PHASE4":17171,"NA":17173},{"trials":17160,"activeCount":109},[],{"trials":17162,"activeCount":109},[],{"trials":17164,"activeCount":109},[],{"trials":17166,"activeCount":109},[17167],{"nctId":17145,"briefTitle":17146,"status":135,"phases":17168,"primaryCompletion":957,"completion":957,"start":15273,"enrollment":140,"conditions":17169,"interventions":17170},[100],[17149,17150],[17134,17152],{"trials":17172,"activeCount":109},[],{"trials":17174,"activeCount":109},[],{"intervention":2657,"totalTrials":3887,"cells":17176},{"EARLY_PHASE1":17177,"PHASE1":17179,"PHASE2":17181,"PHASE3":17233,"PHASE4":17235,"NA":17237},{"trials":17178,"activeCount":109},[],{"trials":17180,"activeCount":109},[],{"trials":17182,"activeCount":109},[17183,17187,17191,17195,17203,17207,17215,17222,17226],{"nctId":2647,"briefTitle":2648,"status":135,"phases":17184,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":2653,"conditions":17185,"interventions":17186},[99],[2655],[2638,2657],{"nctId":13680,"briefTitle":13681,"status":569,"phases":17188,"primaryCompletion":649,"completion":817,"start":13683,"enrollment":168,"conditions":17189,"interventions":17190},[98,99],[34],[13671,661,2657],{"nctId":5291,"briefTitle":5292,"status":569,"phases":17192,"primaryCompletion":5294,"completion":1404,"start":5295,"enrollment":574,"conditions":17193,"interventions":17194},[99],[576,34],[5282,2657],{"nctId":17196,"briefTitle":17197,"status":569,"phases":17198,"primaryCompletion":571,"completion":818,"start":17199,"enrollment":574,"conditions":17200,"interventions":17201},"NCT05471050","The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],"2022-03-02",[34],[17202,2657],"TAC",{"nctId":10436,"briefTitle":10437,"status":569,"phases":17204,"primaryCompletion":2853,"completion":10439,"start":857,"enrollment":574,"conditions":17205,"interventions":17206},[99],[34,10441,3264,10442],[10427,2657],{"nctId":17208,"briefTitle":17209,"status":569,"phases":17210,"primaryCompletion":11518,"completion":6220,"start":8383,"enrollment":17211,"conditions":17212,"interventions":17213},"NCT05852847","Low-dose Baricitinib Plus Danazol for Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],216,[34],[17214,2657],"Baricitinib 2 MG [Olumiant]",{"nctId":17216,"briefTitle":17217,"status":569,"phases":17218,"primaryCompletion":2768,"completion":16864,"start":15951,"enrollment":32,"conditions":17219,"interventions":17220},"NCT04481282","The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],[34],[17221,2657],"Terbutaline",{"nctId":5550,"briefTitle":5551,"status":569,"phases":17223,"primaryCompletion":4238,"completion":5553,"start":5546,"enrollment":5554,"conditions":17224,"interventions":17225},[99],[34],[590,2657],{"nctId":17227,"briefTitle":17228,"status":569,"phases":17229,"primaryCompletion":5294,"completion":2633,"start":1138,"enrollment":17230,"conditions":17231,"interventions":17232},"NCT05494307","The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant\u002FRelapse Immune Thrombocytopenia",[99],228,[34],[17221,2657],{"trials":17234,"activeCount":109},[],{"trials":17236,"activeCount":109},[],{"trials":17238,"activeCount":109},[],{"intervention":3936,"totalTrials":405,"cells":17240},{"EARLY_PHASE1":17241,"PHASE1":17243,"PHASE2":17253,"PHASE3":17270,"PHASE4":17272,"NA":17274},{"trials":17242,"activeCount":109},[],{"trials":17244,"activeCount":109},[17245],{"nctId":17246,"briefTitle":17247,"status":569,"phases":17248,"primaryCompletion":66,"completion":66,"start":5612,"enrollment":728,"conditions":17249,"interventions":17251},"NCT05164848","JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy",[98],[17250],"Esophageal Squamous Carcinoma",[17252,3936],"JMT101",{"trials":17254,"activeCount":109},[17255,17262,17266],{"nctId":17256,"briefTitle":17257,"status":569,"phases":17258,"primaryCompletion":649,"completion":2530,"start":17259,"enrollment":32,"conditions":17260,"interventions":17261},"NCT03940976","Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)",[99],"2019-04-28",[1250],[3936],{"nctId":5496,"briefTitle":5497,"status":569,"phases":17263,"primaryCompletion":3635,"completion":3911,"start":5499,"enrollment":960,"conditions":17264,"interventions":17265},[99],[5501],[3936,1029],{"nctId":3929,"briefTitle":3930,"status":569,"phases":17267,"primaryCompletion":3932,"completion":3680,"start":3933,"enrollment":26,"conditions":17268,"interventions":17269},[99],[1250],[3936,1037],{"trials":17271,"activeCount":109},[],{"trials":17273,"activeCount":109},[],{"trials":17275,"activeCount":109},[],{"intervention":2600,"totalTrials":405,"cells":17277},{"EARLY_PHASE1":17278,"PHASE1":17280,"PHASE2":17282,"PHASE3":17300,"PHASE4":17302,"NA":17304},{"trials":17279,"activeCount":109},[],{"trials":17281,"activeCount":109},[],{"trials":17283,"activeCount":109},[17284,17288,17292,17296],{"nctId":5398,"briefTitle":5399,"status":569,"phases":17285,"primaryCompletion":5401,"completion":5401,"start":5402,"enrollment":1767,"conditions":17286,"interventions":17287},[99],[5404],[2601,2600],{"nctId":15995,"briefTitle":15996,"status":569,"phases":17289,"primaryCompletion":15998,"completion":10699,"start":15999,"enrollment":140,"conditions":17290,"interventions":17291},[99],[8556],[1121,2600],{"nctId":8258,"briefTitle":8259,"status":569,"phases":17293,"primaryCompletion":52,"completion":8261,"start":8262,"enrollment":32,"conditions":17294,"interventions":17295},[99],[2580],[8255,8256,2600],{"nctId":3956,"briefTitle":3957,"status":569,"phases":17297,"primaryCompletion":2700,"completion":1578,"start":3959,"enrollment":3960,"conditions":17298,"interventions":17299},[99],[3903],[1037,2600],{"trials":17301,"activeCount":109},[],{"trials":17303,"activeCount":109},[],{"trials":17305,"activeCount":109},[],{"intervention":3532,"totalTrials":329,"cells":17307},{"EARLY_PHASE1":17308,"PHASE1":17310,"PHASE2":17312,"PHASE3":17331,"PHASE4":17333,"NA":17335},{"trials":17309,"activeCount":109},[],{"trials":17311,"activeCount":109},[],{"trials":17313,"activeCount":109},[17314,17318,17322],{"nctId":3524,"briefTitle":3525,"status":135,"phases":17315,"primaryCompletion":252,"completion":2824,"start":3527,"enrollment":3528,"conditions":17316,"interventions":17317},[99],[3530],[3532,1026,1028],{"nctId":4087,"briefTitle":4088,"status":569,"phases":17319,"primaryCompletion":4090,"completion":4090,"start":3090,"enrollment":4091,"conditions":17320,"interventions":17321},[99],[3122],[3767,3532],{"nctId":17323,"briefTitle":17324,"status":135,"phases":17325,"primaryCompletion":17326,"completion":17327,"start":449,"enrollment":2008,"conditions":17328,"interventions":17330},"NCT03009461","Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis",[99],"2020-06-15","2020-12-28",[17329,10058],"HepatoCellular Carcinoma",[3532],{"trials":17332,"activeCount":109},[],{"trials":17334,"activeCount":109},[],{"trials":17336,"activeCount":109},[],{"intervention":1119,"totalTrials":329,"cells":17338},{"EARLY_PHASE1":17339,"PHASE1":17341,"PHASE2":17343,"PHASE3":17359,"PHASE4":17361,"NA":17363},{"trials":17340,"activeCount":109},[],{"trials":17342,"activeCount":109},[],{"trials":17344,"activeCount":109},[17345,17349,17353],{"nctId":1109,"briefTitle":1110,"status":569,"phases":17346,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":17347,"interventions":17348},[99],[1117],[1119,734,1120,1121,1122,1090],{"nctId":4235,"briefTitle":4236,"status":569,"phases":17350,"primaryCompletion":4238,"completion":637,"start":4239,"enrollment":1767,"conditions":17351,"interventions":17352},[99],[1153],[1035,1119,4242],{"nctId":17354,"briefTitle":17355,"status":569,"phases":17356,"primaryCompletion":5372,"completion":3900,"start":3010,"enrollment":26,"conditions":17357,"interventions":17358},"NCT03611231","Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma",[99],[1117],[1119],{"trials":17360,"activeCount":109},[],{"trials":17362,"activeCount":109},[],{"trials":17364,"activeCount":109},[],{"intervention":3456,"totalTrials":329,"cells":17366},{"EARLY_PHASE1":17367,"PHASE1":17369,"PHASE2":17371,"PHASE3":17392,"PHASE4":17394,"NA":17396},{"trials":17368,"activeCount":109},[],{"trials":17370,"activeCount":109},[],{"trials":17372,"activeCount":109},[17373,17382,17386],{"nctId":17374,"briefTitle":17375,"status":135,"phases":17376,"primaryCompletion":17377,"completion":3451,"start":17378,"enrollment":140,"conditions":17379,"interventions":17381},"NCT02464319","A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome",[99],"2017-03-31","2015-06-01",[17380],"Primary Sjögren's Syndrome",[3456,3457],{"nctId":3447,"briefTitle":3448,"status":135,"phases":17383,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":3453,"conditions":17384,"interventions":17385},[99],[2506],[3456,3457,2911,3458,3459],{"nctId":17387,"briefTitle":17388,"status":569,"phases":17389,"primaryCompletion":253,"completion":668,"start":830,"enrollment":140,"conditions":17390,"interventions":17391},"NCT02465580","A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus",[99],[2836],[3456,3457],{"trials":17393,"activeCount":109},[],{"trials":17395,"activeCount":109},[],{"trials":17397,"activeCount":109},[],{"intervention":3457,"totalTrials":329,"cells":17399},{"EARLY_PHASE1":17400,"PHASE1":17402,"PHASE2":17404,"PHASE3":17418,"PHASE4":17420,"NA":17422},{"trials":17401,"activeCount":109},[],{"trials":17403,"activeCount":109},[],{"trials":17405,"activeCount":109},[17406,17410,17414],{"nctId":17374,"briefTitle":17375,"status":135,"phases":17407,"primaryCompletion":17377,"completion":3451,"start":17378,"enrollment":140,"conditions":17408,"interventions":17409},[99],[17380],[3456,3457],{"nctId":3447,"briefTitle":3448,"status":135,"phases":17411,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":3453,"conditions":17412,"interventions":17413},[99],[2506],[3456,3457,2911,3458,3459],{"nctId":17387,"briefTitle":17388,"status":569,"phases":17415,"primaryCompletion":253,"completion":668,"start":830,"enrollment":140,"conditions":17416,"interventions":17417},[99],[2836],[3456,3457],{"trials":17419,"activeCount":109},[],{"trials":17421,"activeCount":109},[],{"trials":17423,"activeCount":109},[],{"intervention":8255,"totalTrials":329,"cells":17425},{"EARLY_PHASE1":17426,"PHASE1":17428,"PHASE2":17430,"PHASE3":17449,"PHASE4":17451,"NA":17453},{"trials":17427,"activeCount":109},[],{"trials":17429,"activeCount":109},[],{"trials":17431,"activeCount":109},[17432,17436,17445],{"nctId":8248,"briefTitle":8249,"status":569,"phases":17433,"primaryCompletion":375,"completion":8251,"start":8252,"enrollment":1767,"conditions":17434,"interventions":17435},[99],[2580],[8255,8256],{"nctId":17437,"briefTitle":17438,"status":569,"phases":17439,"primaryCompletion":17440,"completion":1201,"start":17441,"enrollment":15476,"conditions":17442,"interventions":17444},"NCT03701022","PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK\u002FT Cell Lymphoma",[99],"2020-03-30","2018-10-20",[17443],"NK\u002FT-cell Lymphoma",[8255],{"nctId":8258,"briefTitle":8259,"status":569,"phases":17446,"primaryCompletion":52,"completion":8261,"start":8262,"enrollment":32,"conditions":17447,"interventions":17448},[99],[2580],[8255,8256,2600],{"trials":17450,"activeCount":109},[],{"trials":17452,"activeCount":109},[],{"trials":17454,"activeCount":109},[],{"intervention":17456,"totalTrials":746,"cells":17457},"Anlotinib Hydrochloride",{"EARLY_PHASE1":17458,"PHASE1":17460,"PHASE2":17462,"PHASE3":17483,"PHASE4":17485,"NA":17487},{"trials":17459,"activeCount":109},[],{"trials":17461,"activeCount":109},[],{"trials":17463,"activeCount":109},[17464,17474],{"nctId":17465,"briefTitle":17466,"status":569,"phases":17467,"primaryCompletion":17468,"completion":1202,"start":17469,"enrollment":140,"conditions":17470,"interventions":17473},"NCT04042597","Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma",[99],"2021-10-30","2019-07-18",[2545,17471,17472,5459],"Quality of Life","Chordoma",[17456],{"nctId":17475,"briefTitle":17476,"status":569,"phases":17477,"primaryCompletion":17478,"completion":969,"start":17479,"enrollment":8079,"conditions":17480,"interventions":17481},"NCT05485350","Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)",[99],"2023-09-21","2022-09-12",[2680],[17456,17482],"penpulimab",{"trials":17484,"activeCount":109},[],{"trials":17486,"activeCount":109},[],{"trials":17488,"activeCount":109},[],{"intervention":4665,"totalTrials":746,"cells":17490},{"EARLY_PHASE1":17491,"PHASE1":17493,"PHASE2":17495,"PHASE3":17505,"PHASE4":17507,"NA":17509},{"trials":17492,"activeCount":109},[],{"trials":17494,"activeCount":109},[],{"trials":17496,"activeCount":109},[17497,17501],{"nctId":4657,"briefTitle":4658,"status":569,"phases":17498,"primaryCompletion":1765,"completion":4660,"start":4661,"enrollment":4662,"conditions":17499,"interventions":17500},[99],[3355],[4665,4119,1059],{"nctId":5416,"briefTitle":5417,"status":135,"phases":17502,"primaryCompletion":5419,"completion":5420,"start":4720,"enrollment":26,"conditions":17503,"interventions":17504},[99],[5375,195,5422,5376],[2601,4665],{"trials":17506,"activeCount":109},[],{"trials":17508,"activeCount":109},[],{"trials":17510,"activeCount":109},[],{"intervention":661,"totalTrials":746,"cells":17512},{"EARLY_PHASE1":17513,"PHASE1":17515,"PHASE2":17517,"PHASE3":17527,"PHASE4":17529,"NA":17531},{"trials":17514,"activeCount":109},[],{"trials":17516,"activeCount":109},[],{"trials":17518,"activeCount":109},[17519,17523],{"nctId":13680,"briefTitle":13681,"status":569,"phases":17520,"primaryCompletion":649,"completion":817,"start":13683,"enrollment":168,"conditions":17521,"interventions":17522},[98,99],[34],[13671,661,2657],{"nctId":654,"briefTitle":655,"status":569,"phases":17524,"primaryCompletion":657,"completion":657,"start":448,"enrollment":658,"conditions":17525,"interventions":17526},[99],[34],[557,661],{"trials":17528,"activeCount":109},[],{"trials":17530,"activeCount":109},[],{"trials":17532,"activeCount":109},[],{"intervention":9948,"totalTrials":746,"cells":17534},{"EARLY_PHASE1":17535,"PHASE1":17537,"PHASE2":17543,"PHASE3":17551,"PHASE4":17553,"NA":17555},{"trials":17536,"activeCount":109},[],{"trials":17538,"activeCount":109},[17539],{"nctId":9938,"briefTitle":9939,"status":135,"phases":17540,"primaryCompletion":9941,"completion":9942,"start":9943,"enrollment":9944,"conditions":17541,"interventions":17542},[98],[9156],[9947,9948,5066],{"trials":17544,"activeCount":109},[17545],{"nctId":17546,"briefTitle":17547,"status":135,"phases":17548,"primaryCompletion":4737,"completion":4737,"start":817,"enrollment":1767,"conditions":17549,"interventions":17550},"NCT06493240","Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer",[99],[4740],[9948],{"trials":17552,"activeCount":109},[],{"trials":17554,"activeCount":109},[],{"trials":17556,"activeCount":109},[],{"intervention":17558,"totalTrials":746,"cells":17559},"tofacitinib",{"EARLY_PHASE1":17560,"PHASE1":17562,"PHASE2":17564,"PHASE3":17581,"PHASE4":17583,"NA":17585},{"trials":17561,"activeCount":109},[],{"trials":17563,"activeCount":109},[],{"trials":17565,"activeCount":109},[17566,17572],{"nctId":17567,"briefTitle":17568,"status":569,"phases":17569,"primaryCompletion":571,"completion":818,"start":1416,"enrollment":477,"conditions":17570,"interventions":17571},"NCT05400889","Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies",[99],[9805],[17558],{"nctId":17573,"briefTitle":17574,"status":569,"phases":17575,"primaryCompletion":817,"completion":17576,"start":17577,"enrollment":477,"conditions":17578,"interventions":17579},"NCT05087589","Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome",[99],"2023-10-01","2021-11-20",[17380],[17580],"Tofacitinib",{"trials":17582,"activeCount":109},[],{"trials":17584,"activeCount":109},[],{"trials":17586,"activeCount":109},[],{"intervention":17588,"totalTrials":746,"cells":17589},"rhTPO",{"EARLY_PHASE1":17590,"PHASE1":17592,"PHASE2":17601,"PHASE3":17610,"PHASE4":17612,"NA":17614},{"trials":17591,"activeCount":109},[],{"trials":17593,"activeCount":109},[17594],{"nctId":17595,"briefTitle":17596,"status":569,"phases":17597,"primaryCompletion":1163,"completion":52,"start":17598,"enrollment":1767,"conditions":17599,"interventions":17600},"NCT04518878","Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER)",[98],"2020-08-31",[34],[2706,17588],{"trials":17602,"activeCount":109},[17603],{"nctId":17604,"briefTitle":17605,"status":569,"phases":17606,"primaryCompletion":13941,"completion":17607,"start":17598,"enrollment":574,"conditions":17608,"interventions":17609},"NCT04516837","Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)",[99],"2022-08",[34],[2706,17588],{"trials":17611,"activeCount":109},[],{"trials":17613,"activeCount":109},[],{"trials":17615,"activeCount":109},[],{"intervention":17617,"totalTrials":746,"cells":17618},"Cytarabine",{"EARLY_PHASE1":17619,"PHASE1":17621,"PHASE2":17623,"PHASE3":17638,"PHASE4":17640,"NA":17642},{"trials":17620,"activeCount":109},[],{"trials":17622,"activeCount":109},[],{"trials":17624,"activeCount":109},[17625,17632],{"nctId":17626,"briefTitle":17627,"status":569,"phases":17628,"primaryCompletion":2203,"completion":2203,"start":17629,"enrollment":728,"conditions":17630,"interventions":17631},"NCT03412409","RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT",[99],"2018-02-01",[946,947],[17617],{"nctId":17633,"briefTitle":17634,"status":569,"phases":17635,"primaryCompletion":571,"completion":571,"start":17629,"enrollment":728,"conditions":17636,"interventions":17637},"NCT03412266","RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT",[99],[947],[17617],{"trials":17639,"activeCount":109},[],{"trials":17641,"activeCount":109},[],{"trials":17643,"activeCount":109},[],{"intervention":17645,"totalTrials":746,"cells":17646},"Nanoparticle Albumin-Bound Paclitaxel",{"EARLY_PHASE1":17647,"PHASE1":17649,"PHASE2":17651,"PHASE3":17664,"PHASE4":17666,"NA":17668},{"trials":17648,"activeCount":109},[],{"trials":17650,"activeCount":109},[],{"trials":17652,"activeCount":109},[17653,17660],{"nctId":17654,"briefTitle":17655,"status":135,"phases":17656,"primaryCompletion":16137,"completion":16137,"start":3511,"enrollment":17657,"conditions":17658,"interventions":17659},"NCT01336062","Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients",[98,99],19,[4705],[17645],{"nctId":4197,"briefTitle":4198,"status":569,"phases":17661,"primaryCompletion":4200,"completion":4201,"start":4202,"enrollment":32,"conditions":17662,"interventions":17663},[99],[684],[4205,4206,1026],{"trials":17665,"activeCount":109},[],{"trials":17667,"activeCount":109},[],{"trials":17669,"activeCount":109},[],{"intervention":17221,"totalTrials":746,"cells":17671},{"EARLY_PHASE1":17672,"PHASE1":17674,"PHASE2":17676,"PHASE3":17686,"PHASE4":17688,"NA":17690},{"trials":17673,"activeCount":109},[],{"trials":17675,"activeCount":109},[],{"trials":17677,"activeCount":109},[17678,17682],{"nctId":17216,"briefTitle":17217,"status":569,"phases":17679,"primaryCompletion":2768,"completion":16864,"start":15951,"enrollment":32,"conditions":17680,"interventions":17681},[99],[34],[17221,2657],{"nctId":17227,"briefTitle":17228,"status":569,"phases":17683,"primaryCompletion":5294,"completion":2633,"start":1138,"enrollment":17230,"conditions":17684,"interventions":17685},[99],[34],[17221,2657],{"trials":17687,"activeCount":109},[],{"trials":17689,"activeCount":109},[],{"trials":17691,"activeCount":109},[],{"intervention":4206,"totalTrials":746,"cells":17693},{"EARLY_PHASE1":17694,"PHASE1":17696,"PHASE2":17698,"PHASE3":17708,"PHASE4":17710,"NA":17712},{"trials":17695,"activeCount":109},[],{"trials":17697,"activeCount":109},[],{"trials":17699,"activeCount":109},[17700,17704],{"nctId":4675,"briefTitle":4676,"status":435,"phases":17701,"primaryCompletion":4678,"completion":4678,"start":4679,"enrollment":109,"conditions":17702,"interventions":17703},[99],[28],[2601,4119,4206],{"nctId":4197,"briefTitle":4198,"status":569,"phases":17705,"primaryCompletion":4200,"completion":4201,"start":4202,"enrollment":32,"conditions":17706,"interventions":17707},[99],[684],[4205,4206,1026],{"trials":17709,"activeCount":109},[],{"trials":17711,"activeCount":109},[],{"trials":17713,"activeCount":109},[],{"intervention":17715,"totalTrials":708,"cells":17716},"68Ga-grazytracer",{"EARLY_PHASE1":17717,"PHASE1":17719,"PHASE2":17721,"PHASE3":17731,"PHASE4":17733,"NA":17735},{"trials":17718,"activeCount":109},[],{"trials":17720,"activeCount":109},[],{"trials":17722,"activeCount":109},[17723],{"nctId":17724,"briefTitle":17725,"status":135,"phases":17726,"primaryCompletion":17727,"completion":1893,"start":17728,"enrollment":38,"conditions":17729,"interventions":17730},"NCT05000372","68Ga-grazytracer PET\u002FCT of Tumor Responses to Immunotherapy",[98,99],"2024-05-25","2021-09-22",[9847],[17715],{"trials":17732,"activeCount":109},[],{"trials":17734,"activeCount":109},[],{"trials":17736,"activeCount":109},[],{"intervention":17738,"totalTrials":708,"cells":17739},"Granulocyte Colony Stimulating Factor",{"EARLY_PHASE1":17740,"PHASE1":17742,"PHASE2":17744,"PHASE3":17755,"PHASE4":17757,"NA":17759},{"trials":17741,"activeCount":109},[],{"trials":17743,"activeCount":109},[],{"trials":17745,"activeCount":109},[17746],{"nctId":17747,"briefTitle":17748,"status":135,"phases":17749,"completion":17750,"start":17751,"enrollment":32,"conditions":17752,"interventions":17753},"NCT00397423","G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response",[99],"2007-08","2006-12",[16078],[17738,17754],"NS",{"trials":17756,"activeCount":109},[],{"trials":17758,"activeCount":109},[],{"trials":17760,"activeCount":109},[],{"intervention":17754,"totalTrials":708,"cells":17762},{"EARLY_PHASE1":17763,"PHASE1":17765,"PHASE2":17767,"PHASE3":17773,"PHASE4":17775,"NA":17777},{"trials":17764,"activeCount":109},[],{"trials":17766,"activeCount":109},[],{"trials":17768,"activeCount":109},[17769],{"nctId":17747,"briefTitle":17748,"status":135,"phases":17770,"completion":17750,"start":17751,"enrollment":32,"conditions":17771,"interventions":17772},[99],[16078],[17738,17754],{"trials":17774,"activeCount":109},[],{"trials":17776,"activeCount":109},[],{"trials":17778,"activeCount":109},[],{"intervention":17780,"totalTrials":708,"cells":17781},"it-hMSC",{"EARLY_PHASE1":17782,"PHASE1":17784,"PHASE2":17786,"PHASE3":17794,"PHASE4":17796,"NA":17798},{"trials":17783,"activeCount":109},[],{"trials":17785,"activeCount":109},[],{"trials":17787,"activeCount":109},[17788],{"nctId":17789,"briefTitle":17790,"status":569,"phases":17791,"primaryCompletion":535,"completion":817,"start":4719,"enrollment":140,"conditions":17792,"interventions":17793},"NCT04953663","Clinical Plan of Ischemic Stroke",[98,99],[5228],[17780],{"trials":17795,"activeCount":109},[],{"trials":17797,"activeCount":109},[],{"trials":17799,"activeCount":109},[],{"intervention":17801,"totalTrials":708,"cells":17802},"proactive Anti-VEGF (conbercept) use",{"EARLY_PHASE1":17803,"PHASE1":17805,"PHASE2":17807,"PHASE3":17817,"PHASE4":17819,"NA":17821},{"trials":17804,"activeCount":109},[],{"trials":17806,"activeCount":109},[],{"trials":17808,"activeCount":109},[17809],{"nctId":17810,"briefTitle":17811,"status":569,"phases":17812,"primaryCompletion":1403,"completion":94,"start":2844,"enrollment":153,"conditions":17813,"interventions":17815},"NCT05642793","Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients",[99],[17814],"Proliferative Diabetic Retinopathy",[17801,17816],"passive Anti-VEGF (conbercept) use",{"trials":17818,"activeCount":109},[],{"trials":17820,"activeCount":109},[],{"trials":17822,"activeCount":109},[],{"intervention":17816,"totalTrials":708,"cells":17824},{"EARLY_PHASE1":17825,"PHASE1":17827,"PHASE2":17829,"PHASE3":17835,"PHASE4":17837,"NA":17839},{"trials":17826,"activeCount":109},[],{"trials":17828,"activeCount":109},[],{"trials":17830,"activeCount":109},[17831],{"nctId":17810,"briefTitle":17811,"status":569,"phases":17832,"primaryCompletion":1403,"completion":94,"start":2844,"enrollment":153,"conditions":17833,"interventions":17834},[99],[17814],[17801,17816],{"trials":17836,"activeCount":109},[],{"trials":17838,"activeCount":109},[],{"trials":17840,"activeCount":109},[],{"intervention":17842,"totalTrials":708,"cells":17843},"Cadonilimab",{"EARLY_PHASE1":17844,"PHASE1":17846,"PHASE2":17848,"PHASE3":17862,"PHASE4":17864,"NA":17866},{"trials":17845,"activeCount":109},[],{"trials":17847,"activeCount":109},[],{"trials":17849,"activeCount":109},[17850],{"nctId":17851,"briefTitle":17852,"status":569,"phases":17853,"primaryCompletion":17854,"completion":17855,"start":17856,"enrollment":140,"conditions":17857,"interventions":17861},"NCT05915481","Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors",[98,99],"2024-06-21","2025-06-21","2023-06-21",[9156,17858,17859,17860,8281],"Stereotactic Body Radiotherapy","Immune Checkpoint Inhibitor","Safety",[17842],{"trials":17863,"activeCount":109},[],{"trials":17865,"activeCount":109},[],{"trials":17867,"activeCount":109},[],{"intervention":17869,"totalTrials":708,"cells":17870},"pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone",{"EARLY_PHASE1":17871,"PHASE1":17873,"PHASE2":17875,"PHASE3":17885,"PHASE4":17887,"NA":17889},{"trials":17872,"activeCount":109},[],{"trials":17874,"activeCount":109},[],{"trials":17876,"activeCount":109},[17877],{"nctId":17878,"briefTitle":17879,"status":569,"phases":17880,"primaryCompletion":1404,"completion":637,"start":17881,"enrollment":640,"conditions":17882,"interventions":17884},"NCT04484506","Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK\u002FT Cell Lymphoma",[99],"2011-10-20",[17883],"NK\u002FT Cell Lymphoma Nos",[17869],{"trials":17886,"activeCount":109},[],{"trials":17888,"activeCount":109},[],{"trials":17890,"activeCount":109},[],{"intervention":17892,"totalTrials":708,"cells":17893},"Ven+CAG",{"EARLY_PHASE1":17894,"PHASE1":17896,"PHASE2":17898,"PHASE3":17906,"PHASE4":17908,"NA":17910},{"trials":17895,"activeCount":109},[],{"trials":17897,"activeCount":109},[],{"trials":17899,"activeCount":109},[17900],{"nctId":17901,"briefTitle":17902,"status":569,"phases":17903,"primaryCompletion":1103,"completion":741,"start":10439,"enrollment":2522,"conditions":17904,"interventions":17905},"NCT05918198","Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory\u002FRelapsed Acute Myeloid Leukemia",[99],[2958],[17892],{"trials":17907,"activeCount":109},[],{"trials":17909,"activeCount":109},[],{"trials":17911,"activeCount":109},[],{"intervention":17913,"totalTrials":708,"cells":17914},"Toripalimab combination with platinum-containing dual-drug chemotherapy.",{"EARLY_PHASE1":17915,"PHASE1":17917,"PHASE2":17919,"PHASE3":17930,"PHASE4":17932,"NA":17934},{"trials":17916,"activeCount":109},[],{"trials":17918,"activeCount":109},[],{"trials":17920,"activeCount":109},[17921],{"nctId":17922,"briefTitle":17923,"status":569,"phases":17924,"primaryCompletion":17925,"completion":9294,"start":17926,"enrollment":376,"conditions":17927,"interventions":17929},"NCT04606303","A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.",[99],"2023-05-21","2020-12-18",[17928],"Locally Advanced NSCLC",[17913],{"trials":17931,"activeCount":109},[],{"trials":17933,"activeCount":109},[],{"trials":17935,"activeCount":109},[],{"intervention":17937,"totalTrials":708,"cells":17938},"metformin and chemotherapy",{"EARLY_PHASE1":17939,"PHASE1":17941,"PHASE2":17943,"PHASE3":17953,"PHASE4":17955,"NA":17957},{"trials":17940,"activeCount":109},[],{"trials":17942,"activeCount":109},[],{"trials":17944,"activeCount":109},[17945],{"nctId":17946,"briefTitle":17947,"status":569,"phases":17948,"primaryCompletion":17949,"completion":13734,"start":17950,"enrollment":2770,"conditions":17951,"interventions":17952},"NCT03833466","Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)",[99],"2020-03-20","2019-02-05",[1250],[17937],{"trials":17954,"activeCount":109},[],{"trials":17956,"activeCount":109},[],{"trials":17958,"activeCount":109},[],{"intervention":3514,"totalTrials":708,"cells":17960},{"EARLY_PHASE1":17961,"PHASE1":17963,"PHASE2":17965,"PHASE3":17971,"PHASE4":17973,"NA":17975},{"trials":17962,"activeCount":109},[],{"trials":17964,"activeCount":109},[],{"trials":17966,"activeCount":109},[17967],{"nctId":3507,"briefTitle":3508,"status":569,"phases":17968,"primaryCompletion":3510,"completion":2824,"start":3511,"enrollment":1894,"conditions":17969,"interventions":17970},[99],[28],[3514,3515,3516],{"trials":17972,"activeCount":109},[],{"trials":17974,"activeCount":109},[],{"trials":17976,"activeCount":109},[],{"intervention":17978,"totalTrials":708,"cells":17979},"oxaliplatin and 5-fluorouracil",{"EARLY_PHASE1":17980,"PHASE1":17982,"PHASE2":17984,"PHASE3":17995,"PHASE4":17997,"NA":17999},{"trials":17981,"activeCount":109},[],{"trials":17983,"activeCount":109},[],{"trials":17985,"activeCount":109},[17986],{"nctId":17987,"briefTitle":17988,"status":135,"phases":17989,"primaryCompletion":17990,"completion":17990,"start":5772,"enrollment":17991,"conditions":17992,"interventions":17994},"NCT05024513","Biliary Drainage Plus HAIC in Locally Advanced pCCA",[99],"2025-10-20",127,[17993],"Perihilar Cholangiocarcinoma",[17978],{"trials":17996,"activeCount":109},[],{"trials":17998,"activeCount":109},[],{"trials":18000,"activeCount":109},[],{"intervention":18002,"totalTrials":708,"cells":18003},"Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab",{"EARLY_PHASE1":18004,"PHASE1":18006,"PHASE2":18008,"PHASE3":18020,"PHASE4":18022,"NA":18024},{"trials":18005,"activeCount":109},[],{"trials":18007,"activeCount":109},[],{"trials":18009,"activeCount":109},[18010],{"nctId":18011,"briefTitle":18012,"status":569,"phases":18013,"primaryCompletion":18014,"completion":18015,"start":18016,"enrollment":3547,"conditions":18017,"interventions":18019},"NCT05398224","R-MTX-zanbrutinib in Secondary CNS Lymphoma",[99],"2024-02-26","2024-05-26","2021-02-26",[18018],"Secondary Central Nervous System Lymphoma",[18002],{"trials":18021,"activeCount":109},[],{"trials":18023,"activeCount":109},[],{"trials":18025,"activeCount":109},[],{"intervention":18027,"totalTrials":708,"cells":18028},"Disitamab Vedotin（RC48-ADC）",{"EARLY_PHASE1":18029,"PHASE1":18031,"PHASE2":18033,"PHASE3":18042,"PHASE4":18044,"NA":18046},{"trials":18030,"activeCount":109},[],{"trials":18032,"activeCount":109},[],{"trials":18034,"activeCount":109},[18035],{"nctId":18036,"briefTitle":18037,"status":569,"phases":18038,"primaryCompletion":5201,"completion":6876,"start":7884,"enrollment":32,"conditions":18039,"interventions":18041},"NCT05955209","Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)",[99],[18040],"Metastatic Castration-resistant Prostate Cancer",[18027],{"trials":18043,"activeCount":109},[],{"trials":18045,"activeCount":109},[],{"trials":18047,"activeCount":109},[],{"intervention":18049,"totalTrials":708,"cells":18050},"SOX sequential S-1",{"EARLY_PHASE1":18051,"PHASE1":18053,"PHASE2":18055,"PHASE3":18066,"PHASE4":18068,"NA":18070},{"trials":18052,"activeCount":109},[],{"trials":18054,"activeCount":109},[],{"trials":18056,"activeCount":109},[18057],{"nctId":18058,"briefTitle":18059,"status":569,"phases":18060,"primaryCompletion":831,"completion":831,"start":18061,"enrollment":32,"conditions":18062,"interventions":18065},"NCT01811277","SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer",[99],"2010-07",[18063,18064,684],"Biliary Tract Cancer","Periampullary Adenocarcinoma",[18049],{"trials":18067,"activeCount":109},[],{"trials":18069,"activeCount":109},[],{"trials":18071,"activeCount":109},[],{"intervention":18073,"totalTrials":708,"cells":18074},"FAM-NP41",{"EARLY_PHASE1":18075,"PHASE1":18077,"PHASE2":18079,"PHASE3":18088,"PHASE4":18090,"NA":18092},{"trials":18076,"activeCount":109},[],{"trials":18078,"activeCount":109},[],{"trials":18080,"activeCount":109},[18081],{"nctId":18082,"briefTitle":18083,"status":569,"phases":18084,"primaryCompletion":17123,"completion":81,"start":535,"enrollment":32,"conditions":18085,"interventions":18087},"NCT05043519","Phase I\u002FII Clinical Trial of NP41 for Cranial Nerve Fluorescence Imaging",[98,99],[18086],"Cranial Nerve Injuries",[18073],{"trials":18089,"activeCount":109},[],{"trials":18091,"activeCount":109},[],{"trials":18093,"activeCount":109},[],{"intervention":18095,"totalTrials":708,"cells":18096},"Radiation: Proton Therapy+PD-1 Ab",{"EARLY_PHASE1":18097,"PHASE1":18099,"PHASE2":18101,"PHASE3":18111,"PHASE4":18113,"NA":18115},{"trials":18098,"activeCount":109},[],{"trials":18100,"activeCount":109},[],{"trials":18102,"activeCount":109},[18103],{"nctId":18104,"briefTitle":18105,"status":569,"phases":18106,"primaryCompletion":535,"completion":2853,"start":3624,"enrollment":1767,"conditions":18107,"interventions":18110},"NCT03765190","Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer",[98,99],[18108,3924,18109],"Proton Therapy","Neoplasm Metastasis",[18095],{"trials":18112,"activeCount":109},[],{"trials":18114,"activeCount":109},[],{"trials":18116,"activeCount":109},[],{"intervention":950,"totalTrials":708,"cells":18118},{"EARLY_PHASE1":18119,"PHASE1":18121,"PHASE2":18123,"PHASE3":18129,"PHASE4":18131,"NA":18133},{"trials":18120,"activeCount":109},[],{"trials":18122,"activeCount":109},[],{"trials":18124,"activeCount":109},[18125],{"nctId":940,"briefTitle":941,"status":569,"phases":18126,"primaryCompletion":604,"completion":943,"start":944,"enrollment":553,"conditions":18127,"interventions":18128},[98,99],[946,947,948],[931,950,951,952],{"trials":18130,"activeCount":109},[],{"trials":18132,"activeCount":109},[],{"trials":18134,"activeCount":109},[],{"intervention":18136,"totalTrials":708,"cells":18137},"JS001",{"EARLY_PHASE1":18138,"PHASE1":18140,"PHASE2":18142,"PHASE3":18153,"PHASE4":18155,"NA":18157},{"trials":18139,"activeCount":109},[],{"trials":18141,"activeCount":109},[],{"trials":18143,"activeCount":109},[18144],{"nctId":18145,"briefTitle":18146,"status":569,"phases":18147,"primaryCompletion":52,"completion":2568,"start":18148,"enrollment":3625,"conditions":18149,"interventions":18151},"NCT03941795","Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma",[99],"2019-11-11",[18150],"Advanced Mucosal Melanoma",[18136,18152],"Axitinib 1 MG [Inlyta]",{"trials":18154,"activeCount":109},[],{"trials":18156,"activeCount":109},[],{"trials":18158,"activeCount":109},[],{"intervention":18152,"totalTrials":708,"cells":18160},{"EARLY_PHASE1":18161,"PHASE1":18163,"PHASE2":18165,"PHASE3":18171,"PHASE4":18173,"NA":18175},{"trials":18162,"activeCount":109},[],{"trials":18164,"activeCount":109},[],{"trials":18166,"activeCount":109},[18167],{"nctId":18145,"briefTitle":18146,"status":569,"phases":18168,"primaryCompletion":52,"completion":2568,"start":18148,"enrollment":3625,"conditions":18169,"interventions":18170},[99],[18150],[18136,18152],{"trials":18172,"activeCount":109},[],{"trials":18174,"activeCount":109},[],{"trials":18176,"activeCount":109},[],{"intervention":18178,"totalTrials":708,"cells":18179},"Anlotinib+ Liposomal Doxorubicin",{"EARLY_PHASE1":18180,"PHASE1":18182,"PHASE2":18184,"PHASE3":18192,"PHASE4":18194,"NA":18196},{"trials":18181,"activeCount":109},[],{"trials":18183,"activeCount":109},[],{"trials":18185,"activeCount":109},[18186],{"nctId":18187,"briefTitle":18188,"status":569,"phases":18189,"primaryCompletion":2588,"completion":5362,"start":5448,"enrollment":536,"conditions":18190,"interventions":18191},"NCT03880695","Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma",[99],[12277],[18178],{"trials":18193,"activeCount":109},[],{"trials":18195,"activeCount":109},[],{"trials":18197,"activeCount":109},[],{"intervention":18199,"totalTrials":708,"cells":18200},"acupoint with TCM",{"EARLY_PHASE1":18201,"PHASE1":18203,"PHASE2":18205,"PHASE3":18217,"PHASE4":18219,"NA":18221},{"trials":18202,"activeCount":109},[],{"trials":18204,"activeCount":109},[],{"trials":18206,"activeCount":109},[18207],{"nctId":18208,"briefTitle":18209,"status":569,"phases":18210,"primaryCompletion":3900,"completion":18211,"start":18212,"enrollment":18213,"conditions":18214,"interventions":18215},"NCT04749381","The Role of TCM on ERAS of Rectal Cancer Patients",[99],"2023-02-20","2020-09-28",264,[3355],[18199,18216],"acupoint with placebo",{"trials":18218,"activeCount":109},[],{"trials":18220,"activeCount":109},[],{"trials":18222,"activeCount":109},[],{"intervention":18216,"totalTrials":708,"cells":18224},{"EARLY_PHASE1":18225,"PHASE1":18227,"PHASE2":18229,"PHASE3":18235,"PHASE4":18237,"NA":18239},{"trials":18226,"activeCount":109},[],{"trials":18228,"activeCount":109},[],{"trials":18230,"activeCount":109},[18231],{"nctId":18208,"briefTitle":18209,"status":569,"phases":18232,"primaryCompletion":3900,"completion":18211,"start":18212,"enrollment":18213,"conditions":18233,"interventions":18234},[99],[3355],[18199,18216],{"trials":18236,"activeCount":109},[],{"trials":18238,"activeCount":109},[],{"trials":18240,"activeCount":109},[],{"intervention":2783,"totalTrials":708,"cells":18242},{"EARLY_PHASE1":18243,"PHASE1":18245,"PHASE2":18247,"PHASE3":18253,"PHASE4":18255,"NA":18257},{"trials":18244,"activeCount":109},[],{"trials":18246,"activeCount":109},[],{"trials":18248,"activeCount":109},[18249],{"nctId":2775,"briefTitle":2776,"status":569,"phases":18250,"primaryCompletion":2778,"completion":2779,"start":2780,"enrollment":47,"conditions":18251,"interventions":18252},[99],[2772],[2756,2783],{"trials":18254,"activeCount":109},[],{"trials":18256,"activeCount":109},[],{"trials":18258,"activeCount":109},[],{"intervention":18260,"totalTrials":708,"cells":18261},"Nimotuzumab and chemotherapy",{"EARLY_PHASE1":18262,"PHASE1":18264,"PHASE2":18266,"PHASE3":18277,"PHASE4":18279,"NA":18281},{"trials":18263,"activeCount":109},[],{"trials":18265,"activeCount":109},[],{"trials":18267,"activeCount":109},[18268],{"nctId":18269,"briefTitle":18270,"status":569,"phases":18271,"primaryCompletion":18272,"completion":3544,"start":18273,"enrollment":536,"conditions":18274,"interventions":18276},"NCT00972465","Study of Nimotuzumab to Treat Colorectal Cancer",[99],"2009-12","2009-06",[18275],"Advanced Colorectal Cancer",[18260],{"trials":18278,"activeCount":109},[],{"trials":18280,"activeCount":109},[],{"trials":18282,"activeCount":109},[],{"intervention":4828,"totalTrials":708,"cells":18284},{"EARLY_PHASE1":18285,"PHASE1":18287,"PHASE2":18289,"PHASE3":18295,"PHASE4":18297,"NA":18299},{"trials":18286,"activeCount":109},[],{"trials":18288,"activeCount":109},[],{"trials":18290,"activeCount":109},[18291],{"nctId":4821,"briefTitle":4822,"status":569,"phases":18292,"primaryCompletion":638,"completion":638,"start":1589,"enrollment":4824,"conditions":18293,"interventions":18294},[99],[4826],[2561,4828],{"trials":18296,"activeCount":109},[],{"trials":18298,"activeCount":109},[],{"trials":18300,"activeCount":109},[],{"intervention":18302,"totalTrials":708,"cells":18303},"Luveris",{"EARLY_PHASE1":18304,"PHASE1":18306,"PHASE2":18308,"PHASE3":18317,"PHASE4":18319,"NA":18321},{"trials":18305,"activeCount":109},[],{"trials":18307,"activeCount":109},[],{"trials":18309,"activeCount":109},[18310],{"nctId":18311,"briefTitle":18312,"status":569,"phases":18313,"primaryCompletion":18314,"completion":4853,"start":18272,"enrollment":640,"conditions":18315,"interventions":18316},"NCT01029470","To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation",[99],"2010-10",[1518],[18302],{"trials":18318,"activeCount":109},[],{"trials":18320,"activeCount":109},[],{"trials":18322,"activeCount":109},[],{"intervention":18324,"totalTrials":708,"cells":18325},"PD-1 antibody",{"EARLY_PHASE1":18326,"PHASE1":18328,"PHASE2":18330,"PHASE3":18339,"PHASE4":18341,"NA":18343},{"trials":18327,"activeCount":109},[],{"trials":18329,"activeCount":109},[],{"trials":18331,"activeCount":109},[18332],{"nctId":18333,"briefTitle":18334,"status":569,"phases":18335,"primaryCompletion":1202,"completion":1215,"start":18336,"enrollment":1767,"conditions":18337,"interventions":18338},"NCT04368273","Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.",[98,99],"2020-05-08",[2681],[18324],{"trials":18340,"activeCount":109},[],{"trials":18342,"activeCount":109},[],{"trials":18344,"activeCount":109},[],{"intervention":18346,"totalTrials":708,"cells":18347},"cetuximab",{"EARLY_PHASE1":18348,"PHASE1":18350,"PHASE2":18352,"PHASE3":18365,"PHASE4":18367,"NA":18369},{"trials":18349,"activeCount":109},[],{"trials":18351,"activeCount":109},[],{"trials":18353,"activeCount":109},[18354],{"nctId":18355,"briefTitle":18356,"status":569,"phases":18357,"primaryCompletion":9968,"completion":18358,"start":18359,"enrollment":640,"conditions":18360,"interventions":18363},"NCT03126708","Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma",[99],"2020-04","2017-04-10",[18361,18362,2533],"Esophageal Cancer, Squamous Cell","Cetuximab Effect",[18346,18364],"cisplatin plus paclitaxel",{"trials":18366,"activeCount":109},[],{"trials":18368,"activeCount":109},[],{"trials":18370,"activeCount":109},[],{"intervention":18364,"totalTrials":708,"cells":18372},{"EARLY_PHASE1":18373,"PHASE1":18375,"PHASE2":18377,"PHASE3":18383,"PHASE4":18385,"NA":18387},{"trials":18374,"activeCount":109},[],{"trials":18376,"activeCount":109},[],{"trials":18378,"activeCount":109},[18379],{"nctId":18355,"briefTitle":18356,"status":569,"phases":18380,"primaryCompletion":9968,"completion":18358,"start":18359,"enrollment":640,"conditions":18381,"interventions":18382},[99],[18361,18362,2533],[18346,18364],{"trials":18384,"activeCount":109},[],{"trials":18386,"activeCount":109},[],{"trials":18388,"activeCount":109},[],{"intervention":2668,"totalTrials":708,"cells":18390},{"EARLY_PHASE1":18391,"PHASE1":18393,"PHASE2":18395,"PHASE3":18401,"PHASE4":18403,"NA":18405},{"trials":18392,"activeCount":109},[],{"trials":18394,"activeCount":109},[],{"trials":18396,"activeCount":109},[18397],{"nctId":2659,"briefTitle":2660,"status":569,"phases":18398,"primaryCompletion":2662,"completion":2663,"start":2664,"enrollment":2665,"conditions":18399,"interventions":18400},[99],[34],[2668,2638],{"trials":18402,"activeCount":109},[],{"trials":18404,"activeCount":109},[],{"trials":18406,"activeCount":109},[],{"intervention":18408,"totalTrials":708,"cells":18409},"Yunnan Baiyao toothpaste",{"EARLY_PHASE1":18410,"PHASE1":18412,"PHASE2":18414,"PHASE3":18425,"PHASE4":18427,"NA":18429},{"trials":18411,"activeCount":109},[],{"trials":18413,"activeCount":109},[],{"trials":18415,"activeCount":109},[18416],{"nctId":18417,"briefTitle":18418,"status":135,"phases":18419,"primaryCompletion":4853,"completion":4853,"start":18420,"enrollment":18421,"conditions":18422,"interventions":18424},"NCT01652625","Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis",[99],"2010-03",227,[18423],"Recurrent Aphthous Stomatitis",[18408],{"trials":18426,"activeCount":109},[],{"trials":18428,"activeCount":109},[],{"trials":18430,"activeCount":109},[],{"intervention":18432,"totalTrials":708,"cells":18433},"nab-paclitaxel regimen1",{"EARLY_PHASE1":18434,"PHASE1":18436,"PHASE2":18438,"PHASE3":18450,"PHASE4":18452,"NA":18454},{"trials":18435,"activeCount":109},[],{"trials":18437,"activeCount":109},[],{"trials":18439,"activeCount":109},[18440],{"nctId":18441,"briefTitle":18442,"status":569,"phases":18443,"primaryCompletion":18444,"completion":18444,"start":18445,"enrollment":18446,"conditions":18447,"interventions":18448},"NCT04192331","Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer",[99],"2023-01-26","2019-02-21",97,[31],[18432,18449],"nab-paclitaxel regimen2",{"trials":18451,"activeCount":109},[],{"trials":18453,"activeCount":109},[],{"trials":18455,"activeCount":109},[],{"intervention":18449,"totalTrials":708,"cells":18457},{"EARLY_PHASE1":18458,"PHASE1":18460,"PHASE2":18462,"PHASE3":18468,"PHASE4":18470,"NA":18472},{"trials":18459,"activeCount":109},[],{"trials":18461,"activeCount":109},[],{"trials":18463,"activeCount":109},[18464],{"nctId":18441,"briefTitle":18442,"status":569,"phases":18465,"primaryCompletion":18444,"completion":18444,"start":18445,"enrollment":18446,"conditions":18466,"interventions":18467},[99],[31],[18432,18449],{"trials":18469,"activeCount":109},[],{"trials":18471,"activeCount":109},[],{"trials":18473,"activeCount":109},[],{"intervention":18475,"totalTrials":708,"cells":18476},"Camrelizumab+Albumin bound paclitaxel+Cisplatin",{"EARLY_PHASE1":18477,"PHASE1":18479,"PHASE2":18481,"PHASE3":18491,"PHASE4":18493,"NA":18495},{"trials":18478,"activeCount":109},[],{"trials":18480,"activeCount":109},[],{"trials":18482,"activeCount":109},[18483],{"nctId":18484,"briefTitle":18485,"status":569,"phases":18486,"primaryCompletion":1138,"completion":2853,"start":1640,"enrollment":32,"conditions":18487,"interventions":18489},"NCT04937673","The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma",[99],[18488],"Thoracic Esophageal Squamous Cell Carcinoma",[18475,18490],"Camrelizumab+ Paclitaxel+ Cisplatin",{"trials":18492,"activeCount":109},[],{"trials":18494,"activeCount":109},[],{"trials":18496,"activeCount":109},[],{"intervention":18490,"totalTrials":708,"cells":18498},{"EARLY_PHASE1":18499,"PHASE1":18501,"PHASE2":18503,"PHASE3":18509,"PHASE4":18511,"NA":18513},{"trials":18500,"activeCount":109},[],{"trials":18502,"activeCount":109},[],{"trials":18504,"activeCount":109},[18505],{"nctId":18484,"briefTitle":18485,"status":569,"phases":18506,"primaryCompletion":1138,"completion":2853,"start":1640,"enrollment":32,"conditions":18507,"interventions":18508},[99],[18488],[18475,18490],{"trials":18510,"activeCount":109},[],{"trials":18512,"activeCount":109},[],{"trials":18514,"activeCount":109},[],{"intervention":18516,"totalTrials":708,"cells":18517},"sofadil【Neu2000KW】",{"EARLY_PHASE1":18518,"PHASE1":18520,"PHASE2":18522,"PHASE3":18533,"PHASE4":18535,"NA":18537},{"trials":18519,"activeCount":109},[],{"trials":18521,"activeCount":109},[],{"trials":18523,"activeCount":109},[18524],{"nctId":18525,"briefTitle":18526,"status":135,"phases":18527,"primaryCompletion":4720,"completion":4720,"start":18528,"enrollment":18529,"conditions":18530,"interventions":18531},"NCT04453800","The Efficacy and Safety of Sofadil for Injection in the Treatment of Acute Ischemic Stroke",[99],"2016-10-01",236,[11702],[18516,18532,18532],"Sofadil",{"trials":18534,"activeCount":109},[],{"trials":18536,"activeCount":109},[],{"trials":18538,"activeCount":109},[],{"intervention":18532,"totalTrials":708,"cells":18540},{"EARLY_PHASE1":18541,"PHASE1":18543,"PHASE2":18545,"PHASE3":18551,"PHASE4":18553,"NA":18555},{"trials":18542,"activeCount":109},[],{"trials":18544,"activeCount":109},[],{"trials":18546,"activeCount":109},[18547],{"nctId":18525,"briefTitle":18526,"status":135,"phases":18548,"primaryCompletion":4720,"completion":4720,"start":18528,"enrollment":18529,"conditions":18549,"interventions":18550},[99],[11702],[18516,18532,18532],{"trials":18552,"activeCount":109},[],{"trials":18554,"activeCount":109},[],{"trials":18556,"activeCount":109},[],{"intervention":18558,"totalTrials":708,"cells":18559},"recombinant teriparatide for",{"EARLY_PHASE1":18560,"PHASE1":18562,"PHASE2":18564,"PHASE3":18573,"PHASE4":18575,"NA":18577},{"trials":18561,"activeCount":109},[],{"trials":18563,"activeCount":109},[],{"trials":18565,"activeCount":109},[18566],{"nctId":18567,"briefTitle":18568,"status":569,"phases":18569,"primaryCompletion":71,"completion":1589,"start":857,"enrollment":153,"conditions":18570,"interventions":18572},"NCT04473989","Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture",[99],[18571],"Colles' Fracture",[18558],{"trials":18574,"activeCount":109},[],{"trials":18576,"activeCount":109},[],{"trials":18578,"activeCount":109},[],{"intervention":18580,"totalTrials":708,"cells":18581},"Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy",{"EARLY_PHASE1":18582,"PHASE1":18584,"PHASE2":18586,"PHASE3":18596,"PHASE4":18598,"NA":18600},{"trials":18583,"activeCount":109},[],{"trials":18585,"activeCount":109},[],{"trials":18587,"activeCount":109},[18588],{"nctId":18589,"briefTitle":18590,"status":569,"phases":18591,"primaryCompletion":18592,"completion":7267,"start":18593,"enrollment":2522,"conditions":18594,"interventions":18595},"NCT05577442","Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +\u002FHER2 + Advanced Breast Cancer",[99],"2023-10-20","2022-10-20",[5615],[18580],{"trials":18597,"activeCount":109},[],{"trials":18599,"activeCount":109},[],{"trials":18601,"activeCount":109},[],{"intervention":18603,"totalTrials":708,"cells":18604},"Furmonertinib",{"EARLY_PHASE1":18605,"PHASE1":18607,"PHASE2":18609,"PHASE3":18618,"PHASE4":18620,"NA":18622},{"trials":18606,"activeCount":109},[],{"trials":18608,"activeCount":109},[],{"trials":18610,"activeCount":109},[18611],{"nctId":18612,"briefTitle":18613,"status":569,"phases":18614,"primaryCompletion":11176,"completion":3326,"start":14635,"enrollment":728,"conditions":18615,"interventions":18617},"NCT05079022","ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas",[98,99],[18616],"Adenocarcinoma of Lung",[18603],{"trials":18619,"activeCount":109},[],{"trials":18621,"activeCount":109},[],{"trials":18623,"activeCount":109},[],{"intervention":18625,"totalTrials":708,"cells":18626},"OXA, 5-FU and bevacizumab plus Toripalimab",{"EARLY_PHASE1":18627,"PHASE1":18629,"PHASE2":18631,"PHASE3":18642,"PHASE4":18644,"NA":18646},{"trials":18628,"activeCount":109},[],{"trials":18630,"activeCount":109},[],{"trials":18632,"activeCount":109},[18633],{"nctId":18634,"briefTitle":18635,"status":135,"phases":18636,"primaryCompletion":18637,"completion":818,"start":18638,"enrollment":8079,"conditions":18639,"interventions":18641},"NCT04217954","HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC",[99],"2023-05-19","2020-07-28",[18640],"Advanced Biliary Tract Cancer",[18625],{"trials":18643,"activeCount":109},[],{"trials":18645,"activeCount":109},[],{"trials":18647,"activeCount":109},[],{"intervention":18649,"totalTrials":708,"cells":18650},"Lenvatinib, Pembrolizumab",{"EARLY_PHASE1":18651,"PHASE1":18653,"PHASE2":18655,"PHASE3":18664,"PHASE4":18666,"NA":18668},{"trials":18652,"activeCount":109},[],{"trials":18654,"activeCount":109},[],{"trials":18656,"activeCount":109},[18657],{"nctId":18658,"briefTitle":18659,"status":569,"phases":18660,"primaryCompletion":4651,"completion":1404,"start":5372,"enrollment":3528,"conditions":18661,"interventions":18663},"NCT04622566","Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma",[99],[3903,18662],"Neoadjuvant Treatment",[18649],{"trials":18665,"activeCount":109},[],{"trials":18667,"activeCount":109},[],{"trials":18669,"activeCount":109},[],{"intervention":18671,"totalTrials":708,"cells":18672},"Hydroxychloroquine Sulfate",{"EARLY_PHASE1":18673,"PHASE1":18675,"PHASE2":18677,"PHASE3":18687,"PHASE4":18689,"NA":18691},{"trials":18674,"activeCount":109},[],{"trials":18676,"activeCount":109},[],{"trials":18678,"activeCount":109},[18679],{"nctId":18680,"briefTitle":18681,"status":135,"phases":18682,"primaryCompletion":5402,"completion":5402,"start":18683,"enrollment":140,"conditions":18684,"interventions":18686},"NCT02942381","A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy",[99],"2016-09-13",[18685,4053],"IgA Patients",[18671],{"trials":18688,"activeCount":109},[],{"trials":18690,"activeCount":109},[],{"trials":18692,"activeCount":109},[],{"intervention":10060,"totalTrials":708,"cells":18694},{"EARLY_PHASE1":18695,"PHASE1":18697,"PHASE2":18699,"PHASE3":18705,"PHASE4":18707,"NA":18709},{"trials":18696,"activeCount":109},[],{"trials":18698,"activeCount":109},[],{"trials":18700,"activeCount":109},[18701],{"nctId":10051,"briefTitle":10052,"status":135,"phases":18702,"primaryCompletion":10054,"completion":10055,"start":10056,"enrollment":6539,"conditions":18703,"interventions":18704},[99],[2591,10058],[4994,4993,10060,10061],{"trials":18706,"activeCount":109},[],{"trials":18708,"activeCount":109},[],{"trials":18710,"activeCount":109},[],{"intervention":10061,"totalTrials":708,"cells":18712},{"EARLY_PHASE1":18713,"PHASE1":18715,"PHASE2":18717,"PHASE3":18723,"PHASE4":18725,"NA":18727},{"trials":18714,"activeCount":109},[],{"trials":18716,"activeCount":109},[],{"trials":18718,"activeCount":109},[18719],{"nctId":10051,"briefTitle":10052,"status":135,"phases":18720,"primaryCompletion":10054,"completion":10055,"start":10056,"enrollment":6539,"conditions":18721,"interventions":18722},[99],[2591,10058],[4994,4993,10060,10061],{"trials":18724,"activeCount":109},[],{"trials":18726,"activeCount":109},[],{"trials":18728,"activeCount":109},[],{"intervention":18730,"totalTrials":708,"cells":18731},"fecal microbiota",{"EARLY_PHASE1":18732,"PHASE1":18734,"PHASE2":18736,"PHASE3":18750,"PHASE4":18752,"NA":18754},{"trials":18733,"activeCount":109},[],{"trials":18735,"activeCount":109},[],{"trials":18737,"activeCount":109},[18738],{"nctId":18739,"briefTitle":18740,"status":135,"phases":18741,"primaryCompletion":18742,"completion":18743,"start":18744,"enrollment":153,"conditions":18745,"interventions":18749},"NCT05917379","The Efficacy and Safty of FMT in Patients With CID",[98,99],"2025-04-10","2025-07-24","2023-10-08",[18746,10897,12912,18747,18748,910],"Insomnia Chronic","Depression","Anxiety",[18730],{"trials":18751,"activeCount":109},[],{"trials":18753,"activeCount":109},[],{"trials":18755,"activeCount":109},[],{"intervention":18757,"totalTrials":708,"cells":18758},"Fasudil",{"EARLY_PHASE1":18759,"PHASE1":18761,"PHASE2":18763,"PHASE3":18771,"PHASE4":18773,"NA":18775},{"trials":18760,"activeCount":109},[],{"trials":18762,"activeCount":109},[],{"trials":18764,"activeCount":109},[18765],{"nctId":18766,"briefTitle":18767,"status":569,"phases":18768,"primaryCompletion":1164,"completion":14387,"start":4690,"enrollment":477,"conditions":18769,"interventions":18770},"NCT01935518","A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)",[99],[16078],[18757],{"trials":18772,"activeCount":109},[],{"trials":18774,"activeCount":109},[],{"trials":18776,"activeCount":109},[],{"intervention":18778,"totalTrials":708,"cells":18779},"Octreotide lar",{"EARLY_PHASE1":18780,"PHASE1":18782,"PHASE2":18784,"PHASE3":18795,"PHASE4":18797,"NA":18799},{"trials":18781,"activeCount":109},[],{"trials":18783,"activeCount":109},[],{"trials":18785,"activeCount":109},[18786],{"nctId":18787,"briefTitle":18788,"status":569,"phases":18789,"primaryCompletion":18790,"completion":4670,"start":16025,"enrollment":8634,"conditions":18791,"interventions":18794},"NCT02409849","Octreotide LAR as Maintenance Treatment for Patients With NEC",[99],"2018-11",[18792,18793],"Gastro-entero-pancreatic Carcinoma","Esophageal Neuroendocrine Carcinoma",[18778],{"trials":18796,"activeCount":109},[],{"trials":18798,"activeCount":109},[],{"trials":18800,"activeCount":109},[],{"intervention":18802,"totalTrials":708,"cells":18803},"Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine",{"EARLY_PHASE1":18804,"PHASE1":18806,"PHASE2":18808,"PHASE3":18817,"PHASE4":18819,"NA":18821},{"trials":18805,"activeCount":109},[],{"trials":18807,"activeCount":109},[],{"trials":18809,"activeCount":109},[18810],{"nctId":18811,"briefTitle":18812,"status":135,"phases":18813,"primaryCompletion":2883,"completion":18814,"start":16288,"enrollment":3699,"conditions":18815,"interventions":18816},"NCT01572324","Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas",[99],"2016-04",[18063],[18802],{"trials":18818,"activeCount":109},[],{"trials":18820,"activeCount":109},[],{"trials":18822,"activeCount":109},[],{"intervention":18824,"totalTrials":708,"cells":18825},"Icotinib combined dihydroaremisinin",{"EARLY_PHASE1":18826,"PHASE1":18828,"PHASE2":18830,"PHASE3":18840,"PHASE4":18842,"NA":18844},{"trials":18827,"activeCount":109},[],{"trials":18829,"activeCount":109},[],{"trials":18831,"activeCount":109},[18832],{"nctId":18833,"briefTitle":18834,"status":569,"phases":18835,"primaryCompletion":14154,"completion":18836,"start":14953,"enrollment":1767,"conditions":18837,"interventions":18839},"NCT03402464","Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC",[99],"2020-09-20",[18838],"EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma",[18824],{"trials":18841,"activeCount":109},[],{"trials":18843,"activeCount":109},[],{"trials":18845,"activeCount":109},[],{"intervention":18847,"totalTrials":708,"cells":18848},"Trastuzumab+Capecitabine+Oxaliplatin",{"EARLY_PHASE1":18849,"PHASE1":18851,"PHASE2":18853,"PHASE3":18861,"PHASE4":18863,"NA":18865},{"trials":18850,"activeCount":109},[],{"trials":18852,"activeCount":109},[],{"trials":18854,"activeCount":109},[18855],{"nctId":18856,"briefTitle":18857,"status":135,"phases":18858,"primaryCompletion":3091,"completion":16522,"start":254,"enrollment":4469,"conditions":18859,"interventions":18860},"NCT01364493","A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and\u002For Metastatic Gastric Cancer",[99],[28],[18847],{"trials":18862,"activeCount":109},[],{"trials":18864,"activeCount":109},[],{"trials":18866,"activeCount":109},[],{"intervention":18868,"totalTrials":708,"cells":18869},"TQB3525",{"EARLY_PHASE1":18870,"PHASE1":18872,"PHASE2":18874,"PHASE3":18885,"PHASE4":18887,"NA":18889},{"trials":18871,"activeCount":109},[],{"trials":18873,"activeCount":109},[],{"trials":18875,"activeCount":109},[18876],{"nctId":18877,"briefTitle":18878,"status":569,"phases":18879,"primaryCompletion":535,"completion":639,"start":18880,"enrollment":105,"conditions":18881,"interventions":18884},"NCT04690725","TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss",[98,99],"2020-10-01",[18882,18883],"Safety Issues","Efficacy, Self",[18868],{"trials":18886,"activeCount":109},[],{"trials":18888,"activeCount":109},[],{"trials":18890,"activeCount":109},[],{"intervention":18892,"totalTrials":708,"cells":18893},"mFOLFIRI",{"EARLY_PHASE1":18894,"PHASE1":18896,"PHASE2":18898,"PHASE3":18907,"PHASE4":18909,"NA":18911},{"trials":18895,"activeCount":109},[],{"trials":18897,"activeCount":109},[],{"trials":18899,"activeCount":109},[18900],{"nctId":18901,"briefTitle":18902,"status":569,"phases":18903,"primaryCompletion":3527,"completion":4153,"start":18904,"enrollment":728,"conditions":18905,"interventions":18906},"NCT01044420","mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel\u002FDDP : a Phase II Single Center Prospective Clinical Trial",[99],"2009-05",[7822],[18892],{"trials":18908,"activeCount":109},[],{"trials":18910,"activeCount":109},[],{"trials":18912,"activeCount":109},[],{"intervention":5650,"totalTrials":708,"cells":18914},{"EARLY_PHASE1":18915,"PHASE1":18917,"PHASE2":18919,"PHASE3":18925,"PHASE4":18927,"NA":18929},{"trials":18916,"activeCount":109},[],{"trials":18918,"activeCount":109},[],{"trials":18920,"activeCount":109},[18921],{"nctId":5644,"briefTitle":5645,"status":569,"phases":18922,"primaryCompletion":81,"completion":1103,"start":5647,"enrollment":2008,"conditions":18923,"interventions":18924},[99],[28],[5650,5624],{"trials":18926,"activeCount":109},[],{"trials":18928,"activeCount":109},[],{"trials":18930,"activeCount":109},[],{"intervention":18932,"totalTrials":708,"cells":18933},"Utidelone and anlotinib",{"EARLY_PHASE1":18934,"PHASE1":18936,"PHASE2":18938,"PHASE3":18946,"PHASE4":18948,"NA":18950},{"trials":18935,"activeCount":109},[],{"trials":18937,"activeCount":109},[],{"trials":18939,"activeCount":109},[18940],{"nctId":18941,"briefTitle":18942,"status":569,"phases":18943,"primaryCompletion":742,"completion":742,"start":856,"enrollment":3453,"conditions":18944,"interventions":18945},"NCT05866510","Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer",[99],[2627],[18932],{"trials":18947,"activeCount":109},[],{"trials":18949,"activeCount":109},[],{"trials":18951,"activeCount":109},[],{"intervention":18953,"totalTrials":708,"cells":18954},"mFOLFIRI+Nimotuzumab",{"EARLY_PHASE1":18955,"PHASE1":18957,"PHASE2":18959,"PHASE3":18969,"PHASE4":18971,"NA":18973},{"trials":18956,"activeCount":109},[],{"trials":18958,"activeCount":109},[],{"trials":18960,"activeCount":109},[18961],{"nctId":18962,"briefTitle":18963,"status":569,"phases":18964,"primaryCompletion":18965,"completion":18965,"start":18966,"enrollment":32,"conditions":18967,"interventions":18968},"NCT01486992","mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus",[99],"2012-11","2011-11",[7822],[18953],{"trials":18970,"activeCount":109},[],{"trials":18972,"activeCount":109},[],{"trials":18974,"activeCount":109},[],{"intervention":2536,"totalTrials":708,"cells":18976},{"EARLY_PHASE1":18977,"PHASE1":18979,"PHASE2":18981,"PHASE3":18987,"PHASE4":18989,"NA":18991},{"trials":18978,"activeCount":109},[],{"trials":18980,"activeCount":109},[],{"trials":18982,"activeCount":109},[18983],{"nctId":2527,"briefTitle":2528,"status":569,"phases":18984,"primaryCompletion":1138,"completion":1215,"start":2530,"enrollment":140,"conditions":18985,"interventions":18986},[99],[2532,1327,2533,2534],[2536,2537,72],{"trials":18988,"activeCount":109},[],{"trials":18990,"activeCount":109},[],{"trials":18992,"activeCount":109},[],{"intervention":18994,"totalTrials":708,"cells":18995},"paclitaxel liposome",{"EARLY_PHASE1":18996,"PHASE1":18998,"PHASE2":19000,"PHASE3":19008,"PHASE4":19010,"NA":19012},{"trials":18997,"activeCount":109},[],{"trials":18999,"activeCount":109},[],{"trials":19001,"activeCount":109},[19002],{"nctId":19003,"briefTitle":19004,"status":569,"phases":19005,"primaryCompletion":3090,"completion":3090,"start":3089,"enrollment":1767,"conditions":19006,"interventions":19007},"NCT02163291","Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer",[99],[16291],[18994],{"trials":19009,"activeCount":109},[],{"trials":19011,"activeCount":109},[],{"trials":19013,"activeCount":109},[],{"intervention":19015,"totalTrials":708,"cells":19016},"intravenous immunoglobulin plus low dose recombinant human thrombopoietin",{"EARLY_PHASE1":19017,"PHASE1":19019,"PHASE2":19021,"PHASE3":19030,"PHASE4":19032,"NA":19034},{"trials":19018,"activeCount":109},[],{"trials":19020,"activeCount":109},[],{"trials":19022,"activeCount":109},[19023],{"nctId":19024,"briefTitle":19025,"status":569,"phases":19026,"primaryCompletion":817,"completion":817,"start":817,"enrollment":728,"conditions":19027,"interventions":19028},"NCT05634824","IVIg Plus Low Dose rhTPO for ITP in Pregnancy",[99],[34,170],[19015,19029],"intravenous immunoglobulin",{"trials":19031,"activeCount":109},[],{"trials":19033,"activeCount":109},[],{"trials":19035,"activeCount":109},[],{"intervention":19029,"totalTrials":708,"cells":19037},{"EARLY_PHASE1":19038,"PHASE1":19040,"PHASE2":19042,"PHASE3":19048,"PHASE4":19050,"NA":19052},{"trials":19039,"activeCount":109},[],{"trials":19041,"activeCount":109},[],{"trials":19043,"activeCount":109},[19044],{"nctId":19024,"briefTitle":19025,"status":569,"phases":19045,"primaryCompletion":817,"completion":817,"start":817,"enrollment":728,"conditions":19046,"interventions":19047},[99],[34,170],[19015,19029],{"trials":19049,"activeCount":109},[],{"trials":19051,"activeCount":109},[],{"trials":19053,"activeCount":109},[],{"intervention":2549,"totalTrials":708,"cells":19055},{"EARLY_PHASE1":19056,"PHASE1":19058,"PHASE2":19060,"PHASE3":19066,"PHASE4":19068,"NA":19070},{"trials":19057,"activeCount":109},[],{"trials":19059,"activeCount":109},[],{"trials":19061,"activeCount":109},[19062],{"nctId":2539,"briefTitle":2540,"status":435,"phases":19063,"primaryCompletion":2542,"completion":1113,"start":2543,"enrollment":109,"conditions":19064,"interventions":19065},[98,99],[2545,2546,2547],[2549,2550,72],{"trials":19067,"activeCount":109},[],{"trials":19069,"activeCount":109},[],{"trials":19071,"activeCount":109},[],{"intervention":19073,"totalTrials":708,"cells":19074},"irinotecan cisplatin",{"EARLY_PHASE1":19075,"PHASE1":19077,"PHASE2":19079,"PHASE3":19091,"PHASE4":19093,"NA":19095},{"trials":19076,"activeCount":109},[],{"trials":19078,"activeCount":109},[],{"trials":19080,"activeCount":109},[19081],{"nctId":19082,"briefTitle":19083,"status":200,"phases":19084,"primaryCompletion":13735,"completion":19085,"start":19086,"enrollment":6539,"conditions":19087,"interventions":19089},"NCT03168594","Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma",[99],"2019-09-20","2017-04-29",[19088],"Neuroendocrine Carcinoma",[19073,19090],"Etoposide cisplatin",{"trials":19092,"activeCount":109},[],{"trials":19094,"activeCount":109},[],{"trials":19096,"activeCount":109},[],{"intervention":19090,"totalTrials":708,"cells":19098},{"EARLY_PHASE1":19099,"PHASE1":19101,"PHASE2":19103,"PHASE3":19109,"PHASE4":19111,"NA":19113},{"trials":19100,"activeCount":109},[],{"trials":19102,"activeCount":109},[],{"trials":19104,"activeCount":109},[19105],{"nctId":19082,"briefTitle":19083,"status":200,"phases":19106,"primaryCompletion":13735,"completion":19085,"start":19086,"enrollment":6539,"conditions":19107,"interventions":19108},[99],[19088],[19073,19090],{"trials":19110,"activeCount":109},[],{"trials":19112,"activeCount":109},[],{"trials":19114,"activeCount":109},[],{"intervention":19116,"totalTrials":708,"cells":19117},"Berberine plus danazol",{"EARLY_PHASE1":19118,"PHASE1":19120,"PHASE2":19122,"PHASE3":19132,"PHASE4":19134,"NA":19136},{"trials":19119,"activeCount":109},[],{"trials":19121,"activeCount":109},[],{"trials":19123,"activeCount":109},[19124],{"nctId":19125,"briefTitle":19126,"status":569,"phases":19127,"primaryCompletion":5372,"completion":1201,"start":19128,"enrollment":3011,"conditions":19129,"interventions":19131},"NCT03909763","Combination of Danazole With Berberine in the Treatment of ITP",[99],"2016-01-20",[19130],"Corticosteroid-resistant or Relapsed ITP",[19116],{"trials":19133,"activeCount":109},[],{"trials":19135,"activeCount":109},[],{"trials":19137,"activeCount":109},[],{"intervention":19139,"totalTrials":708,"cells":19140},"Anti-CD19 CAR T cells",{"EARLY_PHASE1":19141,"PHASE1":19143,"PHASE2":19145,"PHASE3":19155,"PHASE4":19157,"NA":19159},{"trials":19142,"activeCount":109},[],{"trials":19144,"activeCount":109},[],{"trials":19146,"activeCount":109},[19147],{"nctId":19148,"briefTitle":19149,"status":569,"phases":19150,"primaryCompletion":4126,"completion":19151,"start":16036,"enrollment":47,"conditions":19152,"interventions":19154},"NCT02247609","Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas",[98,99],"2017-10",[19153],"B-cell Lymphomas",[19139],{"trials":19156,"activeCount":109},[],{"trials":19158,"activeCount":109},[],{"trials":19160,"activeCount":109},[],{"intervention":19162,"totalTrials":708,"cells":19163},"TQB3616 capsules＋ TQB2450",{"EARLY_PHASE1":19164,"PHASE1":19166,"PHASE2":19168,"PHASE3":19178,"PHASE4":19180,"NA":19182},{"trials":19165,"activeCount":109},[],{"trials":19167,"activeCount":109},[],{"trials":19169,"activeCount":109},[19170],{"nctId":19171,"briefTitle":19172,"status":569,"phases":19173,"primaryCompletion":17576,"completion":17576,"start":19174,"enrollment":140,"conditions":19175,"interventions":19177},"NCT05139082","Study of CDK4\u002F6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1\u002FPD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors",[98,99],"2021-11-24",[19176],"Digestive System Tumors",[19162],{"trials":19179,"activeCount":109},[],{"trials":19181,"activeCount":109},[],{"trials":19183,"activeCount":109},[],{"intervention":19185,"totalTrials":708,"cells":19186},"rhGM-CSF",{"EARLY_PHASE1":19187,"PHASE1":19189,"PHASE2":19191,"PHASE3":19202,"PHASE4":19204,"NA":19206},{"trials":19188,"activeCount":109},[],{"trials":19190,"activeCount":109},[],{"trials":19192,"activeCount":109},[19193],{"nctId":19194,"briefTitle":19195,"status":135,"phases":19196,"primaryCompletion":11429,"completion":19197,"start":19198,"enrollment":32,"conditions":19199,"interventions":19201},"NCT03113851","Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer",[99],"2018-10-14","2017-08-14",[19200],"Lung Cancer Metastatic",[19185],{"trials":19203,"activeCount":109},[],{"trials":19205,"activeCount":109},[],{"trials":19207,"activeCount":109},[],{"intervention":17482,"totalTrials":708,"cells":19209},{"EARLY_PHASE1":19210,"PHASE1":19212,"PHASE2":19214,"PHASE3":19220,"PHASE4":19222,"NA":19224},{"trials":19211,"activeCount":109},[],{"trials":19213,"activeCount":109},[],{"trials":19215,"activeCount":109},[19216],{"nctId":17475,"briefTitle":17476,"status":569,"phases":19217,"primaryCompletion":17478,"completion":969,"start":17479,"enrollment":8079,"conditions":19218,"interventions":19219},[99],[2680],[17456,17482],{"trials":19221,"activeCount":109},[],{"trials":19223,"activeCount":109},[],{"trials":19225,"activeCount":109},[],{"intervention":19227,"totalTrials":708,"cells":19228},"Apatinib+IE",{"EARLY_PHASE1":19229,"PHASE1":19231,"PHASE2":19233,"PHASE3":19244,"PHASE4":19246,"NA":19248},{"trials":19230,"activeCount":109},[],{"trials":19232,"activeCount":109},[],{"trials":19234,"activeCount":109},[19235],{"nctId":19236,"briefTitle":19237,"status":135,"phases":19238,"primaryCompletion":4701,"completion":19239,"start":10361,"enrollment":1203,"conditions":19240,"interventions":19242},"NCT05277480","Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)",[99],"2023-11-26",[5412,19241,5376],"Drug",[19227,19243],"IE",{"trials":19245,"activeCount":109},[],{"trials":19247,"activeCount":109},[],{"trials":19249,"activeCount":109},[],{"intervention":19243,"totalTrials":708,"cells":19251},{"EARLY_PHASE1":19252,"PHASE1":19254,"PHASE2":19256,"PHASE3":19262,"PHASE4":19264,"NA":19266},{"trials":19253,"activeCount":109},[],{"trials":19255,"activeCount":109},[],{"trials":19257,"activeCount":109},[19258],{"nctId":19236,"briefTitle":19237,"status":135,"phases":19259,"primaryCompletion":4701,"completion":19239,"start":10361,"enrollment":1203,"conditions":19260,"interventions":19261},[99],[5412,19241,5376],[19227,19243],{"trials":19263,"activeCount":109},[],{"trials":19265,"activeCount":109},[],{"trials":19267,"activeCount":109},[],{"intervention":19269,"totalTrials":708,"cells":19270},"monosialoganglioside",{"EARLY_PHASE1":19271,"PHASE1":19273,"PHASE2":19275,"PHASE3":19286,"PHASE4":19288,"NA":19290},{"trials":19272,"activeCount":109},[],{"trials":19274,"activeCount":109},[],{"trials":19276,"activeCount":109},[19277],{"nctId":19278,"briefTitle":19279,"status":569,"phases":19280,"primaryCompletion":19281,"completion":4090,"start":19282,"enrollment":4091,"conditions":19283,"interventions":19285},"NCT02500810","Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients",[99],"2018-07","2015-07",[19284],"Neurotoxicity",[19269],{"trials":19287,"activeCount":109},[],{"trials":19289,"activeCount":109},[],{"trials":19291,"activeCount":109},[],{"intervention":17202,"totalTrials":708,"cells":19293},{"EARLY_PHASE1":19294,"PHASE1":19296,"PHASE2":19298,"PHASE3":19304,"PHASE4":19306,"NA":19308},{"trials":19295,"activeCount":109},[],{"trials":19297,"activeCount":109},[],{"trials":19299,"activeCount":109},[19300],{"nctId":17196,"briefTitle":17197,"status":569,"phases":19301,"primaryCompletion":571,"completion":818,"start":17199,"enrollment":574,"conditions":19302,"interventions":19303},[99],[34],[17202,2657],{"trials":19305,"activeCount":109},[],{"trials":19307,"activeCount":109},[],{"trials":19309,"activeCount":109},[],{"intervention":3551,"totalTrials":708,"cells":19311},{"EARLY_PHASE1":19312,"PHASE1":19314,"PHASE2":19316,"PHASE3":19322,"PHASE4":19324,"NA":19326},{"trials":19313,"activeCount":109},[],{"trials":19315,"activeCount":109},[],{"trials":19317,"activeCount":109},[19318],{"nctId":3541,"briefTitle":3542,"status":135,"phases":19319,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":19320,"interventions":19321},[99],[3549],[3551,3552,3516],{"trials":19323,"activeCount":109},[],{"trials":19325,"activeCount":109},[],{"trials":19327,"activeCount":109},[],{"intervention":19329,"totalTrials":708,"cells":19330},"carleilizumab+apathy mesylate+radiotherapy+paclitaxel",{"EARLY_PHASE1":19331,"PHASE1":19333,"PHASE2":19335,"PHASE3":19343,"PHASE4":19345,"NA":19347},{"trials":19332,"activeCount":109},[],{"trials":19334,"activeCount":109},[],{"trials":19336,"activeCount":109},[19337],{"nctId":19338,"briefTitle":19339,"status":569,"phases":19340,"primaryCompletion":1590,"completion":1590,"start":191,"enrollment":1767,"conditions":19341,"interventions":19342},"NCT04723030","The Transformation of Locally Advanced Pancreatic Cancer.",[99],[6328],[19329],{"trials":19344,"activeCount":109},[],{"trials":19346,"activeCount":109},[],{"trials":19348,"activeCount":109},[],{"intervention":609,"totalTrials":708,"cells":19350},{"EARLY_PHASE1":19351,"PHASE1":19353,"PHASE2":19355,"PHASE3":19361,"PHASE4":19363,"NA":19365},{"trials":19352,"activeCount":109},[],{"trials":19354,"activeCount":109},[],{"trials":19356,"activeCount":109},[19357],{"nctId":601,"briefTitle":602,"status":569,"phases":19358,"primaryCompletion":604,"completion":605,"start":606,"enrollment":586,"conditions":19359,"interventions":19360},[99],[34],[609,557],{"trials":19362,"activeCount":109},[],{"trials":19364,"activeCount":109},[],{"trials":19366,"activeCount":109},[],{"intervention":19368,"totalTrials":708,"cells":19369},"SOX",{"EARLY_PHASE1":19370,"PHASE1":19372,"PHASE2":19374,"PHASE3":19382,"PHASE4":19384,"NA":19386},{"trials":19371,"activeCount":109},[],{"trials":19373,"activeCount":109},[],{"trials":19375,"activeCount":109},[19376],{"nctId":19377,"briefTitle":19378,"status":569,"phases":19379,"primaryCompletion":10492,"completion":15757,"start":15273,"enrollment":3547,"conditions":19380,"interventions":19381},"NCT03279614","Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma",[99],[19088],[19368],{"trials":19383,"activeCount":109},[],{"trials":19385,"activeCount":109},[],{"trials":19387,"activeCount":109},[],{"intervention":19389,"totalTrials":708,"cells":19390},"Nitrofurazone Group 1",{"EARLY_PHASE1":19391,"PHASE1":19393,"PHASE2":19395,"PHASE3":19404,"PHASE4":19406,"NA":19408},{"trials":19392,"activeCount":109},[],{"trials":19394,"activeCount":109},[],{"trials":19396,"activeCount":109},[19397],{"nctId":19398,"briefTitle":19399,"status":569,"phases":19400,"primaryCompletion":2916,"completion":1215,"start":13835,"enrollment":640,"conditions":19401,"interventions":19402},"NCT04950647","Efficacy and Safety of Nitrazine in the Treatment of ALS",[99],[16078],[19389,19403],"Nitroketazine Group 2",{"trials":19405,"activeCount":109},[],{"trials":19407,"activeCount":109},[],{"trials":19409,"activeCount":109},[],{"intervention":19403,"totalTrials":708,"cells":19411},{"EARLY_PHASE1":19412,"PHASE1":19414,"PHASE2":19416,"PHASE3":19422,"PHASE4":19424,"NA":19426},{"trials":19413,"activeCount":109},[],{"trials":19415,"activeCount":109},[],{"trials":19417,"activeCount":109},[19418],{"nctId":19398,"briefTitle":19399,"status":569,"phases":19419,"primaryCompletion":2916,"completion":1215,"start":13835,"enrollment":640,"conditions":19420,"interventions":19421},[99],[16078],[19389,19403],{"trials":19423,"activeCount":109},[],{"trials":19425,"activeCount":109},[],{"trials":19427,"activeCount":109},[],{"intervention":19429,"totalTrials":708,"cells":19430},"Gemcitabine Oxaliplatin and 5FU",{"EARLY_PHASE1":19431,"PHASE1":19433,"PHASE2":19435,"PHASE3":19444,"PHASE4":19446,"NA":19448},{"trials":19432,"activeCount":109},[],{"trials":19434,"activeCount":109},[],{"trials":19436,"activeCount":109},[19437],{"nctId":19438,"briefTitle":19439,"status":200,"phases":19440,"primaryCompletion":2674,"completion":2674,"start":1103,"enrollment":708,"conditions":19441,"interventions":19443},"NCT06739252","Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA",[99],[19442,17993],"Intrahepatic Cholangiocarcinoma (Icc)",[19429],{"trials":19445,"activeCount":109},[],{"trials":19447,"activeCount":109},[],{"trials":19449,"activeCount":109},[],{"intervention":19451,"totalTrials":708,"cells":19452},"decitabine＋ TQB2450",{"EARLY_PHASE1":19453,"PHASE1":19455,"PHASE2":19457,"PHASE3":19468,"PHASE4":19470,"NA":19472},{"trials":19454,"activeCount":109},[],{"trials":19456,"activeCount":109},[],{"trials":19458,"activeCount":109},[19459],{"nctId":19460,"briefTitle":19461,"status":569,"phases":19462,"primaryCompletion":2624,"completion":2624,"start":19463,"enrollment":140,"conditions":19464,"interventions":19466},"NCT04611711","Phase I\u002FII Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors",[98,99],"2020-11-01",[19465],"Patients With Digestive System Tumors Resistant to PD-1 Inhibitors",[19451,19467],"decitabine＋ TQB2450 injection＋Anlotinib",{"trials":19469,"activeCount":109},[],{"trials":19471,"activeCount":109},[],{"trials":19473,"activeCount":109},[],{"intervention":19467,"totalTrials":708,"cells":19475},{"EARLY_PHASE1":19476,"PHASE1":19478,"PHASE2":19480,"PHASE3":19486,"PHASE4":19488,"NA":19490},{"trials":19477,"activeCount":109},[],{"trials":19479,"activeCount":109},[],{"trials":19481,"activeCount":109},[19482],{"nctId":19460,"briefTitle":19461,"status":569,"phases":19483,"primaryCompletion":2624,"completion":2624,"start":19463,"enrollment":140,"conditions":19484,"interventions":19485},[98,99],[19465],[19451,19467],{"trials":19487,"activeCount":109},[],{"trials":19489,"activeCount":109},[],{"trials":19491,"activeCount":109},[],{"intervention":19493,"totalTrials":708,"cells":19494},"concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME",{"EARLY_PHASE1":19495,"PHASE1":19497,"PHASE2":19499,"PHASE3":19511,"PHASE4":19513,"NA":19515},{"trials":19496,"activeCount":109},[],{"trials":19498,"activeCount":109},[],{"trials":19500,"activeCount":109},[19501],{"nctId":19502,"briefTitle":19503,"status":569,"phases":19504,"primaryCompletion":1590,"completion":2051,"start":19505,"enrollment":1151,"conditions":19506,"interventions":19509},"NCT03038256","Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial",[99],"2018-01-31",[3355,19507,19508],"Pathological Complete Response","Disease Free Survival",[19493,19510],"concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX",{"trials":19512,"activeCount":109},[],{"trials":19514,"activeCount":109},[],{"trials":19516,"activeCount":109},[],{"intervention":19510,"totalTrials":708,"cells":19518},{"EARLY_PHASE1":19519,"PHASE1":19521,"PHASE2":19523,"PHASE3":19529,"PHASE4":19531,"NA":19533},{"trials":19520,"activeCount":109},[],{"trials":19522,"activeCount":109},[],{"trials":19524,"activeCount":109},[19525],{"nctId":19502,"briefTitle":19503,"status":569,"phases":19526,"primaryCompletion":1590,"completion":2051,"start":19505,"enrollment":1151,"conditions":19527,"interventions":19528},[99],[3355,19507,19508],[19493,19510],{"trials":19530,"activeCount":109},[],{"trials":19532,"activeCount":109},[],{"trials":19534,"activeCount":109},[],{"intervention":1133,"totalTrials":708,"cells":19536},{"EARLY_PHASE1":19537,"PHASE1":19539,"PHASE2":19541,"PHASE3":19547,"PHASE4":19549,"NA":19551},{"trials":19538,"activeCount":109},[],{"trials":19540,"activeCount":109},[],{"trials":19542,"activeCount":109},[19543],{"nctId":1124,"briefTitle":1125,"status":569,"phases":19544,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":19545,"interventions":19546},[99],[34],[1133,1090],{"trials":19548,"activeCount":109},[],{"trials":19550,"activeCount":109},[],{"trials":19552,"activeCount":109},[],{"intervention":19554,"totalTrials":708,"cells":19555},"all trans retinoic acid",{"EARLY_PHASE1":19556,"PHASE1":19558,"PHASE2":19560,"PHASE3":19568,"PHASE4":19570,"NA":19572},{"trials":19557,"activeCount":109},[],{"trials":19559,"activeCount":109},[],{"trials":19561,"activeCount":109},[19562],{"nctId":19563,"briefTitle":19564,"status":569,"phases":19565,"primaryCompletion":14635,"completion":14635,"start":8409,"enrollment":153,"conditions":19566,"interventions":19567},"NCT04618328","A Study of ATRA in the Treatment of ITP",[99],[34],[19554],{"trials":19569,"activeCount":109},[],{"trials":19571,"activeCount":109},[],{"trials":19573,"activeCount":109},[],{"intervention":19575,"totalTrials":708,"cells":19576},"Radiation+PD-1 Ab",{"EARLY_PHASE1":19577,"PHASE1":19579,"PHASE2":19581,"PHASE3":19589,"PHASE4":19591,"NA":19593},{"trials":19578,"activeCount":109},[],{"trials":19580,"activeCount":109},[],{"trials":19582,"activeCount":109},[19583],{"nctId":19584,"briefTitle":19585,"status":569,"phases":19586,"primaryCompletion":4719,"completion":8314,"start":3624,"enrollment":1767,"conditions":19587,"interventions":19588},"NCT03764787","Combination of Hypofractionated Proton Therapy With Immunotherapy",[98,99],[18108,3924],[19575],{"trials":19590,"activeCount":109},[],{"trials":19592,"activeCount":109},[],{"trials":19594,"activeCount":109},[],{"intervention":4004,"totalTrials":708,"cells":19596},{"EARLY_PHASE1":19597,"PHASE1":19599,"PHASE2":19601,"PHASE3":19607,"PHASE4":19609,"NA":19611},{"trials":19598,"activeCount":109},[],{"trials":19600,"activeCount":109},[],{"trials":19602,"activeCount":109},[19603],{"nctId":3996,"briefTitle":3997,"status":569,"phases":19604,"primaryCompletion":3999,"completion":4000,"start":2853,"enrollment":4001,"conditions":19605,"interventions":19606},[99],[1250],[1032,4004],{"trials":19608,"activeCount":109},[],{"trials":19610,"activeCount":109},[],{"trials":19612,"activeCount":109},[],{"intervention":17214,"totalTrials":708,"cells":19614},{"EARLY_PHASE1":19615,"PHASE1":19617,"PHASE2":19619,"PHASE3":19625,"PHASE4":19627,"NA":19629},{"trials":19616,"activeCount":109},[],{"trials":19618,"activeCount":109},[],{"trials":19620,"activeCount":109},[19621],{"nctId":17208,"briefTitle":17209,"status":569,"phases":19622,"primaryCompletion":11518,"completion":6220,"start":8383,"enrollment":17211,"conditions":19623,"interventions":19624},[99],[34],[17214,2657],{"trials":19626,"activeCount":109},[],{"trials":19628,"activeCount":109},[],{"trials":19630,"activeCount":109},[],{"intervention":19632,"totalTrials":708,"cells":19633},"Surufatinib\u002FToripalimab",{"EARLY_PHASE1":19634,"PHASE1":19636,"PHASE2":19638,"PHASE3":19648,"PHASE4":19650,"NA":19652},{"trials":19635,"activeCount":109},[],{"trials":19637,"activeCount":109},[],{"trials":19639,"activeCount":109},[19640],{"nctId":19641,"briefTitle":19642,"status":569,"phases":19643,"primaryCompletion":1149,"completion":10830,"start":19644,"enrollment":960,"conditions":19645,"interventions":19647},"NCT05030246","Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer",[99],"2021-07-14",[19646,2683],"Refractory Metastatic Digestive System Carcinoma",[19632],{"trials":19649,"activeCount":109},[],{"trials":19651,"activeCount":109},[],{"trials":19653,"activeCount":109},[],{"intervention":19655,"totalTrials":708,"cells":19656},"PD-1",{"EARLY_PHASE1":19657,"PHASE1":19659,"PHASE2":19661,"PHASE3":19673,"PHASE4":19675,"NA":19677},{"trials":19658,"activeCount":109},[],{"trials":19660,"activeCount":109},[],{"trials":19662,"activeCount":109},[19663],{"nctId":19664,"briefTitle":19665,"status":569,"phases":19666,"primaryCompletion":1405,"completion":19667,"start":19668,"enrollment":3547,"conditions":19669,"interventions":19672},"NCT04061928","Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ",[98,99],"2023-08-25","2019-08-26",[19655,19670,19671],"Chemoradiotherapy","Gastroesophageal Junction Cancer",[19655],{"trials":19674,"activeCount":109},[],{"trials":19676,"activeCount":109},[],{"trials":19678,"activeCount":109},[],{"intervention":19680,"totalTrials":708,"cells":19681},"low-dose interleukin-2",{"EARLY_PHASE1":19682,"PHASE1":19684,"PHASE2":19686,"PHASE3":19697,"PHASE4":19699,"NA":19701},{"trials":19683,"activeCount":109},[],{"trials":19685,"activeCount":109},[],{"trials":19687,"activeCount":109},[19688],{"nctId":19689,"briefTitle":19690,"status":135,"phases":19691,"primaryCompletion":1404,"completion":2503,"start":19692,"enrollment":1767,"conditions":19693,"interventions":19695},"NCT05605665","Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome",[98,99],"2022-12-05",[19694],"Sjögren's Syndrome",[19680,19696],"rapamycin",{"trials":19698,"activeCount":109},[],{"trials":19700,"activeCount":109},[],{"trials":19702,"activeCount":109},[],{"intervention":19696,"totalTrials":708,"cells":19704},{"EARLY_PHASE1":19705,"PHASE1":19707,"PHASE2":19709,"PHASE3":19715,"PHASE4":19717,"NA":19719},{"trials":19706,"activeCount":109},[],{"trials":19708,"activeCount":109},[],{"trials":19710,"activeCount":109},[19711],{"nctId":19689,"briefTitle":19690,"status":135,"phases":19712,"primaryCompletion":1404,"completion":2503,"start":19692,"enrollment":1767,"conditions":19713,"interventions":19714},[98,99],[19694],[19680,19696],{"trials":19716,"activeCount":109},[],{"trials":19718,"activeCount":109},[],{"trials":19720,"activeCount":109},[],{"intervention":19722,"totalTrials":708,"cells":19723},"donor lymphocyte",{"EARLY_PHASE1":19724,"PHASE1":19726,"PHASE2":19728,"PHASE3":19741,"PHASE4":19743,"NA":19745},{"trials":19725,"activeCount":109},[],{"trials":19727,"activeCount":109},[],{"trials":19729,"activeCount":109},[19730],{"nctId":19731,"briefTitle":19732,"status":569,"phases":19733,"primaryCompletion":18880,"completion":4268,"start":19734,"enrollment":32,"conditions":19735,"interventions":19740},"NCT03297528","Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant",[99],"2017-03-01",[19736,5811,946,19737,19738,19739],"Donor Lymphocyte Infusion","Minimal Residual Disease","Graft-versus-host Disease","Relapse",[19722],{"trials":19742,"activeCount":109},[],{"trials":19744,"activeCount":109},[],{"trials":19746,"activeCount":109},[],{"intervention":19748,"totalTrials":708,"cells":19749},"RC48-ADC and JS001",{"EARLY_PHASE1":19750,"PHASE1":19752,"PHASE2":19754,"PHASE3":19764,"PHASE4":19766,"NA":19768},{"trials":19751,"activeCount":109},[],{"trials":19753,"activeCount":109},[],{"trials":19755,"activeCount":109},[19756],{"nctId":19757,"briefTitle":19758,"status":569,"phases":19759,"primaryCompletion":19760,"completion":1202,"start":19761,"enrollment":8489,"conditions":19762,"interventions":19763},"NCT04264936","A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer",[98,99],"2021-01-30","2020-02-15",[9302],[19748],{"trials":19765,"activeCount":109},[],{"trials":19767,"activeCount":109},[],{"trials":19769,"activeCount":109},[],{"intervention":2582,"totalTrials":708,"cells":19771},{"EARLY_PHASE1":19772,"PHASE1":19774,"PHASE2":19776,"PHASE3":19782,"PHASE4":19784,"NA":19786},{"trials":19773,"activeCount":109},[],{"trials":19775,"activeCount":109},[],{"trials":19777,"activeCount":109},[19778],{"nctId":2574,"briefTitle":2575,"status":569,"phases":19779,"primaryCompletion":2577,"completion":2577,"start":2578,"enrollment":140,"conditions":19780,"interventions":19781},[99],[2580],[2562,2582],{"trials":19783,"activeCount":109},[],{"trials":19785,"activeCount":109},[],{"trials":19787,"activeCount":109},[],{"intervention":19789,"totalTrials":708,"cells":19790},"Lutein",{"EARLY_PHASE1":19791,"PHASE1":19793,"PHASE2":19795,"PHASE3":19805,"PHASE4":19807,"NA":19809},{"trials":19792,"activeCount":109},[],{"trials":19794,"activeCount":109},[],{"trials":19796,"activeCount":109},[19797],{"nctId":19798,"briefTitle":19799,"status":569,"phases":19800,"primaryCompletion":19801,"completion":3091,"start":3544,"enrollment":1767,"conditions":19802,"interventions":19804},"NCT01056094","Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers",[98,99],"2012-07",[19803],"Oxidative Stress in Healthy Subjects",[19789],{"trials":19806,"activeCount":109},[],{"trials":19808,"activeCount":109},[],{"trials":19810,"activeCount":109},[],{"intervention":19812,"totalTrials":708,"cells":19813},"TCM Formula",{"EARLY_PHASE1":19814,"PHASE1":19816,"PHASE2":19818,"PHASE3":19829,"PHASE4":19831,"NA":19833},{"trials":19815,"activeCount":109},[],{"trials":19817,"activeCount":109},[],{"trials":19819,"activeCount":109},[19820],{"nctId":19821,"briefTitle":19822,"status":569,"phases":19823,"primaryCompletion":5294,"completion":4000,"start":19824,"enrollment":19825,"conditions":19826,"interventions":19828},"NCT05229029","RSYR for Fatigue Reduction in Cancer Fatigue Caused by Chemotherapy",[99],"2020-04-02",196,[19827],"Cancer-related Problem\u002FCondition",[19812],{"trials":19830,"activeCount":109},[],{"trials":19832,"activeCount":109},[],{"trials":19834,"activeCount":109},[],{"intervention":3702,"totalTrials":708,"cells":19836},{"EARLY_PHASE1":19837,"PHASE1":19839,"PHASE2":19841,"PHASE3":19847,"PHASE4":19849,"NA":19851},{"trials":19838,"activeCount":109},[],{"trials":19840,"activeCount":109},[],{"trials":19842,"activeCount":109},[19843],{"nctId":3694,"briefTitle":3695,"status":569,"phases":19844,"primaryCompletion":3697,"completion":3697,"start":3698,"enrollment":3699,"conditions":19845,"interventions":19846},[99],[2580],[3702,3703],{"trials":19848,"activeCount":109},[],{"trials":19850,"activeCount":109},[],{"trials":19852,"activeCount":109},[],{"intervention":19854,"totalTrials":708,"cells":19855},"RSYRT decoction",{"EARLY_PHASE1":19856,"PHASE1":19858,"PHASE2":19860,"PHASE3":19869,"PHASE4":19871,"NA":19873},{"trials":19857,"activeCount":109},[],{"trials":19859,"activeCount":109},[],{"trials":19861,"activeCount":109},[19862],{"nctId":19863,"briefTitle":19864,"status":135,"phases":19865,"primaryCompletion":15758,"completion":15758,"start":17378,"enrollment":8634,"conditions":19866,"interventions":19867},"NCT03911921","RSYR for Fatigue Reduction in Cancer Survivors",[99],[19827],[19854,19868],"Astragalus membranaceus",{"trials":19870,"activeCount":109},[],{"trials":19872,"activeCount":109},[],{"trials":19874,"activeCount":109},[],{"intervention":19868,"totalTrials":708,"cells":19876},{"EARLY_PHASE1":19877,"PHASE1":19879,"PHASE2":19881,"PHASE3":19887,"PHASE4":19889,"NA":19891},{"trials":19878,"activeCount":109},[],{"trials":19880,"activeCount":109},[],{"trials":19882,"activeCount":109},[19883],{"nctId":19863,"briefTitle":19864,"status":135,"phases":19884,"primaryCompletion":15758,"completion":15758,"start":17378,"enrollment":8634,"conditions":19885,"interventions":19886},[99],[19827],[19854,19868],{"trials":19888,"activeCount":109},[],{"trials":19890,"activeCount":109},[],{"trials":19892,"activeCount":109},[],{"intervention":19894,"totalTrials":708,"cells":19895},"Everolimus",{"EARLY_PHASE1":19896,"PHASE1":19898,"PHASE2":19900,"PHASE3":19909,"PHASE4":19911,"NA":19913},{"trials":19897,"activeCount":109},[],{"trials":19899,"activeCount":109},[],{"trials":19901,"activeCount":109},[19902],{"nctId":19903,"briefTitle":19904,"status":569,"phases":19905,"primaryCompletion":14387,"start":4690,"enrollment":140,"conditions":19906,"interventions":19908},"NCT01960829","Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study",[99],[2580,19907,18109],"TOR Serine-Threonine Kinases",[19894],{"trials":19910,"activeCount":109},[],{"trials":19912,"activeCount":109},[],{"trials":19914,"activeCount":109},[],{"intervention":19916,"totalTrials":708,"cells":19917},"177Lu-Dotatate PRRT",{"EARLY_PHASE1":19918,"PHASE1":19920,"PHASE2":19922,"PHASE3":19930,"PHASE4":19932,"NA":19934},{"trials":19919,"activeCount":109},[],{"trials":19921,"activeCount":109},[],{"trials":19923,"activeCount":109},[19924],{"nctId":19925,"briefTitle":19926,"status":569,"phases":19927,"primaryCompletion":5372,"completion":4651,"start":19505,"enrollment":47,"conditions":19928,"interventions":19929},"NCT03422029","Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients",[99],[6414],[19916],{"trials":19931,"activeCount":109},[],{"trials":19933,"activeCount":109},[],{"trials":19935,"activeCount":109},[],{"intervention":19937,"totalTrials":708,"cells":19938},"docetaxel\u002Fcisplatin",{"EARLY_PHASE1":19939,"PHASE1":19941,"PHASE2":19943,"PHASE3":19952,"PHASE4":19954,"NA":19956},{"trials":19940,"activeCount":109},[],{"trials":19942,"activeCount":109},[],{"trials":19944,"activeCount":109},[19945],{"nctId":19946,"briefTitle":19947,"status":569,"phases":19948,"primaryCompletion":19949,"start":13757,"enrollment":728,"conditions":19950,"interventions":19951},"NCT01771289","Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel\u002FCisplatin for Resectable IIIA-N2 NSCLC",[99],"2017-01",[2524],[19937],{"trials":19953,"activeCount":109},[],{"trials":19955,"activeCount":109},[],{"trials":19957,"activeCount":109},[],{"intervention":19959,"totalTrials":708,"cells":19960},"Lutein and zeaxanthin",{"EARLY_PHASE1":19961,"PHASE1":19963,"PHASE2":19965,"PHASE3":19976,"PHASE4":19978,"NA":19980},{"trials":19962,"activeCount":109},[],{"trials":19964,"activeCount":109},[],{"trials":19966,"activeCount":109},[19967],{"nctId":19968,"briefTitle":19969,"status":569,"phases":19970,"primaryCompletion":19971,"completion":14527,"start":19972,"enrollment":574,"conditions":19973,"interventions":19975},"NCT01048476","Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration",[98,99],"2012-04","2009-09",[19974],"Age-related Macular Degeneration",[19959],{"trials":19977,"activeCount":109},[],{"trials":19979,"activeCount":109},[],{"trials":19981,"activeCount":109},[],{"intervention":19983,"totalTrials":708,"cells":19984},"Capecitabine, Dacarbazine",{"EARLY_PHASE1":19985,"PHASE1":19987,"PHASE2":19989,"PHASE3":19999,"PHASE4":20001,"NA":20003},{"trials":19986,"activeCount":109},[],{"trials":19988,"activeCount":109},[],{"trials":19990,"activeCount":109},[19991],{"nctId":19992,"briefTitle":19993,"status":569,"phases":19994,"primaryCompletion":10492,"completion":15757,"start":15273,"enrollment":19995,"conditions":19996,"interventions":19997},"NCT03279601","Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor",[99],148,[6414],[19983,19998],"Capecitabine, Temozolomide",{"trials":20000,"activeCount":109},[],{"trials":20002,"activeCount":109},[],{"trials":20004,"activeCount":109},[],{"intervention":19998,"totalTrials":708,"cells":20006},{"EARLY_PHASE1":20007,"PHASE1":20009,"PHASE2":20011,"PHASE3":20017,"PHASE4":20019,"NA":20021},{"trials":20008,"activeCount":109},[],{"trials":20010,"activeCount":109},[],{"trials":20012,"activeCount":109},[20013],{"nctId":19992,"briefTitle":19993,"status":569,"phases":20014,"primaryCompletion":10492,"completion":15757,"start":15273,"enrollment":19995,"conditions":20015,"interventions":20016},[99],[6414],[19983,19998],{"trials":20018,"activeCount":109},[],{"trials":20020,"activeCount":109},[],{"trials":20022,"activeCount":109},[],{"intervention":20024,"totalTrials":708,"cells":20025},"FOLFIRI Protocol",{"EARLY_PHASE1":20026,"PHASE1":20028,"PHASE2":20030,"PHASE3":20041,"PHASE4":20043,"NA":20045},{"trials":20027,"activeCount":109},[],{"trials":20029,"activeCount":109},[],{"trials":20031,"activeCount":109},[20032],{"nctId":20033,"briefTitle":20034,"status":569,"phases":20035,"primaryCompletion":20036,"completion":20037,"start":20038,"enrollment":3547,"conditions":20039,"interventions":20040},"NCT03168607","Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma",[99],"2019-05-02","2020-05-02","2017-05-02",[19088],[20024],{"trials":20042,"activeCount":109},[],{"trials":20044,"activeCount":109},[],{"trials":20046,"activeCount":109},[],{"intervention":20048,"totalTrials":708,"cells":20049},"platinum and gemcitabine",{"EARLY_PHASE1":20050,"PHASE1":20052,"PHASE2":20054,"PHASE3":20062,"PHASE4":20064,"NA":20066},{"trials":20051,"activeCount":109},[],{"trials":20053,"activeCount":109},[],{"trials":20055,"activeCount":109},[20056],{"nctId":20057,"briefTitle":20058,"status":569,"phases":20059,"primaryCompletion":4152,"completion":138,"start":14526,"enrollment":2732,"conditions":20060,"interventions":20061},"NCT02233205","Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System",[98,99],[2691],[20048],{"trials":20063,"activeCount":109},[],{"trials":20065,"activeCount":109},[],{"trials":20067,"activeCount":109},[],{"intervention":20069,"totalTrials":708,"cells":20070},"Oxaliplatin and capecitabine",{"EARLY_PHASE1":20071,"PHASE1":20073,"PHASE2":20075,"PHASE3":20086,"PHASE4":20088,"NA":20090},{"trials":20072,"activeCount":109},[],{"trials":20074,"activeCount":109},[],{"trials":20076,"activeCount":109},[20077],{"nctId":20078,"briefTitle":20079,"status":569,"phases":20080,"primaryCompletion":2588,"completion":20081,"start":20082,"enrollment":20083,"conditions":20084,"interventions":20085},"NCT04296240","Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer",[99],"2024-04","2019-03-01",119,[3355],[20069],{"trials":20087,"activeCount":109},[],{"trials":20089,"activeCount":109},[],{"trials":20091,"activeCount":109},[],{"intervention":20093,"totalTrials":708,"cells":20094},"irinotecan\u002Fcisplatin",{"EARLY_PHASE1":20095,"PHASE1":20097,"PHASE2":20099,"PHASE3":20108,"PHASE4":20110,"NA":20112},{"trials":20096,"activeCount":109},[],{"trials":20098,"activeCount":109},[],{"trials":20100,"activeCount":109},[20101],{"nctId":20102,"briefTitle":20103,"status":569,"phases":20104,"primaryCompletion":15181,"completion":3091,"start":4774,"enrollment":140,"conditions":20105,"interventions":20107},"NCT01051765","Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial",[99],[20106],"Advanced Esophageal Squamous Carcinoma",[20093],{"trials":20109,"activeCount":109},[],{"trials":20111,"activeCount":109},[],{"trials":20113,"activeCount":109},[],{"intervention":20115,"totalTrials":708,"cells":20116},"Chidamide plus DICE Regimen",{"EARLY_PHASE1":20117,"PHASE1":20119,"PHASE2":20121,"PHASE3":20132,"PHASE4":20134,"NA":20136},{"trials":20118,"activeCount":109},[],{"trials":20120,"activeCount":109},[],{"trials":20122,"activeCount":109},[20123],{"nctId":20124,"briefTitle":20125,"status":569,"phases":20126,"primaryCompletion":20127,"completion":15272,"start":20128,"enrollment":6242,"conditions":20129,"interventions":20131},"NCT03105596","Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)",[99],"2018-09-30","2017-04-11",[20130],"B-cell Non-Hodgkin's Lymphoma",[20115],{"trials":20133,"activeCount":109},[],{"trials":20135,"activeCount":109},[],{"trials":20137,"activeCount":109},[],{"intervention":20139,"totalTrials":708,"cells":20140},"Anti-CD30 CAR T cells",{"EARLY_PHASE1":20141,"PHASE1":20143,"PHASE2":20145,"PHASE3":20154,"PHASE4":20156,"NA":20158},{"trials":20142,"activeCount":109},[],{"trials":20144,"activeCount":109},[],{"trials":20146,"activeCount":109},[20147],{"nctId":20148,"briefTitle":20149,"status":569,"phases":20150,"primaryCompletion":4126,"completion":19151,"start":4833,"enrollment":47,"conditions":20151,"interventions":20153},"NCT02274584","CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)",[98,99],[20152],"Lymphomas",[20139],{"trials":20155,"activeCount":109},[],{"trials":20157,"activeCount":109},[],{"trials":20159,"activeCount":109},[],{"intervention":20161,"totalTrials":708,"cells":20162},"Donor-derived CMVpp65-specific T cells",{"EARLY_PHASE1":20163,"PHASE1":20165,"PHASE2":20167,"PHASE3":20177,"PHASE4":20179,"NA":20181},{"trials":20164,"activeCount":109},[],{"trials":20166,"activeCount":109},[],{"trials":20168,"activeCount":109},[20169],{"nctId":20170,"briefTitle":20171,"status":135,"phases":20172,"primaryCompletion":3510,"completion":5448,"start":19949,"enrollment":20173,"conditions":20174,"interventions":20176},"NCT02985775","Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation",[98,99],41,[20175],"CMV Infection",[20161],{"trials":20178,"activeCount":109},[],{"trials":20180,"activeCount":109},[],{"trials":20182,"activeCount":109},[],{"intervention":20184,"totalTrials":708,"cells":20185},"Nab-paclitaxel Combined With Bevacizumab",{"EARLY_PHASE1":20186,"PHASE1":20188,"PHASE2":20190,"PHASE3":20199,"PHASE4":20201,"NA":20203},{"trials":20187,"activeCount":109},[],{"trials":20189,"activeCount":109},[],{"trials":20191,"activeCount":109},[20192],{"nctId":20193,"briefTitle":20194,"status":135,"phases":20195,"primaryCompletion":15561,"completion":15561,"start":20196,"enrollment":8287,"conditions":20197,"interventions":20198},"NCT04705519","Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma",[99],"2021-01-05",[19088],[20184],{"trials":20200,"activeCount":109},[],{"trials":20202,"activeCount":109},[],{"trials":20204,"activeCount":109},[],{"intervention":4242,"totalTrials":708,"cells":20206},{"EARLY_PHASE1":20207,"PHASE1":20209,"PHASE2":20211,"PHASE3":20217,"PHASE4":20219,"NA":20221},{"trials":20208,"activeCount":109},[],{"trials":20210,"activeCount":109},[],{"trials":20212,"activeCount":109},[20213],{"nctId":4235,"briefTitle":4236,"status":569,"phases":20214,"primaryCompletion":4238,"completion":637,"start":4239,"enrollment":1767,"conditions":20215,"interventions":20216},[99],[1153],[1035,1119,4242],{"trials":20218,"activeCount":109},[],{"trials":20220,"activeCount":109},[],{"trials":20222,"activeCount":109},[],{"intervention":20224,"totalTrials":708,"cells":20225},"Low-dose IL-2 and ganciclovir",{"EARLY_PHASE1":20226,"PHASE1":20228,"PHASE2":20230,"PHASE3":20239,"PHASE4":20241,"NA":20243},{"trials":20227,"activeCount":109},[],{"trials":20229,"activeCount":109},[],{"trials":20231,"activeCount":109},[20232],{"nctId":20233,"briefTitle":20234,"status":569,"phases":20235,"primaryCompletion":657,"completion":16722,"start":1964,"enrollment":477,"conditions":20236,"interventions":20238},"NCT04225780","Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus Infection",[98,99],[20237],"Cytomegalovirus Infections",[20224],{"trials":20240,"activeCount":109},[],{"trials":20242,"activeCount":109},[],{"trials":20244,"activeCount":109},[],{"intervention":1142,"totalTrials":708,"cells":20246},{"EARLY_PHASE1":20247,"PHASE1":20249,"PHASE2":20251,"PHASE3":20257,"PHASE4":20259,"NA":20261},{"trials":20248,"activeCount":109},[],{"trials":20250,"activeCount":109},[],{"trials":20252,"activeCount":109},[20253],{"nctId":1135,"briefTitle":1136,"status":569,"phases":20254,"primaryCompletion":639,"completion":1138,"start":857,"enrollment":1139,"conditions":20255,"interventions":20256},[99],[34],[1090,1142],{"trials":20258,"activeCount":109},[],{"trials":20260,"activeCount":109},[],{"trials":20262,"activeCount":109},[],{"intervention":652,"totalTrials":708,"cells":20264},{"EARLY_PHASE1":20265,"PHASE1":20267,"PHASE2":20269,"PHASE3":20275,"PHASE4":20277,"NA":20279},{"trials":20266,"activeCount":109},[],{"trials":20268,"activeCount":109},[],{"trials":20270,"activeCount":109},[20271],{"nctId":645,"briefTitle":646,"status":135,"phases":20272,"primaryCompletion":648,"completion":648,"start":649,"enrollment":586,"conditions":20273,"interventions":20274},[99],[34],[557,652],{"trials":20276,"activeCount":109},[],{"trials":20278,"activeCount":109},[],{"trials":20280,"activeCount":109},[],{"intervention":20282,"totalTrials":708,"cells":20283},"imatinib mesylate",{"EARLY_PHASE1":20284,"PHASE1":20286,"PHASE2":20288,"PHASE3":20297,"PHASE4":20299,"NA":20301},{"trials":20285,"activeCount":109},[],{"trials":20287,"activeCount":109},[],{"trials":20289,"activeCount":109},[20290],{"nctId":20291,"briefTitle":20292,"status":135,"phases":20293,"primaryCompletion":14526,"completion":14526,"start":15249,"enrollment":47,"conditions":20294,"interventions":20296},"NCT01267695","Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor",[99],[20295],"Gastrointestinal Stromal Tumor",[20282],{"trials":20298,"activeCount":109},[],{"trials":20300,"activeCount":109},[],{"trials":20302,"activeCount":109},[],{"intervention":3458,"totalTrials":708,"cells":20304},{"EARLY_PHASE1":20305,"PHASE1":20307,"PHASE2":20309,"PHASE3":20315,"PHASE4":20317,"NA":20319},{"trials":20306,"activeCount":109},[],{"trials":20308,"activeCount":109},[],{"trials":20310,"activeCount":109},[20311],{"nctId":3447,"briefTitle":3448,"status":135,"phases":20312,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":3453,"conditions":20313,"interventions":20314},[99],[2506],[3456,3457,2911,3458,3459],{"trials":20316,"activeCount":109},[],{"trials":20318,"activeCount":109},[],{"trials":20320,"activeCount":109},[],{"intervention":3459,"totalTrials":708,"cells":20322},{"EARLY_PHASE1":20323,"PHASE1":20325,"PHASE2":20327,"PHASE3":20333,"PHASE4":20335,"NA":20337},{"trials":20324,"activeCount":109},[],{"trials":20326,"activeCount":109},[],{"trials":20328,"activeCount":109},[20329],{"nctId":3447,"briefTitle":3448,"status":135,"phases":20330,"primaryCompletion":3450,"completion":3451,"start":3452,"enrollment":3453,"conditions":20331,"interventions":20332},[99],[2506],[3456,3457,2911,3458,3459],{"trials":20334,"activeCount":109},[],{"trials":20336,"activeCount":109},[],{"trials":20338,"activeCount":109},[],{"intervention":20340,"totalTrials":708,"cells":20341},"Cistanche Total Glycosides",{"EARLY_PHASE1":20342,"PHASE1":20344,"PHASE2":20346,"PHASE3":20354,"PHASE4":20356,"NA":20358},{"trials":20343,"activeCount":109},[],{"trials":20345,"activeCount":109},[],{"trials":20347,"activeCount":109},[20348],{"nctId":20349,"briefTitle":20350,"status":569,"phases":20351,"primaryCompletion":5584,"completion":18314,"start":4142,"enrollment":32,"conditions":20352,"interventions":20353},"NCT00753571","Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response",[99],[16078],[20340],{"trials":20355,"activeCount":109},[],{"trials":20357,"activeCount":109},[],{"trials":20359,"activeCount":109},[],{"intervention":20361,"totalTrials":708,"cells":20362},"Eculizumab",{"EARLY_PHASE1":20363,"PHASE1":20365,"PHASE2":20367,"PHASE3":20376,"PHASE4":20378,"NA":20380},{"trials":20364,"activeCount":109},[],{"trials":20366,"activeCount":109},[],{"trials":20368,"activeCount":109},[20369],{"nctId":20370,"briefTitle":20371,"status":135,"phases":20372,"primaryCompletion":20373,"completion":20373,"start":94,"enrollment":558,"conditions":20374,"interventions":20375},"NCT06513338","Complement C5 mAb in the Treatment of Anti-GBM Disease",[99],"2025-11-03",[14704],[20361],{"trials":20377,"activeCount":109},[],{"trials":20379,"activeCount":109},[],{"trials":20381,"activeCount":109},[],{"intervention":20383,"totalTrials":708,"cells":20384},"cTACE-HAIC",{"EARLY_PHASE1":20385,"PHASE1":20387,"PHASE2":20389,"PHASE3":20398,"PHASE4":20400,"NA":20402},{"trials":20386,"activeCount":109},[],{"trials":20388,"activeCount":109},[],{"trials":20390,"activeCount":109},[20391],{"nctId":20392,"briefTitle":20393,"status":569,"phases":20394,"primaryCompletion":13719,"completion":18593,"start":20395,"enrollment":6539,"conditions":20396,"interventions":20397},"NCT04597970","TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC",[99],"2020-10-20",[4918,2591],[20383],{"trials":20399,"activeCount":109},[],{"trials":20401,"activeCount":109},[],{"trials":20403,"activeCount":109},[],{"intervention":20405,"totalTrials":708,"cells":20406},"Camrelizumab with vinorelbine and cisplatin",{"EARLY_PHASE1":20407,"PHASE1":20409,"PHASE2":20411,"PHASE3":20419,"PHASE4":20421,"NA":20423},{"trials":20408,"activeCount":109},[],{"trials":20410,"activeCount":109},[],{"trials":20412,"activeCount":109},[20413],{"nctId":20414,"briefTitle":20415,"status":569,"phases":20416,"primaryCompletion":2633,"completion":1103,"start":17577,"enrollment":1767,"conditions":20417,"interventions":20418},"NCT04848454","Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy",[99],[5775,10078,19507,3924,1027,1028],[20405],{"trials":20420,"activeCount":109},[],{"trials":20422,"activeCount":109},[],{"trials":20424,"activeCount":109},[],{"intervention":20426,"totalTrials":708,"cells":20427},"Irinotecan combined with cisplatin, octreotide lar",{"EARLY_PHASE1":20428,"PHASE1":20430,"PHASE2":20432,"PHASE3":20442,"PHASE4":20444,"NA":20446},{"trials":20429,"activeCount":109},[],{"trials":20431,"activeCount":109},[],{"trials":20433,"activeCount":109},[20434],{"nctId":20435,"briefTitle":20436,"status":135,"phases":20437,"primaryCompletion":20438,"completion":3089,"start":4691,"enrollment":32,"conditions":20439,"interventions":20441},"NCT01480986","IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC",[99],"2012-09",[20440],"Progression Free Survival of the Treatment",[20426],{"trials":20443,"activeCount":109},[],{"trials":20445,"activeCount":109},[],{"trials":20447,"activeCount":109},[],{"intervention":20449,"totalTrials":708,"cells":20450},"Rituximab plus methylprednisolone",{"EARLY_PHASE1":20451,"PHASE1":20453,"PHASE2":20455,"PHASE3":20464,"PHASE4":20466,"NA":20468},{"trials":20452,"activeCount":109},[],{"trials":20454,"activeCount":109},[],{"trials":20456,"activeCount":109},[20457],{"nctId":20458,"briefTitle":20459,"status":569,"phases":20460,"primaryCompletion":668,"completion":4090,"start":5437,"enrollment":2414,"conditions":20461,"interventions":20462},"NCT02757196","Treatment of ITP With Rituximab and \u002F or Accutane",[99],[34],[20449,20463],"methylprednisolone",{"trials":20465,"activeCount":109},[],{"trials":20467,"activeCount":109},[],{"trials":20469,"activeCount":109},[],{"intervention":20463,"totalTrials":708,"cells":20471},{"EARLY_PHASE1":20472,"PHASE1":20474,"PHASE2":20476,"PHASE3":20482,"PHASE4":20484,"NA":20486},{"trials":20473,"activeCount":109},[],{"trials":20475,"activeCount":109},[],{"trials":20477,"activeCount":109},[20478],{"nctId":20458,"briefTitle":20459,"status":569,"phases":20479,"primaryCompletion":668,"completion":4090,"start":5437,"enrollment":2414,"conditions":20480,"interventions":20481},[99],[34],[20449,20463],{"trials":20483,"activeCount":109},[],{"trials":20485,"activeCount":109},[],{"trials":20487,"activeCount":109},[],{"intervention":20489,"totalTrials":708,"cells":20490},"proximod 5mg daily",{"EARLY_PHASE1":20491,"PHASE1":20493,"PHASE2":20495,"PHASE3":20506,"PHASE4":20508,"NA":20510},{"trials":20492,"activeCount":109},[],{"trials":20494,"activeCount":109},[],{"trials":20496,"activeCount":109},[20497],{"nctId":20498,"briefTitle":20499,"status":135,"phases":20500,"primaryCompletion":20501,"completion":20501,"start":229,"enrollment":20502,"conditions":20503,"interventions":20504},"NCT07335952","Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.",[99],"2025-10-09",179,[2506],[20489,20505],"proximod 10mg daily",{"trials":20507,"activeCount":109},[],{"trials":20509,"activeCount":109},[],{"trials":20511,"activeCount":109},[],{"intervention":20505,"totalTrials":708,"cells":20513},{"EARLY_PHASE1":20514,"PHASE1":20516,"PHASE2":20518,"PHASE3":20524,"PHASE4":20526,"NA":20528},{"trials":20515,"activeCount":109},[],{"trials":20517,"activeCount":109},[],{"trials":20519,"activeCount":109},[20520],{"nctId":20498,"briefTitle":20499,"status":135,"phases":20521,"primaryCompletion":20501,"completion":20501,"start":229,"enrollment":20502,"conditions":20522,"interventions":20523},[99],[2506],[20489,20505],{"trials":20525,"activeCount":109},[],{"trials":20527,"activeCount":109},[],{"trials":20529,"activeCount":109},[],{"intervention":20531,"totalTrials":708,"cells":20532},"Dexamethasone, azacytidine, Pegaspargase, Tislelizumab",{"EARLY_PHASE1":20533,"PHASE1":20535,"PHASE2":20537,"PHASE3":20548,"PHASE4":20550,"NA":20552},{"trials":20534,"activeCount":109},[],{"trials":20536,"activeCount":109},[],{"trials":20538,"activeCount":109},[20539],{"nctId":20540,"briefTitle":20541,"status":569,"phases":20542,"primaryCompletion":20543,"completion":20544,"start":20545,"enrollment":728,"conditions":20546,"interventions":20547},"NCT04899414","Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK\u002FT Cell Lymphoma",[99],"2023-05-18","2023-10-18","2021-05-18",[5943],[20531],{"trials":20549,"activeCount":109},[],{"trials":20551,"activeCount":109},[],{"trials":20553,"activeCount":109},[],{"intervention":20555,"totalTrials":708,"cells":20556},"Sodium Butyrate",{"EARLY_PHASE1":20557,"PHASE1":20559,"PHASE2":20561,"PHASE3":20570,"PHASE4":20572,"NA":20574},{"trials":20558,"activeCount":109},[],{"trials":20560,"activeCount":109},[],{"trials":20562,"activeCount":109},[20563],{"nctId":20564,"briefTitle":20565,"status":135,"phases":20566,"primaryCompletion":17576,"completion":4554,"start":20567,"enrollment":1767,"conditions":20568,"interventions":20569},"NCT05576597","Effect of Butyrate Supplement on Rheumatoid Arthritis",[99],"2022-08-23",[2506],[20555],{"trials":20571,"activeCount":109},[],{"trials":20573,"activeCount":109},[],{"trials":20575,"activeCount":109},[],{"intervention":20577,"totalTrials":708,"cells":20578},"JS001+Imatinib mesylate",{"EARLY_PHASE1":20579,"PHASE1":20581,"PHASE2":20583,"PHASE3":20592,"PHASE4":20594,"NA":20596},{"trials":20580,"activeCount":109},[],{"trials":20582,"activeCount":109},[],{"trials":20584,"activeCount":109},[20585],{"nctId":20586,"briefTitle":20587,"status":569,"phases":20588,"primaryCompletion":571,"completion":1149,"start":20589,"enrollment":3699,"conditions":20590,"interventions":20591},"NCT05274438","Imatinib and Toripalimab in Patients With Locally Advanced\u002FMetastatic Melanoma Harbored With CKIT Mut",[99],"2021-01-26",[5404],[20577],{"trials":20593,"activeCount":109},[],{"trials":20595,"activeCount":109},[],{"trials":20597,"activeCount":109},[],{"intervention":20599,"totalTrials":708,"cells":20600},"Plant enteral-extended anti-reflux stents",{"EARLY_PHASE1":20601,"PHASE1":20603,"PHASE2":20605,"PHASE3":20615,"PHASE4":20617,"NA":20619},{"trials":20602,"activeCount":109},[],{"trials":20604,"activeCount":109},[],{"trials":20606,"activeCount":109},[20607],{"nctId":20608,"briefTitle":20609,"status":569,"phases":20610,"primaryCompletion":6043,"completion":741,"start":571,"enrollment":2522,"conditions":20611,"interventions":20613},"NCT05716594","Clinical Evaluation of Enteral-extended Anti-reflux Stents for Pancreatic Pseudocyst",[99],[20612],"Pancreatic Pseudocyst",[20599,20614],"Plant traditional stents",{"trials":20616,"activeCount":109},[],{"trials":20618,"activeCount":109},[],{"trials":20620,"activeCount":109},[],{"intervention":20614,"totalTrials":708,"cells":20622},{"EARLY_PHASE1":20623,"PHASE1":20625,"PHASE2":20627,"PHASE3":20633,"PHASE4":20635,"NA":20637},{"trials":20624,"activeCount":109},[],{"trials":20626,"activeCount":109},[],{"trials":20628,"activeCount":109},[20629],{"nctId":20608,"briefTitle":20609,"status":569,"phases":20630,"primaryCompletion":6043,"completion":741,"start":571,"enrollment":2522,"conditions":20631,"interventions":20632},[99],[20612],[20599,20614],{"trials":20634,"activeCount":109},[],{"trials":20636,"activeCount":109},[],{"trials":20638,"activeCount":109},[],{"intervention":20640,"totalTrials":708,"cells":20641},"SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone",{"EARLY_PHASE1":20642,"PHASE1":20644,"PHASE2":20646,"PHASE3":20656,"PHASE4":20658,"NA":20660},{"trials":20643,"activeCount":109},[],{"trials":20645,"activeCount":109},[],{"trials":20647,"activeCount":109},[20648],{"nctId":20649,"briefTitle":20650,"status":569,"phases":20651,"primaryCompletion":20652,"completion":20653,"start":2701,"enrollment":44,"conditions":20654,"interventions":20655},"NCT05478993","Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement",[99],"2024-07-10","2025-07-10",[5130],[20640],{"trials":20657,"activeCount":109},[],{"trials":20659,"activeCount":109},[],{"trials":20661,"activeCount":109},[],{"intervention":20663,"totalTrials":708,"cells":20664},"Virus specific T cells",{"EARLY_PHASE1":20665,"PHASE1":20667,"PHASE2":20669,"PHASE3":20679,"PHASE4":20681,"NA":20683},{"trials":20666,"activeCount":109},[],{"trials":20668,"activeCount":109},[],{"trials":20670,"activeCount":109},[20671],{"nctId":20672,"briefTitle":20673,"status":569,"phases":20674,"primaryCompletion":629,"completion":3260,"start":316,"enrollment":105,"conditions":20675,"interventions":20678},"NCT06075927","Multivirus-specific T Cells in the Treatment of Refractory CMV and\u002For EBV Infection After Allo-HSCT",[98,99],[20175,20676,20677],"EBV Infection","Stem Cell Transplant",[20663],{"trials":20680,"activeCount":109},[],{"trials":20682,"activeCount":109},[],{"trials":20684,"activeCount":109},[],{"intervention":9959,"totalTrials":708,"cells":20686},{"EARLY_PHASE1":20687,"PHASE1":20689,"PHASE2":20691,"PHASE3":20697,"PHASE4":20699,"NA":20701},{"trials":20688,"activeCount":109},[],{"trials":20690,"activeCount":109},[],{"trials":20692,"activeCount":109},[20693],{"nctId":9952,"briefTitle":9953,"status":569,"phases":20694,"primaryCompletion":2542,"completion":1113,"start":9955,"enrollment":9956,"conditions":20695,"interventions":20696},[99],[5404],[9959,9960],{"trials":20698,"activeCount":109},[],{"trials":20700,"activeCount":109},[],{"trials":20702,"activeCount":109},[],{"intervention":8451,"totalTrials":708,"cells":20704},{"EARLY_PHASE1":20705,"PHASE1":20707,"PHASE2":20709,"PHASE3":20715,"PHASE4":20717,"NA":20719},{"trials":20706,"activeCount":109},[],{"trials":20708,"activeCount":109},[],{"trials":20710,"activeCount":109},[20711],{"nctId":8443,"briefTitle":8444,"status":569,"phases":20712,"primaryCompletion":8446,"completion":8447,"start":1526,"enrollment":47,"conditions":20713,"interventions":20714},[99],[8449],[8451,8401,734],{"trials":20716,"activeCount":109},[],{"trials":20718,"activeCount":109},[],{"trials":20720,"activeCount":109},[],{"intervention":20722,"totalTrials":708,"cells":20723},"cetuximab, cisplatin, capecitabine",{"EARLY_PHASE1":20724,"PHASE1":20726,"PHASE2":20728,"PHASE3":20738,"PHASE4":20740,"NA":20742},{"trials":20725,"activeCount":109},[],{"trials":20727,"activeCount":109},[],{"trials":20729,"activeCount":109},[20730],{"nctId":20731,"briefTitle":20732,"status":135,"phases":20733,"primaryCompletion":5584,"completion":20734,"start":20735,"enrollment":20173,"conditions":20736,"interventions":20737},"NCT00477711","A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer",[99],"2009-02","2007-03",[28],[20722],{"trials":20739,"activeCount":109},[],{"trials":20741,"activeCount":109},[],{"trials":20743,"activeCount":109},[],{"intervention":20745,"totalTrials":708,"cells":20746},"S-1 oxaliplatin",{"EARLY_PHASE1":20747,"PHASE1":20749,"PHASE2":20751,"PHASE3":20759,"PHASE4":20761,"NA":20763},{"trials":20748,"activeCount":109},[],{"trials":20750,"activeCount":109},[],{"trials":20752,"activeCount":109},[20753],{"nctId":20754,"briefTitle":20755,"status":569,"phases":20756,"primaryCompletion":3091,"completion":3091,"start":14700,"enrollment":32,"conditions":20757,"interventions":20758},"NCT01180153","Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)",[99],[18063],[20745],{"trials":20760,"activeCount":109},[],{"trials":20762,"activeCount":109},[],{"trials":20764,"activeCount":109},[],{"intervention":20766,"totalTrials":708,"cells":20767},"mFOLFOX",{"EARLY_PHASE1":20768,"PHASE1":20770,"PHASE2":20772,"PHASE3":20781,"PHASE4":20783,"NA":20785},{"trials":20769,"activeCount":109},[],{"trials":20771,"activeCount":109},[],{"trials":20773,"activeCount":109},[20774],{"nctId":20775,"briefTitle":20776,"status":569,"phases":20777,"primaryCompletion":16137,"completion":16137,"start":4142,"enrollment":20778,"conditions":20779,"interventions":20780},"NCT00591045","Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer",[99],263,[4842,28],[20766],{"trials":20782,"activeCount":109},[],{"trials":20784,"activeCount":109},[],{"trials":20786,"activeCount":109},[],{"intervention":20788,"totalTrials":329,"cells":20789},"salvianolic acid A",{"EARLY_PHASE1":20790,"PHASE1":20792,"PHASE2":20820,"PHASE3":20822,"PHASE4":20824,"NA":20826},{"trials":20791,"activeCount":109},[],{"trials":20793,"activeCount":109},[20794,20802,20812],{"nctId":20795,"briefTitle":20796,"status":569,"phases":20797,"primaryCompletion":3624,"completion":3624,"start":20798,"enrollment":748,"conditions":20799,"interventions":20801},"NCT03791463","Effect of Food on Pharmacokinetics of Salvianolic Acid A in Healthy Subjects",[98],"2018-12-20",[20800],"Healthy",[20788],{"nctId":20803,"briefTitle":20804,"status":569,"phases":20805,"primaryCompletion":20806,"completion":351,"start":20807,"enrollment":32,"conditions":20808,"interventions":20810},"NCT03791125","Phase I Single-dose Escalation Clinical Trial of Salvianolic Acid A Tablets",[98],"2019-03-20","2018-11-20",[20809],"Neuropathy of Diabetes",[20811],"Salvianolic Acid A",{"nctId":20813,"briefTitle":20814,"status":569,"phases":20815,"primaryCompletion":20816,"completion":20817,"start":3623,"enrollment":38,"conditions":20818,"interventions":20819},"NCT03908242","Phase I Study of Continuous Administration of Salvianolic Acid A Tablet",[98],"2019-04-30","2019-05-30",[14870],[20788],{"trials":20821,"activeCount":109},[],{"trials":20823,"activeCount":109},[],{"trials":20825,"activeCount":109},[],{"trials":20827,"activeCount":109},[],{"intervention":4272,"totalTrials":746,"cells":20829},{"EARLY_PHASE1":20830,"PHASE1":20832,"PHASE2":20844,"PHASE3":20846,"PHASE4":20848,"NA":20850},{"trials":20831,"activeCount":109},[],{"trials":20833,"activeCount":109},[20834,20838],{"nctId":4265,"briefTitle":4266,"status":569,"phases":20835,"primaryCompletion":3999,"completion":81,"start":4268,"enrollment":1767,"conditions":20836,"interventions":20837},[98],[4270],[4272,4273,3927],{"nctId":20839,"briefTitle":20840,"status":569,"phases":20841,"primaryCompletion":3999,"completion":81,"start":4268,"enrollment":2770,"conditions":20842,"interventions":20843},"NCT05068453","Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis",[98],[4270],[4272,4273],{"trials":20845,"activeCount":109},[],{"trials":20847,"activeCount":109},[],{"trials":20849,"activeCount":109},[],{"trials":20851,"activeCount":109},[],{"intervention":4273,"totalTrials":746,"cells":20853},{"EARLY_PHASE1":20854,"PHASE1":20856,"PHASE2":20866,"PHASE3":20868,"PHASE4":20870,"NA":20872},{"trials":20855,"activeCount":109},[],{"trials":20857,"activeCount":109},[20858,20862],{"nctId":4265,"briefTitle":4266,"status":569,"phases":20859,"primaryCompletion":3999,"completion":81,"start":4268,"enrollment":1767,"conditions":20860,"interventions":20861},[98],[4270],[4272,4273,3927],{"nctId":20839,"briefTitle":20840,"status":569,"phases":20863,"primaryCompletion":3999,"completion":81,"start":4268,"enrollment":2770,"conditions":20864,"interventions":20865},[98],[4270],[4272,4273],{"trials":20867,"activeCount":109},[],{"trials":20869,"activeCount":109},[],{"trials":20871,"activeCount":109},[],{"trials":20873,"activeCount":109},[],{"intervention":20875,"totalTrials":708,"cells":20876},"JWCAR029",{"EARLY_PHASE1":20877,"PHASE1":20879,"PHASE2":20889,"PHASE3":20891,"PHASE4":20893,"NA":20895},{"trials":20878,"activeCount":109},[],{"trials":20880,"activeCount":109},[20881],{"nctId":20882,"briefTitle":20883,"status":569,"phases":20884,"primaryCompletion":4125,"completion":5321,"start":20885,"enrollment":47,"conditions":20886,"interventions":20888},"NCT03344367","Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",[98],"2017-11-16",[20887],"Non Hodgkin Lymphoma",[20875],{"trials":20890,"activeCount":109},[],{"trials":20892,"activeCount":109},[],{"trials":20894,"activeCount":109},[],{"trials":20896,"activeCount":109},[],{"intervention":20898,"totalTrials":708,"cells":20899},"Super circulating tumor infiltrating lymphocytes",{"EARLY_PHASE1":20900,"PHASE1":20902,"PHASE2":20910,"PHASE3":20912,"PHASE4":20914,"NA":20916},{"trials":20901,"activeCount":109},[],{"trials":20903,"activeCount":109},[20904],{"nctId":20905,"briefTitle":20906,"status":569,"phases":20907,"primaryCompletion":1163,"completion":1163,"start":8262,"enrollment":8079,"conditions":20908,"interventions":20909},"NCT04357509","The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma",[98],[2580],[20898],{"trials":20911,"activeCount":109},[],{"trials":20913,"activeCount":109},[],{"trials":20915,"activeCount":109},[],{"trials":20917,"activeCount":109},[],{"intervention":20919,"totalTrials":708,"cells":20920},"humanized anti-PD-1 monoclonal antibody",{"EARLY_PHASE1":20921,"PHASE1":20923,"PHASE2":20934,"PHASE3":20936,"PHASE4":20938,"NA":20940},{"trials":20922,"activeCount":109},[],{"trials":20924,"activeCount":109},[20925],{"nctId":20926,"briefTitle":20927,"status":135,"phases":20928,"primaryCompletion":20929,"completion":20930,"start":20931,"enrollment":32,"conditions":20932,"interventions":20933},"NCT03167853","Study of JS001 in Patients With Advanced Neuroendocrine Tumors",[98],"2018-12-11","2019-05-11","2017-04-06",[6414],[20919],{"trials":20935,"activeCount":109},[],{"trials":20937,"activeCount":109},[],{"trials":20939,"activeCount":109},[],{"trials":20941,"activeCount":109},[],{"intervention":20943,"totalTrials":708,"cells":20944},"CT048 Autologous",{"EARLY_PHASE1":20945,"PHASE1":20947,"PHASE2":20956,"PHASE3":20958,"PHASE4":20960,"NA":20962},{"trials":20946,"activeCount":109},[],{"trials":20948,"activeCount":109},[20949],{"nctId":20950,"briefTitle":20951,"status":569,"phases":20952,"primaryCompletion":4701,"completion":4238,"start":20953,"enrollment":7820,"conditions":20954,"interventions":20955},"NCT05393986","Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors",[98],"2022-08-04",[4705,684,8822],[20943],{"trials":20957,"activeCount":109},[],{"trials":20959,"activeCount":109},[],{"trials":20961,"activeCount":109},[],{"trials":20963,"activeCount":109},[],{"intervention":20965,"totalTrials":708,"cells":20966},"Surufatinib\u002Fhumanized anti-PD-1 monoclonal antibody",{"EARLY_PHASE1":20967,"PHASE1":20969,"PHASE2":20980,"PHASE3":20982,"PHASE4":20984,"NA":20986},{"trials":20968,"activeCount":109},[],{"trials":20970,"activeCount":109},[20971],{"nctId":20972,"briefTitle":20973,"status":569,"phases":20974,"primaryCompletion":20975,"completion":20976,"start":20977,"enrollment":38,"conditions":20978,"interventions":20979},"NCT03879057","Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors",[98],"2020-12-20","2021-12-20","2018-12-21",[8957],[20965],{"trials":20981,"activeCount":109},[],{"trials":20983,"activeCount":109},[],{"trials":20985,"activeCount":109},[],{"trials":20987,"activeCount":109},[],{"intervention":20989,"totalTrials":708,"cells":20990},"KN026 combined with KN046",{"EARLY_PHASE1":20991,"PHASE1":20993,"PHASE2":21004,"PHASE3":21006,"PHASE4":21008,"NA":21010},{"trials":20992,"activeCount":109},[],{"trials":20994,"activeCount":109},[20995],{"nctId":20996,"briefTitle":20997,"status":135,"phases":20998,"primaryCompletion":20999,"completion":71,"start":21000,"enrollment":536,"conditions":21001,"interventions":21003},"NCT04040699","KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor",[98],"2022-09-22","2019-09-26",[21002],"HER2 Positive Solid Tumor",[20989],{"trials":21005,"activeCount":109},[],{"trials":21007,"activeCount":109},[],{"trials":21009,"activeCount":109},[],{"trials":21011,"activeCount":109},[],{"intervention":21013,"totalTrials":708,"cells":21014},"LILRB4 STAR-T cells",{"EARLY_PHASE1":21015,"PHASE1":21017,"PHASE2":21028,"PHASE3":21030,"PHASE4":21032,"NA":21034},{"trials":21016,"activeCount":109},[],{"trials":21018,"activeCount":109},[21019],{"nctId":21020,"briefTitle":21021,"status":135,"phases":21022,"primaryCompletion":21023,"completion":21023,"start":21024,"enrollment":4065,"conditions":21025,"interventions":21027},"NCT05548088","LILRB4 STAR-T Cells in the Treatment of R\u002FR AML\u002FCMML",[98],"2024-08-03","2023-05-25",[21026],"Relapsed\u002FRefractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia",[21013],{"trials":21029,"activeCount":109},[],{"trials":21031,"activeCount":109},[],{"trials":21033,"activeCount":109},[],{"trials":21035,"activeCount":109},[],{"intervention":21037,"totalTrials":708,"cells":21038},"HAIC combined with intravenous PD-1",{"EARLY_PHASE1":21039,"PHASE1":21041,"PHASE2":21050,"PHASE3":21052,"PHASE4":21054,"NA":21056},{"trials":21040,"activeCount":109},[],{"trials":21042,"activeCount":109},[21043],{"nctId":21044,"briefTitle":21045,"status":135,"phases":21046,"primaryCompletion":20544,"completion":71,"start":21047,"enrollment":4662,"conditions":21048,"interventions":21049},"NCT06184841","HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma",[98],"2020-06-18",[4919,4174,1250],[21037],{"trials":21051,"activeCount":109},[],{"trials":21053,"activeCount":109},[],{"trials":21055,"activeCount":109},[],{"trials":21057,"activeCount":109},[],{"intervention":21059,"totalTrials":708,"cells":21060},"OrienX010 Combination with Toripalimab",{"EARLY_PHASE1":21061,"PHASE1":21063,"PHASE2":21074,"PHASE3":21076,"PHASE4":21078,"NA":21080},{"trials":21062,"activeCount":109},[],{"trials":21064,"activeCount":109},[21065],{"nctId":21066,"briefTitle":21067,"status":569,"phases":21068,"primaryCompletion":21069,"completion":21070,"start":21071,"enrollment":13721,"conditions":21072,"interventions":21073},"NCT04197882","Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma",[98],"2021-05-27","2025-05-27","2019-05-27",[2580],[21059],{"trials":21075,"activeCount":109},[],{"trials":21077,"activeCount":109},[],{"trials":21079,"activeCount":109},[],{"trials":21081,"activeCount":109},[],{"intervention":21083,"totalTrials":708,"cells":21084},"autologous peripheral blood mesenchymal stem cell",{"EARLY_PHASE1":21085,"PHASE1":21087,"PHASE2":21097,"PHASE3":21099,"PHASE4":21101,"NA":21103},{"trials":21086,"activeCount":109},[],{"trials":21088,"activeCount":109},[21089],{"nctId":21090,"briefTitle":21091,"status":569,"phases":21092,"primaryCompletion":81,"completion":81,"start":4201,"enrollment":1445,"conditions":21093,"interventions":21095},"NCT04953572","Treatment of Cartilage Defects With Peripheral Blood Stem Cells",[98],[21094],"Cartilage Injury",[21083,21096],"Microfracture + collagen membrane",{"trials":21098,"activeCount":109},[],{"trials":21100,"activeCount":109},[],{"trials":21102,"activeCount":109},[],{"trials":21104,"activeCount":109},[],{"intervention":21096,"totalTrials":708,"cells":21106},{"EARLY_PHASE1":21107,"PHASE1":21109,"PHASE2":21115,"PHASE3":21117,"PHASE4":21119,"NA":21121},{"trials":21108,"activeCount":109},[],{"trials":21110,"activeCount":109},[21111],{"nctId":21090,"briefTitle":21091,"status":569,"phases":21112,"primaryCompletion":81,"completion":81,"start":4201,"enrollment":1445,"conditions":21113,"interventions":21114},[98],[21094],[21083,21096],{"trials":21116,"activeCount":109},[],{"trials":21118,"activeCount":109},[],{"trials":21120,"activeCount":109},[],{"trials":21122,"activeCount":109},[],{"intervention":21124,"totalTrials":708,"cells":21125},"CT0181 Cells",{"EARLY_PHASE1":21126,"PHASE1":21128,"PHASE2":21138,"PHASE3":21140,"PHASE4":21142,"NA":21144},{"trials":21127,"activeCount":109},[],{"trials":21129,"activeCount":109},[21130],{"nctId":21131,"briefTitle":21132,"status":569,"phases":21133,"primaryCompletion":17607,"completion":6514,"start":21134,"enrollment":1456,"conditions":21135,"interventions":21137},"NCT04973098","Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma",[98],"2021-08-05",[21136],"Advanced Hepatocellular Carcinoma",[21124],{"trials":21139,"activeCount":109},[],{"trials":21141,"activeCount":109},[],{"trials":21143,"activeCount":109},[],{"trials":21145,"activeCount":109},[],{"intervention":21147,"totalTrials":708,"cells":21148},"chemotherapy combined with NK cells",{"EARLY_PHASE1":21149,"PHASE1":21151,"PHASE2":21159,"PHASE3":21161,"PHASE4":21163,"NA":21165},{"trials":21150,"activeCount":109},[],{"trials":21152,"activeCount":109},[21153],{"nctId":21154,"briefTitle":21155,"status":569,"phases":21156,"primaryCompletion":2588,"completion":4660,"start":4170,"enrollment":477,"conditions":21157,"interventions":21158},"NCT04221971","NK Cell Infusion for Patients With Acute Myeloid Leukemia",[98],[2958],[21147],{"trials":21160,"activeCount":109},[],{"trials":21162,"activeCount":109},[],{"trials":21164,"activeCount":109},[],{"trials":21166,"activeCount":109},[],{"intervention":21168,"totalTrials":708,"cells":21169},"NKT cells",{"EARLY_PHASE1":21170,"PHASE1":21172,"PHASE2":21180,"PHASE3":21182,"PHASE4":21184,"NA":21186},{"trials":21171,"activeCount":109},[],{"trials":21173,"activeCount":109},[21174],{"nctId":21175,"briefTitle":21176,"status":569,"phases":21177,"primaryCompletion":4126,"completion":19151,"start":2883,"enrollment":47,"conditions":21178,"interventions":21179},"NCT02619058","A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients",[98],[2580],[21168],{"trials":21181,"activeCount":109},[],{"trials":21183,"activeCount":109},[],{"trials":21185,"activeCount":109},[],{"trials":21187,"activeCount":109},[],{"intervention":21189,"totalTrials":708,"cells":21190},"iPD1 CD19 eCAR T cells",{"EARLY_PHASE1":21191,"PHASE1":21193,"PHASE2":21204,"PHASE3":21206,"PHASE4":21208,"NA":21210},{"trials":21192,"activeCount":109},[],{"trials":21194,"activeCount":109},[21195],{"nctId":21196,"briefTitle":21197,"status":569,"phases":21198,"primaryCompletion":14154,"completion":16091,"start":21199,"enrollment":47,"conditions":21200,"interventions":21202},"NCT03208556","Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma",[98],"2017-06-21",[21201],"Relapsed or Refractory B-cell Lymphoma",[21189,21203],"Fludarabine and cyclophosphamide",{"trials":21205,"activeCount":109},[],{"trials":21207,"activeCount":109},[],{"trials":21209,"activeCount":109},[],{"trials":21211,"activeCount":109},[],{"intervention":21203,"totalTrials":708,"cells":21213},{"EARLY_PHASE1":21214,"PHASE1":21216,"PHASE2":21222,"PHASE3":21224,"PHASE4":21226,"NA":21228},{"trials":21215,"activeCount":109},[],{"trials":21217,"activeCount":109},[21218],{"nctId":21196,"briefTitle":21197,"status":569,"phases":21219,"primaryCompletion":14154,"completion":16091,"start":21199,"enrollment":47,"conditions":21220,"interventions":21221},[98],[21201],[21189,21203],{"trials":21223,"activeCount":109},[],{"trials":21225,"activeCount":109},[],{"trials":21227,"activeCount":109},[],{"trials":21229,"activeCount":109},[],{"intervention":21231,"totalTrials":708,"cells":21232},"Human Dental Pulp Stem Cells",{"EARLY_PHASE1":21233,"PHASE1":21235,"PHASE2":21244,"PHASE3":21246,"PHASE4":21248,"NA":21250},{"trials":21234,"activeCount":109},[],{"trials":21236,"activeCount":109},[21237],{"nctId":21238,"briefTitle":21239,"status":569,"phases":21240,"primaryCompletion":16865,"completion":21241,"start":16864,"enrollment":8489,"conditions":21242,"interventions":21243},"NCT04983225","The Safety and Tolerability of Initial Periodontal Therapy Combined With Human Dental Pulp Stem Cell Injection in the Treatment of Chronic Periodontitis",[98],"2024-08-31",[6130],[21231],{"trials":21245,"activeCount":109},[],{"trials":21247,"activeCount":109},[],{"trials":21249,"activeCount":109},[],{"trials":21251,"activeCount":109},[],{"intervention":21253,"totalTrials":708,"cells":21254},"MC-19PD1 CAR-T cells",{"EARLY_PHASE1":21255,"PHASE1":21257,"PHASE2":21266,"PHASE3":21268,"PHASE4":21270,"NA":21272},{"trials":21256,"activeCount":109},[],{"trials":21258,"activeCount":109},[21259],{"nctId":21260,"briefTitle":21261,"status":569,"phases":21262,"primaryCompletion":21263,"completion":21263,"start":16076,"enrollment":2770,"conditions":21264,"interventions":21265},"NCT03932955","MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma",[98],"2021-05-01",[11636],[21253],{"trials":21267,"activeCount":109},[],{"trials":21269,"activeCount":109},[],{"trials":21271,"activeCount":109},[],{"trials":21273,"activeCount":109},[],{"intervention":21275,"totalTrials":708,"cells":21276},"OrienX010 combination with JS001",{"EARLY_PHASE1":21277,"PHASE1":21279,"PHASE2":21289,"PHASE3":21291,"PHASE4":21293,"NA":21295},{"trials":21278,"activeCount":109},[],{"trials":21280,"activeCount":109},[21281],{"nctId":21282,"briefTitle":21283,"status":569,"phases":21284,"primaryCompletion":21285,"completion":81,"start":21286,"enrollment":1767,"conditions":21287,"interventions":21288},"NCT04206358","Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma",[98],"2021-02-27","2019-05-13",[2580],[21275],{"trials":21290,"activeCount":109},[],{"trials":21292,"activeCount":109},[],{"trials":21294,"activeCount":109},[],{"trials":21296,"activeCount":109},[],{"intervention":21298,"totalTrials":708,"cells":21299},"CapulinTM",{"EARLY_PHASE1":21300,"PHASE1":21302,"PHASE2":21311,"PHASE3":21313,"PHASE4":21315,"NA":21317},{"trials":21301,"activeCount":109},[],{"trials":21303,"activeCount":109},[21304],{"nctId":21305,"briefTitle":21306,"status":135,"phases":21307,"primaryCompletion":2789,"completion":21308,"start":13459,"enrollment":1767,"conditions":21309,"interventions":21310},"NCT03973073","Effects of Combination Therapy With Camouflage in the Repigmentation of Vitiligo",[98],"2019-11-21",[12024],[21298],{"trials":21312,"activeCount":109},[],{"trials":21314,"activeCount":109},[],{"trials":21316,"activeCount":109},[],{"trials":21318,"activeCount":109},[],{"intervention":21320,"totalTrials":708,"cells":21321},"Claudin18.2-Targeted Chimeric Antigen Receptor T Cell",{"EARLY_PHASE1":21322,"PHASE1":21324,"PHASE2":21334,"PHASE3":21336,"PHASE4":21338,"NA":21340},{"trials":21323,"activeCount":109},[],{"trials":21325,"activeCount":109},[21326],{"nctId":21327,"briefTitle":21328,"status":569,"phases":21329,"primaryCompletion":21330,"completion":21330,"start":21331,"enrollment":2509,"conditions":21332,"interventions":21333},"NCT06353152","Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric\u002FGastroesophageal Junction Adenocarcinoma",[98],"2025-11-16","2023-11-17",[4705,8822],[21320],{"trials":21335,"activeCount":109},[],{"trials":21337,"activeCount":109},[],{"trials":21339,"activeCount":109},[],{"trials":21341,"activeCount":109},[],{"intervention":21343,"totalTrials":708,"cells":21344},"ScTIL",{"EARLY_PHASE1":21345,"PHASE1":21347,"PHASE2":21357,"PHASE3":21359,"PHASE4":21361,"NA":21363},{"trials":21346,"activeCount":109},[],{"trials":21348,"activeCount":109},[21349],{"nctId":21350,"briefTitle":21351,"status":569,"phases":21352,"primaryCompletion":6221,"completion":3327,"start":8261,"enrollment":536,"conditions":21353,"interventions":21355},"NCT05730361","Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors",[98],[21354],"Digestive System Malignant Solid Tumors",[21343,21356],"ScTIL injection and B lymphocytes adjuvant",{"trials":21358,"activeCount":109},[],{"trials":21360,"activeCount":109},[],{"trials":21362,"activeCount":109},[],{"trials":21364,"activeCount":109},[],{"intervention":21356,"totalTrials":708,"cells":21366},{"EARLY_PHASE1":21367,"PHASE1":21369,"PHASE2":21375,"PHASE3":21377,"PHASE4":21379,"NA":21381},{"trials":21368,"activeCount":109},[],{"trials":21370,"activeCount":109},[21371],{"nctId":21350,"briefTitle":21351,"status":569,"phases":21372,"primaryCompletion":6221,"completion":3327,"start":8261,"enrollment":536,"conditions":21373,"interventions":21374},[98],[21354],[21343,21356],{"trials":21376,"activeCount":109},[],{"trials":21378,"activeCount":109},[],{"trials":21380,"activeCount":109},[],{"trials":21382,"activeCount":109},[],{"intervention":21384,"totalTrials":708,"cells":21385},"Experimental: Food effect group",{"EARLY_PHASE1":21386,"PHASE1":21388,"PHASE2":21402,"PHASE3":21404,"PHASE4":21406,"NA":21408},{"trials":21387,"activeCount":109},[],{"trials":21389,"activeCount":109},[21390],{"nctId":21391,"briefTitle":21392,"status":135,"phases":21393,"primaryCompletion":21394,"completion":21395,"start":3970,"enrollment":21396,"conditions":21397,"interventions":21400},"NCT07618351","A Phase I SAD\u002FMAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .",[98],"2025-01-23","2026-03-12",627,[21398,21399],"Thrombosis","Cardiovascular Diseases",[21384,21401],"Active Comparator: Multiple dose group",{"trials":21403,"activeCount":109},[],{"trials":21405,"activeCount":109},[],{"trials":21407,"activeCount":109},[],{"trials":21409,"activeCount":109},[],{"intervention":21401,"totalTrials":708,"cells":21411},{"EARLY_PHASE1":21412,"PHASE1":21414,"PHASE2":21420,"PHASE3":21422,"PHASE4":21424,"NA":21426},{"trials":21413,"activeCount":109},[],{"trials":21415,"activeCount":109},[21416],{"nctId":21391,"briefTitle":21392,"status":135,"phases":21417,"primaryCompletion":21394,"completion":21395,"start":3970,"enrollment":21396,"conditions":21418,"interventions":21419},[98],[21398,21399],[21384,21401],{"trials":21421,"activeCount":109},[],{"trials":21423,"activeCount":109},[],{"trials":21425,"activeCount":109},[],{"trials":21427,"activeCount":109},[],{"intervention":21429,"totalTrials":708,"cells":21430},"LCAR-G08 cells",{"EARLY_PHASE1":21431,"PHASE1":21433,"PHASE2":21444,"PHASE3":21446,"PHASE4":21448,"NA":21450},{"trials":21432,"activeCount":109},[],{"trials":21434,"activeCount":109},[21435],{"nctId":21436,"briefTitle":21437,"status":200,"phases":21438,"primaryCompletion":13182,"completion":13182,"start":21439,"enrollment":21440,"conditions":21441,"interventions":21443},"NCT06197178","A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)",[98],"2023-12-28",17,[21442],"Advanced Gastrointestinal Tumors",[21429],{"trials":21445,"activeCount":109},[],{"trials":21447,"activeCount":109},[],{"trials":21449,"activeCount":109},[],{"trials":21451,"activeCount":109},[],{"intervention":9947,"totalTrials":708,"cells":21453},{"EARLY_PHASE1":21454,"PHASE1":21456,"PHASE2":21462,"PHASE3":21464,"PHASE4":21466,"NA":21468},{"trials":21455,"activeCount":109},[],{"trials":21457,"activeCount":109},[21458],{"nctId":9938,"briefTitle":9939,"status":135,"phases":21459,"primaryCompletion":9941,"completion":9942,"start":9943,"enrollment":9944,"conditions":21460,"interventions":21461},[98],[9156],[9947,9948,5066],{"trials":21463,"activeCount":109},[],{"trials":21465,"activeCount":109},[],{"trials":21467,"activeCount":109},[],{"trials":21469,"activeCount":109},[],{"intervention":21471,"totalTrials":708,"cells":21472},"SHR6390",{"EARLY_PHASE1":21473,"PHASE1":21475,"PHASE2":21484,"PHASE3":21486,"PHASE4":21488,"NA":21490},{"trials":21474,"activeCount":109},[],{"trials":21476,"activeCount":109},[21477],{"nctId":21478,"briefTitle":21479,"status":569,"phases":21480,"primaryCompletion":4755,"completion":8352,"start":21481,"enrollment":32,"conditions":21482,"interventions":21483},"NCT03480256","Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer",[98],"2018-07-27",[28],[21471],{"trials":21485,"activeCount":109},[],{"trials":21487,"activeCount":109},[],{"trials":21489,"activeCount":109},[],{"trials":21491,"activeCount":109},[],{"intervention":21493,"totalTrials":708,"cells":21494},"CD19\u002FCD20-directed Chimeric Antigen Receptor T Cells",{"EARLY_PHASE1":21495,"PHASE1":21497,"PHASE2":21507,"PHASE3":21509,"PHASE4":21511,"NA":21513},{"trials":21496,"activeCount":109},[],{"trials":21498,"activeCount":109},[21499],{"nctId":21500,"briefTitle":21501,"status":135,"phases":21502,"primaryCompletion":7157,"completion":350,"start":21503,"enrollment":329,"conditions":21504,"interventions":21506},"NCT05149391","A Study of C-CAR039 in Subjects With Relapsed and\u002For Refractory B Cell Non-Hodgkin's Lymphoma",[98],"2021-07-20",[21505],"B Cell Non-Hodgkin's Lymphoma",[21493],{"trials":21508,"activeCount":109},[],{"trials":21510,"activeCount":109},[],{"trials":21512,"activeCount":109},[],{"trials":21514,"activeCount":109},[],{"intervention":21516,"totalTrials":708,"cells":21517},"Urinary Microbiota Transplantation",{"EARLY_PHASE1":21518,"PHASE1":21520,"PHASE2":21532,"PHASE3":21534,"PHASE4":21536,"NA":21538},{"trials":21519,"activeCount":109},[],{"trials":21521,"activeCount":109},[21522],{"nctId":21523,"briefTitle":21524,"status":135,"phases":21525,"primaryCompletion":637,"completion":21526,"start":5063,"enrollment":3566,"conditions":21527,"interventions":21530},"NCT07530627","Efficacy of UMT in CG Patients With PL",[98],"2026-02-28",[21528,21529],"Pelvic Lipomatosis","Cystitis Glandularis",[21516,21531],"0.9% Sodium Chloride",{"trials":21533,"activeCount":109},[],{"trials":21535,"activeCount":109},[],{"trials":21537,"activeCount":109},[],{"trials":21539,"activeCount":109},[],{"intervention":21541,"totalTrials":708,"cells":21542},"RC48-ADC in combinaton with JS001",{"EARLY_PHASE1":21543,"PHASE1":21545,"PHASE2":21555,"PHASE3":21557,"PHASE4":21559,"NA":21561},{"trials":21544,"activeCount":109},[],{"trials":21546,"activeCount":109},[21547],{"nctId":21548,"briefTitle":21549,"status":569,"phases":21550,"primaryCompletion":2930,"completion":2930,"start":21551,"enrollment":728,"conditions":21552,"interventions":21554},"NCT04280341","JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors",[98],"2020-06-03",[21553],"HER2-Positive Solid Tumors",[21541],{"trials":21556,"activeCount":109},[],{"trials":21558,"activeCount":109},[],{"trials":21560,"activeCount":109},[],{"trials":21562,"activeCount":109},[],{"intervention":21564,"totalTrials":708,"cells":21565},"UCLM802 Cell",{"EARLY_PHASE1":21566,"PHASE1":21568,"PHASE2":21576,"PHASE3":21578,"PHASE4":21580,"NA":21582},{"trials":21567,"activeCount":109},[],{"trials":21569,"activeCount":109},[21570],{"nctId":21571,"briefTitle":21572,"status":569,"phases":21573,"primaryCompletion":6221,"completion":6151,"start":11176,"enrollment":4127,"conditions":21574,"interventions":21575},"NCT05775666","UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors",[98],[8957],[21564],{"trials":21577,"activeCount":109},[],{"trials":21579,"activeCount":109},[],{"trials":21581,"activeCount":109},[],{"trials":21583,"activeCount":109},[],{"intervention":21585,"totalTrials":708,"cells":21586},"MSLN STAR-T cells",{"EARLY_PHASE1":21587,"PHASE1":21589,"PHASE2":21598,"PHASE3":21600,"PHASE4":21602,"NA":21604},{"trials":21588,"activeCount":109},[],{"trials":21590,"activeCount":109},[21591],{"nctId":21592,"briefTitle":21593,"status":569,"phases":21594,"primaryCompletion":15474,"completion":1780,"start":21595,"enrollment":2509,"conditions":21596,"interventions":21597},"NCT05344976","MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors",[98],"2022-04-14",[],[21585],{"trials":21599,"activeCount":109},[],{"trials":21601,"activeCount":109},[],{"trials":21603,"activeCount":109},[],{"trials":21605,"activeCount":109},[],{"intervention":8240,"totalTrials":708,"cells":21607},{"EARLY_PHASE1":21608,"PHASE1":21610,"PHASE2":21616,"PHASE3":21618,"PHASE4":21620,"NA":21622},{"trials":21609,"activeCount":109},[],{"trials":21611,"activeCount":109},[21612],{"nctId":8234,"briefTitle":8235,"status":569,"phases":21613,"primaryCompletion":4670,"completion":4125,"start":5437,"enrollment":1767,"conditions":21614,"interventions":21615},[98],[8238],[2537,8240],{"trials":21617,"activeCount":109},[],{"trials":21619,"activeCount":109},[],{"trials":21621,"activeCount":109},[],{"trials":21623,"activeCount":109},[],{"intervention":21625,"totalTrials":708,"cells":21626},"GPC3-CAR-T cells",{"EARLY_PHASE1":21627,"PHASE1":21629,"PHASE2":21637,"PHASE3":21639,"PHASE4":21641,"NA":21643},{"trials":21628,"activeCount":109},[],{"trials":21630,"activeCount":109},[21631],{"nctId":21632,"briefTitle":21633,"status":569,"phases":21634,"primaryCompletion":15474,"completion":5063,"start":21595,"enrollment":2509,"conditions":21635,"interventions":21636},"NCT05344664","Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma",[98],[],[21625],{"trials":21638,"activeCount":109},[],{"trials":21640,"activeCount":109},[],{"trials":21642,"activeCount":109},[],{"trials":21644,"activeCount":109},[],{"intervention":21646,"totalTrials":708,"cells":21647},"autologous anti-CD19 CAR T cells",{"EARLY_PHASE1":21648,"PHASE1":21650,"PHASE2":21660,"PHASE3":21662,"PHASE4":21664,"NA":21666},{"trials":21649,"activeCount":109},[],{"trials":21651,"activeCount":109},[21652],{"nctId":21653,"briefTitle":21654,"status":569,"phases":21655,"primaryCompletion":21656,"completion":21657,"start":138,"enrollment":4662,"conditions":21658,"interventions":21659},"NCT02842138","Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma",[98],"2018-02-28","2019-08",[8449],[21646],{"trials":21661,"activeCount":109},[],{"trials":21663,"activeCount":109},[],{"trials":21665,"activeCount":109},[],{"trials":21667,"activeCount":109},[],{"intervention":21669,"totalTrials":708,"cells":21670},"FMT",{"EARLY_PHASE1":21671,"PHASE1":21673,"PHASE2":21684,"PHASE3":21686,"PHASE4":21688,"NA":21690},{"trials":21672,"activeCount":109},[],{"trials":21674,"activeCount":109},[21675],{"nctId":21676,"briefTitle":21677,"status":135,"phases":21678,"primaryCompletion":10439,"completion":21679,"start":21680,"enrollment":477,"conditions":21681,"interventions":21683},"NCT04130763","Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1",[98],"2024-01-29","2019-12-05",[21682],"Gastrointestinal System Cancer",[21669],{"trials":21685,"activeCount":109},[],{"trials":21687,"activeCount":109},[],{"trials":21689,"activeCount":109},[],{"trials":21691,"activeCount":109},[],{"intervention":21693,"totalTrials":708,"cells":21694},"AZD6422 CLDN18.2 CAR-T product",{"EARLY_PHASE1":21695,"PHASE1":21697,"PHASE2":21708,"PHASE3":21710,"PHASE4":21712,"NA":21714},{"trials":21696,"activeCount":109},[],{"trials":21698,"activeCount":109},[21699],{"nctId":21700,"briefTitle":21701,"status":135,"phases":21702,"primaryCompletion":21703,"completion":21703,"start":21704,"enrollment":3642,"conditions":21705,"interventions":21707},"NCT05981235","Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors",[98],"2025-06-25","2023-12-14",[21706],"Gastrointestinal Tumors",[21693],{"trials":21709,"activeCount":109},[],{"trials":21711,"activeCount":109},[],{"trials":21713,"activeCount":109},[],{"trials":21715,"activeCount":109},[],{"intervention":17252,"totalTrials":708,"cells":21717},{"EARLY_PHASE1":21718,"PHASE1":21720,"PHASE2":21726,"PHASE3":21728,"PHASE4":21730,"NA":21732},{"trials":21719,"activeCount":109},[],{"trials":21721,"activeCount":109},[21722],{"nctId":17246,"briefTitle":17247,"status":569,"phases":21723,"primaryCompletion":66,"completion":66,"start":5612,"enrollment":728,"conditions":21724,"interventions":21725},[98],[17250],[17252,3936],{"trials":21727,"activeCount":109},[],{"trials":21729,"activeCount":109},[],{"trials":21731,"activeCount":109},[],{"trials":21733,"activeCount":109},[],{"intervention":21735,"totalTrials":708,"cells":21736},"UTAA06 injection for treatment of advanced malignant solid tumors",{"EARLY_PHASE1":21737,"PHASE1":21739,"PHASE2":21749,"PHASE3":21751,"PHASE4":21753,"NA":21755},{"trials":21738,"activeCount":109},[],{"trials":21740,"activeCount":109},[21741],{"nctId":21742,"briefTitle":21743,"status":135,"phases":21744,"primaryCompletion":21745,"completion":21745,"start":5546,"enrollment":477,"conditions":21746,"interventions":21748},"NCT06372236","UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors",[98],"2025-05-08",[21747],"Conditions or Focus of Study: B7-H3 Positive Relapsed\u002FAdvanced Malignant Solid Tumor",[21735],{"trials":21750,"activeCount":109},[],{"trials":21752,"activeCount":109},[],{"trials":21754,"activeCount":109},[],{"trials":21756,"activeCount":109},[],{"intervention":21758,"totalTrials":708,"cells":21759},"melphalan hydrochloride for",{"EARLY_PHASE1":21760,"PHASE1":21762,"PHASE2":21771,"PHASE3":21773,"PHASE4":21775,"NA":21777},{"trials":21761,"activeCount":109},[],{"trials":21763,"activeCount":109},[21764],{"nctId":21765,"briefTitle":21766,"status":569,"phases":21767,"primaryCompletion":81,"completion":81,"start":21768,"enrollment":38,"conditions":21769,"interventions":21770},"NCT05438394","Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R\u002FR MM",[98],"2022-10-13",[5130],[21758],{"trials":21772,"activeCount":109},[],{"trials":21774,"activeCount":109},[],{"trials":21776,"activeCount":109},[],{"trials":21778,"activeCount":109},[],{"intervention":21780,"totalTrials":708,"cells":21781},"6B11-OCIK",{"EARLY_PHASE1":21782,"PHASE1":21784,"PHASE2":21795,"PHASE3":21797,"PHASE4":21799,"NA":21801},{"trials":21783,"activeCount":109},[],{"trials":21785,"activeCount":109},[21786],{"nctId":21787,"briefTitle":21788,"status":569,"phases":21789,"primaryCompletion":3900,"completion":1404,"start":21790,"enrollment":3887,"conditions":21791,"interventions":21794},"NCT03542669","Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer",[98],"2018-08-03",[21792,21793],"Recurrent Ovarian Carcinoma","Platinum-resistant Ovarian Cancer",[21780,1120],{"trials":21796,"activeCount":109},[],{"trials":21798,"activeCount":109},[],{"trials":21800,"activeCount":109},[],{"trials":21802,"activeCount":109},[],{"intervention":21804,"totalTrials":708,"cells":21805},"Cell",{"EARLY_PHASE1":21806,"PHASE1":21814,"PHASE2":21816,"PHASE3":21818,"PHASE4":21820,"NA":21822},{"trials":21807,"activeCount":109},[21808],{"nctId":21809,"briefTitle":21810,"status":569,"phases":21811,"primaryCompletion":9279,"completion":4737,"start":2844,"enrollment":8489,"conditions":21812,"interventions":21813},"NCT05284968","RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors",[97],[8957],[21804],{"trials":21815,"activeCount":109},[],{"trials":21817,"activeCount":109},[],{"trials":21819,"activeCount":109},[],{"trials":21821,"activeCount":109},[],{"trials":21823,"activeCount":109},[],{"intervention":21825,"totalTrials":708,"cells":21826},"ZVS101e",{"EARLY_PHASE1":21827,"PHASE1":21837,"PHASE2":21839,"PHASE3":21841,"PHASE4":21843,"NA":21845},{"trials":21828,"activeCount":109},[21829],{"nctId":21830,"briefTitle":21831,"status":569,"phases":21832,"primaryCompletion":7971,"completion":7971,"start":21833,"enrollment":553,"conditions":21834,"interventions":21836},"NCT05714904","Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy",[97],"2022-09-23",[21835],"Bietti's Crystalline Dystrophy",[21825],{"trials":21838,"activeCount":109},[],{"trials":21840,"activeCount":109},[],{"trials":21842,"activeCount":109},[],{"trials":21844,"activeCount":109},[],{"trials":21846,"activeCount":109},[],{"intervention":21848,"totalTrials":708,"cells":21849},"CD147- CAR T cells",{"EARLY_PHASE1":21850,"PHASE1":21859,"PHASE2":21861,"PHASE3":21863,"PHASE4":21865,"NA":21867},{"trials":21851,"activeCount":109},[21852],{"nctId":21853,"briefTitle":21854,"status":569,"phases":21855,"primaryCompletion":4308,"completion":773,"start":3679,"enrollment":2509,"conditions":21856,"interventions":21858},"NCT05013372","CD147-CAR T Cells for Relapsed\u002FRefractory T Cell Non-Hodgkin's Lymphoma",[97],[21857],"T-cell Non-Hodgkin's Lymphoma",[21848],{"trials":21860,"activeCount":109},[],{"trials":21862,"activeCount":109},[],{"trials":21864,"activeCount":109},[],{"trials":21866,"activeCount":109},[],{"trials":21868,"activeCount":109},[],{"intervention":21870,"totalTrials":708,"cells":21871},"ZVS203e",{"EARLY_PHASE1":21872,"PHASE1":21881,"PHASE2":21883,"PHASE3":21885,"PHASE4":21887,"NA":21889},{"trials":21873,"activeCount":109},[21874],{"nctId":21875,"briefTitle":21876,"status":569,"phases":21877,"primaryCompletion":805,"completion":805,"start":414,"enrollment":3887,"conditions":21878,"interventions":21880},"NCT05805007","Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa",[97],[21879],"Retinitis Pigmentosa",[21870],{"trials":21882,"activeCount":109},[],{"trials":21884,"activeCount":109},[],{"trials":21886,"activeCount":109},[],{"trials":21888,"activeCount":109},[],{"trials":21890,"activeCount":109},[],{"intervention":21892,"totalTrials":708,"cells":21893},"[68Ga] MDM2\u002FMDMX Peptide",{"EARLY_PHASE1":21894,"PHASE1":21906,"PHASE2":21908,"PHASE3":21910,"PHASE4":21912,"NA":21914},{"trials":21895,"activeCount":109},[21896],{"nctId":21897,"briefTitle":21898,"status":135,"phases":21899,"primaryCompletion":228,"completion":1617,"start":21900,"enrollment":329,"conditions":21901,"interventions":21905},"NCT06443762","First Human Trial of Targeting MDM2\u002FMDMX PET Imaging",[97],"2025-01-03",[21902,21903,21904],"MDM2\u002FMDMX Gene Mutation","Nuclear Medicine","Positron Emission Tomography Imaing",[21892],{"trials":21907,"activeCount":109},[],{"trials":21909,"activeCount":109},[],{"trials":21911,"activeCount":109},[],{"trials":21913,"activeCount":109},[],{"trials":21915,"activeCount":109},[],{"intervention":16080,"totalTrials":708,"cells":21917},{"EARLY_PHASE1":21918,"PHASE1":21924,"PHASE2":21926,"PHASE3":21928,"PHASE4":21930,"NA":21932},{"trials":21919,"activeCount":109},[21920],{"nctId":16073,"briefTitle":16074,"status":135,"phases":21921,"primaryCompletion":16076,"completion":16076,"start":10296,"enrollment":47,"conditions":21922,"interventions":21923},[97],[16078],[16080,16068],{"trials":21925,"activeCount":109},[],{"trials":21927,"activeCount":109},[],{"trials":21929,"activeCount":109},[],{"trials":21931,"activeCount":109},[],{"trials":21933,"activeCount":109},[],{"intervention":21935,"totalTrials":708,"cells":21936},"treatment of drug screening",{"EARLY_PHASE1":21937,"PHASE1":21946,"PHASE2":21948,"PHASE3":21950,"PHASE4":21952,"NA":21954},{"trials":21938,"activeCount":109},[21939],{"nctId":21940,"briefTitle":21941,"status":569,"phases":21942,"primaryCompletion":1163,"completion":1163,"start":15411,"enrollment":168,"conditions":21943,"interventions":21945},"NCT04130750","Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physician's Choice",[97],[31,16028,21944],"Drug Effect",[21935],{"trials":21947,"activeCount":109},[],{"trials":21949,"activeCount":109},[],{"trials":21951,"activeCount":109},[],{"trials":21953,"activeCount":109},[],{"trials":21955,"activeCount":109},[],{"intervention":21957,"totalTrials":708,"cells":21958},"99mTc-RWY",{"EARLY_PHASE1":21959,"PHASE1":21968,"PHASE2":21970,"PHASE3":21972,"PHASE4":21974,"NA":21976},{"trials":21960,"activeCount":109},[21961],{"nctId":21962,"briefTitle":21963,"status":135,"phases":21964,"primaryCompletion":14154,"completion":958,"start":21965,"enrollment":3887,"conditions":21966,"interventions":21967},"NCT04289532","Integrin α6-targeted SPECT Imaging of Breast Cancer",[97],"2018-03-08",[31],[21957],{"trials":21969,"activeCount":109},[],{"trials":21971,"activeCount":109},[],{"trials":21973,"activeCount":109},[],{"trials":21975,"activeCount":109},[],{"trials":21977,"activeCount":109},[],{"intervention":172,"totalTrials":553,"cells":21979},{"EARLY_PHASE1":21980,"PHASE1":21982,"PHASE2":21984,"PHASE3":21986,"PHASE4":21988,"NA":22006},{"trials":21981,"activeCount":109},[],{"trials":21983,"activeCount":109},[],{"trials":21985,"activeCount":109},[],{"trials":21987,"activeCount":109},[],{"trials":21989,"activeCount":109},[21990,21994,21998,22002],{"nctId":162,"briefTitle":163,"status":135,"phases":21991,"primaryCompletion":165,"completion":166,"start":167,"enrollment":168,"conditions":21992,"interventions":21993},[101],[170],[25,172],{"nctId":262,"briefTitle":263,"status":135,"phases":21995,"primaryCompletion":265,"completion":266,"start":267,"enrollment":168,"conditions":21996,"interventions":21997},[101],[269,270,271,25,172],[271,25,172],{"nctId":360,"briefTitle":361,"status":135,"phases":21999,"primaryCompletion":363,"completion":363,"start":364,"enrollment":365,"conditions":22000,"interventions":22001},[101],[269,270,40,25,367],[40,25,172],{"nctId":814,"briefTitle":815,"status":135,"phases":22003,"primaryCompletion":817,"completion":818,"start":819,"enrollment":153,"conditions":22004,"interventions":22005},[101],[821],[172,823,824,825],{"trials":22007,"activeCount":109},[22008,22012],{"nctId":1486,"briefTitle":1487,"status":135,"phases":22009,"primaryCompletion":1489,"completion":1489,"start":1490,"enrollment":341,"conditions":22010,"interventions":22011},[102],[1492],[172,1494,1427],{"nctId":1412,"briefTitle":1413,"status":569,"phases":22013,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":29,"conditions":22014,"interventions":22015},[102],[1419,1420],[380,1422,1234,1423,1424,172,380,1234,1425,1424],{"intervention":8413,"totalTrials":1428,"cells":22017},{"EARLY_PHASE1":22018,"PHASE1":22020,"PHASE2":22030,"PHASE3":22038,"PHASE4":22040,"NA":22042},{"trials":22019,"activeCount":109},[],{"trials":22021,"activeCount":109},[22022,22026],{"nctId":8406,"briefTitle":8407,"status":435,"phases":22023,"primaryCompletion":8409,"completion":8409,"start":5343,"enrollment":109,"conditions":22024,"interventions":22025},[98],[3122],[8412,734,8413],{"nctId":8428,"briefTitle":8429,"status":435,"phases":22027,"primaryCompletion":8431,"completion":8431,"start":8432,"enrollment":109,"conditions":22028,"interventions":22029},[98],[8434],[8412,734,8413],{"trials":22031,"activeCount":109},[22032],{"nctId":22033,"briefTitle":22034,"status":569,"phases":22035,"primaryCompletion":1202,"completion":1215,"start":649,"enrollment":1456,"conditions":22036,"interventions":22037},"NCT04952155","Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome",[99],[16078],[8413],{"trials":22039,"activeCount":109},[],{"trials":22041,"activeCount":109},[],{"trials":22043,"activeCount":109},[22044,22052],{"nctId":22045,"briefTitle":22046,"status":569,"phases":22047,"primaryCompletion":5772,"completion":4651,"start":22048,"enrollment":1070,"conditions":22049,"interventions":22051},"NCT04136106","The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients",[],"2019-07-01",[22050],"Infection",[8413],{"nctId":8471,"briefTitle":8472,"status":435,"phases":22053,"primaryCompletion":8409,"completion":3594,"start":5343,"enrollment":109,"conditions":22054,"interventions":22055},[],[8475],[8412,734,8413],{"intervention":2706,"totalTrials":1428,"cells":22057},{"EARLY_PHASE1":22058,"PHASE1":22060,"PHASE2":22066,"PHASE3":22076,"PHASE4":22082,"NA":22084},{"trials":22059,"activeCount":109},[],{"trials":22061,"activeCount":109},[22062],{"nctId":17595,"briefTitle":17596,"status":569,"phases":22063,"primaryCompletion":1163,"completion":52,"start":17598,"enrollment":1767,"conditions":22064,"interventions":22065},[98],[34],[2706,17588],{"trials":22067,"activeCount":109},[22068,22072],{"nctId":17604,"briefTitle":17605,"status":569,"phases":22069,"primaryCompletion":13941,"completion":17607,"start":17598,"enrollment":574,"conditions":22070,"interventions":22071},[99],[34],[2706,17588],{"nctId":10310,"briefTitle":10311,"status":569,"phases":22073,"primaryCompletion":2051,"completion":637,"start":639,"enrollment":640,"conditions":22074,"interventions":22075},[99],[34],[643,2706],{"trials":22077,"activeCount":109},[22078],{"nctId":2697,"briefTitle":2698,"status":135,"phases":22079,"primaryCompletion":2700,"completion":2700,"start":2701,"enrollment":846,"conditions":22080,"interventions":22081},[100],[2703],[2705,2706],{"trials":22083,"activeCount":109},[],{"trials":22085,"activeCount":109},[22086],{"nctId":22087,"briefTitle":22088,"status":569,"phases":22089,"primaryCompletion":22090,"completion":2568,"start":649,"enrollment":376,"conditions":22091,"interventions":22092},"NCT04214951","A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia",[],"2022-08-01",[19130],[2706,22093],"Recombinant human thrombopoietin",{"intervention":1120,"totalTrials":405,"cells":22095},{"EARLY_PHASE1":22096,"PHASE1":22098,"PHASE2":22104,"PHASE3":22110,"PHASE4":22116,"NA":22118},{"trials":22097,"activeCount":109},[],{"trials":22099,"activeCount":109},[22100],{"nctId":21787,"briefTitle":21788,"status":569,"phases":22101,"primaryCompletion":3900,"completion":1404,"start":21790,"enrollment":3887,"conditions":22102,"interventions":22103},[98],[21792,21793],[21780,1120],{"trials":22105,"activeCount":109},[22106],{"nctId":1109,"briefTitle":1110,"status":569,"phases":22107,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":22108,"interventions":22109},[99],[1117],[1119,734,1120,1121,1122,1090],{"trials":22111,"activeCount":109},[22112],{"nctId":1146,"briefTitle":1147,"status":569,"phases":22113,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":22114,"interventions":22115},[100],[1153],[734,1155,1121,1090,1120],{"trials":22117,"activeCount":109},[],{"trials":22119,"activeCount":109},[22120],{"nctId":3631,"briefTitle":3632,"status":569,"phases":22121,"primaryCompletion":3634,"completion":3635,"start":3636,"enrollment":376,"conditions":22122,"interventions":22123},[102],[3638],[1120,1028,3640,2550],{"intervention":380,"totalTrials":405,"cells":22125},{"EARLY_PHASE1":22126,"PHASE1":22128,"PHASE2":22130,"PHASE3":22132,"PHASE4":22134,"NA":22148},{"trials":22127,"activeCount":109},[],{"trials":22129,"activeCount":109},[],{"trials":22131,"activeCount":109},[],{"trials":22133,"activeCount":109},[],{"trials":22135,"activeCount":109},[22136,22140,22144],{"nctId":1198,"briefTitle":1199,"status":135,"phases":22137,"primaryCompletion":1201,"completion":1202,"start":191,"enrollment":1203,"conditions":22138,"interventions":22139},[101],[539,380,779],[538,1206,380,779],{"nctId":530,"briefTitle":531,"status":135,"phases":22141,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":22142,"interventions":22143},[101],[506,538,539],[538,40,380],{"nctId":370,"briefTitle":371,"status":135,"phases":22145,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":22146,"interventions":22147},[101],[378,25],[25,380],{"trials":22149,"activeCount":109},[22150],{"nctId":1412,"briefTitle":1413,"status":569,"phases":22151,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":29,"conditions":22152,"interventions":22153},[102],[1419,1420],[380,1422,1234,1423,1424,172,380,1234,1425,1424],{"intervention":4911,"totalTrials":329,"cells":22155},{"EARLY_PHASE1":22156,"PHASE1":22158,"PHASE2":22160,"PHASE3":22170,"PHASE4":22172,"NA":22174},{"trials":22157,"activeCount":109},[],{"trials":22159,"activeCount":109},[],{"trials":22161,"activeCount":109},[22162],{"nctId":22163,"briefTitle":22164,"status":569,"phases":22165,"primaryCompletion":15298,"completion":22166,"start":278,"enrollment":3520,"conditions":22167,"interventions":22169},"NCT05406206","Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy",[99],"2024-10-31",[22168,13117],"Advanced Colorectal Carcinoma",[4911],{"trials":22171,"activeCount":109},[],{"trials":22173,"activeCount":109},[],{"trials":22175,"activeCount":109},[22176,22187],{"nctId":22177,"briefTitle":22178,"status":135,"phases":22179,"primaryCompletion":22180,"completion":13860,"start":22181,"enrollment":5554,"conditions":22182,"interventions":22186},"NCT06202599","Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance",[],"2023-08-29","2021-11-25",[22183,22184,22185],"Bone Sarcoma","Soft Tissue Sarcoma","Refractory Tumor",[4911],{"nctId":4904,"briefTitle":4905,"status":569,"phases":22188,"primaryCompletion":4201,"completion":4907,"start":4661,"enrollment":4908,"conditions":22189,"interventions":22190},[],[2692],[3713,4911],{"intervention":952,"totalTrials":329,"cells":22192},{"EARLY_PHASE1":22193,"PHASE1":22195,"PHASE2":22197,"PHASE3":22203,"PHASE4":22209,"NA":22211},{"trials":22194,"activeCount":109},[],{"trials":22196,"activeCount":109},[],{"trials":22198,"activeCount":109},[22199],{"nctId":940,"briefTitle":941,"status":569,"phases":22200,"primaryCompletion":604,"completion":943,"start":944,"enrollment":553,"conditions":22201,"interventions":22202},[98,99],[946,947,948],[931,950,951,952],{"trials":22204,"activeCount":109},[22205],{"nctId":16990,"briefTitle":16991,"status":200,"phases":22206,"primaryCompletion":1103,"completion":1103,"start":316,"enrollment":6539,"conditions":22207,"interventions":22208},[100],[16994],[16979,952],{"trials":22210,"activeCount":109},[],{"trials":22212,"activeCount":109},[22213],{"nctId":22214,"briefTitle":22215,"status":569,"phases":22216,"primaryCompletion":5352,"completion":315,"start":2853,"enrollment":4171,"conditions":22217,"interventions":22219},"NCT05629260","The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation",[],[22218],"Hematological Malignancy",[952,22220],"Post-transplantation cyclophosphamide",{"intervention":3640,"totalTrials":329,"cells":22222},{"EARLY_PHASE1":22223,"PHASE1":22225,"PHASE2":22227,"PHASE3":22242,"PHASE4":22244,"NA":22246},{"trials":22224,"activeCount":109},[],{"trials":22226,"activeCount":109},[],{"trials":22228,"activeCount":109},[22229,22236],{"nctId":22230,"briefTitle":22231,"status":569,"phases":22232,"primaryCompletion":857,"completion":52,"start":22233,"enrollment":1767,"conditions":22234,"interventions":22235},"NCT04677868","MTX and Steroid for aGVHD Treatment",[99],"2020-12-23",[2920],[3640],{"nctId":22237,"briefTitle":22238,"status":569,"phases":22239,"primaryCompletion":1215,"completion":364,"start":11020,"enrollment":1767,"conditions":22240,"interventions":22241},"NCT04958538","MTX and Steroid for III-IV aGVHD Treatment",[99],[2909],[3640],{"trials":22243,"activeCount":109},[],{"trials":22245,"activeCount":109},[],{"trials":22247,"activeCount":109},[22248],{"nctId":3631,"briefTitle":3632,"status":569,"phases":22249,"primaryCompletion":3634,"completion":3635,"start":3636,"enrollment":376,"conditions":22250,"interventions":22251},[102],[3638],[1120,1028,3640,2550],{"intervention":1122,"totalTrials":329,"cells":22253},{"EARLY_PHASE1":22254,"PHASE1":22256,"PHASE2":22258,"PHASE3":22272,"PHASE4":22274,"NA":22276},{"trials":22255,"activeCount":109},[],{"trials":22257,"activeCount":109},[],{"trials":22259,"activeCount":109},[22260,22268],{"nctId":22261,"briefTitle":22262,"status":569,"phases":22263,"primaryCompletion":8432,"completion":16035,"start":22264,"enrollment":4143,"conditions":22265,"interventions":22267},"NCT02179528","Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)",[99],"2014-09",[22266],"Small Cell Lung Cancer Extensive Stage",[1122],{"nctId":1109,"briefTitle":1110,"status":569,"phases":22269,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":22270,"interventions":22271},[99],[1117],[1119,734,1120,1121,1122,1090],{"trials":22273,"activeCount":109},[],{"trials":22275,"activeCount":109},[],{"trials":22277,"activeCount":109},[22278],{"nctId":22279,"briefTitle":22280,"status":569,"phases":22281,"primaryCompletion":1103,"completion":1103,"start":817,"enrollment":1248,"conditions":22282,"interventions":22286},"NCT05832320","Optimum Induction Therapy of Low-risk APL",[102],[22283,22284,22285],"Acute Promyelocytic Leukemia","Induction Therapy","Oral",[1122,22287],"Daunorubicin",{"intervention":8412,"totalTrials":329,"cells":22289},{"EARLY_PHASE1":22290,"PHASE1":22292,"PHASE2":22302,"PHASE3":22304,"PHASE4":22306,"NA":22308},{"trials":22291,"activeCount":109},[],{"trials":22293,"activeCount":109},[22294,22298],{"nctId":8406,"briefTitle":8407,"status":435,"phases":22295,"primaryCompletion":8409,"completion":8409,"start":5343,"enrollment":109,"conditions":22296,"interventions":22297},[98],[3122],[8412,734,8413],{"nctId":8428,"briefTitle":8429,"status":435,"phases":22299,"primaryCompletion":8431,"completion":8431,"start":8432,"enrollment":109,"conditions":22300,"interventions":22301},[98],[8434],[8412,734,8413],{"trials":22303,"activeCount":109},[],{"trials":22305,"activeCount":109},[],{"trials":22307,"activeCount":109},[],{"trials":22309,"activeCount":109},[22310],{"nctId":8471,"briefTitle":8472,"status":435,"phases":22311,"primaryCompletion":8409,"completion":3594,"start":5343,"enrollment":109,"conditions":22312,"interventions":22313},[],[8475],[8412,734,8413],{"intervention":22315,"totalTrials":329,"cells":22316},"Aripiprazole",{"EARLY_PHASE1":22317,"PHASE1":22319,"PHASE2":22321,"PHASE3":22323,"PHASE4":22325,"NA":22341},{"trials":22318,"activeCount":109},[],{"trials":22320,"activeCount":109},[],{"trials":22322,"activeCount":109},[],{"trials":22324,"activeCount":109},[],{"trials":22326,"activeCount":109},[22327,22331],{"nctId":14243,"briefTitle":14244,"status":569,"phases":22328,"primaryCompletion":14246,"completion":14246,"start":449,"enrollment":4171,"conditions":22329,"interventions":22330},[101],[10277],[14249,14250,14230],{"nctId":22332,"briefTitle":22333,"status":135,"phases":22334,"primaryCompletion":22335,"completion":22336,"start":15273,"enrollment":22337,"conditions":22338,"interventions":22340},"NCT03289026","Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study",[101],"2020-01-23","2021-02-02",770,[22339],"Acute Schizophrenia Episode",[22315],{"trials":22342,"activeCount":109},[22343],{"nctId":22344,"briefTitle":22345,"status":569,"phases":22346,"primaryCompletion":4853,"start":22347,"enrollment":11520,"conditions":22348,"interventions":22349},"NCT01057849","Standard Comprehensive Intervention to Treat First-episode Schizophrenia",[102],"2008-09",[9585],[14249,22350,22315],"olanzapine",{"intervention":8387,"totalTrials":329,"cells":22352},{"EARLY_PHASE1":22353,"PHASE1":22355,"PHASE2":22357,"PHASE3":22367,"PHASE4":22376,"NA":22378},{"trials":22354,"activeCount":109},[],{"trials":22356,"activeCount":109},[],{"trials":22358,"activeCount":109},[22359],{"nctId":22360,"briefTitle":22361,"status":569,"phases":22362,"primaryCompletion":668,"completion":22363,"start":4126,"enrollment":670,"conditions":22364,"interventions":22365},"NCT03095079","Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma",[99],"2018-10",[2580],[22366],"recombinant human endostatin",{"trials":22368,"activeCount":109},[22369],{"nctId":22370,"briefTitle":22371,"status":569,"phases":22372,"primaryCompletion":19282,"completion":14954,"start":16036,"enrollment":140,"conditions":22373,"interventions":22374},"NCT02350361","Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.",[99,100],[43],[22375],"Recombinant human endostatin",{"trials":22377,"activeCount":109},[],{"trials":22379,"activeCount":109},[22380],{"nctId":8379,"briefTitle":8380,"status":569,"phases":22381,"primaryCompletion":6743,"completion":8382,"start":8383,"enrollment":1767,"conditions":22382,"interventions":22383},[],[2681],[8386,1040,8387],{"intervention":16028,"totalTrials":746,"cells":22385},{"EARLY_PHASE1":22386,"PHASE1":22388,"PHASE2":22390,"PHASE3":22396,"PHASE4":22398,"NA":22400},{"trials":22387,"activeCount":109},[],{"trials":22389,"activeCount":109},[],{"trials":22391,"activeCount":109},[22392],{"nctId":16021,"briefTitle":16022,"status":569,"phases":22393,"primaryCompletion":279,"completion":16024,"start":16025,"enrollment":1940,"conditions":22394,"interventions":22395},[99],[28],[16028,4724],{"trials":22397,"activeCount":109},[],{"trials":22399,"activeCount":109},[],{"trials":22401,"activeCount":109},[22402],{"nctId":22403,"briefTitle":22404,"status":569,"phases":22405,"primaryCompletion":10056,"completion":10056,"start":22406,"enrollment":22407,"conditions":22408,"interventions":22410},"NCT04408859","Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy",[],"2018-04-17",290,[22409],"QOL; Quality of Life;Gastric Cancer; Gastrectomy;Neoadjuvant Chemotherapy",[16028],{"intervention":22412,"totalTrials":746,"cells":22413},"Favipiravir",{"EARLY_PHASE1":22414,"PHASE1":22416,"PHASE2":22418,"PHASE3":22420,"PHASE4":22422,"NA":22424},{"trials":22415,"activeCount":109},[],{"trials":22417,"activeCount":109},[],{"trials":22419,"activeCount":109},[],{"trials":22421,"activeCount":109},[],{"trials":22423,"activeCount":109},[],{"trials":22425,"activeCount":109},[22426,22435],{"nctId":22427,"briefTitle":22428,"status":569,"phases":22429,"primaryCompletion":8262,"completion":8262,"start":22430,"enrollment":640,"conditions":22431,"interventions":22432},"NCT04310228","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019",[102],"2020-03-08",[2494],[22433,22412,22434],"Favipiravir Combined With Tocilizumab","Tocilizumab",{"nctId":22436,"briefTitle":22437,"status":569,"phases":22438,"primaryCompletion":16091,"completion":22439,"start":1641,"enrollment":4143,"conditions":22440,"interventions":22441},"NCT04333589","Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",[102],"2020-09-15",[2494],[22412],{"intervention":22443,"totalTrials":746,"cells":22444},"Dexmedetomidine supplemented morphine analgesia",{"EARLY_PHASE1":22445,"PHASE1":22447,"PHASE2":22449,"PHASE3":22451,"PHASE4":22453,"NA":22455},{"trials":22446,"activeCount":109},[],{"trials":22448,"activeCount":109},[],{"trials":22450,"activeCount":109},[],{"trials":22452,"activeCount":109},[],{"trials":22454,"activeCount":109},[],{"trials":22456,"activeCount":109},[22457,22467],{"nctId":22458,"briefTitle":22459,"status":135,"phases":22460,"primaryCompletion":15873,"completion":22461,"start":22462,"enrollment":11297,"conditions":22463,"interventions":22465},"NCT03012984","Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium",[102],"2022-06-11","2017-01-06",[182,46,183,25,22464,245],"Complication, Postoperative",[22443,22466],"Morphine analgesia",{"nctId":22468,"briefTitle":22469,"status":135,"phases":22470,"primaryCompletion":22471,"completion":22471,"start":22462,"enrollment":11297,"conditions":22472,"interventions":22473},"NCT03012971","Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery",[102],"2024-12-11",[182,46,183,25,296],[22443,22466],{"intervention":22466,"totalTrials":746,"cells":22475},{"EARLY_PHASE1":22476,"PHASE1":22478,"PHASE2":22480,"PHASE3":22482,"PHASE4":22484,"NA":22486},{"trials":22477,"activeCount":109},[],{"trials":22479,"activeCount":109},[],{"trials":22481,"activeCount":109},[],{"trials":22483,"activeCount":109},[],{"trials":22485,"activeCount":109},[],{"trials":22487,"activeCount":109},[22488,22492],{"nctId":22458,"briefTitle":22459,"status":135,"phases":22489,"primaryCompletion":15873,"completion":22461,"start":22462,"enrollment":11297,"conditions":22490,"interventions":22491},[102],[182,46,183,25,22464,245],[22443,22466],{"nctId":22468,"briefTitle":22469,"status":135,"phases":22493,"primaryCompletion":22471,"completion":22471,"start":22462,"enrollment":11297,"conditions":22494,"interventions":22495},[102],[182,46,183,25,296],[22443,22466],{"intervention":951,"totalTrials":746,"cells":22497},{"EARLY_PHASE1":22498,"PHASE1":22500,"PHASE2":22502,"PHASE3":22508,"PHASE4":22510,"NA":22512},{"trials":22499,"activeCount":109},[],{"trials":22501,"activeCount":109},[],{"trials":22503,"activeCount":109},[22504],{"nctId":940,"briefTitle":941,"status":569,"phases":22505,"primaryCompletion":604,"completion":943,"start":944,"enrollment":553,"conditions":22506,"interventions":22507},[98,99],[946,947,948],[931,950,951,952],{"trials":22509,"activeCount":109},[],{"trials":22511,"activeCount":109},[],{"trials":22513,"activeCount":109},[22514],{"nctId":22515,"briefTitle":22516,"status":569,"phases":22517,"primaryCompletion":1163,"completion":2568,"start":1164,"enrollment":168,"conditions":22518,"interventions":22520},"NCT02978274","Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation",[],[22519],"Natural Killer Cell Mediated Immunity",[951,951],{"intervention":22522,"totalTrials":746,"cells":22523},"Carbon Nanoparticles",{"EARLY_PHASE1":22524,"PHASE1":22526,"PHASE2":22528,"PHASE3":22530,"PHASE4":22538,"NA":22540},{"trials":22525,"activeCount":109},[],{"trials":22527,"activeCount":109},[],{"trials":22529,"activeCount":109},[],{"trials":22531,"activeCount":109},[22532],{"nctId":22533,"briefTitle":22534,"status":569,"phases":22535,"primaryCompletion":2825,"start":3089,"enrollment":1767,"conditions":22536,"interventions":22537},"NCT02123407","Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer",[100],[3549],[22522],{"trials":22539,"activeCount":109},[],{"trials":22541,"activeCount":109},[22542],{"nctId":22543,"briefTitle":22544,"status":135,"phases":22545,"primaryCompletion":669,"completion":669,"start":1490,"enrollment":1480,"conditions":22546,"interventions":22548},"NCT02724176","Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer",[102],[22547],"Thyroid Cancer",[22549],"carbon nanoparticles",{"intervention":22551,"totalTrials":746,"cells":22552},"Benvitimod Cream",{"EARLY_PHASE1":22553,"PHASE1":22555,"PHASE2":22557,"PHASE3":22559,"PHASE4":22568,"NA":22570},{"trials":22554,"activeCount":109},[],{"trials":22556,"activeCount":109},[],{"trials":22558,"activeCount":109},[],{"trials":22560,"activeCount":109},[22561],{"nctId":22562,"briefTitle":22563,"status":569,"phases":22564,"primaryCompletion":6514,"completion":437,"start":4660,"enrollment":1165,"conditions":22565,"interventions":22567},"NCT05326672","Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis",[100],[22566],"Atopic Dermatitis",[22551],{"trials":22569,"activeCount":109},[],{"trials":22571,"activeCount":109},[22572],{"nctId":22573,"briefTitle":22574,"status":569,"phases":22575,"primaryCompletion":6514,"completion":2587,"start":4660,"enrollment":22576,"conditions":22577,"interventions":22578},"NCT05326659","Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis",[102],390,[11213],[22551],{"intervention":21531,"totalTrials":746,"cells":22580},{"EARLY_PHASE1":22581,"PHASE1":22583,"PHASE2":22589,"PHASE3":22591,"PHASE4":22593,"NA":22595},{"trials":22582,"activeCount":109},[],{"trials":22584,"activeCount":109},[22585],{"nctId":21523,"briefTitle":21524,"status":135,"phases":22586,"primaryCompletion":637,"completion":21526,"start":5063,"enrollment":3566,"conditions":22587,"interventions":22588},[98],[21528,21529],[21516,21531],{"trials":22590,"activeCount":109},[],{"trials":22592,"activeCount":109},[],{"trials":22594,"activeCount":109},[],{"trials":22596,"activeCount":109},[22597],{"nctId":22598,"briefTitle":22599,"status":569,"phases":22600,"primaryCompletion":13941,"completion":17607,"start":13718,"enrollment":1165,"conditions":22601,"interventions":22602},"NCT04652427","Application of Dexmedetomidine Hydrochloride Injection in Anesthesia for Patients Without Tracheal Intubation",[102],[539],[22603,21531],"Dexmedetomidine Hydrochloride 0.1 MG\u002FML",{"intervention":14249,"totalTrials":746,"cells":22605},{"EARLY_PHASE1":22606,"PHASE1":22608,"PHASE2":22610,"PHASE3":22612,"PHASE4":22614,"NA":22620},{"trials":22607,"activeCount":109},[],{"trials":22609,"activeCount":109},[],{"trials":22611,"activeCount":109},[],{"trials":22613,"activeCount":109},[],{"trials":22615,"activeCount":109},[22616],{"nctId":14243,"briefTitle":14244,"status":569,"phases":22617,"primaryCompletion":14246,"completion":14246,"start":449,"enrollment":4171,"conditions":22618,"interventions":22619},[101],[10277],[14249,14250,14230],{"trials":22621,"activeCount":109},[22622],{"nctId":22344,"briefTitle":22345,"status":569,"phases":22623,"primaryCompletion":4853,"start":22347,"enrollment":11520,"conditions":22624,"interventions":22625},[102],[9585],[14249,22350,22315],{"intervention":22627,"totalTrials":746,"cells":22628},"Interferon-alpha",{"EARLY_PHASE1":22629,"PHASE1":22631,"PHASE2":22633,"PHASE3":22635,"PHASE4":22637,"NA":22645},{"trials":22630,"activeCount":109},[],{"trials":22632,"activeCount":109},[],{"trials":22634,"activeCount":109},[],{"trials":22636,"activeCount":109},[],{"trials":22638,"activeCount":109},[22639],{"nctId":22640,"briefTitle":22641,"status":569,"phases":22642,"primaryCompletion":19151,"completion":19151,"start":15137,"enrollment":32,"conditions":22643,"interventions":22644},"NCT02027064","Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT",[101],[2958],[22627],{"trials":22646,"activeCount":109},[22647],{"nctId":22648,"briefTitle":22649,"status":435,"phases":22650,"primaryCompletion":2521,"completion":2521,"start":1470,"enrollment":109,"conditions":22651,"interventions":22655},"NCT03121079","Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation",[102],[22652,19739,22653,22654],"Interferon-A-2B","Prevention","Hematopietic Stem Cell Transplantation",[22627],{"intervention":22657,"totalTrials":746,"cells":22658},"Vitamin D2",{"EARLY_PHASE1":22659,"PHASE1":22661,"PHASE2":22663,"PHASE3":22665,"PHASE4":22667,"NA":22669},{"trials":22660,"activeCount":109},[],{"trials":22662,"activeCount":109},[],{"trials":22664,"activeCount":109},[],{"trials":22666,"activeCount":109},[],{"trials":22668,"activeCount":109},[],{"trials":22670,"activeCount":109},[22671,22680],{"nctId":22672,"briefTitle":22673,"status":569,"phases":22674,"primaryCompletion":22675,"completion":18211,"start":22676,"enrollment":2907,"conditions":22677,"interventions":22679},"NCT05673980","Oral Vitamin D2 for Prevention of COVID-19",[102],"2023-01-19","2022-12-18",[22678],"Healthy Volunteers",[22657],{"nctId":22681,"briefTitle":22682,"status":569,"phases":22683,"primaryCompletion":22684,"completion":4152,"start":19971,"enrollment":10160,"conditions":22685,"interventions":22686},"NCT01672047","Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients",[102],"2014-04",[14847,1736],[22657],{"intervention":1423,"totalTrials":746,"cells":22688},{"EARLY_PHASE1":22689,"PHASE1":22691,"PHASE2":22693,"PHASE3":22695,"PHASE4":22697,"NA":22703},{"trials":22690,"activeCount":109},[],{"trials":22692,"activeCount":109},[],{"trials":22694,"activeCount":109},[],{"trials":22696,"activeCount":109},[],{"trials":22698,"activeCount":109},[22699],{"nctId":14523,"briefTitle":14524,"status":569,"phases":22700,"primaryCompletion":14526,"completion":3090,"start":14527,"enrollment":14528,"conditions":22701,"interventions":22702},[101],[14530,14531],[14510,1423,14533],{"trials":22704,"activeCount":109},[22705],{"nctId":1412,"briefTitle":1413,"status":569,"phases":22706,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":29,"conditions":22707,"interventions":22708},[102],[1419,1420],[380,1422,1234,1423,1424,172,380,1234,1425,1424],{"intervention":22710,"totalTrials":746,"cells":22711},"Denosumab",{"EARLY_PHASE1":22712,"PHASE1":22714,"PHASE2":22716,"PHASE3":22730,"PHASE4":22732,"NA":22734},{"trials":22713,"activeCount":109},[],{"trials":22715,"activeCount":109},[],{"trials":22717,"activeCount":109},[22718],{"nctId":22719,"briefTitle":22720,"status":135,"phases":22721,"primaryCompletion":22722,"completion":22723,"start":22724,"enrollment":553,"conditions":22725,"interventions":22729},"NCT03415477","Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts",[98,99],"2016-12-31","2017-12-31","2014-01-01",[22726,22727,22728,22185],"Bone Cyst Aneurysmal","Pathological Fracture","Recurrent Disease",[22710],{"trials":22731,"activeCount":109},[],{"trials":22733,"activeCount":109},[],{"trials":22735,"activeCount":109},[22736],{"nctId":22737,"briefTitle":22738,"status":569,"phases":22739,"primaryCompletion":657,"completion":857,"start":5265,"enrollment":376,"conditions":22740,"interventions":22742},"NCT03358212","Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China",[],[22741],"Giant Cell Tumor of Bone",[22710],{"intervention":22744,"totalTrials":746,"cells":22745},"opioid free anesthesia",{"EARLY_PHASE1":22746,"PHASE1":22748,"PHASE2":22750,"PHASE3":22752,"PHASE4":22754,"NA":22756},{"trials":22747,"activeCount":109},[],{"trials":22749,"activeCount":109},[],{"trials":22751,"activeCount":109},[],{"trials":22753,"activeCount":109},[],{"trials":22755,"activeCount":109},[],{"trials":22757,"activeCount":109},[22758,22766],{"nctId":22759,"briefTitle":22760,"status":135,"phases":22761,"primaryCompletion":8798,"completion":22762,"start":13835,"enrollment":153,"conditions":22763,"interventions":22765},"NCT04390698","Opioid Free Anesthesia in Breast Cancer Surgery",[102],"2022-03-15",[22764],"Opioid Free Anesthesia",[22744],{"nctId":22767,"briefTitle":22768,"status":569,"phases":22769,"primaryCompletion":3933,"completion":22770,"start":8352,"enrollment":376,"conditions":22771,"interventions":22772},"NCT04507165","Opioid-free Anesthesia in VATS Lung Resection",[102],"2022-07",[22764],[22744,22773],"opioid based anesthesia",{"intervention":2550,"totalTrials":746,"cells":22775},{"EARLY_PHASE1":22776,"PHASE1":22778,"PHASE2":22780,"PHASE3":22786,"PHASE4":22788,"NA":22790},{"trials":22777,"activeCount":109},[],{"trials":22779,"activeCount":109},[],{"trials":22781,"activeCount":109},[22782],{"nctId":2539,"briefTitle":2540,"status":435,"phases":22783,"primaryCompletion":2542,"completion":1113,"start":2543,"enrollment":109,"conditions":22784,"interventions":22785},[98,99],[2545,2546,2547],[2549,2550,72],{"trials":22787,"activeCount":109},[],{"trials":22789,"activeCount":109},[],{"trials":22791,"activeCount":109},[22792],{"nctId":3631,"briefTitle":3632,"status":569,"phases":22793,"primaryCompletion":3634,"completion":3635,"start":3636,"enrollment":376,"conditions":22794,"interventions":22795},[102],[3638],[1120,1028,3640,2550],{"intervention":22797,"totalTrials":746,"cells":22798},"Immune checkpoint inhibitor",{"EARLY_PHASE1":22799,"PHASE1":22801,"PHASE2":22803,"PHASE3":22805,"PHASE4":22807,"NA":22809},{"trials":22800,"activeCount":109},[],{"trials":22802,"activeCount":109},[],{"trials":22804,"activeCount":109},[],{"trials":22806,"activeCount":109},[],{"trials":22808,"activeCount":109},[],{"trials":22810,"activeCount":109},[22811,22820],{"nctId":22812,"briefTitle":22813,"status":569,"phases":22814,"primaryCompletion":10361,"completion":639,"start":22815,"enrollment":693,"conditions":22816,"interventions":22818},"NCT04137588","Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer",[],"2021-03-03",[22817],"Advanced Non-squamous Non-small Cell Lung Cancer",[22819,22797],"Antiangiogenesis Agents",{"nctId":22821,"briefTitle":22822,"status":569,"phases":22823,"primaryCompletion":3709,"completion":3709,"start":22815,"enrollment":153,"conditions":22824,"interventions":22825},"NCT04629027","Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC",[],[5693],[22797],{"intervention":15327,"totalTrials":746,"cells":22827},{"EARLY_PHASE1":22828,"PHASE1":22830,"PHASE2":22832,"PHASE3":22834,"PHASE4":22836,"NA":22838},{"trials":22829,"activeCount":109},[],{"trials":22831,"activeCount":109},[],{"trials":22833,"activeCount":109},[],{"trials":22835,"activeCount":109},[],{"trials":22837,"activeCount":109},[],{"trials":22839,"activeCount":109},[22840,22849],{"nctId":22841,"briefTitle":22842,"status":135,"phases":22843,"primaryCompletion":1149,"completion":1404,"start":22844,"enrollment":1480,"conditions":22845,"interventions":22848},"NCT05320718","Analgesia in Minimally Invasive Direct Coronary Artery Bypass Grafting: Programmed Intermittent Bolus Infusions of Erector Spinae Plane Block Versus Paravertebral Block",[102],"2022-04-15",[22846,22847,46],"Regional Anesthesia","Anesthesia, Local",[15327],{"nctId":22850,"briefTitle":22851,"status":569,"phases":22852,"primaryCompletion":81,"completion":1103,"start":22853,"enrollment":13985,"conditions":22854,"interventions":22856},"NCT05753644","The Effect of Preoperative SGB on POAF After VATS",[102],"2023-03-27",[22855],"Atrial Fibrillation",[15327,22857],"Sham treatment",{"intervention":10279,"totalTrials":746,"cells":22859},{"EARLY_PHASE1":22860,"PHASE1":22862,"PHASE2":22864,"PHASE3":22866,"PHASE4":22868,"NA":22870},{"trials":22861,"activeCount":109},[],{"trials":22863,"activeCount":109},[],{"trials":22865,"activeCount":109},[],{"trials":22867,"activeCount":109},[],{"trials":22869,"activeCount":109},[],{"trials":22871,"activeCount":109},[22872,22882],{"nctId":22873,"briefTitle":22874,"status":569,"phases":22875,"primaryCompletion":1163,"completion":17607,"start":669,"enrollment":8354,"conditions":22876,"interventions":22878},"NCT03294525","Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders",[],[22877],"Affective Disorder",[22879,10279,22880,22881],"Escitalopram Pill","Mirtazapine Pill","Other Antidepressants",{"nctId":10273,"briefTitle":10274,"status":569,"phases":22883,"primaryCompletion":4651,"completion":57,"start":449,"enrollment":574,"conditions":22884,"interventions":22885},[102],[10277],[10239,10279,10280],{"intervention":15697,"totalTrials":746,"cells":22887},{"EARLY_PHASE1":22888,"PHASE1":22890,"PHASE2":22892,"PHASE3":22894,"PHASE4":22896,"NA":22902},{"trials":22889,"activeCount":109},[],{"trials":22891,"activeCount":109},[],{"trials":22893,"activeCount":109},[],{"trials":22895,"activeCount":109},[],{"trials":22897,"activeCount":109},[22898],{"nctId":15691,"briefTitle":15692,"status":569,"phases":22899,"primaryCompletion":3023,"completion":3023,"start":449,"enrollment":376,"conditions":22900,"interventions":22901},[101],[15695],[15697,15678],{"trials":22903,"activeCount":109},[22904],{"nctId":22905,"briefTitle":22906,"status":569,"phases":22907,"primaryCompletion":1103,"completion":1103,"start":22908,"enrollment":11520,"conditions":22909,"interventions":22914},"NCT06424613","Effects of Lithium on Suicide Prevention in Adolescents and Young Adults With Bipolar Disorder in China",[],"2024-04-18",[22910,22911,22912,22913],"Bipolar Disorder","Suicidal Ideation","Suicide, Attempted","Nonsuicidal Self Injury",[15697,22915],"Non-lithium medication",{"intervention":22220,"totalTrials":746,"cells":22917},{"EARLY_PHASE1":22918,"PHASE1":22920,"PHASE2":22922,"PHASE3":22924,"PHASE4":22926,"NA":22935},{"trials":22919,"activeCount":109},[],{"trials":22921,"activeCount":109},[],{"trials":22923,"activeCount":109},[],{"trials":22925,"activeCount":109},[],{"trials":22927,"activeCount":109},[22928],{"nctId":22929,"briefTitle":22930,"status":135,"phases":22931,"primaryCompletion":4671,"completion":3120,"start":1164,"enrollment":1767,"conditions":22932,"interventions":22933},"NCT02412423","Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors",[101],[15208],[22934],"post-transplantation cyclophosphamide",{"trials":22936,"activeCount":109},[22937],{"nctId":22214,"briefTitle":22215,"status":569,"phases":22938,"primaryCompletion":5352,"completion":315,"start":2853,"enrollment":4171,"conditions":22939,"interventions":22940},[],[22218],[952,22220],{"intervention":834,"totalTrials":746,"cells":22942},{"EARLY_PHASE1":22943,"PHASE1":22945,"PHASE2":22947,"PHASE3":22949,"PHASE4":22951,"NA":22957},{"trials":22944,"activeCount":109},[],{"trials":22946,"activeCount":109},[],{"trials":22948,"activeCount":109},[],{"trials":22950,"activeCount":109},[],{"trials":22952,"activeCount":109},[22953],{"nctId":827,"briefTitle":828,"status":569,"phases":22954,"primaryCompletion":830,"start":831,"enrollment":376,"conditions":22955,"interventions":22956},[101],[245],[538,834,236],{"trials":22958,"activeCount":109},[22959],{"nctId":915,"briefTitle":916,"status":135,"phases":22960,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":22961,"interventions":22962},[102],[923,924,40,25],[392,834,824],{"intervention":824,"totalTrials":746,"cells":22964},{"EARLY_PHASE1":22965,"PHASE1":22967,"PHASE2":22969,"PHASE3":22971,"PHASE4":22973,"NA":22979},{"trials":22966,"activeCount":109},[],{"trials":22968,"activeCount":109},[],{"trials":22970,"activeCount":109},[],{"trials":22972,"activeCount":109},[],{"trials":22974,"activeCount":109},[22975],{"nctId":814,"briefTitle":815,"status":135,"phases":22976,"primaryCompletion":817,"completion":818,"start":819,"enrollment":153,"conditions":22977,"interventions":22978},[101],[821],[172,823,824,825],{"trials":22980,"activeCount":109},[22981],{"nctId":915,"briefTitle":916,"status":135,"phases":22982,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":22983,"interventions":22984},[102],[923,924,40,25],[392,834,824],{"intervention":22986,"totalTrials":746,"cells":22987},"Rosuvastatin",{"EARLY_PHASE1":22988,"PHASE1":22990,"PHASE2":22992,"PHASE3":22994,"PHASE4":22996,"NA":23005},{"trials":22989,"activeCount":109},[],{"trials":22991,"activeCount":109},[],{"trials":22993,"activeCount":109},[],{"trials":22995,"activeCount":109},[],{"trials":22997,"activeCount":109},[22998],{"nctId":22999,"briefTitle":23000,"status":569,"phases":23001,"primaryCompletion":23002,"completion":23002,"start":4853,"enrollment":11520,"conditions":23003,"interventions":23004},"NCT01382277","Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume",[101],"2013-04",[11479,15953],[22986],{"trials":23006,"activeCount":109},[23007],{"nctId":23008,"briefTitle":23009,"status":569,"phases":23010,"primaryCompletion":830,"completion":4152,"start":19971,"enrollment":5215,"conditions":23011,"interventions":23013},"NCT01653119","Peking and Rotterdam on Mission to Reduce Coronary Artery Disease",[102],[23012,11895],"Acute Coronary Syndrome",[22986],{"intervention":23015,"totalTrials":746,"cells":23016},"Combined epidural-general anesthesia",{"EARLY_PHASE1":23017,"PHASE1":23019,"PHASE2":23021,"PHASE3":23023,"PHASE4":23025,"NA":23027},{"trials":23018,"activeCount":109},[],{"trials":23020,"activeCount":109},[],{"trials":23022,"activeCount":109},[],{"trials":23024,"activeCount":109},[],{"trials":23026,"activeCount":109},[],{"trials":23028,"activeCount":109},[23029,23041],{"nctId":23030,"briefTitle":23031,"status":135,"phases":23032,"primaryCompletion":23033,"completion":151,"start":23034,"enrollment":8354,"conditions":23035,"interventions":23039},"NCT02801409","Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery",[102],"2017-11-11","2015-05-25",[43,23036,23037,23038,18109],"Thoracic Surgery","Anesthesia, Epidural","Neoplasm Recurrence, Local",[23040,23015],"General anesthesia alone",{"nctId":23042,"briefTitle":23043,"status":135,"phases":23044,"primaryCompletion":15272,"completion":15272,"start":23045,"enrollment":23046,"conditions":23047,"interventions":23051},"NCT03012945","Epidural Anesthesia-analgesia and Long-term Outcome",[102],"2014-11-01",1802,[182,23048,23049,23050,296],"Malignant Tumor","Surgical Resection","Epidural Anesthesia",[23015,23052],"General anesthesia",{"intervention":23054,"totalTrials":746,"cells":23055},"vancomycin",{"EARLY_PHASE1":23056,"PHASE1":23058,"PHASE2":23060,"PHASE3":23062,"PHASE4":23064,"NA":23066},{"trials":23057,"activeCount":109},[],{"trials":23059,"activeCount":109},[],{"trials":23061,"activeCount":109},[],{"trials":23063,"activeCount":109},[],{"trials":23065,"activeCount":109},[],{"trials":23067,"activeCount":109},[23068,23077],{"nctId":23069,"briefTitle":23070,"status":135,"phases":23071,"primaryCompletion":18814,"completion":18814,"start":18965,"enrollment":153,"conditions":23072,"interventions":23074},"NCT02787057","Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis",[102],[23073],"Peritoneal Dialysis Associated Peritonitis",[23054,23075,23076],"moxifloxacin","ceftazidime",{"nctId":23078,"briefTitle":23079,"status":569,"phases":23080,"primaryCompletion":150,"completion":2521,"start":23081,"enrollment":23082,"conditions":23083,"interventions":23088},"NCT03456544","Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China",[],"2018-10-31",10000,[23084,23085,23086,11434,23087],"Vancomycin","Staphylococcal Infections","Adverse Effect","Cross-sectional Study",[23084],{"intervention":23075,"totalTrials":746,"cells":23090},{"EARLY_PHASE1":23091,"PHASE1":23093,"PHASE2":23095,"PHASE3":23097,"PHASE4":23099,"NA":23101},{"trials":23092,"activeCount":109},[],{"trials":23094,"activeCount":109},[],{"trials":23096,"activeCount":109},[],{"trials":23098,"activeCount":109},[],{"trials":23100,"activeCount":109},[],{"trials":23102,"activeCount":109},[23103,23107],{"nctId":23069,"briefTitle":23070,"status":135,"phases":23104,"primaryCompletion":18814,"completion":18814,"start":18965,"enrollment":153,"conditions":23105,"interventions":23106},[102],[23073],[23054,23075,23076],{"nctId":23108,"briefTitle":23109,"status":569,"phases":23110,"primaryCompletion":20438,"completion":14527,"start":19801,"enrollment":8489,"conditions":23111,"interventions":23113},"NCT01653990","Moxifloxacin_QT Study in Chinese Healthy Volunteer",[102],[23112],"QT Interval Prolongation",[23075,23114],"moxifloxacin-placebo",{"intervention":22350,"totalTrials":746,"cells":23116},{"EARLY_PHASE1":23117,"PHASE1":23119,"PHASE2":23121,"PHASE3":23130,"PHASE4":23132,"NA":23134},{"trials":23118,"activeCount":109},[],{"trials":23120,"activeCount":109},[],{"trials":23122,"activeCount":109},[23123],{"nctId":23124,"briefTitle":23125,"status":569,"phases":23126,"primaryCompletion":5362,"completion":2797,"start":19281,"enrollment":341,"conditions":23127,"interventions":23128},"NCT03575637","Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer",[99],[28],[23129],"Olanzapine",{"trials":23131,"activeCount":109},[],{"trials":23133,"activeCount":109},[],{"trials":23135,"activeCount":109},[23136],{"nctId":22344,"briefTitle":22345,"status":569,"phases":23137,"primaryCompletion":4853,"start":22347,"enrollment":11520,"conditions":23138,"interventions":23139},[102],[9585],[14249,22350,22315],{"intervention":23141,"totalTrials":746,"cells":23142},"dexmedetomidine hydrochloride for",{"EARLY_PHASE1":23143,"PHASE1":23145,"PHASE2":23147,"PHASE3":23149,"PHASE4":23151,"NA":23163},{"trials":23144,"activeCount":109},[],{"trials":23146,"activeCount":109},[],{"trials":23148,"activeCount":109},[],{"trials":23150,"activeCount":109},[],{"trials":23152,"activeCount":109},[23153],{"nctId":23154,"briefTitle":23155,"status":135,"phases":23156,"primaryCompletion":2874,"completion":23157,"start":2882,"enrollment":23158,"conditions":23159,"interventions":23161},"NCT02267538","Dexmedetomidine and Delirium in Patients After Cardiac Surgery",[101],"2015-11",285,[245,23160,357],"C.Surgical Procedure; Cardiac",[23141,23162],"0.9% sodium chloride for",{"trials":23164,"activeCount":109},[23165],{"nctId":23166,"briefTitle":23167,"status":135,"phases":23168,"primaryCompletion":23169,"completion":23169,"start":23170,"enrollment":23158,"conditions":23171,"interventions":23173},"NCT03289325","Dexmedetomidine and Long-term Outcomes in Elderly Patients After Cardiac Surgery",[102],"2022-05-03","2021-10-21",[23172,25,296,258,17471],"Cardiac Surgery",[23141,23162],{"intervention":23162,"totalTrials":746,"cells":23175},{"EARLY_PHASE1":23176,"PHASE1":23178,"PHASE2":23180,"PHASE3":23182,"PHASE4":23184,"NA":23190},{"trials":23177,"activeCount":109},[],{"trials":23179,"activeCount":109},[],{"trials":23181,"activeCount":109},[],{"trials":23183,"activeCount":109},[],{"trials":23185,"activeCount":109},[23186],{"nctId":23154,"briefTitle":23155,"status":135,"phases":23187,"primaryCompletion":2874,"completion":23157,"start":2882,"enrollment":23158,"conditions":23188,"interventions":23189},[101],[245,23160,357],[23141,23162],{"trials":23191,"activeCount":109},[23192],{"nctId":23166,"briefTitle":23167,"status":135,"phases":23193,"primaryCompletion":23169,"completion":23169,"start":23170,"enrollment":23158,"conditions":23194,"interventions":23195},[102],[23172,25,296,258,17471],[23141,23162],{"intervention":23197,"totalTrials":708,"cells":23198},"VIA combination treatment",{"EARLY_PHASE1":23199,"PHASE1":23201,"PHASE2":23203,"PHASE3":23205,"PHASE4":23207,"NA":23209},{"trials":23200,"activeCount":109},[],{"trials":23202,"activeCount":109},[],{"trials":23204,"activeCount":109},[],{"trials":23206,"activeCount":109},[],{"trials":23208,"activeCount":109},[],{"trials":23210,"activeCount":109},[23211],{"nctId":23212,"briefTitle":23213,"status":435,"phases":23214,"primaryCompletion":5273,"completion":5128,"start":4201,"enrollment":109,"conditions":23215,"interventions":23217},"NCT05656222","Irinotecan and Anlotinib for Epithelioid Sarcoma",[102],[23216,195],"Objective Response",[23197],{"intervention":23219,"totalTrials":708,"cells":23220},"Fruquintinib and Everolimus",{"EARLY_PHASE1":23221,"PHASE1":23223,"PHASE2":23225,"PHASE3":23227,"PHASE4":23229,"NA":23231},{"trials":23222,"activeCount":109},[],{"trials":23224,"activeCount":109},[],{"trials":23226,"activeCount":109},[],{"trials":23228,"activeCount":109},[],{"trials":23230,"activeCount":109},[],{"trials":23232,"activeCount":109},[23233],{"nctId":23234,"briefTitle":23235,"status":569,"phases":23236,"primaryCompletion":6876,"completion":2370,"start":15475,"enrollment":8489,"conditions":23237,"interventions":23239},"NCT06317298","Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy",[102],[23238],"Renal Cell Carcinoma, Clear Cell, Somatic",[23219],{"intervention":23241,"totalTrials":708,"cells":23242},"hAECs",{"EARLY_PHASE1":23243,"PHASE1":23245,"PHASE2":23247,"PHASE3":23249,"PHASE4":23251,"NA":23253},{"trials":23244,"activeCount":109},[],{"trials":23246,"activeCount":109},[],{"trials":23248,"activeCount":109},[],{"trials":23250,"activeCount":109},[],{"trials":23252,"activeCount":109},[],{"trials":23254,"activeCount":109},[23255],{"nctId":23256,"briefTitle":23257,"status":569,"phases":23258,"primaryCompletion":1640,"completion":23259,"start":13835,"enrollment":3520,"conditions":23260,"interventions":23262},"NCT03764228","Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation",[102],"2022-07-01",[23261],"Acute-graft-versus-host Disease",[23241],{"intervention":22433,"totalTrials":708,"cells":23264},{"EARLY_PHASE1":23265,"PHASE1":23267,"PHASE2":23269,"PHASE3":23271,"PHASE4":23273,"NA":23275},{"trials":23266,"activeCount":109},[],{"trials":23268,"activeCount":109},[],{"trials":23270,"activeCount":109},[],{"trials":23272,"activeCount":109},[],{"trials":23274,"activeCount":109},[],{"trials":23276,"activeCount":109},[23277],{"nctId":22427,"briefTitle":22428,"status":569,"phases":23278,"primaryCompletion":8262,"completion":8262,"start":22430,"enrollment":640,"conditions":23279,"interventions":23280},[102],[2494],[22433,22412,22434],{"intervention":22434,"totalTrials":708,"cells":23282},{"EARLY_PHASE1":23283,"PHASE1":23285,"PHASE2":23287,"PHASE3":23289,"PHASE4":23291,"NA":23293},{"trials":23284,"activeCount":109},[],{"trials":23286,"activeCount":109},[],{"trials":23288,"activeCount":109},[],{"trials":23290,"activeCount":109},[],{"trials":23292,"activeCount":109},[],{"trials":23294,"activeCount":109},[23295],{"nctId":22427,"briefTitle":22428,"status":569,"phases":23296,"primaryCompletion":8262,"completion":8262,"start":22430,"enrollment":640,"conditions":23297,"interventions":23298},[102],[2494],[22433,22412,22434],{"intervention":23300,"totalTrials":708,"cells":23301},"Sodium Hyaluronate",{"EARLY_PHASE1":23302,"PHASE1":23304,"PHASE2":23306,"PHASE3":23308,"PHASE4":23310,"NA":23312},{"trials":23303,"activeCount":109},[],{"trials":23305,"activeCount":109},[],{"trials":23307,"activeCount":109},[],{"trials":23309,"activeCount":109},[],{"trials":23311,"activeCount":109},[],{"trials":23313,"activeCount":109},[23314],{"nctId":23315,"briefTitle":23316,"status":569,"phases":23317,"primaryCompletion":1641,"completion":1641,"start":13984,"enrollment":400,"conditions":23318,"interventions":23320},"NCT03365388","A Validation Study of Sodium Hyaluronate in Patients With Periarthritis of Shoulder",[102],[23319],"Periarthritis",[23300,23321],"Aerzhi",{"intervention":23321,"totalTrials":708,"cells":23323},{"EARLY_PHASE1":23324,"PHASE1":23326,"PHASE2":23328,"PHASE3":23330,"PHASE4":23332,"NA":23334},{"trials":23325,"activeCount":109},[],{"trials":23327,"activeCount":109},[],{"trials":23329,"activeCount":109},[],{"trials":23331,"activeCount":109},[],{"trials":23333,"activeCount":109},[],{"trials":23335,"activeCount":109},[23336],{"nctId":23315,"briefTitle":23316,"status":569,"phases":23337,"primaryCompletion":1641,"completion":1641,"start":13984,"enrollment":400,"conditions":23338,"interventions":23339},[102],[23319],[23300,23321],{"intervention":23341,"totalTrials":708,"cells":23342},"Liangxue ointment（Traditional Chinese Ointment）",{"EARLY_PHASE1":23343,"PHASE1":23345,"PHASE2":23347,"PHASE3":23349,"PHASE4":23351,"NA":23353},{"trials":23344,"activeCount":109},[],{"trials":23346,"activeCount":109},[],{"trials":23348,"activeCount":109},[],{"trials":23350,"activeCount":109},[],{"trials":23352,"activeCount":109},[],{"trials":23354,"activeCount":109},[23355],{"nctId":23356,"briefTitle":23357,"status":569,"phases":23358,"primaryCompletion":23359,"completion":23359,"start":8554,"enrollment":2052,"conditions":23360,"interventions":23362},"NCT06583369","The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs",[102],"2025-03-25",[23361],"Hand-Foot Syndrome",[23341,23363],"Urea cream",{"intervention":23363,"totalTrials":708,"cells":23365},{"EARLY_PHASE1":23366,"PHASE1":23368,"PHASE2":23370,"PHASE3":23372,"PHASE4":23374,"NA":23376},{"trials":23367,"activeCount":109},[],{"trials":23369,"activeCount":109},[],{"trials":23371,"activeCount":109},[],{"trials":23373,"activeCount":109},[],{"trials":23375,"activeCount":109},[],{"trials":23377,"activeCount":109},[23378],{"nctId":23356,"briefTitle":23357,"status":569,"phases":23379,"primaryCompletion":23359,"completion":23359,"start":8554,"enrollment":2052,"conditions":23380,"interventions":23381},[102],[23361],[23341,23363],{"intervention":23383,"totalTrials":708,"cells":23384},"Pregabalin 75mg tid + Duloxetine",{"EARLY_PHASE1":23385,"PHASE1":23387,"PHASE2":23389,"PHASE3":23391,"PHASE4":23393,"NA":23395},{"trials":23386,"activeCount":109},[],{"trials":23388,"activeCount":109},[],{"trials":23390,"activeCount":109},[],{"trials":23392,"activeCount":109},[],{"trials":23394,"activeCount":109},[],{"trials":23396,"activeCount":109},[23397],{"nctId":23398,"briefTitle":23399,"status":569,"phases":23400,"primaryCompletion":1215,"completion":571,"start":21263,"enrollment":153,"conditions":23401,"interventions":23404},"NCT04847245","Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder",[102],[23402,23403],"Chronic Visceral Pain","Major Depressive Disorder",[23383,23405,23406,23407],"Intravenous administration of esketamine 0.125 mg\u002Fkg+Duloxetine","Intravenous administration of esketamine 0.25 mg\u002Fkg +Duloxetine","Intravenous administration of esketamine 0.50 mg\u002Fkg+Duloxetine",{"intervention":23405,"totalTrials":708,"cells":23409},{"EARLY_PHASE1":23410,"PHASE1":23412,"PHASE2":23414,"PHASE3":23416,"PHASE4":23418,"NA":23420},{"trials":23411,"activeCount":109},[],{"trials":23413,"activeCount":109},[],{"trials":23415,"activeCount":109},[],{"trials":23417,"activeCount":109},[],{"trials":23419,"activeCount":109},[],{"trials":23421,"activeCount":109},[23422],{"nctId":23398,"briefTitle":23399,"status":569,"phases":23423,"primaryCompletion":1215,"completion":571,"start":21263,"enrollment":153,"conditions":23424,"interventions":23425},[102],[23402,23403],[23383,23405,23406,23407],{"intervention":23406,"totalTrials":708,"cells":23427},{"EARLY_PHASE1":23428,"PHASE1":23430,"PHASE2":23432,"PHASE3":23434,"PHASE4":23436,"NA":23438},{"trials":23429,"activeCount":109},[],{"trials":23431,"activeCount":109},[],{"trials":23433,"activeCount":109},[],{"trials":23435,"activeCount":109},[],{"trials":23437,"activeCount":109},[],{"trials":23439,"activeCount":109},[23440],{"nctId":23398,"briefTitle":23399,"status":569,"phases":23441,"primaryCompletion":1215,"completion":571,"start":21263,"enrollment":153,"conditions":23442,"interventions":23443},[102],[23402,23403],[23383,23405,23406,23407],{"intervention":23407,"totalTrials":708,"cells":23445},{"EARLY_PHASE1":23446,"PHASE1":23448,"PHASE2":23450,"PHASE3":23452,"PHASE4":23454,"NA":23456},{"trials":23447,"activeCount":109},[],{"trials":23449,"activeCount":109},[],{"trials":23451,"activeCount":109},[],{"trials":23453,"activeCount":109},[],{"trials":23455,"activeCount":109},[],{"trials":23457,"activeCount":109},[23458],{"nctId":23398,"briefTitle":23399,"status":569,"phases":23459,"primaryCompletion":1215,"completion":571,"start":21263,"enrollment":153,"conditions":23460,"interventions":23461},[102],[23402,23403],[23383,23405,23406,23407],{"intervention":23463,"totalTrials":708,"cells":23464},"NET or NCT",{"EARLY_PHASE1":23465,"PHASE1":23467,"PHASE2":23469,"PHASE3":23471,"PHASE4":23473,"NA":23475},{"trials":23466,"activeCount":109},[],{"trials":23468,"activeCount":109},[],{"trials":23470,"activeCount":109},[],{"trials":23472,"activeCount":109},[],{"trials":23474,"activeCount":109},[],{"trials":23476,"activeCount":109},[23477],{"nctId":23478,"briefTitle":23479,"status":135,"phases":23480,"primaryCompletion":22090,"completion":5839,"start":373,"enrollment":23481,"conditions":23482,"interventions":23483},"NCT05673850","Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy",[],518,[12300],[23463],{"intervention":23485,"totalTrials":708,"cells":23486},"cytokine",{"EARLY_PHASE1":23487,"PHASE1":23489,"PHASE2":23491,"PHASE3":23493,"PHASE4":23495,"NA":23497},{"trials":23488,"activeCount":109},[],{"trials":23490,"activeCount":109},[],{"trials":23492,"activeCount":109},[],{"trials":23494,"activeCount":109},[],{"trials":23496,"activeCount":109},[],{"trials":23498,"activeCount":109},[23499],{"nctId":23500,"briefTitle":23501,"status":135,"phases":23502,"primaryCompletion":13757,"completion":3089,"start":23503,"enrollment":8489,"conditions":23504,"interventions":23506},"NCT01256801","Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion",[],"2010-11",[12300,18109,23505,3924],"Gene Expression Profiling",[23485],{"intervention":23508,"totalTrials":708,"cells":23509},"Cladribine",{"EARLY_PHASE1":23510,"PHASE1":23512,"PHASE2":23514,"PHASE3":23516,"PHASE4":23518,"NA":23520},{"trials":23511,"activeCount":109},[],{"trials":23513,"activeCount":109},[],{"trials":23515,"activeCount":109},[],{"trials":23517,"activeCount":109},[],{"trials":23519,"activeCount":109},[],{"trials":23521,"activeCount":109},[23522],{"nctId":23523,"briefTitle":23524,"status":569,"phases":23525,"primaryCompletion":1163,"completion":437,"start":3594,"enrollment":728,"conditions":23526,"interventions":23527},"NCT04679506","the Efficacy and Safety of CLAE in R\u002FR T-ALL\u002FLBL",[],[6770],[23508],{"intervention":23529,"totalTrials":708,"cells":23530},"Intravenous morphine analgesia",{"EARLY_PHASE1":23531,"PHASE1":23533,"PHASE2":23535,"PHASE3":23537,"PHASE4":23539,"NA":23541},{"trials":23532,"activeCount":109},[],{"trials":23534,"activeCount":109},[],{"trials":23536,"activeCount":109},[],{"trials":23538,"activeCount":109},[],{"trials":23540,"activeCount":109},[],{"trials":23542,"activeCount":109},[23543],{"nctId":23544,"briefTitle":23545,"status":135,"phases":23546,"primaryCompletion":23547,"completion":23548,"start":15583,"enrollment":3566,"conditions":23549,"interventions":23552},"NCT03203967","Epidural Morphine for Postoperative Analgesia After Total Knee Arthroplasty",[102],"2018-04-30","2018-05-30",[23550,282,15325,283,23551],"Adult Patients","Analgesic Adverse Reaction",[23529],{"intervention":23554,"totalTrials":708,"cells":23555},"Ulinastatin",{"EARLY_PHASE1":23556,"PHASE1":23558,"PHASE2":23560,"PHASE3":23562,"PHASE4":23564,"NA":23566},{"trials":23557,"activeCount":109},[],{"trials":23559,"activeCount":109},[],{"trials":23561,"activeCount":109},[],{"trials":23563,"activeCount":109},[],{"trials":23565,"activeCount":109},[],{"trials":23567,"activeCount":109},[23568],{"nctId":23569,"briefTitle":23570,"status":135,"phases":23571,"primaryCompletion":23572,"completion":1640,"start":23573,"enrollment":23574,"conditions":23575,"interventions":23578},"NCT03089957","Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)",[102],"2020-12-17","2017-02-20",840,[23576,23577],"Acute Respiratory Distress Syndrome","Critical Illness",[23554],{"intervention":23580,"totalTrials":708,"cells":23581},"Qingre Huashi Granules combined the modified dual therapy",{"EARLY_PHASE1":23582,"PHASE1":23584,"PHASE2":23586,"PHASE3":23588,"PHASE4":23590,"NA":23592},{"trials":23583,"activeCount":109},[],{"trials":23585,"activeCount":109},[],{"trials":23587,"activeCount":109},[],{"trials":23589,"activeCount":109},[],{"trials":23591,"activeCount":109},[],{"trials":23593,"activeCount":109},[23594],{"nctId":23595,"briefTitle":23596,"status":569,"phases":23597,"primaryCompletion":5128,"completion":1103,"start":23598,"enrollment":1894,"conditions":23599,"interventions":23600},"NCT05364619","Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection",[102],"2022-08-05",[10921],[23580,23601],"Bismuth containing quadruple therapy",{"intervention":23601,"totalTrials":708,"cells":23603},{"EARLY_PHASE1":23604,"PHASE1":23606,"PHASE2":23608,"PHASE3":23610,"PHASE4":23612,"NA":23614},{"trials":23605,"activeCount":109},[],{"trials":23607,"activeCount":109},[],{"trials":23609,"activeCount":109},[],{"trials":23611,"activeCount":109},[],{"trials":23613,"activeCount":109},[],{"trials":23615,"activeCount":109},[23616],{"nctId":23595,"briefTitle":23596,"status":569,"phases":23617,"primaryCompletion":5128,"completion":1103,"start":23598,"enrollment":1894,"conditions":23618,"interventions":23619},[102],[10921],[23580,23601],{"intervention":23621,"totalTrials":708,"cells":23622},"autologous stem cell transplantation",{"EARLY_PHASE1":23623,"PHASE1":23625,"PHASE2":23627,"PHASE3":23629,"PHASE4":23631,"NA":23633},{"trials":23624,"activeCount":109},[],{"trials":23626,"activeCount":109},[],{"trials":23628,"activeCount":109},[],{"trials":23630,"activeCount":109},[],{"trials":23632,"activeCount":109},[],{"trials":23634,"activeCount":109},[23635],{"nctId":23636,"briefTitle":23637,"status":569,"phases":23638,"primaryCompletion":15411,"completion":15411,"start":19281,"enrollment":640,"conditions":23639,"interventions":23640},"NCT03283111","Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma",[102],[11636],[23621],{"intervention":8358,"totalTrials":708,"cells":23642},{"EARLY_PHASE1":23643,"PHASE1":23645,"PHASE2":23647,"PHASE3":23649,"PHASE4":23651,"NA":23653},{"trials":23644,"activeCount":109},[],{"trials":23646,"activeCount":109},[],{"trials":23648,"activeCount":109},[],{"trials":23650,"activeCount":109},[],{"trials":23652,"activeCount":109},[],{"trials":23654,"activeCount":109},[23655],{"nctId":8349,"briefTitle":8350,"status":569,"phases":23656,"primaryCompletion":8352,"completion":3594,"start":8353,"enrollment":8354,"conditions":23657,"interventions":23658},[102],[8356],[8358,8359,8328],{"intervention":8359,"totalTrials":708,"cells":23660},{"EARLY_PHASE1":23661,"PHASE1":23663,"PHASE2":23665,"PHASE3":23667,"PHASE4":23669,"NA":23671},{"trials":23662,"activeCount":109},[],{"trials":23664,"activeCount":109},[],{"trials":23666,"activeCount":109},[],{"trials":23668,"activeCount":109},[],{"trials":23670,"activeCount":109},[],{"trials":23672,"activeCount":109},[23673],{"nctId":8349,"briefTitle":8350,"status":569,"phases":23674,"primaryCompletion":8352,"completion":3594,"start":8353,"enrollment":8354,"conditions":23675,"interventions":23676},[102],[8356],[8358,8359,8328],{"intervention":22603,"totalTrials":708,"cells":23678},{"EARLY_PHASE1":23679,"PHASE1":23681,"PHASE2":23683,"PHASE3":23685,"PHASE4":23687,"NA":23689},{"trials":23680,"activeCount":109},[],{"trials":23682,"activeCount":109},[],{"trials":23684,"activeCount":109},[],{"trials":23686,"activeCount":109},[],{"trials":23688,"activeCount":109},[],{"trials":23690,"activeCount":109},[23691],{"nctId":22598,"briefTitle":22599,"status":569,"phases":23692,"primaryCompletion":13941,"completion":17607,"start":13718,"enrollment":1165,"conditions":23693,"interventions":23694},[102],[539],[22603,21531],{"intervention":23696,"totalTrials":708,"cells":23697},"shRNA",{"EARLY_PHASE1":23698,"PHASE1":23700,"PHASE2":23702,"PHASE3":23704,"PHASE4":23706,"NA":23708},{"trials":23699,"activeCount":109},[],{"trials":23701,"activeCount":109},[],{"trials":23703,"activeCount":109},[],{"trials":23705,"activeCount":109},[],{"trials":23707,"activeCount":109},[],{"trials":23709,"activeCount":109},[23710],{"nctId":23711,"briefTitle":23712,"status":569,"phases":23713,"primaryCompletion":4090,"completion":15411,"start":252,"enrollment":670,"conditions":23714,"interventions":23715},"NCT02757586","Treatment of Chronic Lymphocytic Leukemia",[],[16765],[23696],{"intervention":23717,"totalTrials":708,"cells":23718},"camrelizumab+apatinib+hyperfractionated radiotherapy",{"EARLY_PHASE1":23719,"PHASE1":23721,"PHASE2":23723,"PHASE3":23725,"PHASE4":23727,"NA":23729},{"trials":23720,"activeCount":109},[],{"trials":23722,"activeCount":109},[],{"trials":23724,"activeCount":109},[],{"trials":23726,"activeCount":109},[],{"trials":23728,"activeCount":109},[],{"trials":23730,"activeCount":109},[23731],{"nctId":23732,"briefTitle":23733,"status":569,"phases":23734,"primaryCompletion":363,"completion":23735,"start":20395,"enrollment":1767,"conditions":23736,"interventions":23737},"NCT04609293","Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma",[],"2024-05-07",[3530],[23717],{"intervention":23739,"totalTrials":708,"cells":23740},"chlorhexidine acetate gargle",{"EARLY_PHASE1":23741,"PHASE1":23743,"PHASE2":23745,"PHASE3":23747,"PHASE4":23749,"NA":23751},{"trials":23742,"activeCount":109},[],{"trials":23744,"activeCount":109},[],{"trials":23746,"activeCount":109},[],{"trials":23748,"activeCount":109},[],{"trials":23750,"activeCount":109},[],{"trials":23752,"activeCount":109},[23753],{"nctId":23754,"briefTitle":23755,"status":569,"phases":23756,"primaryCompletion":4670,"completion":8431,"start":449,"enrollment":23757,"conditions":23758,"interventions":23759},"NCT03492827","Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD",[102],306,[2627,28],[23739],{"intervention":23761,"totalTrials":708,"cells":23762},"Epidural analgesia",{"EARLY_PHASE1":23763,"PHASE1":23765,"PHASE2":23767,"PHASE3":23769,"PHASE4":23771,"NA":23773},{"trials":23764,"activeCount":109},[],{"trials":23766,"activeCount":109},[],{"trials":23768,"activeCount":109},[],{"trials":23770,"activeCount":109},[],{"trials":23772,"activeCount":109},[],{"trials":23774,"activeCount":109},[23775],{"nctId":23776,"briefTitle":23777,"status":135,"phases":23778,"primaryCompletion":23779,"completion":23780,"start":1417,"enrollment":23781,"conditions":23782,"interventions":23785},"NCT04940091","Epidural Analgesia and Maternal Fever During Labor",[],"2022-02-05","2022-03-21",1051,[15325,23783,23784],"Analgesic Effect","Fever",[23761],{"intervention":23787,"totalTrials":708,"cells":23788},"Yangxue Qingnao Granules",{"EARLY_PHASE1":23789,"PHASE1":23791,"PHASE2":23793,"PHASE3":23795,"PHASE4":23797,"NA":23799},{"trials":23790,"activeCount":109},[],{"trials":23792,"activeCount":109},[],{"trials":23794,"activeCount":109},[],{"trials":23796,"activeCount":109},[],{"trials":23798,"activeCount":109},[],{"trials":23800,"activeCount":109},[23801],{"nctId":23802,"briefTitle":23803,"status":569,"phases":23804,"primaryCompletion":773,"completion":2051,"start":4308,"enrollment":140,"conditions":23805,"interventions":23807},"NCT06344312","Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction",[102],[23806],"Stroke, Acute Ischemic",[23787],{"intervention":23809,"totalTrials":708,"cells":23810},"Quatiapine Fumarate",{"EARLY_PHASE1":23811,"PHASE1":23813,"PHASE2":23815,"PHASE3":23817,"PHASE4":23819,"NA":23821},{"trials":23812,"activeCount":109},[],{"trials":23814,"activeCount":109},[],{"trials":23816,"activeCount":109},[],{"trials":23818,"activeCount":109},[],{"trials":23820,"activeCount":109},[],{"trials":23822,"activeCount":109},[23823],{"nctId":23824,"briefTitle":23825,"status":135,"phases":23826,"primaryCompletion":4142,"completion":23827,"start":23828,"enrollment":153,"conditions":23829,"interventions":23830},"NCT00631722","Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia",[102],"2008-05","2007-05",[9585],[23809,23831],"Haloperidol",{"intervention":23831,"totalTrials":708,"cells":23833},{"EARLY_PHASE1":23834,"PHASE1":23836,"PHASE2":23838,"PHASE3":23840,"PHASE4":23842,"NA":23844},{"trials":23835,"activeCount":109},[],{"trials":23837,"activeCount":109},[],{"trials":23839,"activeCount":109},[],{"trials":23841,"activeCount":109},[],{"trials":23843,"activeCount":109},[],{"trials":23845,"activeCount":109},[23846],{"nctId":23824,"briefTitle":23825,"status":135,"phases":23847,"primaryCompletion":4142,"completion":23827,"start":23828,"enrollment":153,"conditions":23848,"interventions":23849},[102],[9585],[23809,23831],{"intervention":23851,"totalTrials":708,"cells":23852},"Sodium hyaluronate eye drops",{"EARLY_PHASE1":23853,"PHASE1":23855,"PHASE2":23857,"PHASE3":23859,"PHASE4":23861,"NA":23863},{"trials":23854,"activeCount":109},[],{"trials":23856,"activeCount":109},[],{"trials":23858,"activeCount":109},[],{"trials":23860,"activeCount":109},[],{"trials":23862,"activeCount":109},[],{"trials":23864,"activeCount":109},[23865],{"nctId":23866,"briefTitle":23867,"status":135,"phases":23868,"primaryCompletion":8537,"completion":57,"start":23869,"enrollment":47,"conditions":23870,"interventions":23871},"NCT04668131","Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease",[102],"2020-09-22",[13634],[23851],{"intervention":23873,"totalTrials":708,"cells":23874},"mesenchymal stem cells from umbilical cord",{"EARLY_PHASE1":23875,"PHASE1":23877,"PHASE2":23879,"PHASE3":23881,"PHASE4":23883,"NA":23885},{"trials":23876,"activeCount":109},[],{"trials":23878,"activeCount":109},[],{"trials":23880,"activeCount":109},[],{"trials":23882,"activeCount":109},[],{"trials":23884,"activeCount":109},[],{"trials":23886,"activeCount":109},[23887],{"nctId":23888,"briefTitle":23889,"status":569,"phases":23890,"primaryCompletion":16091,"completion":2624,"start":4720,"enrollment":3887,"conditions":23891,"interventions":23893},"NCT03358654","Evaluating Safety and Efficacy of Mesenchymal Stem Cells From Umbilical Cord",[102],[23892,2416],"Umbilical Cord Bleeding",[23873],{"intervention":23895,"totalTrials":708,"cells":23896},"99mTc-MIRC208",{"EARLY_PHASE1":23897,"PHASE1":23899,"PHASE2":23901,"PHASE3":23903,"PHASE4":23905,"NA":23907},{"trials":23898,"activeCount":109},[],{"trials":23900,"activeCount":109},[],{"trials":23902,"activeCount":109},[],{"trials":23904,"activeCount":109},[],{"trials":23906,"activeCount":109},[],{"trials":23908,"activeCount":109},[23909],{"nctId":23910,"briefTitle":23911,"status":569,"phases":23912,"primaryCompletion":2577,"completion":2577,"start":15757,"enrollment":168,"conditions":23913,"interventions":23914},"NCT04591652","99mTc-MIRC208 SPECT\u002FCT Imaging for HER2-Positive Cancer Patients",[102],[9847],[23895],{"intervention":23916,"totalTrials":708,"cells":23917},"prednisone + Inhibace\u002FCozaar",{"EARLY_PHASE1":23918,"PHASE1":23920,"PHASE2":23922,"PHASE3":23924,"PHASE4":23926,"NA":23928},{"trials":23919,"activeCount":109},[],{"trials":23921,"activeCount":109},[],{"trials":23923,"activeCount":109},[],{"trials":23925,"activeCount":109},[],{"trials":23927,"activeCount":109},[],{"trials":23929,"activeCount":109},[23930],{"nctId":23931,"briefTitle":23932,"status":569,"phases":23933,"completion":23934,"start":23935,"conditions":23936,"interventions":23937},"NCT00378443","ACEi\u002FARB Alone Versus ACEi\u002FARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT",[102],"2007-06","2006-01",[16397],[23916,23938],"Inhibace\u002FCozaar",{"intervention":23938,"totalTrials":708,"cells":23940},{"EARLY_PHASE1":23941,"PHASE1":23943,"PHASE2":23945,"PHASE3":23947,"PHASE4":23949,"NA":23951},{"trials":23942,"activeCount":109},[],{"trials":23944,"activeCount":109},[],{"trials":23946,"activeCount":109},[],{"trials":23948,"activeCount":109},[],{"trials":23950,"activeCount":109},[],{"trials":23952,"activeCount":109},[23953],{"nctId":23931,"briefTitle":23932,"status":569,"phases":23954,"completion":23934,"start":23935,"conditions":23955,"interventions":23956},[102],[16397],[23916,23938],{"intervention":23958,"totalTrials":708,"cells":23959},"MLD",{"EARLY_PHASE1":23960,"PHASE1":23962,"PHASE2":23964,"PHASE3":23966,"PHASE4":23968,"NA":23970},{"trials":23961,"activeCount":109},[],{"trials":23963,"activeCount":109},[],{"trials":23965,"activeCount":109},[],{"trials":23967,"activeCount":109},[],{"trials":23969,"activeCount":109},[],{"trials":23971,"activeCount":109},[23972],{"nctId":23973,"briefTitle":23974,"status":569,"phases":23975,"primaryCompletion":1103,"completion":741,"start":23976,"enrollment":3615,"conditions":23977,"interventions":23979},"NCT05388890","Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation",[],"2022-08-02",[23978],"Chronic Atrophic Gastritis",[23958,23980],"WFC",{"intervention":23980,"totalTrials":708,"cells":23982},{"EARLY_PHASE1":23983,"PHASE1":23985,"PHASE2":23987,"PHASE3":23989,"PHASE4":23991,"NA":23993},{"trials":23984,"activeCount":109},[],{"trials":23986,"activeCount":109},[],{"trials":23988,"activeCount":109},[],{"trials":23990,"activeCount":109},[],{"trials":23992,"activeCount":109},[],{"trials":23994,"activeCount":109},[23995],{"nctId":23973,"briefTitle":23974,"status":569,"phases":23996,"primaryCompletion":1103,"completion":741,"start":23976,"enrollment":3615,"conditions":23997,"interventions":23998},[],[23978],[23958,23980],{"intervention":24000,"totalTrials":708,"cells":24001},"Metformin intervention for 12 weeks",{"EARLY_PHASE1":24002,"PHASE1":24004,"PHASE2":24006,"PHASE3":24008,"PHASE4":24010,"NA":24012},{"trials":24003,"activeCount":109},[],{"trials":24005,"activeCount":109},[],{"trials":24007,"activeCount":109},[],{"trials":24009,"activeCount":109},[],{"trials":24011,"activeCount":109},[],{"trials":24013,"activeCount":109},[24014],{"nctId":24015,"briefTitle":24016,"status":135,"phases":24017,"primaryCompletion":639,"completion":9279,"start":16091,"enrollment":24018,"conditions":24019,"interventions":24021},"NCT05802212","Effect of Metformin on Patients With Polycystic Ovary Syndrome",[102],77,[24020],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries",[24000],{"intervention":24023,"totalTrials":708,"cells":24024},"Forced administration of furosemide",{"EARLY_PHASE1":24025,"PHASE1":24027,"PHASE2":24029,"PHASE3":24031,"PHASE4":24033,"NA":24035},{"trials":24026,"activeCount":109},[],{"trials":24028,"activeCount":109},[],{"trials":24030,"activeCount":109},[],{"trials":24032,"activeCount":109},[],{"trials":24034,"activeCount":109},[],{"trials":24036,"activeCount":109},[24037],{"nctId":24038,"briefTitle":24039,"status":135,"phases":24040,"primaryCompletion":24041,"completion":24042,"start":24043,"enrollment":2665,"conditions":24044,"interventions":24049},"NCT05939193","Effect of Urine-guided Hydration on Acute Kidney Injury After CRS-HIPEC",[102],"2024-07-19","2025-02-04","2023-07-24",[24045,24046,24047,24048,11434,357],"Cytoreductive Surgery","Hyperthermic Intraperitoneal Chemotherapy","Hydration","Diuresis",[24023,24050],"Routine administration of furosemide",{"intervention":24050,"totalTrials":708,"cells":24052},{"EARLY_PHASE1":24053,"PHASE1":24055,"PHASE2":24057,"PHASE3":24059,"PHASE4":24061,"NA":24063},{"trials":24054,"activeCount":109},[],{"trials":24056,"activeCount":109},[],{"trials":24058,"activeCount":109},[],{"trials":24060,"activeCount":109},[],{"trials":24062,"activeCount":109},[],{"trials":24064,"activeCount":109},[24065],{"nctId":24038,"briefTitle":24039,"status":135,"phases":24066,"primaryCompletion":24041,"completion":24042,"start":24043,"enrollment":2665,"conditions":24067,"interventions":24068},[102],[24045,24046,24047,24048,11434,357],[24023,24050],{"intervention":24070,"totalTrials":708,"cells":24071},"Entecavir 0.5 mg",{"EARLY_PHASE1":24072,"PHASE1":24074,"PHASE2":24076,"PHASE3":24078,"PHASE4":24080,"NA":24082},{"trials":24073,"activeCount":109},[],{"trials":24075,"activeCount":109},[],{"trials":24077,"activeCount":109},[],{"trials":24079,"activeCount":109},[],{"trials":24081,"activeCount":109},[],{"trials":24083,"activeCount":109},[24084],{"nctId":24085,"briefTitle":24086,"status":569,"phases":24087,"primaryCompletion":657,"completion":2542,"start":24088,"enrollment":24089,"conditions":24090,"interventions":24092},"NCT03568578","A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers",[102],"2018-01-28",450,[13759,24091],"Liver Fibrosis",[24070,24093],"Anluohuaxian Pill 12g",{"intervention":24093,"totalTrials":708,"cells":24095},{"EARLY_PHASE1":24096,"PHASE1":24098,"PHASE2":24100,"PHASE3":24102,"PHASE4":24104,"NA":24106},{"trials":24097,"activeCount":109},[],{"trials":24099,"activeCount":109},[],{"trials":24101,"activeCount":109},[],{"trials":24103,"activeCount":109},[],{"trials":24105,"activeCount":109},[],{"trials":24107,"activeCount":109},[24108],{"nctId":24085,"briefTitle":24086,"status":569,"phases":24109,"primaryCompletion":657,"completion":2542,"start":24088,"enrollment":24089,"conditions":24110,"interventions":24111},[102],[13759,24091],[24070,24093],{"intervention":24113,"totalTrials":708,"cells":24114},"Tylenol",{"EARLY_PHASE1":24115,"PHASE1":24117,"PHASE2":24119,"PHASE3":24121,"PHASE4":24123,"NA":24125},{"trials":24116,"activeCount":109},[],{"trials":24118,"activeCount":109},[],{"trials":24120,"activeCount":109},[],{"trials":24122,"activeCount":109},[],{"trials":24124,"activeCount":109},[],{"trials":24126,"activeCount":109},[24127],{"nctId":24128,"briefTitle":24129,"status":135,"phases":24130,"primaryCompletion":151,"completion":14246,"start":24131,"enrollment":24132,"conditions":24133,"interventions":24137},"NCT04042948","Clinical Effect of Preventive Use of Tylenol on Fever After Removal of Drainage Tube in Lumbar Fusion Surgery",[102],"2019-06-24",183,[24134,24135,24136],"Lumbar Spinal Stenosis","Lumbar Disc Herniation","Lumbar Radiculopathy",[24113],{"intervention":24139,"totalTrials":708,"cells":24140},"dasatinib",{"EARLY_PHASE1":24141,"PHASE1":24143,"PHASE2":24145,"PHASE3":24147,"PHASE4":24149,"NA":24151},{"trials":24142,"activeCount":109},[],{"trials":24144,"activeCount":109},[],{"trials":24146,"activeCount":109},[],{"trials":24148,"activeCount":109},[],{"trials":24150,"activeCount":109},[],{"trials":24152,"activeCount":109},[24153],{"nctId":24154,"briefTitle":24155,"status":569,"phases":24156,"primaryCompletion":19151,"completion":24157,"start":5437,"enrollment":5941,"conditions":24158,"interventions":24159},"NCT02776878","A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST",[102],"2018-05",[20295],[24139],{"intervention":24161,"totalTrials":708,"cells":24162},"camrelizumab+hyperfractionated radiotherapy",{"EARLY_PHASE1":24163,"PHASE1":24165,"PHASE2":24167,"PHASE3":24169,"PHASE4":24171,"NA":24173},{"trials":24164,"activeCount":109},[],{"trials":24166,"activeCount":109},[],{"trials":24168,"activeCount":109},[],{"trials":24170,"activeCount":109},[],{"trials":24172,"activeCount":109},[],{"trials":24174,"activeCount":109},[24175],{"nctId":24176,"briefTitle":24177,"status":569,"phases":24178,"primaryCompletion":24179,"completion":71,"start":24180,"enrollment":140,"conditions":24181,"interventions":24184},"NCT04587817","Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors",[],"2022-09-19","2020-10-15",[3924,24182,24183],"SBRT","Bulky Tumor",[24161],{"intervention":24186,"totalTrials":708,"cells":24187},"Geleli",{"EARLY_PHASE1":24188,"PHASE1":24190,"PHASE2":24192,"PHASE3":24194,"PHASE4":24196,"NA":24198},{"trials":24189,"activeCount":109},[],{"trials":24191,"activeCount":109},[],{"trials":24193,"activeCount":109},[],{"trials":24195,"activeCount":109},[],{"trials":24197,"activeCount":109},[],{"trials":24199,"activeCount":109},[24200],{"nctId":24201,"briefTitle":24202,"status":569,"phases":24203,"primaryCompletion":2633,"completion":2577,"start":2504,"enrollment":13296,"conditions":24204,"interventions":24205},"NCT05240859","Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis",[],[2506],[24186],{"intervention":24207,"totalTrials":708,"cells":24208},"Fast Inpatient Rehabilitation",{"EARLY_PHASE1":24209,"PHASE1":24211,"PHASE2":24213,"PHASE3":24215,"PHASE4":24217,"NA":24219},{"trials":24210,"activeCount":109},[],{"trials":24212,"activeCount":109},[],{"trials":24214,"activeCount":109},[],{"trials":24216,"activeCount":109},[],{"trials":24218,"activeCount":109},[],{"trials":24220,"activeCount":109},[24221],{"nctId":24222,"briefTitle":24223,"status":569,"phases":24224,"primaryCompletion":24225,"completion":24226,"start":24227,"enrollment":140,"conditions":24228,"interventions":24230},"NCT04458480","Effect of Fast Inpatient Rehabilitation After TKA",[],"2020-09-06","2021-03-06","2019-09-07",[282,24229],"Rehabilitation",[24207],{"intervention":24232,"totalTrials":708,"cells":24233},"Ensatinib",{"EARLY_PHASE1":24234,"PHASE1":24236,"PHASE2":24238,"PHASE3":24240,"PHASE4":24242,"NA":24244},{"trials":24235,"activeCount":109},[],{"trials":24237,"activeCount":109},[],{"trials":24239,"activeCount":109},[],{"trials":24241,"activeCount":109},[],{"trials":24243,"activeCount":109},[],{"trials":24245,"activeCount":109},[24246],{"nctId":24247,"briefTitle":24248,"status":569,"phases":24249,"primaryCompletion":855,"completion":3259,"start":24250,"enrollment":341,"conditions":24251,"interventions":24254},"NCT05132218","Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer",[],"2021-10-19",[24252,24253,6694],"ALK Positive","NSCLC Stage IIIB",[24232],{"intervention":24256,"totalTrials":708,"cells":24257},"YJ001",{"EARLY_PHASE1":24258,"PHASE1":24260,"PHASE2":24262,"PHASE3":24264,"PHASE4":24266,"NA":24268},{"trials":24259,"activeCount":109},[],{"trials":24261,"activeCount":109},[],{"trials":24263,"activeCount":109},[],{"trials":24265,"activeCount":109},[],{"trials":24267,"activeCount":109},[],{"trials":24269,"activeCount":109},[24270],{"nctId":24271,"briefTitle":24272,"status":569,"phases":24273,"primaryCompletion":23259,"completion":572,"start":1640,"enrollment":24274,"conditions":24275,"interventions":24277},"NCT04953221","The Effect of YJ001 on Diabetic Peripheral Neuropathic Pain.",[],225,[24276],"Diabetic Peripheral Neuropathic Pain",[24256],{"intervention":24279,"totalTrials":708,"cells":24280},"Goserelin Acetate",{"EARLY_PHASE1":24281,"PHASE1":24283,"PHASE2":24285,"PHASE3":24287,"PHASE4":24289,"NA":24291},{"trials":24282,"activeCount":109},[],{"trials":24284,"activeCount":109},[],{"trials":24286,"activeCount":109},[],{"trials":24288,"activeCount":109},[],{"trials":24290,"activeCount":109},[],{"trials":24292,"activeCount":109},[24293],{"nctId":24294,"briefTitle":24295,"status":569,"phases":24296,"primaryCompletion":8262,"completion":5362,"start":5437,"enrollment":24297,"conditions":24298,"interventions":24300},"NCT02779387","Reproductive Outcome of EM Treated by GnRH-a Associated With Laparoscopy",[102],1184,[24299],"Infertility Associated With Endometriosis",[24279],{"intervention":24302,"totalTrials":708,"cells":24303},"Single cell sequencing, whole genome and metabolomic sequencing",{"EARLY_PHASE1":24304,"PHASE1":24306,"PHASE2":24308,"PHASE3":24310,"PHASE4":24312,"NA":24314},{"trials":24305,"activeCount":109},[],{"trials":24307,"activeCount":109},[],{"trials":24309,"activeCount":109},[],{"trials":24311,"activeCount":109},[],{"trials":24313,"activeCount":109},[],{"trials":24315,"activeCount":109},[24316],{"nctId":24317,"briefTitle":24318,"status":569,"phases":24319,"primaryCompletion":1578,"completion":7451,"start":24320,"enrollment":4171,"conditions":24321,"interventions":24323},"NCT06391879","Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma",[],"2023-09-08",[24322,3530],"VHL Syndrome",[24302],{"intervention":24325,"totalTrials":708,"cells":24326},"Clinical probes",{"EARLY_PHASE1":24327,"PHASE1":24329,"PHASE2":24331,"PHASE3":24333,"PHASE4":24335,"NA":24337},{"trials":24328,"activeCount":109},[],{"trials":24330,"activeCount":109},[],{"trials":24332,"activeCount":109},[],{"trials":24334,"activeCount":109},[],{"trials":24336,"activeCount":109},[],{"trials":24338,"activeCount":109},[24339],{"nctId":24340,"briefTitle":24341,"status":569,"phases":24342,"primaryCompletion":944,"completion":20081,"start":24343,"enrollment":24344,"conditions":24345,"interventions":24347},"NCT05893849","Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults",[],"2023-03-28",624,[24346],"Aging",[24325],{"intervention":24349,"totalTrials":708,"cells":24350},"Tobramycin and Dexamethasone Ophthalmic Ointment",{"EARLY_PHASE1":24351,"PHASE1":24353,"PHASE2":24355,"PHASE3":24357,"PHASE4":24359,"NA":24361},{"trials":24352,"activeCount":109},[],{"trials":24354,"activeCount":109},[],{"trials":24356,"activeCount":109},[],{"trials":24358,"activeCount":109},[],{"trials":24360,"activeCount":109},[],{"trials":24362,"activeCount":109},[24363],{"nctId":24364,"briefTitle":24365,"status":135,"phases":24366,"primaryCompletion":3478,"completion":3120,"start":5343,"enrollment":47,"conditions":24367,"interventions":24369},"NCT02958514","Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction",[102],[24368],"Dry Eye Syndrome",[24349],{"intervention":24371,"totalTrials":708,"cells":24372},"metoprolol",{"EARLY_PHASE1":24373,"PHASE1":24375,"PHASE2":24377,"PHASE3":24379,"PHASE4":24381,"NA":24383},{"trials":24374,"activeCount":109},[],{"trials":24376,"activeCount":109},[],{"trials":24378,"activeCount":109},[],{"trials":24380,"activeCount":109},[],{"trials":24382,"activeCount":109},[],{"trials":24384,"activeCount":109},[24385],{"nctId":24386,"briefTitle":24387,"status":135,"phases":24388,"completion":24389,"start":24390,"enrollment":3871,"conditions":24391,"interventions":24393},"NCT00475462","The Effectiveness of Metoprolol in the Prevention of Syncope Recurrence in Children and Adolescents",[102],"2003-12","2001-07",[24392],"Syncope, Vasovagal",[24371,24394],"conventional treatment",{"intervention":24394,"totalTrials":708,"cells":24396},{"EARLY_PHASE1":24397,"PHASE1":24399,"PHASE2":24401,"PHASE3":24403,"PHASE4":24405,"NA":24407},{"trials":24398,"activeCount":109},[],{"trials":24400,"activeCount":109},[],{"trials":24402,"activeCount":109},[],{"trials":24404,"activeCount":109},[],{"trials":24406,"activeCount":109},[],{"trials":24408,"activeCount":109},[24409],{"nctId":24386,"briefTitle":24387,"status":135,"phases":24410,"completion":24389,"start":24390,"enrollment":3871,"conditions":24411,"interventions":24412},[102],[24392],[24371,24394],{"intervention":24414,"totalTrials":708,"cells":24415},"Dun Ye Guan Xin Ning",{"EARLY_PHASE1":24416,"PHASE1":24418,"PHASE2":24420,"PHASE3":24422,"PHASE4":24424,"NA":24426},{"trials":24417,"activeCount":109},[],{"trials":24419,"activeCount":109},[],{"trials":24421,"activeCount":109},[],{"trials":24423,"activeCount":109},[],{"trials":24425,"activeCount":109},[],{"trials":24427,"activeCount":109},[24428],{"nctId":24429,"briefTitle":24430,"status":569,"phases":24431,"primaryCompletion":959,"completion":957,"start":24432,"enrollment":5215,"conditions":24433,"interventions":24435},"NCT03198091","Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris",[102],"2017-03-30",[24434],"Coronary Heart Disease",[24414],{"intervention":24437,"totalTrials":708,"cells":24438},"Anluohuaxian",{"EARLY_PHASE1":24439,"PHASE1":24441,"PHASE2":24443,"PHASE3":24445,"PHASE4":24447,"NA":24449},{"trials":24440,"activeCount":109},[],{"trials":24442,"activeCount":109},[],{"trials":24444,"activeCount":109},[],{"trials":24446,"activeCount":109},[],{"trials":24448,"activeCount":109},[],{"trials":24450,"activeCount":109},[24451],{"nctId":24452,"briefTitle":24453,"status":569,"phases":24454,"primaryCompletion":16091,"completion":2624,"start":1641,"enrollment":14572,"conditions":24455,"interventions":24456},"NCT04334265","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019",[102],[2494],[24437],{"intervention":24458,"totalTrials":708,"cells":24459},"Respiratory rehabilitation",{"EARLY_PHASE1":24460,"PHASE1":24462,"PHASE2":24464,"PHASE3":24466,"PHASE4":24468,"NA":24470},{"trials":24461,"activeCount":109},[],{"trials":24463,"activeCount":109},[],{"trials":24465,"activeCount":109},[],{"trials":24467,"activeCount":109},[],{"trials":24469,"activeCount":109},[],{"trials":24471,"activeCount":109},[24472],{"nctId":24473,"briefTitle":24474,"status":569,"phases":24475,"primaryCompletion":1112,"completion":657,"start":24476,"enrollment":4171,"conditions":24477,"interventions":24481},"NCT04382534","A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction",[],"2020-03-10",[24478,24479,23087,24480],"Covid19","Respiratory Rehabilitation","Cohort Study",[24458],{"intervention":24483,"totalTrials":708,"cells":24484},"transdermal clonidine",{"EARLY_PHASE1":24485,"PHASE1":24487,"PHASE2":24489,"PHASE3":24491,"PHASE4":24493,"NA":24495},{"trials":24486,"activeCount":109},[],{"trials":24488,"activeCount":109},[],{"trials":24490,"activeCount":109},[],{"trials":24492,"activeCount":109},[],{"trials":24494,"activeCount":109},[],{"trials":24496,"activeCount":109},[24497],{"nctId":24498,"briefTitle":24499,"status":569,"phases":24500,"primaryCompletion":5437,"completion":5437,"start":14387,"enrollment":3547,"conditions":24501,"interventions":24503},"NCT02545530","Transdermal Clonidine in Chronic Hemodialysis Patients",[102],[24502],"Renal Dialysis",[24483],{"intervention":24505,"totalTrials":708,"cells":24506},"mesenchymal stem cells",{"EARLY_PHASE1":24507,"PHASE1":24509,"PHASE2":24511,"PHASE3":24513,"PHASE4":24515,"NA":24517},{"trials":24508,"activeCount":109},[],{"trials":24510,"activeCount":109},[],{"trials":24512,"activeCount":109},[],{"trials":24514,"activeCount":109},[],{"trials":24516,"activeCount":109},[],{"trials":24518,"activeCount":109},[24519],{"nctId":24520,"briefTitle":24521,"status":569,"phases":24522,"primaryCompletion":2624,"completion":857,"start":4720,"enrollment":3887,"conditions":24523,"interventions":24524},"NCT03357770","The Maximum Tolerated Dose of Mesenchymal Stem Cells From Umbilical Cord",[102],[2416,23892],[24505],{"intervention":24526,"totalTrials":708,"cells":24527},"the timing of embryo transfer in freeze-all cycles",{"EARLY_PHASE1":24528,"PHASE1":24530,"PHASE2":24532,"PHASE3":24534,"PHASE4":24536,"NA":24538},{"trials":24529,"activeCount":109},[],{"trials":24531,"activeCount":109},[],{"trials":24533,"activeCount":109},[],{"trials":24535,"activeCount":109},[],{"trials":24537,"activeCount":109},[],{"trials":24539,"activeCount":109},[24540],{"nctId":24541,"briefTitle":24542,"status":135,"phases":24543,"primaryCompletion":15015,"completion":24544,"start":24545,"enrollment":24546,"conditions":24547,"interventions":24548},"NCT05483270","Immediate Versus Postponed Freeze-all Embryo Transfer in Hyperresponders",[102],"2024-11-24","2022-08-30",845,[13185],[24526],{"intervention":24550,"totalTrials":708,"cells":24551},"SSRIs",{"EARLY_PHASE1":24552,"PHASE1":24554,"PHASE2":24556,"PHASE3":24558,"PHASE4":24560,"NA":24562},{"trials":24553,"activeCount":109},[],{"trials":24555,"activeCount":109},[],{"trials":24557,"activeCount":109},[],{"trials":24559,"activeCount":109},[],{"trials":24561,"activeCount":109},[],{"trials":24563,"activeCount":109},[24564],{"nctId":24565,"briefTitle":24566,"status":569,"phases":24567,"primaryCompletion":252,"completion":252,"start":241,"enrollment":24568,"conditions":24569,"interventions":24570},"NCT02023567","Objective Diagnostic Markers and Personalized Intervention in MDD Patients",[102],2400,[10299],[24550],{"intervention":24572,"totalTrials":708,"cells":24573},"trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy",{"EARLY_PHASE1":24574,"PHASE1":24576,"PHASE2":24578,"PHASE3":24580,"PHASE4":24582,"NA":24584},{"trials":24575,"activeCount":109},[],{"trials":24577,"activeCount":109},[],{"trials":24579,"activeCount":109},[],{"trials":24581,"activeCount":109},[],{"trials":24583,"activeCount":109},[],{"trials":24585,"activeCount":109},[24586],{"nctId":24587,"briefTitle":24588,"status":569,"phases":24589,"primaryCompletion":24590,"completion":24590,"start":24591,"enrollment":140,"conditions":24592,"interventions":24596},"NCT05188495","Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab",[],"2023-12-10","2021-05-10",[24593,24594,24595],"HER2-positive Metastatic Breast Cancer","Previously Treated With Trastuzumab","Trastuzumab Combined With Pertuzumab and Chemotherapy",[24572],{"intervention":1595,"totalTrials":708,"cells":24598},{"EARLY_PHASE1":24599,"PHASE1":24601,"PHASE2":24603,"PHASE3":24605,"PHASE4":24607,"NA":24609},{"trials":24600,"activeCount":109},[],{"trials":24602,"activeCount":109},[],{"trials":24604,"activeCount":109},[],{"trials":24606,"activeCount":109},[],{"trials":24608,"activeCount":109},[],{"trials":24610,"activeCount":109},[24611],{"nctId":1586,"briefTitle":1587,"status":569,"phases":24612,"primaryCompletion":81,"completion":1589,"start":1590,"enrollment":1591,"conditions":24613,"interventions":24614},[102],[1593],[1555,1595],{"intervention":24616,"totalTrials":708,"cells":24617},"Nitrate ketone oxazine",{"EARLY_PHASE1":24618,"PHASE1":24620,"PHASE2":24622,"PHASE3":24624,"PHASE4":24626,"NA":24628},{"trials":24619,"activeCount":109},[],{"trials":24621,"activeCount":109},[],{"trials":24623,"activeCount":109},[],{"trials":24625,"activeCount":109},[],{"trials":24627,"activeCount":109},[],{"trials":24629,"activeCount":109},[24630],{"nctId":24631,"briefTitle":24632,"status":569,"phases":24633,"primaryCompletion":2624,"completion":8314,"start":959,"enrollment":168,"conditions":24634,"interventions":24635},"NCT04951440","Study on the Effectiveness and Safety of Nitrone for Injection in Patients With Acute Ischemic Stroke",[102],[11702],[24616],{"intervention":24637,"totalTrials":708,"cells":24638},"Chidamide combined with Toripalimab",{"EARLY_PHASE1":24639,"PHASE1":24641,"PHASE2":24643,"PHASE3":24645,"PHASE4":24647,"NA":24649},{"trials":24640,"activeCount":109},[],{"trials":24642,"activeCount":109},[],{"trials":24644,"activeCount":109},[],{"trials":24646,"activeCount":109},[],{"trials":24648,"activeCount":109},[],{"trials":24650,"activeCount":109},[24651],{"nctId":24652,"briefTitle":24653,"status":569,"phases":24654,"primaryCompletion":2587,"completion":3327,"start":24655,"enrollment":26,"conditions":24656,"interventions":24657},"NCT05478473","Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma",[102],"2022-10-27",[2580],[24637],{"intervention":24659,"totalTrials":708,"cells":24660},"Transplant, Autologous",{"EARLY_PHASE1":24661,"PHASE1":24663,"PHASE2":24665,"PHASE3":24667,"PHASE4":24669,"NA":24671},{"trials":24662,"activeCount":109},[],{"trials":24664,"activeCount":109},[],{"trials":24666,"activeCount":109},[],{"trials":24668,"activeCount":109},[],{"trials":24670,"activeCount":109},[],{"trials":24672,"activeCount":109},[24673],{"nctId":24674,"briefTitle":24675,"status":569,"phases":24676,"primaryCompletion":14761,"completion":2744,"start":24677,"enrollment":140,"conditions":24678,"interventions":24680},"NCT04489264","The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma",[],"2020-11-30",[24679],"Peripheral T Cell Lymphoma",[24659],{"intervention":4147,"totalTrials":708,"cells":24682},{"EARLY_PHASE1":24683,"PHASE1":24685,"PHASE2":24687,"PHASE3":24689,"PHASE4":24691,"NA":24693},{"trials":24684,"activeCount":109},[],{"trials":24686,"activeCount":109},[],{"trials":24688,"activeCount":109},[],{"trials":24690,"activeCount":109},[],{"trials":24692,"activeCount":109},[],{"trials":24694,"activeCount":109},[24695],{"nctId":4138,"briefTitle":4139,"status":135,"phases":24696,"primaryCompletion":4141,"completion":3545,"start":4142,"enrollment":4143,"conditions":24697,"interventions":24698},[102],[4145],[4147,3767],{"intervention":10261,"totalTrials":708,"cells":24700},{"EARLY_PHASE1":24701,"PHASE1":24703,"PHASE2":24705,"PHASE3":24707,"PHASE4":24709,"NA":24711},{"trials":24702,"activeCount":109},[],{"trials":24704,"activeCount":109},[],{"trials":24706,"activeCount":109},[],{"trials":24708,"activeCount":109},[],{"trials":24710,"activeCount":109},[],{"trials":24712,"activeCount":109},[24713],{"nctId":10254,"briefTitle":10255,"status":569,"phases":24714,"primaryCompletion":2930,"completion":315,"start":10257,"enrollment":1445,"conditions":24715,"interventions":24716},[102],[10259],[10239,10261,10262,10263],{"intervention":10262,"totalTrials":708,"cells":24718},{"EARLY_PHASE1":24719,"PHASE1":24721,"PHASE2":24723,"PHASE3":24725,"PHASE4":24727,"NA":24729},{"trials":24720,"activeCount":109},[],{"trials":24722,"activeCount":109},[],{"trials":24724,"activeCount":109},[],{"trials":24726,"activeCount":109},[],{"trials":24728,"activeCount":109},[],{"trials":24730,"activeCount":109},[24731],{"nctId":10254,"briefTitle":10255,"status":569,"phases":24732,"primaryCompletion":2930,"completion":315,"start":10257,"enrollment":1445,"conditions":24733,"interventions":24734},[102],[10259],[10239,10261,10262,10263],{"intervention":10263,"totalTrials":708,"cells":24736},{"EARLY_PHASE1":24737,"PHASE1":24739,"PHASE2":24741,"PHASE3":24743,"PHASE4":24745,"NA":24747},{"trials":24738,"activeCount":109},[],{"trials":24740,"activeCount":109},[],{"trials":24742,"activeCount":109},[],{"trials":24744,"activeCount":109},[],{"trials":24746,"activeCount":109},[],{"trials":24748,"activeCount":109},[24749],{"nctId":10254,"briefTitle":10255,"status":569,"phases":24750,"primaryCompletion":2930,"completion":315,"start":10257,"enrollment":1445,"conditions":24751,"interventions":24752},[102],[10259],[10239,10261,10262,10263],{"intervention":24754,"totalTrials":708,"cells":24755},"Beijing protocol",{"EARLY_PHASE1":24756,"PHASE1":24758,"PHASE2":24760,"PHASE3":24762,"PHASE4":24764,"NA":24766},{"trials":24757,"activeCount":109},[],{"trials":24759,"activeCount":109},[],{"trials":24761,"activeCount":109},[],{"trials":24763,"activeCount":109},[],{"trials":24765,"activeCount":109},[],{"trials":24767,"activeCount":109},[24768],{"nctId":24769,"briefTitle":24770,"status":569,"phases":24771,"primaryCompletion":1893,"completion":1746,"start":818,"enrollment":47,"conditions":24772,"interventions":24773},"NCT05921318","Beijing Protocol in Patients Receiving More Than 5\u002F10 HLA-mismatched Allo-HSCT",[],[16994,3013],[24754],{"intervention":24775,"totalTrials":708,"cells":24776},"Letermovir",{"EARLY_PHASE1":24777,"PHASE1":24779,"PHASE2":24781,"PHASE3":24783,"PHASE4":24785,"NA":24787},{"trials":24778,"activeCount":109},[],{"trials":24780,"activeCount":109},[],{"trials":24782,"activeCount":109},[],{"trials":24784,"activeCount":109},[],{"trials":24786,"activeCount":109},[],{"trials":24788,"activeCount":109},[24789],{"nctId":24790,"briefTitle":24791,"status":569,"phases":24792,"primaryCompletion":2930,"completion":315,"start":1526,"enrollment":574,"conditions":24793,"interventions":24794},"NCT05656599","Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies",[],[20175,15208],[24775],{"intervention":24796,"totalTrials":708,"cells":24797},"first-line chemotherapy",{"EARLY_PHASE1":24798,"PHASE1":24800,"PHASE2":24802,"PHASE3":24804,"PHASE4":24806,"NA":24808},{"trials":24799,"activeCount":109},[],{"trials":24801,"activeCount":109},[],{"trials":24803,"activeCount":109},[],{"trials":24805,"activeCount":109},[],{"trials":24807,"activeCount":109},[],{"trials":24809,"activeCount":109},[24810],{"nctId":24811,"briefTitle":24812,"status":135,"phases":24813,"primaryCompletion":22723,"completion":24814,"start":449,"enrollment":13765,"conditions":24815,"interventions":24819},"NCT03742063","Clinical Evaluation of Neoadjuvant Chemotherapy for Primary Malignant Sarcomas That Originate in Bone",[],"2018-10-30",[24816,24817,24818],"Clinical Response","Histopathological Response","Prognosis",[24796],{"intervention":24821,"totalTrials":708,"cells":24822},"Penehyclidine hydrochloride",{"EARLY_PHASE1":24823,"PHASE1":24825,"PHASE2":24827,"PHASE3":24829,"PHASE4":24831,"NA":24833},{"trials":24824,"activeCount":109},[],{"trials":24826,"activeCount":109},[],{"trials":24828,"activeCount":109},[],{"trials":24830,"activeCount":109},[],{"trials":24832,"activeCount":109},[],{"trials":24834,"activeCount":109},[24835],{"nctId":24836,"briefTitle":24837,"status":135,"phases":24838,"primaryCompletion":14246,"completion":14246,"start":192,"enrollment":24839,"conditions":24840,"interventions":24843},"NCT04112771","Penehyclidine and Postoperative Nausea and Vomiting After Bimaxillary Surgery",[],243,[24841,1220,24842],"Penehyclidine","Bimaxillar Surgery",[24821],{"intervention":22819,"totalTrials":708,"cells":24845},{"EARLY_PHASE1":24846,"PHASE1":24848,"PHASE2":24850,"PHASE3":24852,"PHASE4":24854,"NA":24856},{"trials":24847,"activeCount":109},[],{"trials":24849,"activeCount":109},[],{"trials":24851,"activeCount":109},[],{"trials":24853,"activeCount":109},[],{"trials":24855,"activeCount":109},[],{"trials":24857,"activeCount":109},[24858],{"nctId":22812,"briefTitle":22813,"status":569,"phases":24859,"primaryCompletion":10361,"completion":639,"start":22815,"enrollment":693,"conditions":24860,"interventions":24861},[],[22817],[22819,22797],{"intervention":24863,"totalTrials":708,"cells":24864},"Developmental assessment",{"EARLY_PHASE1":24865,"PHASE1":24867,"PHASE2":24869,"PHASE3":24871,"PHASE4":24873,"NA":24875},{"trials":24866,"activeCount":109},[],{"trials":24868,"activeCount":109},[],{"trials":24870,"activeCount":109},[],{"trials":24872,"activeCount":109},[],{"trials":24874,"activeCount":109},[],{"trials":24876,"activeCount":109},[24877],{"nctId":24878,"briefTitle":24879,"status":569,"phases":24880,"primaryCompletion":14761,"completion":14761,"start":2624,"enrollment":24568,"conditions":24881,"interventions":24883},"NCT04817878","Cohort Construction for Preterm Infants With Growth Retardation and Its Influencing Factors",[],[24882],"Problem With Growth of an Infant",[24863],{"intervention":24885,"totalTrials":708,"cells":24886},"low-dose glucocorticoid Methylprednisolone",{"EARLY_PHASE1":24887,"PHASE1":24889,"PHASE2":24891,"PHASE3":24893,"PHASE4":24895,"NA":24897},{"trials":24888,"activeCount":109},[],{"trials":24890,"activeCount":109},[],{"trials":24892,"activeCount":109},[],{"trials":24894,"activeCount":109},[],{"trials":24896,"activeCount":109},[],{"trials":24898,"activeCount":109},[24899],{"nctId":24900,"briefTitle":24901,"status":135,"phases":24902,"primaryCompletion":241,"completion":16522,"start":4153,"enrollment":9956,"conditions":24903,"interventions":24904},"NCT01607580","Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)",[102],[2876],[24885],{"intervention":24906,"totalTrials":708,"cells":24907},"Imatinib 400mg",{"EARLY_PHASE1":24908,"PHASE1":24910,"PHASE2":24912,"PHASE3":24914,"PHASE4":24916,"NA":24918},{"trials":24909,"activeCount":109},[],{"trials":24911,"activeCount":109},[],{"trials":24913,"activeCount":109},[],{"trials":24915,"activeCount":109},[],{"trials":24917,"activeCount":109},[],{"trials":24919,"activeCount":109},[24920],{"nctId":24921,"briefTitle":24922,"status":569,"phases":24923,"primaryCompletion":24924,"completion":24925,"start":24926,"enrollment":140,"conditions":24927,"interventions":24929},"NCT03424876","To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.",[],"2018-06-02","2018-08-08","2017-06-02",[24928],"GIST",[24906,24930],"Sunitinib 37.5Mg Oral",{"intervention":24930,"totalTrials":708,"cells":24932},{"EARLY_PHASE1":24933,"PHASE1":24935,"PHASE2":24937,"PHASE3":24939,"PHASE4":24941,"NA":24943},{"trials":24934,"activeCount":109},[],{"trials":24936,"activeCount":109},[],{"trials":24938,"activeCount":109},[],{"trials":24940,"activeCount":109},[],{"trials":24942,"activeCount":109},[],{"trials":24944,"activeCount":109},[24945],{"nctId":24921,"briefTitle":24922,"status":569,"phases":24946,"primaryCompletion":24924,"completion":24925,"start":24926,"enrollment":140,"conditions":24947,"interventions":24948},[],[24928],[24906,24930],{"intervention":24950,"totalTrials":708,"cells":24951},"peritoneal rest",{"EARLY_PHASE1":24952,"PHASE1":24954,"PHASE2":24956,"PHASE3":24958,"PHASE4":24960,"NA":24962},{"trials":24953,"activeCount":109},[],{"trials":24955,"activeCount":109},[],{"trials":24957,"activeCount":109},[],{"trials":24959,"activeCount":109},[],{"trials":24961,"activeCount":109},[],{"trials":24963,"activeCount":109},[24964],{"nctId":24965,"briefTitle":24966,"status":135,"phases":24967,"primaryCompletion":2503,"completion":3708,"start":7316,"enrollment":2732,"conditions":24968,"interventions":24970},"NCT05805813","Cross-control Study on the Effect of Peritoneal Rest on Peritoneal Transport Function in Peritoneal Dialysis Patients",[102],[24969],"Chronic Kidney Disease 5D",[24950],{"intervention":24972,"totalTrials":708,"cells":24973},"Neupro",{"EARLY_PHASE1":24974,"PHASE1":24976,"PHASE2":24978,"PHASE3":24980,"PHASE4":24982,"NA":24984},{"trials":24975,"activeCount":109},[],{"trials":24977,"activeCount":109},[],{"trials":24979,"activeCount":109},[],{"trials":24981,"activeCount":109},[],{"trials":24983,"activeCount":109},[],{"trials":24985,"activeCount":109},[24986],{"nctId":24987,"briefTitle":24988,"status":569,"phases":24989,"primaryCompletion":1202,"completion":24990,"start":1640,"enrollment":24991,"conditions":24992,"interventions":24993},"NCT04957420","The Practical Effect of Neupro",[],"2022-04-30",3000,[16647],[24972],{"intervention":24995,"totalTrials":708,"cells":24996},"Electret electrostatic physiotherapyFilm",{"EARLY_PHASE1":24997,"PHASE1":24999,"PHASE2":25001,"PHASE3":25003,"PHASE4":25005,"NA":25007},{"trials":24998,"activeCount":109},[],{"trials":25000,"activeCount":109},[],{"trials":25002,"activeCount":109},[],{"trials":25004,"activeCount":109},[],{"trials":25006,"activeCount":109},[],{"trials":25008,"activeCount":109},[25009],{"nctId":25010,"briefTitle":25011,"status":135,"phases":25012,"primaryCompletion":25013,"completion":25013,"start":25014,"enrollment":140,"conditions":25015,"interventions":25016},"NCT03365037","Study of Therapeutic Effect of Electret Static Physiotherapy Film on Acute Soft Tissue Closed Injury",[102],"2012-09-30","2012-04-01",[14114],[24995,25017],"Fracture healing film",{"intervention":25017,"totalTrials":708,"cells":25019},{"EARLY_PHASE1":25020,"PHASE1":25022,"PHASE2":25024,"PHASE3":25026,"PHASE4":25028,"NA":25030},{"trials":25021,"activeCount":109},[],{"trials":25023,"activeCount":109},[],{"trials":25025,"activeCount":109},[],{"trials":25027,"activeCount":109},[],{"trials":25029,"activeCount":109},[],{"trials":25031,"activeCount":109},[25032],{"nctId":25010,"briefTitle":25011,"status":135,"phases":25033,"primaryCompletion":25013,"completion":25013,"start":25014,"enrollment":140,"conditions":25034,"interventions":25035},[102],[14114],[24995,25017],{"intervention":25037,"totalTrials":708,"cells":25038},"sodium bicarbonate",{"EARLY_PHASE1":25039,"PHASE1":25041,"PHASE2":25043,"PHASE3":25045,"PHASE4":25047,"NA":25049},{"trials":25040,"activeCount":109},[],{"trials":25042,"activeCount":109},[],{"trials":25044,"activeCount":109},[],{"trials":25046,"activeCount":109},[],{"trials":25048,"activeCount":109},[],{"trials":25050,"activeCount":109},[25051],{"nctId":25052,"briefTitle":25053,"status":135,"phases":25054,"primaryCompletion":1964,"completion":15757,"start":13459,"enrollment":25055,"conditions":25056,"interventions":25058},"NCT04953013","Risk Potential for Organ Dysfunction Associated With Sodium Bicarbonate Therapy (SBT) in Critically Ill Patients",[],664,[25057],"Metabolic Acidosis; Critically Ill Patients; Organ Dysfunction",[25037],{"intervention":22879,"totalTrials":708,"cells":25060},{"EARLY_PHASE1":25061,"PHASE1":25063,"PHASE2":25065,"PHASE3":25067,"PHASE4":25069,"NA":25071},{"trials":25062,"activeCount":109},[],{"trials":25064,"activeCount":109},[],{"trials":25066,"activeCount":109},[],{"trials":25068,"activeCount":109},[],{"trials":25070,"activeCount":109},[],{"trials":25072,"activeCount":109},[25073],{"nctId":22873,"briefTitle":22874,"status":569,"phases":25074,"primaryCompletion":1163,"completion":17607,"start":669,"enrollment":8354,"conditions":25075,"interventions":25076},[],[22877],[22879,10279,22880,22881],{"intervention":22880,"totalTrials":708,"cells":25078},{"EARLY_PHASE1":25079,"PHASE1":25081,"PHASE2":25083,"PHASE3":25085,"PHASE4":25087,"NA":25089},{"trials":25080,"activeCount":109},[],{"trials":25082,"activeCount":109},[],{"trials":25084,"activeCount":109},[],{"trials":25086,"activeCount":109},[],{"trials":25088,"activeCount":109},[],{"trials":25090,"activeCount":109},[25091],{"nctId":22873,"briefTitle":22874,"status":569,"phases":25092,"primaryCompletion":1163,"completion":17607,"start":669,"enrollment":8354,"conditions":25093,"interventions":25094},[],[22877],[22879,10279,22880,22881],{"intervention":22881,"totalTrials":708,"cells":25096},{"EARLY_PHASE1":25097,"PHASE1":25099,"PHASE2":25101,"PHASE3":25103,"PHASE4":25105,"NA":25107},{"trials":25098,"activeCount":109},[],{"trials":25100,"activeCount":109},[],{"trials":25102,"activeCount":109},[],{"trials":25104,"activeCount":109},[],{"trials":25106,"activeCount":109},[],{"trials":25108,"activeCount":109},[25109],{"nctId":22873,"briefTitle":22874,"status":569,"phases":25110,"primaryCompletion":1163,"completion":17607,"start":669,"enrollment":8354,"conditions":25111,"interventions":25112},[],[22877],[22879,10279,22880,22881],{"intervention":22915,"totalTrials":708,"cells":25114},{"EARLY_PHASE1":25115,"PHASE1":25117,"PHASE2":25119,"PHASE3":25121,"PHASE4":25123,"NA":25125},{"trials":25116,"activeCount":109},[],{"trials":25118,"activeCount":109},[],{"trials":25120,"activeCount":109},[],{"trials":25122,"activeCount":109},[],{"trials":25124,"activeCount":109},[],{"trials":25126,"activeCount":109},[25127],{"nctId":22905,"briefTitle":22906,"status":569,"phases":25128,"primaryCompletion":1103,"completion":1103,"start":22908,"enrollment":11520,"conditions":25129,"interventions":25130},[],[22910,22911,22912,22913],[15697,22915],{"intervention":25132,"totalTrials":708,"cells":25133},"pMDT",{"EARLY_PHASE1":25134,"PHASE1":25136,"PHASE2":25138,"PHASE3":25140,"PHASE4":25142,"NA":25144},{"trials":25135,"activeCount":109},[],{"trials":25137,"activeCount":109},[],{"trials":25139,"activeCount":109},[],{"trials":25141,"activeCount":109},[],{"trials":25143,"activeCount":109},[],{"trials":25145,"activeCount":109},[25146],{"nctId":25147,"briefTitle":25148,"status":135,"phases":25149,"primaryCompletion":17122,"completion":17122,"start":3023,"enrollment":13985,"conditions":25150,"interventions":25152},"NCT03761550","pMDT in Thoracic Surgery--The Process Implementation Stage",[],[25151],"Pain, Postoperative",[25132],{"intervention":10280,"totalTrials":708,"cells":25154},{"EARLY_PHASE1":25155,"PHASE1":25157,"PHASE2":25159,"PHASE3":25161,"PHASE4":25163,"NA":25165},{"trials":25156,"activeCount":109},[],{"trials":25158,"activeCount":109},[],{"trials":25160,"activeCount":109},[],{"trials":25162,"activeCount":109},[],{"trials":25164,"activeCount":109},[],{"trials":25166,"activeCount":109},[25167],{"nctId":10273,"briefTitle":10274,"status":569,"phases":25168,"primaryCompletion":4651,"completion":57,"start":449,"enrollment":574,"conditions":25169,"interventions":25170},[102],[10277],[10239,10279,10280],{"intervention":25172,"totalTrials":708,"cells":25173},"Shuganjieyu",{"EARLY_PHASE1":25174,"PHASE1":25176,"PHASE2":25178,"PHASE3":25180,"PHASE4":25182,"NA":25184},{"trials":25175,"activeCount":109},[],{"trials":25177,"activeCount":109},[],{"trials":25179,"activeCount":109},[],{"trials":25181,"activeCount":109},[],{"trials":25183,"activeCount":109},[],{"trials":25185,"activeCount":109},[25186],{"nctId":25187,"briefTitle":25188,"status":569,"phases":25189,"primaryCompletion":1149,"completion":1403,"start":17037,"enrollment":1894,"conditions":25190,"interventions":25191},"NCT05361330","A Multicenter Clinical Study on Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression",[102],[10259],[25172,25192],"Fluoxetine",{"intervention":25192,"totalTrials":708,"cells":25194},{"EARLY_PHASE1":25195,"PHASE1":25197,"PHASE2":25199,"PHASE3":25201,"PHASE4":25203,"NA":25205},{"trials":25196,"activeCount":109},[],{"trials":25198,"activeCount":109},[],{"trials":25200,"activeCount":109},[],{"trials":25202,"activeCount":109},[],{"trials":25204,"activeCount":109},[],{"trials":25206,"activeCount":109},[25207],{"nctId":25187,"briefTitle":25188,"status":569,"phases":25208,"primaryCompletion":1149,"completion":1403,"start":17037,"enrollment":1894,"conditions":25209,"interventions":25210},[102],[10259],[25172,25192],{"intervention":22093,"totalTrials":708,"cells":25212},{"EARLY_PHASE1":25213,"PHASE1":25215,"PHASE2":25217,"PHASE3":25219,"PHASE4":25221,"NA":25223},{"trials":25214,"activeCount":109},[],{"trials":25216,"activeCount":109},[],{"trials":25218,"activeCount":109},[],{"trials":25220,"activeCount":109},[],{"trials":25222,"activeCount":109},[],{"trials":25224,"activeCount":109},[25225],{"nctId":22087,"briefTitle":22088,"status":569,"phases":25226,"primaryCompletion":22090,"completion":2568,"start":649,"enrollment":376,"conditions":25227,"interventions":25228},[],[19130],[2706,22093],{"intervention":25230,"totalTrials":708,"cells":25231},"Remimazolam Besylate",{"EARLY_PHASE1":25232,"PHASE1":25234,"PHASE2":25236,"PHASE3":25238,"PHASE4":25240,"NA":25242},{"trials":25233,"activeCount":109},[],{"trials":25235,"activeCount":109},[],{"trials":25237,"activeCount":109},[],{"trials":25239,"activeCount":109},[],{"trials":25241,"activeCount":109},[],{"trials":25243,"activeCount":109},[25244],{"nctId":25245,"briefTitle":25246,"status":135,"phases":25247,"primaryCompletion":2853,"completion":1361,"start":4268,"enrollment":574,"conditions":25248,"interventions":25252},"NCT05103696","A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients",[102],[25249,25250,25230,25251],"Elderly Patients","Gastrointestinal Endoscopy","Etomidate Combined With Propofol",[25230,25253],"etomidate combined with propofol",{"intervention":25253,"totalTrials":708,"cells":25255},{"EARLY_PHASE1":25256,"PHASE1":25258,"PHASE2":25260,"PHASE3":25262,"PHASE4":25264,"NA":25266},{"trials":25257,"activeCount":109},[],{"trials":25259,"activeCount":109},[],{"trials":25261,"activeCount":109},[],{"trials":25263,"activeCount":109},[],{"trials":25265,"activeCount":109},[],{"trials":25267,"activeCount":109},[25268],{"nctId":25245,"briefTitle":25246,"status":135,"phases":25269,"primaryCompletion":2853,"completion":1361,"start":4268,"enrollment":574,"conditions":25270,"interventions":25271},[102],[25249,25250,25230,25251],[25230,25253],{"intervention":23040,"totalTrials":708,"cells":25273},{"EARLY_PHASE1":25274,"PHASE1":25276,"PHASE2":25278,"PHASE3":25280,"PHASE4":25282,"NA":25284},{"trials":25275,"activeCount":109},[],{"trials":25277,"activeCount":109},[],{"trials":25279,"activeCount":109},[],{"trials":25281,"activeCount":109},[],{"trials":25283,"activeCount":109},[],{"trials":25285,"activeCount":109},[25286],{"nctId":23030,"briefTitle":23031,"status":135,"phases":25287,"primaryCompletion":23033,"completion":151,"start":23034,"enrollment":8354,"conditions":25288,"interventions":25289},[102],[43,23036,23037,23038,18109],[23040,23015],{"intervention":10290,"totalTrials":708,"cells":25291},{"EARLY_PHASE1":25292,"PHASE1":25294,"PHASE2":25296,"PHASE3":25298,"PHASE4":25300,"NA":25302},{"trials":25293,"activeCount":109},[],{"trials":25295,"activeCount":109},[],{"trials":25297,"activeCount":109},[],{"trials":25299,"activeCount":109},[],{"trials":25301,"activeCount":109},[],{"trials":25303,"activeCount":109},[25304],{"nctId":10282,"briefTitle":10283,"status":135,"phases":25305,"primaryCompletion":10285,"completion":10285,"start":10286,"enrollment":640,"conditions":25306,"interventions":25307},[102],[10288],[10290,10239],{"intervention":25309,"totalTrials":708,"cells":25310},"Xuanfei Baidu granule",{"EARLY_PHASE1":25311,"PHASE1":25313,"PHASE2":25315,"PHASE3":25317,"PHASE4":25319,"NA":25321},{"trials":25312,"activeCount":109},[],{"trials":25314,"activeCount":109},[],{"trials":25316,"activeCount":109},[],{"trials":25318,"activeCount":109},[],{"trials":25320,"activeCount":109},[],{"trials":25322,"activeCount":109},[25323],{"nctId":25324,"briefTitle":25325,"status":569,"phases":25326,"primaryCompletion":2930,"completion":943,"start":14571,"enrollment":25327,"conditions":25328,"interventions":25330},"NCT06134063","A Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[102],375,[25329],"Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[25309,25331],"Xuanfei Baidu granule Placebo",{"intervention":25331,"totalTrials":708,"cells":25333},{"EARLY_PHASE1":25334,"PHASE1":25336,"PHASE2":25338,"PHASE3":25340,"PHASE4":25342,"NA":25344},{"trials":25335,"activeCount":109},[],{"trials":25337,"activeCount":109},[],{"trials":25339,"activeCount":109},[],{"trials":25341,"activeCount":109},[],{"trials":25343,"activeCount":109},[],{"trials":25345,"activeCount":109},[25346],{"nctId":25324,"briefTitle":25325,"status":569,"phases":25347,"primaryCompletion":2930,"completion":943,"start":14571,"enrollment":25327,"conditions":25348,"interventions":25349},[102],[25329],[25309,25331],{"intervention":25351,"totalTrials":708,"cells":25352},"Compound Methyl Salicylate Liniment",{"EARLY_PHASE1":25353,"PHASE1":25355,"PHASE2":25357,"PHASE3":25359,"PHASE4":25361,"NA":25363},{"trials":25354,"activeCount":109},[],{"trials":25356,"activeCount":109},[],{"trials":25358,"activeCount":109},[],{"trials":25360,"activeCount":109},[],{"trials":25362,"activeCount":109},[],{"trials":25364,"activeCount":109},[25365],{"nctId":25366,"briefTitle":25367,"status":135,"phases":25368,"primaryCompletion":25369,"completion":25370,"start":25371,"enrollment":17211,"conditions":25372,"interventions":25373},"NCT03362216","Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment",[102],"2009-05-22","2009-06-12","2009-04-07",[14114],[25351,25374],"Diclofenac Sodium Liniment",{"intervention":25374,"totalTrials":708,"cells":25376},{"EARLY_PHASE1":25377,"PHASE1":25379,"PHASE2":25381,"PHASE3":25383,"PHASE4":25385,"NA":25387},{"trials":25378,"activeCount":109},[],{"trials":25380,"activeCount":109},[],{"trials":25382,"activeCount":109},[],{"trials":25384,"activeCount":109},[],{"trials":25386,"activeCount":109},[],{"trials":25388,"activeCount":109},[25389],{"nctId":25366,"briefTitle":25367,"status":135,"phases":25390,"primaryCompletion":25369,"completion":25370,"start":25371,"enrollment":17211,"conditions":25391,"interventions":25392},[102],[14114],[25351,25374],{"intervention":2937,"totalTrials":708,"cells":25394},{"EARLY_PHASE1":25395,"PHASE1":25397,"PHASE2":25399,"PHASE3":25401,"PHASE4":25403,"NA":25405},{"trials":25396,"activeCount":109},[],{"trials":25398,"activeCount":109},[],{"trials":25400,"activeCount":109},[],{"trials":25402,"activeCount":109},[],{"trials":25404,"activeCount":109},[],{"trials":25406,"activeCount":109},[25407],{"nctId":2927,"briefTitle":2928,"status":569,"phases":25408,"primaryCompletion":2930,"completion":2930,"start":669,"enrollment":2931,"conditions":25409,"interventions":25410},[],[2933,2934,2935],[983,734,2937,2938,2939],{"intervention":2938,"totalTrials":708,"cells":25412},{"EARLY_PHASE1":25413,"PHASE1":25415,"PHASE2":25417,"PHASE3":25419,"PHASE4":25421,"NA":25423},{"trials":25414,"activeCount":109},[],{"trials":25416,"activeCount":109},[],{"trials":25418,"activeCount":109},[],{"trials":25420,"activeCount":109},[],{"trials":25422,"activeCount":109},[],{"trials":25424,"activeCount":109},[25425],{"nctId":2927,"briefTitle":2928,"status":569,"phases":25426,"primaryCompletion":2930,"completion":2930,"start":669,"enrollment":2931,"conditions":25427,"interventions":25428},[],[2933,2934,2935],[983,734,2937,2938,2939],{"intervention":2939,"totalTrials":708,"cells":25430},{"EARLY_PHASE1":25431,"PHASE1":25433,"PHASE2":25435,"PHASE3":25437,"PHASE4":25439,"NA":25441},{"trials":25432,"activeCount":109},[],{"trials":25434,"activeCount":109},[],{"trials":25436,"activeCount":109},[],{"trials":25438,"activeCount":109},[],{"trials":25440,"activeCount":109},[],{"trials":25442,"activeCount":109},[25443],{"nctId":2927,"briefTitle":2928,"status":569,"phases":25444,"primaryCompletion":2930,"completion":2930,"start":669,"enrollment":2931,"conditions":25445,"interventions":25446},[],[2933,2934,2935],[983,734,2937,2938,2939],{"intervention":25448,"totalTrials":708,"cells":25449},"C-CAR011",{"EARLY_PHASE1":25450,"PHASE1":25452,"PHASE2":25454,"PHASE3":25456,"PHASE4":25458,"NA":25460},{"trials":25451,"activeCount":109},[],{"trials":25453,"activeCount":109},[],{"trials":25455,"activeCount":109},[],{"trials":25457,"activeCount":109},[],{"trials":25459,"activeCount":109},[],{"trials":25461,"activeCount":109},[25462],{"nctId":25463,"briefTitle":25464,"status":569,"phases":25465,"primaryCompletion":2663,"completion":25466,"start":5265,"enrollment":32,"conditions":25467,"interventions":25469},"NCT03327285","C-CAR011 Treatment in Subjects With ALL After HSCT",[102],"2021-04-30",[25468],"Acute Lymphoblastic Leukemia(ALL)",[25448],{"intervention":8386,"totalTrials":708,"cells":25471},{"EARLY_PHASE1":25472,"PHASE1":25474,"PHASE2":25476,"PHASE3":25478,"PHASE4":25480,"NA":25482},{"trials":25473,"activeCount":109},[],{"trials":25475,"activeCount":109},[],{"trials":25477,"activeCount":109},[],{"trials":25479,"activeCount":109},[],{"trials":25481,"activeCount":109},[],{"trials":25483,"activeCount":109},[25484],{"nctId":8379,"briefTitle":8380,"status":569,"phases":25485,"primaryCompletion":6743,"completion":8382,"start":8383,"enrollment":1767,"conditions":25486,"interventions":25487},[],[2681],[8386,1040,8387],{"intervention":25489,"totalTrials":708,"cells":25490},"Intercostal Nerve Block with PCIA",{"EARLY_PHASE1":25491,"PHASE1":25493,"PHASE2":25495,"PHASE3":25497,"PHASE4":25499,"NA":25501},{"trials":25492,"activeCount":109},[],{"trials":25494,"activeCount":109},[],{"trials":25496,"activeCount":109},[],{"trials":25498,"activeCount":109},[],{"trials":25500,"activeCount":109},[],{"trials":25502,"activeCount":109},[25503],{"nctId":25504,"briefTitle":25505,"status":135,"phases":25506,"primaryCompletion":25507,"completion":25507,"start":25508,"enrollment":670,"conditions":25509,"interventions":25511},"NCT03682354","ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery",[102],"2019-03-15","2018-09-27",[25510],"Lung Diseases",[25489,25512],"Erector Spinae Plane Block",{"intervention":25512,"totalTrials":708,"cells":25514},{"EARLY_PHASE1":25515,"PHASE1":25517,"PHASE2":25519,"PHASE3":25521,"PHASE4":25523,"NA":25525},{"trials":25516,"activeCount":109},[],{"trials":25518,"activeCount":109},[],{"trials":25520,"activeCount":109},[],{"trials":25522,"activeCount":109},[],{"trials":25524,"activeCount":109},[],{"trials":25526,"activeCount":109},[25527],{"nctId":25504,"briefTitle":25505,"status":135,"phases":25528,"primaryCompletion":25507,"completion":25507,"start":25508,"enrollment":670,"conditions":25529,"interventions":25530},[102],[25510],[25489,25512],{"intervention":25532,"totalTrials":708,"cells":25533},"antidepressant treatment",{"EARLY_PHASE1":25534,"PHASE1":25536,"PHASE2":25538,"PHASE3":25540,"PHASE4":25542,"NA":25544},{"trials":25535,"activeCount":109},[],{"trials":25537,"activeCount":109},[],{"trials":25539,"activeCount":109},[],{"trials":25541,"activeCount":109},[],{"trials":25543,"activeCount":109},[],{"trials":25545,"activeCount":109},[25546],{"nctId":25547,"briefTitle":25548,"status":569,"phases":25549,"primaryCompletion":1215,"completion":4701,"start":5295,"enrollment":25550,"conditions":25551,"interventions":25553},"NCT04684277","Internet-Based Interventions for MDD",[102],440,[18747,25552],"Medication Adherence",[25532],{"intervention":25555,"totalTrials":708,"cells":25556},"Drug: Cisplatin; nab-paclitaxel",{"EARLY_PHASE1":25557,"PHASE1":25559,"PHASE2":25561,"PHASE3":25563,"PHASE4":25565,"NA":25567},{"trials":25558,"activeCount":109},[],{"trials":25560,"activeCount":109},[],{"trials":25562,"activeCount":109},[],{"trials":25564,"activeCount":109},[],{"trials":25566,"activeCount":109},[],{"trials":25568,"activeCount":109},[25569],{"nctId":25570,"briefTitle":25571,"status":569,"phases":25572,"primaryCompletion":17326,"completion":25573,"start":10492,"enrollment":2770,"conditions":25574,"interventions":25575},"NCT04017377","VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer",[102],"2020-07-15",[2681],[25555],{"intervention":23076,"totalTrials":708,"cells":25577},{"EARLY_PHASE1":25578,"PHASE1":25580,"PHASE2":25582,"PHASE3":25584,"PHASE4":25586,"NA":25588},{"trials":25579,"activeCount":109},[],{"trials":25581,"activeCount":109},[],{"trials":25583,"activeCount":109},[],{"trials":25585,"activeCount":109},[],{"trials":25587,"activeCount":109},[],{"trials":25589,"activeCount":109},[25590],{"nctId":23069,"briefTitle":23070,"status":135,"phases":25591,"primaryCompletion":18814,"completion":18814,"start":18965,"enrollment":153,"conditions":25592,"interventions":25593},[102],[23073],[23054,23075,23076],{"intervention":25595,"totalTrials":708,"cells":25596},"Xinglouchengqi decoction",{"EARLY_PHASE1":25597,"PHASE1":25599,"PHASE2":25601,"PHASE3":25603,"PHASE4":25605,"NA":25607},{"trials":25598,"activeCount":109},[],{"trials":25600,"activeCount":109},[],{"trials":25602,"activeCount":109},[],{"trials":25604,"activeCount":109},[],{"trials":25606,"activeCount":109},[],{"trials":25608,"activeCount":109},[25609],{"nctId":25610,"briefTitle":25611,"status":569,"phases":25612,"primaryCompletion":373,"completion":1138,"start":5295,"enrollment":1767,"conditions":25613,"interventions":25614},"NCT04970797","Mechanism of Xinglouchengqi Decoction in Improving Nerve Injury in the Acute Stage of Stroke by EEG and Metabolomics",[],[5228],[25595],{"intervention":25616,"totalTrials":708,"cells":25617},"expanded NK cells",{"EARLY_PHASE1":25618,"PHASE1":25620,"PHASE2":25622,"PHASE3":25624,"PHASE4":25626,"NA":25628},{"trials":25619,"activeCount":109},[],{"trials":25621,"activeCount":109},[],{"trials":25623,"activeCount":109},[],{"trials":25625,"activeCount":109},[],{"trials":25627,"activeCount":109},[],{"trials":25629,"activeCount":109},[25630],{"nctId":25631,"briefTitle":25632,"status":569,"phases":25633,"primaryCompletion":1202,"completion":1202,"start":25634,"enrollment":1767,"conditions":25635,"interventions":25638},"NCT04320303","CMV Infection and Immune Intervention After Transplantation",[102],"2020-03-23",[25636,25637],"CMV Viremia","Transplantation Infection",[25616],{"intervention":25640,"totalTrials":708,"cells":25641},"PD-(L)1 antibody immunotherapy",{"EARLY_PHASE1":25642,"PHASE1":25644,"PHASE2":25646,"PHASE3":25648,"PHASE4":25650,"NA":25652},{"trials":25643,"activeCount":109},[],{"trials":25645,"activeCount":109},[],{"trials":25647,"activeCount":109},[],{"trials":25649,"activeCount":109},[],{"trials":25651,"activeCount":109},[],{"trials":25653,"activeCount":109},[25654],{"nctId":25655,"briefTitle":25656,"status":135,"phases":25657,"primaryCompletion":25658,"completion":5128,"start":25659,"enrollment":2665,"conditions":25660,"interventions":25662},"NCT05933863","Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance",[],"2024-07-18","2022-03-29",[25661],"SCLC,Extensive Stage",[25640],{"intervention":23052,"totalTrials":708,"cells":25664},{"EARLY_PHASE1":25665,"PHASE1":25667,"PHASE2":25669,"PHASE3":25671,"PHASE4":25673,"NA":25675},{"trials":25666,"activeCount":109},[],{"trials":25668,"activeCount":109},[],{"trials":25670,"activeCount":109},[],{"trials":25672,"activeCount":109},[],{"trials":25674,"activeCount":109},[],{"trials":25676,"activeCount":109},[25677],{"nctId":23042,"briefTitle":23043,"status":135,"phases":25678,"primaryCompletion":15272,"completion":15272,"start":23045,"enrollment":23046,"conditions":25679,"interventions":25680},[102],[182,23048,23049,23050,296],[23015,23052],{"intervention":25682,"totalTrials":708,"cells":25683},"Antitumor drugs",{"EARLY_PHASE1":25684,"PHASE1":25686,"PHASE2":25688,"PHASE3":25690,"PHASE4":25692,"NA":25694},{"trials":25685,"activeCount":109},[],{"trials":25687,"activeCount":109},[],{"trials":25689,"activeCount":109},[],{"trials":25691,"activeCount":109},[],{"trials":25693,"activeCount":109},[],{"trials":25695,"activeCount":109},[25696],{"nctId":25697,"briefTitle":25698,"status":569,"phases":25699,"primaryCompletion":818,"completion":71,"start":23259,"enrollment":728,"conditions":25700,"interventions":25701},"NCT05728788","Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy",[],[3605],[25682],{"intervention":25703,"totalTrials":708,"cells":25704},"Interferon Alfa-2b",{"EARLY_PHASE1":25705,"PHASE1":25707,"PHASE2":25709,"PHASE3":25711,"PHASE4":25713,"NA":25715},{"trials":25706,"activeCount":109},[],{"trials":25708,"activeCount":109},[],{"trials":25710,"activeCount":109},[],{"trials":25712,"activeCount":109},[],{"trials":25714,"activeCount":109},[],{"trials":25716,"activeCount":109},[25717],{"nctId":25718,"briefTitle":25719,"status":569,"phases":25720,"primaryCompletion":2797,"completion":2797,"start":2825,"enrollment":1203,"conditions":25721,"interventions":25722},"NCT02185261","Interferon α for the Therapy of Minimal Residual Disease",[102],[2876],[25703],{"intervention":25724,"totalTrials":708,"cells":25725},"NACT",{"EARLY_PHASE1":25726,"PHASE1":25728,"PHASE2":25730,"PHASE3":25732,"PHASE4":25734,"NA":25736},{"trials":25727,"activeCount":109},[],{"trials":25729,"activeCount":109},[],{"trials":25731,"activeCount":109},[],{"trials":25733,"activeCount":109},[],{"trials":25735,"activeCount":109},[],{"trials":25737,"activeCount":109},[25738],{"nctId":25739,"briefTitle":25740,"status":569,"phases":25741,"primaryCompletion":25742,"completion":1526,"start":25743,"enrollment":376,"conditions":25744,"interventions":25745},"NCT03413514","Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making",[102],"2019-01-03","2018-01-03",[28],[25724,25746],"ACT",{"intervention":25746,"totalTrials":708,"cells":25748},{"EARLY_PHASE1":25749,"PHASE1":25751,"PHASE2":25753,"PHASE3":25755,"PHASE4":25757,"NA":25759},{"trials":25750,"activeCount":109},[],{"trials":25752,"activeCount":109},[],{"trials":25754,"activeCount":109},[],{"trials":25756,"activeCount":109},[],{"trials":25758,"activeCount":109},[],{"trials":25760,"activeCount":109},[25761],{"nctId":25739,"briefTitle":25740,"status":569,"phases":25762,"primaryCompletion":25742,"completion":1526,"start":25743,"enrollment":376,"conditions":25763,"interventions":25764},[102],[28],[25724,25746],{"intervention":22773,"totalTrials":708,"cells":25766},{"EARLY_PHASE1":25767,"PHASE1":25769,"PHASE2":25771,"PHASE3":25773,"PHASE4":25775,"NA":25777},{"trials":25768,"activeCount":109},[],{"trials":25770,"activeCount":109},[],{"trials":25772,"activeCount":109},[],{"trials":25774,"activeCount":109},[],{"trials":25776,"activeCount":109},[],{"trials":25778,"activeCount":109},[25779],{"nctId":22767,"briefTitle":22768,"status":569,"phases":25780,"primaryCompletion":3933,"completion":22770,"start":8352,"enrollment":376,"conditions":25781,"interventions":25782},[102],[22764],[22744,22773],{"intervention":25784,"totalTrials":708,"cells":25785},"Types and exposure of different air pollutants",{"EARLY_PHASE1":25786,"PHASE1":25788,"PHASE2":25790,"PHASE3":25792,"PHASE4":25794,"NA":25796},{"trials":25787,"activeCount":109},[],{"trials":25789,"activeCount":109},[],{"trials":25791,"activeCount":109},[],{"trials":25793,"activeCount":109},[],{"trials":25795,"activeCount":109},[],{"trials":25797,"activeCount":109},[25798],{"nctId":25799,"briefTitle":25800,"status":135,"phases":25801,"primaryCompletion":25802,"completion":5264,"start":25803,"enrollment":1830,"conditions":25804,"interventions":25806},"NCT04960410","Real Time Early Warning Model and Mobile Medical Assistant System for the Impact of Air Pollution on AECOPD Disease",[],"2017-04-23","2017-01-01",[25805],"COPD",[25784],{"intervention":25808,"totalTrials":708,"cells":25809},"Clinical chemo-drugs",{"EARLY_PHASE1":25810,"PHASE1":25812,"PHASE2":25814,"PHASE3":25816,"PHASE4":25818,"NA":25820},{"trials":25811,"activeCount":109},[],{"trials":25813,"activeCount":109},[],{"trials":25815,"activeCount":109},[],{"trials":25817,"activeCount":109},[],{"trials":25819,"activeCount":109},[],{"trials":25821,"activeCount":109},[25822],{"nctId":25823,"briefTitle":25824,"status":135,"phases":25825,"primaryCompletion":25826,"completion":25826,"start":18966,"enrollment":25827,"conditions":25828,"interventions":25829},"NCT01472250","A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China",[],"2016-07",498,[3549],[25808],{"intervention":25831,"totalTrials":708,"cells":25832},"Methylsulfonic apatinib",{"EARLY_PHASE1":25833,"PHASE1":25835,"PHASE2":25837,"PHASE3":25839,"PHASE4":25841,"NA":25843},{"trials":25834,"activeCount":109},[],{"trials":25836,"activeCount":109},[],{"trials":25838,"activeCount":109},[],{"trials":25840,"activeCount":109},[],{"trials":25842,"activeCount":109},[],{"trials":25844,"activeCount":109},[25845],{"nctId":25846,"briefTitle":25847,"status":135,"phases":25848,"primaryCompletion":22722,"completion":2651,"start":17378,"enrollment":1830,"conditions":25849,"interventions":25850},"NCT03491371","Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use",[102],[8281,5376],[25831],{"intervention":25852,"totalTrials":708,"cells":25853},"Guided cartilage regeneration membrane",{"EARLY_PHASE1":25854,"PHASE1":25856,"PHASE2":25858,"PHASE3":25860,"PHASE4":25862,"NA":25864},{"trials":25855,"activeCount":109},[],{"trials":25857,"activeCount":109},[],{"trials":25859,"activeCount":109},[],{"trials":25861,"activeCount":109},[],{"trials":25863,"activeCount":109},[],{"trials":25865,"activeCount":109},[25866],{"nctId":25867,"briefTitle":25868,"status":569,"phases":25869,"primaryCompletion":10224,"completion":2906,"start":25870,"enrollment":640,"conditions":25871,"interventions":25874},"NCT04463238","Guided Cartilage Regeneration Membrane",[102],"2020-08-03",[25872,25873],"Articular Cartilage Injury","Knee Ligament Injury",[25852],{"intervention":25876,"totalTrials":708,"cells":25877},"JWC containing quadruple therapy",{"EARLY_PHASE1":25878,"PHASE1":25880,"PHASE2":25882,"PHASE3":25884,"PHASE4":25886,"NA":25888},{"trials":25879,"activeCount":109},[],{"trials":25881,"activeCount":109},[],{"trials":25883,"activeCount":109},[],{"trials":25885,"activeCount":109},[],{"trials":25887,"activeCount":109},[],{"trials":25889,"activeCount":109},[25890],{"nctId":25891,"briefTitle":25892,"status":569,"phases":25893,"primaryCompletion":2700,"completion":1103,"start":3969,"enrollment":153,"conditions":25894,"interventions":25895},"NCT05320133","Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection",[102],[10921],[25876,25896],"Bismuth-containing quadruple therapy",{"intervention":25896,"totalTrials":708,"cells":25898},{"EARLY_PHASE1":25899,"PHASE1":25901,"PHASE2":25903,"PHASE3":25905,"PHASE4":25907,"NA":25909},{"trials":25900,"activeCount":109},[],{"trials":25902,"activeCount":109},[],{"trials":25904,"activeCount":109},[],{"trials":25906,"activeCount":109},[],{"trials":25908,"activeCount":109},[],{"trials":25910,"activeCount":109},[25911],{"nctId":25891,"briefTitle":25892,"status":569,"phases":25912,"primaryCompletion":2700,"completion":1103,"start":3969,"enrollment":153,"conditions":25913,"interventions":25914},[102],[10921],[25876,25896],{"intervention":25916,"totalTrials":708,"cells":25917},"remimazolam tosilate group",{"EARLY_PHASE1":25918,"PHASE1":25920,"PHASE2":25922,"PHASE3":25924,"PHASE4":25926,"NA":25928},{"trials":25919,"activeCount":109},[],{"trials":25921,"activeCount":109},[],{"trials":25923,"activeCount":109},[],{"trials":25925,"activeCount":109},[],{"trials":25927,"activeCount":109},[],{"trials":25929,"activeCount":109},[25930],{"nctId":25931,"briefTitle":25932,"status":135,"phases":25933,"primaryCompletion":1215,"completion":1215,"start":191,"enrollment":14613,"conditions":25934,"interventions":25935},"NCT04656964","Comparison Between Remimazolam Tosilate and Midazolam in Elderly Patients Undergoing Gastrointestinal Endoscopy",[102],[25249,25250,380,779],[25916,25936],"Midazolam group",{"intervention":25936,"totalTrials":708,"cells":25938},{"EARLY_PHASE1":25939,"PHASE1":25941,"PHASE2":25943,"PHASE3":25945,"PHASE4":25947,"NA":25949},{"trials":25940,"activeCount":109},[],{"trials":25942,"activeCount":109},[],{"trials":25944,"activeCount":109},[],{"trials":25946,"activeCount":109},[],{"trials":25948,"activeCount":109},[],{"trials":25950,"activeCount":109},[25951],{"nctId":25931,"briefTitle":25932,"status":135,"phases":25952,"primaryCompletion":1215,"completion":1215,"start":191,"enrollment":14613,"conditions":25953,"interventions":25954},[102],[25249,25250,380,779],[25916,25936],{"intervention":25956,"totalTrials":708,"cells":25957},"Yangxue Qingnao pill",{"EARLY_PHASE1":25958,"PHASE1":25960,"PHASE2":25962,"PHASE3":25964,"PHASE4":25966,"NA":25968},{"trials":25959,"activeCount":109},[],{"trials":25961,"activeCount":109},[],{"trials":25963,"activeCount":109},[],{"trials":25965,"activeCount":109},[],{"trials":25967,"activeCount":109},[],{"trials":25969,"activeCount":109},[25970],{"nctId":25971,"briefTitle":25972,"status":135,"phases":25973,"primaryCompletion":19505,"completion":25974,"start":2866,"enrollment":140,"conditions":25975,"interventions":25977},"NCT04958512","Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill",[102],"2018-03-31",[25976],"Cerebrovascular Diseases",[25956,25978],"Hydergotoxine mesylate",{"intervention":25978,"totalTrials":708,"cells":25980},{"EARLY_PHASE1":25981,"PHASE1":25983,"PHASE2":25985,"PHASE3":25987,"PHASE4":25989,"NA":25991},{"trials":25982,"activeCount":109},[],{"trials":25984,"activeCount":109},[],{"trials":25986,"activeCount":109},[],{"trials":25988,"activeCount":109},[],{"trials":25990,"activeCount":109},[],{"trials":25992,"activeCount":109},[25993],{"nctId":25971,"briefTitle":25972,"status":135,"phases":25994,"primaryCompletion":19505,"completion":25974,"start":2866,"enrollment":140,"conditions":25995,"interventions":25996},[102],[25976],[25956,25978],{"intervention":865,"totalTrials":708,"cells":25998},{"EARLY_PHASE1":25999,"PHASE1":26001,"PHASE2":26003,"PHASE3":26005,"PHASE4":26007,"NA":26009},{"trials":26000,"activeCount":109},[],{"trials":26002,"activeCount":109},[],{"trials":26004,"activeCount":109},[],{"trials":26006,"activeCount":109},[],{"trials":26008,"activeCount":109},[],{"trials":26010,"activeCount":109},[26011],{"nctId":852,"briefTitle":853,"status":569,"phases":26012,"primaryCompletion":855,"completion":856,"start":857,"enrollment":846,"conditions":26013,"interventions":26014},[102],[859,860,861,862,863],[865,145],{"intervention":8291,"totalTrials":708,"cells":26016},{"EARLY_PHASE1":26017,"PHASE1":26019,"PHASE2":26021,"PHASE3":26023,"PHASE4":26025,"NA":26027},{"trials":26018,"activeCount":109},[],{"trials":26020,"activeCount":109},[],{"trials":26022,"activeCount":109},[],{"trials":26024,"activeCount":109},[],{"trials":26026,"activeCount":109},[],{"trials":26028,"activeCount":109},[26029],{"nctId":8284,"briefTitle":8285,"status":135,"phases":26030,"primaryCompletion":573,"completion":857,"start":2624,"enrollment":8287,"conditions":26031,"interventions":26032},[102],[5412,2534,8289],[2537,8291],{"intervention":26034,"totalTrials":708,"cells":26035},"Anti-VEGF",{"EARLY_PHASE1":26036,"PHASE1":26038,"PHASE2":26040,"PHASE3":26042,"PHASE4":26044,"NA":26046},{"trials":26037,"activeCount":109},[],{"trials":26039,"activeCount":109},[],{"trials":26041,"activeCount":109},[],{"trials":26043,"activeCount":109},[],{"trials":26045,"activeCount":109},[],{"trials":26047,"activeCount":109},[26048],{"nctId":26049,"briefTitle":26050,"status":569,"phases":26051,"primaryCompletion":8314,"completion":4651,"start":8315,"enrollment":1767,"conditions":26052,"interventions":26055},"NCT04962438","Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function",[],[8325,26053,26054],"VEGF","Endothelial Dysfunction",[26034],{"intervention":26057,"totalTrials":708,"cells":26058},"Memantine",{"EARLY_PHASE1":26059,"PHASE1":26061,"PHASE2":26063,"PHASE3":26065,"PHASE4":26067,"NA":26069},{"trials":26060,"activeCount":109},[],{"trials":26062,"activeCount":109},[],{"trials":26064,"activeCount":109},[],{"trials":26066,"activeCount":109},[],{"trials":26068,"activeCount":109},[],{"trials":26070,"activeCount":109},[26071],{"nctId":26072,"briefTitle":26073,"status":569,"phases":26074,"primaryCompletion":3089,"completion":2825,"start":5225,"enrollment":728,"conditions":26075,"interventions":26077},"NCT00703430","Memantine on Aggression and Agitation of Alzheimer's Disease (AD)",[102],[26076],"Alzheimer's Disease",[26057],{"intervention":26079,"totalTrials":708,"cells":26080},"Dexamethasone Phosphate",{"EARLY_PHASE1":26081,"PHASE1":26083,"PHASE2":26085,"PHASE3":26087,"PHASE4":26089,"NA":26091},{"trials":26082,"activeCount":109},[],{"trials":26084,"activeCount":109},[],{"trials":26086,"activeCount":109},[],{"trials":26088,"activeCount":109},[],{"trials":26090,"activeCount":109},[],{"trials":26092,"activeCount":109},[26093],{"nctId":26094,"briefTitle":26095,"status":569,"phases":26096,"primaryCompletion":252,"completion":252,"start":16036,"enrollment":4171,"conditions":26097,"interventions":26099},"NCT02026479","Sudden Hearing Loss Multi-center Clinical Trial",[102],[26098],"Full-frequency Sudden Hearing Loss",[26079,26079,26100],"Ginaton",{"intervention":26100,"totalTrials":708,"cells":26102},{"EARLY_PHASE1":26103,"PHASE1":26105,"PHASE2":26107,"PHASE3":26109,"PHASE4":26111,"NA":26113},{"trials":26104,"activeCount":109},[],{"trials":26106,"activeCount":109},[],{"trials":26108,"activeCount":109},[],{"trials":26110,"activeCount":109},[],{"trials":26112,"activeCount":109},[],{"trials":26114,"activeCount":109},[26115],{"nctId":26094,"briefTitle":26095,"status":569,"phases":26116,"primaryCompletion":252,"completion":252,"start":16036,"enrollment":4171,"conditions":26117,"interventions":26118},[102],[26098],[26079,26079,26100],{"intervention":26120,"totalTrials":708,"cells":26121},"Endostar",{"EARLY_PHASE1":26122,"PHASE1":26124,"PHASE2":26126,"PHASE3":26128,"PHASE4":26130,"NA":26132},{"trials":26123,"activeCount":109},[],{"trials":26125,"activeCount":109},[],{"trials":26127,"activeCount":109},[],{"trials":26129,"activeCount":109},[],{"trials":26131,"activeCount":109},[],{"trials":26133,"activeCount":109},[26134],{"nctId":26135,"briefTitle":26136,"status":569,"phases":26137,"primaryCompletion":26138,"completion":364,"start":1641,"enrollment":140,"conditions":26139,"interventions":26140},"NCT04274270","SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer",[102],"2022-01-30",[6198],[26120],{"intervention":26142,"totalTrials":708,"cells":26143},"inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil",{"EARLY_PHASE1":26144,"PHASE1":26146,"PHASE2":26148,"PHASE3":26150,"PHASE4":26152,"NA":26154},{"trials":26145,"activeCount":109},[],{"trials":26147,"activeCount":109},[],{"trials":26149,"activeCount":109},[],{"trials":26151,"activeCount":109},[],{"trials":26153,"activeCount":109},[],{"trials":26155,"activeCount":109},[26156],{"nctId":26157,"briefTitle":26158,"status":200,"phases":26159,"primaryCompletion":5246,"completion":26160,"start":22722,"enrollment":26161,"conditions":26162,"interventions":26164},"NCT03335579","General Anesthetic Mode and Postoperative Complications",[],"2017-10-10",50000,[26163],"Anesthesia",[26142],{"intervention":22287,"totalTrials":708,"cells":26166},{"EARLY_PHASE1":26167,"PHASE1":26169,"PHASE2":26171,"PHASE3":26173,"PHASE4":26175,"NA":26177},{"trials":26168,"activeCount":109},[],{"trials":26170,"activeCount":109},[],{"trials":26172,"activeCount":109},[],{"trials":26174,"activeCount":109},[],{"trials":26176,"activeCount":109},[],{"trials":26178,"activeCount":109},[26179],{"nctId":22279,"briefTitle":22280,"status":569,"phases":26180,"primaryCompletion":1103,"completion":1103,"start":817,"enrollment":1248,"conditions":26181,"interventions":26182},[102],[22283,22284,22285],[1122,22287],{"intervention":26184,"totalTrials":708,"cells":26185},"pabolizumab",{"EARLY_PHASE1":26186,"PHASE1":26188,"PHASE2":26190,"PHASE3":26192,"PHASE4":26194,"NA":26196},{"trials":26187,"activeCount":109},[],{"trials":26189,"activeCount":109},[],{"trials":26191,"activeCount":109},[],{"trials":26193,"activeCount":109},[],{"trials":26195,"activeCount":109},[],{"trials":26197,"activeCount":109},[26198],{"nctId":26199,"briefTitle":26200,"status":569,"phases":26201,"primaryCompletion":94,"completion":94,"start":571,"enrollment":8079,"conditions":26202,"interventions":26203},"NCT05816863","Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma",[],[28,4705],[26184],{"intervention":26205,"totalTrials":708,"cells":26206},"Raise serum brain granules",{"EARLY_PHASE1":26207,"PHASE1":26209,"PHASE2":26211,"PHASE3":26213,"PHASE4":26215,"NA":26217},{"trials":26208,"activeCount":109},[],{"trials":26210,"activeCount":109},[],{"trials":26212,"activeCount":109},[],{"trials":26214,"activeCount":109},[],{"trials":26216,"activeCount":109},[],{"trials":26218,"activeCount":109},[26219],{"nctId":26220,"briefTitle":26221,"status":135,"phases":26222,"primaryCompletion":15757,"completion":19463,"start":14154,"enrollment":640,"conditions":26223,"interventions":26225},"NCT04949906","Study on Yangxue Nao Granules Reducing the Risk of Stroke",[],[26224],"Cerebral Infarction",[26205,26226],"No nourishing serum brain granules are used",{"intervention":26226,"totalTrials":708,"cells":26228},{"EARLY_PHASE1":26229,"PHASE1":26231,"PHASE2":26233,"PHASE3":26235,"PHASE4":26237,"NA":26239},{"trials":26230,"activeCount":109},[],{"trials":26232,"activeCount":109},[],{"trials":26234,"activeCount":109},[],{"trials":26236,"activeCount":109},[],{"trials":26238,"activeCount":109},[],{"trials":26240,"activeCount":109},[26241],{"nctId":26220,"briefTitle":26221,"status":135,"phases":26242,"primaryCompletion":15757,"completion":19463,"start":14154,"enrollment":640,"conditions":26243,"interventions":26244},[],[26224],[26205,26226],{"intervention":26246,"totalTrials":708,"cells":26247},"FK-506",{"EARLY_PHASE1":26248,"PHASE1":26250,"PHASE2":26252,"PHASE3":26254,"PHASE4":26256,"NA":26258},{"trials":26249,"activeCount":109},[],{"trials":26251,"activeCount":109},[],{"trials":26253,"activeCount":109},[],{"trials":26255,"activeCount":109},[],{"trials":26257,"activeCount":109},[],{"trials":26259,"activeCount":109},[26260],{"nctId":26261,"briefTitle":26262,"status":569,"phases":26263,"primaryCompletion":13941,"completion":10344,"start":18880,"enrollment":1767,"conditions":26264,"interventions":26266},"NCT04590183","The Effectiveness and Safety of FK-506 for the Treatment of Posner-Schlossman Syndrome",[102],[26265],"Posner Schlossman Syndrome",[26246,26267],"Prednisolone Acetate 1% Oph Susp",{"intervention":26267,"totalTrials":708,"cells":26269},{"EARLY_PHASE1":26270,"PHASE1":26272,"PHASE2":26274,"PHASE3":26276,"PHASE4":26278,"NA":26280},{"trials":26271,"activeCount":109},[],{"trials":26273,"activeCount":109},[],{"trials":26275,"activeCount":109},[],{"trials":26277,"activeCount":109},[],{"trials":26279,"activeCount":109},[],{"trials":26281,"activeCount":109},[26282],{"nctId":26261,"briefTitle":26262,"status":569,"phases":26283,"primaryCompletion":13941,"completion":10344,"start":18880,"enrollment":1767,"conditions":26284,"interventions":26285},[102],[26265],[26246,26267],{"intervention":1494,"totalTrials":708,"cells":26287},{"EARLY_PHASE1":26288,"PHASE1":26290,"PHASE2":26292,"PHASE3":26294,"PHASE4":26296,"NA":26298},{"trials":26289,"activeCount":109},[],{"trials":26291,"activeCount":109},[],{"trials":26293,"activeCount":109},[],{"trials":26295,"activeCount":109},[],{"trials":26297,"activeCount":109},[],{"trials":26299,"activeCount":109},[26300],{"nctId":1486,"briefTitle":1487,"status":135,"phases":26301,"primaryCompletion":1489,"completion":1489,"start":1490,"enrollment":341,"conditions":26302,"interventions":26303},[102],[1492],[172,1494,1427],{"intervention":26305,"totalTrials":708,"cells":26306},"risperidone, olanzapine, aripiprazole",{"EARLY_PHASE1":26307,"PHASE1":26309,"PHASE2":26311,"PHASE3":26313,"PHASE4":26315,"NA":26317},{"trials":26308,"activeCount":109},[],{"trials":26310,"activeCount":109},[],{"trials":26312,"activeCount":109},[],{"trials":26314,"activeCount":109},[],{"trials":26316,"activeCount":109},[],{"trials":26318,"activeCount":109},[26319],{"nctId":26320,"briefTitle":26321,"status":569,"phases":26322,"primaryCompletion":26323,"completion":26324,"start":71,"enrollment":4171,"conditions":26325,"interventions":26327},"NCT06128408","The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset",[],"2024-10-12","2024-10-13",[26326],"Treatment-resistant Schizophrenia",[26305],{"intervention":26329,"totalTrials":708,"cells":26330},"Single-nucleotide Polymorphism of genes related with Dyslipidemia",{"EARLY_PHASE1":26331,"PHASE1":26333,"PHASE2":26335,"PHASE3":26337,"PHASE4":26339,"NA":26341},{"trials":26332,"activeCount":109},[],{"trials":26334,"activeCount":109},[],{"trials":26336,"activeCount":109},[],{"trials":26338,"activeCount":109},[],{"trials":26340,"activeCount":109},[],{"trials":26342,"activeCount":109},[26343],{"nctId":26344,"briefTitle":26345,"status":135,"phases":26346,"primaryCompletion":22722,"completion":22722,"start":26347,"enrollment":26348,"conditions":26349,"interventions":26350},"NCT04950699","Peking University & University of Michigan Study of MI and Atherosclerosis",[],"2012-01-01",4700,[24434],[26329],{"intervention":26352,"totalTrials":708,"cells":26353},"Deucravacitinib",{"EARLY_PHASE1":26354,"PHASE1":26356,"PHASE2":26358,"PHASE3":26360,"PHASE4":26362,"NA":26364},{"trials":26355,"activeCount":109},[],{"trials":26357,"activeCount":109},[],{"trials":26359,"activeCount":109},[],{"trials":26361,"activeCount":109},[],{"trials":26363,"activeCount":109},[],{"trials":26365,"activeCount":109},[26366],{"nctId":26367,"briefTitle":26368,"status":200,"phases":26369,"primaryCompletion":2744,"completion":2370,"start":845,"enrollment":329,"conditions":26370,"interventions":26372},"NCT07000630","Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis",[102],[26371],"Palmoplantar Pustulosis",[26352],{"intervention":26374,"totalTrials":708,"cells":26375},"Ripretinib Oral",{"EARLY_PHASE1":26376,"PHASE1":26378,"PHASE2":26380,"PHASE3":26382,"PHASE4":26384,"NA":26386},{"trials":26377,"activeCount":109},[],{"trials":26379,"activeCount":109},[],{"trials":26381,"activeCount":109},[],{"trials":26383,"activeCount":109},[],{"trials":26385,"activeCount":109},[],{"trials":26387,"activeCount":109},[26388],{"nctId":26389,"briefTitle":26390,"status":569,"phases":26391,"primaryCompletion":24545,"completion":1404,"start":26392,"enrollment":26393,"conditions":26394,"interventions":26395},"NCT05697107","Ripretinib in Chinese Patients With Advanced GIST: a Real World Study",[],"2021-05-20",308,[11523],[26374],{"intervention":26397,"totalTrials":708,"cells":26398},"Bortezomib\u002FDexamethasone\u002FMelphalan",{"EARLY_PHASE1":26399,"PHASE1":26401,"PHASE2":26403,"PHASE3":26405,"PHASE4":26407,"NA":26409},{"trials":26400,"activeCount":109},[],{"trials":26402,"activeCount":109},[],{"trials":26404,"activeCount":109},[],{"trials":26406,"activeCount":109},[],{"trials":26408,"activeCount":109},[],{"trials":26410,"activeCount":109},[26411],{"nctId":26412,"briefTitle":26413,"status":26414,"phases":26415,"conditions":26416,"interventions":26417},"NCT01250808","Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy","AVAILABLE",[],[5130],[26397],{"intervention":23114,"totalTrials":708,"cells":26419},{"EARLY_PHASE1":26420,"PHASE1":26422,"PHASE2":26424,"PHASE3":26426,"PHASE4":26428,"NA":26430},{"trials":26421,"activeCount":109},[],{"trials":26423,"activeCount":109},[],{"trials":26425,"activeCount":109},[],{"trials":26427,"activeCount":109},[],{"trials":26429,"activeCount":109},[],{"trials":26431,"activeCount":109},[26432],{"nctId":23108,"briefTitle":23109,"status":569,"phases":26433,"primaryCompletion":20438,"completion":14527,"start":19801,"enrollment":8489,"conditions":26434,"interventions":26435},[102],[23112],[23075,23114],{"intervention":26437,"totalTrials":708,"cells":26438},"Fuzhegn Nizeng Decoction",{"EARLY_PHASE1":26439,"PHASE1":26441,"PHASE2":26443,"PHASE3":26445,"PHASE4":26447,"NA":26449},{"trials":26440,"activeCount":109},[],{"trials":26442,"activeCount":109},[],{"trials":26444,"activeCount":109},[],{"trials":26446,"activeCount":109},[],{"trials":26448,"activeCount":109},[],{"trials":26450,"activeCount":109},[26451],{"nctId":26452,"briefTitle":26453,"status":569,"phases":26454,"primaryCompletion":1103,"completion":1103,"start":26455,"enrollment":16092,"conditions":26456,"interventions":26458},"NCT06324825","Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial",[102],"2022-10-24",[26457],"Atrophic Gastritis With Low-grade Intraepithelial Neoplasia",[26437,26459],"Moluodan granules",{"intervention":26459,"totalTrials":708,"cells":26461},{"EARLY_PHASE1":26462,"PHASE1":26464,"PHASE2":26466,"PHASE3":26468,"PHASE4":26470,"NA":26472},{"trials":26463,"activeCount":109},[],{"trials":26465,"activeCount":109},[],{"trials":26467,"activeCount":109},[],{"trials":26469,"activeCount":109},[],{"trials":26471,"activeCount":109},[],{"trials":26473,"activeCount":109},[26474],{"nctId":26452,"briefTitle":26453,"status":569,"phases":26475,"primaryCompletion":1103,"completion":1103,"start":26455,"enrollment":16092,"conditions":26476,"interventions":26477},[102],[26457],[26437,26459],{"intervention":26479,"totalTrials":708,"cells":26480},"Ceramides",{"EARLY_PHASE1":26481,"PHASE1":26483,"PHASE2":26485,"PHASE3":26487,"PHASE4":26489,"NA":26491},{"trials":26482,"activeCount":109},[],{"trials":26484,"activeCount":109},[],{"trials":26486,"activeCount":109},[],{"trials":26488,"activeCount":109},[],{"trials":26490,"activeCount":109},[],{"trials":26492,"activeCount":109},[26493],{"nctId":26494,"briefTitle":26495,"status":569,"phases":26496,"primaryCompletion":15411,"completion":2569,"start":19085,"enrollment":1767,"conditions":26497,"interventions":26499},"NCT04185025","Compare the Skin Barrier Repair Function of Two Ceramide Containing Moisturizers",[102],[26498],"CeraVe Moisturising Lotion",[26479],{"intervention":26501,"totalTrials":708,"cells":26502},"MPH",{"EARLY_PHASE1":26503,"PHASE1":26505,"PHASE2":26507,"PHASE3":26509,"PHASE4":26511,"NA":26513},{"trials":26504,"activeCount":109},[],{"trials":26506,"activeCount":109},[],{"trials":26508,"activeCount":109},[],{"trials":26510,"activeCount":109},[],{"trials":26512,"activeCount":109},[],{"trials":26514,"activeCount":109},[26515],{"nctId":26516,"briefTitle":26517,"status":569,"phases":26518,"primaryCompletion":1215,"completion":81,"start":669,"enrollment":2956,"conditions":26519,"interventions":26521},"NCT05229627","Multimodal Magnetic Resonance Imaging Study on the Neural Mechanisms of Remission in Children With ADHD",[],[26520],"ADHD",[26501,26522],"ATX",{"intervention":26522,"totalTrials":708,"cells":26524},{"EARLY_PHASE1":26525,"PHASE1":26527,"PHASE2":26529,"PHASE3":26531,"PHASE4":26533,"NA":26535},{"trials":26526,"activeCount":109},[],{"trials":26528,"activeCount":109},[],{"trials":26530,"activeCount":109},[],{"trials":26532,"activeCount":109},[],{"trials":26534,"activeCount":109},[],{"trials":26536,"activeCount":109},[26537],{"nctId":26516,"briefTitle":26517,"status":569,"phases":26538,"primaryCompletion":1215,"completion":81,"start":669,"enrollment":2956,"conditions":26539,"interventions":26540},[],[26520],[26501,26522],{"intervention":26542,"totalTrials":708,"cells":26543},"Dupilumab",{"EARLY_PHASE1":26544,"PHASE1":26546,"PHASE2":26548,"PHASE3":26550,"PHASE4":26552,"NA":26554},{"trials":26545,"activeCount":109},[],{"trials":26547,"activeCount":109},[],{"trials":26549,"activeCount":109},[],{"trials":26551,"activeCount":109},[],{"trials":26553,"activeCount":109},[],{"trials":26555,"activeCount":109},[26556],{"nctId":26557,"briefTitle":26558,"status":135,"phases":26559,"primaryCompletion":1215,"completion":10030,"start":1138,"enrollment":26560,"conditions":26561,"interventions":26563},"NCT05649579","Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid",[],146,[26562],"Bullous Pemphigoid",[26542],{"intervention":26565,"totalTrials":708,"cells":26566},"PD-1 blocking antibody",{"EARLY_PHASE1":26567,"PHASE1":26569,"PHASE2":26571,"PHASE3":26573,"PHASE4":26575,"NA":26577},{"trials":26568,"activeCount":109},[],{"trials":26570,"activeCount":109},[],{"trials":26572,"activeCount":109},[],{"trials":26574,"activeCount":109},[],{"trials":26576,"activeCount":109},[],{"trials":26578,"activeCount":109},[26579],{"nctId":26580,"briefTitle":26581,"status":135,"phases":26582,"primaryCompletion":17925,"completion":76,"start":2624,"enrollment":17657,"conditions":26583,"interventions":26584},"NCT06195254","Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer",[],[17858,4993,684],[26565],{"intervention":26586,"totalTrials":708,"cells":26587},"Individualized epidural analgesia",{"EARLY_PHASE1":26588,"PHASE1":26590,"PHASE2":26592,"PHASE3":26594,"PHASE4":26596,"NA":26598},{"trials":26589,"activeCount":109},[],{"trials":26591,"activeCount":109},[],{"trials":26593,"activeCount":109},[],{"trials":26595,"activeCount":109},[],{"trials":26597,"activeCount":109},[],{"trials":26599,"activeCount":109},[26600],{"nctId":26601,"briefTitle":26602,"status":135,"phases":26603,"primaryCompletion":253,"completion":26604,"start":4671,"enrollment":168,"conditions":26605,"interventions":26608},"NCT02920489","Individualized Timing of Analgesia and Effectiveness of Labor Analgesia",[102],"2017-07",[15326,26606,26607],"Analgesia, Obstetrical","Early Medical Intervention",[26586,26609],"Routine epidural analgesia",{"intervention":26609,"totalTrials":708,"cells":26611},{"EARLY_PHASE1":26612,"PHASE1":26614,"PHASE2":26616,"PHASE3":26618,"PHASE4":26620,"NA":26622},{"trials":26613,"activeCount":109},[],{"trials":26615,"activeCount":109},[],{"trials":26617,"activeCount":109},[],{"trials":26619,"activeCount":109},[],{"trials":26621,"activeCount":109},[],{"trials":26623,"activeCount":109},[26624],{"nctId":26601,"briefTitle":26602,"status":135,"phases":26625,"primaryCompletion":253,"completion":26604,"start":4671,"enrollment":168,"conditions":26626,"interventions":26627},[102],[15326,26606,26607],[26586,26609],{"intervention":1410,"totalTrials":708,"cells":26629},{"EARLY_PHASE1":26630,"PHASE1":26632,"PHASE2":26634,"PHASE3":26636,"PHASE4":26638,"NA":26640},{"trials":26631,"activeCount":109},[],{"trials":26633,"activeCount":109},[],{"trials":26635,"activeCount":109},[],{"trials":26637,"activeCount":109},[],{"trials":26639,"activeCount":109},[],{"trials":26641,"activeCount":109},[26642],{"nctId":1400,"briefTitle":1401,"status":569,"phases":26643,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":168,"conditions":26644,"interventions":26645},[102],[1407,1408],[1410,1391],{"intervention":26647,"totalTrials":708,"cells":26648},"Budesonide\u002Fformoterol",{"EARLY_PHASE1":26649,"PHASE1":26651,"PHASE2":26653,"PHASE3":26655,"PHASE4":26657,"NA":26659},{"trials":26650,"activeCount":109},[],{"trials":26652,"activeCount":109},[],{"trials":26654,"activeCount":109},[],{"trials":26656,"activeCount":109},[],{"trials":26658,"activeCount":109},[],{"trials":26660,"activeCount":109},[26661],{"nctId":26662,"briefTitle":26663,"status":135,"phases":26664,"primaryCompletion":26665,"completion":26665,"start":26666,"enrollment":26667,"conditions":26668,"interventions":26671},"NCT03083067","Salvational Intervention for Reducing AECOPD Under Severe Air Pollution",[102],"2022-03-16","2017-03-20",402,[26669,26670],"COPD Exacerbation","Air Pollution",[26647,26672],"tiotropium bromide",{"intervention":26672,"totalTrials":708,"cells":26674},{"EARLY_PHASE1":26675,"PHASE1":26677,"PHASE2":26679,"PHASE3":26681,"PHASE4":26683,"NA":26685},{"trials":26676,"activeCount":109},[],{"trials":26678,"activeCount":109},[],{"trials":26680,"activeCount":109},[],{"trials":26682,"activeCount":109},[],{"trials":26684,"activeCount":109},[],{"trials":26686,"activeCount":109},[26687],{"nctId":26662,"briefTitle":26663,"status":135,"phases":26688,"primaryCompletion":26665,"completion":26665,"start":26666,"enrollment":26667,"conditions":26689,"interventions":26690},[102],[26669,26670],[26647,26672],{"intervention":26692,"totalTrials":708,"cells":26693},"Cinepazide Maleate",{"EARLY_PHASE1":26694,"PHASE1":26696,"PHASE2":26698,"PHASE3":26700,"PHASE4":26702,"NA":26704},{"trials":26695,"activeCount":109},[],{"trials":26697,"activeCount":109},[],{"trials":26699,"activeCount":109},[],{"trials":26701,"activeCount":109},[],{"trials":26703,"activeCount":109},[],{"trials":26705,"activeCount":109},[26706],{"nctId":26707,"briefTitle":26708,"status":135,"phases":26709,"primaryCompletion":22462,"completion":22462,"start":26710,"enrollment":5215,"conditions":26711,"interventions":26713},"NCT04951232","Clinical Study of Cinepazide Maleate Injection in the Treatment of Acute Ischemic Stroke",[102],"2016-07-04",[26712],"Stroke, Ischemic",[26692],{"intervention":26715,"totalTrials":708,"cells":26716},"Different concentration of ropivacaine for single brachial plexus block",{"EARLY_PHASE1":26717,"PHASE1":26719,"PHASE2":26721,"PHASE3":26723,"PHASE4":26725,"NA":26727},{"trials":26718,"activeCount":109},[],{"trials":26720,"activeCount":109},[],{"trials":26722,"activeCount":109},[],{"trials":26724,"activeCount":109},[],{"trials":26726,"activeCount":109},[],{"trials":26728,"activeCount":109},[26729],{"nctId":26730,"briefTitle":26731,"status":135,"phases":26732,"primaryCompletion":26733,"completion":26733,"start":26734,"enrollment":32,"conditions":26735,"interventions":26739},"NCT06640621","The Effect of Brachial Plexus Block on Diaphragm Movement",[102],"2023-10-07","2022-11-08",[26736,26737,26738],"Phrenic Paralysis","Shoulder Joint Surgery","Rotator Cuff Injury",[26715],{"intervention":1422,"totalTrials":708,"cells":26741},{"EARLY_PHASE1":26742,"PHASE1":26744,"PHASE2":26746,"PHASE3":26748,"PHASE4":26750,"NA":26752},{"trials":26743,"activeCount":109},[],{"trials":26745,"activeCount":109},[],{"trials":26747,"activeCount":109},[],{"trials":26749,"activeCount":109},[],{"trials":26751,"activeCount":109},[],{"trials":26753,"activeCount":109},[26754],{"nctId":1412,"briefTitle":1413,"status":569,"phases":26755,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":29,"conditions":26756,"interventions":26757},[102],[1419,1420],[380,1422,1234,1423,1424,172,380,1234,1425,1424],{"intervention":1424,"totalTrials":708,"cells":26759},{"EARLY_PHASE1":26760,"PHASE1":26762,"PHASE2":26764,"PHASE3":26766,"PHASE4":26768,"NA":26770},{"trials":26761,"activeCount":109},[],{"trials":26763,"activeCount":109},[],{"trials":26765,"activeCount":109},[],{"trials":26767,"activeCount":109},[],{"trials":26769,"activeCount":109},[],{"trials":26771,"activeCount":109},[26772],{"nctId":1412,"briefTitle":1413,"status":569,"phases":26773,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":29,"conditions":26774,"interventions":26775},[102],[1419,1420],[380,1422,1234,1423,1424,172,380,1234,1425,1424],{"intervention":1425,"totalTrials":708,"cells":26777},{"EARLY_PHASE1":26778,"PHASE1":26780,"PHASE2":26782,"PHASE3":26784,"PHASE4":26786,"NA":26788},{"trials":26779,"activeCount":109},[],{"trials":26781,"activeCount":109},[],{"trials":26783,"activeCount":109},[],{"trials":26785,"activeCount":109},[],{"trials":26787,"activeCount":109},[],{"trials":26789,"activeCount":109},[26790],{"nctId":1412,"briefTitle":1413,"status":569,"phases":26791,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":29,"conditions":26792,"interventions":26793},[102],[1419,1420],[380,1422,1234,1423,1424,172,380,1234,1425,1424],{"intervention":26795,"totalTrials":708,"cells":26796},"Dabigatran Etexilate",{"EARLY_PHASE1":26797,"PHASE1":26799,"PHASE2":26801,"PHASE3":26803,"PHASE4":26805,"NA":26807},{"trials":26798,"activeCount":109},[],{"trials":26800,"activeCount":109},[],{"trials":26802,"activeCount":109},[],{"trials":26804,"activeCount":109},[],{"trials":26806,"activeCount":109},[],{"trials":26808,"activeCount":109},[26809],{"nctId":26810,"briefTitle":26811,"status":569,"phases":26812,"primaryCompletion":2700,"completion":1103,"start":9918,"enrollment":2509,"conditions":26813,"interventions":26815},"NCT06360055","Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults",[102],[26814],"Health",[26795],{"intervention":3483,"totalTrials":708,"cells":26817},{"EARLY_PHASE1":26818,"PHASE1":26820,"PHASE2":26822,"PHASE3":26824,"PHASE4":26826,"NA":26828},{"trials":26819,"activeCount":109},[],{"trials":26821,"activeCount":109},[],{"trials":26823,"activeCount":109},[],{"trials":26825,"activeCount":109},[],{"trials":26827,"activeCount":109},[],{"trials":26829,"activeCount":109},[26830],{"nctId":3475,"briefTitle":3476,"status":569,"phases":26831,"primaryCompletion":3478,"completion":3479,"start":2883,"enrollment":1165,"conditions":26832,"interventions":26833},[102],[3481],[3483,3484,2911],{"intervention":3484,"totalTrials":708,"cells":26835},{"EARLY_PHASE1":26836,"PHASE1":26838,"PHASE2":26840,"PHASE3":26842,"PHASE4":26844,"NA":26846},{"trials":26837,"activeCount":109},[],{"trials":26839,"activeCount":109},[],{"trials":26841,"activeCount":109},[],{"trials":26843,"activeCount":109},[],{"trials":26845,"activeCount":109},[],{"trials":26847,"activeCount":109},[26848],{"nctId":3475,"briefTitle":3476,"status":569,"phases":26849,"primaryCompletion":3478,"completion":3479,"start":2883,"enrollment":1165,"conditions":26850,"interventions":26851},[102],[3481],[3483,3484,2911],{"intervention":26853,"totalTrials":708,"cells":26854},"Gefitinib",{"EARLY_PHASE1":26855,"PHASE1":26857,"PHASE2":26859,"PHASE3":26861,"PHASE4":26863,"NA":26865},{"trials":26856,"activeCount":109},[],{"trials":26858,"activeCount":109},[],{"trials":26860,"activeCount":109},[],{"trials":26862,"activeCount":109},[],{"trials":26864,"activeCount":109},[],{"trials":26866,"activeCount":109},[26867],{"nctId":26868,"briefTitle":26869,"status":569,"phases":26870,"primaryCompletion":668,"completion":9967,"start":14526,"enrollment":26871,"conditions":26872,"interventions":26874},"NCT02282267","Blood Detection of EGFR Mutation For Iressa Treatment",[102],188,[26873],"Lung Adenocarcinoma",[26853],{"intervention":26876,"totalTrials":708,"cells":26877},"Topical Human Granulocyte Macrophage Stimulating Factor Gel",{"EARLY_PHASE1":26878,"PHASE1":26880,"PHASE2":26882,"PHASE3":26884,"PHASE4":26886,"NA":26888},{"trials":26879,"activeCount":109},[],{"trials":26881,"activeCount":109},[],{"trials":26883,"activeCount":109},[],{"trials":26885,"activeCount":109},[],{"trials":26887,"activeCount":109},[],{"trials":26889,"activeCount":109},[26890],{"nctId":26891,"briefTitle":26892,"status":135,"phases":26893,"primaryCompletion":26894,"completion":4099,"start":26323,"enrollment":32,"conditions":26895,"interventions":26896},"NCT06608303","Macrophage Stimulating Factor in the Treatment of Diabetic Wounds",[102],"2025-03-12",[10594],[26876,26897],"Saline",{"intervention":26897,"totalTrials":708,"cells":26899},{"EARLY_PHASE1":26900,"PHASE1":26902,"PHASE2":26904,"PHASE3":26906,"PHASE4":26908,"NA":26910},{"trials":26901,"activeCount":109},[],{"trials":26903,"activeCount":109},[],{"trials":26905,"activeCount":109},[],{"trials":26907,"activeCount":109},[],{"trials":26909,"activeCount":109},[],{"trials":26911,"activeCount":109},[26912],{"nctId":26891,"briefTitle":26892,"status":135,"phases":26913,"primaryCompletion":26894,"completion":4099,"start":26323,"enrollment":32,"conditions":26914,"interventions":26915},[102],[10594],[26876,26897],{"intervention":22857,"totalTrials":708,"cells":26917},{"EARLY_PHASE1":26918,"PHASE1":26920,"PHASE2":26922,"PHASE3":26924,"PHASE4":26926,"NA":26928},{"trials":26919,"activeCount":109},[],{"trials":26921,"activeCount":109},[],{"trials":26923,"activeCount":109},[],{"trials":26925,"activeCount":109},[],{"trials":26927,"activeCount":109},[],{"trials":26929,"activeCount":109},[26930],{"nctId":22850,"briefTitle":22851,"status":569,"phases":26931,"primaryCompletion":81,"completion":1103,"start":22853,"enrollment":13985,"conditions":26932,"interventions":26933},[102],[22855],[15327,22857],{"intervention":26935,"totalTrials":708,"cells":26936},"promestriene vaginal soft",{"EARLY_PHASE1":26937,"PHASE1":26939,"PHASE2":26941,"PHASE3":26943,"PHASE4":26945,"NA":26947},{"trials":26938,"activeCount":109},[],{"trials":26940,"activeCount":109},[],{"trials":26942,"activeCount":109},[],{"trials":26944,"activeCount":109},[],{"trials":26946,"activeCount":109},[],{"trials":26948,"activeCount":109},[26949],{"nctId":26950,"briefTitle":26951,"status":569,"phases":26952,"primaryCompletion":1163,"completion":1163,"start":26953,"enrollment":168,"conditions":26954,"interventions":26956},"NCT04657536","Evaluating the Efficacy of Temperature-controlled Radiofrequency (TRF) in the Treatment of Vulvovaginal Atrophy.",[102],"2020-12-08",[26955],"Postmenopausal Vulvovaginal Atrophy",[26935],{"intervention":26958,"totalTrials":708,"cells":26959},"Single injection of penehyclidine",{"EARLY_PHASE1":26960,"PHASE1":26962,"PHASE2":26964,"PHASE3":26966,"PHASE4":26968,"NA":26970},{"trials":26961,"activeCount":109},[],{"trials":26963,"activeCount":109},[],{"trials":26965,"activeCount":109},[],{"trials":26967,"activeCount":109},[],{"trials":26969,"activeCount":109},[],{"trials":26971,"activeCount":109},[26972],{"nctId":26973,"briefTitle":26974,"status":135,"phases":26975,"primaryCompletion":8798,"completion":4239,"start":26976,"enrollment":26977,"conditions":26978,"interventions":26979},"NCT04454866","Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery",[102],"2020-07-07",354,[24841,1220,24842],[26958,26980],"Continuous infusion of penehyclidine",{"intervention":26980,"totalTrials":708,"cells":26982},{"EARLY_PHASE1":26983,"PHASE1":26985,"PHASE2":26987,"PHASE3":26989,"PHASE4":26991,"NA":26993},{"trials":26984,"activeCount":109},[],{"trials":26986,"activeCount":109},[],{"trials":26988,"activeCount":109},[],{"trials":26990,"activeCount":109},[],{"trials":26992,"activeCount":109},[],{"trials":26994,"activeCount":109},[26995],{"nctId":26973,"briefTitle":26974,"status":135,"phases":26996,"primaryCompletion":8798,"completion":4239,"start":26976,"enrollment":26977,"conditions":26997,"interventions":26998},[102],[24841,1220,24842],[26958,26980],{"intervention":27000,"totalTrials":708,"cells":27001},"Latanoprost",{"EARLY_PHASE1":27002,"PHASE1":27004,"PHASE2":27006,"PHASE3":27008,"PHASE4":27010,"NA":27012},{"trials":27003,"activeCount":109},[],{"trials":27005,"activeCount":109},[],{"trials":27007,"activeCount":109},[],{"trials":27009,"activeCount":109},[],{"trials":27011,"activeCount":109},[],{"trials":27013,"activeCount":109},[27014],{"nctId":27015,"briefTitle":27016,"status":569,"phases":27017,"primaryCompletion":15248,"completion":3545,"start":27018,"enrollment":2653,"conditions":27019,"interventions":27021},"NCT01084902","Efficacy Comparison of Xalatan and Azopt on POAG and OH",[102],"2010-02",[27020],"Ocular Hypertension",[27000,27022],"Brinzolamide",{"intervention":27022,"totalTrials":708,"cells":27024},{"EARLY_PHASE1":27025,"PHASE1":27027,"PHASE2":27029,"PHASE3":27031,"PHASE4":27033,"NA":27035},{"trials":27026,"activeCount":109},[],{"trials":27028,"activeCount":109},[],{"trials":27030,"activeCount":109},[],{"trials":27032,"activeCount":109},[],{"trials":27034,"activeCount":109},[],{"trials":27036,"activeCount":109},[27037],{"nctId":27015,"briefTitle":27016,"status":569,"phases":27038,"primaryCompletion":15248,"completion":3545,"start":27018,"enrollment":2653,"conditions":27039,"interventions":27040},[102],[27020],[27000,27022],{"intervention":27042,"totalTrials":708,"cells":27043},"Mesenchymal Stem Cells from adipose",{"EARLY_PHASE1":27044,"PHASE1":27046,"PHASE2":27048,"PHASE3":27050,"PHASE4":27052,"NA":27054},{"trials":27045,"activeCount":109},[],{"trials":27047,"activeCount":109},[],{"trials":27049,"activeCount":109},[],{"trials":27051,"activeCount":109},[],{"trials":27053,"activeCount":109},[],{"trials":27055,"activeCount":109},[27056],{"nctId":27057,"briefTitle":27058,"status":569,"phases":27059,"primaryCompletion":16091,"completion":2624,"start":4720,"enrollment":748,"conditions":27060,"interventions":27061},"NCT03357575","The Comparison of Efficacy and Safety of the Mesenchymal Stem Cells From Adipose and Hyaluronic Acid",[102],[2416],[27042,27062],"Hyaluronic Acid",{"intervention":27062,"totalTrials":708,"cells":27064},{"EARLY_PHASE1":27065,"PHASE1":27067,"PHASE2":27069,"PHASE3":27071,"PHASE4":27073,"NA":27075},{"trials":27066,"activeCount":109},[],{"trials":27068,"activeCount":109},[],{"trials":27070,"activeCount":109},[],{"trials":27072,"activeCount":109},[],{"trials":27074,"activeCount":109},[],{"trials":27076,"activeCount":109},[27077],{"nctId":27057,"briefTitle":27058,"status":569,"phases":27078,"primaryCompletion":16091,"completion":2624,"start":4720,"enrollment":748,"conditions":27079,"interventions":27080},[102],[2416],[27042,27062]]